,sentence_text,e1,e2,relation_type,normalized_sentence
0,Concurrent administration of a TNF antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.,TNF antagonist,ORENCIA,effect,Concurrent_bf administration_bf TNF_bf antagonist_bf OTHER_DRUG associated_be increased_be risk_be serious_be infections_be significant_be additional_be efficacy_be use_be TNF_be antagonists_be alone_be ._be
1,Concurrent therapy with ORENCIA and TNF antagonists is not recommended.,ORENCIA,TNF antagonists,advise,Concurrent_bf therapy_bf DRUG TNF_be antagonists_be recommended_be ._be
2,"There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.",ORENCIA,anakinra,advise,"There_bf insufficient_bf experience_bf assess_bf safety_bf efficacy_bf DRUG administered_be concurrently_be OTHER_DRUG ,_af therefore_af use_af recommended_af ._af"
3,Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.,naltrexone,Acamprosate,mechanism,Co-administration_bf DRUG OTHER_DRUG produced_af 25%_af increase_af AUC_af 33%_af increase_af Cmax_af OTHER_DRUG ._af
4,"Patients taking Acamprosate concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.",Acamprosate,antidepressants,effect,"Patients_bf taking_bf DRUG concomitantly_be OTHER_DRUG commonly_af reported_af weight_af gain_af weight_af loss_af ,_af compared_af patients_af taking_af either_af medication_af alone_af ._af"
5,"Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",Intestinal adsorbents,Acarbose,mechanism,"Intestinal_bf adsorbents_bf (e_bf ._bf g_bf ._bf ,_bf charcoal)_bf digestive_bf enzyme_bf preparations_bf containing_bf carbohydrate-splitting_bf enzymes_bf (e_bf ._bf g_bf ._bf ,_bf amylase_bf ,_bf pancreatin)_bf may_bf reduce_bf effect_bf OTHER_DRUG taken_be concomitantly_be ._be"
6,"Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",charcoal,Acarbose,mechanism,"Intestinal_bf adsorbents_bf (e_bf ._bf g_bf ._bf ,_bf charcoal)_bf digestive_bf enzyme_bf preparations_bf containing_bf carbohydrate-splitting_bf enzymes_bf (e_bf ._bf g_bf ._bf ,_bf amylase_bf ,_bf pancreatin)_bf may_bf reduce_bf effect_bf OTHER_DRUG taken_be concomitantly_be ._be"
7,"Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",amylase,Acarbose,mechanism,"Intestinal_bf adsorbents_bf (e_bf ._bf g_bf ._bf ,_bf charcoal)_bf digestive_bf enzyme_bf preparations_bf containing_bf carbohydrate-splitting_bf enzymes_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be pancreatin)_be may_be reduce_be effect_be OTHER_DRUG taken_af concomitantly_af ._af"
8,"Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",pancreatin,Acarbose,mechanism,"Intestinal_bf adsorbents_bf (e_bf ._bf g_bf ._bf ,_bf charcoal)_bf digestive_bf enzyme_bf preparations_bf containing_bf carbohydrate-splitting_bf enzymes_bf (e_bf ._bf g_bf ._bf ,_bf amylase_bf ,_bf pancreatin)_bf may_bf reduce_bf effect_bf OTHER_DRUG taken_be concomitantly_be ._be"
9,"Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.",Acarbose,digoxin,mechanism,"DRUG shown_be change_be bioavailabillty_be OTHER_DRUG co-administered_af ,_af may_af require_af OTHER_DRUG dose_af adjustment_af ._af"
10,"However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.",metformin,Acarbose,mechanism,"However_bf ,_bf peak_bf plasma_bf level_bf DRUG reduced_be approximately_be 20%_be taking_be OTHER_DRUG due_af slight_af delay_af absorption_af DRUG ._af"
11,"However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.",Acarbose,metformin,mechanism,"However_bf ,_bf peak_bf plasma_bf level_bf OTHER_DRUG reduced_be approximately_be 20%_be taking_be DRUG due_af slight_af delay_af absorption_af OTHER_DRUG ._af"
12,"Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.",Catecholamine-depleting drugs,beta-blocking agents,effect,"Catecholamine-depleting_bf drugs_bf ,_bf reserpine_bf ,_bf may_bf additive_bf effect_bf given_bf beta-blocking_bf agents_bf ._bf"
13,"Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.",reserpine,beta-blocking agents,effect,"Catecholamine-depleting_bf drugs_bf ,_bf DRUG ,_be may_be additive_be effect_be given_be beta-blocking_be agents_be ._be"
14,"Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.",acebutolol,catecholamine depletors,advise,"Patients_bf treated_bf DRUG plus_be catecholamine_be depletors_be ,_be therefore_be ,_be observed_be closely_be evidence_be marked_be bradycardia_be hypotension_be may_be present_be vertigo_be ,_be syncope/presyncope_be ,_be orthostatic_be changes_be blood_be pressure_be without_be compensatory_be tachycardia_be ._be"
15,"Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic antagonists and alpha-adrenergic stimulants, including those contained in proprietary cold remedies and vasoconstrictive nasal drops.",beta-adrenergic antagonists,alpha-adrenergic stimulants,effect,"Exaggerated_bf hypertensive_bf responses_bf reported_bf combined_bf use_bf beta-adrenergic_bf antagonists_bf alpha-adrenergic_bf stimulants_bf ,_bf including_bf contained_bf proprietary_bf cold_bf remedies_bf vasoconstrictive_bf nasal_bf drops_bf ._bf"
16,Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.,beta-adrenoceptor blocking agents,nonsteroidal anti-inflammatory drugs,effect,Blunting_bf antihypertensive_bf effect_bf beta-adrenoceptor_bf blocking_bf agents_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf reported_bf ._bf
17,DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.,DIAMOX,phenytoin,mechanism,DRUG modifies_be OTHER_DRUG metabolism_af increased_af serum_af levels_af OTHER_DRUG ._af
18,DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.,DIAMOX,phenytoin,mechanism,DRUG modifies_be OTHER_DRUG metabolism_af increased_af serum_af levels_af OTHER_DRUG ._af
19,"By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.",DIAMOX,primidone,mechanism,"By_bf decreasing_bf gastrointestinal_bf absorption_bf OTHER_DRUG ,_be DRUG may_af decrease_af serum_af concentrations_af OTHER_DRUG metabolites_af ,_af consequent_af possible_af decrease_af anticonvulsant_af effect_af ._af"
20,"Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.",DIAMOX,primidone,advise,"Caution_bf advised_bf beginning_bf ,_bf discontinuing_bf ,_bf changing_bf dose_bf DRUG patients_be receiving_be OTHER_DRUG ._af"
21,Acetazolamide may increase the effects of other folic acid antagonists.,Acetazolamide,folic acid antagonists,effect,DRUG may_be increase_be effects_be folic_be acid_be antagonists_be ._be
22,Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.,Acetazolamide,amphetamine,mechanism,DRUG decreases_be urinary_be excretion_be OTHER_DRUG may_af enhance_af magnitude_af duration_af effect_af ._af
23,Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.,Acetazolamide,quinidine,mechanism,DRUG reduces_be urinary_be excretion_be OTHER_DRUG may_af enhance_af effect_af ._af
24,Acetazolamide may prevent the urinary antiseptic effect of methenamine.,Acetazolamide,methenamine,effect,DRUG may_be prevent_be urinary_be antiseptic_be effect_be OTHER_DRUG ._af
25,Acetazolamide increases lithium excretion and the lithium may be decreased.,Acetazolamide,lithium,mechanism,DRUG increases_be OTHER_DRUG excretion_af OTHER_DRUG may_af decreased_af ._af
26,Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.,Acetazolamide,sodium bicarbonate,effect,DRUG sodium_be bicarbonate_be used_be concurrently_be increases_be risk_be renal_be calculus_be formation_be ._be
27,Acetazolamide may elevate cyclosporine levels.,Acetazolamide,cyclosporine,mechanism,DRUG may_be elevate_be OTHER_DRUG levels_af ._af
28,Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.,probenecid,acyclovir,mechanism,Co-administration_bf DRUG OTHER_DRUG shown_af increase_af mean_af half-life_af area_af concentration-time_af curve_af ._af
29,Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.,acitretin,ethanol,mechanism,Ethanol:Clinical_bf evidence_bf shown_bf etretinate_bf formed_bf concurrent_bf ingestion_bf DRUG OTHER_DRUG ._af
30,"Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.",acitretin,glibenclamide,effect,"Glibenclamide:_bf In_bf study_bf 7_bf healthy_bf male_bf volunteers_bf ,_bf DRUG treatment_be potentiated_be blood_be glucose_be lowering_be effect_be OTHER_DRUG (a_af sulfonylurea_af similar_af chlorpropamide)_af 3_af 7_af subjects_af ._af"
31,"However, it has been established that acitretin interferes with the contraceptive effect of microdosed progestin minipill preparations.",acitretin,progestin,effect,"However_bf ,_bf established_bf DRUG interferes_be contraceptive_be effect_be microdosed_be OTHER_DRUG minipill_af preparations_af ._af"
32,Microdosed minipill progestin preparations are not recommended for use with Soriatane.,progestin,Soriatane,advise,Microdosed_bf minipill_bf DRUG preparations_be recommended_be use_be OTHER_DRUG ._af
33,Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.,methotrexate,etretinate,effect,Methotrexate:_bf An_bf increased_bf risk_bf hepatitis_bf reported_bf result_bf combined_bf use_bf DRUG OTHER_DRUG ._af
34,"Consequently, the combination of methotrexate with acitretin is also contraindicated.",methotrexate,acitretin,advise,"Consequently_bf ,_bf combination_bf DRUG OTHER_DRUG also_af contraindicated_af ._af"
35,"Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.",acitretin,phenytoin,mechanism,"Phenytoin:_bf If_bf DRUG given_be concurrently_be OTHER_DRUG ,_af protein_af binding_af OTHER_DRUG may_af reduced_af ._af"
36,"Tetracyclines: Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.",acitretin,tetracyclines,effect,"Tetracyclines:_bf Since_bf DRUG OTHER_DRUG cause_af increased_af intracranial_af pressure_af ,_af combined_af use_af contraindicated_af ._af"
37,Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.,vitamin A,acitretin,advise,Vitamin_bf A_bf oral_bf retinoids:_bf Concomitant_bf administration_bf vitamin_bf A_bf and/or_bf oral_bf retinoids_bf OTHER_DRUG must_be avoided_be risk_be hypervitaminosis_be A_be ._be
38,Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.,retinoids,acitretin,advise,Vitamin_bf A_bf oral_bf retinoids:_bf Concomitant_bf administration_bf vitamin_bf A_bf and/or_bf oral_bf DRUG OTHER_DRUG must_af avoided_af risk_af hypervitaminosis_af A_af ._af
39,"Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.",anakinra,TNF-blocking agent,effect,"Anakinra:_bf Concurrent_bf administration_bf DRUG (an_be interleukin-1_be antagonist)_be another_be TNF-blocking_be agent_be associated_be increased_be risk_be serious_be infections_be ,_be increased_be risk_be neutropenia_be additional_be benefit_be compared_be medicinal_be products_be alone_be ._be"
40,"Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.",interleukin-1 antagonist,TNF-blocking agent,effect,"Anakinra:_bf Concurrent_bf administration_bf anakinra_bf (an_bf interleukin-1_bf antagonist)_bf another_bf TNF-blocking_bf agent_bf associated_bf increased_bf risk_bf serious_bf infections_bf ,_bf increased_bf risk_bf neutropenia_bf additional_bf benefit_bf compared_bf medicinal_bf products_bf alone_bf ._bf"
41,"Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.",anakinra,TNF-blocking agents,effect,"Therefore_bf ,_bf combination_bf DRUG TNF-blocking_be agents_be ,_be including_be HUMIRA_be ,_be may_be also_be result_be n_be similar_be toxicities_be ._be"
42,"Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.",anakinra,HUMIRA,effect,"Therefore_bf ,_bf combination_bf DRUG TNF-blocking_be agents_be ,_be including_be OTHER_DRUG ,_af may_af also_af result_af n_af similar_af toxicities_af ._af"
43,Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.,Digoxin,Adenocard,effect,DRUG verapamil_be use_be may_be rarely_be associated_be ventricular_be fibrillation_be combined_be OTHER_DRUG ._af
44,Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.,verapamil,Adenocard,effect,Digoxin_bf DRUG use_be may_be rarely_be associated_be ventricular_be fibrillation_be combined_be OTHER_DRUG ._af
45,The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation.,Adenocard,digitalis,effect,The_bf use_bf DRUG patients_be receiving_be OTHER_DRUG may_af rarely_af associated_af ventricular_af fibrillation_af ._af
46,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.,adenosine,methylxanthines,effect,The_bf effects_bf DRUG antagonized_be OTHER_DRUG caffeine_af theophylline_af ._af
47,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.,adenosine,caffeine,effect,The_bf effects_bf DRUG antagonized_be methylxanthines_be OTHER_DRUG theophylline_af ._af
48,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.,adenosine,theophylline,effect,The_bf effects_bf DRUG antagonized_be methylxanthines_be caffeine_be OTHER_DRUG ._af
49,"In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.",methylxanthines,adenosine,advise,"In_bf presence_bf DRUG ,_be larger_be doses_be OTHER_DRUG may_af required_af OTHER_DRUG may_af effective_af ._af"
50,"In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.",methylxanthines,adenosine,advise,"In_bf presence_bf DRUG ,_be larger_be doses_be OTHER_DRUG may_af required_af OTHER_DRUG may_af effective_af ._af"
51,Adenosine effects are potentiated by dipyridamole.,Adenosine,dipyridamole,effect,DRUG effects_be potentiated_be OTHER_DRUG ._af
52,"Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.",adenosine,dipyridamole,effect,"Thus_bf ,_bf smaller_bf doses_bf DRUG may_be effective_be presence_be OTHER_DRUG ._af"
53,"As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.",adenosine,carbamazepine,effect,"As_bf primary_bf effect_bf DRUG decrease_be conduction_be A-V_be node_be ,_be higher_be degrees_be heart_be block_be may_be produced_be presence_be OTHER_DRUG ._af"
54,"Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).",Nafazodone,Xanax,advise,"DRUG ,_be fluvoxamine_be ,_be cimetidine_be (consider_be OTHER_DRUG dose_af reduction)_af ._af"
55,"Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).",fluvoxamine,Xanax,advise,"Nafazodone_bf ,_bf DRUG ,_be cimetidine_be (consider_be OTHER_DRUG dose_af reduction)_af ._af"
56,"Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).",cimetidine,Xanax,advise,"Nafazodone_bf ,_bf fluvoxamine_bf ,_bf DRUG (consider_be OTHER_DRUG dose_af reduction)_af ._af"
57,Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.,dexamethasone,albendazole,mechanism,Dexamethasone:_bf Steady-state_bf trough_bf concentrations_bf OTHER_DRUG sulfoxide_be 56%_be higher_be 8_be mg_be DRUG coadministered_af dose_af OTHER_DRUG (15_af mg/kg/day)_af eight_af neurocysticercosis_af patients_af ._af
58,"Praziquantel: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.",praziquantel,albendazole sulfoxide,mechanism,"Praziquantel:_bf In_bf fed_bf state_bf ,_bf DRUG (40_be mg/kg)_be increased_be mean_be maximum_be plasma_be concentration_be area_be curve_be albendazole_be sulfoxide_be 50%_be healthy_be subjects_be (n=10)_be compared_be separate_be group_be subjects_be (n=6)_be given_be albendazole_be alone_be ._be"
59,Cimetidine: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).,Albendazole sulfoxide,cimetidine,mechanism,Cimetidine:_bf Albendazole_bf sulfoxide_bf concentrations_bf bile_bf cystic_bf fluid_bf increased_bf (about_bf 2-fold)_bf hydatid_bf cyst_bf patients_bf treated_bf OTHER_DRUG (10_be mg/kg/day)_be (n=7)_be compared_be albendazole_be (20_be mg/kg/day)_be alone_be (n=12)_be ._be
60,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",aminoglycosides,PROLEUKIN,effect,"Concurrent_bf administration_bf drugs_bf possessing_bf nephrotoxic_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be indomethacin)_be ,_be myelotoxic_be (e_be ._be g_be ._be ,_be cytotoxic_be chemotherapy)_be ,_be cardiotoxic_be (e_be ._be g_be ._be ,_be doxorubicin)_be hepatotoxic_be (e_be ._be g_be ._be ,_be methotrexate_be ,_be asparaginase)_be effects_be OTHER_DRUG may_af increase_af toxicity_af organ_af systems_af ._af"
61,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",indomethacin,PROLEUKIN,effect,"Concurrent_bf administration_bf drugs_bf possessing_bf nephrotoxic_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf indomethacin)_bf ,_bf myelotoxic_bf (e_bf ._bf g_bf ._bf ,_bf cytotoxic_bf chemotherapy)_bf ,_bf cardiotoxic_bf (e_bf ._bf g_bf ._bf ,_bf doxorubicin)_bf hepatotoxic_bf (e_bf ._bf g_bf ._bf ,_bf methotrexate_bf ,_bf asparaginase)_bf effects_bf OTHER_DRUG may_be increase_be toxicity_be organ_be systems_be ._be"
62,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",cytotoxic,PROLEUKIN,effect,"Concurrent_bf administration_bf drugs_bf possessing_bf nephrotoxic_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf indomethacin)_bf ,_bf myelotoxic_bf (e_bf ._bf g_bf ._bf ,_bf DRUG chemotherapy)_be ,_be cardiotoxic_be (e_be ._be g_be ._be ,_be doxorubicin)_be hepatotoxic_be (e_be ._be g_be ._be ,_be methotrexate_be ,_be asparaginase)_be effects_be OTHER_DRUG may_af increase_af toxicity_af organ_af systems_af ._af"
63,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",doxorubicin,PROLEUKIN,effect,"Concurrent_bf administration_bf drugs_bf possessing_bf nephrotoxic_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf indomethacin)_bf ,_bf myelotoxic_bf (e_bf ._bf g_bf ._bf ,_bf cytotoxic_bf chemotherapy)_bf ,_bf cardiotoxic_bf (e_bf ._bf g_bf ._bf ,_bf doxorubicin)_bf hepatotoxic_bf (e_bf ._bf g_bf ._bf ,_bf methotrexate_bf ,_bf asparaginase)_bf effects_bf OTHER_DRUG may_be increase_be toxicity_be organ_be systems_be ._be"
64,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",methotrexate,PROLEUKIN,effect,"Concurrent_bf administration_bf drugs_bf possessing_bf nephrotoxic_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf indomethacin)_bf ,_bf myelotoxic_bf (e_bf ._bf g_bf ._bf ,_bf cytotoxic_bf chemotherapy)_bf ,_bf cardiotoxic_bf (e_bf ._bf g_bf ._bf ,_bf doxorubicin)_bf hepatotoxic_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be asparaginase)_be effects_be OTHER_DRUG may_af increase_af toxicity_af organ_af systems_af ._af"
65,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",asparaginase,PROLEUKIN,effect,"Concurrent_bf administration_bf drugs_bf possessing_bf nephrotoxic_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf indomethacin)_bf ,_bf myelotoxic_bf (e_bf ._bf g_bf ._bf ,_bf cytotoxic_bf chemotherapy)_bf ,_bf cardiotoxic_bf (e_bf ._bf g_bf ._bf ,_bf doxorubicin)_bf hepatotoxic_bf (e_bf ._bf g_bf ._bf ,_bf methotrexate_bf ,_bf asparaginase)_bf effects_bf OTHER_DRUG may_be increase_be toxicity_be organ_be systems_be ._be"
66,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,antineoplastic agents,effect,"Hypersensitivity_bf reactions_bf reported_bf patients_bf receiving_bf combination_bf regimens_bf containing_bf sequential_bf high_bf dose_bf DRUG antineoplastic_be agents_be ,_be specifically_be ,_be dacarbazine_be ,_be cis-platinum_be ,_be tamoxifen_be interferon-alfa_be ._be"
67,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,dacarbazine,effect,"Hypersensitivity_bf reactions_bf reported_bf patients_bf receiving_bf combination_bf regimens_bf containing_bf sequential_bf high_bf dose_bf DRUG antineoplastic_be agents_be ,_be specifically_be ,_be OTHER_DRUG ,_af cis-platinum_af ,_af tamoxifen_af interferon-alfa_af ._af"
68,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,cis-platinum,effect,"Hypersensitivity_bf reactions_bf reported_bf patients_bf receiving_bf combination_bf regimens_bf containing_bf sequential_bf high_bf dose_bf DRUG antineoplastic_be agents_be ,_be specifically_be ,_be dacarbazine_be ,_be OTHER_DRUG ,_af tamoxifen_af interferon-alfa_af ._af"
69,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,tamoxifen,effect,"Hypersensitivity_bf reactions_bf reported_bf patients_bf receiving_bf combination_bf regimens_bf containing_bf sequential_bf high_bf dose_bf DRUG antineoplastic_be agents_be ,_be specifically_be ,_be dacarbazine_be ,_be cis-platinum_be ,_be OTHER_DRUG interferon-alfa_af ._af"
70,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,interferon-alfa,effect,"Hypersensitivity_bf reactions_bf reported_bf patients_bf receiving_bf combination_bf regimens_bf containing_bf sequential_bf high_bf dose_bf DRUG antineoplastic_be agents_be ,_be specifically_be ,_be dacarbazine_be ,_be cis-platinum_be ,_be tamoxifen_be OTHER_DRUG ._af"
71,"Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving PROLEUKIN and interferon-alfa concurrently.",PROLEUKIN,interferon-alfa,effect,"Myocardial_bf injury_bf ,_bf including_bf myocardial_bf infarction_bf ,_bf myocarditis_bf ,_bf ventricular_bf hypokinesia_bf ,_bf severe_bf rhabdomyolysis_bf appear_bf increased_bf patients_bf receiving_bf DRUG OTHER_DRUG concurrently_af ._af"
72,"Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of interferon-alfa and PROLEUKIN, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.",interferon-alfa,PROLEUKIN,effect,"Exacerbation_bf initial_bf presentation_bf number_bf autoimmune_bf inflammatory_bf disorders_bf observed_bf following_bf concurrent_bf use_bf DRUG OTHER_DRUG ,_af including_af crescentic_af IgA_af glomerulonephritis_af ,_af oculo-bulbar_af myasthenia_af gravis_af ,_af inflammatory_af arthritis_af ,_af thyroiditis_af ,_af bullous_af pemphigoid_af ,_af Stevens-Johnson_af syndrome_af ._af"
73,"Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.",glucocorticoids,PROLEUKIN,effect,"Although_bf DRUG shown_be reduce_be PROLEUKIN-induced_be side_be effects_be including_be fever_be ,_be renal_be insufficiency_be ,_be hyperbilirubinemia_be ,_be confusion_be ,_be dyspnea_be ,_be concomitant_be administration_be agents_be OTHER_DRUG may_af reduce_af antitumor_af effectiveness_af OTHER_DRUG thus_af avoided_af ._af 12_af Beta-blockers_af antihypertensives_af may_af potentiate_af hypotension_af seen_af OTHER_DRUG ._af"
74,"Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.",Beta-blockers,PROLEUKIN,effect,"Although_bf glucocorticoids_bf shown_bf reduce_bf PROLEUKIN-induced_bf side_bf effects_bf including_bf fever_bf ,_bf renal_bf insufficiency_bf ,_bf hyperbilirubinemia_bf ,_bf confusion_bf ,_bf dyspnea_bf ,_bf concomitant_bf administration_bf agents_bf OTHER_DRUG may_be reduce_be antitumor_be effectiveness_be OTHER_DRUG thus_af avoided_af ._af 12_af DRUG antihypertensives_af may_af potentiate_af hypotension_af seen_af OTHER_DRUG ._af"
75,"Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.",antihypertensives,PROLEUKIN,effect,"Although_bf glucocorticoids_bf shown_bf reduce_bf PROLEUKIN-induced_bf side_bf effects_bf including_bf fever_bf ,_bf renal_bf insufficiency_bf ,_bf hyperbilirubinemia_bf ,_bf confusion_bf ,_bf dyspnea_bf ,_bf concomitant_bf administration_bf agents_bf OTHER_DRUG may_be reduce_be antitumor_be effectiveness_be OTHER_DRUG thus_af avoided_af ._af 12_af Beta-blockers_af DRUG may_af potentiate_af hypotension_af seen_af OTHER_DRUG ._af"
76,"Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.",interleukin-2,radiographic iodinated contrast media,effect,"Delayed_bf Adverse_bf Reactions_bf Iodinated_bf Contrast_bf Media:_bf A_bf review_bf literature_bf revealed_bf 12_bf ._bf 6%_bf (range_bf 11-28%)_bf 501_bf patients_bf treated_bf various_bf DRUG containing_be regimens_be subsequently_be administered_be radiographic_be iodinated_be contrast_be media_be experienced_be acute_be ,_be atypical_be adverse_be reactions_be ._be"
77,"However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.",UROXATRAL,alpha-blockers,advise,"However_bf ,_bf interactions_bf may_bf expected_bf ,_bf DRUG NOT_be used_be combination_be OTHER_DRUG ._af"
78,Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.,irbesartan,aliskiren,mechanism,Co-administration_bf DRUG reduced_be OTHER_DRUG Cmax_af 50%_af multiple_af dosing_af ._af
79,Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.,atorvastatin,aliskiren,mechanism,Co-administration_bf DRUG resulted_be 50%_be increase_be OTHER_DRUG Cmax_af AUC_af multiple_af dosing_af ._af
80,Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.,ketoconazole,aliskiren,mechanism,Ketoconazole:_bf Co-administration_bf 200_bf mg_bf twice-daily_bf DRUG OTHER_DRUG resulted_af approximate_af 80%_af increase_af plasma_af levels_af OTHER_DRUG ._af
81,"Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.",aliskiren,furosemide,mechanism,"Furosemide:_bf When_bf DRUG co-administered_be OTHER_DRUG ,_af AUC_af Cmax_af OTHER_DRUG reduced_af 30%_af 50%_af ,_af respectively_af ._af"
82,Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.,Allopurinol,mercaptopurine,mechanism,Mercaptopurine/Azathioprine:_bf DRUG inhibits_be enzymatic_be oxidation_be OTHER_DRUG azathioprine_af 6-thiouric_af acid_af ._af
83,Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.,Allopurinol,azathioprine,mechanism,Mercaptopurine/Azathioprine:_bf DRUG inhibits_be enzymatic_be oxidation_be mercaptopurine_be OTHER_DRUG 6-thiouric_af acid_af ._af
84,"In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.",allopurinol,mercaptopurine,advise,"In_bf patients_bf receiving_bf OTHER_DRUG (Purinethol)_be azathioprine_be (Imuran)_be ,_be concomitant_be administration_be 300-600_be mg_be DRUG per_af day_af require_af reduction_af dose_af approximately_af one-third_af one-fourth_af usual_af dose_af OTHER_DRUG azathioprine_af ._af"
85,"In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.",allopurinol,azathioprine,advise,"In_bf patients_bf receiving_bf mercaptopurine_bf (Purinethol)_bf OTHER_DRUG (Imuran)_be ,_be concomitant_be administration_be 300-600_be mg_be DRUG per_af day_af require_af reduction_af dose_af approximately_af one-third_af one-fourth_af usual_af dose_af mercaptopurine_af OTHER_DRUG ._af"
86,"Dicumarol: It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol.",allopurinol,dicumarol,mechanism,"Dicumarol:_bf It_bf reported_bf DRUG prolongs_be half-life_be anticoagulant_be ,_be OTHER_DRUG ._af"
87,"Uricosuric Agents: Since the excretion of oxipurinol is similar to that of urate, uricosuric agents, which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.",uricosuric agents,oxipurinol,mechanism,"Uricosuric_bf Agents:_bf Since_bf excretion_bf OTHER_DRUG similar_be urate_be ,_be uricosuric_be agents_be ,_be increase_be excretion_be urate_be ,_be also_be likely_be increase_be excretion_be OTHER_DRUG thus_af lower_af degree_af inhibition_af xanthine_af oxidase_af ._af"
88,The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.,uricosuric agents,allopurinol,mechanism,The_bf concomitant_bf administration_bf uricosuric_bf agents_bf OTHER_DRUG associated_be decrease_be excretion_be oxypurines_be (hypoxanthine_be xanthine)_be increase_be urinary_be uric_be acid_be excretion_be compared_be observed_be OTHER_DRUG alone_af ._af
89,Thiazide Diuretics: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.,allopurinol,thiazide diuretics,effect,Thiazide_bf Diuretics:_bf The_bf reports_bf concomitant_bf use_bf DRUG thiazide_be diuretics_be may_be contribute_be enhancement_be DRUG toxicity_af patients_af reviewed_af attempt_af establish_af cause-and-effect_af relationship_af mechanism_af causation_af ._af
90,"Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on thiazide diuretics and allopurinol even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected..",thiazide diuretics,allopurinol,advise,"Although_bf causal_bf mechanism_bf cause-and-effect_bf relationship_bf established_bf ,_bf current_bf evidence_bf suggests_bf renal_bf function_bf monitored_bf patients_bf thiazide_bf diuretics_bf OTHER_DRUG even_be absence_be renal_be failure_be ,_be dosage_be levels_be even_be conservatively_be adjusted_be patients_be combined_be therapy_be diminished_be renal_be function_be detected_be ._be ._be"
91,Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.,ampicillin,allopurinol,effect,Ampicillin/Amoxicillin:_bf An_bf increase_bf frequency_bf skin_bf rash_bf reported_bf among_bf patients_bf receiving_bf DRUG amoxicillin_be concurrently_be OTHER_DRUG compared_af patients_af receiving_af drugs_af ._af
92,Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.,amoxicillin,allopurinol,effect,Ampicillin/Amoxicillin:_bf An_bf increase_bf frequency_bf skin_bf rash_bf reported_bf among_bf patients_bf receiving_bf ampicillin_bf DRUG concurrently_be OTHER_DRUG compared_af patients_af receiving_af drugs_af ._af
93,"Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.",cyclophosphamide,allopurinol,effect,"Cytotoxic_bf Agents:_bf Enhanced_bf bone_bf marrow_bf suppression_bf DRUG cytotoxic_be agents_be reported_be among_be patients_be neoplastic_be disease_be ,_be except_be leukemia_be ,_be presence_be OTHER_DRUG ._af"
94,"Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.",cytotoxic agents,allopurinol,effect,"Cytotoxic_bf Agents:_bf Enhanced_bf bone_bf marrow_bf suppression_bf cyclophosphamide_bf cytotoxic_bf agents_bf reported_bf among_bf patients_bf neoplastic_bf disease_bf ,_bf except_bf leukemia_bf ,_bf presence_bf OTHER_DRUG ._be"
95,"Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.",Chlorpropamide,allopurinol,mechanism,"Chlorpropamide:_bf Chlorpropamides_bf plasma_bf half-life_bf may_bf prolonged_bf OTHER_DRUG ,_be since_be OTHER_DRUG DRUG may_af compete_af excretion_af renal_af tubule_af ._af"
96,"Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.",allopurinol,chlorpropamide,mechanism,"Chlorpropamide:_bf Chlorpropamides_bf plasma_bf half-life_bf may_bf prolonged_bf DRUG ,_be since_be DRUG OTHER_DRUG may_af compete_af excretion_af renal_af tubule_af ._af"
97,The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.,allopurinol,chlorpropamide,effect,The_bf risk_bf hypoglycemia_bf secondary_bf mechanism_bf may_bf increased_bf DRUG OTHER_DRUG given_af concomitantly_af presence_af renal_af insufficiency_af ._af
98,Cyclosporin: Reports indicate that cyclosporine levels may be increased during concomitant treatment with allopurinol sodium for injection.,cyclosporine,allopurinol sodium,mechanism,Cyclosporin:_bf Reports_bf indicate_bf DRUG levels_be may_be increased_be concomitant_be treatment_be allopurinol_be sodium_be injection_be ._be
99,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.",ergotamine,AXERT,advise,"Because_bf theoretical_bf basis_bf effects_bf may_bf additive_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf dihydroergotamine_bf methysergide)_bf OTHER_DRUG within_be 24_be hours_be avoided_be ._be"
100,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.",ergot-type medications,AXERT,advise,"Because_bf theoretical_bf basis_bf effects_bf may_bf additive_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf dihydroergotamine_bf methysergide)_bf OTHER_DRUG within_be 24_be hours_be avoided_be ._be"
101,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.",dihydroergotamine,AXERT,advise,"Because_bf theoretical_bf basis_bf effects_bf may_bf additive_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf DRUG methysergide)_be OTHER_DRUG within_af 24_af hours_af avoided_af ._af"
102,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.",methysergide,AXERT,advise,"Because_bf theoretical_bf basis_bf effects_bf may_bf additive_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf dihydroergotamine_bf methysergide)_bf OTHER_DRUG within_be 24_be hours_be avoided_be ._be"
103,Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.,moclobemide,almotriptan,mechanism,Monoamine_bf Oxidase_bf Inhibitors:_bf Coadministration_bf DRUG resulted_be 27%_be decrease_be OTHER_DRUG clearance_af increase_af Cmax_af approximately_af 6%_af ._af
104,Other 5-HT1B/1D Agonists Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with AXERT is contraindicated.,5-HT1B/1D agonists,AXERT,advise,Other_bf 5-HT1B/1D_bf Agonists_bf Concomitant_bf use_bf 5-HT1B/1D_bf agonists_bf within_bf 24_bf hours_bf treatment_bf OTHER_DRUG contraindicated_be ._be
105,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",SSRIs,5-HT1 agonists,effect,"Selective_bf Serotonin_bf Reuptake_bf Inhibitors_bf (SSRIs):_bf DRUG (e_be ._be g_be ._be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be paroxetine_be ,_be sertraline)_be rarely_be reported_be cause_be weakness_be ,_be hyperreflexia_be ,_be incoordination_be coadministered_be 5-HT1_be agonists_be ._be"
106,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",fluoxetine,5-HT1 agonists,effect,"Selective_bf Serotonin_bf Reuptake_bf Inhibitors_bf (SSRIs):_bf SSRIs_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be fluvoxamine_be ,_be paroxetine_be ,_be sertraline)_be rarely_be reported_be cause_be weakness_be ,_be hyperreflexia_be ,_be incoordination_be coadministered_be 5-HT1_be agonists_be ._be"
107,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",fluvoxamine,5-HT1 agonists,effect,"Selective_bf Serotonin_bf Reuptake_bf Inhibitors_bf (SSRIs):_bf SSRIs_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf DRUG ,_be paroxetine_be ,_be sertraline)_be rarely_be reported_be cause_be weakness_be ,_be hyperreflexia_be ,_be incoordination_be coadministered_be 5-HT1_be agonists_be ._be"
108,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",paroxetine,5-HT1 agonists,effect,"Selective_bf Serotonin_bf Reuptake_bf Inhibitors_bf (SSRIs):_bf SSRIs_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf DRUG ,_be sertraline)_be rarely_be reported_be cause_be weakness_be ,_be hyperreflexia_be ,_be incoordination_be coadministered_be 5-HT1_be agonists_be ._be"
109,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",sertraline,5-HT1 agonists,effect,"Selective_bf Serotonin_bf Reuptake_bf Inhibitors_bf (SSRIs):_bf SSRIs_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf paroxetine_bf ,_bf sertraline)_bf rarely_bf reported_bf cause_bf weakness_bf ,_bf hyperreflexia_bf ,_bf incoordination_bf coadministered_bf 5-HT1_bf agonists_bf ._bf"
110,"If concomitant treatment with AXERT and an SSRI is clinically warranted, appropriate observation of the patient is advised.",AXERT,SSRI,advise,"If_bf concomitant_bf treatment_bf DRUG OTHER_DRUG clinically_af warranted_af ,_af appropriate_af observation_af patient_af advised_af ._af"
111,Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.,almotriptan,verapamil,mechanism,Verapamil:_bf Coadministration_bf DRUG OTHER_DRUG resulted_af 24%_af increase_af plasma_af concentrations_af DRUG ._af
112,Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.,almotriptan,ketoconazole,mechanism,Coadministration_bf DRUG potent_be CYP3A4_be inhibitor_be OTHER_DRUG (400_af mg_af q_af ._af ._af 3_af days)_af resulted_af approximately_af 60%_af increase_af area_af plasma_af concentration-time_af curve_af maximal_af plasma_af concentrations_af DRUG ._af
113,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.",itraconazole,almotriptan,advise,"Although_bf interaction_bf OTHER_DRUG potent_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be DRUG ,_af ritonavir_af ,_af erythromycin)_af studied_af ,_af increased_af exposures_af OTHER_DRUG may_af expected_af OTHER_DRUG used_af concomitantly_af medications_af ._af"
114,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.",ritonavir,almotriptan,advise,"Although_bf interaction_bf OTHER_DRUG potent_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be itraconazole_be ,_be DRUG ,_af erythromycin)_af studied_af ,_af increased_af exposures_af OTHER_DRUG may_af expected_af OTHER_DRUG used_af concomitantly_af medications_af ._af"
115,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.",erythromycin,almotriptan,advise,"Although_bf interaction_bf OTHER_DRUG potent_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be itraconazole_be ,_be ritonavir_be ,_be erythromycin)_be studied_be ,_be increased_be exposures_be OTHER_DRUG may_af expected_af OTHER_DRUG used_af concomitantly_af medications_af ._af"
116,Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.,Fluvoxamine,alosetron,mechanism,DRUG increased_be mean_be OTHER_DRUG plasma_af concentrations_af (AUC)_af approximately_af 6-fold_af prolonged_af half-life_af approximately_af 3-fold_af ._af
117,Concomitant administration of alosetron and fluvoxamine is contraindicated.,alosetron,fluvoxamine,advise,Concomitant_bf administration_bf DRUG OTHER_DRUG contraindicated_af ._af
118,"Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.",alosetron,quinolone antibiotics,advise,"Concomitant_bf administration_bf DRUG moderate_be CYP1A2_be inhibitors_be ,_be including_be quinolone_be antibiotics_be cimetidine_be ,_be evaluated_be ,_be avoided_be unless_be clinically_be necessary_be similar_be potential_be drug_be interactions_be ._be"
119,"Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.",alosetron,cimetidine,advise,"Concomitant_bf administration_bf DRUG moderate_be CYP1A2_be inhibitors_be ,_be including_be quinolone_be antibiotics_be OTHER_DRUG ,_af evaluated_af ,_af avoided_af unless_af clinically_af necessary_af similar_af potential_af drug_af interactions_af ._af"
120,Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.,Ketoconazole,alosetron,mechanism,DRUG increased_be mean_be OTHER_DRUG plasma_af concentrations_af (AUC)_af 29%_af ._af
121,Caution should be used when alosetron and ketoconazole are administered concomitantly.,alosetron,ketoconazole,advise,Caution_bf used_bf DRUG OTHER_DRUG administered_af concomitantly_af ._af
122,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,clarithromycin,advise,"Coadministration_bf DRUG strong_be CYP3A4_be inhibitors_be ,_be OTHER_DRUG ,_af telithromycin_af ,_af protease_af inhibitors_af ,_af voriconazole_af ,_af itraconazole_af evaluated_af undertaken_af caution_af similar_af potential_af drug_af interactions_af ._af"
123,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,telithromycin,advise,"Coadministration_bf DRUG strong_be CYP3A4_be inhibitors_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af protease_af inhibitors_af ,_af voriconazole_af ,_af itraconazole_af evaluated_af undertaken_af caution_af similar_af potential_af drug_af interactions_af ._af"
124,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,protease inhibitors,advise,"Coadministration_bf DRUG strong_be CYP3A4_be inhibitors_be ,_be clarithromycin_be ,_be telithromycin_be ,_be protease_be inhibitors_be ,_be voriconazole_be ,_be itraconazole_be evaluated_be undertaken_be caution_be similar_be potential_be drug_be interactions_be ._be"
125,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,voriconazole,advise,"Coadministration_bf DRUG strong_be CYP3A4_be inhibitors_be ,_be clarithromycin_be ,_be telithromycin_be ,_be protease_be inhibitors_be ,_be OTHER_DRUG ,_af itraconazole_af evaluated_af undertaken_af caution_af similar_af potential_af drug_af interactions_af ._af"
126,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,itraconazole,advise,"Coadministration_bf DRUG strong_be CYP3A4_be inhibitors_be ,_be clarithromycin_be ,_be telithromycin_be ,_be protease_be inhibitors_be ,_be voriconazole_be ,_be OTHER_DRUG evaluated_af undertaken_af caution_af similar_af potential_af drug_af interactions_af ._af"
127,"Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.",alosetron,isoniazid,effect,"Although_bf studied_bf DRUG ,_be inhibition_be N-acetyltransferase_be may_be clinically_be relevant_be consequences_be drugs_be OTHER_DRUG ,_af procainamide_af ,_af hydralazine_af ._af"
128,"Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.",alosetron,procainamide,effect,"Although_bf studied_bf DRUG ,_be inhibition_be N-acetyltransferase_be may_be clinically_be relevant_be consequences_be drugs_be isoniazid_be ,_be OTHER_DRUG ,_af hydralazine_af ._af"
129,"Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.",alosetron,hydralazine,effect,"Although_bf studied_bf DRUG ,_be inhibition_be N-acetyltransferase_be may_be clinically_be relevant_be consequences_be drugs_be isoniazid_be ,_be procainamide_be ,_be OTHER_DRUG ._af"
130,Careful observation is required when amantadine is administered concurrently with central nervous system stimulants.,amantadine,central nervous system stimulants,advise,Careful_bf observation_bf required_bf DRUG administered_be concurrently_be central_be nervous_be system_be stimulants_be ._be
131,Special consideration should be given to the administration of ETHYOL in patients receiving antihypertensive medications or other drugs that could cause or potentiate hypotension.,ETHYOL,antihypertensive medications,advise,Special_bf consideration_bf given_bf administration_bf DRUG patients_be receiving_be antihypertensive_be medications_be drugs_be could_be cause_be potentiate_be hypotension_be ._be
132,"When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, the risk of hyperkalemia may be increased.",amiloride,angiotensin-converting enzyme inhibitor,effect,"When_bf DRUG HCl_be administered_be concomitantly_be angiotensin-converting_be enzyme_be inhibitor_be ,_be risk_be hyperkalemia_be may_be increased_be ._be"
133,Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.,Lithium,diuretics,advise,DRUG generally_be given_be OTHER_DRUG reduce_af renal_af clearance_af add_af high_af risk_af DRUG toxicity_af ._af
134,"In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,loop diuretics,effect,"In_bf patients_bf ,_bf administration_bf non-steroidal_bf anti-inflammatory_bf agent_bf reduce_bf diuretic_bf ,_bf natriuretic_bf ,_bf antihypertensive_bf effects_bf loop_bf ,_bf potassium-sparing_bf thiazide_bf diuretics_bf ._bf"
135,"In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,potassium-sparing diuretics,effect,"In_bf patients_bf ,_bf administration_bf non-steroidal_bf anti-inflammatory_bf agent_bf reduce_bf diuretic_bf ,_bf natriuretic_bf ,_bf antihypertensive_bf effects_bf loop_bf ,_bf potassium-sparing_bf thiazide_bf diuretics_bf ._bf"
136,"In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,thiazide diuretics,effect,"In_bf patients_bf ,_bf administration_bf non-steroidal_bf anti-inflammatory_bf agent_bf reduce_bf diuretic_bf ,_bf natriuretic_bf ,_bf antihypertensive_bf effects_bf loop_bf ,_bf potassium-sparing_bf thiazide_bf diuretics_bf ._bf"
137,"Therefore, when MIDAMOR and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.",MIDAMOR,non-steroidal anti-inflammatory agents,advise,"Therefore_bf ,_bf DRUG non-steroidal_be anti-inflammatory_be agents_be used_be concomitantly_be ,_be patient_be observed_be closely_be determine_be desired_be effect_be diuretic_be obtained_be ._be"
138,"Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.",indomethacin,potassium-sparing diuretics,effect,"Since_bf DRUG potassium-sparing_be diuretics_be ,_be including_be MIDAMOR_be ,_be may_be associated_be increased_be serum_be potassium_be levels_be ,_be potential_be effects_be potassium_be kinetics_be renal_be function_be considered_be agents_be administered_be concurrently_be ._be"
139,"Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.",indomethacin,MIDAMOR,effect,"Since_bf DRUG potassium-sparing_be diuretics_be ,_be including_be OTHER_DRUG ,_af may_af associated_af increased_af serum_af potassium_af levels_af ,_af potential_af effects_af potassium_af kinetics_af renal_af function_af considered_af agents_af administered_af concurrently_af ._af"
140,A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.,amiodarone,indinavir,mechanism,A_bf case_bf report_bf one_bf patient_bf taking_bf DRUG 200_be mg_be OTHER_DRUG 800_af mg_af three_af times_af day_af resulted_af increases_af DRUG concentrations_af 0_af ._af 9_af mg/L_af 1_af ._af 3_af mg/L_af ._af
141,Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.,amiodarone,protease inhibitor,advise,Monitoring_bf DRUG toxicity_be serial_be measurement_be DRUG serum_af concentration_af concomitant_af protease_af inhibitor_af therapy_af considered_af ._af
142,Histamine H2 antagonists: Cimetidine inhibits CYP3A4 and can increase serum amiodarone levels.,Histamine H2 antagonists,Cimetidine,mechanism,Histamine_bf H2_bf antagonists:_bf OTHER_DRUG inhibits_be CYP3A4_be increase_be serum_be amiodarone_be levels_be ._be
143,"On administration of oral amiodarone, the need for digitalis therapy should be reviewed and the dose reduced by approximately 50% or discontinued.",amiodarone,digitalis,advise,"On_bf administration_bf oral_bf DRUG ,_be need_be OTHER_DRUG therapy_af reviewed_af dose_af reduced_af approximately_af 50%_af discontinued_af ._af"
144,The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.,SSRI,TCA,effect,The_bf extent_bf SSRI-TCA_bf interactions_bf may_bf pose_bf clinical_bf problems_bf depend_bf degree_bf inhibition_bf pharmacokinetics_bf DRUG involved_be ._be
145,"Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other.",TCAs,SSRIs,advise,"Nevertheless_bf ,_bf caution_bf indicated_bf coadministration_bf DRUG OTHER_DRUG also_af switching_af one_af class_af ._af"
146,"Hyperpyrexia has been reported when amitriptyline HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.",amitriptyline HCl,anticholinergic,effect,"Hyperpyrexia_bf reported_bf amitriptyline_bf HCl_bf administered_bf OTHER_DRUG agents_be neuroleptic_be drugs_be ,_be particularly_be hot_be weather_be ._be"
147,Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic-type drugs.,tricyclic antidepressants,anticholinergic,effect,Paralytic_bf ileus_bf may_bf occur_bf patients_bf taking_bf tricyclic_bf antidepressants_bf combination_bf anticholinergic-type_bf drugs_bf ._bf
148,"Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs.",Cimetidine,tricyclic antidepressants,mechanism,"DRUG reported_be reduce_be hepatic_be metabolism_be certain_be tricyclic_be antidepressants_be ,_be thereby_be delaying_be elimination_be increasing_be steady-state_be concentrations_be drugs_be ._be"
149,Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine.,tricyclic antidepressants,cimetidine,effect,Clinically_bf significant_bf effects_bf reported_bf tricyclic_bf antidepressants_bf used_bf concomitantly_bf OTHER_DRUG ._be
150,"Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when cimetidine was added to the drug regimen.",tricyclic antidepressants,cimetidine,mechanism,"Increases_bf plasma_bf levels_bf tricyclic_bf antidepressants_bf ,_bf frequency_bf severity_bf side_bf effects_bf ,_bf particularly_bf anticholinergic_bf ,_bf reported_bf OTHER_DRUG added_be drug_be regimen_be ._be"
151,Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.,tricyclic antidepressants,cimetidine,mechanism,Discontinuation_bf OTHER_DRUG well-controlled_be patients_be receiving_be tricyclic_be antidepressants_be OTHER_DRUG may_af decrease_af plasma_af levels_af efficacy_af antidepressants_af ._af
152,Transient delirium has been reported in patients who were treated with one gram of ethchlorvynol and 75 - 150 mg of amitriptyline HCl.,ethchlorvynol,amitriptyline HCl,effect,Transient_bf delirium_bf reported_bf patients_bf treated_bf one_bf gram_bf DRUG 75_be -_be 150_be mg_be amitriptyline_be HCl_be ._be
153,"When administered concurrently, the following drugs may interact with amphotericin B: Antineoplastic agents: may enhance the potential for renal toxicity, bronchospasm and hypotension.",amphotericin B,Antineoplastic agents,effect,"When_bf administered_bf concurrently_bf ,_bf following_bf drugs_bf may_bf interact_bf amphotericin_bf B:_bf Antineoplastic_bf agents:_bf may_bf enhance_bf potential_bf renal_bf toxicity_bf ,_bf bronchospasm_bf hypotension_bf ._bf"
154,Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.,Corticosteroids,amphotericin B,effect,DRUG Corticotropin_be (ACTH):_be may_be potentiate_be amphotericin_be B-_be induced_be hypokalemia_be may_be predispose_be patient_be cardiac_be dysfunction_be ._be
155,Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.,Corticotropin,amphotericin B,effect,Corticosteroids_bf DRUG (ACTH):_be may_be potentiate_be amphotericin_be B-_be induced_be hypokalemia_be may_be predispose_be patient_be cardiac_be dysfunction_be ._be
156,Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.,ACTH,amphotericin B,effect,Corticosteroids_bf Corticotropin_bf (ACTH):_bf may_bf potentiate_bf amphotericin_bf B-_bf induced_bf hypokalemia_bf may_bf predispose_bf patient_bf cardiac_bf dysfunction_bf ._bf
157,Digitalis glycosides: amphotericin B-induced hypokalemia may potentiate digitalis toxicity.,amphotericin B,digitalis,effect,OTHER_DRUG glycosides:_be amphotericin_be B-induced_be hypokalemia_be may_be potentiate_be OTHER_DRUG toxicity_af ._af
158,"Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.",amphotericin B,flucytosine,effect,"Flucytosine:_bf synergistic_bf relationship_bf amphotericin_bf B_bf reported_bf ,_bf concomitant_bf use_bf may_bf increase_bf toxicity_bf OTHER_DRUG possibly_be increasing_be cellular_be uptake_be and/or_be impairing_be renal_be excretion_be ._be"
159,"Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.",imidazoles,amphotericin B,effect,"DRUG (e_be ._be g_be ._be ,_be ketoconazole_be ,_be miconazole_be ,_be clotrimazole_be ,_be fluconazole_be ,_be etc_be ._be ):_be vitro_be animal_be studies_be combination_be amphotericin_be B_be DRUG suggest_af DRUG may_af induce_af fungal_af resistance_af amphotericin_af B_af ._af"
160,"Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).",amphotericin B,skeletal muscle relaxants,effect,"Skeletal_bf muscle_bf relaxants:_bf amphotericin_bf B-induced_bf hypokalemia_bf may_bf enhance_bf curariform_bf effect_bf skeletal_bf muscle_bf relaxants_bf (e_bf ._bf g_bf ._bf ,_bf tubocurarine)_bf ._bf"
161,"Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).",amphotericin B,tubocurarine,effect,"Skeletal_bf muscle_bf relaxants:_bf amphotericin_bf B-induced_bf hypokalemia_bf may_bf enhance_bf curariform_bf effect_bf skeletal_bf muscle_bf relaxants_bf (e_bf ._bf g_bf ._bf ,_bf tubocurarine)_bf ._bf"
162,Leukocyte transfusions: acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin B and leukocyte transfusions.,amphotericin B,leukocyte transfusions,effect,Leukocyte_bf transfusions:_bf acute_bf pulmonary_bf toxicity_bf reported_bf patients_bf receiving_bf intravenous_bf amphotericin_bf B_bf leukocyte_bf transfusions_bf ._bf
163,"Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.",Chloramphenicol,penicillins,effect,"Bacteriostatic_bf Antibiotics:_bf DRUG ,_be erythromycins_be ,_be sulfonamides_be ,_be tetracyclines_be may_be interfere_be bactericidal_be effect_be OTHER_DRUG ._af"
164,"Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.",erythromycins,penicillins,effect,"Bacteriostatic_bf Antibiotics:_bf Chloramphenicol_bf ,_bf DRUG ,_be sulfonamides_be ,_be tetracyclines_be may_be interfere_be bactericidal_be effect_be OTHER_DRUG ._af"
165,"Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.",sulfonamides,penicillins,effect,"Bacteriostatic_bf Antibiotics:_bf Chloramphenicol_bf ,_bf erythromycins_bf ,_bf DRUG ,_be tetracyclines_be may_be interfere_be bactericidal_be effect_be OTHER_DRUG ._af"
166,"Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.",tetracyclines,penicillins,effect,"Bacteriostatic_bf Antibiotics:_bf Chloramphenicol_bf ,_bf erythromycins_bf ,_bf sulfonamides_bf ,_bf DRUG may_be interfere_be bactericidal_be effect_be OTHER_DRUG ._af"
167,Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.,Probenecid,ampicillin,mechanism,Probenecid:_bf May_bf decrease_bf renal_bf tubular_bf secretion_bf OTHER_DRUG resulting_be increased_be blood_be levels_be and/or_be OTHER_DRUG toxicity_af ._af
168,"Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.",Indinavir,amprenavir,mechanism,"DRUG steady-state_be Cmax_be ,_be A_be ._be C_be ._be Cmin_be decreased_be 22%_be ,_be 38%_be ,_be 27%_be ,_be respectively_be ,_be concomitant_be OTHER_DRUG ._af"
169,"Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.",Saquinavir,amprenavir,mechanism,"DRUG steady-state_be Cmax_be ,_be A_be ._be C_be ._be Cmin_be increased_be 21%_be ,_be decreased_be 19%_be ,_be decreased_be 48%_be ,_be respectively_be ,_be concomitant_be OTHER_DRUG ._af"
170,"Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.",Nelfinavir,amprenavir,mechanism,"DRUG steady-state_be Cmax_be ,_be A_be ._be C_be ._be Cmin_be increased_be 12%_be ,_be 15%_be ,_be 14%_be ,_be respectively_be ,_be concomitant_be OTHER_DRUG ._af"
171,Methadone: Coadministration of amprenavir and methadone can decrease plasma levels of methadone.,amprenavir,methadone,effect,Methadone:_bf Coadministration_bf DRUG OTHER_DRUG decrease_af plasma_af levels_af OTHER_DRUG ._af
172,"Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.",amprenavir,methadone,mechanism,"Coadministration_bf DRUG OTHER_DRUG compared_af non-matched_af historicalcontrol_af group_af resulted_af 30%_af ,_af 27%_af ,_af 25%_af decrease_af serum_af DRUG AUC_af ,_af Cmax_af ,_af andCmin_af ,_af respectively_af ._af"
173,"Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.",Amprenavir,ritonavir,effect,"Laboratory_bf Tests:_bf The_bf combination_bf DRUG low-dose_be OTHER_DRUG associated_af elevations_af cholesterol_af triglycerides_af ,_af SGOT_af (AST)_af ,_af SGPT_af (ALT)_af patients_af ._af"
174,Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.,Amprenavir,ritonavir,advise,Appropriate_bf laboratory_bf testing_bf considered_bf prior_bf initiating_bf combination_bf therapy_bf DRUG OTHER_DRUG periodic_af intervals_af clinical_af signs_af symptoms_af hyperlipidemia_af elevated_af liver_af function_af tests_af occur_af therapy_af ._af
175,"Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.",Anagrelide,aspirin,effect,"DRUG alone_be effect_be platelet_be aggregation_be ,_be slightly_be enhance_be inhibition_be platelet_be aggregation_be OTHER_DRUG ._af"
176,"It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.",fluvoxamine,anagrelide,mechanism,"It_bf known_bf CYP1A2_bf inhibited_bf several_bf medicinal_bf products_bf ,_bf including_bf DRUG ,_be medicinal_be products_be could_be theoretically_be adversely_be influence_be clearance_be OTHER_DRUG ._af"
177,Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline.,Anagrelide,theophylline,mechanism,DRUG demonstrates_be limited_be inhibitory_be activity_be towards_be CYP1A2_be may_be present_be theoretical_be potential_be interaction_be coadministered_be medicinal_be products_be sharing_be clearance_be mechanism_be ._be g_be ._be OTHER_DRUG ._af
178,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",milrinone,anagrelide,effect,"The_bf effects_bf medicinal_bf products_bf similar_bf properties_bf inotropes_bf DRUG ,_be enoximone_be ,_be amrinone_be ,_be olprinone_be cilostazol_be may_be exacerbated_be OTHER_DRUG ._af"
179,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",enoximone,anagrelide,effect,"The_bf effects_bf medicinal_bf products_bf similar_bf properties_bf inotropes_bf milrinone_bf ,_bf DRUG ,_be amrinone_be ,_be olprinone_be cilostazol_be may_be exacerbated_be OTHER_DRUG ._af"
180,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",amrinone,anagrelide,effect,"The_bf effects_bf medicinal_bf products_bf similar_bf properties_bf inotropes_bf milrinone_bf ,_bf enoximone_bf ,_bf DRUG ,_be olprinone_be cilostazol_be may_be exacerbated_be OTHER_DRUG ._af"
181,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",olprinone,anagrelide,effect,"The_bf effects_bf medicinal_bf products_bf similar_bf properties_bf inotropes_bf milrinone_bf ,_bf enoximone_bf ,_bf amrinone_bf ,_bf DRUG cilostazol_be may_be exacerbated_be OTHER_DRUG ._af"
182,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",cilostazol,anagrelide,effect,"The_bf effects_bf medicinal_bf products_bf similar_bf properties_bf inotropes_bf milrinone_bf ,_bf enoximone_bf ,_bf amrinone_bf ,_bf olprinone_bf DRUG may_be exacerbated_be OTHER_DRUG ._af"
183,"There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption.",sucralfate,anagrelide,mechanism,"There_bf single_bf case_bf report_bf ,_bf suggests_bf DRUG may_be interfere_be OTHER_DRUG absorption_af ._af"
184,"In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).",Kineret,etanercept,effect,"In_bf study_bf patients_bf active_bf RA_bf treated_bf 24_bf weeks_bf concurrent_bf DRUG OTHER_DRUG therapy_af ,_af 7%_af rate_af serious_af infections_af observed_af ,_af higher_af observed_af OTHER_DRUG alone_af (0%)_af ._af"
185,Two percent of patients treated concurrently with Kineret and etanercept developed neutropenia (ANC  1 x 109/L).,Kineret,etanercept,effect,Two_bf percent_bf patients_bf treated_bf concurrently_bf DRUG OTHER_DRUG developed_af neutropenia_af (ANC_af 1_af x_af 109/L)_af ._af
186,"Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).",tamoxifen,anastrozole,advise,"Based_bf clinical_bf pharmacokinetic_bf results_bf ATAC_bf trial_bf ,_bf DRUG administered_be OTHER_DRUG (see_af CLINICAL_af PHARMACOLOGY_af Drug_af Interactions_af CLINICAL_af PHARMACOLOGY_af -_af Clinical_af Studies_af -_af Adjuvant_af Treatment_af Breast_af Cancer_af Postmenopausal_af Women_af subsections)_af ._af"
187,Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.,anastrozole,tamoxifen,mechanism,Co-administration_bf DRUG OTHER_DRUG resulted_af reduction_af DRUG plasma_af levels_af 27%_af compared_af achieved_af DRUG alone_af ._af
188,Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.,Estrogen,ARIMIDEX,advise,Estrogen-containing_bf therapies_bf used_bf OTHER_DRUG may_be diminish_be pharmacologic_be action_be ._be
189,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,ondansetron,effect,"5HT3_bf Antagonists:_bf Based_bf reports_bf profound_bf hypotension_bf loss_bf consciousness_bf DRUG administered_be OTHER_DRUG ,_af concomitant_af use_af DRUG drugs_af 5HT3_af antagonist_af class_af (including_af ,_af example_af ,_af OTHER_DRUG ,_af granisetron_af ,_af dolasetron_af ,_af palonosetron_af ,_af alosetron)_af contraindicated_af ._af"
190,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,5HT3 antagonist class,advise,"5HT3_bf Antagonists:_bf Based_bf reports_bf profound_bf hypotension_bf loss_bf consciousness_bf DRUG administered_be ondansetron_be ,_be concomitant_be use_be DRUG drugs_af 5HT3_af antagonist_af class_af (including_af ,_af example_af ,_af ondansetron_af ,_af granisetron_af ,_af dolasetron_af ,_af palonosetron_af ,_af alosetron)_af contraindicated_af ._af"
191,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,ondansetron,advise,"5HT3_bf Antagonists:_bf Based_bf reports_bf profound_bf hypotension_bf loss_bf consciousness_bf DRUG administered_be OTHER_DRUG ,_af concomitant_af use_af DRUG drugs_af 5HT3_af antagonist_af class_af (including_af ,_af example_af ,_af OTHER_DRUG ,_af granisetron_af ,_af dolasetron_af ,_af palonosetron_af ,_af alosetron)_af contraindicated_af ._af"
192,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,granisetron,advise,"5HT3_bf Antagonists:_bf Based_bf reports_bf profound_bf hypotension_bf loss_bf consciousness_bf DRUG administered_be ondansetron_be ,_be concomitant_be use_be DRUG drugs_af 5HT3_af antagonist_af class_af (including_af ,_af example_af ,_af ondansetron_af ,_af OTHER_DRUG ,_af dolasetron_af ,_af palonosetron_af ,_af alosetron)_af contraindicated_af ._af"
193,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,dolasetron,advise,"5HT3_bf Antagonists:_bf Based_bf reports_bf profound_bf hypotension_bf loss_bf consciousness_bf DRUG administered_be ondansetron_be ,_be concomitant_be use_be DRUG drugs_af 5HT3_af antagonist_af class_af (including_af ,_af example_af ,_af ondansetron_af ,_af granisetron_af ,_af OTHER_DRUG ,_af palonosetron_af ,_af alosetron)_af contraindicated_af ._af"
194,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,palonosetron,advise,"5HT3_bf Antagonists:_bf Based_bf reports_bf profound_bf hypotension_bf loss_bf consciousness_bf DRUG administered_be ondansetron_be ,_be concomitant_be use_be DRUG drugs_af 5HT3_af antagonist_af class_af (including_af ,_af example_af ,_af ondansetron_af ,_af granisetron_af ,_af dolasetron_af ,_af OTHER_DRUG ,_af alosetron)_af contraindicated_af ._af"
195,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,alosetron,advise,"5HT3_bf Antagonists:_bf Based_bf reports_bf profound_bf hypotension_bf loss_bf consciousness_bf DRUG administered_be ondansetron_be ,_be concomitant_be use_be DRUG drugs_af 5HT3_af antagonist_af class_af (including_af ,_af example_af ,_af ondansetron_af ,_af granisetron_af ,_af dolasetron_af ,_af palonosetron_af ,_af alosetron)_af contraindicated_af ._af"
196,"Antihypertensive Medications and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.",antihypertensive medications,vasodilators,effect,"Antihypertensive_bf Medications_bf Vasodilators:_bf The_bf following_bf adverse_bf events_bf experienced_bf commonly_bf patients_bf receiving_bf concomitant_bf antihypertensive_bf medications_bf OTHER_DRUG (n_be =_be 94)_be compared_be patients_be receiving_be concomitant_be drugs_be (n_be =_be 456):_be hypotension_be 10%_be vs_be 4%_be ,_be myocardial_be infarction_be 3%_be vs_be 1%_be ,_be serious_be pneumonia_be 5%_be vs_be 3%_be ,_be serious_be falls_be 9%_be vs_be 3%_be ,_be bone_be joint_be injuries_be 6%_be vs_be 2%_be ._be"
197,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",dopamine antagonists,metoclopramide,effect,"Dopamine_bf Antagonists:_bf Since_bf apomorphine_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf OTHER_DRUG ,_be may_be diminish_be effectiveness_be APOKYN_be ._be"
198,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",phenothiazines,APOKYN,effect,"Dopamine_bf Antagonists:_bf Since_bf apomorphine_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf OTHER_DRUG ._be"
199,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",butyrophenones,APOKYN,effect,"Dopamine_bf Antagonists:_bf Since_bf apomorphine_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf DRUG ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be OTHER_DRUG ._af"
200,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",thioxanthenes,APOKYN,effect,"Dopamine_bf Antagonists:_bf Since_bf apomorphine_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf OTHER_DRUG ._be"
201,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",metoclopramide,APOKYN,effect,"Dopamine_bf Antagonists:_bf Since_bf apomorphine_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf DRUG ,_be may_be diminish_be effectiveness_be OTHER_DRUG ._af"
202,"Patients with major psychotic disorders, treated with neuroleptics, should be treated with dopamine agonists only if the potential benefits outweigh the risks.",neuroleptics,dopamine agonists,advise,"Patients_bf major_bf psychotic_bf disorders_bf ,_bf treated_bf DRUG ,_be treated_be dopamine_be agonists_be potential_be benefits_be outweigh_be risks_be ._be"
203,Apraclonidine should not be used in patients receiving MAO inhibitors..,Apraclonidine,MAO inhibitors,advise,DRUG used_be patients_be receiving_be MAO_be inhibitors_be ._be ._be
204,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,CNS depressants,advise,"Although_bf specific_bf drug_bf interactions_bf topical_bf glaucoma_bf drugs_bf systemic_bf medications_bf identified_bf clinical_bf studies_bf DRUG 0_be ._be 5%_be Ophthalmic_be Solution_be ,_be possibility_be additive_be potentiating_be effect_be CNS_be depressants_be (alcohol_be ,_be barbiturates_be ,_be opiates_be ,_be sedatives_be ,_be anesthetics)_be considered_be ._be"
205,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,alcohol,advise,"Although_bf specific_bf drug_bf interactions_bf topical_bf glaucoma_bf drugs_bf systemic_bf medications_bf identified_bf clinical_bf studies_bf DRUG 0_be ._be 5%_be Ophthalmic_be Solution_be ,_be possibility_be additive_be potentiating_be effect_be CNS_be depressants_be (alcohol_be ,_be barbiturates_be ,_be opiates_be ,_be sedatives_be ,_be anesthetics)_be considered_be ._be"
206,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,barbiturates,advise,"Although_bf specific_bf drug_bf interactions_bf topical_bf glaucoma_bf drugs_bf systemic_bf medications_bf identified_bf clinical_bf studies_bf DRUG 0_be ._be 5%_be Ophthalmic_be Solution_be ,_be possibility_be additive_be potentiating_be effect_be CNS_be depressants_be (alcohol_be ,_be OTHER_DRUG ,_af opiates_af ,_af sedatives_af ,_af anesthetics)_af considered_af ._af"
207,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,opiates,advise,"Although_bf specific_bf drug_bf interactions_bf topical_bf glaucoma_bf drugs_bf systemic_bf medications_bf identified_bf clinical_bf studies_bf DRUG 0_be ._be 5%_be Ophthalmic_be Solution_be ,_be possibility_be additive_be potentiating_be effect_be CNS_be depressants_be (alcohol_be ,_be barbiturates_be ,_be OTHER_DRUG ,_af sedatives_af ,_af anesthetics)_af considered_af ._af"
208,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,sedatives,advise,"Although_bf specific_bf drug_bf interactions_bf topical_bf glaucoma_bf drugs_bf systemic_bf medications_bf identified_bf clinical_bf studies_bf DRUG 0_be ._be 5%_be Ophthalmic_be Solution_be ,_be possibility_be additive_be potentiating_be effect_be CNS_be depressants_be (alcohol_be ,_be barbiturates_be ,_be opiates_be ,_be OTHER_DRUG ,_af anesthetics)_af considered_af ._af"
209,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,anesthetics,advise,"Although_bf specific_bf drug_bf interactions_bf topical_bf glaucoma_bf drugs_bf systemic_bf medications_bf identified_bf clinical_bf studies_bf DRUG 0_be ._be 5%_be Ophthalmic_be Solution_be ,_be possibility_be additive_be potentiating_be effect_be CNS_be depressants_be (alcohol_be ,_be barbiturates_be ,_be opiates_be ,_be sedatives_be ,_be anesthetics)_be considered_be ._be"
210,Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.,Tricyclic antidepressants,clonidine,effect,Tricyclic_bf antidepressants_bf reported_bf blunt_bf hypotensive_bf effect_bf systemic_bf OTHER_DRUG ._be
211,An additive hypotensive effect has been reported with the combination of systemic clonidine and neuroleptic therapy.,clonidine,neuroleptic,effect,An_bf additive_bf hypotensive_bf effect_bf reported_bf combination_bf systemic_bf DRUG OTHER_DRUG therapy_af ._af
212,"Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.",apraclonidine,beta-blockers,advise,"Since_bf DRUG may_be reduce_be pulse_be blood_be pressure_be ,_be caution_be using_be drugs_be OTHER_DRUG (ophthalmic_af systemic)_af ,_af antihypertensives_af ,_af cardiac_af glycosides_af advised_af ._af"
213,"Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.",apraclonidine,antihypertensives,advise,"Since_bf DRUG may_be reduce_be pulse_be blood_be pressure_be ,_be caution_be using_be drugs_be beta-blockers_be (ophthalmic_be systemic)_be ,_be OTHER_DRUG ,_af cardiac_af glycosides_af advised_af ._af"
214,"Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.",apraclonidine,cardiac glycosides,advise,"Since_bf DRUG may_be reduce_be pulse_be blood_be pressure_be ,_be caution_be using_be drugs_be beta-blockers_be (ophthalmic_be systemic)_be ,_be antihypertensives_be ,_be cardiac_be glycosides_be advised_be ._be"
215,"Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.",Aprepitant,S(-) warfarin,mechanism,"DRUG shown_be induce_be metabolism_be S(-)_be warfarin_be tolbutamide_be ,_be metabolized_be CYP2C9_be ._be"
216,"Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.",Aprepitant,tolbutamide,mechanism,"DRUG shown_be induce_be metabolism_be S(-)_be warfarin_be OTHER_DRUG ,_af metabolized_af CYP2C9_af ._af"
217,"Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.",Aprepitant,phenytoin,mechanism,"Coadministration_bf DRUG drugs_be drugs_be known_be metabolized_be CYP2C9_be ,_be OTHER_DRUG ,_af may_af result_af lower_af plasma_af concentrations_af drugs_af ._af"
218,"Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.",Aprepitant,dexamethasone,mechanism,"Corticosteroids:_bf Dexamethasone:_bf DRUG ,_be given_be regimen_be 125mg_be OTHER_DRUG coadministered_af orally_af 20_af mg_af Day_af 1_af ,_af DRUG given_af 80_af mg/day_af OTHER_DRUG coadministered_af orally_af 8_af mg_af Days_af 2_af 5_af ,_af increased_af AUC_af OTHER_DRUG ,_af CYP3A4_af substrate_af 2_af ._af 2-fold_af ,_af Days_af 1_af 5_af ._af"
219,"Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.",Aprepitant,dexamethasone,mechanism,"Corticosteroids:_bf Dexamethasone:_bf DRUG ,_be given_be regimen_be 125mg_be OTHER_DRUG coadministered_af orally_af 20_af mg_af Day_af 1_af ,_af DRUG given_af 80_af mg/day_af OTHER_DRUG coadministered_af orally_af 8_af mg_af Days_af 2_af 5_af ,_af increased_af AUC_af OTHER_DRUG ,_af CYP3A4_af substrate_af 2_af ._af 2-fold_af ,_af Days_af 1_af 5_af ._af"
220,"The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.",dexamethasone,Aprepitant,advise,"The_bf oral_bf DRUG doses_be reduced_be approximately_be 50%_be coadministered_be OTHER_DRUG ,_af achieve_af exposures_af DRUG similar_af obtained_af given_af without_af OTHER_DRUG ._af"
221,The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.,dexamethasone,Aprepitant,mechanism,The_bf daily_bf dose_bf DRUG administered_be clinical_be studies_be OTHER_DRUG reflects_af approximate_af 50%_af reduction_af dose_af DRUG ._af
222,"Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.",Aprepitant,methylprednisolone,mechanism,"DRUG ,_be given_be regimen_be 125_be mg_be Day_be 1_be 80_be mg/day_be Days_be 2_be 3_be ,_be increased_be AUC_be OTHER_DRUG ,_af CYP3A4_af substrate_af ,_af 1_af ._af 34-fold_af Day_af 1_af 2_af ._af 5-fold_af Day_af 3_af ,_af OTHER_DRUG coadministered_af intravenously_af 125_af mg_af Day_af 1_af orally_af 40_af mg_af Days_af 2_af 3_af ._af"
223,"The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.",methylprednisolone,Aprepitant,advise,"The_bf IV_bf DRUG dose_be reduced_be approximately_be 25%_be ,_be oral_be DRUG dose_af reduced_af approximately_af 50%_af coadministered_af OTHER_DRUG achieve_af exposures_af DRUG similar_af obtained_af given_af without_af OTHER_DRUG ._af"
224,"The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.",methylprednisolone,Aprepitant,advise,"The_bf IV_bf DRUG dose_be reduced_be approximately_be 25%_be ,_be oral_be DRUG dose_af reduced_af approximately_af 50%_af coadministered_af OTHER_DRUG achieve_af exposures_af DRUG similar_af obtained_af given_af without_af OTHER_DRUG ._af"
225,"Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.",S(-)warfarin,Aprepitant,mechanism,"Although_bf effect_bf OTHER_DRUG plasma_be AUC_be R(+)_be S(-)_be warfarin_be determined_be Day_be 3_be ,_be 34%_be decrease_be DRUG (a_af CYP2C9_af substrate)_af trough_af concentration_af accompanied_af 14%_af decrease_af prothrombin_af time_af (reported_af International_af Normalized_af Ratio_af INR)_af 5_af days_af completion_af dosing_af OTHER_DRUG ._af"
226,"In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of Aprepitant with each chemotherapy cycle.",warfarin,Aprepitant,advise,"In_bf patients_bf chronic_bf DRUG therapy_be ,_be prothrombin_be time_be (INR)_be closely_be monitored_be 2-week_be period_be ,_be particularly_be 7_be 10_be days_be ,_be following_be initiation_be 3-day_be regimen_be OTHER_DRUG chemotherapy_af cycle_af ._af"
227,"Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.",tolbutamide,Aprepitant,mechanism,"Tolbutamide:_bf OTHER_DRUG ,_be given_be 125_be mg_be Day_be 1_be 80_be mg/day_be Days_be 2_be 3_be ,_be decreased_be AUC_be DRUG (a_af CYP2C9_af substrate)_af 23%_af Day_af 4_af ,_af 28%_af Day_af 8_af ,_af 15%_af Day_af 15_af ,_af single_af dose_af DRUG 500_af mg_af admini_af ,_af stered_af orally_af prior_af administration_af 3-day_af regimen_af OTHER_DRUG Days_af 4_af ,_af 8_af ,_af 15_af ._af"
228,"Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;",Aprepitant,ethinyl estradiol,mechanism,"Oral_bf contraceptives:_bf DRUG ,_be given_be daily_be 14_be days_be 100-mg_be capsule_be oral_be contraceptive_be containing_be 35_be mcg_be ethinyl_be estradiol_be 1_be mg_be norethindrone_be ,_be decreased_be AUC_be ethinyl_be estradiol_be 43%_be ,_be decreased_be AUC_be norethindrone_be 8%;_be"
229,"Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;",Aprepitant,norethindrone,mechanism,"Oral_bf contraceptives:_bf DRUG ,_be given_be daily_be 14_be days_be 100-mg_be capsule_be oral_be contraceptive_be containing_be 35_be mcg_be ethinyl_be estradiol_be 1_be mg_be OTHER_DRUG ,_af decreased_af AUC_af ethinyl_af estradiol_af 43%_af ,_af decreased_af AUC_af OTHER_DRUG 8%;_af"
230,"therefore, the efficacy of oral contraceptives during administration of Aprepitant may be reduced.",contraceptives,Aprepitant,effect,"therefore_bf ,_bf efficacy_bf oral_bf DRUG administration_be OTHER_DRUG may_af reduced_af ._af"
231,"Although a 3-day regimen of Aprepitant given concomitantly with oral contraceptives has not been studied, alternative or back-up methods of contraception should be used.",Aprepitant,contraceptives,advise,"Although_bf 3-day_bf regimen_bf DRUG given_be concomitantly_be oral_be OTHER_DRUG studied_af ,_af alternative_af back-up_af methods_af contraception_af used_af ._af"
232,"Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.",Aprepitant,midazolam,mechanism,"Midazolam:_bf DRUG increased_be AUC_be OTHER_DRUG ,_af sensitive_af CYP3A4_af substrate_af ,_af 2_af ._af 3-fold_af Day_af 1_af 3_af ._af 3-fold_af Day_af 5_af ,_af single_af oral_af dose_af OTHER_DRUG 2_af mg_af coadministered_af Day_af 1_af Day_af 5_af regimen_af DRUG 125_af mg_af Day_af 1_af 80_af mg/day_af Days_af 2_af 5_af ._af"
233,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.",midazolam,Aprepitant,advise,"The_bf potential_bf effects_bf increased_bf plasma_bf concentrations_bf DRUG benzodiazepines_be metabolized_be via_be CYP3A4_be (alprazolam_be ,_be triazolam)_be considered_be coadministering_be agents_be OTHER_DRUG ._af"
234,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.",benzodiazepines,Aprepitant,advise,"The_bf potential_bf effects_bf increased_bf plasma_bf concentrations_bf midazolam_bf DRUG metabolized_be via_be CYP3A4_be (alprazolam_be ,_be triazolam)_be considered_be coadministering_be agents_be OTHER_DRUG ._af"
235,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.",alprazolam,Aprepitant,advise,"The_bf potential_bf effects_bf increased_bf plasma_bf concentrations_bf midazolam_bf benzodiazepines_bf metabolized_bf via_bf CYP3A4_bf (alprazolam_bf ,_bf triazolam)_bf considered_bf coadministering_bf agents_bf OTHER_DRUG ._be"
236,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.",triazolam,Aprepitant,advise,"The_bf potential_bf effects_bf increased_bf plasma_bf concentrations_bf midazolam_bf benzodiazepines_bf metabolized_bf via_bf CYP3A4_bf (alprazolam_bf ,_bf triazolam)_bf considered_bf coadministering_bf agents_bf OTHER_DRUG ._be"
237,Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.,Aprepitant,midazolam,mechanism,DRUG increased_be AUC_be OTHER_DRUG 25%_af Day_af 4_af decreased_af AUC_af OTHER_DRUG 19%_af Day_af 8_af relative_af dosing_af DRUG Days_af 1_af 3_af ._af
238,Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.,Aprepitant,midazolam,mechanism,DRUG increased_be AUC_be OTHER_DRUG 25%_af Day_af 4_af decreased_af AUC_af OTHER_DRUG 19%_af Day_af 8_af relative_af dosing_af DRUG Days_af 1_af 3_af ._af
239,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,ketoconazole,advise,"Consequently_bf ,_bf concomitant_bf administration_bf DRUG strong_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af itraconazole_af ,_af nefazodone_af ,_af troleandomycin_af ,_af clarithromycin_af ,_af ritonavir_af ,_af nelfinavir)_af approached_af caution_af ._af"
240,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,itraconazole,advise,"Consequently_bf ,_bf concomitant_bf administration_bf DRUG strong_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be OTHER_DRUG ,_af nefazodone_af ,_af troleandomycin_af ,_af clarithromycin_af ,_af ritonavir_af ,_af nelfinavir)_af approached_af caution_af ._af"
241,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,nefazodone,advise,"Consequently_bf ,_bf concomitant_bf administration_bf DRUG strong_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be OTHER_DRUG ,_af troleandomycin_af ,_af clarithromycin_af ,_af ritonavir_af ,_af nelfinavir)_af approached_af caution_af ._af"
242,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,troleandomycin,advise,"Consequently_bf ,_bf concomitant_bf administration_bf DRUG strong_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be nefazodone_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af ritonavir_af ,_af nelfinavir)_af approached_af caution_af ._af"
243,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,clarithromycin,advise,"Consequently_bf ,_bf concomitant_bf administration_bf DRUG strong_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be nefazodone_be ,_be troleandomycin_be ,_be OTHER_DRUG ,_af ritonavir_af ,_af nelfinavir)_af approached_af caution_af ._af"
244,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,ritonavir,advise,"Consequently_bf ,_bf concomitant_bf administration_bf DRUG strong_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be nefazodone_be ,_be troleandomycin_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af nelfinavir)_af approached_af caution_af ._af"
245,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,nelfinavir,advise,"Consequently_bf ,_bf concomitant_bf administration_bf DRUG strong_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be nefazodone_be ,_be troleandomycin_be ,_be clarithromycin_be ,_be ritonavir_be ,_be nelfinavir)_be approached_be caution_be ._be"
246,"Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.",diltiazem,aprepitant,advise,"Because_bf moderate_bf CYP3A4_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf diltiazem)_bf result_bf 2-fold_bf increase_bf plasma_bf concentrations_bf OTHER_DRUG ,_be concomitant_be administration_be also_be approached_be caution_be ._be"
247,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",Aprepitant,rifampin,mechanism,"therefore_bf ,_bf coadministration_bf DRUG drugs_be strongly_be induce_be CYP3A4_be activity_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af carbamazepine_af ,_af phenytoin)_af may_af result_af reduced_af plasma_af concentrations_af DRUG may_af result_af decreased_af efficacy_af DRUG ._af"
248,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",Aprepitant,phenytoin,mechanism,"therefore_bf ,_bf coadministration_bf DRUG drugs_be strongly_be induce_be CYP3A4_be activity_be (e_be ._be g_be ._be ,_be rifampin_be ,_be carbamazepine_be ,_be phenytoin)_be may_be result_be reduced_be plasma_be concentrations_be DRUG may_af result_af decreased_af efficacy_af DRUG ._af"
249,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",Aprepitant,aprepitant,mechanism,"therefore_bf ,_bf coadministration_bf DRUG drugs_be strongly_be induce_be CYP3A4_be activity_be (e_be ._be g_be ._be ,_be rifampin_be ,_be carbamazepine_be ,_be phenytoin)_be may_be result_be reduced_be plasma_be concentrations_be DRUG may_af result_af decreased_af efficacy_af DRUG ._af"
250,"Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.",Aprepitant,ketoconazole,mechanism,"Ketoconazole:_bf When_bf single_bf 125-mg_bf dose_bf DRUG administered_be Day5_be 10-day_be regimen_be 400_be mg/day_be OTHER_DRUG ,_af strong_af CYP3A4_af inhibitor_af ,_af AUC_af DRUG increased_af approximately_af 5-fold_af mean_af terminal_af half-life_af DRUG increased_af approximately_af 3-fold_af ._af"
251,"Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.",Aprepitant,rifampin,mechanism,"Rifampin:_bf When_bf single_bf 375-mg_bf dose_bf DRUG administered_be Day9_be 14-day_be regimen_be 600_be mg/day_be OTHER_DRUG ,_af strong_af CYP3A4_af inducer_af ,_af AUC_af DRUG decreased_af approximately_af 11-fold_af mean_af terminal_af half-life_af decreased_af approximately_af 3-fold_af ._af"
252,"Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.",aprepitant,diltiazem,mechanism,"Diltiazem:_bf In_bf patients_bf mild_bf moderate_bf hypertension_bf ,_bf administration_bf DRUG daily_be ,_be tablet_be formulation_be comparable_be 230_be mg_be capsule_be formulation_be ,_be OTHER_DRUG 120_af mg_af 3_af times_af daily_af 5_af days_af ,_af resulted_af 2-fold_af increase_af DRUG AUC_af simultaneous_af 1_af ._af 7-fold_af increase_af OTHER_DRUG AUC_af ._af"
253,"Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.",aprepitant,paroxetine,mechanism,"Paroxetine:_bf Coadministration_bf daily_bf doses_bf DRUG ,_be tablet_be formulation_be comparable_be 85_be mg_be 170_be mg_be capsule_be formulation_be ,_be OTHER_DRUG 20_af mg_af daily_af ,_af resulted_af decrease_af AUC_af approximately_af 25%_af Cmax_af ,_af approximately_af 20%_af DRUG OTHER_DRUG ._af"
254,"However, the concomitant use of Argatroban and warfarin (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).",Argatroban,warfarin,effect,"However_bf ,_bf concomitant_bf use_bf DRUG OTHER_DRUG (5-7_af ._af 5_af mg_af initial_af oral_af dose_af followed_af 2_af ._af 5-6_af mg/day_af orally_af 6-10_af days)_af results_af prolongation_af prothrombin_af time_af (PT)_af International_af Normalized_af Ratio_af (INR)_af ._af"
255,"Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.",Argatroban,antiplatelet agents,effect,"Co-administration:_bf Concomitant_bf use_bf DRUG antiplatelet_be agents_be ,_be thrombolytics_be ,_be anticoagulants_be may_be increase_be risk_be bleeding_be ._be"
256,"Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.",Argatroban,thrombolytics,effect,"Co-administration:_bf Concomitant_bf use_bf DRUG antiplatelet_be agents_be ,_be OTHER_DRUG ,_af anticoagulants_af may_af increase_af risk_af bleeding_af ._af"
257,"Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.",Argatroban,anticoagulants,effect,"Co-administration:_bf Concomitant_bf use_bf DRUG antiplatelet_be agents_be ,_be thrombolytics_be ,_be OTHER_DRUG may_af increase_af risk_af bleeding_af ._af"
258,"Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.",ABILIFY,centrally acting drugs,advise,"Drug-Drug_bf Interactions_bf Given_bf primary_bf CNS_bf effects_bf aripiprazole_bf ,_bf caution_bf used_bf DRUG taken_be combination_be centrally_be acting_be drugs_be alcohol_be ._be"
259,"Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.",ABILIFY,alcohol,advise,"Drug-Drug_bf Interactions_bf Given_bf primary_bf CNS_bf effects_bf aripiprazole_bf ,_bf caution_bf used_bf DRUG taken_be combination_be centrally_be acting_be drugs_be OTHER_DRUG ._af"
260,"1- adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.",aripiprazole,antihypertensive agents,effect,"1-_bf adrenergic_bf receptor_bf antagonism_bf ,_bf DRUG potential_be enhance_be effect_be certain_be antihypertensive_be agents_be ._be"
261,"Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.",carbamazepine,aripiprazole,mechanism,"Agents_bf induce_bf CYP3A4_bf (eg_bf ,_bf carbamazepine)_bf could_bf cause_bf increase_bf OTHER_DRUG clearance_be lower_be blood_be levels_be ._be"
262,"Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",ketoconazole,aripiprazole,mechanism,"Inhibitors_bf CYP3A4_bf (eg_bf ,_bf ketoconazole)_bf CYP2D6_bf (eg_bf ,_bf quinidine_bf ,_bf fluoxetine_bf ,_bf paroxetine)_bf inhibit_bf OTHER_DRUG elimination_be cause_be increased_be blood_be levels_be ._be"
263,"Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",quinidine,aripiprazole,mechanism,"Inhibitors_bf CYP3A4_bf (eg_bf ,_bf ketoconazole)_bf CYP2D6_bf (eg_bf ,_bf DRUG ,_be fluoxetine_be ,_be paroxetine)_be inhibit_be OTHER_DRUG elimination_af cause_af increased_af blood_af levels_af ._af"
264,"Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",fluoxetine,aripiprazole,mechanism,"Inhibitors_bf CYP3A4_bf (eg_bf ,_bf ketoconazole)_bf CYP2D6_bf (eg_bf ,_bf quinidine_bf ,_bf DRUG ,_be paroxetine)_be inhibit_be OTHER_DRUG elimination_af cause_af increased_af blood_af levels_af ._af"
265,"Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",paroxetine,aripiprazole,mechanism,"Inhibitors_bf CYP3A4_bf (eg_bf ,_bf ketoconazole)_bf CYP2D6_bf (eg_bf ,_bf quinidine_bf ,_bf fluoxetine_bf ,_bf paroxetine)_bf inhibit_bf OTHER_DRUG elimination_be cause_be increased_be blood_be levels_be ._be"
266,"Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.",ketoconazole,aripiprazole,mechanism,"Ketoconazole:_bf Coadministration_bf DRUG (200_be mg/day_be 14_be days)_be 15-mg_be single_be dose_be OTHER_DRUG increased_af AUC_af OTHER_DRUG active_af metabolite_af 63%_af 77%_af ,_af respectively_af ._af"
267,"When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.",ketoconazole,aripiprazole,advise,"When_bf concomitant_bf administration_bf DRUG OTHER_DRUG occurs_af ,_af OTHER_DRUG dose_af reduced_af one-half_af normal_af dose_af ._af"
268,"Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.",aripiprazole,quinidine,mechanism,"Quinidine:_bf Coadministration_bf 10-mg_bf single_bf dose_bf DRUG OTHER_DRUG (166_af mg/day_af 13_af days)_af ,_af potent_af inhibitor_af CYP2D6_af ,_af increased_af AUC_af DRUG 112%_af decreased_af AUC_af active_af metabolite_af ,_af dehydroaripiprazole_af ,_af 35%_af ._af"
269,Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.,quinidine,aripiprazole,advise,OTHER_DRUG dose_be reduced_be one-half_be normal_be dose_be concomitant_be administration_be DRUG OTHER_DRUG occurs_af ._af
270,"Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.",carbamazepine,aripiprazole,mechanism,"Carbamazepine:_bf Coadministration_bf DRUG (200_be mg_be BID)_be ,_be potent_be CYP3A4_be inducer_be ,_be OTHER_DRUG (30_af mg_af QD)_af resulted_af approximate_af 70%_af decrease_af Cmax_af AUC_af values_af OTHER_DRUG active_af metabolite_af ,_af dehydro-aripiprazole_af ._af"
271,"When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.",carbamazepine,aripiprazole,advise,"When_bf DRUG added_be OTHER_DRUG therapy_af ,_af OTHER_DRUG dose_af doubled_af ._af"
272,"When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.",carbamazepine,aripiprazole,advise,"When_bf DRUG withdrawn_be combination_be therapy_be ,_be OTHER_DRUG dose_af reduced_af ._af"
273,"As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY",alcohol,ABILIFY,advise,"As_bf psychoactive_bf medications_bf ,_bf patients_bf advised_bf avoid_bf DRUG taking_be OTHER_DRUG"
274,Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).,TRISENOX,antiarrhythmics,advise,Caution_bf advised_bf DRUG coadministered_be medications_be prolong_be QT_be interval_be (e_be ._be g_be ._be certain_be OTHER_DRUG thioridazine)_af lead_af electrolyte_af abnormalities_af (such_af diuretics_af amphotericin_af B)_af ._af
275,Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).,TRISENOX,thioridazine,advise,Caution_bf advised_bf DRUG coadministered_be medications_be prolong_be QT_be interval_be (e_be ._be g_be ._be certain_be antiarrhythmics_be thioridazine)_be lead_be electrolyte_be abnormalities_be (such_be diuretics_be amphotericin_be B)_be ._be
276,Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).,TRISENOX,diuretics,advise,Caution_bf advised_bf DRUG coadministered_be medications_be prolong_be QT_be interval_be (e_be ._be g_be ._be certain_be antiarrhythmics_be thioridazine)_be lead_be electrolyte_be abnormalities_be (such_be OTHER_DRUG amphotericin_af B)_af ._af
277,Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).,TRISENOX,amphotericin B,advise,Caution_bf advised_bf DRUG coadministered_be medications_be prolong_be QT_be interval_be (e_be ._be g_be ._be certain_be antiarrhythmics_be thioridazine)_be lead_be electrolyte_be abnormalities_be (such_be diuretics_be amphotericin_be B)_be ._be
278,Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.,ELSPAR,methotrexate,effect,Tissue_bf culture_bf animal_bf studies_bf indicate_bf DRUG diminish_be abolish_be effect_be OTHER_DRUG malignant_af cells_af ._af 14_af This_af effect_af OTHER_DRUG activity_af persists_af long_af plasma_af asparagine_af levels_af suppressed_af ._af
279,"These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.",methotrexate,ELSPAR,advise,"These_bf results_bf would_bf seem_bf dictate_bf clinical_bf use_bf DRUG OTHER_DRUG ,_af period_af following_af OTHER_DRUG therapy_af plasma_af asparagine_af levels_af normal_af ._af"
280,"Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.",Aspirin,probenecid,effect,"Uricosuric_bf Agents:_bf DRUG may_be decrease_be effects_be OTHER_DRUG ,_af sulfinpyrazone_af ,_af phenylbutazone_af ._af"
281,"Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.",Aspirin,sulfinpyrazone,effect,"Uricosuric_bf Agents:_bf DRUG may_be decrease_be effects_be probenecid_be ,_be OTHER_DRUG ,_af phenylbutazone_af ._af"
282,"Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.",Aspirin,phenylbutazone,effect,"Uricosuric_bf Agents:_bf DRUG may_be decrease_be effects_be probenecid_be ,_be sulfinpyrazone_be ,_be OTHER_DRUG ._af"
283,Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.,Alcohol,aspirin,effect,Alcohol:_bf Has_bf synergistic_bf effect_bf OTHER_DRUG causing_be gastrointestinal_be bleeding_be ._be
284,Corticosteroids: Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels.,Corticosteroids,aspirin,effect,Corticosteroids:_bf Concomitant_bf administration_bf OTHER_DRUG may_be increase_be risk_be gastrointestinal_be ulceration_be may_be reduce_be serum_be salicylate_be levels_be ._be
285,"Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.",Pyrazolone Derivatives,aspirin,effect,"Pyrazolone_bf Derivatives_bf (phenylbutazone_bf ,_bf oxyphenbutazone_bf ,_bf possibly_bf dipyrone):_bf Concomitant_bf administration_bf OTHER_DRUG may_be increase_be risk_be gastrointestinal_be ulceration_be ._be"
286,"Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.",phenylbutazone,aspirin,effect,"Pyrazolone_bf Derivatives_bf (phenylbutazone_bf ,_bf oxyphenbutazone_bf ,_bf possibly_bf dipyrone):_bf Concomitant_bf administration_bf OTHER_DRUG may_be increase_be risk_be gastrointestinal_be ulceration_be ._be"
287,"Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.",oxyphenbutazone,aspirin,effect,"Pyrazolone_bf Derivatives_bf (phenylbutazone_bf ,_bf DRUG ,_be possibly_be dipyrone):_be Concomitant_be administration_be OTHER_DRUG may_af increase_af risk_af gastrointestinal_af ulceration_af ._af"
288,"Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.",dipyrone,aspirin,effect,"Pyrazolone_bf Derivatives_bf (phenylbutazone_bf ,_bf oxyphenbutazone_bf ,_bf possibly_bf dipyrone):_bf Concomitant_bf administration_bf OTHER_DRUG may_be increase_be risk_be gastrointestinal_be ulceration_be ._be"
289,Nonsteroidal Antiinflammatory Agents: Aspirin is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.,Aspirin,nonsteroidal anti-inflammatory,advise,Nonsteroidal_bf Antiinflammatory_bf Agents:_bf DRUG contraindicated_be patients_be hypersensitive_be nonsteroidal_be anti-inflammatory_be agents_be ._be
290,Phenobarbital: Decreases aspirin effectiveness by enzyme induction.,Phenobarbital,aspirin,mechanism,Phenobarbital:_bf Decreases_bf OTHER_DRUG effectiveness_be enzyme_be induction_be ._be
291,Phenytoin: Serum phenytoin levels may be increased by aspirin.,phenytoin,aspirin,effect,Phenytoin:_bf Serum_bf DRUG levels_be may_be increased_be OTHER_DRUG ._af
292,Propranolol: May decrease aspirins anti-inflammatory action by competing for the same receptors.,Propranolol,aspirins,effect,Propranolol:_bf May_bf decrease_bf OTHER_DRUG anti-inflammatory_be action_be competing_be receptors_be ._be
293,"Antacids: Enteric Coated Aspirin should not be given concurrently with antacids, since an increase in the pH of the stomach may effect the enteric coating of the tablets.",Aspirin,antacids,advise,"Antacids:_bf Enteric_bf Coated_bf DRUG given_be concurrently_be OTHER_DRUG ,_af since_af increase_af pH_af stomach_af may_af effect_af enteric_af coating_af tablets_af ._af"
294,"Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with beta-blocking agents.",reserpine,beta-blocking agent,effect,"Catecholamine-depleting_bf drugs_bf (eg_bf ,_bf reserpine)_bf may_bf additive_bf effect_bf given_bf beta-blocking_bf agents_bf ._bf"
295,Calcium channel blockers may also have an additive effect when given with TENORMIN .,Calcium channel blockers,TENORMIN,effect,Calcium_bf channel_bf blockers_bf may_bf also_bf additive_bf effect_bf given_bf OTHER_DRUG ._be
296,Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine.,Beta blockers,clonidine,effect,Beta_bf blockers_bf may_bf exacerbate_bf rebound_bf hypertension_bf follow_bf withdrawal_bf OTHER_DRUG ._be
297,"If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine.",beta blocker,clonidine,advise,"If_bf two_bf drugs_bf coadministered_bf ,_bf beta_bf blocker_bf withdrawn_bf several_bf days_bf gradual_bf withdrawal_bf OTHER_DRUG ._be"
298,"If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.",beta blockers,clonidine,advise,"If_bf replacing_bf OTHER_DRUG beta-blocker_be therapy_be ,_be introduction_be beta_be blockers_be delayed_be several_be days_be OTHER_DRUG administration_af stopped_af ._af"
299,"Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin, may decrease the hypotensive effects of beta blockers.",indomethacin,beta blockers,effect,"Concomitant_bf use_bf prostaglandin_bf synthase_bf inhibiting_bf drugs_bf ,_bf eg_bf ,_bf DRUG ,_be may_be decrease_be hypotensive_be effects_be beta_be blockers_be ._be"
300,MAO inhibitors prolong and intensify the effects of antihistamines.,MAO inhibitors,antihistamines,effect,MAO_bf inhibitors_bf prolong_bf intensify_bf effects_bf OTHER_DRUG ._be
301,"Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",antihistamines,alcohol,effect,"Concomitant_bf use_bf DRUG OTHER_DRUG ,_af tricyclic_af antidepressants_af ,_af barbiturates_af ,_af central_af nervous_af system_af depressants_af may_af additive_af effect_af ._af"
302,"Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",antihistamines,tricyclic antidepressants,effect,"Concomitant_bf use_bf DRUG alcohol_be ,_be tricyclic_be antidepressants_be ,_be barbiturates_be ,_be central_be nervous_be system_be depressants_be may_be additive_be effect_be ._be"
303,"Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",antihistamines,barbiturates,effect,"Concomitant_bf use_bf DRUG alcohol_be ,_be tricyclic_be antidepressants_be ,_be OTHER_DRUG ,_af central_af nervous_af system_af depressants_af may_af additive_af effect_af ._af"
304,"Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",antihistamines,central nervous system depressants,effect,"Concomitant_bf use_bf DRUG alcohol_be ,_be tricyclic_be antidepressants_be ,_be barbiturates_be ,_be central_be nervous_be system_be depressants_be may_be additive_be effect_be ._be"
305,"When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur.",sympathomimetic drugs,monoamine oxidase inhibitors,effect,"When_bf sympathomimetic_bf drugs_bf given_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf ,_bf hypertensive_bf reactions_bf ,_bf including_bf hypertensive_bf crises_bf ,_bf may_bf occur_bf ._bf"
306,"The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.",methyldopa,sympathomimetics,effect,"The_bf antihypertensive_bf effects_bf DRUG ,_be mecamylamine_be ,_be reserpine_be ,_be veratrum_be alkaloids_be may_be reduced_be OTHER_DRUG ._af"
307,"The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.",mecamylamine,sympathomimetics,effect,"The_bf antihypertensive_bf effects_bf methyldopa_bf ,_bf DRUG ,_be reserpine_be ,_be veratrum_be alkaloids_be may_be reduced_be OTHER_DRUG ._af"
308,"The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.",reserpine,sympathomimetics,effect,"The_bf antihypertensive_bf effects_bf methyldopa_bf ,_bf mecamylamine_bf ,_bf DRUG ,_be veratrum_be alkaloids_be may_be reduced_be OTHER_DRUG ._af"
309,"The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.",veratrum alkaloids,sympathomimetics,effect,"The_bf antihypertensive_bf effects_bf methyldopa_bf ,_bf mecamylamine_bf ,_bf reserpine_bf ,_bf veratrum_bf alkaloids_bf may_bf reduced_bf OTHER_DRUG ._be"
310,Beta-adrenergic blocking agents may also interact with sympathomimetics.,Beta-adrenergic blocking agents,sympathomimetics,int,Beta-adrenergic_bf blocking_bf agents_bf may_bf also_bf interact_bf OTHER_DRUG ._be
311,Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis.,pseudoephedrine,digitalis,effect,Increased_bf ectopic_bf pacemaker_bf activity_bf occur_bf DRUG used_be concomitantly_be OTHER_DRUG ._af
312,"Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.",Antacids,pseudoephedrine,mechanism,"DRUG increase_be rate_be absorption_be OTHER_DRUG ,_af kaolin_af decreases_af ._af"
313,"Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.",pseudoephedrine,kaolin,mechanism,"Antacids_bf increase_bf rate_bf absorption_bf DRUG ,_be OTHER_DRUG decreases_af ._af"
314,Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.,azathioprine,allopurinol,mechanism,Use_bf Allopurinol:_bf The_bf principal_bf pathway_bf detoxification_bf DRUG inhibited_be OTHER_DRUG ._af
315,"Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.",azathioprine,allopurinol,advise,"Patients_bf receiving_bf DRUG OTHER_DRUG concomitantly_af dose_af reduction_af DRUG ,_af approximately_af 1/3_af 1/4_af usual_af dose_af ._af"
316,Use with Angiotensln Converting Enzyme Inhibitors: The use of angiotensin converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.,angiotensin converting enzyme inhibitors,azathioprine,effect,Use_bf Angiotensln_bf Converting_bf Enzyme_bf Inhibitors:_bf The_bf use_bf angiotensin_bf converting_bf enzyme_bf inhibitors_bf control_bf hypertension_bf patients_bf OTHER_DRUG reported_be induce_be severe_be leukopenia_be ._be
317,Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 x 600 mg tablets) results in increased azithromycin serum concentrations.,nelfinavir,azithromycin,effect,Co-administration_bf DRUG steady-state_be single_be dose_be OTHER_DRUG (2_af x_af 600_af mg_af tablets)_af results_af increased_af OTHER_DRUG serum_af concentrations_af ._af
318,"Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted.",azithromycin,nelfinavir,advise,"Although_bf dose_bf adjustment_bf DRUG recommended_be administered_be combination_be OTHER_DRUG ,_af close_af monitoring_af known_af side_af effects_af DRUG ,_af liver_af enzyme_af abnormalities_af hearing_af impairment_af ,_af warranted_af ._af"
319,"However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with azithromycin and warfarin concomitantly.",azithromycin,warfarin,advise,"However_bf ,_bf prudent_bf medical_bf practice_bf dictates_bf careful_bf monitoring_bf prothrombin_bf time_bf patients_bf treated_bf DRUG OTHER_DRUG concomitantly_af ._af"
320,Concurrent use of macrolides and warfarin in clinical practice has been associated with increased anticoagulant effects.,macrolides,warfarin,effect,Concurrent_bf use_bf DRUG OTHER_DRUG clinical_af practice_af associated_af increased_af anticoagulant_af effects_af ._af
321,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,atorvastatin,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be OTHER_DRUG ,_af carbamazepine_af ,_af cetirizine_af ,_af didanosine_af ,_af efavirenz_af ,_af fluconazole_af ,_af indinavir_af ,_af midazolam_af ,_af rifabutin_af ,_af sildenafil_af ,_af theophylline_af (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
322,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,carbamazepine,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be OTHER_DRUG ,_af cetirizine_af ,_af didanosine_af ,_af efavirenz_af ,_af fluconazole_af ,_af indinavir_af ,_af midazolam_af ,_af rifabutin_af ,_af sildenafil_af ,_af theophylline_af (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
323,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,cetirizine,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be OTHER_DRUG ,_af didanosine_af ,_af efavirenz_af ,_af fluconazole_af ,_af indinavir_af ,_af midazolam_af ,_af rifabutin_af ,_af sildenafil_af ,_af theophylline_af (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
324,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,didanosine,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be OTHER_DRUG ,_af efavirenz_af ,_af fluconazole_af ,_af indinavir_af ,_af midazolam_af ,_af rifabutin_af ,_af sildenafil_af ,_af theophylline_af (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
325,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,efavirenz,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be OTHER_DRUG ,_af fluconazole_af ,_af indinavir_af ,_af midazolam_af ,_af rifabutin_af ,_af sildenafil_af ,_af theophylline_af (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
326,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,fluconazole,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be efavirenz_be ,_be OTHER_DRUG ,_af indinavir_af ,_af midazolam_af ,_af rifabutin_af ,_af sildenafil_af ,_af theophylline_af (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
327,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,indinavir,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be efavirenz_be ,_be fluconazole_be ,_be OTHER_DRUG ,_af midazolam_af ,_af rifabutin_af ,_af sildenafil_af ,_af theophylline_af (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
328,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,midazolam,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be efavirenz_be ,_be fluconazole_be ,_be indinavir_be ,_be OTHER_DRUG ,_af rifabutin_af ,_af sildenafil_af ,_af theophylline_af (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
329,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,rifabutin,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be efavirenz_be ,_be fluconazole_be ,_be indinavir_be ,_be midazolam_be ,_be OTHER_DRUG ,_af sildenafil_af ,_af theophylline_af (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
330,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,sildenafil,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be efavirenz_be ,_be fluconazole_be ,_be indinavir_be ,_be midazolam_be ,_be rifabutin_be ,_be OTHER_DRUG ,_af theophylline_af (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
331,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,theophylline,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be efavirenz_be ,_be fluconazole_be ,_be indinavir_be ,_be midazolam_be ,_be rifabutin_be ,_be sildenafil_be ,_be OTHER_DRUG (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
332,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,triazolam,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be efavirenz_be ,_be fluconazole_be ,_be indinavir_be ,_be midazolam_be ,_be rifabutin_be ,_be sildenafil_be ,_be theophylline_be (intravenous_be oral)_be ,_be OTHER_DRUG ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
333,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,trimethoprim,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be efavirenz_be ,_be fluconazole_be ,_be indinavir_be ,_be midazolam_be ,_be rifabutin_be ,_be sildenafil_be ,_be theophylline_be (intravenous_be oral)_be ,_be triazolam_be ,_be trimethoprim/sulfamethoxazole_be zidovudine_be ._be"
334,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,sulfamethoxazole,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be efavirenz_be ,_be fluconazole_be ,_be indinavir_be ,_be midazolam_be ,_be rifabutin_be ,_be sildenafil_be ,_be theophylline_be (intravenous_be oral)_be ,_be triazolam_be ,_be trimethoprim/sulfamethoxazole_be zidovudine_be ._be"
335,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,zidovudine,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be efavirenz_be ,_be fluconazole_be ,_be indinavir_be ,_be midazolam_be ,_be rifabutin_be ,_be sildenafil_be ,_be theophylline_be (intravenous_be oral)_be ,_be triazolam_be ,_be trimethoprim/sulfamethoxazole_be OTHER_DRUG ._af"
336,Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.,efavirenz,azithromycin,mechanism,Co-administration_bf DRUG fluconazole_be modest_be effect_be pharmacokinetics_be OTHER_DRUG ._af
337,Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.,fluconazole,azithromycin,mechanism,Co-administration_bf efavirenz_bf DRUG modest_be effect_be pharmacokinetics_be OTHER_DRUG ._af
338,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,amikacin,advise,"DRUG administered_be concomitantly_be OTHER_DRUG ,_af ciprofloxacin_af ,_af gentamicin_af ,_af netilmicin_af ,_af tobramycin_af ._af"
339,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,ciprofloxacin,advise,"DRUG administered_be concomitantly_be amikacin_be ,_be OTHER_DRUG ,_af gentamicin_af ,_af netilmicin_af ,_af tobramycin_af ._af"
340,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,gentamicin,advise,"DRUG administered_be concomitantly_be amikacin_be ,_be ciprofloxacin_be ,_be OTHER_DRUG ,_af netilmicin_af ,_af tobramycin_af ._af"
341,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,netilmicin,advise,"DRUG administered_be concomitantly_be amikacin_be ,_be ciprofloxacin_be ,_be gentamicin_be ,_be OTHER_DRUG ,_af tobramycin_af ._af"
342,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,tobramycin,advise,"DRUG administered_be concomitantly_be amikacin_be ,_be ciprofloxacin_be ,_be gentamicin_be ,_be netilmicin_be ,_be OTHER_DRUG ._af"
343,Interactions attributed to the combined use of baclofen injection and epidural morphine include hypotension and dyspnea.,baclofen,morphine,effect,Interactions_bf attributed_bf combined_bf use_bf DRUG injection_be epidural_be OTHER_DRUG include_af hypotension_af dyspnea_af ._af
344,"Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.",Simulect,azathioprine,mechanism,"Total_bf body_bf clearance_bf DRUG reduced_be average_be 22%_be 51%_be OTHER_DRUG mycophenolate_af mofetil_af ,_af respectively_af ,_af added_af regimen_af consisting_af cyclosporine_af ,_af USP_af (MODIFIED)_af corticosteroids_af ._af"
345,"Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.",Simulect,mycophenolate mofetil,mechanism,"Total_bf body_bf clearance_bf DRUG reduced_be average_be 22%_be 51%_be azathioprine_be mycophenolate_be mofetil_be ,_be respectively_be ,_be added_be regimen_be consisting_be cyclosporine_be ,_be USP_be (MODIFIED)_be corticosteroids_be ._be"
346,"Diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Lotensin.",diuretics,Lotensin,effect,"Diuretics:_bf Patients_bf DRUG ,_be especially_be diuretic_be therapy_be recently_be instituted_be ,_be may_be occasionally_be experience_be excessive_be reduction_be blood_be pressure_be initiation_be therapy_be OTHER_DRUG ._af"
347,The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin.,diuretic,Lotensin,advise,The_bf possibility_bf hypotensive_bf effects_bf OTHER_DRUG minimized_be either_be discontinuing_be DRUG increasing_af salt_af intake_af prior_af initiation_af treatment_af OTHER_DRUG ._af
348,Potassium Supplements and Potassium-Sparing Diuretics Lotensin can attenuate potassium loss caused by thiazide diuretics.,Potassium-Sparing Diuretics,thiazide diuretics,effect,Potassium_bf Supplements_bf Potassium-Sparing_bf Diuretics_bf Lotensin_bf attenuate_bf potassium_bf loss_bf caused_bf thiazide_bf diuretics_bf ._bf
349,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.,ACE inhibitors,lithium,mechanism,Lithium:_bf Increased_bf serum_bf OTHER_DRUG levels_be symptoms_be OTHER_DRUG toxicity_af reported_af patients_af receiving_af ACE_af inhibitors_af therapy_af OTHER_DRUG ._af
350,"If a diuretic is also used, the risk of lithium toxicity may be increased.",diuretic,lithium,effect,"If_bf DRUG also_be used_be ,_be risk_be OTHER_DRUG toxicity_af may_af increased_af ._af"
351,"Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system",Benazepril,beta-adrenergic blockers,effect,"DRUG ,_be like_be ACE_be inhibitors_be ,_be less_be additive_be effects_be beta-adrenergic_be blockers_be ,_be presumably_be drugs_be lower_be blood_be pressure_be inhibiting_be parts_be renin-angiotensin_be system_be"
352,"Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system",ACE inhibitors,beta-adrenergic blockers,effect,"Benazepril_bf ,_bf like_bf ACE_bf inhibitors_bf ,_bf less_bf additive_bf effects_bf beta-adrenergic_bf blockers_bf ,_bf presumably_bf drugs_bf lower_bf blood_bf pressure_bf inhibiting_bf parts_bf renin-angiotensin_bf system_bf"
353,"May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;",cholestyramine,thiazide diuretics,effect,"May_bf interact_bf following:_bf DRUG ,_be colestipol_be (use_be thiazide_be diuretics_be may_be prevent_be diuretic_be working_be properly;_be"
354,"May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;",colestipol,thiazide diuretics,effect,"May_bf interact_bf following:_bf cholestyramine_bf ,_bf DRUG (use_be thiazide_be diuretics_be may_be prevent_be diuretic_be working_be properly;_be"
355,Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly within14 days following use of monoamine oxidase inhibitors.,sympathomimetic amines,monoamine oxidase inhibitors,effect,Hypertensive_bf crises_bf resulted_bf sympathomimetic_bf amines_bf used_bf concomitantly_bf within14_bf days_bf following_bf use_bf monoamine_bf oxidase_bf inhibitors_bf ._bf
356,DIDREX should not be used concomitantly with other CNS stimulants.,DIDREX,CNS stimulants,advise,DRUG used_be concomitantly_be CNS_be stimulants_be ._be
357,Amphetamines may decrease the hypotensive effect of antihypertensives.,Amphetamines,antihypertensives,effect,DRUG may_be decrease_be hypotensive_be effect_be OTHER_DRUG ._af
358,Amphetamines may enhance the effects of tricyclic antidepressants.,Amphetamines,tricyclic antidepressants,effect,DRUG may_be enhance_be effects_be tricyclic_be antidepressants_be ._be
359,Urinary acidifying agents decrease blood levels and increase excretion of amphetamines.,Urinary acidifying,amphetamines,mechanism,Urinary_bf acidifying_bf agents_bf decrease_bf blood_bf levels_bf increase_bf excretion_bf OTHER_DRUG ._be
360,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,alcohol,int,"DRUG may_be interact_be OTHER_DRUG ,_af blood_af thinners_af ,_af decongestant_af drugs_af (allergy_af ,_af cold_af ,_af sinus_af medicines)_af ,_af diabetic_af drugs_af ,_af lithium_af ,_af norepinephrine_af ,_af NSAIDs_af like_af Aleve_af Ibuprofen_af ,_af high_af blood_af pressure_af medications_af ._af"
361,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,blood thinner,int,"DRUG may_be interact_be alcohol_be ,_be blood_be thinners_be ,_be decongestant_be drugs_be (allergy_be ,_be cold_be ,_be sinus_be medicines)_be ,_be diabetic_be drugs_be ,_be lithium_be ,_be norepinephrine_be ,_be NSAIDs_be like_be Aleve_be Ibuprofen_be ,_be high_be blood_be pressure_be medications_be ._be"
362,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,decongestant drugs,int,"DRUG may_be interact_be alcohol_be ,_be blood_be thinners_be ,_be decongestant_be drugs_be (allergy_be ,_be cold_be ,_be sinus_be medicines)_be ,_be diabetic_be drugs_be ,_be lithium_be ,_be norepinephrine_be ,_be NSAIDs_be like_be Aleve_be Ibuprofen_be ,_be high_be blood_be pressure_be medications_be ._be"
363,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,lithium,int,"DRUG may_be interact_be alcohol_be ,_be blood_be thinners_be ,_be decongestant_be drugs_be (allergy_be ,_be cold_be ,_be sinus_be medicines)_be ,_be diabetic_be drugs_be ,_be OTHER_DRUG ,_af norepinephrine_af ,_af NSAIDs_af like_af Aleve_af Ibuprofen_af ,_af high_af blood_af pressure_af medications_af ._af"
364,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,norepinephrine,int,"DRUG may_be interact_be alcohol_be ,_be blood_be thinners_be ,_be decongestant_be drugs_be (allergy_be ,_be cold_be ,_be sinus_be medicines)_be ,_be diabetic_be drugs_be ,_be lithium_be ,_be OTHER_DRUG ,_af NSAIDs_af like_af Aleve_af Ibuprofen_af ,_af high_af blood_af pressure_af medications_af ._af"
365,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,NSAIDs,int,"DRUG may_be interact_be alcohol_be ,_be blood_be thinners_be ,_be decongestant_be drugs_be (allergy_be ,_be cold_be ,_be sinus_be medicines)_be ,_be diabetic_be drugs_be ,_be lithium_be ,_be norepinephrine_be ,_be OTHER_DRUG like_af Aleve_af Ibuprofen_af ,_af high_af blood_af pressure_af medications_af ._af"
366,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,Aleve,int,"DRUG may_be interact_be alcohol_be ,_be blood_be thinners_be ,_be decongestant_be drugs_be (allergy_be ,_be cold_be ,_be sinus_be medicines)_be ,_be diabetic_be drugs_be ,_be lithium_be ,_be norepinephrine_be ,_be NSAIDs_be like_be OTHER_DRUG Ibuprofen_af ,_af high_af blood_af pressure_af medications_af ._af"
367,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,Ibuprofen,int,"DRUG may_be interact_be alcohol_be ,_be blood_be thinners_be ,_be decongestant_be drugs_be (allergy_be ,_be cold_be ,_be sinus_be medicines)_be ,_be diabetic_be drugs_be ,_be lithium_be ,_be norepinephrine_be ,_be NSAIDs_be like_be Aleve_be OTHER_DRUG ,_af high_af blood_af pressure_af medications_af ._af"
368,"Digoxin: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.",bepridil hydrochloride,digoxin,mechanism,"Digoxin:_bf In_bf controlled_bf studies_bf healthy_bf volunteers_bf ,_bf bepridil_bf hydrochloride_bf either_bf effect_bf (one_bf study)_bf associated_bf modest_bf increases_bf ,_bf 30%_bf (two_bf studies)_bf steady-state_bf serum_bf OTHER_DRUG concentrations_be ._be"
369,Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.,Anti-arrhythmics,bepridil hydrochloride,effect,DRUG tricyclic_be anti-depressants_be could_be exaggerate_be prolongation_be QT_be interval_be observed_be bepridil_be hydrochloride_be ._be
370,Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.,tricyclic anti-depressants,bepridil hydrochloride,effect,Anti-arrhythmics_bf tricyclic_bf anti-depressants_bf could_bf exaggerate_bf prolongation_bf QT_bf interval_bf observed_bf bepridil_bf hydrochloride_bf ._bf
371,Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.,Cardiac glycosides,bepridil hydrochloride,effect,Cardiac_bf glycosides_bf could_bf exaggerate_bf depression_bf AV_bf nodal_bf conduction_bf observed_bf bepridil_bf hydrochloride_bf ._bf
372,"Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.",reserpine,beta-blocking,effect,"Catecholamine-depleting_bf drugs_bf (e_bf ._bf g_bf ._bf ,_bf reserpine)_bf may_bf additive_bf effect_bf given_bf OTHER_DRUG agents_be ._be"
373,"Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.",beta-blockers,clonidine,advise,"Should_bf decided_bf discontinue_bf therapy_bf patients_bf receiving_bf DRUG OTHER_DRUG concurrently_af ,_af beta-blocker_af discontinued_af slowly_af several_af days_af gradual_af withdrawal_af OTHER_DRUG ._af"
374,"Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.",beta-blocker,clonidine,advise,"Should_bf decided_bf discontinue_bf therapy_bf patients_bf receiving_bf beta-blockers_bf OTHER_DRUG concurrently_be ,_be DRUG discontinued_af slowly_af several_af days_af gradual_af withdrawal_af OTHER_DRUG ._af"
375,"Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function.",calcium antagonists,beta-adrenergic blocking agents,advise,"Literature_bf reports_bf suggest_bf oral_bf calcium_bf antagonists_bf may_bf used_bf combination_bf beta-adrenergic_bf blocking_bf agents_bf heart_bf function_bf normal_bf ,_bf avoided_bf patients_bf impaired_bf cardiac_bf function_bf ._bf"
376,"Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving beta-adrenergic blocking agents when an oral calcium antagonist was added to the treatment regimen.",beta-adrenergic blocking agents,calcium antagonist,effect,"Hypotension_bf ,_bf AV_bf conduction_bf disturbances_bf ,_bf left_bf ventricular_bf failure_bf reported_bf patients_bf receiving_bf beta-adrenergic_bf blocking_bf agents_bf oral_bf calcium_bf antagonist_bf added_bf treatment_bf regimen_bf ._bf"
377,"Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.",beta-blockers,epinephrine,effect,"Risk_bf Anaphylactic_bf Reaction:_bf Although_bf known_bf patients_bf DRUG may_be refractory_be OTHER_DRUG treatment_af anaphylactic_af shock_af ,_af DRUG ,_af addition_af ,_af interfere_af modulation_af allergic_af reaction_af lead_af increased_af severity_af and/or_af frequency_af attacks_af ._af"
378,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",ketoconazole,bexarotene,mechanism,"On_bf basis_bf metabolism_bf OTHER_DRUG cytochrome_be P450_be 3A4_be ,_be DRUG ,_af itraconazole_af ,_af erythromycin_af ,_af gemfibrozil_af ,_af grapefruit_af juice_af ,_af inhibitors_af cytochrome_af P450_af 3A4_af would_af expected_af lead_af increase_af plasma_af OTHER_DRUG concentrations_af ._af"
379,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",itraconazole,bexarotene,mechanism,"On_bf basis_bf metabolism_bf OTHER_DRUG cytochrome_be P450_be 3A4_be ,_be ketoconazole_be ,_be DRUG ,_af erythromycin_af ,_af gemfibrozil_af ,_af grapefruit_af juice_af ,_af inhibitors_af cytochrome_af P450_af 3A4_af would_af expected_af lead_af increase_af plasma_af OTHER_DRUG concentrations_af ._af"
380,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",erythromycin,bexarotene,mechanism,"On_bf basis_bf metabolism_bf OTHER_DRUG cytochrome_be P450_be 3A4_be ,_be ketoconazole_be ,_be itraconazole_be ,_be DRUG ,_af gemfibrozil_af ,_af grapefruit_af juice_af ,_af inhibitors_af cytochrome_af P450_af 3A4_af would_af expected_af lead_af increase_af plasma_af OTHER_DRUG concentrations_af ._af"
381,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",gemfibrozil,bexarotene,mechanism,"On_bf basis_bf metabolism_bf OTHER_DRUG cytochrome_be P450_be 3A4_be ,_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be DRUG ,_af grapefruit_af juice_af ,_af inhibitors_af cytochrome_af P450_af 3A4_af would_af expected_af lead_af increase_af plasma_af OTHER_DRUG concentrations_af ._af"
382,"Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.",rifampin,bexarotene,mechanism,"Furthermore_bf ,_bf DRUG ,_be phenytoin_be ,_be phenobarbital_be ,_be inducers_be cytochrome_be P450_be 3A4_be may_be cause_be reduction_be plasma_be OTHER_DRUG concentrations_af ._af"
383,"Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.",phenytoin,bexarotene,mechanism,"Furthermore_bf ,_bf rifampin_bf ,_bf DRUG ,_be phenobarbital_be ,_be inducers_be cytochrome_be P450_be 3A4_be may_be cause_be reduction_be plasma_be OTHER_DRUG concentrations_af ._af"
384,"Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.",phenobarbital,bexarotene,mechanism,"Furthermore_bf ,_bf rifampin_bf ,_bf phenytoin_bf ,_bf DRUG ,_be inducers_be cytochrome_be P450_be 3A4_be may_be cause_be reduction_be plasma_be OTHER_DRUG concentrations_af ._af"
385,"Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.",Targretin,gemfibrozil,mechanism,"Concomitant_bf administration_bf DRUG capsules_be OTHER_DRUG resulted_af substantial_af increases_af plasma_af concentrations_af bexarotene_af ,_af probably_af least_af partially_af related_af cytochrome_af P450_af 3A4_af inhibition_af OTHER_DRUG ._af"
386,Concomitant administration of gemfibrozil with Targretin capsules is not recommended.,gemfibrozil,Targretin,advise,Concomitant_bf administration_bf DRUG OTHER_DRUG capsules_af recommended_af ._af
387,When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.,Bezalip,anticoagulants of the coumarin type,effect,When_bf DRUG DRUG retard_af used_af time_af medicines_af substances_af following_af interactions_af must_af taken_af account:_af -_af DRUG DRUG retard_af may_af enhance_af action_af anticoagulants_af coumarin_af type_af ._af
388,When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.,Bezalip retard,anticoagulants of the coumarin type,effect,When_bf Bezalip_bf Bezalip_bf retard_bf used_bf time_bf medicines_bf substances_bf following_bf interactions_bf must_bf taken_bf account:_bf -_bf Bezalip_bf Bezalip_bf retard_bf may_bf enhance_bf action_bf anticoagulants_bf coumarin_bf type_bf ._bf
389,"For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters",anticoagulant,Bezalip,advise,"For_bf reason_bf ,_bf dose_bf DRUG reduced_be 30_be -_be 50%_be start_be treatment_be OTHER_DRUG OTHER_DRUG retard_af titrated_af according_af blood_af clotting_af parameters_af"
390,"For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters",anticoagulant,Bezalip,advise,"For_bf reason_bf ,_bf dose_bf DRUG reduced_be 30_be -_be 50%_be start_be treatment_be OTHER_DRUG OTHER_DRUG retard_af titrated_af according_af blood_af clotting_af parameters_af"
391,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.,sulphonylureas,Bezalip,effect,-_bf The_bf action_bf DRUG insulin_be may_be enhanced_be OTHER_DRUG OTHER_DRUG retard_af ._af
392,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.,sulphonylureas,Bezalip retard,effect,-_bf The_bf action_bf DRUG insulin_be may_be enhanced_be Bezalip_be Bezalip_be retard_be ._be
393,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.,insulin,Bezalip,effect,-_bf The_bf action_bf sulphonylureas_bf DRUG may_be enhanced_be OTHER_DRUG OTHER_DRUG retard_af ._af
394,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.,insulin,Bezalip retard,effect,-_bf The_bf action_bf sulphonylureas_bf DRUG may_be enhanced_be Bezalip_be Bezalip_be retard_be ._be
395,"- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving immuno-suppressant therapy and concomitant bezafibrate.",immuno-suppressant,bezafibrate,effect,"-_bf In_bf isolated_bf cases_bf ,_bf pronounced_bf though_bf reversible_bf ,_bf impairment_bf renal_bf function_bf (accompanied_bf corresponding_bf increase_bf serum_bf creatinine_bf level)_bf reported_bf organ_bf transplant_bf patients_bf receiving_bf DRUG therapy_be concomitant_be OTHER_DRUG ._af"
396,"- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired",Bezalip,anion-exchange resins,advise,"-_bf When_bf DRUG DRUG retard_af used_af concurrently_af anion-exchange_af resins_af (e_af ._af g_af ._af cholestryramine)_af ,_af interval_af least_af 2_af hours_af maintained_af two_af medicines_af ,_af since_af absorption_af DRUG DRUG retard_af impaired_af"
397,"- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired",Bezalip,cholestryramine,advise,"-_bf When_bf DRUG DRUG retard_af used_af concurrently_af anion-exchange_af resins_af (e_af ._af g_af ._af cholestryramine)_af ,_af interval_af least_af 2_af hours_af maintained_af two_af medicines_af ,_af since_af absorption_af DRUG DRUG retard_af impaired_af"
398,"- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired",Bezalip retard,anion-exchange resins,advise,"-_bf When_bf Bezalip_bf Bezalip_bf retard_bf used_bf concurrently_bf anion-exchange_bf resins_bf (e_bf ._bf g_bf ._bf cholestryramine)_bf ,_bf interval_bf least_bf 2_bf hours_bf maintained_bf two_bf medicines_bf ,_bf since_bf absorption_bf Bezalip_bf Bezalip_bf retard_bf impaired_bf"
399,"- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired",Bezalip retard,cholestryramine,advise,"-_bf When_bf Bezalip_bf Bezalip_bf retard_bf used_bf concurrently_bf anion-exchange_bf resins_bf (e_bf ._bf g_bf ._bf cholestryramine)_bf ,_bf interval_bf least_bf 2_bf hours_bf maintained_bf two_bf medicines_bf ,_bf since_bf absorption_bf Bezalip_bf Bezalip_bf retard_bf impaired_bf"
400,- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.,Perhexiline hydrogen maleate,Bezalip,advise,-_bf Perhexiline_bf hydrogen_bf maleate_bf MAO-inhibitors_bf (with_bf hepatotoxic_bf potential)_bf must_bf administered_bf together_bf OTHER_DRUG OTHER_DRUG retard_af ._af
401,- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.,Perhexiline hydrogen maleate,Bezalip retard,advise,-_bf Perhexiline_bf hydrogen_bf maleate_bf MAO-inhibitors_bf (with_bf hepatotoxic_bf potential)_bf must_bf administered_bf together_bf Bezalip_bf Bezalip_bf retard_bf ._bf
402,- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.,MAO-inhibitors,Bezalip,advise,-_bf Perhexiline_bf hydrogen_bf maleate_bf DRUG (with_be hepatotoxic_be potential)_be must_be administered_be together_be OTHER_DRUG OTHER_DRUG retard_af ._af
403,- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.,MAO-inhibitors,Bezalip retard,advise,-_bf Perhexiline_bf hydrogen_bf maleate_bf DRUG (with_be hepatotoxic_be potential)_be must_be administered_be together_be Bezalip_be Bezalip_be retard_be ._be
404,"In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.",CASODEX,coumarin anticoagulant,mechanism,"In_bf vitro_bf studies_bf shown_bf DRUG displace_be coumarin_be anticoagulants_be ,_be warfarin_be ,_be protein-binding_be sites_be ._be"
405,"In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.",CASODEX,warfarin,mechanism,"In_bf vitro_bf studies_bf shown_bf DRUG displace_be coumarin_be anticoagulants_be ,_be OTHER_DRUG ,_af protein-binding_af sites_af ._af"
406,"It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.",CASODEX,coumarin anticoagulants,advise,"It_bf recommended_bf DRUG started_be patients_be already_be receiving_be coumarin_be anticoagulants_be ,_be prothrombin_be times_be closely_be monitored_be adjustment_be anticoagulant_be dose_be may_be necessary_be ._be"
407,"It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.",CASODEX,anticoagulant,advise,"It_bf recommended_bf DRUG started_be patients_be already_be receiving_be coumarin_be anticoagulants_be ,_be prothrombin_be times_be closely_be monitored_be adjustment_be OTHER_DRUG dose_af may_af necessary_af ._af"
408,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,narcotic analgesics,effect,"Drug_bf Interactions:_bf The_bf central_bf DRUG syndrome_be occur_be DRUG agents_af AKINETON_af administered_af concomitantly_af drugs_af secondary_af DRUG actions_af ,_af ._af g_af ._af ,_af certain_af narcotic_af analgesics_af meperidine_af ,_af phenothiazines_af antipsychotics_af ,_af tricyclic_af antidepressants_af ,_af certain_af antiarrhythmics_af quinidine_af salts_af ,_af antihistamines_af ._af"
409,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,meperidine,effect,"Drug_bf Interactions:_bf The_bf central_bf DRUG syndrome_be occur_be DRUG agents_af AKINETON_af administered_af concomitantly_af drugs_af secondary_af DRUG actions_af ,_af ._af g_af ._af ,_af certain_af narcotic_af analgesics_af OTHER_DRUG ,_af phenothiazines_af antipsychotics_af ,_af tricyclic_af antidepressants_af ,_af certain_af antiarrhythmics_af quinidine_af salts_af ,_af antihistamines_af ._af"
410,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,phenothiazines,effect,"Drug_bf Interactions:_bf The_bf central_bf DRUG syndrome_be occur_be DRUG agents_af AKINETON_af administered_af concomitantly_af drugs_af secondary_af DRUG actions_af ,_af ._af g_af ._af ,_af certain_af narcotic_af analgesics_af meperidine_af ,_af OTHER_DRUG antipsychotics_af ,_af tricyclic_af antidepressants_af ,_af certain_af antiarrhythmics_af quinidine_af salts_af ,_af antihistamines_af ._af"
411,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,antipsychotics,effect,"Drug_bf Interactions:_bf The_bf central_bf DRUG syndrome_be occur_be DRUG agents_af AKINETON_af administered_af concomitantly_af drugs_af secondary_af DRUG actions_af ,_af ._af g_af ._af ,_af certain_af narcotic_af analgesics_af meperidine_af ,_af phenothiazines_af OTHER_DRUG ,_af tricyclic_af antidepressants_af ,_af certain_af antiarrhythmics_af quinidine_af salts_af ,_af antihistamines_af ._af"
412,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,tricyclic antidepressants,effect,"Drug_bf Interactions:_bf The_bf central_bf DRUG syndrome_be occur_be DRUG agents_af AKINETON_af administered_af concomitantly_af drugs_af secondary_af DRUG actions_af ,_af ._af g_af ._af ,_af certain_af narcotic_af analgesics_af meperidine_af ,_af phenothiazines_af antipsychotics_af ,_af tricyclic_af antidepressants_af ,_af certain_af antiarrhythmics_af quinidine_af salts_af ,_af antihistamines_af ._af"
413,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,antiarrhythmics,effect,"Drug_bf Interactions:_bf The_bf central_bf DRUG syndrome_be occur_be DRUG agents_af AKINETON_af administered_af concomitantly_af drugs_af secondary_af DRUG actions_af ,_af ._af g_af ._af ,_af certain_af narcotic_af analgesics_af meperidine_af ,_af phenothiazines_af antipsychotics_af ,_af tricyclic_af antidepressants_af ,_af certain_af OTHER_DRUG quinidine_af salts_af ,_af antihistamines_af ._af"
414,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,quinidine,effect,"Drug_bf Interactions:_bf The_bf central_bf DRUG syndrome_be occur_be DRUG agents_af AKINETON_af administered_af concomitantly_af drugs_af secondary_af DRUG actions_af ,_af ._af g_af ._af ,_af certain_af narcotic_af analgesics_af meperidine_af ,_af phenothiazines_af antipsychotics_af ,_af tricyclic_af antidepressants_af ,_af certain_af antiarrhythmics_af OTHER_DRUG salts_af ,_af antihistamines_af ._af"
415,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,antihistamines,effect,"Drug_bf Interactions:_bf The_bf central_bf DRUG syndrome_be occur_be DRUG agents_af AKINETON_af administered_af concomitantly_af drugs_af secondary_af DRUG actions_af ,_af ._af g_af ._af ,_af certain_af narcotic_af analgesics_af meperidine_af ,_af phenothiazines_af antipsychotics_af ,_af tricyclic_af antidepressants_af ,_af certain_af antiarrhythmics_af quinidine_af salts_af ,_af OTHER_DRUG ._af"
416,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,narcotic analgesics,effect,"Drug_bf Interactions:_bf The_bf central_bf anticholinergic_bf syndrome_bf occur_bf anticholinergic_bf agents_bf DRUG administered_be concomitantly_be drugs_be secondary_be anticholinergic_be actions_be ,_be ._be g_be ._be ,_be certain_be narcotic_be analgesics_be meperidine_be ,_be phenothiazines_be antipsychotics_be ,_be tricyclic_be antidepressants_be ,_be certain_be antiarrhythmics_be quinidine_be salts_be ,_be antihistamines_be ._be"
417,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,meperidine,effect,"Drug_bf Interactions:_bf The_bf central_bf anticholinergic_bf syndrome_bf occur_bf anticholinergic_bf agents_bf DRUG administered_be concomitantly_be drugs_be secondary_be anticholinergic_be actions_be ,_be ._be g_be ._be ,_be certain_be narcotic_be analgesics_be OTHER_DRUG ,_af phenothiazines_af antipsychotics_af ,_af tricyclic_af antidepressants_af ,_af certain_af antiarrhythmics_af quinidine_af salts_af ,_af antihistamines_af ._af"
418,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,phenothiazines,effect,"Drug_bf Interactions:_bf The_bf central_bf anticholinergic_bf syndrome_bf occur_bf anticholinergic_bf agents_bf DRUG administered_be concomitantly_be drugs_be secondary_be anticholinergic_be actions_be ,_be ._be g_be ._be ,_be certain_be narcotic_be analgesics_be meperidine_be ,_be OTHER_DRUG antipsychotics_af ,_af tricyclic_af antidepressants_af ,_af certain_af antiarrhythmics_af quinidine_af salts_af ,_af antihistamines_af ._af"
419,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,antipsychotics,effect,"Drug_bf Interactions:_bf The_bf central_bf anticholinergic_bf syndrome_bf occur_bf anticholinergic_bf agents_bf DRUG administered_be concomitantly_be drugs_be secondary_be anticholinergic_be actions_be ,_be ._be g_be ._be ,_be certain_be narcotic_be analgesics_be meperidine_be ,_be phenothiazines_be OTHER_DRUG ,_af tricyclic_af antidepressants_af ,_af certain_af antiarrhythmics_af quinidine_af salts_af ,_af antihistamines_af ._af"
420,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,tricyclic antidepressants,effect,"Drug_bf Interactions:_bf The_bf central_bf anticholinergic_bf syndrome_bf occur_bf anticholinergic_bf agents_bf DRUG administered_be concomitantly_be drugs_be secondary_be anticholinergic_be actions_be ,_be ._be g_be ._be ,_be certain_be narcotic_be analgesics_be meperidine_be ,_be phenothiazines_be antipsychotics_be ,_be tricyclic_be antidepressants_be ,_be certain_be antiarrhythmics_be quinidine_be salts_be ,_be antihistamines_be ._be"
421,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,antiarrhythmics,effect,"Drug_bf Interactions:_bf The_bf central_bf anticholinergic_bf syndrome_bf occur_bf anticholinergic_bf agents_bf DRUG administered_be concomitantly_be drugs_be secondary_be anticholinergic_be actions_be ,_be ._be g_be ._be ,_be certain_be narcotic_be analgesics_be meperidine_be ,_be phenothiazines_be antipsychotics_be ,_be tricyclic_be antidepressants_be ,_be certain_be OTHER_DRUG quinidine_af salts_af ,_af antihistamines_af ._af"
422,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,quinidine,effect,"Drug_bf Interactions:_bf The_bf central_bf anticholinergic_bf syndrome_bf occur_bf anticholinergic_bf agents_bf DRUG administered_be concomitantly_be drugs_be secondary_be anticholinergic_be actions_be ,_be ._be g_be ._be ,_be certain_be narcotic_be analgesics_be meperidine_be ,_be phenothiazines_be antipsychotics_be ,_be tricyclic_be antidepressants_be ,_be certain_be antiarrhythmics_be OTHER_DRUG salts_af ,_af antihistamines_af ._af"
423,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,antihistamines,effect,"Drug_bf Interactions:_bf The_bf central_bf anticholinergic_bf syndrome_bf occur_bf anticholinergic_bf agents_bf DRUG administered_be concomitantly_be drugs_be secondary_be anticholinergic_be actions_be ,_be ._be g_be ._be ,_be certain_be narcotic_be analgesics_be meperidine_be ,_be phenothiazines_be antipsychotics_be ,_be tricyclic_be antidepressants_be ,_be certain_be antiarrhythmics_be quinidine_be salts_be ,_be OTHER_DRUG ._af"
424,Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.,antidiabetic agents,VELCADE,advise,Patients_bf oral_bf antidiabetic_bf agents_bf receiving_bf OTHER_DRUG treatment_be may_be require_be close_be monitoring_be blood_be glucose_be levels_be adjustment_be dose_be antidiabetic_be medication_be ._be
425,"Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.",bosentan,Ortho-Novum,mechanism,"Hormonal_bf Contraceptives_bf ,_bf Including_bf Oral_bf ,_bf Injectable_bf ,_bf Transdermal_bf ,_bf Implantable_bf Contraceptives:_bf An_bf interaction_bf study_bf demonstrated_bf co-administration_bf DRUG oral_be hormonal_be contraceptive_be OTHER_DRUG produced_af average_af decreases_af norethindrone_af ethinyl_af estradiol_af levels_af 14%_af 31%_af ,_af respectively_af ._af"
426,"Therefore, hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when TRACLEER is co-administered.",hormonal contraceptives,TRACLEER,effect,"Therefore_bf ,_bf hormonal_bf contraceptives_bf ,_bf including_bf oral_bf ,_bf injectable_bf ,_bf transdermal_bf ,_bf implantable_bf forms_bf ,_bf may_bf reliable_bf OTHER_DRUG co-administered_be ._be"
427,Steady-state bosentan plasma concentrations were 3- to 4-fold higher than in the absence of cyclosporine A.,bosentan,cyclosporine A,mechanism,Steady-state_bf DRUG plasma_be concentrations_be 3-_be 4-fold_be higher_be absence_be cyclosporine_be A_be ._be
428,The concomitant administration of bosentan and cyclosporine A is contraindicated.,bosentan,cyclosporine A,advise,The_bf concomitant_bf administration_bf DRUG cyclosporine_be A_be contraindicated_be ._be
429,Co-administration of bosentan decreased the plasma concentrations of cyclosporine A (a CYP3A4 substrate) by approximately 50%.,bosentan,cyclosporine A,mechanism,Co-administration_bf DRUG decreased_be plasma_be concentrations_be cyclosporine_be A_be (a_be CYP3A4_be substrate)_be approximately_be 50%_be ._be
430,Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.,tacrolimus,bosentan,mechanism,Co-administration_bf DRUG OTHER_DRUG resulted_af markedly_af increased_af plasma_af concentrations_af OTHER_DRUG animals_af ._af
431,Caution should be exercised if tacrolimus and bosentan are used together.,tacrolimus,bosentan,advise,Caution_bf exercised_bf DRUG OTHER_DRUG used_af together_af ._af
432,"Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic agents should be considered.",TRACLEER,glyburide,advise,"Therefore_bf ,_bf concomitant_bf administration_bf DRUG OTHER_DRUG contraindicated_af ,_af alternative_af hypoglycemic_af agents_af considered_af ._af"
433,Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.,bosentan,glyburide,mechanism,Co-administration_bf DRUG decreased_be plasma_be concentrations_be OTHER_DRUG approximately_af 40%_af ._af
434,Bosentan is also expected to reduce plasma concentrations of other oral hypoglycemic agents that are predominantly metabolized by CYP2C9 or CYP3A4.,Bosentan,hypoglycemic agents,mechanism,DRUG also_be expected_be reduce_be plasma_be concentrations_be oral_be hypoglycemic_be agents_be predominantly_be metabolized_be CYP2C9_be CYP3A4_be ._be
435,"Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.",bosentan,ketoconazole,mechanism,"Ketoconazole:_bf Co-administration_bf DRUG 125_be mg_be b_be ._be ._be ._be OTHER_DRUG ,_af potent_af CYP3A4_af inhibitor_af ,_af increased_af plasma_af concentrations_af DRUG approximately_af 2-fold_af ._af"
436,"Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.",bosentan,simvastatin,mechanism,"OTHER_DRUG Other_be Statins:_be Co-administration_be DRUG decreased_af plasma_af concentrations_af OTHER_DRUG (a_af CYP3A4_af substrate)_af ,_af active_af -hydroxy_af acid_af metabolite_af ,_af approximately_af 50%_af ._af"
437,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.",Bosentan,statins,mechanism,"DRUG also_be expected_be reduce_be plasma_be concentrations_be OTHER_DRUG significant_af metabolism_af CYP3A4_af ,_af lovastatin_af atorvastatin_af ._af"
438,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.",Bosentan,lovastatin,mechanism,"DRUG also_be expected_be reduce_be plasma_be concentrations_be statins_be significant_be metabolism_be CYP3A4_be ,_be OTHER_DRUG atorvastatin_af ._af"
439,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.",Bosentan,atorvastatin,mechanism,"DRUG also_be expected_be reduce_be plasma_be concentrations_be statins_be significant_be metabolism_be CYP3A4_be ,_be lovastatin_be OTHER_DRUG ._af"
440,Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after TRACLEER is initiated to see whether the statin dose needs adjustment.,statins,TRACLEER,advise,Patients_bf using_bf CYP3A4_bf metabolized_bf DRUG cholesterol_be levels_be monitored_be OTHER_DRUG initiated_af see_af whether_af statin_af dose_af needs_af adjustment_af ._af
441,"Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.",bosentan,S-warfarin,mechanism,"Warfarin:_bf Co-administration_bf DRUG 500_be mg_be b_be ._be ._be ._be 6_be days_be decreased_be plasma_be concentrations_be OTHER_DRUG (a_af CYP2C9_af substrate)_af R-warfarin_af (a_af CYP3A4_af substrate)_af 29_af 38%_af ,_af respectively_af ._af"
442,"Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.",bosentan,R-warfarin,mechanism,"Warfarin:_bf Co-administration_bf DRUG 500_be mg_be b_be ._be ._be ._be 6_be days_be decreased_be plasma_be concentrations_be S-warfarin_be (a_be CYP2C9_be substrate)_be OTHER_DRUG (a_af CYP3A4_af substrate)_af 29_af 38%_af ,_af respectively_af ._af"
443,"Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.",BOTOX,aminoglycosides,advise,"Co-administration_bf DRUG OTHER_DRUG agents_af interfering_af neuromuscular_af transmission_af (e_af ._af g_af ._af ,_af curare-like_af compounds)_af performed_af caution_af effect_af toxin_af may_af potentiated_af ._af"
444,"Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.",BOTOX,curare-like compounds,advise,"Co-administration_bf DRUG aminoglycosides_be agents_be interfering_be neuromuscular_be transmission_be (e_be ._be g_be ._be ,_be curare-like_be compounds)_be performed_be caution_be effect_be toxin_be may_be potentiated_be ._be"
445,Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.,botulinum toxin,botulinum toxin,effect,Excessive_bf neuromuscular_bf weakness_bf may_bf exacerbated_bf administration_bf another_bf botulinum_bf toxin_bf prior_bf resolution_bf effects_bf previously_bf administered_bf botulinum_bf toxin_bf ._bf
446,"Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.",MYOBLOC,aminoglycosides,advise,"Co-administration_bf DRUG OTHER_DRUG agents_af interfering_af neuromuscular_af transmission_af (e_af ._af g_af ._af ,_af curare-like_af compounds)_af performed_af caution_af effect_af toxin_af may_af potentiated_af ._af"
447,"Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.",MYOBLOC,curare-like compounds,advise,"Co-administration_bf DRUG aminoglycosides_be agents_be interfering_be neuromuscular_be transmission_be (e_be ._be g_be ._be ,_be curare-like_be compounds)_be performed_be caution_be effect_be toxin_be may_be potentiated_be ._be"
448,Digitalis toxicity may be aggravated by the initial release of norepinephrine caused by Bretylium Tosylate Injection.,Digitalis,Bretylium Tosylate,effect,DRUG toxicity_be may_be aggravated_be initial_be release_be norepinephrine_be caused_be Bretylium_be Tosylate_be Injection_be ._be
449,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.,catecholamines,Bretylium Tosylate,effect,The_bf pressor_bf effects_bf DRUG dopamine_be norepinephrine_be enhanced_be Bretylium_be Tosylate_be ._be
450,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.,dopamine,Bretylium Tosylate,effect,The_bf pressor_bf effects_bf catecholamines_bf DRUG norepinephrine_be enhanced_be Bretylium_be Tosylate_be ._be
451,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.,norepinephrine,Bretylium Tosylate,effect,The_bf pressor_bf effects_bf catecholamines_bf dopamine_bf DRUG enhanced_be Bretylium_be Tosylate_be ._be
452,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,CNS depressants,advise,"Although_bf specific_bf drug_bf interaction_bf studies_bf conducted_bf ALPHAGAN_bf P_bf ,_bf possibility_bf additive_bf potentiating_bf effect_bf CNS_bf depressants_bf (alcohol_bf ,_bf barbiturates_bf ,_bf opiates_bf ,_bf sedatives_bf ,_bf anesthetics)_bf considered_bf ._bf"
453,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,alcohol,advise,"Although_bf specific_bf drug_bf interaction_bf studies_bf conducted_bf ALPHAGAN_bf P_bf ,_bf possibility_bf additive_bf potentiating_bf effect_bf CNS_bf depressants_bf (alcohol_bf ,_bf barbiturates_bf ,_bf opiates_bf ,_bf sedatives_bf ,_bf anesthetics)_bf considered_bf ._bf"
454,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,barbiturates,advise,"Although_bf specific_bf drug_bf interaction_bf studies_bf conducted_bf ALPHAGAN_bf P_bf ,_bf possibility_bf additive_bf potentiating_bf effect_bf CNS_bf depressants_bf (alcohol_bf ,_bf OTHER_DRUG ,_be opiates_be ,_be sedatives_be ,_be anesthetics)_be considered_be ._be"
455,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,opiates,advise,"Although_bf specific_bf drug_bf interaction_bf studies_bf conducted_bf ALPHAGAN_bf P_bf ,_bf possibility_bf additive_bf potentiating_bf effect_bf CNS_bf depressants_bf (alcohol_bf ,_bf barbiturates_bf ,_bf OTHER_DRUG ,_be sedatives_be ,_be anesthetics)_be considered_be ._be"
456,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,sedatives,advise,"Although_bf specific_bf drug_bf interaction_bf studies_bf conducted_bf ALPHAGAN_bf P_bf ,_bf possibility_bf additive_bf potentiating_bf effect_bf CNS_bf depressants_bf (alcohol_bf ,_bf barbiturates_bf ,_bf opiates_bf ,_bf OTHER_DRUG ,_be anesthetics)_be considered_be ._be"
457,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,anesthetics,advise,"Although_bf specific_bf drug_bf interaction_bf studies_bf conducted_bf ALPHAGAN_bf P_bf ,_bf possibility_bf additive_bf potentiating_bf effect_bf CNS_bf depressants_bf (alcohol_bf ,_bf barbiturates_bf ,_bf opiates_bf ,_bf sedatives_bf ,_bf anesthetics)_bf considered_bf ._bf"
458,Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.,Tricyclic antidepressants,clonidine,effect,Tricyclic_bf antidepressants_bf reported_bf blunt_bf hypotensive_bf effect_bf systemic_bf OTHER_DRUG ._be It_be known_be whether_be concurrent_be use_be agents_be ALPHAGAN_be P_be humans_be lead_be resulting_be interference_be IOP_be lowering_be effect_be ._be
459,"However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of drug interactions have occurred with high-dose salicylate therapy.",carbonic anhydrase inhibitors,salicylate,int,"However_bf ,_bf patients_bf treated_bf oral_bf carbonic_bf anhydrase_bf inhibitors_bf ,_bf rare_bf instances_bf drug_bf interactions_bf occurred_bf high-dose_bf OTHER_DRUG therapy_be ._be"
460,"The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate.",alcohol,bromocriptine mesylate,effect,"The_bf risk_bf using_bf bromocriptine_bf mesylate_bf combination_bf drugs_bf systematically_bf evaluated_bf ,_bf DRUG may_be potentiate_be side_be effects_be bromocriptine_be mesylate_be ._be"
461,"Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.",Bromocriptine mesylate,dopamine antagonists,int,"Bromocriptine_bf mesylate_bf may_bf interact_bf dopamine_bf antagonists_bf ,_bf butyrophenones_bf ,_bf certain_bf agents_bf ._bf"
462,"Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.",Bromocriptine mesylate,butyrophenones,int,"Bromocriptine_bf mesylate_bf may_bf interact_bf dopamine_bf antagonists_bf ,_bf OTHER_DRUG ,_be certain_be agents_be ._be"
463,"Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.",bromocriptine mesylate,phenothiazines,effect,"Compounds_bf categories_bf result_bf decreased_bf efficacy_bf bromocriptine_bf mesylate:_bf OTHER_DRUG ,_be haloperidol_be ,_be metoclopramide_be ,_be pimozide_be ._be"
464,"Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.",bromocriptine mesylate,haloperidol,effect,"Compounds_bf categories_bf result_bf decreased_bf efficacy_bf bromocriptine_bf mesylate:_bf phenothiazines_bf ,_bf OTHER_DRUG ,_be metoclopramide_be ,_be pimozide_be ._be"
465,"Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.",bromocriptine mesylate,metoclopramide,effect,"Compounds_bf categories_bf result_bf decreased_bf efficacy_bf bromocriptine_bf mesylate:_bf phenothiazines_bf ,_bf haloperidol_bf ,_bf OTHER_DRUG ,_be pimozide_be ._be"
466,"Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.",bromocriptine mesylate,pimozide,effect,"Compounds_bf categories_bf result_bf decreased_bf efficacy_bf bromocriptine_bf mesylate:_bf phenothiazines_bf ,_bf haloperidol_bf ,_bf metoclopramide_bf ,_bf OTHER_DRUG ._be"
467,Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.,bromocriptine mesylate,ergot alkaloids,advise,Concomitant_bf use_bf bromocriptine_bf mesylate_bf ergot_bf alkaloids_bf recommended_bf ._bf
468,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,alcohol,effect,"DRUG interact_be OTHER_DRUG CNS_af depressants_af (may_af potentiate_af CNS_af depressant_af effects_af either_af medications_af antihistamines)_af ,_af anticholinergics_af medications_af anticholinergic_af activity_af (anticholinergic_af effects_af may_af potentiated_af medications_af used_af concurrently_af antihistamines)_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af (concurrent_af use_af antihistamines_af may_af prolong_af intensify_af anticholinergic_af CNS_af depressant_af effects_af antihistamines)_af ._af"
469,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,CNS depressants,effect,"DRUG interact_be alcohol_be CNS_be depressants_be (may_be potentiate_be CNS_be depressant_be effects_be either_be medications_be antihistamines)_be ,_be anticholinergics_be medications_be anticholinergic_be activity_be (anticholinergic_be effects_be may_be potentiated_be medications_be used_be concurrently_be antihistamines)_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be (concurrent_be use_be antihistamines_be may_be prolong_be intensify_be anticholinergic_be CNS_be depressant_be effects_be antihistamines)_be ._be"
470,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,anticholinergics,effect,"DRUG interact_be alcohol_be CNS_be depressants_be (may_be potentiate_be CNS_be depressant_be effects_be either_be medications_be antihistamines)_be ,_be OTHER_DRUG medications_af anticholinergic_af activity_af (anticholinergic_af effects_af may_af potentiated_af medications_af used_af concurrently_af antihistamines)_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af (concurrent_af use_af antihistamines_af may_af prolong_af intensify_af anticholinergic_af CNS_af depressant_af effects_af antihistamines)_af ._af"
471,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,monoamine oxidase (MAO) inhibitors,effect,"DRUG interact_be alcohol_be CNS_be depressants_be (may_be potentiate_be CNS_be depressant_be effects_be either_be medications_be antihistamines)_be ,_be anticholinergics_be medications_be anticholinergic_be activity_be (anticholinergic_be effects_be may_be potentiated_be medications_be used_be concurrently_be antihistamines)_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be (concurrent_be use_be antihistamines_be may_be prolong_be intensify_be anticholinergic_be CNS_be depressant_be effects_be antihistamines)_be ._be"
472,Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide.,ketoconazole,budesonide,mechanism,Concomitant_bf oral_bf administration_bf DRUG (a_be known_be inhibitor_be CYP3A4_be activity_be liver_be intestinal_be mucosa)_be caused_be eight-fold_be increase_be systemic_be exposure_be oral_be OTHER_DRUG ._af
473,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",ketoconazole,budesonide,advise,"If_bf treatment_bf inhibitors_bf CYP3A4_bf activity_bf (such_bf DRUG ,_be intraconazole_be ,_be ritonavir_be ,_be indinavir_be ,_be saquinavir_be ,_be erythromycin_be ,_be etc_be ._be )_be indicated_be ,_be reduction_be OTHER_DRUG dose_af considered_af ._af"
474,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",intraconazole,budesonide,advise,"If_bf treatment_bf inhibitors_bf CYP3A4_bf activity_bf (such_bf ketoconazole_bf ,_bf DRUG ,_be ritonavir_be ,_be indinavir_be ,_be saquinavir_be ,_be erythromycin_be ,_be etc_be ._be )_be indicated_be ,_be reduction_be OTHER_DRUG dose_af considered_af ._af"
475,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",ritonavir,budesonide,advise,"If_bf treatment_bf inhibitors_bf CYP3A4_bf activity_bf (such_bf ketoconazole_bf ,_bf intraconazole_bf ,_bf DRUG ,_be indinavir_be ,_be saquinavir_be ,_be erythromycin_be ,_be etc_be ._be )_be indicated_be ,_be reduction_be OTHER_DRUG dose_af considered_af ._af"
476,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",indinavir,budesonide,advise,"If_bf treatment_bf inhibitors_bf CYP3A4_bf activity_bf (such_bf ketoconazole_bf ,_bf intraconazole_bf ,_bf ritonavir_bf ,_bf DRUG ,_be saquinavir_be ,_be erythromycin_be ,_be etc_be ._be )_be indicated_be ,_be reduction_be OTHER_DRUG dose_af considered_af ._af"
477,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",saquinavir,budesonide,advise,"If_bf treatment_bf inhibitors_bf CYP3A4_bf activity_bf (such_bf ketoconazole_bf ,_bf intraconazole_bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf DRUG ,_be erythromycin_be ,_be etc_be ._be )_be indicated_be ,_be reduction_be OTHER_DRUG dose_af considered_af ._af"
478,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",erythromycin,budesonide,advise,"If_bf treatment_bf inhibitors_bf CYP3A4_bf activity_bf (such_bf ketoconazole_bf ,_bf intraconazole_bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf saquinavir_bf ,_bf DRUG ,_be etc_be ._be )_be indicated_be ,_be reduction_be OTHER_DRUG dose_af considered_af ._af"
479,"- Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions.",bumetanide,aminoglycoside antibiotics,advise,"-_bf Drugs_bf ototoxic_bf potential:_bf Especially_bf presence_bf impaired_bf renal_bf function_bf ,_bf use_bf parenterally_bf administered_bf DRUG patients_be aminoglycoside_be antibiotics_be also_be given_be avoided_be ,_be except_be life-threatening_be conditions_be ._be"
480,- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.,Lithium,diuretics,advise,-_bf Lithium:_bf DRUG generally_be given_be OTHER_DRUG (such_af bumetanide)_af reduce_af renal_af clearance_af add_af high_af risk_af DRUG toxicity_af ._af
481,- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.,Lithium,bumetanide,advise,-_bf Lithium:_bf DRUG generally_be given_be diuretics_be (such_be bumetanide)_be reduce_be renal_be clearance_be add_be high_be risk_be DRUG toxicity_af ._af
482,- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.,probenecid,bumetanide,effect,-_bf Probenecid:_bf Pretreatment_bf DRUG reduces_be natriuresis_be hyperreninemia_be produced_be OTHER_DRUG ._af
483,This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.,probenecid,bumetanide,mechanism,This_bf antagonistic_bf effect_bf DRUG OTHER_DRUG natriuresis_af due_af direct_af action_af sodium_af excretion_af probably_af secondary_af inhibitory_af effect_af renal_af tubular_af secretion_af OTHER_DRUG ._af
484,"Thus, probenecid should not be administered concurrently with bumetanide.",probenecid,bumetanide,advise,"Thus_bf ,_bf DRUG administered_be concurrently_be OTHER_DRUG ._af"
485,- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.,Indomethacin,bumetanide,mechanism,-_bf Indomethacin:_bf DRUG blunts_be increases_be urine_be volume_be sodium_be excretion_be seen_be OTHER_DRUG treatment_af inhibits_af bumetanide-induced_af increase_af plasma_af renin_af activity_af ._af
486,- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.,Indomethacin,bumetanide,effect,-_bf Indomethacin:_bf DRUG blunts_be increases_be urine_be volume_be sodium_be excretion_be seen_be OTHER_DRUG treatment_af inhibits_af bumetanide-induced_af increase_af plasma_af renin_af activity_af ._af
487,"- Antihypertensives: Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.",Bumetanide,antihypertensive drugs,effect,"-_bf Antihypertensives:_bf DRUG may_be potentiate_be effect_be various_be antihypertensive_be drugs_be ,_be necessitating_be reduction_be dosage_be drugs_be ._be"
488,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",epinephrine,monoamine oxidase inhibitors,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf DRUG norepinephrine_be patients_be receiving_be monoamine_be oxidase_be inhibitors_be tricyclic_be antidepressants_be may_be produce_be severe_be ,_be prolonged_be hypertension_be ._be"
489,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",epinephrine,tricyclic antidepressants,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf DRUG norepinephrine_be patients_be receiving_be monoamine_be oxidase_be inhibitors_be tricyclic_be antidepressants_be may_be produce_be severe_be ,_be prolonged_be hypertension_be ._be"
490,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",norepinephrine,monoamine oxidase inhibitors,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf epinephrine_bf DRUG patients_be receiving_be monoamine_be oxidase_be inhibitors_be tricyclic_be antidepressants_be may_be produce_be severe_be ,_be prolonged_be hypertension_be ._be"
491,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",norepinephrine,tricyclic antidepressants,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf epinephrine_bf DRUG patients_be receiving_be monoamine_be oxidase_be inhibitors_be tricyclic_be antidepressants_be may_be produce_be severe_be ,_be prolonged_be hypertension_be ._be"
492,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.,Phenothiazines,epinephrine,effect,DRUG butyrophenones_be may_be reduce_be reverse_be pressor_be effect_be OTHER_DRUG ._af
493,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.,butyrophenones,epinephrine,effect,Phenothiazines_bf DRUG may_be reduce_be reverse_be pressor_be effect_be OTHER_DRUG ._af
494,"Based on anecdotal reports, there may be an interaction between buprenorphine and benzodiazepines.",buprenorphine,benzodiazepines,int,"Based_bf anecdotal_bf reports_bf ,_bf may_bf interaction_bf DRUG OTHER_DRUG ._af"
495,There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of buprenorphine and benzodiazepines by addicts.,buprenorphine,benzodiazepines,effect,There_bf number_bf reports_bf post-marketing_bf experience_bf coma_bf death_bf associated_bf concomitant_bf intravenous_bf misuse_bf DRUG OTHER_DRUG addicts_af ._af
496,"SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.",SUBUTEX,benzodiazepines,advise,"DRUG SUBOXONE_be prescribed_be caution_be patients_be OTHER_DRUG drugs_af act_af central_af nervous_af system_af ,_af regardless_af whether_af drugs_af taken_af advice_af physician_af taken_af drugs_af abuse_af ._af"
497,"SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.",SUBOXONE,benzodiazepines,advise,"SUBUTEX_bf DRUG prescribed_be caution_be patients_be OTHER_DRUG drugs_af act_af central_af nervous_af system_af ,_af regardless_af whether_af drugs_af taken_af advice_af physician_af taken_af drugs_af abuse_af ._af"
498,Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.,benzodiazepines,SUBOXONE,advise,Patients_bf warned_bf potential_bf danger_bf intravenous_bf self-administration_bf DRUG treatment_be OTHER_DRUG SUBUTEX_af ._af
499,Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.,benzodiazepines,SUBUTEX,advise,Patients_bf warned_bf potential_bf danger_bf intravenous_bf self-administration_bf DRUG treatment_be SUBOXONE_be OTHER_DRUG ._af
500,"Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).",WELLBUTRIN,orphenadrine,int,"Therefore_bf ,_bf potential_bf exists_bf drug_bf interaction_bf DRUG drugs_be affect_be CYP2B6_be isoenzyme_be (e_be ._be g_be ._be ,_be OTHER_DRUG cyclophosphamide)_af ._af"
501,"Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).",WELLBUTRIN,cyclophosphamide,int,"Therefore_bf ,_bf potential_bf exists_bf drug_bf interaction_bf DRUG drugs_be affect_be CYP2B6_be isoenzyme_be (e_be ._be g_be ._be ,_be orphenadrine_be cyclophosphamide)_be ._be"
502,"While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).",bupropion,carbamazepine,mechanism,"While_bf systematically_bf studied_bf ,_bf certain_bf drugs_bf may_bf induce_bf metabolism_bf DRUG (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af phenobarbital_af ,_af phenytoin)_af ._af"
503,"While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).",bupropion,phenobarbital,mechanism,"While_bf systematically_bf studied_bf ,_bf certain_bf drugs_bf may_bf induce_bf metabolism_bf DRUG (e_be ._be g_be ._be ,_be carbamazepine_be ,_be OTHER_DRUG ,_af phenytoin)_af ._af"
504,"While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).",bupropion,phenytoin,mechanism,"While_bf systematically_bf studied_bf ,_bf certain_bf drugs_bf may_bf induce_bf metabolism_bf DRUG (e_be ._be g_be ._be ,_be carbamazepine_be ,_be phenobarbital_be ,_be phenytoin)_be ._be"
505,"In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.",bupropion,desipramine,mechanism,"In_bf study_bf 15_bf male_bf subjects_bf (ages_bf 19_bf 35_bf years)_bf extensive_bf metabolizers_bf CYP2D6_bf isoenzyme_bf ,_bf daily_bf doses_bf DRUG given_be 150_be mg_be twice_be daily_be followed_be single_be dose_be 50_be mg_be OTHER_DRUG increased_af Cmax_af ,_af AUC_af ,_af t1/2_af OTHER_DRUG average_af approximately_af 2-_af ,_af 5-_af 2-fold_af ,_af respectively_af ._af"
506,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,antidepressants,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be OTHER_DRUG (e_af ._af g_af ._af ,_af nortriptyline_af ,_af imipramine_af ,_af desipramine_af ,_af paroxetine_af ,_af fluoxetine_af ,_af sertraline)_af ,_af antipsychotics_af (e_af ._af g_af ._af ,_af haloperidol_af ,_af risperidone_af ,_af thioridazine)_af ,_af beta-blockers_af (e_af ._af g_af ._af ,_af metoprolol)_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
507,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,nortriptyline,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af imipramine_af ,_af desipramine_af ,_af paroxetine_af ,_af fluoxetine_af ,_af sertraline)_af ,_af antipsychotics_af (e_af ._af g_af ._af ,_af haloperidol_af ,_af risperidone_af ,_af thioridazine)_af ,_af beta-blockers_af (e_af ._af g_af ._af ,_af metoprolol)_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
508,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,imipramine,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be OTHER_DRUG ,_af desipramine_af ,_af paroxetine_af ,_af fluoxetine_af ,_af sertraline)_af ,_af antipsychotics_af (e_af ._af g_af ._af ,_af haloperidol_af ,_af risperidone_af ,_af thioridazine)_af ,_af beta-blockers_af (e_af ._af g_af ._af ,_af metoprolol)_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
509,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,desipramine,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be OTHER_DRUG ,_af paroxetine_af ,_af fluoxetine_af ,_af sertraline)_af ,_af antipsychotics_af (e_af ._af g_af ._af ,_af haloperidol_af ,_af risperidone_af ,_af thioridazine)_af ,_af beta-blockers_af (e_af ._af g_af ._af ,_af metoprolol)_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
510,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,paroxetine,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be OTHER_DRUG ,_af fluoxetine_af ,_af sertraline)_af ,_af antipsychotics_af (e_af ._af g_af ._af ,_af haloperidol_af ,_af risperidone_af ,_af thioridazine)_af ,_af beta-blockers_af (e_af ._af g_af ._af ,_af metoprolol)_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
511,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,fluoxetine,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be OTHER_DRUG ,_af sertraline)_af ,_af antipsychotics_af (e_af ._af g_af ._af ,_af haloperidol_af ,_af risperidone_af ,_af thioridazine)_af ,_af beta-blockers_af (e_af ._af g_af ._af ,_af metoprolol)_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
512,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,sertraline,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be fluoxetine_be ,_be sertraline)_be ,_be antipsychotics_be (e_be ._be g_be ._be ,_be haloperidol_be ,_be risperidone_be ,_be thioridazine)_be ,_be beta-blockers_be (e_be ._be g_be ._be ,_be metoprolol)_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide)_be ,_be approached_be caution_be initiated_be lower_be end_be dose_be range_be concomitant_be medication_be ._be"
513,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,antipsychotics,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be fluoxetine_be ,_be sertraline)_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af haloperidol_af ,_af risperidone_af ,_af thioridazine)_af ,_af beta-blockers_af (e_af ._af g_af ._af ,_af metoprolol)_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
514,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,haloperidol,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be fluoxetine_be ,_be sertraline)_be ,_be antipsychotics_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af risperidone_af ,_af thioridazine)_af ,_af beta-blockers_af (e_af ._af g_af ._af ,_af metoprolol)_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
515,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,risperidone,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be fluoxetine_be ,_be sertraline)_be ,_be antipsychotics_be (e_be ._be g_be ._be ,_be haloperidol_be ,_be OTHER_DRUG ,_af thioridazine)_af ,_af beta-blockers_af (e_af ._af g_af ._af ,_af metoprolol)_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
516,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,thioridazine,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be fluoxetine_be ,_be sertraline)_be ,_be antipsychotics_be (e_be ._be g_be ._be ,_be haloperidol_be ,_be risperidone_be ,_be thioridazine)_be ,_be beta-blockers_be (e_be ._be g_be ._be ,_be metoprolol)_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide)_be ,_be approached_be caution_be initiated_be lower_be end_be dose_be range_be concomitant_be medication_be ._be"
517,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,beta-blockers,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be fluoxetine_be ,_be sertraline)_be ,_be antipsychotics_be (e_be ._be g_be ._be ,_be haloperidol_be ,_be risperidone_be ,_be thioridazine)_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af metoprolol)_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
518,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,metoprolol,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be fluoxetine_be ,_be sertraline)_be ,_be antipsychotics_be (e_be ._be g_be ._be ,_be haloperidol_be ,_be risperidone_be ,_be thioridazine)_be ,_be beta-blockers_be (e_be ._be g_be ._be ,_be metoprolol)_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide)_be ,_be approached_be caution_be initiated_be lower_be end_be dose_be range_be concomitant_be medication_be ._be"
519,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,Type 1C antiarrhythmics,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be fluoxetine_be ,_be sertraline)_be ,_be antipsychotics_be (e_be ._be g_be ._be ,_be haloperidol_be ,_be risperidone_be ,_be thioridazine)_be ,_be beta-blockers_be (e_be ._be g_be ._be ,_be metoprolol)_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide)_be ,_be approached_be caution_be initiated_be lower_be end_be dose_be range_be concomitant_be medication_be ._be"
520,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,propafenone,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be fluoxetine_be ,_be sertraline)_be ,_be antipsychotics_be (e_be ._be g_be ._be ,_be haloperidol_be ,_be risperidone_be ,_be thioridazine)_be ,_be beta-blockers_be (e_be ._be g_be ._be ,_be metoprolol)_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
521,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,flecainide,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be fluoxetine_be ,_be sertraline)_be ,_be antipsychotics_be (e_be ._be g_be ._be ,_be haloperidol_be ,_be risperidone_be ,_be thioridazine)_be ,_be beta-blockers_be (e_be ._be g_be ._be ,_be metoprolol)_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide)_be ,_be approached_be caution_be initiated_be lower_be end_be dose_be range_be concomitant_be medication_be ._be"
522,MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .,bupropion,phenelzine,effect,MAO_bf Inhibitors:_bf Studies_bf animals_bf demonstrate_bf acute_bf toxicity_bf DRUG enhanced_be MAO_be inhibitor_be OTHER_DRUG ._af
523,Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.,bupropion,levodopa,effect,OTHER_DRUG Amantadine:_be Limited_be clinical_be data_be suggest_be higher_be incidence_be adverse_be experiences_be patients_be receiving_be DRUG concurrently_af either_af OTHER_DRUG amantadine_af ._af
524,Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.,bupropion,amantadine,effect,Levodopa_bf Amantadine:_bf Limited_bf clinical_bf data_bf suggest_bf higher_bf incidence_bf adverse_bf experiences_bf patients_bf receiving_bf DRUG concurrently_be either_be levodopa_be OTHER_DRUG ._af
525,"Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.",WELLBUTRIN,levodopa,advise,"Administration_bf DRUG Tablets_be patients_be receiving_be either_be OTHER_DRUG amantadine_af concurrently_af undertaken_af caution_af ,_af using_af small_af initial_af doses_af small_af gradual_af dose_af increases_af ._af"
526,"Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.",WELLBUTRIN,amantadine,advise,"Administration_bf DRUG Tablets_be patients_be receiving_be either_be levodopa_be OTHER_DRUG concurrently_af undertaken_af caution_af ,_af using_af small_af initial_af doses_af small_af gradual_af dose_af increases_af ._af"
527,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,antipsychotics,advise,"Drugs_bf Lower_bf Seizure_bf Threshold:_bf Concurrent_bf administration_bf DRUG agents_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af antidepressants_af ,_af theophylline_af ,_af systemic_af steroids_af ,_af etc_af ._af )_af lower_af seizure_af threshold_af undertaken_af extreme_af caution_af ._af"
528,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,antidepressants,advise,"Drugs_bf Lower_bf Seizure_bf Threshold:_bf Concurrent_bf administration_bf DRUG agents_be (e_be ._be g_be ._be ,_be antipsychotics_be ,_be OTHER_DRUG ,_af theophylline_af ,_af systemic_af steroids_af ,_af etc_af ._af )_af lower_af seizure_af threshold_af undertaken_af extreme_af caution_af ._af"
529,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,theophylline,advise,"Drugs_bf Lower_bf Seizure_bf Threshold:_bf Concurrent_bf administration_bf DRUG agents_be (e_be ._be g_be ._be ,_be antipsychotics_be ,_be antidepressants_be ,_be OTHER_DRUG ,_af systemic_af steroids_af ,_af etc_af ._af )_af lower_af seizure_af threshold_af undertaken_af extreme_af caution_af ._af"
530,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,steroids,advise,"Drugs_bf Lower_bf Seizure_bf Threshold:_bf Concurrent_bf administration_bf DRUG agents_be (e_be ._be g_be ._be ,_be antipsychotics_be ,_be antidepressants_be ,_be theophylline_be ,_be systemic_be OTHER_DRUG ,_af etc_af ._af )_af lower_af seizure_af threshold_af undertaken_af extreme_af caution_af ._af"
531,"Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.",alcohol,WELLBUTRIN,effect,"Alcohol:_bf In_bf post-marketing_bf experience_bf ,_bf rare_bf reports_bf adverse_bf neuropsychiatric_bf events_bf reduced_bf DRUG tolerance_be patients_be drinking_be DRUG treatment_af OTHER_DRUG ._af"
532,The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS),alcohol,WELLBUTRIN,advise,The_bf consumption_bf DRUG treatment_be OTHER_DRUG minimized_af avoided_af (also_af see_af href=_af bupropz_od_af ._af htm#CI_af CONTRAINDICATIONS)_af
533,"It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.",buspirone hydrochloride,MAO inhibitors,advise,"It_bf recommended_bf buspirone_bf hydrochloride_bf used_bf concomitantly_bf MAO_bf inhibitors_bf Because_bf effects_bf concomitant_bf administration_bf buspirone_bf HCl_bf psychotropic_bf drugs_bf studied_bf ,_bf concomitant_bf use_bf buspirone_bf HCl_bf CNS-active_bf drugs_bf approached_bf caution_bf ._bf"
534,There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.,trazodone hydrochloride,buspirone HCl,effect,There_bf one_bf report_bf suggesting_bf concomitant_bf use_bf trazodone_bf hydrochloride_bf (Desyrel)_bf buspirone_bf HCl_bf may_bf caused_bf 3-_bf 6-fold_bf elevations_bf SGPT_bf (ALT)_bf patients_bf ._bf
535,There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.,Desyrel,buspirone HCl,effect,There_bf one_bf report_bf suggesting_bf concomitant_bf use_bf trazodone_bf hydrochloride_bf (Desyrel)_bf buspirone_bf HCl_bf may_bf caused_bf 3-_bf 6-fold_bf elevations_bf SGPT_bf (ALT)_bf patients_bf ._bf
536,"In a study in normal volunteers, concomitant administration of buspirone HCl and haloperidol resulted in increased serum haloperidol concentrations.",buspirone HCl,haloperidol,mechanism,"In_bf study_bf normal_bf volunteers_bf ,_bf concomitant_bf administration_bf buspirone_bf HCl_bf OTHER_DRUG resulted_be increased_be serum_be OTHER_DRUG concentrations_af ._af"
537,"However, there has been one report of prolonged prothrombin time when buspirone was added to the regimen of a patient treated with warfarin.",buspirone,warfarin,effect,"However_bf ,_bf one_bf report_bf prolonged_bf prothrombin_bf time_bf DRUG added_be regimen_be patient_be treated_be OTHER_DRUG ._af"
538,"In vitro, buspirone may displace less firmly bound drugs like digoxin.",buspirone,digoxin,mechanism,"In_bf vitro_bf ,_bf DRUG may_be displace_be less_be firmly_be bound_be drugs_be like_be OTHER_DRUG ._af"
539,"Itraconazole decreases busulfan clearance by up to 25%, and may produce AUCs   1500  M min in some patients.",Itraconazole,busulfan,mechanism,"DRUG decreases_be OTHER_DRUG clearance_af 25%_af ,_af may_af produce_af AUCs_af 1500_af M_af min_af patients_af ._af"
540,"Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase.",Phenytoin,busulfan,mechanism,"DRUG increases_be clearance_be OTHER_DRUG 15%_af ,_af possibly_af due_af induction_af glutathione-S-transferase_af ._af"
541,"Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.",BUSULFEX,phenytoin,mechanism,"Since_bf pharmacokinetics_bf DRUG studied_be patients_be treated_be OTHER_DRUG ,_af clearance_af DRUG recommended_af dose_af may_af lower_af exposure_af (AUC)_af higher_af patients_af treated_af OTHER_DRUG ._af"
542,"Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.",acetaminophen,BUSULFEX,mechanism,"Because_bf busulfan_bf eliminated_bf body_bf via_bf conjugation_bf glutathione_bf ,_bf use_bf DRUG prior_be (_be 72_be hours)_be concurrent_be OTHER_DRUG may_af result_af reduced_af busulfan_af clearance_af based_af upon_af known_af property_af DRUG decrease_af glutathione_af levels_af blood_af tissues_af ._af"
543,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",barbiturates,contraceptives,effect,"Interactions_bf may_bf occur_bf following:_bf adrenocorticoids_bf (cortisone-like_bf medicine)_bf ,_bf anticoagulants_bf (blood_bf thinners)_bf ,_bf carbamazepine_bf ,_bf corticotropin_bf (barbiturates_bf may_bf decrease_bf effects_bf medicines)_bf ,_bf central_bf nervous_bf system_bf (CNS)_bf depressants_bf (using_bf medicines_bf DRUG may_be result_be increased_be CNS_be depressant_be effects)_be ,_be divalproex_be sodium_be ,_be valproic_be acid_be (using_be medicines_be DRUG may_af change_af amount_af either_af medicine_af need_af take)_af ,_af oral_af OTHER_DRUG containing_af estrogens_af (barbiturates_af may_af decrease_af effectiveness_af oral_af OTHER_DRUG ,_af may_af need_af change_af different_af type_af birth_af control)_af ._af"
544,The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.,butalbital,monoamine oxidase (MAO) inhibitors,effect,The_bf CNS_bf effects_bf DRUG may_be enhanced_be monoamine_be oxidase_be (MAO)_be inhibitors_be ._be
545,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,narcotic analgesic,effect,"DRUG ,_be acetaminophen_be caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be chlordiazepoxide_be ,_be sedative-hypnotics_be ,_be CNS_be depressants_be ,_be causing_be increased_be CNS_be depression_be ._be"
546,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,alcohol,effect,"DRUG ,_be acetaminophen_be caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be OTHER_DRUG ,_af general_af anesthetics_af ,_af tranquilizers_af chlordiazepoxide_af ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
547,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,anesthetics,effect,"DRUG ,_be acetaminophen_be caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be OTHER_DRUG ,_af tranquilizers_af chlordiazepoxide_af ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
548,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,tranquilizers,effect,"DRUG ,_be acetaminophen_be caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be OTHER_DRUG chlordiazepoxide_af ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
549,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,chlordiazepoxide,effect,"DRUG ,_be acetaminophen_be caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be OTHER_DRUG ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
550,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,sedative-hypnotics,effect,"DRUG ,_be acetaminophen_be caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be chlordiazepoxide_be ,_be OTHER_DRUG ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
551,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,CNS depressants,effect,"DRUG ,_be acetaminophen_be caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be chlordiazepoxide_be ,_be sedative-hypnotics_be ,_be CNS_be depressants_be ,_be causing_be increased_be CNS_be depression_be ._be"
552,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,narcotic analgesic,effect,"Butalbital_bf ,_bf DRUG caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be chlordiazepoxide_be ,_be sedative-hypnotics_be ,_be CNS_be depressants_be ,_be causing_be increased_be CNS_be depression_be ._be"
553,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,alcohol,effect,"Butalbital_bf ,_bf DRUG caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be OTHER_DRUG ,_af general_af anesthetics_af ,_af tranquilizers_af chlordiazepoxide_af ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
554,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,anesthetics,effect,"Butalbital_bf ,_bf DRUG caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be OTHER_DRUG ,_af tranquilizers_af chlordiazepoxide_af ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
555,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,tranquilizers,effect,"Butalbital_bf ,_bf DRUG caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be OTHER_DRUG chlordiazepoxide_af ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
556,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,chlordiazepoxide,effect,"Butalbital_bf ,_bf DRUG caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be OTHER_DRUG ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
557,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,sedative-hypnotics,effect,"Butalbital_bf ,_bf DRUG caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be chlordiazepoxide_be ,_be OTHER_DRUG ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
558,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,CNS depressants,effect,"Butalbital_bf ,_bf DRUG caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be chlordiazepoxide_be ,_be sedative-hypnotics_be ,_be CNS_be depressants_be ,_be causing_be increased_be CNS_be depression_be ._be"
559,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,narcotic analgesic,effect,"Butalbital_bf ,_bf acetaminophen_bf DRUG may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be chlordiazepoxide_be ,_be sedative-hypnotics_be ,_be CNS_be depressants_be ,_be causing_be increased_be CNS_be depression_be ._be"
560,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,alcohol,effect,"Butalbital_bf ,_bf acetaminophen_bf DRUG may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be OTHER_DRUG ,_af general_af anesthetics_af ,_af tranquilizers_af chlordiazepoxide_af ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
561,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,anesthetics,effect,"Butalbital_bf ,_bf acetaminophen_bf DRUG may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be OTHER_DRUG ,_af tranquilizers_af chlordiazepoxide_af ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
562,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,tranquilizers,effect,"Butalbital_bf ,_bf acetaminophen_bf DRUG may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be OTHER_DRUG chlordiazepoxide_af ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
563,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,chlordiazepoxide,effect,"Butalbital_bf ,_bf acetaminophen_bf DRUG may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be OTHER_DRUG ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
564,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,sedative-hypnotics,effect,"Butalbital_bf ,_bf acetaminophen_bf DRUG may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be chlordiazepoxide_be ,_be OTHER_DRUG ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
565,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,CNS depressants,effect,"Butalbital_bf ,_bf acetaminophen_bf DRUG may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be chlordiazepoxide_be ,_be sedative-hypnotics_be ,_be CNS_be depressants_be ,_be causing_be increased_be CNS_be depression_be ._be"
566,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,central nervous system depressants,effect,"Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (e_be ._be g_be ._be ,_be alcohol_be ,_be barbiturates_be ,_be tranquilizers_be ,_be antihistamines)_be may_be result_be increased_be central_be nervous_be system_be depressant_be effects_be ._be"
567,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,alcohol,effect,"Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af barbiturates_af ,_af tranquilizers_af ,_af antihistamines)_af may_af result_af increased_af central_af nervous_af system_af depressant_af effects_af ._af"
568,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,barbiturates,effect,"Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (e_be ._be g_be ._be ,_be alcohol_be ,_be OTHER_DRUG ,_af tranquilizers_af ,_af antihistamines)_af may_af result_af increased_af central_af nervous_af system_af depressant_af effects_af ._af"
569,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,tranquilizers,effect,"Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (e_be ._be g_be ._be ,_be alcohol_be ,_be barbiturates_be ,_be OTHER_DRUG ,_af antihistamines)_af may_af result_af increased_af central_af nervous_af system_af depressant_af effects_af ._af"
570,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,antihistamines,effect,"Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (e_be ._be g_be ._be ,_be alcohol_be ,_be barbiturates_be ,_be tranquilizers_be ,_be antihistamines)_be may_be result_be increased_be central_be nervous_be system_be depressant_be effects_be ._be"
571,"However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.",STADOL NS,sumatriptan,mechanism,"However_bf ,_bf another_bf study_bf healthy_bf volunteers_bf ,_bf pharmacokinetics_bf butorphanol_bf significantly_bf altered_bf (29%_bf decrease_bf AUC_bf 38%_bf decrease_bf Cmax)_bf 1-mg_bf dose_bf STADOL_bf NS_bf administered_bf 1_bf minute_bf 20-mg_bf dose_bf OTHER_DRUG nasal_be spray_be ._be"
572,"When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.",STADOL NS,sumatriptan,mechanism,"When_bf STADOL_bf NS_bf administered_bf 30_bf minutes_bf OTHER_DRUG nasal_be spray_be ,_be AUC_be butorphanol_be increased_be 11%_be Cmax_be decreased_be 18%_be ._be"
573,"These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.",STADOL NS,sumatriptan,effect,"These_bf results_bf suggest_bf analgesic_bf effect_bf STADOL_bf NS_bf may_bf diminished_bf administered_bf shortly_bf OTHER_DRUG nasal_be spray_be ,_be 30_be minutes_be reduction_be effect_be minimal_be ._be"
574,"It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs (erythromycin, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.",butorphanol,erythromycin,advise,"It_bf known_bf effects_bf DRUG altered_be concomitant_be medications_be affect_be hepatic_be metabolism_be drugs_be (erythromycin_be ,_be etc_be ._be )_be ,_be physicians_be alert_be possibility_be smaller_be initial_be dose_be longer_be intervals_be doses_be may_be needed_be ._be"
575,"Therefore, a slower onset can be anticipated if STADOL NS is administered concomitantly with, or immediately following, a nasal vasoconstrictor.",STADOL NS,nasal vasoconstrictor,effect,"Therefore_bf ,_bf slower_bf onset_bf anticipated_bf STADOL_bf NS_bf administered_bf concomitantly_bf ,_bf immediately_bf following_bf ,_bf nasal_bf vasoconstrictor_bf ._bf"
576,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.",DOSTINEX,phenothiazines,advise,"DRUG administered_be concurrently_be D2-antagonists_be ,_be OTHER_DRUG ,_af butyrophenones_af ,_af thioxanthines_af ,_af metoclopramide_af ._af"
577,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.",DOSTINEX,butyrophenones,advise,"DRUG administered_be concurrently_be D2-antagonists_be ,_be phenothiazines_be ,_be OTHER_DRUG ,_af thioxanthines_af ,_af metoclopramide_af ._af"
578,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.",DOSTINEX,thioxanthines,advise,"DRUG administered_be concurrently_be D2-antagonists_be ,_be phenothiazines_be ,_be butyrophenones_be ,_be OTHER_DRUG ,_af metoclopramide_af ._af"
579,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.",DOSTINEX,metoclopramide,advise,"DRUG administered_be concurrently_be D2-antagonists_be ,_be phenothiazines_be ,_be butyrophenones_be ,_be thioxanthines_be ,_be OTHER_DRUG ._af"
580,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",caffeine,cimetidine,advise,"Based_bf adult_bf data_bf ,_bf lower_bf doses_bf DRUG may_be needed_be following_be coadministration_be drugs_be reported_be decrease_be DRUG elimination_af (e_af ._af g_af ._af ,_af OTHER_DRUG ketoconazole)_af higher_af DRUG doses_af may_af needed_af following_af coadministration_af drugs_af increase_af DRUG elimination_af (e_af ._af g_af ._af ,_af phenobarbital_af phenytoin)_af ._af"
581,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",caffeine,ketoconazole,advise,"Based_bf adult_bf data_bf ,_bf lower_bf doses_bf DRUG may_be needed_be following_be coadministration_be drugs_be reported_be decrease_be DRUG elimination_af (e_af ._af g_af ._af ,_af cimetidine_af ketoconazole)_af higher_af DRUG doses_af may_af needed_af following_af coadministration_af drugs_af increase_af DRUG elimination_af (e_af ._af g_af ._af ,_af phenobarbital_af phenytoin)_af ._af"
582,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",caffeine,phenobarbital,advise,"Based_bf adult_bf data_bf ,_bf lower_bf doses_bf DRUG may_be needed_be following_be coadministration_be drugs_be reported_be decrease_be DRUG elimination_af (e_af ._af g_af ._af ,_af cimetidine_af ketoconazole)_af higher_af DRUG doses_af may_af needed_af following_af coadministration_af drugs_af increase_af DRUG elimination_af (e_af ._af g_af ._af ,_af OTHER_DRUG phenytoin)_af ._af"
583,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",caffeine,phenytoin,advise,"Based_bf adult_bf data_bf ,_bf lower_bf doses_bf DRUG may_be needed_be following_be coadministration_be drugs_be reported_be decrease_be DRUG elimination_af (e_af ._af g_af ._af ,_af cimetidine_af ketoconazole)_af higher_af DRUG doses_af may_af needed_af following_af coadministration_af drugs_af increase_af DRUG elimination_af (e_af ._af g_af ._af ,_af phenobarbital_af phenytoin)_af ._af"
584,Caffeine administered concurrently with ketoprofen reduced the urine volume in 4 healthy volunteers.,Caffeine,ketoprofen,effect,DRUG administered_be concurrently_be OTHER_DRUG reduced_af urine_af volume_af 4_af healthy_af volunteers_af ._af
585,"Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;",Cholestyramine,fat soluble vitamins,mechanism,"Interactions_bf vitamin_bf D_bf analogues_bf (Vitamin_bf D2_bf ,_bf Vitamin_bf D3_bf ,_bf Calcitriol_bf ,_bf Calcidiol):_bf Cholestyramine:_bf DRUG reported_be reduce_be intestinal_be absorption_be fat_be soluble_be vitamins;_be"
586,"Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.",phenytoin,calcitriol,mechanism,"Phenytoin/Phenobarbital:_bf The_bf coadministration_bf DRUG phenobarbital_be affect_be plasma_be concentrations_be vitamin_be D_be ,_be may_be reduce_be endogenous_be plasma_be levels_be calcitriol/ergocalcitriol_be accelerating_be metabolism_be ._be"
587,"Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.",phenobarbital,calcitriol,mechanism,"Phenytoin/Phenobarbital:_bf The_bf coadministration_bf phenytoin_bf DRUG affect_be plasma_be concentrations_be vitamin_be D_be ,_be may_be reduce_be endogenous_be plasma_be levels_be calcitriol/ergocalcitriol_be accelerating_be metabolism_be ._be"
588,Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.,thiazides,vitamin D,effect,Some_bf reports_bf shown_bf concomitant_bf administration_bf DRUG vitamin_be D_be causes_be hypercalcemia_be ._be
589,"Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.",Vitamin D,digitalis,advise,"Digitalis:_bf Vitamin_bf D_bf dosage_bf must_bf determined_bf care_bf patients_bf undergoing_bf treatment_bf OTHER_DRUG ,_be hypercalcemia_be patients_be may_be precipitate_be cardiac_be arrhythmias_be ._be"
590,Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.,Ketoconazole,vitamin D,mechanism,Ketoconazole:_bf DRUG may_be inhibit_be synthetic_be catabolic_be enzymes_be vitamin_be D_be ._be
591,"Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.",vitamin D analogues,corticosteroids,mechanism,"Corticosteroids:_bf A_bf relationship_bf functional_bf antagonism_bf exists_bf vitamin_bf D_bf analogues_bf ,_bf promote_bf calcium_bf absorption_bf ,_bf OTHER_DRUG ,_be inhibit_be calcium_be absorption_be ._be"
592,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",Magnesium,vitamin D,advise,"Magnesium:_bf Magnesium-containing_bf preparations_bf (eg_bf ,_bf antacids)_bf may_bf cause_bf hypermagnesemia_bf therefore_bf taken_bf therapy_bf vitamin_bf D_bf patients_bf chronic_bf renal_bf dialysis_bf ._bf"
593,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",antacids,vitamin D,advise,"Magnesium:_bf Magnesium-containing_bf preparations_bf (eg_bf ,_bf antacids)_bf may_bf cause_bf hypermagnesemia_bf therefore_bf taken_bf therapy_bf vitamin_bf D_bf patients_bf chronic_bf renal_bf dialysis_bf ._bf"
594,"Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;",Cholestyramine,fat soluble vitamins,mechanism,"Interactions_bf vitamin_bf D_bf analogues_bf (Vitamin_bf D2_bf ,_bf Vitamin_bf D3_bf ,_bf Calcitriol_bf ,_bf Calcidiol):_bf Cholestyramine:_bf DRUG reported_be reduce_be intestinal_be absorption_be fat_be soluble_be vitamins;_be"
595,"Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.",phenytoin,calcitriol,mechanism,"Phenytoin/Phenobarbital:_bf The_bf coadministration_bf DRUG phenobarbital_be affect_be plasma_be concentrations_be vitamin_be D_be ,_be may_be reduce_be endogenous_be plasma_be levels_be calcitriol/ergocalcitriol_be accelerating_be metabolism_be ._be"
596,"Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.",phenobarbital,calcitriol,mechanism,"Phenytoin/Phenobarbital:_bf The_bf coadministration_bf phenytoin_bf DRUG affect_be plasma_be concentrations_be vitamin_be D_be ,_be may_be reduce_be endogenous_be plasma_be levels_be calcitriol/ergocalcitriol_be accelerating_be metabolism_be ._be"
597,Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.,thiazides,vitamin D,effect,Some_bf reports_bf shown_bf concomitant_bf administration_bf DRUG vitamin_be D_be causes_be hypercalcemia_be ._be
598,"Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.",Vitamin D,digitalis,advise,"Digitalis:_bf Vitamin_bf D_bf dosage_bf must_bf determined_bf care_bf patients_bf undergoing_bf treatment_bf OTHER_DRUG ,_be hypercalcemia_be patients_be may_be precipitate_be cardiac_be arrhythmias_be ._be"
599,Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.,Ketoconazole,vitamin D,mechanism,Ketoconazole:_bf DRUG may_be inhibit_be synthetic_be catabolic_be enzymes_be vitamin_be D_be ._be
600,"Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.",vitamin D analogues,corticosteroids,mechanism,"Corticosteroids:_bf A_bf relationship_bf functional_bf antagonism_bf exists_bf vitamin_bf D_bf analogues_bf ,_bf promote_bf calcium_bf absorption_bf ,_bf OTHER_DRUG ,_be inhibit_be calcium_be absorption_be ._be"
601,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",Magnesium,vitamin D,advise,"Magnesium:_bf Magnesium-containing_bf preparations_bf (eg_bf ,_bf antacids)_bf may_bf cause_bf hypermagnesemia_bf therefore_bf taken_bf therapy_bf vitamin_bf D_bf patients_bf chronic_bf renal_bf dialysis_bf ._bf"
602,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",antacids,vitamin D,advise,"Magnesium:_bf Magnesium-containing_bf preparations_bf (eg_bf ,_bf antacids)_bf may_bf cause_bf hypermagnesemia_bf therefore_bf taken_bf therapy_bf vitamin_bf D_bf patients_bf chronic_bf renal_bf dialysis_bf ._bf"
603,"Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.",lithium,ACE inhibitors,mechanism,"DRUG Reversible_be increases_be serum_be DRUG concentrations_af toxicity_af reported_af concomitant_af administration_af DRUG ACE_af inhibitors_af ,_af angiotensin_af II_af receptor_af antagonists_af ._af"
604,"Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.",lithium,angiotensin II receptor antagonists,mechanism,"DRUG Reversible_be increases_be serum_be DRUG concentrations_af toxicity_af reported_af concomitant_af administration_af DRUG ACE_af inhibitors_af ,_af angiotensin_af II_af receptor_af antagonists_af ._af"
605,"An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.",lithium,ATACAND,mechanism,"An_bf increase_bf serum_bf DRUG concentration_be reported_be concomitant_be administration_be DRUG OTHER_DRUG ,_af careful_af monitoring_af serum_af DRUG levels_af recommended_af concomitant_af use_af ._af"
606,Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.,capecitabine,coumarin-derivative anticoagulants,effect,Coumarin_bf Anticoagulants_bf Altered_bf coagulation_bf parameters_bf and/or_bf bleeding_bf reported_bf patients_bf taking_bf DRUG concomitantly_be coumarin-derivative_be anticoagulants_be warfarin_be phenprocoumon_be ._be
607,Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.,capecitabine,phenprocoumon,effect,Coumarin_bf Anticoagulants_bf Altered_bf coagulation_bf parameters_bf and/or_bf bleeding_bf reported_bf patients_bf taking_bf DRUG concomitantly_be coumarin-derivative_be anticoagulants_be warfarin_be OTHER_DRUG ._af
608,Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR).,coumarin-derivative anticoagulants,capecitabine,advise,Patients_bf taking_bf coumarin-derivative_bf anticoagulants_bf concomitantly_bf OTHER_DRUG monitored_be regularly_be alterations_be coagulation_be parameters_be (PT_be INR)_be ._be
609,Leucovorin: The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.,5-fluorouracil,leucovorin,mechanism,Leucovorin:_bf The_bf concentration_bf DRUG increased_be toxicity_be may_be enhanced_be OTHER_DRUG ._af
610,"Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.",leucovorin,fluorouracil,effect,"Deaths_bf severe_bf enterocolitis_bf ,_bf diarrhea_bf ,_bf dehydration_bf reported_bf elderly_bf patients_bf receiving_bf weekly_bf DRUG OTHER_DRUG ._af"
611,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,Acetazolamide,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be OTHER_DRUG ,_af azole_af antifungals_af ,_af cimetidine_af ,_af clarithromycin(1)_af ,_af dalfopristin_af ,_af danazol_af ,_af delavirdine_af ,_af diltiazem_af ,_af erythromycin(1)_af ,_af fluoxetine_af ,_af fluvoxamine_af ,_af grapefruit_af juice_af ,_af isoniazid_af ,_af itraconazole_af ,_af ketoconazole_af ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
612,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,azole antifungals,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be propoxyphene_be ,_be quinine_be ,_be quinupristin_be ,_be troleandomycin_be ,_be valproate(1)_be ,_be verapamil_be ,_be zileuton_be ._be"
613,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,cimetidine,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be OTHER_DRUG ,_af clarithromycin(1)_af ,_af dalfopristin_af ,_af danazol_af ,_af delavirdine_af ,_af diltiazem_af ,_af erythromycin(1)_af ,_af fluoxetine_af ,_af fluvoxamine_af ,_af grapefruit_af juice_af ,_af isoniazid_af ,_af itraconazole_af ,_af ketoconazole_af ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
614,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,clarithromycin,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be propoxyphene_be ,_be quinine_be ,_be quinupristin_be ,_be troleandomycin_be ,_be valproate(1)_be ,_be verapamil_be ,_be zileuton_be ._be"
615,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,dalfopristin,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be OTHER_DRUG ,_af danazol_af ,_af delavirdine_af ,_af diltiazem_af ,_af erythromycin(1)_af ,_af fluoxetine_af ,_af fluvoxamine_af ,_af grapefruit_af juice_af ,_af isoniazid_af ,_af itraconazole_af ,_af ketoconazole_af ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
616,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,danazol,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be OTHER_DRUG ,_af delavirdine_af ,_af diltiazem_af ,_af erythromycin(1)_af ,_af fluoxetine_af ,_af fluvoxamine_af ,_af grapefruit_af juice_af ,_af isoniazid_af ,_af itraconazole_af ,_af ketoconazole_af ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
617,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,delavirdine,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be OTHER_DRUG ,_af diltiazem_af ,_af erythromycin(1)_af ,_af fluoxetine_af ,_af fluvoxamine_af ,_af grapefruit_af juice_af ,_af isoniazid_af ,_af itraconazole_af ,_af ketoconazole_af ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
618,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,diltiazem,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be OTHER_DRUG ,_af erythromycin(1)_af ,_af fluoxetine_af ,_af fluvoxamine_af ,_af grapefruit_af juice_af ,_af isoniazid_af ,_af itraconazole_af ,_af ketoconazole_af ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
619,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,erythromycin,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be propoxyphene_be ,_be quinine_be ,_be quinupristin_be ,_be troleandomycin_be ,_be valproate(1)_be ,_be verapamil_be ,_be zileuton_be ._be"
620,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,fluoxetine,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be OTHER_DRUG ,_af fluvoxamine_af ,_af grapefruit_af juice_af ,_af isoniazid_af ,_af itraconazole_af ,_af ketoconazole_af ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
621,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,fluvoxamine,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be OTHER_DRUG ,_af grapefruit_af juice_af ,_af isoniazid_af ,_af itraconazole_af ,_af ketoconazole_af ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
622,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,isoniazid,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be OTHER_DRUG ,_af itraconazole_af ,_af ketoconazole_af ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
623,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,itraconazole,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be OTHER_DRUG ,_af ketoconazole_af ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
624,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,ketoconazole,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be OTHER_DRUG ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
625,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,loratadine,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be OTHER_DRUG ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
626,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,nefazodone,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be OTHER_DRUG ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
627,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,niacinamide,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be OTHER_DRUG ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
628,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,nicotinamide,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be OTHER_DRUG ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
629,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,protease inhibitors,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be propoxyphene_be ,_be quinine_be ,_be quinupristin_be ,_be troleandomycin_be ,_be valproate(1)_be ,_be verapamil_be ,_be zileuton_be ._be"
630,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,propoxyphene,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be OTHER_DRUG ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
631,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,quinine,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be propoxyphene_be ,_be OTHER_DRUG ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
632,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,quinupristin,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be propoxyphene_be ,_be quinine_be ,_be OTHER_DRUG ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
633,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,troleandomycin,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be propoxyphene_be ,_be quinine_be ,_be quinupristin_be ,_be OTHER_DRUG ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
634,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,valproate,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be propoxyphene_be ,_be quinine_be ,_be quinupristin_be ,_be troleandomycin_be ,_be valproate(1)_be ,_be verapamil_be ,_be zileuton_be ._be"
635,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,verapamil,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be propoxyphene_be ,_be quinine_be ,_be quinupristin_be ,_be troleandomycin_be ,_be valproate(1)_be ,_be OTHER_DRUG ,_af zileuton_af ._af"
636,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,zileuton,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be propoxyphene_be ,_be quinine_be ,_be quinupristin_be ,_be troleandomycin_be ,_be valproate(1)_be ,_be verapamil_be ,_be OTHER_DRUG ._af"
637,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,Cisplatin,mechanism,"Agents_bf CYP_bf inducers_bf found_bf ,_bf expected_bf ,_bf decrease_bf plasma_bf levels_bf DRUG following:_be OTHER_DRUG ,_af doxorubicin_af HCL_af ,_af felbamate_af ,_af rifampin_af ,_af phenobarbital_af ,_af Phenytoin(2)_af ,_af primidone_af ,_af methsuximide_af ,_af theophylline_af Thus_af ,_af patient_af titrated_af stable_af dosage_af DRUG ,_af begins_af course_af treatment_af one_af CYP3A4_af inducers_af ,_af reasonable_af expect_af dose_af increase_af DRUG may_af necessary_af ._af"
638,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,doxorubicin HCL,mechanism,"Agents_bf CYP_bf inducers_bf found_bf ,_bf expected_bf ,_bf decrease_bf plasma_bf levels_bf DRUG following:_be Cisplatin_be ,_be doxorubicin_be HCL_be ,_be felbamate_be ,_be rifampin_be ,_be phenobarbital_be ,_be Phenytoin(2)_be ,_be primidone_be ,_be methsuximide_be ,_be theophylline_be Thus_be ,_be patient_be titrated_be stable_be dosage_be DRUG ,_af begins_af course_af treatment_af one_af CYP3A4_af inducers_af ,_af reasonable_af expect_af dose_af increase_af DRUG may_af necessary_af ._af"
639,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,felbamate,mechanism,"Agents_bf CYP_bf inducers_bf found_bf ,_bf expected_bf ,_bf decrease_bf plasma_bf levels_bf DRUG following:_be Cisplatin_be ,_be doxorubicin_be HCL_be ,_be OTHER_DRUG ,_af rifampin_af ,_af phenobarbital_af ,_af Phenytoin(2)_af ,_af primidone_af ,_af methsuximide_af ,_af theophylline_af Thus_af ,_af patient_af titrated_af stable_af dosage_af DRUG ,_af begins_af course_af treatment_af one_af CYP3A4_af inducers_af ,_af reasonable_af expect_af dose_af increase_af DRUG may_af necessary_af ._af"
640,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,rifampin,mechanism,"Agents_bf CYP_bf inducers_bf found_bf ,_bf expected_bf ,_bf decrease_bf plasma_bf levels_bf DRUG following:_be Cisplatin_be ,_be doxorubicin_be HCL_be ,_be felbamate_be ,_be OTHER_DRUG ,_af phenobarbital_af ,_af Phenytoin(2)_af ,_af primidone_af ,_af methsuximide_af ,_af theophylline_af Thus_af ,_af patient_af titrated_af stable_af dosage_af DRUG ,_af begins_af course_af treatment_af one_af CYP3A4_af inducers_af ,_af reasonable_af expect_af dose_af increase_af DRUG may_af necessary_af ._af"
641,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,phenobarbital,mechanism,"Agents_bf CYP_bf inducers_bf found_bf ,_bf expected_bf ,_bf decrease_bf plasma_bf levels_bf DRUG following:_be Cisplatin_be ,_be doxorubicin_be HCL_be ,_be felbamate_be ,_be rifampin_be ,_be OTHER_DRUG ,_af Phenytoin(2)_af ,_af primidone_af ,_af methsuximide_af ,_af theophylline_af Thus_af ,_af patient_af titrated_af stable_af dosage_af DRUG ,_af begins_af course_af treatment_af one_af CYP3A4_af inducers_af ,_af reasonable_af expect_af dose_af increase_af DRUG may_af necessary_af ._af"
642,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,Phenytoin,mechanism,"Agents_bf CYP_bf inducers_bf found_bf ,_bf expected_bf ,_bf decrease_bf plasma_bf levels_bf DRUG following:_be Cisplatin_be ,_be doxorubicin_be HCL_be ,_be felbamate_be ,_be rifampin_be ,_be phenobarbital_be ,_be Phenytoin(2)_be ,_be primidone_be ,_be methsuximide_be ,_be theophylline_be Thus_be ,_be patient_be titrated_be stable_be dosage_be DRUG ,_af begins_af course_af treatment_af one_af CYP3A4_af inducers_af ,_af reasonable_af expect_af dose_af increase_af DRUG may_af necessary_af ._af"
643,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,primidone,mechanism,"Agents_bf CYP_bf inducers_bf found_bf ,_bf expected_bf ,_bf decrease_bf plasma_bf levels_bf DRUG following:_be Cisplatin_be ,_be doxorubicin_be HCL_be ,_be felbamate_be ,_be rifampin_be ,_be phenobarbital_be ,_be Phenytoin(2)_be ,_be OTHER_DRUG ,_af methsuximide_af ,_af theophylline_af Thus_af ,_af patient_af titrated_af stable_af dosage_af DRUG ,_af begins_af course_af treatment_af one_af CYP3A4_af inducers_af ,_af reasonable_af expect_af dose_af increase_af DRUG may_af necessary_af ._af"
644,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,methsuximide,mechanism,"Agents_bf CYP_bf inducers_bf found_bf ,_bf expected_bf ,_bf decrease_bf plasma_bf levels_bf DRUG following:_be Cisplatin_be ,_be doxorubicin_be HCL_be ,_be felbamate_be ,_be rifampin_be ,_be phenobarbital_be ,_be Phenytoin(2)_be ,_be primidone_be ,_be OTHER_DRUG ,_af theophylline_af Thus_af ,_af patient_af titrated_af stable_af dosage_af DRUG ,_af begins_af course_af treatment_af one_af CYP3A4_af inducers_af ,_af reasonable_af expect_af dose_af increase_af DRUG may_af necessary_af ._af"
645,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,theophylline,mechanism,"Agents_bf CYP_bf inducers_bf found_bf ,_bf expected_bf ,_bf decrease_bf plasma_bf levels_bf DRUG following:_be Cisplatin_be ,_be doxorubicin_be HCL_be ,_be felbamate_be ,_be rifampin_be ,_be phenobarbital_be ,_be Phenytoin(2)_be ,_be primidone_be ,_be methsuximide_be ,_be OTHER_DRUG Thus_af ,_af patient_af titrated_af stable_af dosage_af DRUG ,_af begins_af course_af treatment_af one_af CYP3A4_af inducers_af ,_af reasonable_af expect_af dose_af increase_af DRUG may_af necessary_af ._af"
646,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,Acetaminophen,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be OTHER_DRUG ,_af alprazolam_af ,_af amitriptyline_af ,_af bupropion_af ,_af buspirone_af ,_af citalopram_af ,_af clobazam_af ,_af clonazepam_af ,_af clozapine_af ,_af cyclosporin_af ,_af delavirdine_af ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
647,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,alprazolam,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be OTHER_DRUG ,_af amitriptyline_af ,_af bupropion_af ,_af buspirone_af ,_af citalopram_af ,_af clobazam_af ,_af clonazepam_af ,_af clozapine_af ,_af cyclosporin_af ,_af delavirdine_af ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
648,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,amitriptyline,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be OTHER_DRUG ,_af bupropion_af ,_af buspirone_af ,_af citalopram_af ,_af clobazam_af ,_af clonazepam_af ,_af clozapine_af ,_af cyclosporin_af ,_af delavirdine_af ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
649,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,bupropion,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be OTHER_DRUG ,_af buspirone_af ,_af citalopram_af ,_af clobazam_af ,_af clonazepam_af ,_af clozapine_af ,_af cyclosporin_af ,_af delavirdine_af ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
650,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,buspirone,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be OTHER_DRUG ,_af citalopram_af ,_af clobazam_af ,_af clonazepam_af ,_af clozapine_af ,_af cyclosporin_af ,_af delavirdine_af ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
651,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,citalopram,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be OTHER_DRUG ,_af clobazam_af ,_af clonazepam_af ,_af clozapine_af ,_af cyclosporin_af ,_af delavirdine_af ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
652,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,clobazam,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be OTHER_DRUG ,_af clonazepam_af ,_af clozapine_af ,_af cyclosporin_af ,_af delavirdine_af ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
653,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,clonazepam,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be OTHER_DRUG ,_af clozapine_af ,_af cyclosporin_af ,_af delavirdine_af ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
654,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,clozapine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be OTHER_DRUG ,_af cyclosporin_af ,_af delavirdine_af ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
655,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,cyclosporin,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be OTHER_DRUG ,_af delavirdine_af ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
656,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,delavirdine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be OTHER_DRUG ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
657,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,desipramine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be OTHER_DRUG ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
658,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,diazepam,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be OTHER_DRUG ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
659,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,dicumarol,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be OTHER_DRUG ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
660,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,doxycycline,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be OTHER_DRUG ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
661,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,ethosuximide,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be OTHER_DRUG ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
662,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,felbamate,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be OTHER_DRUG ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
663,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,felodipine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be OTHER_DRUG ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
664,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,glucocorticoids,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be OTHER_DRUG ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
665,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,haloperidol,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be OTHER_DRUG ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
666,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,itraconazole,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be OTHER_DRUG ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
667,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,lamotrigine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be OTHER_DRUG ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
668,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,levothyroxine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be OTHER_DRUG ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
669,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,lorazepam,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be OTHER_DRUG ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
670,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,methadone,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be OTHER_DRUG ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
671,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,midazolam,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be OTHER_DRUG ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
672,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,mirtazapine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be OTHER_DRUG ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
673,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,nortriptyline,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be OTHER_DRUG ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
674,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,olanzapine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be OTHER_DRUG ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
675,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,contraceptives,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be topiramate_be ,_be tiagabine_be ,_be tramadol_be ,_be triazolam_be ,_be valproate_be ,_be warfarin(5)_be ,_be ziprasidone_be ,_be zonisamide_be ._be"
676,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,oxcarbazepine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be OTHER_DRUG ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
677,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,Phenytoin,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be topiramate_be ,_be tiagabine_be ,_be tramadol_be ,_be triazolam_be ,_be valproate_be ,_be warfarin(5)_be ,_be ziprasidone_be ,_be zonisamide_be ._be"
678,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,praziquantel,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be OTHER_DRUG ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
679,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,protease inhibitors,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be topiramate_be ,_be tiagabine_be ,_be tramadol_be ,_be triazolam_be ,_be valproate_be ,_be warfarin(5)_be ,_be ziprasidone_be ,_be zonisamide_be ._be"
680,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,quetiapine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be OTHER_DRUG ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
681,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,risperidone,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be OTHER_DRUG ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
682,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,theophylline,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be OTHER_DRUG ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
683,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,topiramate,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be OTHER_DRUG ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
684,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,tiagabine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be topiramate_be ,_be OTHER_DRUG ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
685,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,tramadol,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be topiramate_be ,_be tiagabine_be ,_be OTHER_DRUG ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
686,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,triazolam,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be topiramate_be ,_be tiagabine_be ,_be tramadol_be ,_be OTHER_DRUG ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
687,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,valproate,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be topiramate_be ,_be tiagabine_be ,_be tramadol_be ,_be triazolam_be ,_be OTHER_DRUG ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
688,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,warfarin,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be topiramate_be ,_be tiagabine_be ,_be tramadol_be ,_be triazolam_be ,_be valproate_be ,_be warfarin(5)_be ,_be ziprasidone_be ,_be zonisamide_be ._be"
689,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,ziprasidone,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be topiramate_be ,_be tiagabine_be ,_be tramadol_be ,_be triazolam_be ,_be valproate_be ,_be warfarin(5)_be ,_be OTHER_DRUG ,_af zonisamide_af ._af"
690,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,zonisamide,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be topiramate_be ,_be tiagabine_be ,_be tramadol_be ,_be triazolam_be ,_be valproate_be ,_be warfarin(5)_be ,_be ziprasidone_be ,_be OTHER_DRUG ._af"
691,"Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.",EQUETROTM,Clomipramine HCl,mechanism,"Agents_bf Increased_bf Levels_bf Presence_bf Carbamazepine:_bf DRUG increases_be plasma_be levels_be following_be agents:_be Clomipramine_be HCl_be ,_be Phenytoin(6)_be ,_be primidone_be Thus_be ,_be patient_be titrated_be stable_be dosage_be one_be agents_be category_be ,_be begins_be course_be treatment_be DRUG ,_af reasonable_af expect_af dose_af decrease_af concomitant_af agent_af may_af necessary_af ._af"
692,"Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.",EQUETROTM,Phenytoin,mechanism,"Agents_bf Increased_bf Levels_bf Presence_bf Carbamazepine:_bf DRUG increases_be plasma_be levels_be following_be agents:_be Clomipramine_be HCl_be ,_be Phenytoin(6)_be ,_be primidone_be Thus_be ,_be patient_be titrated_be stable_be dosage_be one_be agents_be category_be ,_be begins_be course_be treatment_be DRUG ,_af reasonable_af expect_af dose_af decrease_af concomitant_af agent_af may_af necessary_af ._af"
693,"Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.",EQUETROTM,primidone,mechanism,"Agents_bf Increased_bf Levels_bf Presence_bf Carbamazepine:_bf DRUG increases_be plasma_be levels_be following_be agents:_be Clomipramine_be HCl_be ,_be Phenytoin(6)_be ,_be OTHER_DRUG Thus_af ,_af patient_af titrated_af stable_af dosage_af one_af agents_af category_af ,_af begins_af course_af treatment_af DRUG ,_af reasonable_af expect_af dose_af decrease_af concomitant_af agent_af may_af necessary_af ._af"
694,Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.,carbamazepine,lithium,effect,Pharmacological/Pharmacodynamic_bf Interactions_bf DRUG Concomitant_be administration_be DRUG OTHER_DRUG may_af increase_af risk_af neurotoxic_af side_af effects_af ._af
695,"Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.",anti-malarial drugs,carbamazepine,effect,"Additionally_bf ,_bf anti-malarial_bf drugs_bf ,_bf chloroquine_bf mefloquine_bf ,_bf may_bf antagonize_bf activity_bf OTHER_DRUG ._be"
696,"Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.",chloroquine,carbamazepine,effect,"Additionally_bf ,_bf anti-malarial_bf drugs_bf ,_bf DRUG mefloquine_be ,_be may_be antagonize_be activity_be OTHER_DRUG ._af"
697,"Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.",mefloquine,carbamazepine,effect,"Additionally_bf ,_bf anti-malarial_bf drugs_bf ,_bf chloroquine_bf DRUG ,_be may_be antagonize_be activity_be OTHER_DRUG ._af"
698,"Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.",EQUETROTM,centrally acting drugs,advise,"Because_bf primary_bf CNS_bf effect_bf ,_bf caution_bf used_bf DRUG taken_be centrally_be acting_be drugs_be alcohol_be ._be"
699,"Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.",EQUETROTM,alcohol,advise,"Because_bf primary_bf CNS_bf effect_bf ,_bf caution_bf used_bf DRUG taken_be centrally_be acting_be drugs_be OTHER_DRUG ._af"
700,Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.,Geocillin,probenecid,mechanism,DRUG (carbenicillin_be indanyl_be sodium)_be blood_be levels_be may_be increased_be prolonged_be concurrent_be administration_be OTHER_DRUG ._af
701,Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.,carbenicillin indanyl sodium,probenecid,mechanism,Geocillin_bf (carbenicillin_bf indanyl_bf sodium)_bf blood_bf levels_bf may_bf increased_bf prolonged_bf concurrent_bf administration_bf OTHER_DRUG ._be
702,"Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.",Iodine,Carbimazole,effect,"DRUG DRUG excess_af may_af decrease_af effect_af OTHER_DRUG ,_af DRUG deficiency_af increase_af effect_af OTHER_DRUG ._af"
703,"Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.",iodine,Carbimazole,effect,"DRUG DRUG excess_af may_af decrease_af effect_af OTHER_DRUG ,_af DRUG deficiency_af increase_af effect_af OTHER_DRUG ._af"
704,Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.,digoxin,antithyroid agents,mechanism,Serum_bf concentration_bf DRUG digitoxin_be may_be increase_be patients_be take_be antithyroid_be agents_be ._be
705,Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.,digitoxin,antithyroid agents,mechanism,Serum_bf concentration_bf digoxin_bf DRUG may_be increase_be patients_be take_be antithyroid_be agents_be ._be
706,"Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole.",Antithyroid agents,sodium iodide I131,effect,"Antithyroid_bf agents_bf may_bf decrease_bf thyroidal_bf uptake_bf sodium_bf iodide_bf I131_bf ,_bf rebound_bf uptake_bf may_bf occur_bf 5_bf days_bf sudden_bf withdrawal_bf Carbimazole_bf ._bf"
707,"Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.",Antihistamines,tricyclic antidepressants,effect,"DRUG may_be enhance_be effects_be tricyclic_be antidepressants_be ,_be barbiturates_be ,_be alcohol_be ,_be CNS_be depressants_be ._be"
708,"Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.",Antihistamines,barbiturates,effect,"DRUG may_be enhance_be effects_be tricyclic_be antidepressants_be ,_be OTHER_DRUG ,_af alcohol_af ,_af CNS_af depressants_af ._af"
709,"Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.",Antihistamines,alcohol,effect,"DRUG may_be enhance_be effects_be tricyclic_be antidepressants_be ,_be barbiturates_be ,_be OTHER_DRUG ,_af CNS_af depressants_af ._af"
710,"Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.",Antihistamines,CNS depressants,effect,"DRUG may_be enhance_be effects_be tricyclic_be antidepressants_be ,_be barbiturates_be ,_be alcohol_be ,_be CNS_be depressants_be ._be"
711,MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.,MAO inhibitors,antihistamines,effect,MAO_bf inhibitors_bf prolong_bf intensify_bf anticholinergic_bf effects_bf OTHER_DRUG ._be
712,"Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.",Sympathomimetic amines,reserpine,effect,"Sympathomimetic_bf amines_bf may_bf reduce_bf antihypertensive_bf effects_bf OTHER_DRUG ,_be veratrum_be alkaloids_be ,_be methyldopa_be mecamylamine_be ._be"
713,"Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.",Sympathomimetic amines,veratrum alkaloids,effect,"Sympathomimetic_bf amines_bf may_bf reduce_bf antihypertensive_bf effects_bf reserpine_bf ,_bf veratrum_bf alkaloids_bf ,_bf methyldopa_bf mecamylamine_bf ._bf"
714,"Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.",Sympathomimetic amines,methyldopa,effect,"Sympathomimetic_bf amines_bf may_bf reduce_bf antihypertensive_bf effects_bf reserpine_bf ,_bf veratrum_bf alkaloids_bf ,_bf OTHER_DRUG mecamylamine_be ._be"
715,"Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.",Sympathomimetic amines,mecamylamine,effect,"Sympathomimetic_bf amines_bf may_bf reduce_bf antihypertensive_bf effects_bf reserpine_bf ,_bf veratrum_bf alkaloids_bf ,_bf methyldopa_bf OTHER_DRUG ._be"
716,Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.,sympathomimetics,MAO inhibitors,effect,Effects_bf DRUG increased_be MAO_be inhibitors_be beta_be adrenergic_be blockers_be ._be
717,Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.,sympathomimetics,beta adrenergic blockers,effect,Effects_bf DRUG increased_be MAO_be inhibitors_be beta_be adrenergic_be blockers_be ._be
718,HEMABATE may augment the activity of other oxytocic agents.,HEMABATE,oxytocic agents,effect,DRUG may_be augment_be activity_be oxytocic_be agents_be ._be
719,Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.,Ocupress,beta-adrenergic blocking agent,advise,DRUG used_be caution_be patients_be receiving_be beta-adrenergic_be blocking_be agent_be orally_be potential_be additive_be effects_be systemic_be beta-blockade_be ._be
720,"Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.",beta-blocker,reserpine,advise,"Close_bf observation_bf patient_bf recommended_bf DRUG administered_be patients_be receiving_be catecholamine-depleting_be drugs_be OTHER_DRUG ,_af possible_af additive_af effects_af production_af hypotension_af and/or_af marked_af bradycardia_af ,_af may_af produce_af vertigo_af ,_af syncope_af ,_af postural_af hypotension_af ._af"
721,"poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .",quinidine,carvedilol,effect,"poor_bf metabolizers_bf debrisoquin:_bf Interactions_bf OTHER_DRUG strong_be inhibitors_be CYP2D6_be (such_be DRUG ,_af fluoxetine_af ,_af paroxetine_af ,_af propafenone)_af studied_af ,_af drugs_af would_af expected_af increase_af blood_af levels_af R(+)_af enantiomer_af OTHER_DRUG ._af"
722,"poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .",fluoxetine,carvedilol,effect,"poor_bf metabolizers_bf debrisoquin:_bf Interactions_bf OTHER_DRUG strong_be inhibitors_be CYP2D6_be (such_be quinidine_be ,_be DRUG ,_af paroxetine_af ,_af propafenone)_af studied_af ,_af drugs_af would_af expected_af increase_af blood_af levels_af R(+)_af enantiomer_af OTHER_DRUG ._af"
723,"poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .",paroxetine,carvedilol,effect,"poor_bf metabolizers_bf debrisoquin:_bf Interactions_bf OTHER_DRUG strong_be inhibitors_be CYP2D6_be (such_be quinidine_be ,_be fluoxetine_be ,_be DRUG ,_af propafenone)_af studied_af ,_af drugs_af would_af expected_af increase_af blood_af levels_af R(+)_af enantiomer_af OTHER_DRUG ._af"
724,"poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .",propafenone,carvedilol,effect,"poor_bf metabolizers_bf debrisoquin:_bf Interactions_bf OTHER_DRUG strong_be inhibitors_be CYP2D6_be (such_be quinidine_be ,_be fluoxetine_be ,_be paroxetine_be ,_be propafenone)_be studied_be ,_be drugs_be would_be expected_be increase_be blood_be levels_be R(+)_be enantiomer_be OTHER_DRUG ._af"
725,"Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.",agents with b-blocking properties,reserpine,effect,"Catecholamine-depleting_bf Agents:_bf Patients_bf taking_bf agents_bf b-blocking_bf properties_bf drug_bf deplete_bf catecholamines_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG monoamine_be oxidase_be inhibitors)_be observed_be closely_be signs_be hypotension_be and/or_be severe_be bradycardia_be ._be"
726,"Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.",agents with b-blocking properties,monoamine oxidase inhibitors,effect,"Catecholamine-depleting_bf Agents:_bf Patients_bf taking_bf agents_bf b-blocking_bf properties_bf drug_bf deplete_bf catecholamines_bf (e_bf ._bf g_bf ._bf ,_bf reserpine_bf monoamine_bf oxidase_bf inhibitors)_bf observed_bf closely_bf signs_bf hypotension_bf and/or_bf severe_bf bradycardia_bf ._bf"
727,Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.,clonidine,agents with b-blocking properties,effect,Clonidine:_bf Concomitant_bf administration_bf DRUG agents_be b-blocking_be properties_be may_be potentiate_be blood-pressure-_be heart-rate-lowering_be effects_be ._be
728,"When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.",agents with b-blocking properties,clonidine,advise,"When_bf concomitant_bf treatment_bf agents_bf b-blocking_bf properties_bf OTHER_DRUG terminated_be ,_be b-blocking_be agent_be discontinued_be first_be ._be"
729,Cyclosporine: Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.,cyclosporine,carvedilol,mechanism,Cyclosporine:_bf Modest_bf increases_bf mean_bf trough_bf DRUG concentrations_be observed_be following_be initiation_be OTHER_DRUG treatment_af 21_af renal_af transplant_af patients_af suffering_af chronic_af vascular_af rejection_af ._af
730,"Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.",cyclosporine,carvedilol,advise,"Due_bf wide_bf interindividual_bf variability_bf dose_bf adjustment_bf required_bf ,_bf recommended_bf DRUG concentrations_be monitored_be closely_be initiation_be OTHER_DRUG therapy_af dose_af DRUG adjusted_af appropriate_af ._af"
731,"Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.",carvedilol,cyclosporine,advise,"Due_bf wide_bf interindividual_bf variability_bf dose_bf adjustment_bf required_bf ,_bf recommended_bf OTHER_DRUG concentrations_be monitored_be closely_be initiation_be DRUG therapy_af dose_af OTHER_DRUG adjusted_af appropriate_af ._af"
732,Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.,digoxin,carvedilol,mechanism,Digoxin:_bf DRUG concentrations_be increased_be 15%_be DRUG OTHER_DRUG administered_af concomitantly_af ._af
733,Both digoxin and COREG slow AV conduction.,digoxin,COREG,effect,Both_bf DRUG OTHER_DRUG slow_af AV_af conduction_af ._af
734,"Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.",digoxin,COREG,advise,"Therefore_bf ,_bf increased_bf monitoring_bf DRUG recommended_be initiating_be ,_be adjusting_be ,_be discontinuing_be OTHER_DRUG ._af"
735,Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.,Rifampin,carvedilol,mechanism,Inducers_bf Inhibitors_bf Hepatic_bf Metabolism:_bf DRUG reduced_be plasma_be concentrations_be OTHER_DRUG 70%_af ._af
736,Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.,COREG,diltiazem,effect,Calcium_bf Channel_bf Blockers:_bf Isolated_bf cases_bf conduction_bf disturbance_bf (rarely_bf hemodynamic_bf compromise)_bf observed_bf DRUG co-administered_be OTHER_DRUG ._af
737,"As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.",COREG,verapamil,advise,"As_bf agents_bf b-blocking_bf properties_bf ,_bf DRUG administered_be orally_be calcium_be channel_be blockers_be OTHER_DRUG diltiazem_af type_af ,_af recommended_af ECG_af blood_af pressure_af monitored_af ._af"
738,"As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.",COREG,diltiazem,advise,"As_bf agents_bf b-blocking_bf properties_bf ,_bf DRUG administered_be orally_be calcium_be channel_be blockers_be verapamil_be OTHER_DRUG type_af ,_af recommended_af ECG_af blood_af pressure_af monitored_af ._af"
739,Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.,Agents with b-blocking properties,insulin,effect,OTHER_DRUG Oral_be Hypoglycemics:_be Agents_be b-blocking_be properties_be may_be enhance_be blood-sugar-reducing_be effect_be OTHER_DRUG oral_af hypoglycemics_af ._af
740,Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.,Agents with b-blocking properties,hypoglycemics,effect,Insulin_bf Oral_bf Hypoglycemics:_bf Agents_bf b-blocking_bf properties_bf may_bf enhance_bf blood-sugar-reducing_bf effect_bf insulin_bf oral_bf OTHER_DRUG ._be
741,"CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.",CANCIDAS,tacrolimus,mechanism,"DRUG reduced_be blood_be AUC0-12_be OTHER_DRUG approximately_af 20%_af ,_af peak_af blood_af concentration_af (Cmax)_af 16%_af ,_af 12-hour_af blood_af concentration_af (C12hr)_af 26%_af healthy_af subjects_af OTHER_DRUG (2_af doses_af 0_af ._af 1_af mg/kg_af 12_af hours_af apart)_af administered_af 10th_af day_af DRUG 70_af mg_af daily_af ,_af compared_af results_af control_af period_af OTHER_DRUG administered_af alone_af ._af"
742,"In two clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin by approximately 35%.",cyclosporine,caspofungin,mechanism,"In_bf two_bf clinical_bf studies_bf ,_bf DRUG (one_be 4_be mg/kg_be dose_be two_be 3_be mg/kg_be doses)_be increased_be AUC_be OTHER_DRUG approximately_af 35%_af ._af"
743,There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.,CANCIDAS,cyclosporine,effect,There_bf transient_bf increases_bf liver_bf ALT_bf AST_bf DRUG OTHER_DRUG co-administered_af ._af
744,A drug-drug interaction study with rifampin in healthy volunteers has shown a 30% decrease in caspofungin trough concentrations.,rifampin,caspofungin,mechanism,A_bf drug-drug_bf interaction_bf study_bf DRUG healthy_be volunteers_be shown_be 30%_be decrease_be OTHER_DRUG trough_af concentrations_af ._af
745,Patients on rifampin should receive 70 mg of CANCIDAS daily.,rifampin,CANCIDAS,advise,Patients_bf DRUG receive_be 70_be mg_be OTHER_DRUG daily_af ._af
746,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",efavirenz,CANCIDAS,mechanism,"In_bf addition_bf ,_bf results_bf regression_bf analyses_bf patient_bf pharmacokinetic_bf data_bf suggest_bf co-administration_bf inducers_bf drug_bf clearance_bf (efavirenz_bf ,_bf nevirapine_bf ,_bf phenytoin_bf ,_bf dexamethasone_bf ,_bf carbamazepine)_bf OTHER_DRUG may_be result_be clinically_be meaningful_be reductions_be caspofungin_be concentrations_be ._be"
747,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",nevirapine,CANCIDAS,mechanism,"In_bf addition_bf ,_bf results_bf regression_bf analyses_bf patient_bf pharmacokinetic_bf data_bf suggest_bf co-administration_bf inducers_bf drug_bf clearance_bf (efavirenz_bf ,_bf DRUG ,_be phenytoin_be ,_be dexamethasone_be ,_be carbamazepine)_be OTHER_DRUG may_af result_af clinically_af meaningful_af reductions_af caspofungin_af concentrations_af ._af"
748,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",phenytoin,CANCIDAS,mechanism,"In_bf addition_bf ,_bf results_bf regression_bf analyses_bf patient_bf pharmacokinetic_bf data_bf suggest_bf co-administration_bf inducers_bf drug_bf clearance_bf (efavirenz_bf ,_bf nevirapine_bf ,_bf DRUG ,_be dexamethasone_be ,_be carbamazepine)_be OTHER_DRUG may_af result_af clinically_af meaningful_af reductions_af caspofungin_af concentrations_af ._af"
749,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",dexamethasone,CANCIDAS,mechanism,"In_bf addition_bf ,_bf results_bf regression_bf analyses_bf patient_bf pharmacokinetic_bf data_bf suggest_bf co-administration_bf inducers_bf drug_bf clearance_bf (efavirenz_bf ,_bf nevirapine_bf ,_bf phenytoin_bf ,_bf DRUG ,_be carbamazepine)_be OTHER_DRUG may_af result_af clinically_af meaningful_af reductions_af caspofungin_af concentrations_af ._af"
750,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",carbamazepine,CANCIDAS,mechanism,"In_bf addition_bf ,_bf results_bf regression_bf analyses_bf patient_bf pharmacokinetic_bf data_bf suggest_bf co-administration_bf inducers_bf drug_bf clearance_bf (efavirenz_bf ,_bf nevirapine_bf ,_bf phenytoin_bf ,_bf dexamethasone_bf ,_bf carbamazepine)_bf OTHER_DRUG may_be result_be clinically_be meaningful_be reductions_be caspofungin_be concentrations_be ._be"
751,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,efavirenz,advise,"When_bf DRUG co-administered_be inducers_be drug_be clearance_be ,_be OTHER_DRUG ,_af nevirapine_af ,_af phenytoin_af ,_af dexamethasone_af ,_af carbamazepine_af ,_af use_af daily_af dose_af 70_af mg_af DRUG considered_af"
752,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,nevirapine,advise,"When_bf DRUG co-administered_be inducers_be drug_be clearance_be ,_be efavirenz_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af dexamethasone_af ,_af carbamazepine_af ,_af use_af daily_af dose_af 70_af mg_af DRUG considered_af"
753,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,phenytoin,advise,"When_bf DRUG co-administered_be inducers_be drug_be clearance_be ,_be efavirenz_be ,_be nevirapine_be ,_be OTHER_DRUG ,_af dexamethasone_af ,_af carbamazepine_af ,_af use_af daily_af dose_af 70_af mg_af DRUG considered_af"
754,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,dexamethasone,advise,"When_bf DRUG co-administered_be inducers_be drug_be clearance_be ,_be efavirenz_be ,_be nevirapine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af carbamazepine_af ,_af use_af daily_af dose_af 70_af mg_af DRUG considered_af"
755,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,carbamazepine,advise,"When_bf DRUG co-administered_be inducers_be drug_be clearance_be ,_be efavirenz_be ,_be nevirapine_be ,_be phenytoin_be ,_be dexamethasone_be ,_be OTHER_DRUG ,_af use_af daily_af dose_af 70_af mg_af DRUG considered_af"
756,"Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.",Probenecid,cephalosporins,mechanism,"DRUG may_be decrease_be renal_be tubular_be secretion_be OTHER_DRUG used_af concurrently_af ,_af resulting_af increased_af prolonged_af cephalosporin_af blood_af levels_af ._af"
757,"Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with antacids.",cefditoren pivoxil,antacids,advise,"Although_bf clinical_bf significance_bf known_bf ,_bf recommended_bf cefditoren_bf pivoxil_bf taken_bf concomitantly_bf OTHER_DRUG ._be"
758,"H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.",famotidine,cefditoren pivoxil,mechanism,"H2-Receptor_bf Antagonists:_bf Co-administration_bf single_bf dose_bf intravenously_bf administered_bf DRUG (20_be mg)_be reduced_be oral_be absorption_be single_be 400_be mg_be dose_be cefditoren_be pivoxil_be administered_be following_be meal_be ,_be evidenced_be 27%_be decrease_be mean_be Cmax_be 22%_be decrease_be mean_be AUC_be ._be"
759,"Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.",b-lactam antibiotics,cefditoren pivoxil,mechanism,"Probenecid:_bf As_bf b-lactam_bf antibiotics_bf ,_bf co-administration_bf probenecid_bf cefditoren_bf pivoxil_bf resulted_bf increase_bf plasma_bf exposure_bf cefditoren_bf ,_bf 49%_bf increase_bf mean_bf Cmax_bf ,_bf 122%_bf increase_bf mean_bf AUC_bf ,_bf 53%_bf increase_bf half-life_bf ._bf"
760,"Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.",probenecid,cefditoren pivoxil,mechanism,"Probenecid:_bf As_bf b-lactam_bf antibiotics_bf ,_bf co-administration_bf DRUG cefditoren_be pivoxil_be resulted_be increase_be plasma_be exposure_be cefditoren_be ,_be 49%_be increase_be mean_be Cmax_be ,_be 122%_be increase_be mean_be AUC_be ,_be 53%_be increase_be half-life_be ._be"
761,Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.,aminoglycosides,MAXIPIME,advise,Renal_bf function_bf monitored_bf carefully_bf high_bf doses_bf DRUG administered_be OTHER_DRUG increased_af potential_af nephrotoxicity_af ototoxicity_af aminoglycoside_af antibiotics_af ._af
762,Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.,cephalosporins,diuretics,effect,Nephrotoxicity_bf reported_bf following_bf concomitant_bf administration_bf DRUG potent_be OTHER_DRUG furosemide_af ._af
763,Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.,cephalosporins,furosemide,effect,Nephrotoxicity_bf reported_bf following_bf concomitant_bf administration_bf DRUG potent_be diuretics_be OTHER_DRUG ._af
764,Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.,carbamazepine,SUPRAX,mechanism,Carbamazepine:_bf Elevated_bf DRUG levels_be reported_be postmarketing_be experience_be OTHER_DRUG administered_af concomitantly_af ._af
765,"Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.",Warfarin,cefixime,effect,"DRUG Anticoagulants:_be Increased_be prothrombin_be time_be ,_be without_be clinical_be bleeding_be ,_be reported_be OTHER_DRUG administered_af concomitantly_af ._af"
766,"Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.",Anticoagulants,cefixime,effect,"Warfarin_bf Anticoagulants:_bf Increased_bf prothrombin_bf time_bf ,_bf without_bf clinical_bf bleeding_bf ,_bf reported_bf OTHER_DRUG administered_be concomitantly_be ._be"
767,Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.,cephalosporins,aminoglycoside antibiotics,effect,Increased_bf nephrotoxicity_bf reported_bf following_bf concomitant_bf administration_bf DRUG aminoglycoside_be antibiotics_be ._be
768,"If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.",CEFOTAN,aminoglycoside,effect,"If_bf DRUG OTHER_DRUG used_af concomitantly_af ,_af renal_af function_af carefully_af monitored_af ,_af nephrotoxicity_af may_af potentiated_af ._af"
769,Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.,cephalosporins,aminoglycoside antibiotics,effect,Increased_bf nephrotoxicity_bf reported_bf following_bf concomitant_bf administration_bf DRUG aminoglycoside_be antibiotics_be ._be
770,Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics.,aminoglycoside antibiotics,cephalosporin antibiotics,effect,Nephrotoxicity_bf reported_bf following_bf concomitant_bf administration_bf aminoglycoside_bf antibiotics_bf cephalosporin_bf antibiotics_bf ._bf
771,Concomitant administration of probenecid doubled the AUC for cefprozil.,probenecid,cefprozil,mechanism,Concomitant_bf administration_bf DRUG doubled_be AUC_be OTHER_DRUG ._af
772,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.,cephalosporins,aminoglycoside antibiotics,effect,Nephrotoxicity_bf reported_bf following_bf concomitant_bf administration_bf DRUG aminoglycoside_be antibiotics_be potent_be diuretics_be furosemide_be ._be
773,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.,cephalosporins,diuretics,effect,Nephrotoxicity_bf reported_bf following_bf concomitant_bf administration_bf DRUG aminoglycoside_be antibiotics_be potent_be OTHER_DRUG furosemide_af ._af
774,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.,cephalosporins,furosemide,effect,Nephrotoxicity_bf reported_bf following_bf concomitant_bf administration_bf DRUG aminoglycoside_be antibiotics_be potent_be diuretics_be OTHER_DRUG ._af
775,"Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.",Chloramphenicol,beta-lactam antibiotics,effect,"DRUG shown_be antagonistic_be beta-lactam_be antibiotics_be ,_be including_be ceftazidime_be ,_be based_be vitro_be studies_be time_be kill_be curves_be enteric_be gram-negative_be bacilli_be ._be"
776,"Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.",Chloramphenicol,ceftazidime,effect,"DRUG shown_be antagonistic_be beta-lactam_be antibiotics_be ,_be including_be OTHER_DRUG ,_af based_af vitro_af studies_af time_af kill_af curves_af enteric_af gram-negative_af bacilli_af ._af"
777,"however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.",ranitidine,ceftibuten,mechanism,"however_bf ,_bf 150_bf mg_bf DRUG q12h_be 3_be days_be increased_be OTHER_DRUG C_af max_af 23%_af OTHER_DRUG AUC_af 16%_af ._af"
778,"however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.",ranitidine,ceftibuten,mechanism,"however_bf ,_bf 150_bf mg_bf DRUG q12h_be 3_be days_be increased_be OTHER_DRUG C_af max_af 23%_af OTHER_DRUG AUC_af 16%_af ._af"
779,"Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides.",cephalosporins,aminoglycosides,effect,"Although_bf occurrence_bf reported_bf Cefizox_bf ,_bf nephrotoxicity_bf reported_bf following_bf concomitant_bf administration_bf DRUG OTHER_DRUG ._af"
780,Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.,celecoxib,fluconazole,int,Clinical_bf studies_bf DRUG identified_be potentially_be significant_be interactions_be OTHER_DRUG lithium_af ._af
781,Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.,celecoxib,lithium,int,Clinical_bf studies_bf DRUG identified_be potentially_be significant_be interactions_be fluconazole_be OTHER_DRUG ._af
782,Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.,nonsteroidal anti-inflammatory drugs,furosemide,int,Experience_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf (NSAIDs)_bf suggests_bf potential_bf interactions_bf OTHER_DRUG ACE_be inhibitors_be ._be
783,Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.,nonsteroidal anti-inflammatory drugs,ACE inhibitors,int,Experience_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf (NSAIDs)_bf suggests_bf potential_bf interactions_bf furosemide_bf ACE_bf inhibitors_bf ._bf
784,Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.,NSAIDs,furosemide,int,Experience_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf (NSAIDs)_bf suggests_bf potential_bf interactions_bf OTHER_DRUG ACE_be inhibitors_be ._be
785,Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.,NSAIDs,ACE inhibitors,int,Experience_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf (NSAIDs)_bf suggests_bf potential_bf interactions_bf furosemide_bf ACE_bf inhibitors_bf ._bf
786,ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.,NSAIDs,Angiotensin Converting Enzyme (ACE) inhibitors,effect,ACE_bf inhibitors:_bf Reports_bf suggest_bf DRUG may_be diminish_be antihypertensive_be effect_be Angiotensin_be Converting_be Enzyme_be (ACE)_be inhibitors_be ._be
787,This interaction should be given consideration in patients taking CELEBREX concomitantly with ACE-inhibitors.,CELEBREX,ACE-inhibitors,advise,This_bf interaction_bf given_bf consideration_bf patients_bf taking_bf DRUG concomitantly_be OTHER_DRUG ._af
788,"Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,furosemide,effect,"Furosemide:_bf Clinical_bf studies_bf ,_bf well_bf post_bf marketing_bf observations_bf ,_bf shown_bf DRUG reduce_be natriuretic_be effect_be OTHER_DRUG thiazides_af patients_af ._af"
789,"Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,thiazides,effect,"Furosemide:_bf Clinical_bf studies_bf ,_bf well_bf post_bf marketing_bf observations_bf ,_bf shown_bf DRUG reduce_be natriuretic_be effect_be furosemide_be OTHER_DRUG patients_af ._af"
790,Aspirin: CELEBREX can be used with low dose aspirin.,CELEBREX,aspirin,advise,Aspirin:_bf DRUG used_be low_be dose_be OTHER_DRUG ._af
791,"However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.",aspirin,CELEBREX,effect,"However_bf ,_bf concomitant_bf administration_bf DRUG OTHER_DRUG may_af result_af increased_af rate_af GI_af ulceration_af complications_af ,_af compared_af use_af OTHER_DRUG alone_af ._af"
792,Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.,fluconazole,celecoxib,mechanism,Fluconazole:_bf Concomitant_bf administration_bf DRUG 200_be mg_be QD_be resulted_be two-fold_be increase_be OTHER_DRUG plasma_af concentration_af ._af
793,This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).,celecoxib,fluconazole,mechanism,This_bf increase_bf due_bf inhibition_bf DRUG metabolism_be via_be P450_be 2C9_be OTHER_DRUG (see_af CLINICAL_af PHARMACOLOGY_af -_af Pharmacokinetics:_af Metabolism)_af ._af
794,CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.,CELEBREX,fluconazole,advise,DRUG introduced_be lowest_be recommended_be dose_be patients_be receiving_be OTHER_DRUG ._af
795,"Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.",lithium,CELEBREX,mechanism,"Lithium:_bf In_bf study_bf conducted_bf healthy_bf subjects_bf ,_bf mean_bf steady-state_bf DRUG plasma_be levels_be increased_be approximately_be 17%_be subjects_be receiving_be DRUG 450_af mg_af BID_af OTHER_DRUG 200_af mg_af BID_af compared_af subjects_af receiving_af DRUG alone_af ._af"
796,Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.,lithium,CELEBREX,advise,Patients_bf DRUG treatment_be closely_be monitored_be OTHER_DRUG introduced_af withdrawn_af ._af
797,"However, caution should be used when administering CELEBREX with warfarin since these patients are at increased risk of bleeding complications.",CELEBREX,warfarin,advise,"However_bf ,_bf caution_bf used_bf administering_bf DRUG OTHER_DRUG since_af patients_af increased_af risk_af bleeding_af complications_af ._af"
798,"Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.",cephalexin,metformin,mechanism,"Metformin:_bf In_bf healthy_bf subjects_bf given_bf single_bf 500_bf mg_bf doses_bf DRUG OTHER_DRUG ,_af plasma_af OTHER_DRUG mean_af cmax_af AUC_af increased_af average_af 34%_af 24%_af ,_af respectively_af ,_af OTHER_DRUG mean_af renal_af clearance_af decreased_af 14%_af ._af"
799,"Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.",cephalexin,metformin,mechanism,"Although_bf observed_bf study_bf ,_bf adverse_bf effects_bf could_bf potentially_bf arise_bf co-administration_bf DRUG OTHER_DRUG inhibition_af tubular_af secretion_af via_af organic_af cationic_af transporter_af systems_af ._af"
800,"Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.",cephalexin,metformin,advise,"Accordingly_bf ,_bf careful_bf patient_bf monitoring_bf dose_bf adjustment_bf OTHER_DRUG recommended_be patients_be concomitantly_be taking_be DRUG OTHER_DRUG ._af"
801,"Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.",cephalexin,probenecid,mechanism,"Probenecid:_bf As_bf b-lactams_bf ,_bf renal_bf excretion_bf DRUG inhibited_be OTHER_DRUG ._af"
802,"In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.",cerivastatin sodium,cholestyramine,mechanism,"In_bf first_bf study_bf ,_bf concomitant_bf administration_bf 0_bf ._bf 2_bf mg_bf cerivastatin_bf sodium_bf 12_bf g_bf OTHER_DRUG resulted_be decreases_be 22%_be AUC_be 40%_be Cmax_be compared_be dosing_be cerivastatin_be sodium_be alone_be ._be"
803,"However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.",cholestyramine,cerivastatin sodium,mechanism,"However_bf ,_bf second_bf study_bf ,_bf administration_bf 12_bf g_bf DRUG 1_be hour_be evening_be meal_be 0_be ._be 3_be mg_be cerivastatin_be sodium_be approximately_be 4_be hours_be evening_be meal_be resulted_be decrease_be cerivastatin_be AUC_be less_be 8%_be ,_be decrease_be Cmax_be 30%_be compared_be dosing_be cerivastatin_be sodium_be alone_be ._be"
804,"ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.",cerivastatin,erythromycin,mechanism,"ERYTHROMYCIN:_bf In_bf hypercholesterolemic_bf patients_bf ,_bf steady-state_bf DRUG AUC_be Cmax_be increased_be approximately_be 50%_be 24%_be respectively_be 10_be days_be co-administration_be OTHER_DRUG ,_af known_af inhibitor_af cytochrome_af P450_af 3A4_af ._af"
805,"In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.",theophylline,cetirizine,mechanism,"In_bf multiple_bf dose_bf study_bf DRUG (400_be mg_be daily_be 3_be days)_be OTHER_DRUG (20_af mg_af daily_af 3_af days)_af ,_af 16%_af decrease_af clearance_af OTHER_DRUG observed_af ._af"
806,There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline;,cetirizine,theophylline,mechanism,There_bf small_bf decrease_bf clearance_bf DRUG caused_be 400-mg_be dose_be theophylline;_be
807,"Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances.",Cevimeline,beta adrenergic antagonists,advise,"DRUG administered_be caution_be patients_be taking_be beta_be adrenergic_be antagonists_be ,_be possibility_be conduction_be disturbances_be ._be"
808,"Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide.",anticoagulants,chlordiazepoxide,effect,"Although_bf clinical_bf studies_bf established_bf cause_bf effect_bf relationship_bf ,_bf physicians_bf aware_bf variable_bf effects_bf blood_bf coagulation_bf reported_bf rarely_bf patients_bf receiving_bf oral_bf DRUG OTHER_DRUG ._af"
809,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",anesthetic solutions,tricyclic antidepressants,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf epinephrine_bf norepinephrine_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf ,_bf tricyclic_bf antidepressants_bf phenothiazines_bf may_bf produce_bf severe_bf ,_bf prolonged_bf hypotension_bf hypertension_bf ._bf"
810,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",anesthetic solutions,phenothiazines,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf epinephrine_bf norepinephrine_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf ,_bf tricyclic_bf antidepressants_bf OTHER_DRUG may_be produce_be severe_be ,_be prolonged_be hypotension_be hypertension_be ._be"
811,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",epinephrine,monoamine oxidase inhibitors,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf DRUG norepinephrine_be patients_be receiving_be monoamine_be oxidase_be inhibitors_be ,_be tricyclic_be antidepressants_be phenothiazines_be may_be produce_be severe_be ,_be prolonged_be hypotension_be hypertension_be ._be"
812,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",epinephrine,tricyclic antidepressants,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf DRUG norepinephrine_be patients_be receiving_be monoamine_be oxidase_be inhibitors_be ,_be tricyclic_be antidepressants_be phenothiazines_be may_be produce_be severe_be ,_be prolonged_be hypotension_be hypertension_be ._be"
813,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",epinephrine,phenothiazines,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf DRUG norepinephrine_be patients_be receiving_be monoamine_be oxidase_be inhibitors_be ,_be tricyclic_be antidepressants_be OTHER_DRUG may_af produce_af severe_af ,_af prolonged_af hypotension_af hypertension_af ._af"
814,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",norepinephrine,monoamine oxidase inhibitors,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf epinephrine_bf DRUG patients_be receiving_be monoamine_be oxidase_be inhibitors_be ,_be tricyclic_be antidepressants_be phenothiazines_be may_be produce_be severe_be ,_be prolonged_be hypotension_be hypertension_be ._be"
815,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",norepinephrine,tricyclic antidepressants,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf epinephrine_bf DRUG patients_be receiving_be monoamine_be oxidase_be inhibitors_be ,_be tricyclic_be antidepressants_be phenothiazines_be may_be produce_be severe_be ,_be prolonged_be hypotension_be hypertension_be ._be"
816,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",norepinephrine,phenothiazines,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf epinephrine_bf DRUG patients_be receiving_be monoamine_be oxidase_be inhibitors_be ,_be tricyclic_be antidepressants_be OTHER_DRUG may_af produce_af severe_af ,_af prolonged_af hypotension_af hypertension_af ._af"
817,"Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.",vasopressor drugs,ergot-type oxytocic drugs,effect,"Concurrent_bf administration_bf vasopressor_bf drugs_bf (for_bf treatment_bf hypotension_bf related_bf obstetric_bf blocks)_bf ergot-type_bf oxytocic_bf drugs_bf may_bf cause_bf severe_bf ,_bf persistent_bf hypertension_bf cerebrovascular_bf accidents_bf ._bf"
818,"Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed.",chloroprocaine,sulfonamide drug,advise,"Therefore_bf ,_bf DRUG used_be condition_be sulfonamide_be drug_be employed_be ._be"
819,Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;,Antacids,chloroquine,mechanism,DRUG kaolin:_be DRUG kaolin_af reduce_af absorption_af chloroquine;_af
820,Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;,kaolin,chloroquine,mechanism,Antacids_bf kaolin:_bf Antacids_bf DRUG reduce_be absorption_be chloroquine;_be
821,"Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level.",Cimetidine,chloroquine,mechanism,"Cimetidine:_bf DRUG inhibit_be metabolism_be OTHER_DRUG ,_af increasing_af plasma_af level_af ._af"
822,"Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin.",chloroquine,ampicillin,mechanism,"Ampicillin:_bf In_bf study_bf healthy_bf volunteers_bf ,_bf DRUG significantly_be reduced_be bioavailability_be OTHER_DRUG ._af"
823,"Cyclosporin: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporin level has been reported.",chloroquine,cyclosporin,mechanism,"Cyclosporin:_bf After_bf introduction_bf DRUG (oral_be form)_be ,_be sudden_be increase_be serum_be OTHER_DRUG level_af reported_af ._af"
824,- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract,Cholestytamine,thiazide diuretics,mechanism,-_bf Cholestyramine_bf colestipol_bf resins:_bf DRUG colestipol_be resins_be potential_be binding_be thiazide_be diuretics_be reducing_be diuretic_be absorption_be gastrointestinal_be tract_be
825,- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract,colestipol,thiazide diuretics,mechanism,-_bf Cholestyramine_bf DRUG resins:_be Cholestytamine_be DRUG resins_af potential_af binding_af thiazide_af diuretics_af reducing_af diuretic_af absorption_af gastrointestinal_af tract_af
826,- Lithium: Generally should not be given with diuretics.,Lithium,diuretics,advise,-_bf Lithium:_bf Generally_bf given_bf OTHER_DRUG ._be
827,Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.,Diuretic agents,lithium,mechanism,Diuretic_bf agents_bf reduce_bf renal_bf clearance_bf OTHER_DRUG add_be high_be risk_be OTHER_DRUG toxicity_af ._af
828,Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.,Diuretic agents,lithium,mechanism,Diuretic_bf agents_bf reduce_bf renal_bf clearance_bf OTHER_DRUG add_be high_be risk_be OTHER_DRUG toxicity_af ._af
829,Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide,lithium,chlorothiazide,advise,Refer_bf package_bf insert_bf DRUG preparations_be use_be preparations_be OTHER_DRUG
830,"- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,loop diuretics,effect,"-_bf Non-steroidal_bf Anti-inflammatory_bf Drugs:_bf In_bf patients_bf ,_bf administration_bf non-steroidal_bf anti-inflammatory_bf agent_bf reduce_bf diuretic_bf ,_bf natriuretic_bf ,_bf antihypertensive_bf effects_bf loop_bf ,_bf potassium-sparing_bf thiazide_bf diuretics_bf ._bf"
831,"- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,potassium-sparing diuretics,effect,"-_bf Non-steroidal_bf Anti-inflammatory_bf Drugs:_bf In_bf patients_bf ,_bf administration_bf non-steroidal_bf anti-inflammatory_bf agent_bf reduce_bf diuretic_bf ,_bf natriuretic_bf ,_bf antihypertensive_bf effects_bf loop_bf ,_bf potassium-sparing_bf thiazide_bf diuretics_bf ._bf"
832,"- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,thiazide diuretics,effect,"-_bf Non-steroidal_bf Anti-inflammatory_bf Drugs:_bf In_bf patients_bf ,_bf administration_bf non-steroidal_bf anti-inflammatory_bf agent_bf reduce_bf diuretic_bf ,_bf natriuretic_bf ,_bf antihypertensive_bf effects_bf loop_bf ,_bf potassium-sparing_bf thiazide_bf diuretics_bf ._bf"
833,"Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained",chlorothiazide,non-steroidal anti-inflammatory agents,advise,"Therefore_bf ,_bf DRUG non-steroidal_be anti-inflammatory_be agents_be used_be concomitantly_be ,_be patient_be observed_be closely_be determine_be desired_be effect_be diuretic_be obtained_be"
834,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,antidepressants,int,"DRUG may_be interact_be OTHER_DRUG ,_af aspirin_af ,_af barbiturates_af ,_af bromocriptine_af ,_af calcium_af supplements_af ,_af corticosteroids_af ,_af corticotropin_af ,_af cyclosporine_af ,_af dantrolene_af ,_af nicotine_af ,_af somatropin_af ,_af tamoxifen_af ,_af warfarin_af ._af"
835,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,aspirin,int,"DRUG may_be interact_be antidepressants_be ,_be OTHER_DRUG ,_af barbiturates_af ,_af bromocriptine_af ,_af calcium_af supplements_af ,_af corticosteroids_af ,_af corticotropin_af ,_af cyclosporine_af ,_af dantrolene_af ,_af nicotine_af ,_af somatropin_af ,_af tamoxifen_af ,_af warfarin_af ._af"
836,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,barbiturates,int,"DRUG may_be interact_be antidepressants_be ,_be aspirin_be ,_be OTHER_DRUG ,_af bromocriptine_af ,_af calcium_af supplements_af ,_af corticosteroids_af ,_af corticotropin_af ,_af cyclosporine_af ,_af dantrolene_af ,_af nicotine_af ,_af somatropin_af ,_af tamoxifen_af ,_af warfarin_af ._af"
837,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,bromocriptine,int,"DRUG may_be interact_be antidepressants_be ,_be aspirin_be ,_be barbiturates_be ,_be OTHER_DRUG ,_af calcium_af supplements_af ,_af corticosteroids_af ,_af corticotropin_af ,_af cyclosporine_af ,_af dantrolene_af ,_af nicotine_af ,_af somatropin_af ,_af tamoxifen_af ,_af warfarin_af ._af"
838,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,calcium,int,"DRUG may_be interact_be antidepressants_be ,_be aspirin_be ,_be barbiturates_be ,_be bromocriptine_be ,_be OTHER_DRUG supplements_af ,_af corticosteroids_af ,_af corticotropin_af ,_af cyclosporine_af ,_af dantrolene_af ,_af nicotine_af ,_af somatropin_af ,_af tamoxifen_af ,_af warfarin_af ._af"
839,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,corticosteroids,int,"DRUG may_be interact_be antidepressants_be ,_be aspirin_be ,_be barbiturates_be ,_be bromocriptine_be ,_be calcium_be supplements_be ,_be OTHER_DRUG ,_af corticotropin_af ,_af cyclosporine_af ,_af dantrolene_af ,_af nicotine_af ,_af somatropin_af ,_af tamoxifen_af ,_af warfarin_af ._af"
840,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,corticotropin,int,"DRUG may_be interact_be antidepressants_be ,_be aspirin_be ,_be barbiturates_be ,_be bromocriptine_be ,_be calcium_be supplements_be ,_be corticosteroids_be ,_be OTHER_DRUG ,_af cyclosporine_af ,_af dantrolene_af ,_af nicotine_af ,_af somatropin_af ,_af tamoxifen_af ,_af warfarin_af ._af"
841,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,cyclosporine,int,"DRUG may_be interact_be antidepressants_be ,_be aspirin_be ,_be barbiturates_be ,_be bromocriptine_be ,_be calcium_be supplements_be ,_be corticosteroids_be ,_be corticotropin_be ,_be OTHER_DRUG ,_af dantrolene_af ,_af nicotine_af ,_af somatropin_af ,_af tamoxifen_af ,_af warfarin_af ._af"
842,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,dantrolene,int,"DRUG may_be interact_be antidepressants_be ,_be aspirin_be ,_be barbiturates_be ,_be bromocriptine_be ,_be calcium_be supplements_be ,_be corticosteroids_be ,_be corticotropin_be ,_be cyclosporine_be ,_be OTHER_DRUG ,_af nicotine_af ,_af somatropin_af ,_af tamoxifen_af ,_af warfarin_af ._af"
843,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,nicotine,int,"DRUG may_be interact_be antidepressants_be ,_be aspirin_be ,_be barbiturates_be ,_be bromocriptine_be ,_be calcium_be supplements_be ,_be corticosteroids_be ,_be corticotropin_be ,_be cyclosporine_be ,_be dantrolene_be ,_be OTHER_DRUG ,_af somatropin_af ,_af tamoxifen_af ,_af warfarin_af ._af"
844,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,somatropin,int,"DRUG may_be interact_be antidepressants_be ,_be aspirin_be ,_be barbiturates_be ,_be bromocriptine_be ,_be calcium_be supplements_be ,_be corticosteroids_be ,_be corticotropin_be ,_be cyclosporine_be ,_be dantrolene_be ,_be nicotine_be ,_be OTHER_DRUG ,_af tamoxifen_af ,_af warfarin_af ._af"
845,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,tamoxifen,int,"DRUG may_be interact_be antidepressants_be ,_be aspirin_be ,_be barbiturates_be ,_be bromocriptine_be ,_be calcium_be supplements_be ,_be corticosteroids_be ,_be corticotropin_be ,_be cyclosporine_be ,_be dantrolene_be ,_be nicotine_be ,_be somatropin_be ,_be OTHER_DRUG ,_af warfarin_af ._af"
846,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,warfarin,int,"DRUG may_be interact_be antidepressants_be ,_be aspirin_be ,_be barbiturates_be ,_be bromocriptine_be ,_be calcium_be supplements_be ,_be corticosteroids_be ,_be corticotropin_be ,_be cyclosporine_be ,_be dantrolene_be ,_be nicotine_be ,_be somatropin_be ,_be tamoxifen_be ,_be OTHER_DRUG ._af"
847,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antipsychotic drug,antiparkinsonian drug,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
848,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antipsychotic drug,trihexyphenidyl,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
849,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antipsychotic drug,tricyclic antidepressant,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
850,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antipsychotic drug,amitriptyline,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
851,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",chlorpromazine,antiparkinsonian drug,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
852,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",chlorpromazine,trihexyphenidyl,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
853,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",chlorpromazine,tricyclic antidepressant,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
854,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",chlorpromazine,amitriptyline,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
855,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antiparkinsonian drug,tricyclic antidepressant,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
856,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antiparkinsonian drug,amitriptyline,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
857,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",trihexyphenidyl,tricyclic antidepressant,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
858,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",trihexyphenidyl,amitriptyline,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
859,Chlorprothixene may increase the plasma-level of concomitantly given lithium.,Chlorprothixene,lithium,mechanism,DRUG may_be increase_be plasma-level_be concomitantly_be given_be OTHER_DRUG ._af
860,"If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.",chlorprothixene,opioids,advise,"If_bf DRUG given_be concomitantly_be OTHER_DRUG ,_af opioid_af dose_af reduced_af (by_af approx_af ._af 50%)_af ,_af DRUG amplifies_af therapeutic_af actions_af side-effects_af OTHER_DRUG massively_af ._af"
861,"If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.",chlorprothixene,opioids,effect,"If_bf DRUG given_be concomitantly_be OTHER_DRUG ,_af opioid_af dose_af reduced_af (by_af approx_af ._af 50%)_af ,_af DRUG amplifies_af therapeutic_af actions_af side-effects_af OTHER_DRUG massively_af ._af"
862,Avoid the concomitant use of chlorprothixene and tramadol (Ultram).,chlorprothixene,tramadol,advise,Avoid_bf concomitant_bf use_bf DRUG OTHER_DRUG (Ultram)_af ._af
863,Avoid the concomitant use of chlorprothixene and tramadol (Ultram).,chlorprothixene,Ultram,advise,Avoid_bf concomitant_bf use_bf DRUG tramadol_be (Ultram)_be ._be
864,"Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.",chlorprothixene,benzodiazepines,effect,"Consider_bf additive_bf sedative_bf effects_bf confusional_bf states_bf emerge_bf ,_bf DRUG given_be OTHER_DRUG barbituates_af ._af"
865,"Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.",chlorprothixene,barbituates,effect,"Consider_bf additive_bf sedative_bf effects_bf confusional_bf states_bf emerge_bf ,_bf DRUG given_be benzodiazepines_be OTHER_DRUG ._af"
866,"Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",chlorprothixene,anticholinergic drugs,advise,"Exert_bf particular_bf caution_bf combining_bf DRUG anticholinergic_be drugs_be (tricyclic_be antidepressants_be antiparkinsonian_be agents):_be Particularly_be elderly_be may_be develop_be delirium_be ,_be high_be fever_be ,_be severe_be obstipation_be ,_be even_be ileus_be glaucoma_be ._be"
867,"Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",chlorprothixene,tricyclic antidepressants,advise,"Exert_bf particular_bf caution_bf combining_bf DRUG anticholinergic_be drugs_be (tricyclic_be antidepressants_be antiparkinsonian_be agents):_be Particularly_be elderly_be may_be develop_be delirium_be ,_be high_be fever_be ,_be severe_be obstipation_be ,_be even_be ileus_be glaucoma_be ._be"
868,"Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",chlorprothixene,antiparkinsonian agents,advise,"Exert_bf particular_bf caution_bf combining_bf DRUG anticholinergic_be drugs_be (tricyclic_be antidepressants_be antiparkinsonian_be agents):_be Particularly_be elderly_be may_be develop_be delirium_be ,_be high_be fever_be ,_be severe_be obstipation_be ,_be even_be ileus_be glaucoma_be ._be"
869,"Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;",Cholestyramine,fat soluble vitamins,mechanism,"Interactions_bf vitamin_bf D_bf analogues_bf (Vitamin_bf D2_bf ,_bf Vitamin_bf D3_bf ,_bf Calcitriol_bf ,_bf Calcidiol):_bf Cholestyramine:_bf DRUG reported_be reduce_be intestinal_be absorption_be fat_be soluble_be vitamins;_be"
870,Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.,thiazides,vitamin D,effect,Some_bf reports_bf shown_bf concomitant_bf administration_bf DRUG vitamin_be D_be causes_be hypercalcemia_be ._be
871,"Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.",Vitamin D,digitalis,advise,"Digitalis:_bf Vitamin_bf D_bf dosage_bf must_bf determined_bf care_bf patients_bf undergoing_bf treatment_bf OTHER_DRUG ,_be hypercalcemia_be patients_be may_be precipitate_be cardiac_be arrhythmias_be ._be"
872,Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.,Ketoconazole,vitamin D,mechanism,Ketoconazole:_bf DRUG may_be inhibit_be synthetic_be catabolic_be enzymes_be vitamin_be D_be ._be
873,"Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.",vitamin D,corticosteroids,effect,"Corticosteroids:_bf A_bf relationship_bf functional_bf antagonism_bf exists_bf vitamin_bf D_bf analogues_bf ,_bf promote_bf calcium_bf absorption_bf ,_bf OTHER_DRUG ,_be inhibit_be calcium_be absorption_be ._be"
874,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",Magnesium,vitamin D,effect,"Magnesium:_bf Magnesium-containing_bf preparations_bf (eg_bf ,_bf antacids)_bf may_bf cause_bf hypermagnesemia_bf therefore_bf taken_bf therapy_bf vitamin_bf D_bf patients_bf chronic_bf renal_bf dialysis_bf ._bf"
875,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",antacids,vitamin D,effect,"Magnesium:_bf Magnesium-containing_bf preparations_bf (eg_bf ,_bf antacids)_bf may_bf cause_bf hypermagnesemia_bf therefore_bf taken_bf therapy_bf vitamin_bf D_bf patients_bf chronic_bf renal_bf dialysis_bf ._bf"
876,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,phenylbutazone,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be OTHER_DRUG ,_af warfarin_af ,_af thiazide_af diuretics_af (acidic)_af propranolol_af (basic)_af ,_af well_af tetracycline_af penicillin_af G_af ,_af phenobarbital_af ,_af thyroid_af thyroxine_af preparations_af ,_af estrogens_af progestins_af ,_af digitalis_af ._af"
877,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,warfarin,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be phenylbutazone_be ,_be OTHER_DRUG ,_af thiazide_af diuretics_af (acidic)_af propranolol_af (basic)_af ,_af well_af tetracycline_af penicillin_af G_af ,_af phenobarbital_af ,_af thyroid_af thyroxine_af preparations_af ,_af estrogens_af progestins_af ,_af digitalis_af ._af"
878,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,thiazide diuretics,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be phenylbutazone_be ,_be warfarin_be ,_be thiazide_be diuretics_be (acidic)_be propranolol_be (basic)_be ,_be well_be tetracycline_be penicillin_be G_be ,_be phenobarbital_be ,_be thyroid_be thyroxine_be preparations_be ,_be estrogens_be progestins_be ,_be digitalis_be ._be"
879,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,propranolol,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be phenylbutazone_be ,_be warfarin_be ,_be thiazide_be diuretics_be (acidic)_be OTHER_DRUG (basic)_af ,_af well_af tetracycline_af penicillin_af G_af ,_af phenobarbital_af ,_af thyroid_af thyroxine_af preparations_af ,_af estrogens_af progestins_af ,_af digitalis_af ._af"
880,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,tetracycline,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be phenylbutazone_be ,_be warfarin_be ,_be thiazide_be diuretics_be (acidic)_be propranolol_be (basic)_be ,_be well_be OTHER_DRUG penicillin_af G_af ,_af phenobarbital_af ,_af thyroid_af thyroxine_af preparations_af ,_af estrogens_af progestins_af ,_af digitalis_af ._af"
881,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,penicillin G,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be phenylbutazone_be ,_be warfarin_be ,_be thiazide_be diuretics_be (acidic)_be propranolol_be (basic)_be ,_be well_be tetracycline_be penicillin_be G_be ,_be phenobarbital_be ,_be thyroid_be thyroxine_be preparations_be ,_be estrogens_be progestins_be ,_be digitalis_be ._be"
882,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,phenobarbital,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be phenylbutazone_be ,_be warfarin_be ,_be thiazide_be diuretics_be (acidic)_be propranolol_be (basic)_be ,_be well_be tetracycline_be penicillin_be G_be ,_be OTHER_DRUG ,_af thyroid_af thyroxine_af preparations_af ,_af estrogens_af progestins_af ,_af digitalis_af ._af"
883,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,thyroxine,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be phenylbutazone_be ,_be warfarin_be ,_be thiazide_be diuretics_be (acidic)_be propranolol_be (basic)_be ,_be well_be tetracycline_be penicillin_be G_be ,_be phenobarbital_be ,_be thyroid_be OTHER_DRUG preparations_af ,_af estrogens_af progestins_af ,_af digitalis_af ._af"
884,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,estrogens,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be phenylbutazone_be ,_be warfarin_be ,_be thiazide_be diuretics_be (acidic)_be propranolol_be (basic)_be ,_be well_be tetracycline_be penicillin_be G_be ,_be phenobarbital_be ,_be thyroid_be thyroxine_be preparations_be ,_be OTHER_DRUG progestins_af ,_af digitalis_af ._af"
885,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,progestins,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be phenylbutazone_be ,_be warfarin_be ,_be thiazide_be diuretics_be (acidic)_be propranolol_be (basic)_be ,_be well_be tetracycline_be penicillin_be G_be ,_be phenobarbital_be ,_be thyroid_be thyroxine_be preparations_be ,_be estrogens_be OTHER_DRUG ,_af digitalis_af ._af"
886,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,digitalis,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be phenylbutazone_be ,_be warfarin_be ,_be thiazide_be diuretics_be (acidic)_be propranolol_be (basic)_be ,_be well_be tetracycline_be penicillin_be G_be ,_be phenobarbital_be ,_be thyroid_be thyroxine_be preparations_be ,_be estrogens_be progestins_be ,_be OTHER_DRUG ._af"
887,"Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.",cholestyramine,digitalis,mechanism,"DRUG resin_be may_be interfere_be pharmacokinetics_be drugs_be undergo_be enterohepatic_be circulation_be ,_be The_be discontinuance_be DRUG resin_af could_af pose_af hazard_af health_af potentially_af toxic_af drug_af OTHER_DRUG filtrated_af maintenance_af level_af patient_af taking_af DRUG resin_af ._af"
888,"In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.",ciclesonide,ketoconazole,mechanism,"In_bf another_bf drug_bf interaction_bf study_bf ,_bf co-administration_bf orally_bf inhaled_bf DRUG oral_be OTHER_DRUG ,_af potent_af inhibitor_af cytochrome_af P450_af 3A4_af ,_af increased_af exposure_af (AUC)_af des-ciclesonide_af approximately_af 3_af ._af 6-fold_af steady_af state_af ,_af levels_af DRUG remained_af unchanged_af ._af"
889,"Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.",ketoconazole,ciclesonide,advise,"Therefore_bf ,_bf DRUG administered_be caution_be intranasal_be OTHER_DRUG ._af"
890,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,acetaminophen,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af OTHER_DRUG ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
891,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,acyclovir,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af OTHER_DRUG ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
892,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,angiotensin-converting enzyme inhibitors,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
893,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,aminosalicylic acid,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
894,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,barbiturates,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af OTHER_DRUG ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
895,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,benzodiazepines,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af OTHER_DRUG ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
896,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,bumetanide,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af OTHER_DRUG ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
897,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,clofibrate,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af OTHER_DRUG ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
898,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,methotrexate,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af OTHER_DRUG ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
899,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,famotidine,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af OTHER_DRUG ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
900,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,furosemide,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af OTHER_DRUG ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
901,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,nonsteroidal anti-inflammatory,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
902,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,theophylline,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af OTHER_DRUG ,_af zidovudine)_af ._af"
903,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,zidovudine,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
904,Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.,Zidovudine,probenecid,advise,DRUG either_be temporarily_be discontinued_be decreased_be 50%_be coadministered_be OTHER_DRUG day_af VISTIDE_af infusion_af ._af
905,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,aminoglycosides,advise,"Nephrotoxic_bf agents_bf :_bf Concomitant_bf administration_bf DRUG agents_be nephrotoxic_be potential_be [e_be ._be g_be ._be ,_be intravenous_be OTHER_DRUG (e_af ._af g_af ._af ,_af tobramycin_af ,_af gentamicin_af ,_af amikacin)_af ,_af amphotericin_af B_af ,_af foscarnet_af ,_af intravenous_af pentamidine_af ,_af vancomycin_af ,_af non-steroidal_af anti-inflammatory_af agents]_af contraindicated_af ._af"
906,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,tobramycin,advise,"Nephrotoxic_bf agents_bf :_bf Concomitant_bf administration_bf DRUG agents_be nephrotoxic_be potential_be [e_be ._be g_be ._be ,_be intravenous_be aminoglycosides_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af gentamicin_af ,_af amikacin)_af ,_af amphotericin_af B_af ,_af foscarnet_af ,_af intravenous_af pentamidine_af ,_af vancomycin_af ,_af non-steroidal_af anti-inflammatory_af agents]_af contraindicated_af ._af"
907,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,gentamicin,advise,"Nephrotoxic_bf agents_bf :_bf Concomitant_bf administration_bf DRUG agents_be nephrotoxic_be potential_be [e_be ._be g_be ._be ,_be intravenous_be aminoglycosides_be (e_be ._be g_be ._be ,_be tobramycin_be ,_be OTHER_DRUG ,_af amikacin)_af ,_af amphotericin_af B_af ,_af foscarnet_af ,_af intravenous_af pentamidine_af ,_af vancomycin_af ,_af non-steroidal_af anti-inflammatory_af agents]_af contraindicated_af ._af"
908,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,amikacin,advise,"Nephrotoxic_bf agents_bf :_bf Concomitant_bf administration_bf DRUG agents_be nephrotoxic_be potential_be [e_be ._be g_be ._be ,_be intravenous_be aminoglycosides_be (e_be ._be g_be ._be ,_be tobramycin_be ,_be gentamicin_be ,_be amikacin)_be ,_be amphotericin_be B_be ,_be foscarnet_be ,_be intravenous_be pentamidine_be ,_be vancomycin_be ,_be non-steroidal_be anti-inflammatory_be agents]_be contraindicated_be ._be"
909,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,amphotericin B,advise,"Nephrotoxic_bf agents_bf :_bf Concomitant_bf administration_bf DRUG agents_be nephrotoxic_be potential_be [e_be ._be g_be ._be ,_be intravenous_be aminoglycosides_be (e_be ._be g_be ._be ,_be tobramycin_be ,_be gentamicin_be ,_be amikacin)_be ,_be amphotericin_be B_be ,_be foscarnet_be ,_be intravenous_be pentamidine_be ,_be vancomycin_be ,_be non-steroidal_be anti-inflammatory_be agents]_be contraindicated_be ._be"
910,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,foscarnet,advise,"Nephrotoxic_bf agents_bf :_bf Concomitant_bf administration_bf DRUG agents_be nephrotoxic_be potential_be [e_be ._be g_be ._be ,_be intravenous_be aminoglycosides_be (e_be ._be g_be ._be ,_be tobramycin_be ,_be gentamicin_be ,_be amikacin)_be ,_be amphotericin_be B_be ,_be OTHER_DRUG ,_af intravenous_af pentamidine_af ,_af vancomycin_af ,_af non-steroidal_af anti-inflammatory_af agents]_af contraindicated_af ._af"
911,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,pentamidine,advise,"Nephrotoxic_bf agents_bf :_bf Concomitant_bf administration_bf DRUG agents_be nephrotoxic_be potential_be [e_be ._be g_be ._be ,_be intravenous_be aminoglycosides_be (e_be ._be g_be ._be ,_be tobramycin_be ,_be gentamicin_be ,_be amikacin)_be ,_be amphotericin_be B_be ,_be foscarnet_be ,_be intravenous_be OTHER_DRUG ,_af vancomycin_af ,_af non-steroidal_af anti-inflammatory_af agents]_af contraindicated_af ._af"
912,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,vancomycin,advise,"Nephrotoxic_bf agents_bf :_bf Concomitant_bf administration_bf DRUG agents_be nephrotoxic_be potential_be [e_be ._be g_be ._be ,_be intravenous_be aminoglycosides_be (e_be ._be g_be ._be ,_be tobramycin_be ,_be gentamicin_be ,_be amikacin)_be ,_be amphotericin_be B_be ,_be foscarnet_be ,_be intravenous_be pentamidine_be ,_be OTHER_DRUG ,_af non-steroidal_af anti-inflammatory_af agents]_af contraindicated_af ._af"
913,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,non-steroidal anti-inflammatory agents,advise,"Nephrotoxic_bf agents_bf :_bf Concomitant_bf administration_bf DRUG agents_be nephrotoxic_be potential_be [e_be ._be g_be ._be ,_be intravenous_be aminoglycosides_be (e_be ._be g_be ._be ,_be tobramycin_be ,_be gentamicin_be ,_be amikacin)_be ,_be amphotericin_be B_be ,_be foscarnet_be ,_be intravenous_be pentamidine_be ,_be vancomycin_be ,_be non-steroidal_be anti-inflammatory_be agents]_be contraindicated_be ._be"
914,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.",PLETAL,ketoconazole,advise,"Since_bf DRUG extensively_be metabolized_be cytochrome_be P-450_be isoenzymes_be ,_be caution_be exercised_be DRUG coadministered_af inhibitors_af C_af ._af P_af ._af A_af ._af OTHER_DRUG erythromycin_af inhibitors_af CYP2C19_af omeprazole_af ._af"
915,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.",PLETAL,erythromycin,advise,"Since_bf DRUG extensively_be metabolized_be cytochrome_be P-450_be isoenzymes_be ,_be caution_be exercised_be DRUG coadministered_af inhibitors_af C_af ._af P_af ._af A_af ._af ketoconazole_af OTHER_DRUG inhibitors_af CYP2C19_af omeprazole_af ._af"
916,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.",PLETAL,omeprazole,advise,"Since_bf DRUG extensively_be metabolized_be cytochrome_be P-450_be isoenzymes_be ,_be caution_be exercised_be DRUG coadministered_af inhibitors_af C_af ._af P_af ._af A_af ._af ketoconazole_af erythromycin_af inhibitors_af CYP2C19_af OTHER_DRUG ._af"
917,Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.,omeprazole,cilostazol,mechanism,Pharmacokinetic_bf studies_bf demonstrated_bf DRUG erythromycin_be significantly_be increased_be systemic_be exposure_be OTHER_DRUG and/or_af major_af metabolites_af ._af
918,Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.,erythromycin,cilostazol,mechanism,Pharmacokinetic_bf studies_bf demonstrated_bf omeprazole_bf DRUG significantly_be increased_be systemic_be exposure_be OTHER_DRUG and/or_af major_af metabolites_af ._af
919,"Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..",cilostazol,diltiazem,mechanism,"Population_bf pharmacokinetic_bf studies_bf showed_bf higher_bf concentrations_bf DRUG among_be patients_be concurrently_be treated_be OTHER_DRUG ,_af inhibitor_af C_af ._af P_af ._af A_af ._af ._af"
920,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,warfarin-type anticoagulants,mechanism,"DRUG ,_be apparently_be effect_be certain_be microsomal_be enzyme_be systems_be ,_be reported_be reduce_be hepatic_be metabolism_be warfarin-type_be anticoagulants_be ,_be phenytoin_be ,_be propranolol_be ,_be nifedipine_be ,_be chlordiazepoxide_be ,_be diazepam_be ,_be certain_be tricyclic_be antidepressants_be ,_be lidocaine_be ,_be theophylline_be metronidazole_be ,_be thereby_be delaying_be elimination_be increasing_be blood_be levels_be drugs_be ._be"
921,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,phenytoin,mechanism,"DRUG ,_be apparently_be effect_be certain_be microsomal_be enzyme_be systems_be ,_be reported_be reduce_be hepatic_be metabolism_be warfarin-type_be anticoagulants_be ,_be OTHER_DRUG ,_af propranolol_af ,_af nifedipine_af ,_af chlordiazepoxide_af ,_af diazepam_af ,_af certain_af tricyclic_af antidepressants_af ,_af lidocaine_af ,_af theophylline_af metronidazole_af ,_af thereby_af delaying_af elimination_af increasing_af blood_af levels_af drugs_af ._af"
922,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,propranolol,mechanism,"DRUG ,_be apparently_be effect_be certain_be microsomal_be enzyme_be systems_be ,_be reported_be reduce_be hepatic_be metabolism_be warfarin-type_be anticoagulants_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af nifedipine_af ,_af chlordiazepoxide_af ,_af diazepam_af ,_af certain_af tricyclic_af antidepressants_af ,_af lidocaine_af ,_af theophylline_af metronidazole_af ,_af thereby_af delaying_af elimination_af increasing_af blood_af levels_af drugs_af ._af"
923,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,nifedipine,mechanism,"DRUG ,_be apparently_be effect_be certain_be microsomal_be enzyme_be systems_be ,_be reported_be reduce_be hepatic_be metabolism_be warfarin-type_be anticoagulants_be ,_be phenytoin_be ,_be propranolol_be ,_be OTHER_DRUG ,_af chlordiazepoxide_af ,_af diazepam_af ,_af certain_af tricyclic_af antidepressants_af ,_af lidocaine_af ,_af theophylline_af metronidazole_af ,_af thereby_af delaying_af elimination_af increasing_af blood_af levels_af drugs_af ._af"
924,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,chlordiazepoxide,mechanism,"DRUG ,_be apparently_be effect_be certain_be microsomal_be enzyme_be systems_be ,_be reported_be reduce_be hepatic_be metabolism_be warfarin-type_be anticoagulants_be ,_be phenytoin_be ,_be propranolol_be ,_be nifedipine_be ,_be OTHER_DRUG ,_af diazepam_af ,_af certain_af tricyclic_af antidepressants_af ,_af lidocaine_af ,_af theophylline_af metronidazole_af ,_af thereby_af delaying_af elimination_af increasing_af blood_af levels_af drugs_af ._af"
925,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,diazepam,mechanism,"DRUG ,_be apparently_be effect_be certain_be microsomal_be enzyme_be systems_be ,_be reported_be reduce_be hepatic_be metabolism_be warfarin-type_be anticoagulants_be ,_be phenytoin_be ,_be propranolol_be ,_be nifedipine_be ,_be chlordiazepoxide_be ,_be OTHER_DRUG ,_af certain_af tricyclic_af antidepressants_af ,_af lidocaine_af ,_af theophylline_af metronidazole_af ,_af thereby_af delaying_af elimination_af increasing_af blood_af levels_af drugs_af ._af"
926,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,tricyclic antidepressants,mechanism,"DRUG ,_be apparently_be effect_be certain_be microsomal_be enzyme_be systems_be ,_be reported_be reduce_be hepatic_be metabolism_be warfarin-type_be anticoagulants_be ,_be phenytoin_be ,_be propranolol_be ,_be nifedipine_be ,_be chlordiazepoxide_be ,_be diazepam_be ,_be certain_be tricyclic_be antidepressants_be ,_be lidocaine_be ,_be theophylline_be metronidazole_be ,_be thereby_be delaying_be elimination_be increasing_be blood_be levels_be drugs_be ._be"
927,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,lidocaine,mechanism,"DRUG ,_be apparently_be effect_be certain_be microsomal_be enzyme_be systems_be ,_be reported_be reduce_be hepatic_be metabolism_be warfarin-type_be anticoagulants_be ,_be phenytoin_be ,_be propranolol_be ,_be nifedipine_be ,_be chlordiazepoxide_be ,_be diazepam_be ,_be certain_be tricyclic_be antidepressants_be ,_be OTHER_DRUG ,_af theophylline_af metronidazole_af ,_af thereby_af delaying_af elimination_af increasing_af blood_af levels_af drugs_af ._af"
928,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,theophylline,mechanism,"DRUG ,_be apparently_be effect_be certain_be microsomal_be enzyme_be systems_be ,_be reported_be reduce_be hepatic_be metabolism_be warfarin-type_be anticoagulants_be ,_be phenytoin_be ,_be propranolol_be ,_be nifedipine_be ,_be chlordiazepoxide_be ,_be diazepam_be ,_be certain_be tricyclic_be antidepressants_be ,_be lidocaine_be ,_be OTHER_DRUG metronidazole_af ,_af thereby_af delaying_af elimination_af increasing_af blood_af levels_af drugs_af ._af"
929,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,metronidazole,mechanism,"DRUG ,_be apparently_be effect_be certain_be microsomal_be enzyme_be systems_be ,_be reported_be reduce_be hepatic_be metabolism_be warfarin-type_be anticoagulants_be ,_be phenytoin_be ,_be propranolol_be ,_be nifedipine_be ,_be chlordiazepoxide_be ,_be diazepam_be ,_be certain_be tricyclic_be antidepressants_be ,_be lidocaine_be ,_be theophylline_be OTHER_DRUG ,_af thereby_af delaying_af elimination_af increasing_af blood_af levels_af drugs_af ._af"
930,"therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly.",anticoagulant,Tagamet,advise,"therefore_bf ,_bf close_bf monitoring_bf prothrombin_bf time_bf recommended_bf ,_bf adjustment_bf DRUG dose_be may_be necessary_be OTHER_DRUG administered_af concomitantly_af ._af"
931,"However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.",Tagamet,theophylline,mechanism,"However_bf ,_bf crossover_bf study_bf healthy_bf subjects_bf receiving_bf either_bf DRUG 300_be mg_be q_be ._be ._be ._be 800_be mg_be ._be ._be concomitantly_be 300_be mg_be b_be ._be ._be ._be dosage_be OTHER_DRUG (Theo-Dur_af ,_af Key_af Pharmaceuticals_af ,_af Inc_af ._af )_af demonstrated_af less_af alteration_af steady-state_af OTHER_DRUG peak_af serum_af levels_af 800_af mg_af ._af ._af regimen_af ,_af particularly_af subjects_af aged_af 54_af years_af older_af ._af"
932,"However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.",Tagamet,Theo-Dur,mechanism,"However_bf ,_bf crossover_bf study_bf healthy_bf subjects_bf receiving_bf either_bf DRUG 300_be mg_be q_be ._be ._be ._be 800_be mg_be ._be ._be concomitantly_be 300_be mg_be b_be ._be ._be ._be dosage_be theophylline_be (Theo-Dur_be ,_be Key_be Pharmaceuticals_be ,_be Inc_be ._be )_be demonstrated_be less_be alteration_be steady-state_be theophylline_be peak_be serum_be levels_be 800_be mg_be ._be ._be regimen_be ,_be particularly_be subjects_be aged_be 54_be years_be older_be ._be"
933,Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.,cinacalcet,amitriptyline,mechanism,Amitriptyline:_bf Concurrent_bf administration_bf 25_bf mg_bf 100_bf mg_bf DRUG 50_be mg_be OTHER_DRUG increased_af OTHER_DRUG exposure_af nortriptyline_af (active_af metabolite)_af exposure_af approximately_af 20%_af CYP2D6_af extensive_af metabolizers_af ._af
934,"Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.",ketoconazole,cinacalcet,mechanism,"Co-administration_bf DRUG ,_be strong_be inhibitor_be CYP3A4_be ,_be increased_be OTHER_DRUG exposure_af following_af single_af 90_af mg_af dose_af Sensipar_af 2_af ._af 3_af fold_af ._af"
935,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;",Sensipar,ketoconazole,advise,"Dose_bf adjustment_bf DRUG may_be required_be PTH_be serum_be calcium_be concentrations_be closely_be monitored_be patient_be initiates_be discontinues_be therapy_be strong_be CYP3A4_be inhibitor_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af erythromycin_af ,_af itraconazole;_af"
936,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;",Sensipar,erythromycin,advise,"Dose_bf adjustment_bf DRUG may_be required_be PTH_be serum_be calcium_be concentrations_be closely_be monitored_be patient_be initiates_be discontinues_be therapy_be strong_be CYP3A4_be inhibitor_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be OTHER_DRUG ,_af itraconazole;_af"
937,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;",Sensipar,itraconazole,advise,"Dose_bf adjustment_bf DRUG may_be required_be PTH_be serum_be calcium_be concentrations_be closely_be monitored_be patient_be initiates_be discontinues_be therapy_be strong_be CYP3A4_be inhibitor_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be erythromycin_be ,_be itraconazole;_be"
938,Elevated plasma levels of theophylline have been reported with concomitant use of some quinolones.,theophylline,quinolones,mechanism,Elevated_bf plasma_bf levels_bf DRUG reported_be concomitant_be use_be OTHER_DRUG ._af
939,There have been reports of theophylline-related side-effects in patients on concomitant theophylline-quinolone therapy.,theophylline,quinolone,effect,There_bf reports_bf theophylline-related_bf side-effects_bf patients_bf concomitant_bf theophylline-quinolone_bf therapy_bf ._bf
940,Quinolones have also been shown to interfere with the metabolism of caffeine.,Quinolones,caffeine,mechanism,DRUG also_be shown_be interfere_be metabolism_be OTHER_DRUG ._af
941,"Although this interaction has not been reported with cinoxacin, caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.",cinoxacin,caffeine,advise,"Although_bf interaction_bf reported_bf DRUG ,_be caution_be exercised_be DRUG given_af concomitantly_af caffeine-containing_af products_af ._af"
942,"Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.",Antacids,quinolones,mechanism,"DRUG sucralfate_be substantially_be interfere_be absorption_be OTHER_DRUG ,_af resulting_af low_af urine_af levels_af ._af"
943,"Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.",sucralfate,quinolones,mechanism,"Antacids_bf DRUG substantially_be interfere_be absorption_be OTHER_DRUG ,_af resulting_af low_af urine_af levels_af ._af"
944,"Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.",quinolones,iron,mechanism,"Also_bf ,_bf concomitant_bf administration_bf DRUG products_be containing_be OTHER_DRUG ,_af multivitamins_af containing_af zinc_af ,_af Videx_af (didanosine)_af chewable/buffered_af tablets_af pediatric_af powder_af oral_af solution_af may_af result_af low_af urine_af levels_af ._af"
945,"Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.",quinolones,zinc,mechanism,"Also_bf ,_bf concomitant_bf administration_bf DRUG products_be containing_be iron_be ,_be multivitamins_be containing_be OTHER_DRUG ,_af Videx_af (didanosine)_af chewable/buffered_af tablets_af pediatric_af powder_af oral_af solution_af may_af result_af low_af urine_af levels_af ._af"
946,"Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.",quinolones,Videx,mechanism,"Also_bf ,_bf concomitant_bf administration_bf DRUG products_be containing_be iron_be ,_be multivitamins_be containing_be zinc_be ,_be OTHER_DRUG (didanosine)_af chewable/buffered_af tablets_af pediatric_af powder_af oral_af solution_af may_af result_af low_af urine_af levels_af ._af"
947,"Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.",quinolones,didanosine,mechanism,"Also_bf ,_bf concomitant_bf administration_bf DRUG products_be containing_be iron_be ,_be multivitamins_be containing_be zinc_be ,_be Videx_be (didanosine)_be chewable/buffered_be tablets_be pediatric_be powder_be oral_be solution_be may_be result_be low_be urine_be levels_be ._be"
948,"Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.",Quinolones,anticoagulants,effect,"DRUG ,_be including_be cinoxacin_be ,_be may_be enhance_be effects_be oral_be OTHER_DRUG ,_af warfarin_af derivatives_af ._af"
949,"Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.",Quinolones,warfarin,effect,"DRUG ,_be including_be cinoxacin_be ,_be may_be enhance_be effects_be oral_be anticoagulants_be ,_be OTHER_DRUG derivatives_af ._af"
950,"Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.",cinoxacin,anticoagulants,effect,"Quinolones_bf ,_bf including_bf DRUG ,_be may_be enhance_be effects_be oral_be OTHER_DRUG ,_af warfarin_af derivatives_af ._af"
951,"Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.",cinoxacin,warfarin,effect,"Quinolones_bf ,_bf including_bf DRUG ,_be may_be enhance_be effects_be oral_be anticoagulants_be ,_be OTHER_DRUG derivatives_af ._af"
952,Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.,quinolone class antimicrobial,nonsteroidal anti-inflammatory drug,effect,Seizures_bf reported_bf patients_bf taking_bf another_bf quinolone_bf class_bf antimicrobial_bf nonsteroidal_bf anti-inflammatory_bf drug_bf fenbufen_bf concurrently_bf ._bf
953,Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.,quinolone class antimicrobial,fenbufen,effect,Seizures_bf reported_bf patients_bf taking_bf another_bf quinolone_bf class_bf antimicrobial_bf nonsteroidal_bf anti-inflammatory_bf drug_bf OTHER_DRUG concurrently_be ._be
954,Physicians are provided this information to increase awareness of the potential for serious interactions when cinoxacin and certain nonsteroidal anti-inflammatory agents are administered concomitantly.,cinoxacin,nonsteroidal anti-inflammatory agents,advise,Physicians_bf provided_bf information_bf increase_bf awareness_bf potential_bf serious_bf interactions_bf DRUG certain_be nonsteroidal_be anti-inflammatory_be agents_be administered_be concomitantly_be ._be
955,Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine.,quinolones,cyclosporine,mechanism,Elevated_bf OTHER_DRUG serum_be levels_be reported_be concomitant_be use_be DRUG OTHER_DRUG ._af
956,"Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.",quinolones,caffeine,mechanism,"Some_bf DRUG ,_be including_be ciprofloxacin_be ,_be also_be shown_be interfere_be metabolism_be OTHER_DRUG ._af"
957,"Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.",ciprofloxacin,caffeine,mechanism,"Some_bf quinolones_bf ,_bf including_bf DRUG ,_be also_be shown_be interfere_be metabolism_be OTHER_DRUG ._af"
958,"Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.",quinolones,cyclosporine,effect,"Some_bf DRUG ,_be including_be ciprofloxacin_be ,_be associated_be transient_be elevations_be serum_be creatinine_be patients_be receiving_be OTHER_DRUG concomitantly_af ._af"
959,"Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.",ciprofloxacin,cyclosporine,effect,"Some_bf quinolones_bf ,_bf including_bf DRUG ,_be associated_be transient_be elevations_be serum_be creatinine_be patients_be receiving_be OTHER_DRUG concomitantly_af ._af"
960,"Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.",ciprofloxacin,sulfonylurea,effect,"Glyburide:_bf The_bf concomitant_bf administration_bf DRUG OTHER_DRUG glyburide_af ,_af rare_af occasions_af ,_af resulted_af severe_af hypoglycemia_af ._af"
961,"Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.",ciprofloxacin,glyburide,effect,"Glyburide:_bf The_bf concomitant_bf administration_bf DRUG sulfonylurea_be OTHER_DRUG ,_af rare_af occasions_af ,_af resulted_af severe_af hypoglycemia_af ._af"
962,"Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.",methotrexate,ciprofloxacin,mechanism,"DRUG Renal_be tubular_be transport_be DRUG may_af inhibited_af concomitant_af administration_af OTHER_DRUG ,_af potentially_af leading_af increased_af plasma_af levels_af DRUG ._af"
963,"Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.",methotrexate,ciprofloxacin,advise,"Therefore_bf ,_bf patients_bf DRUG therapy_be carefully_be monitored_be concomitant_be OTHER_DRUG therapy_af indicated_af ._af"
964,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,magnesium,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf DRUG ,_be including_be ciprofloxacin_be ,_be multivalent_be cation-containing_be products_be OTHER_DRUG aluminum_af antacids_af ,_af sucralfate_af ,_af VIDEX_af chewable/buffered_af tablets_af pediatric_af powder_af ,_af products_af containing_af calcium_af ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af ciprofloxacin_af ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
965,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,aluminum,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf DRUG ,_be including_be ciprofloxacin_be ,_be multivalent_be cation-containing_be products_be magnesium_be OTHER_DRUG antacids_af ,_af sucralfate_af ,_af VIDEX_af chewable/buffered_af tablets_af pediatric_af powder_af ,_af products_af containing_af calcium_af ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af ciprofloxacin_af ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
966,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,antacids,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf DRUG ,_be including_be ciprofloxacin_be ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be OTHER_DRUG ,_af sucralfate_af ,_af VIDEX_af chewable/buffered_af tablets_af pediatric_af powder_af ,_af products_af containing_af calcium_af ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af ciprofloxacin_af ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
967,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,sucralfate,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf DRUG ,_be including_be ciprofloxacin_be ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be OTHER_DRUG ,_af VIDEX_af chewable/buffered_af tablets_af pediatric_af powder_af ,_af products_af containing_af calcium_af ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af ciprofloxacin_af ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
968,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,VIDEX,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf DRUG ,_be including_be ciprofloxacin_be ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be sucralfate_be ,_be OTHER_DRUG chewable/buffered_af tablets_af pediatric_af powder_af ,_af products_af containing_af calcium_af ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af ciprofloxacin_af ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
969,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,calcium,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf DRUG ,_be including_be ciprofloxacin_be ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be sucralfate_be ,_be VIDEX_be chewable/buffered_be tablets_be pediatric_be powder_be ,_be products_be containing_be OTHER_DRUG ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af ciprofloxacin_af ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
970,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,iron,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf DRUG ,_be including_be ciprofloxacin_be ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be sucralfate_be ,_be VIDEX_be chewable/buffered_be tablets_be pediatric_be powder_be ,_be products_be containing_be calcium_be ,_be OTHER_DRUG ,_af zinc_af may_af substantially_af decrease_af absorption_af ciprofloxacin_af ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
971,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,zinc,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf DRUG ,_be including_be ciprofloxacin_be ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be sucralfate_be ,_be VIDEX_be chewable/buffered_be tablets_be pediatric_be powder_be ,_be products_be containing_be calcium_be ,_be iron_be ,_be OTHER_DRUG may_af substantially_af decrease_af absorption_af ciprofloxacin_af ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
972,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,magnesium,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf quinolone_bf ,_bf including_bf DRUG ,_be multivalent_be cation-containing_be products_be OTHER_DRUG aluminum_af antacids_af ,_af sucralfate_af ,_af VIDEX_af chewable/buffered_af tablets_af pediatric_af powder_af ,_af products_af containing_af calcium_af ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af DRUG ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
973,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,aluminum,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf quinolone_bf ,_bf including_bf DRUG ,_be multivalent_be cation-containing_be products_be magnesium_be OTHER_DRUG antacids_af ,_af sucralfate_af ,_af VIDEX_af chewable/buffered_af tablets_af pediatric_af powder_af ,_af products_af containing_af calcium_af ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af DRUG ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
974,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,antacids,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf quinolone_bf ,_bf including_bf DRUG ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be OTHER_DRUG ,_af sucralfate_af ,_af VIDEX_af chewable/buffered_af tablets_af pediatric_af powder_af ,_af products_af containing_af calcium_af ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af DRUG ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
975,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,sucralfate,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf quinolone_bf ,_bf including_bf DRUG ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be OTHER_DRUG ,_af VIDEX_af chewable/buffered_af tablets_af pediatric_af powder_af ,_af products_af containing_af calcium_af ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af DRUG ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
976,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,VIDEX,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf quinolone_bf ,_bf including_bf DRUG ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be sucralfate_be ,_be OTHER_DRUG chewable/buffered_af tablets_af pediatric_af powder_af ,_af products_af containing_af calcium_af ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af DRUG ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
977,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,calcium,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf quinolone_bf ,_bf including_bf DRUG ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be sucralfate_be ,_be VIDEX_be chewable/buffered_be tablets_be pediatric_be powder_be ,_be products_be containing_be OTHER_DRUG ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af DRUG ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
978,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,iron,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf quinolone_bf ,_bf including_bf DRUG ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be sucralfate_be ,_be VIDEX_be chewable/buffered_be tablets_be pediatric_be powder_be ,_be products_be containing_be calcium_be ,_be OTHER_DRUG ,_af zinc_af may_af substantially_af decrease_af absorption_af DRUG ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
979,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,zinc,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf quinolone_bf ,_bf including_bf DRUG ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be sucralfate_be ,_be VIDEX_be chewable/buffered_be tablets_be pediatric_be powder_be ,_be products_be containing_be calcium_be ,_be iron_be ,_be OTHER_DRUG may_af substantially_af decrease_af absorption_af DRUG ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
980,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,ciprofloxacin,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf quinolone_bf ,_bf including_bf DRUG ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be sucralfate_be ,_be VIDEX_be chewable/buffered_be tablets_be pediatric_be powder_be ,_be products_be containing_be calcium_be ,_be iron_be ,_be zinc_be may_be substantially_be decrease_be absorption_be DRUG ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
981,"This time window is different than for other oral formulations of ciprofloxacin, which are usually administered 2 hours before or 6 hours after antacids.",ciprofloxacin,antacids,advise,"This_bf time_bf window_bf different_bf oral_bf formulations_bf DRUG ,_be usually_be administered_be 2_be hours_be 6_be hours_be OTHER_DRUG ._af"
982,Phenytoin: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.,phenytoin,ciprofloxacin,mechanism,Phenytoin:_bf Altered_bf serum_bf levels_bf DRUG (increased_be decreased)_be reported_be patients_be receiving_be concomitant_be OTHER_DRUG ._af
983,Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.,Probenecid,ciprofloxacin,mechanism,Probenecid:_bf DRUG interferes_be renal_be tubular_be secretion_be OTHER_DRUG produces_af increase_af level_af OTHER_DRUG serum_af ._af
984,Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.,Probenecid,ciprofloxacin,mechanism,Probenecid:_bf DRUG interferes_be renal_be tubular_be secretion_be OTHER_DRUG produces_af increase_af level_af OTHER_DRUG serum_af ._af
985,"Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.",quinolones,theophylline,mechanism,"Theophylline:_bf As_bf DRUG ,_be concurrent_be administration_be ciprofloxacin_be OTHER_DRUG may_af lead_af elevated_af serum_af concentrations_af OTHER_DRUG prolongation_af elimination_af half-life_af ._af"
986,"Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.",ciprofloxacin,theophylline,mechanism,"Theophylline:_bf As_bf quinolones_bf ,_bf concurrent_bf administration_bf DRUG OTHER_DRUG may_af lead_af elevated_af serum_af concentrations_af OTHER_DRUG prolongation_af elimination_af half-life_af ._af"
987,Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.,Quinolones,warfarin,effect,Warfarin:_bf DRUG reported_be enhance_be effects_be oral_be anticoagulant_be OTHER_DRUG derivatives_af ._af
988,"Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",clarithromycin,cisapride,mechanism,"Antibiotics:_bf In_bf vitro_bf and/or_bf vivo_bf data_bf show_bf DRUG ,_be erythromycin_be ,_be troleandomycin_be markedly_be inhibit_be metabolism_be OTHER_DRUG ,_af result_af increase_af plasma_af OTHER_DRUG levels_af prolongation_af QT_af interval_af ECG_af ._af"
989,"Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",erythromycin,cisapride,mechanism,"Antibiotics:_bf In_bf vitro_bf and/or_bf vivo_bf data_bf show_bf clarithromycin_bf ,_bf DRUG ,_be troleandomycin_be markedly_be inhibit_be metabolism_be OTHER_DRUG ,_af result_af increase_af plasma_af OTHER_DRUG levels_af prolongation_af QT_af interval_af ECG_af ._af"
990,"Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",troleandomycin,cisapride,mechanism,"Antibiotics:_bf In_bf vitro_bf and/or_bf vivo_bf data_bf show_bf clarithromycin_bf ,_bf erythromycin_bf ,_bf DRUG markedly_be inhibit_be metabolism_be OTHER_DRUG ,_af result_af increase_af plasma_af OTHER_DRUG levels_af prolongation_af QT_af interval_af ECG_af ._af"
991,"Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.",anticholinergic compounds,cisapride,effect,"Anticholinergics:_bf Concurrent_bf administration_bf certain_bf anticholinergic_bf compounds_bf ,_bf belladonna_bf alkaloids_bf dicyclomine_bf ,_bf would_bf expected_bf compromise_bf beneficial_bf effects_bf OTHER_DRUG ._be"
992,"Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.",belladonna alkaloids,cisapride,effect,"Anticholinergics:_bf Concurrent_bf administration_bf certain_bf anticholinergic_bf compounds_bf ,_bf belladonna_bf alkaloids_bf dicyclomine_bf ,_bf would_bf expected_bf compromise_bf beneficial_bf effects_bf OTHER_DRUG ._be"
993,"Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.",dicyclomine,cisapride,effect,"Anticholinergics:_bf Concurrent_bf administration_bf certain_bf anticholinergic_bf compounds_bf ,_bf belladonna_bf alkaloids_bf DRUG ,_be would_be expected_be compromise_be beneficial_be effects_be OTHER_DRUG ._af"
994,"It is advisable to check coagulation time within the first few days after the start and discontinuation of cisapride therapy, with an appropriate adjustment of the anticoagulant dose, if necessary.",cisapride,anticoagulant,advise,"It_bf advisable_bf check_bf coagulation_bf time_bf within_bf first_bf days_bf start_bf discontinuation_bf DRUG therapy_be ,_be appropriate_be adjustment_be OTHER_DRUG dose_af ,_af necessary_af ._af"
995,"Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",nefazodone,cisapride,mechanism,"Antidepressants:_bf In_bf vitro_bf data_bf indicate_bf DRUG inhibits_be metabolism_be OTHER_DRUG ,_af result_af increase_af plasma_af OTHER_DRUG levels_af prolongation_af QT_af interval_af ECG_af ._af"
996,"Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",fluconazole,cisapride,mechanism,"Antifungals:_bf In_bf vitro_bf and/or_bf vivo_bf data_bf indicate_bf DRUG ,_be itraconazole_be ,_be oral_be ketoconazole_be markedly_be inhibit_be metabolism_be OTHER_DRUG ,_af result_af increase_af plasma_af OTHER_DRUG levels_af prolongation_af QT_af interval_af ECG_af ._af"
997,"Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",itraconazole,cisapride,mechanism,"Antifungals:_bf In_bf vitro_bf and/or_bf vivo_bf data_bf indicate_bf fluconazole_bf ,_bf DRUG ,_be oral_be ketoconazole_be markedly_be inhibit_be metabolism_be OTHER_DRUG ,_af result_af increase_af plasma_af OTHER_DRUG levels_af prolongation_af QT_af interval_af ECG_af ._af"
998,"Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",ketoconazole,cisapride,mechanism,"Antifungals:_bf In_bf vitro_bf and/or_bf vivo_bf data_bf indicate_bf fluconazole_bf ,_bf itraconazole_bf ,_bf oral_bf DRUG markedly_be inhibit_be metabolism_be OTHER_DRUG ,_af result_af increase_af plasma_af OTHER_DRUG levels_af prolongation_af QT_af interval_af ECG_af ._af"
999,"Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.",ketoconazole,cisapride,mechanism,"Human_bf pharmacokinetic_bf data_bf indicate_bf oral_bf DRUG markedly_be inhibits_be metabolism_be OTHER_DRUG ,_af resulting_af mean_af eight-fold_af increase_af AUC_af OTHER_DRUG ._af"
1000,A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.,cisapride,ketoconazole,effect,A_bf study_bf 14_bf normal_bf male_bf female_bf volunteers_bf suggests_bf coadministration_bf DRUG OTHER_DRUG result_af prolongation_af QT_af interval_af ECG_af ._af
1001,"H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.",Cimetidine,cisapride,mechanism,"H2_bf Receptor_bf Antagonists:_bf DRUG coadministration_be leads_be increased_be peak_be plasma_be concentration_be AUC_be OTHER_DRUG ,_af effect_af OTHER_DRUG absorption_af coadministered_af ranitidine_af ._af"
1002,The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.,cimetidine,cisapride,mechanism,The_bf gastrointestinal_bf absorption_bf DRUG ranitidine_be accelerated_be coadministered_be OTHER_DRUG ._af
1003,The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.,ranitidine,cisapride,mechanism,The_bf gastrointestinal_bf absorption_bf cimetidine_bf DRUG accelerated_be coadministered_be OTHER_DRUG ._af
1004,Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.,indinavir,cisapride,mechanism,Protease_bf Inhibitors:_bf In_bf vitro_bf data_bf indicate_bf DRUG ritonavir_be markedly_be inhibit_be metabolism_be OTHER_DRUG result_af increase_af plasma_af OTHER_DRUG levels_af prolongation_af QT_af interval_af ECG_af ._af
1005,Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.,ritonavir,cisapride,mechanism,Protease_bf Inhibitors:_bf In_bf vitro_bf data_bf indicate_bf indinavir_bf DRUG markedly_be inhibit_be metabolism_be OTHER_DRUG result_af increase_af plasma_af OTHER_DRUG levels_af prolongation_af QT_af interval_af ECG_af ._af
1006,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",Cisapride,antiarrhythmics,advise,"DRUG used_be concomitantly_be drugs_be known_be prolong_be QT_be interval:_be certain_be OTHER_DRUG ,_af including_af Class_af IA_af (such_af quinidine_af procainamide)_af Class_af III_af (such_af sotalol);_af"
1007,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",Cisapride,quinidine,advise,"DRUG used_be concomitantly_be drugs_be known_be prolong_be QT_be interval:_be certain_be antiarrhythmics_be ,_be including_be Class_be IA_be (such_be OTHER_DRUG procainamide)_af Class_af III_af (such_af sotalol);_af"
1008,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",Cisapride,procainamide,advise,"DRUG used_be concomitantly_be drugs_be known_be prolong_be QT_be interval:_be certain_be antiarrhythmics_be ,_be including_be Class_be IA_be (such_be quinidine_be procainamide)_be Class_be III_be (such_be sotalol);_be"
1009,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",Cisapride,sotalol,advise,"DRUG used_be concomitantly_be drugs_be known_be prolong_be QT_be interval:_be certain_be antiarrhythmics_be ,_be including_be Class_be IA_be (such_be quinidine_be procainamide)_be Class_be III_be (such_be sotalol);_be"
1010,Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.,NIMBEX,succinylcholine,effect,Administration_bf 0_bf ._bf 1-mg/kg_bf (2_bf x_bf ED95)_bf DRUG 10%_be 95%_be recovery_be following_be intubating_be dose_be OTHER_DRUG (1_af mg/kg)_af produced_af 95%_af neuromuscular_af block_af ._af
1011,The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.,NIMBEX,succinylcholine,effect,The_bf time_bf onset_bf maximum_bf block_bf following_bf DRUG approximately_be 2_be minutes_be faster_be prior_be administration_be OTHER_DRUG ._af
1012,Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.,succinylcholine,NIMBEX,effect,Infusion_bf requirements_bf OTHER_DRUG patients_be administered_be DRUG prior_af infusions_af OTHER_DRUG comparable_af slightly_af greater_af DRUG administered_af ._af
1013,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,Isoflurane,NIMBEX,effect,DRUG enflurane_be administered_be nitrous_be oxide/oxygen_be achieve_be 1_be ._be 25_be MAC_be [Minimum_be Alveolar_be Concentration]_be may_be prolong_be clinically_be effective_be duration_be action_be initial_be maintenance_be doses_be OTHER_DRUG decrease_af required_af infusion_af rate_af OTHER_DRUG ._af
1014,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,Isoflurane,NIMBEX,effect,DRUG enflurane_be administered_be nitrous_be oxide/oxygen_be achieve_be 1_be ._be 25_be MAC_be [Minimum_be Alveolar_be Concentration]_be may_be prolong_be clinically_be effective_be duration_be action_be initial_be maintenance_be doses_be OTHER_DRUG decrease_af required_af infusion_af rate_af OTHER_DRUG ._af
1015,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,enflurane,NIMBEX,effect,Isoflurane_bf DRUG administered_be nitrous_be oxide/oxygen_be achieve_be 1_be ._be 25_be MAC_be [Minimum_be Alveolar_be Concentration]_be may_be prolong_be clinically_be effective_be duration_be action_be initial_be maintenance_be doses_be OTHER_DRUG decrease_af required_af infusion_af rate_af OTHER_DRUG ._af
1016,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,enflurane,NIMBEX,effect,Isoflurane_bf DRUG administered_be nitrous_be oxide/oxygen_be achieve_be 1_be ._be 25_be MAC_be [Minimum_be Alveolar_be Concentration]_be may_be prolong_be clinically_be effective_be duration_be action_be initial_be maintenance_be doses_be OTHER_DRUG decrease_af required_af infusion_af rate_af OTHER_DRUG ._af
1017,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,nitrous oxide,NIMBEX,effect,Isoflurane_bf enflurane_bf administered_bf nitrous_bf oxide/oxygen_bf achieve_bf 1_bf ._bf 25_bf MAC_bf [Minimum_bf Alveolar_bf Concentration]_bf may_bf prolong_bf clinically_bf effective_bf duration_bf action_bf initial_bf maintenance_bf doses_bf OTHER_DRUG decrease_be required_be infusion_be rate_be OTHER_DRUG ._af
1018,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,nitrous oxide,NIMBEX,effect,Isoflurane_bf enflurane_bf administered_bf nitrous_bf oxide/oxygen_bf achieve_bf 1_bf ._bf 25_bf MAC_bf [Minimum_bf Alveolar_bf Concentration]_bf may_bf prolong_bf clinically_bf effective_bf duration_bf action_bf initial_bf maintenance_bf doses_bf OTHER_DRUG decrease_be required_be infusion_be rate_be OTHER_DRUG ._af
1019,"In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.",enflurane,NIMBEX,advise,"In_bf long_bf surgical_bf procedures_bf DRUG isoflurane_be anesthesia_be ,_be less_be frequent_be maintenance_be dosing_be ,_be lower_be maintenance_be doses_be ,_be reduced_be infusion_be rates_be OTHER_DRUG may_af necessary_af ._af"
1020,"In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.",isoflurane,NIMBEX,advise,"In_bf long_bf surgical_bf procedures_bf enflurane_bf DRUG anesthesia_be ,_be less_be frequent_be maintenance_be dosing_be ,_be lower_be maintenance_be doses_be ,_be reduced_be infusion_be rates_be OTHER_DRUG may_af necessary_af ._af"
1021,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,NIMBEX,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf OTHER_DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1022,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,antibiotics,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf OTHER_DRUG (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1023,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,aminoglycosides,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1024,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,tetracyclines,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf OTHER_DRUG ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1025,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,bacitracin,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf OTHER_DRUG ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1026,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,polymyxins,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf OTHER_DRUG ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1027,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,lincomycin,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf OTHER_DRUG ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1028,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,clindamycin,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf OTHER_DRUG ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1029,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,colistin,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf OTHER_DRUG ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1030,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,sodium colistemethate,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistemethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf anesthetics_bf ,_bf procainamide_bf ,_bf quinidine_bf ._bf"
1031,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,magnesium,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistemethate)_bf ,_bf OTHER_DRUG salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1032,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,lithium,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistemethate)_bf ,_bf magnesium_bf salts_bf ,_bf OTHER_DRUG ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1033,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,anesthetics,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistemethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf OTHER_DRUG ,_be procainamide_be ,_be quinidine_be ._be"
1034,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,procainamide,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistemethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf anesthetics_bf ,_bf OTHER_DRUG ,_be quinidine_be ._be"
1035,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,quinidine,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistemethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf anesthetics_bf ,_bf procainamide_bf ,_bf OTHER_DRUG ._be"
1036,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,antibiotics,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be OTHER_DRUG (e_af ._af g_af ._af ,_af aminoglycosides_af ,_af tetracyclines_af ,_af bacitracin_af ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistemethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1037,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,aminoglycosides,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af tetracyclines_af ,_af bacitracin_af ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistemethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1038,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,tetracyclines,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be OTHER_DRUG ,_af bacitracin_af ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistemethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1039,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,bacitracin,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be OTHER_DRUG ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistemethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1040,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,polymyxins,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be OTHER_DRUG ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistemethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1041,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,lincomycin,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be OTHER_DRUG ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistemethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1042,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,clindamycin,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be OTHER_DRUG ,_af colistin_af ,_af sodium_af colistemethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1043,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,colistin,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be OTHER_DRUG ,_af sodium_af colistemethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1044,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,sodium colistemethate,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1045,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,magnesium,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be OTHER_DRUG salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1046,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,lithium,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be OTHER_DRUG ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1047,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,anesthetics,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be OTHER_DRUG ,_af procainamide_af ,_af quinidine_af ._af"
1048,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,procainamide,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
1049,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,quinidine,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be OTHER_DRUG ._af"
1050,Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.,nondepolarizing neuromuscular blocking agents,phenytoin,effect,Resistance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf neuromuscular_bf blocking_bf agents_bf demonstrated_bf patients_bf chronically_bf administered_bf OTHER_DRUG carbamazepine_be ._be
1051,Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.,nondepolarizing neuromuscular blocking agents,carbamazepine,effect,Resistance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf neuromuscular_bf blocking_bf agents_bf demonstrated_bf patients_bf chronically_bf administered_bf phenytoin_bf OTHER_DRUG ._be
1052,"While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.",phenytoin,NIMBEX,effect,"While_bf effects_bf chronic_bf DRUG carbamazepine_be therapy_be action_be OTHER_DRUG unknown_af ,_af slightly_af shorter_af durations_af neuromuscular_af block_af may_af anticipated_af infusion_af rate_af requirements_af may_af higher_af ._af"
1053,"While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.",carbamazepine,NIMBEX,effect,"While_bf effects_bf chronic_bf phenytoin_bf DRUG therapy_be action_be OTHER_DRUG unknown_af ,_af slightly_af shorter_af durations_af neuromuscular_af block_af may_af anticipated_af infusion_af rate_af requirements_af may_af higher_af ._af"
1054,Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy.,anticonvulsant agents,cisplatin,mechanism,Plasma_bf levels_bf anticonvulsant_bf agents_bf may_bf become_bf subtherapeutic_bf OTHER_DRUG therapy_be ._be
1055,The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.,allopurinol,ampicillin,effect,The_bf concurrent_bf administration_bf DRUG OTHER_DRUG increases_af substantially_af incidence_af rashes_af patients_af receiving_af drugs_af compared_af patients_af receiving_af OTHER_DRUG alone_af ._af
1056,It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.,ampicillin,allopurinol,effect,It_bf known_bf whether_bf potentiation_bf DRUG rashes_be due_be OTHER_DRUG hyperuricemia_af present_af patients_af ._af
1057,"In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives",broad-spectrum antibiotics,contraceptives,effect,"In_bf common_bf broad-spectrum_bf antibiotics_bf ,_bf AUGMENTIN_bf XR_bf may_bf reduce_bf efficacy_bf oral_bf OTHER_DRUG"
1058,"In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives",AUGMENTIN XR,contraceptives,effect,"In_bf common_bf broad-spectrum_bf antibiotics_bf ,_bf AUGMENTIN_bf XR_bf may_bf reduce_bf efficacy_bf oral_bf OTHER_DRUG"
1059,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.",antihistamines,CNS depressants,effect,"Additive_bf CNS_bf depression_bf may_bf occur_bf DRUG administered_be concomitantly_be CNS_be depressants_be including_be barbiturates_be ,_be tranquilizers_be ,_be alcohol_be ._be"
1060,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.",antihistamines,barbiturates,effect,"Additive_bf CNS_bf depression_bf may_bf occur_bf DRUG administered_be concomitantly_be CNS_be depressants_be including_be OTHER_DRUG ,_af tranquilizers_af ,_af alcohol_af ._af"
1061,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.",antihistamines,tranquilizers,effect,"Additive_bf CNS_bf depression_bf may_bf occur_bf DRUG administered_be concomitantly_be CNS_be depressants_be including_be barbiturates_be ,_be OTHER_DRUG ,_af alcohol_af ._af"
1062,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.",antihistamines,alcohol,effect,"Additive_bf CNS_bf depression_bf may_bf occur_bf DRUG administered_be concomitantly_be CNS_be depressants_be including_be barbiturates_be ,_be tranquilizers_be ,_be OTHER_DRUG ._af"
1063,Patients receiving antihistamines should be advised against the concurrent use of other CNS depressant drugs.,antihistamines,CNS depressant drugs,advise,Patients_bf receiving_bf DRUG advised_be concurrent_be use_be CNS_be depressant_be drugs_be ._be
1064,Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines.,Monoamine oxidase (MAO) inhibitors,antihistamines,effect,Monoamine_bf oxidase_bf (MAO)_bf inhibitors_bf prolong_bf intensify_bf anticholinergic_bf effects_bf OTHER_DRUG ._be
1065,"Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.",Amantadine,clidinium,effect,"DRUG ,_be tricyclic_be antidepressants_be ,_be MAOIs_be may_be increase_be anticholinergic_be effect_be OTHER_DRUG ._af"
1066,"Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.",tricyclic antidepressants,clidinium,effect,"Amantadine_bf ,_bf tricyclic_bf antidepressants_bf ,_bf MAOIs_bf may_bf increase_bf anticholinergic_bf effect_bf OTHER_DRUG ._be"
1067,"Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.",MAOIs,clidinium,effect,"Amantadine_bf ,_bf tricyclic_bf antidepressants_bf ,_bf DRUG may_be increase_be anticholinergic_be effect_be OTHER_DRUG ._af"
1068,"Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.",Clidinium,phenothiazines,effect,"DRUG may_be decrease_be effect_be OTHER_DRUG ,_af levodopa_af ,_af ketoconazole_af ._af"
1069,"Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.",Clidinium,levodopa,effect,"DRUG may_be decrease_be effect_be phenothiazines_be ,_be OTHER_DRUG ,_af ketoconazole_af ._af"
1070,"Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.",Clidinium,ketoconazole,effect,"DRUG may_be decrease_be effect_be phenothiazines_be ,_be levodopa_be ,_be OTHER_DRUG ._af"
1071,Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.,dapsone,Lamprene,effect,Preliminary_bf data_bf suggest_bf DRUG may_be inhibit_be anti-inflammatory_be activity_be OTHER_DRUG confirmed_af ._af
1072,"If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.",dapsone,clofazimine,advise,"If_bf leprosy-associated_bf inflammatory_bf reactions_bf develop_bf patients_bf treated_bf DRUG OTHER_DRUG ,_af still_af advisable_af continue_af treatment_af drugs_af ._af"
1073,Caution should be exercised when anticoagulants are given in conjunction with Atromid-S.,anticoagulants,Atromid-S,advise,Caution_bf exercised_bf DRUG given_be conjunction_be OTHER_DRUG ._af
1074,Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.,Atromid-S,phenytoin,mechanism,DRUG may_be displace_be acidic_be drugs_be OTHER_DRUG tolbutamide_af binding_af sites_af ._af
1075,Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.,Atromid-S,tolbutamide,mechanism,DRUG may_be displace_be acidic_be drugs_be phenytoin_be OTHER_DRUG binding_af sites_af ._af
1076,The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.,tolbutamide,Atromid-S,effect,The_bf hypoglycemic_bf effect_bf DRUG reported_be increase_be OTHER_DRUG given_af concurrently_af ._af
1077,Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months.,fibrate,lovastatin,effect,Fulminant_bf rhabdomyolysis_bf seen_bf early_bf three_bf weeks_bf initiation_bf combined_bf therapy_bf another_bf DRUG OTHER_DRUG may_af seen_af several_af months_af ._af
1078,"For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with lovastatin and a fibrate do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.",lovastatin,fibrate,effect,"For_bf reasons_bf ,_bf felt_bf ,_bf subjects_bf unsatisfactory_bf lipid_bf response_bf either_bf drug_bf alone_bf ,_bf possible_bf benefits_bf combined_bf therapy_bf DRUG OTHER_DRUG outweigh_af risks_af severe_af myopathy_af ,_af rhabdomyolysis_af ,_af acute_af renal_af failure_af ._af"
1079,"Therefore, the combined use of lovastatin with fibrates should generally be avoided.",lovastatin,fibrates,advise,"Therefore_bf ,_bf combined_bf use_bf DRUG OTHER_DRUG generally_af avoided_af ._af"
1080,"Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.",clorazepate dipotassium,hexobarbital,effect,"Animal_bf experience_bf indicates_bf clorazepate_bf dipotassium_bf prolongs_bf sleeping_bf time_bf OTHER_DRUG ethyl_be alcohol_be ,_be increases_be inhibitory_be effects_be chlorpromazine_be ,_be exhibit_be monoamine_be oxidase_be inhibition_be ._be"
1081,"Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.",clorazepate dipotassium,ethyl alcohol,effect,"Animal_bf experience_bf indicates_bf clorazepate_bf dipotassium_bf prolongs_bf sleeping_bf time_bf hexobarbital_bf ethyl_bf alcohol_bf ,_bf increases_bf inhibitory_bf effects_bf chlorpromazine_bf ,_bf exhibit_bf monoamine_bf oxidase_bf inhibition_bf ._bf"
1082,"Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.",clorazepate dipotassium,chlorpromazine,effect,"Animal_bf experience_bf indicates_bf clorazepate_bf dipotassium_bf prolongs_bf sleeping_bf time_bf hexobarbital_bf ethyl_bf alcohol_bf ,_bf increases_bf inhibitory_bf effects_bf OTHER_DRUG ,_be exhibit_be monoamine_be oxidase_be inhibition_be ._be"
1083,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,barbiturates,effect,"The_bf actions_bf DRUG may_be potentiated_be OTHER_DRUG ,_af narcotics_af ,_af phenothiazines_af ,_af monoamine_af oxidase_af inhibitors_af antidepressants_af ._af"
1084,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,narcotics,effect,"The_bf actions_bf DRUG may_be potentiated_be barbiturates_be ,_be OTHER_DRUG ,_af phenothiazines_af ,_af monoamine_af oxidase_af inhibitors_af antidepressants_af ._af"
1085,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,phenothiazines,effect,"The_bf actions_bf DRUG may_be potentiated_be barbiturates_be ,_be narcotics_be ,_be OTHER_DRUG ,_af monoamine_af oxidase_af inhibitors_af antidepressants_af ._af"
1086,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,monoamine oxidase inhibitors,effect,"The_bf actions_bf DRUG may_be potentiated_be barbiturates_be ,_be narcotics_be ,_be phenothiazines_be ,_be monoamine_be oxidase_be inhibitors_be antidepressants_be ._be"
1087,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,antidepressants,effect,"The_bf actions_bf DRUG may_be potentiated_be barbiturates_be ,_be narcotics_be ,_be phenothiazines_be ,_be monoamine_be oxidase_be inhibitors_be OTHER_DRUG ._af"
1088,"Given the primary CNS effects of Clozapine, caution is advised in using it concomitantly with other CNS-active drugs or alcohol.",Clozapine,alcohol,effect,"Given_bf primary_bf CNS_bf effects_bf DRUG ,_be caution_be advised_be using_be concomitantly_be CNS-active_be drugs_be OTHER_DRUG ._af"
1089,"Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.",clozapine,benzodiazepine,advise,"Although_bf established_bf interaction_bf DRUG benzodiazepines_be psychotropics_be ,_be caution_be advised_be DRUG initiated_af patients_af taking_af OTHER_DRUG psychotropic_af drug_af ._af"
1090,"Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.",clozapine,psychotropic drug,advise,"Although_bf established_bf interaction_bf DRUG benzodiazepines_be psychotropics_be ,_be caution_be advised_be DRUG initiated_af patients_af taking_af benzodiazepine_af psychotropic_af drug_af ._af"
1091,Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.,Clozapine,antihypertensive drugs,effect,DRUG may_be potentiate_be hypotensive_be effects_be antihypertensive_be drugs_be anticholinergic_be effects_be atropine-type_be drugs_be ._be
1092,Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.,Clozapine,atropine,effect,DRUG may_be potentiate_be hypotensive_be effects_be antihypertensive_be drugs_be anticholinergic_be effects_be atropine-type_be drugs_be ._be
1093,"Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.",Phenytoin,Clozapine,mechanism,"DRUG ,_be nicotine_be ,_be rifampin_be may_be decrease_be OTHER_DRUG plasma_af levels_af ,_af resulting_af decrease_af effectiveness_af previously_af effective_af OTHER_DRUG dose_af ._af"
1094,"Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.",nicotine,Clozapine,mechanism,"Phenytoin_bf ,_bf DRUG ,_be rifampin_be may_be decrease_be OTHER_DRUG plasma_af levels_af ,_af resulting_af decrease_af effectiveness_af previously_af effective_af OTHER_DRUG dose_af ._af"
1095,"Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.",rifampin,Clozapine,mechanism,"Phenytoin_bf ,_bf nicotine_bf ,_bf DRUG may_be decrease_be OTHER_DRUG plasma_af levels_af ,_af resulting_af decrease_af effectiveness_af previously_af effective_af OTHER_DRUG dose_af ._af"
1096,"Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.",Cimetidine,Clozapine,mechanism,"DRUG ,_be caffeine_be ,_be erythromycin_be may_be increase_be plasma_be levels_be OTHER_DRUG ,_af potentially_af resulting_af adverse_af effects_af ._af"
1097,"Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.",caffeine,Clozapine,mechanism,"Cimetidine_bf ,_bf DRUG ,_be erythromycin_be may_be increase_be plasma_be levels_be OTHER_DRUG ,_af potentially_af resulting_af adverse_af effects_af ._af"
1098,"Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.",erythromycin,Clozapine,mechanism,"Cimetidine_bf ,_bf caffeine_bf ,_bf DRUG may_be increase_be plasma_be levels_be OTHER_DRUG ,_af potentially_af resulting_af adverse_af effects_af ._af"
1099,"Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.",Clozapine,carbamazepine,advise,"Although_bf concomitant_bf use_bf DRUG OTHER_DRUG recommended_af ,_af noted_af discontinuation_af concomitant_af OTHER_DRUG administration_af may_af result_af increase_af DRUG plasma_af levels_af ._af"
1100,"Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.",carbamazepine,Clozapine,mechanism,"Although_bf concomitant_bf use_bf OTHER_DRUG DRUG recommended_af ,_af noted_af discontinuation_af concomitant_af DRUG administration_af may_af result_af increase_af OTHER_DRUG plasma_af levels_af ._af"
1101,Paroxetine produced only minor changes in the levels of clozapine and its metabolites.,Paroxetine,clozapine,mechanism,DRUG produced_be minor_be changes_be levels_be OTHER_DRUG metabolites_af ._af
1102,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.",clozapine,paroxetine,mechanism,"However_bf ,_bf published_bf reports_bf describe_bf modest_bf elevations_bf (less_bf two-fold)_bf DRUG metabolite_be concentrations_be DRUG taken_af OTHER_DRUG ,_af fluoxetine_af ,_af sertraline_af ._af"
1103,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.",clozapine,fluoxetine,mechanism,"However_bf ,_bf published_bf reports_bf describe_bf modest_bf elevations_bf (less_bf two-fold)_bf DRUG metabolite_be concentrations_be DRUG taken_af paroxetine_af ,_af OTHER_DRUG ,_af sertraline_af ._af"
1104,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.",clozapine,sertraline,mechanism,"However_bf ,_bf published_bf reports_bf describe_bf modest_bf elevations_bf (less_bf two-fold)_bf DRUG metabolite_be concentrations_be DRUG taken_af paroxetine_af ,_af fluoxetine_af ,_af OTHER_DRUG ._af"
1105,"Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.",Clozapine,fluvoxamine,advise,"Therefore_bf ,_bf combined_bf treatment_bf approached_bf caution_bf patients_bf monitored_bf closely_bf DRUG combined_be drugs_be ,_be particularly_be OTHER_DRUG ._af"
1106,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,antidepressants,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be isozyme_be ,_be including_be OTHER_DRUG ,_af phenothiazines_af ,_af carbamazepine_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide_af encainide)_af ,_af inhibit_af enzyme_af (e_af ._af g_af ._af ,_af quinidine)_af ,_af approached_af caution_af ._af"
1107,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,phenothiazines,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be isozyme_be ,_be including_be antidepressants_be ,_be OTHER_DRUG ,_af carbamazepine_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide_af encainide)_af ,_af inhibit_af enzyme_af (e_af ._af g_af ._af ,_af quinidine)_af ,_af approached_af caution_af ._af"
1108,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,carbamazepine,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be isozyme_be ,_be including_be antidepressants_be ,_be phenothiazines_be ,_be OTHER_DRUG ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide_af encainide)_af ,_af inhibit_af enzyme_af (e_af ._af g_af ._af ,_af quinidine)_af ,_af approached_af caution_af ._af"
1109,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,Type 1C antiarrhythmics,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be isozyme_be ,_be including_be antidepressants_be ,_be phenothiazines_be ,_be carbamazepine_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide_be encainide)_be ,_be inhibit_be enzyme_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be approached_be caution_be ._be"
1110,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,propafenone,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be isozyme_be ,_be including_be antidepressants_be ,_be phenothiazines_be ,_be carbamazepine_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af flecainide_af encainide)_af ,_af inhibit_af enzyme_af (e_af ._af g_af ._af ,_af quinidine)_af ,_af approached_af caution_af ._af"
1111,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,flecainide,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be isozyme_be ,_be including_be antidepressants_be ,_be phenothiazines_be ,_be carbamazepine_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be OTHER_DRUG encainide)_af ,_af inhibit_af enzyme_af (e_af ._af g_af ._af ,_af quinidine)_af ,_af approached_af caution_af ._af"
1112,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,encainide,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be isozyme_be ,_be including_be antidepressants_be ,_be phenothiazines_be ,_be carbamazepine_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide_be encainide)_be ,_be inhibit_be enzyme_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be approached_be caution_be ._be"
1113,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,quinidine,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be isozyme_be ,_be including_be antidepressants_be ,_be phenothiazines_be ,_be carbamazepine_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide_be encainide)_be ,_be inhibit_be enzyme_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be approached_be caution_be ._be"
1114,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,narcotic analgesics,effect,"DRUG combination_be narcotic_be analgesics_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be tranquilizers_be ,_be sedative-hypnotics_be ,_be CNS_be depressants_be (including_be alcohol)_be additive_be depressant_be effects_be ._be"
1115,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,anesthetics,effect,"DRUG combination_be narcotic_be analgesics_be ,_be general_be OTHER_DRUG ,_af phenothiazines_af ,_af tranquilizers_af ,_af sedative-hypnotics_af ,_af CNS_af depressants_af (including_af alcohol)_af additive_af depressant_af effects_af ._af"
1116,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,phenothiazines,effect,"DRUG combination_be narcotic_be analgesics_be ,_be general_be anesthetics_be ,_be OTHER_DRUG ,_af tranquilizers_af ,_af sedative-hypnotics_af ,_af CNS_af depressants_af (including_af alcohol)_af additive_af depressant_af effects_af ._af"
1117,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,tranquilizers,effect,"DRUG combination_be narcotic_be analgesics_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be OTHER_DRUG ,_af sedative-hypnotics_af ,_af CNS_af depressants_af (including_af alcohol)_af additive_af depressant_af effects_af ._af"
1118,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,sedative-hypnotics,effect,"DRUG combination_be narcotic_be analgesics_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be tranquilizers_be ,_be OTHER_DRUG ,_af CNS_af depressants_af (including_af alcohol)_af additive_af depressant_af effects_af ._af"
1119,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,CNS depressants,effect,"DRUG combination_be narcotic_be analgesics_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be tranquilizers_be ,_be sedative-hypnotics_be ,_be CNS_be depressants_be (including_be alcohol)_be additive_be depressant_be effects_be ._be"
1120,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,alcohol,effect,"DRUG combination_be narcotic_be analgesics_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be tranquilizers_be ,_be sedative-hypnotics_be ,_be CNS_be depressants_be (including_be alcohol)_be additive_be depressant_be effects_be ._be"
1121,Colchicine is inhibited by acidifying agents.,Colchicine,acidifying agents,mechanism,DRUG inhibited_be acidifying_be agents_be ._be
1122,The action of colchicine is potentiated by alkalinizing agents.,colchicine,alkalinizing agents,mechanism,The_bf action_bf DRUG potentiated_be alkalinizing_be agents_be ._be
1123,Colchicine may increase sensitivity to the CNS depressants.,Colchicine,CNS depressants,effect,DRUG may_be increase_be sensitivity_be CNS_be depressants_be ._be
1124,Response to sympathomimetic agents may be enhanced by colchicine.,sympathomimetic agents,colchicine,effect,Response_bf sympathomimetic_bf agents_bf may_bf enhanced_bf OTHER_DRUG ._be
1125,"WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.",WelChol,verapamil,mechanism,"DRUG decreased_be Cmax_be AUC_be sustained-release_be OTHER_DRUG (Calan_af SR_af )_af approximately_af 31%_af 11%_af ,_af respectively_af ._af"
1126,"WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.",WelChol,Calan SR,mechanism,"DRUG decreased_be Cmax_be AUC_be sustained-release_be verapamil_be (Calan_be SR_be )_be approximately_be 31%_be 11%_be ,_be respectively_be ._be"
1127,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",Curariform muscle relaxants,Coly-Mycin M,effect,"Curariform_bf muscle_bf relaxants_bf (eg_bf ,_bf tubocurarine)_bf drugs_bf ,_bf including_bf ether_bf ,_bf succinylcholine_bf ,_bf gallamine_bf ,_bf decamethonium_bf sodium_bf citrate_bf ,_bf potentiate_bf neuromuscular_bf blocking_bf effect_bf used_bf extreme_bf caution_bf patients_bf treated_bf Coly-Mycin_bf M_bf Parenteral_bf ._bf"
1128,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",tubocurarine,Coly-Mycin M,effect,"Curariform_bf muscle_bf relaxants_bf (eg_bf ,_bf tubocurarine)_bf drugs_bf ,_bf including_bf ether_bf ,_bf succinylcholine_bf ,_bf gallamine_bf ,_bf decamethonium_bf sodium_bf citrate_bf ,_bf potentiate_bf neuromuscular_bf blocking_bf effect_bf used_bf extreme_bf caution_bf patients_bf treated_bf Coly-Mycin_bf M_bf Parenteral_bf ._bf"
1129,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",succinylcholine,Coly-Mycin M,effect,"Curariform_bf muscle_bf relaxants_bf (eg_bf ,_bf tubocurarine)_bf drugs_bf ,_bf including_bf ether_bf ,_bf DRUG ,_be gallamine_be ,_be decamethonium_be sodium_be citrate_be ,_be potentiate_be neuromuscular_be blocking_be effect_be used_be extreme_be caution_be patients_be treated_be Coly-Mycin_be M_be Parenteral_be ._be"
1130,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",gallamine,Coly-Mycin M,effect,"Curariform_bf muscle_bf relaxants_bf (eg_bf ,_bf tubocurarine)_bf drugs_bf ,_bf including_bf ether_bf ,_bf succinylcholine_bf ,_bf DRUG ,_be decamethonium_be sodium_be citrate_be ,_be potentiate_be neuromuscular_be blocking_be effect_be used_be extreme_be caution_be patients_be treated_be Coly-Mycin_be M_be Parenteral_be ._be"
1131,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",decamethonium,Coly-Mycin M,effect,"Curariform_bf muscle_bf relaxants_bf (eg_bf ,_bf tubocurarine)_bf drugs_bf ,_bf including_bf ether_bf ,_bf succinylcholine_bf ,_bf gallamine_bf ,_bf DRUG sodium_be citrate_be ,_be potentiate_be neuromuscular_be blocking_be effect_be used_be extreme_be caution_be patients_be treated_be Coly-Mycin_be M_be Parenteral_be ._be"
1132,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",sodium citrate,Coly-Mycin M,effect,"Curariform_bf muscle_bf relaxants_bf (eg_bf ,_bf tubocurarine)_bf drugs_bf ,_bf including_bf ether_bf ,_bf succinylcholine_bf ,_bf gallamine_bf ,_bf decamethonium_bf sodium_bf citrate_bf ,_bf potentiate_bf neuromuscular_bf blocking_bf effect_bf used_bf extreme_bf caution_bf patients_bf treated_bf Coly-Mycin_bf M_bf Parenteral_bf ._bf"
1133,Sodium cephalothin may enhance the nephrotoxicity of Coly-Mycin M Parenteral.,Sodium cephalothin,Coly-Mycin M,effect,Sodium_bf cephalothin_bf may_bf enhance_bf nephrotoxicity_bf Coly-Mycin_bf M_bf Parenteral_bf ._bf
1134,The concomitant use of sodium cephalothin and Coly-Mycin M Parenteral should be avoided.,sodium cephalothin,Coly-Mycin M,advise,The_bf concomitant_bf use_bf sodium_bf cephalothin_bf Coly-Mycin_bf M_bf Parenteral_bf avoided_bf ._bf
1135,"Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.",digoxin,conivaptan,mechanism,"Digoxin:_bf Coadministration_bf DRUG ,_be P-glycoprotein_be substrate_be ,_be oral_be OTHER_DRUG resulted_af reduction_af clearance_af increase_af DRUG Cmax_af AUC_af values_af ._af"
1136,"Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.",digoxin,VAPRISOL,mechanism,"Therefore_bf ,_bf DRUG administered_be OTHER_DRUG ,_af clinician_af alert_af possibility_af increases_af DRUG levels_af ._af"
1137,Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.,Corticotropin,diuretic,effect,DRUG may_be accentuate_be electrolyte_be loss_be associated_be OTHER_DRUG therapy_af ._af
1138,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",phenobarbital,corticosteroids,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf DRUG ,_be phenytoin_be rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increases_af corticosteroid_af dose_af achieve_af desired_af response_af ._af"
1139,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",phenobarbital,corticosteroid,advise,"Drugs_bf induce_bf hepatic_bf enzymes_bf DRUG ,_be phenytoin_be rifampin_be may_be increase_be clearance_be corticosteroids_be may_be require_be increases_be OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
1140,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",phenytoin,corticosteroids,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf DRUG rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increases_af corticosteroid_af dose_af achieve_af desired_af response_af ._af"
1141,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",phenytoin,corticosteroid,advise,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf DRUG rifampin_be may_be increase_be clearance_be corticosteroids_be may_be require_be increases_be OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
1142,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",rifampin,corticosteroids,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf phenytoin_bf DRUG may_be increase_be clearance_be OTHER_DRUG may_af require_af increases_af corticosteroid_af dose_af achieve_af desired_af response_af ._af"
1143,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",rifampin,corticosteroid,advise,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf phenytoin_bf DRUG may_be increase_be clearance_be corticosteroids_be may_be require_be increases_be OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
1144,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.,troleandomycin,corticosteroids,mechanism,Drugs_bf DRUG ketoconazole_be may_be inhibit_be metabolism_be OTHER_DRUG thus_af decrease_af clearance_af ._af
1145,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.,ketoconazole,corticosteroids,mechanism,Drugs_bf troleandomycin_bf DRUG may_be inhibit_be metabolism_be OTHER_DRUG thus_af decrease_af clearance_af ._af
1146,Corticosteroids may increase the clearance of chronic high dose aspirin.,Corticosteroids,aspirin,effect,DRUG may_be increase_be clearance_be chronic_be high_be dose_be OTHER_DRUG ._af
1147,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.,salicylate,corticosteroid,effect,This_bf could_bf lead_bf decreased_bf DRUG serum_be levels_be increase_be risk_be DRUG toxicity_af OTHER_DRUG withdrawn_af ._af
1148,Aspirin should be used cautiously in conjunction with cortico-steroids in patients suffering from hypopro-thrombinemia.,Aspirin,cortico-steroids,advise,DRUG used_be cautiously_be conjunction_be OTHER_DRUG patients_af suffering_af hypopro-thrombinemia_af ._af
1149,The effect of corticosteroids on oral anticoagulants is variable.,corticosteroids,anticoagulants,effect,The_bf effect_bf DRUG oral_be OTHER_DRUG variable_af ._af
1150,There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.,anticoagulants,corticosteroids,effect,There_bf reports_bf enhanced_bf well_bf diminished_bf effects_bf DRUG given_be concurrently_be OTHER_DRUG ._af
1151,Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.,Corticotropin,diuretic,effect,DRUG may_be accentuate_be electrolyte_be loss_be associated_be OTHER_DRUG therapy_af ._af
1152,The addition of 540 mg/kg/day of cromolyn sodium (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of isoproterenol (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.,cromolyn sodium,isoproterenol,effect,The_bf addition_bf 540_bf mg/kg/day_bf cromolyn_bf sodium_bf (approximately_bf 340_bf times_bf maximum_bf recommended_bf daily_bf inhalation_bf dose_bf adults_bf mg/m2_bf basis)_bf 2_bf ._bf 7_bf mg/kg/day_bf OTHER_DRUG (approximately_be 7_be times_be maximum_be recommended_be daily_be inhalation_be dose_be adults_be mg/m2_be basis)_be appears_be increased_be incidence_be resorptions_be malformations_be ._be
1153,Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.,Colchicine,vitamin B12,mechanism,DRUG para-aminosalicylic_be acid_be heavy_be alcohol_be intake_be longer_be 2_be weeks_be may_be produce_be malabsorption_be vitamin_be B12_be ._be
1154,Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.,para-aminosalicylic acid,vitamin B12,mechanism,Colchicine_bf para-aminosalicylic_bf acid_bf heavy_bf alcohol_bf intake_bf longer_bf 2_bf weeks_bf may_bf produce_bf malabsorption_bf vitamin_bf B12_bf ._bf
1155,Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.,alcohol,vitamin B12,mechanism,Colchicine_bf para-aminosalicylic_bf acid_bf heavy_bf DRUG intake_be longer_be 2_be weeks_be may_be produce_be malabsorption_be vitamin_be B12_be ._be
1156,FLEXERIL may have life-threatening interactions with MAO inhibitors.,FLEXERIL,MAO inhibitors,int,DRUG may_be life-threatening_be interactions_be MAO_be inhibitors_be ._be
1157,"FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.",FLEXERIL,alcohol,effect,"DRUG may_be enhance_be effects_be OTHER_DRUG ,_af barbiturates_af ,_af CNS_af depressants_af ._af"
1158,"FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.",FLEXERIL,barbiturates,effect,"DRUG may_be enhance_be effects_be alcohol_be ,_be OTHER_DRUG ,_af CNS_af depressants_af ._af"
1159,"FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.",FLEXERIL,CNS depressants,effect,"DRUG may_be enhance_be effects_be alcohol_be ,_be barbiturates_be ,_be CNS_be depressants_be ._be"
1160,Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.,Tricyclic antidepressants,guanethidine,effect,Tricyclic_bf antidepressants_bf may_bf block_bf antihypertensive_bf action_bf OTHER_DRUG similarly_be acting_be compounds_be ._be
1161,Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol,Tricyclic antidepressants,tramadol,effect,Tricyclic_bf antidepressants_bf may_bf enhance_bf seizure_bf risk_bf patients_bf taking_bf OTHER_DRUG
1162,Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;,Cyclopentolate,carbachol,effect,DRUG may_be interfere_be anti-glaucoma_be action_be OTHER_DRUG pilocarpine;_af
1163,Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;,Cyclopentolate,pilocarpine,effect,DRUG may_be interfere_be anti-glaucoma_be action_be carbachol_be pilocarpine;_be
1164,MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.,MAO inhibitors,antihistamines,effect,MAO_bf inhibitors_bf prolong_bf intensify_bf anticholinergic_bf effects_bf OTHER_DRUG ._be
1165,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,alcohol,effect,"DRUG may_be additive_be effects_be OTHER_DRUG CNS_af depressants_af ,_af ._af g_af ._af ,_af hypnotics_af ,_af sedatives_af ,_af tranquilizers_af ,_af antianxiety_af agents_af ._af"
1166,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,CNS depressants,effect,"DRUG may_be additive_be effects_be alcohol_be CNS_be depressants_be ,_be ._be g_be ._be ,_be hypnotics_be ,_be sedatives_be ,_be tranquilizers_be ,_be antianxiety_be agents_be ._be"
1167,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,hypnotics,effect,"DRUG may_be additive_be effects_be alcohol_be CNS_be depressants_be ,_be ._be g_be ._be ,_be OTHER_DRUG ,_af sedatives_af ,_af tranquilizers_af ,_af antianxiety_af agents_af ._af"
1168,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,sedatives,effect,"DRUG may_be additive_be effects_be alcohol_be CNS_be depressants_be ,_be ._be g_be ._be ,_be hypnotics_be ,_be OTHER_DRUG ,_af tranquilizers_af ,_af antianxiety_af agents_af ._af"
1169,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,tranquilizers,effect,"DRUG may_be additive_be effects_be alcohol_be CNS_be depressants_be ,_be ._be g_be ._be ,_be hypnotics_be ,_be sedatives_be ,_be OTHER_DRUG ,_af antianxiety_af agents_af ._af"
1170,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,antianxiety agents,effect,"DRUG may_be additive_be effects_be alcohol_be CNS_be depressants_be ,_be ._be g_be ._be ,_be hypnotics_be ,_be sedatives_be ,_be tranquilizers_be ,_be antianxiety_be agents_be ._be"
1171,"It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.",dantrolene sodium,calcium channel blockers,advise,"It_bf recommended_bf combination_bf intravenous_bf dantrolene_bf sodium_bf calcium_bf channel_bf blockers_bf ,_bf verapamil_bf ,_bf used_bf together_bf management_bf malignant_bf hyperthermia_bf crisis_bf relevance_bf findings_bf humans_bf established_bf ._bf"
1172,"It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.",dantrolene sodium,verapamil,advise,"It_bf recommended_bf combination_bf intravenous_bf dantrolene_bf sodium_bf calcium_bf channel_bf blockers_bf ,_bf OTHER_DRUG ,_be used_be together_be management_be malignant_be hyperthermia_be crisis_be relevance_be findings_be humans_be established_be ._be"
1173,Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.,dantrolene,vecuronium,effect,Administration_bf DRUG may_be potentiate_be vecuronium-induced_be neuromuscular_be block_be ._be
1174,"Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.",HMG-CoA reductase inhibitors,Fentanyl,advise,"Experience_bf co-administration_bf HMG-CoA_bf reductase_bf inhibitors_bf OTHER_DRUG patients_be limited_be ,_be therefore_be ,_be consideration_be given_be temporarily_be suspending_be use_be HMG-CoA_be reductase_be inhibitors_be patients_be receiving_be OTHER_DRUG ._af"
1175,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,ketoconazole,advise,"The_bf daily_bf dose_bf DRUG exceed_be 7_be ._be 5_be mg_be coadministered_be potent_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af itraconazole_af ,_af ritonavir_af ,_af nelfinavir_af ,_af clarithromycin_af nefazadone)_af ._af"
1176,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,itraconazole,advise,"The_bf daily_bf dose_bf DRUG exceed_be 7_be ._be 5_be mg_be coadministered_be potent_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be OTHER_DRUG ,_af ritonavir_af ,_af nelfinavir_af ,_af clarithromycin_af nefazadone)_af ._af"
1177,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,ritonavir,advise,"The_bf daily_bf dose_bf DRUG exceed_be 7_be ._be 5_be mg_be coadministered_be potent_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be OTHER_DRUG ,_af nelfinavir_af ,_af clarithromycin_af nefazadone)_af ._af"
1178,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,nelfinavir,advise,"The_bf daily_bf dose_bf DRUG exceed_be 7_be ._be 5_be mg_be coadministered_be potent_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be ritonavir_be ,_be OTHER_DRUG ,_af clarithromycin_af nefazadone)_af ._af"
1179,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,clarithromycin,advise,"The_bf daily_bf dose_bf DRUG exceed_be 7_be ._be 5_be mg_be coadministered_be potent_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be ritonavir_be ,_be nelfinavir_be ,_be OTHER_DRUG nefazadone)_af ._af"
1180,"Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).",ENABLEX,flecainide,advise,"Caution_bf taken_bf DRUG used_be concomitantly_be medications_be predominantly_be metabolized_be CYP2D6_be narrow_be therapeutic_be window_be ,_be OTHER_DRUG ,_af thioridazine_af tricyclic_af antidepressants_af (see_af CLINICAL_af PHARMACOLOGY)_af ._af"
1181,"Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).",ENABLEX,thioridazine,advise,"Caution_bf taken_bf DRUG used_be concomitantly_be medications_be predominantly_be metabolized_be CYP2D6_be narrow_be therapeutic_be window_be ,_be flecainide_be ,_be OTHER_DRUG tricyclic_af antidepressants_af (see_af CLINICAL_af PHARMACOLOGY)_af ._af"
1182,"Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).",ENABLEX,tricyclic antidepressants,advise,"Caution_bf taken_bf DRUG used_be concomitantly_be medications_be predominantly_be metabolized_be CYP2D6_be narrow_be therapeutic_be window_be ,_be flecainide_be ,_be thioridazine_be tricyclic_be antidepressants_be (see_be CLINICAL_be PHARMACOLOGY)_be ._be"
1183,"The concomitant use of ENABLEX with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects.",ENABLEX,anticholinergic agents,effect,"The_bf concomitant_bf use_bf DRUG anticholinergic_be agents_be may_be increase_be frequency_be and/or_be severity_be dry_be mouth_be ,_be constipation_be ,_be blurred_be vision_be anticholinergic_be pharmacological_be effects_be ._be"
1184,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,ketoconazole,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be OTHER_DRUG ,_af itraconazole_af ,_af erythromycin_af ,_af clarithromycin_af ,_af ritonavir_af ,_af atazanavir_af ,_af indinavir_af ,_af nefazodone_af ,_af nelfinavir_af ,_af saquinavir_af ,_af telithromycin)_af may_af increase_af exposure_af dasatinib_af avoided_af ._af"
1185,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,itraconazole,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be ketoconazole_be ,_be OTHER_DRUG ,_af erythromycin_af ,_af clarithromycin_af ,_af ritonavir_af ,_af atazanavir_af ,_af indinavir_af ,_af nefazodone_af ,_af nelfinavir_af ,_af saquinavir_af ,_af telithromycin)_af may_af increase_af exposure_af dasatinib_af avoided_af ._af"
1186,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,erythromycin,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be ketoconazole_be ,_be itraconazole_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af ritonavir_af ,_af atazanavir_af ,_af indinavir_af ,_af nefazodone_af ,_af nelfinavir_af ,_af saquinavir_af ,_af telithromycin)_af may_af increase_af exposure_af dasatinib_af avoided_af ._af"
1187,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,clarithromycin,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be OTHER_DRUG ,_af ritonavir_af ,_af atazanavir_af ,_af indinavir_af ,_af nefazodone_af ,_af nelfinavir_af ,_af saquinavir_af ,_af telithromycin)_af may_af increase_af exposure_af dasatinib_af avoided_af ._af"
1188,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,ritonavir,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af atazanavir_af ,_af indinavir_af ,_af nefazodone_af ,_af nelfinavir_af ,_af saquinavir_af ,_af telithromycin)_af may_af increase_af exposure_af dasatinib_af avoided_af ._af"
1189,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,atazanavir,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be clarithromycin_be ,_be ritonavir_be ,_be OTHER_DRUG ,_af indinavir_af ,_af nefazodone_af ,_af nelfinavir_af ,_af saquinavir_af ,_af telithromycin)_af may_af increase_af exposure_af dasatinib_af avoided_af ._af"
1190,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,indinavir,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be clarithromycin_be ,_be ritonavir_be ,_be atazanavir_be ,_be OTHER_DRUG ,_af nefazodone_af ,_af nelfinavir_af ,_af saquinavir_af ,_af telithromycin)_af may_af increase_af exposure_af dasatinib_af avoided_af ._af"
1191,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,nefazodone,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be clarithromycin_be ,_be ritonavir_be ,_be atazanavir_be ,_be indinavir_be ,_be OTHER_DRUG ,_af nelfinavir_af ,_af saquinavir_af ,_af telithromycin)_af may_af increase_af exposure_af dasatinib_af avoided_af ._af"
1192,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,nelfinavir,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be clarithromycin_be ,_be ritonavir_be ,_be atazanavir_be ,_be indinavir_be ,_be nefazodone_be ,_be OTHER_DRUG ,_af saquinavir_af ,_af telithromycin)_af may_af increase_af exposure_af dasatinib_af avoided_af ._af"
1193,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,saquinavir,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be clarithromycin_be ,_be ritonavir_be ,_be atazanavir_be ,_be indinavir_be ,_be nefazodone_be ,_be nelfinavir_be ,_be OTHER_DRUG ,_af telithromycin)_af may_af increase_af exposure_af dasatinib_af avoided_af ._af"
1194,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,telithromycin,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be clarithromycin_be ,_be ritonavir_be ,_be atazanavir_be ,_be indinavir_be ,_be nefazodone_be ,_be nelfinavir_be ,_be saquinavir_be ,_be telithromycin)_be may_be increase_be exposure_be dasatinib_be avoided_be ._be"
1195,Simultaneous administration of SPRYCEL with antacids should be avoided.,SPRYCEL,antacids,advise,Simultaneous_bf administration_bf DRUG OTHER_DRUG avoided_af ._af
1196,"If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of SPRYCEL.",antacid,SPRYCEL,advise,"If_bf DRUG therapy_be needed_be ,_be DRUG dose_af administered_af least_af 2_af hours_af prior_af 2_af hours_af dose_af OTHER_DRUG ._af"
1197,"H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",H2 blockers,dasatinib,effect,"H2_bf Blockers/Proton_bf Pump_bf Inhibitors:_bf Long-term_bf suppression_bf gastric_bf acid_bf secretion_bf H2_bf blockers_bf proton_bf pump_bf inhibitors_bf (eg_bf ,_bf famotidine_bf omeprazole)_bf likely_bf reduce_bf OTHER_DRUG exposure_be ._be"
1198,"H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",proton pump inhibitors,dasatinib,effect,"H2_bf Blockers/Proton_bf Pump_bf Inhibitors:_bf Long-term_bf suppression_bf gastric_bf acid_bf secretion_bf H2_bf blockers_bf proton_bf pump_bf inhibitors_bf (eg_bf ,_bf famotidine_bf omeprazole)_bf likely_bf reduce_bf OTHER_DRUG exposure_be ._be"
1199,"H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",famotidine,dasatinib,effect,"H2_bf Blockers/Proton_bf Pump_bf Inhibitors:_bf Long-term_bf suppression_bf gastric_bf acid_bf secretion_bf H2_bf blockers_bf proton_bf pump_bf inhibitors_bf (eg_bf ,_bf DRUG omeprazole)_be likely_be reduce_be OTHER_DRUG exposure_af ._af"
1200,"H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",omeprazole,dasatinib,effect,"H2_bf Blockers/Proton_bf Pump_bf Inhibitors:_bf Long-term_bf suppression_bf gastric_bf acid_bf secretion_bf H2_bf blockers_bf proton_bf pump_bf inhibitors_bf (eg_bf ,_bf famotidine_bf omeprazole)_bf likely_bf reduce_bf OTHER_DRUG exposure_be ._be"
1201,The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.,H2 blockers,SPRYCEL,advise,The_bf concomitant_bf use_bf H2_bf blockers_bf proton_bf pump_bf inhibitors_bf OTHER_DRUG recommended_be ._be
1202,The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.,proton pump inhibitors,SPRYCEL,advise,The_bf concomitant_bf use_bf H2_bf blockers_bf proton_bf pump_bf inhibitors_bf OTHER_DRUG recommended_be ._be
1203,The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.,H2 blockers,SPRYCEL,advise,The_bf use_bf antacids_bf considered_bf place_bf H2_bf blockers_bf proton_bf pump_bf inhibitors_bf patients_bf receiving_bf OTHER_DRUG therapy_be ._be
1204,The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.,proton pump inhibitors,SPRYCEL,advise,The_bf use_bf antacids_bf considered_bf place_bf H2_bf blockers_bf proton_bf pump_bf inhibitors_bf patients_bf receiving_bf OTHER_DRUG therapy_be ._be
1205,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",alfentanil,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf DRUG ,_be astemizole_be ,_be terfenadine_be ,_be cisapride_be ,_be cyclosporine_be ,_be fentanyl_be ,_be pimozide_be ,_be quinidine_be ,_be sirolimus_be ,_be tacrolimus_be ,_be ergot_be alkaloids_be (ergotamine_be ,_be dihydroergotamine)_be administered_be caution_be patients_be receiving_be OTHER_DRUG ._af"
1206,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",astemizole,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf DRUG ,_be terfenadine_be ,_be cisapride_be ,_be cyclosporine_be ,_be fentanyl_be ,_be pimozide_be ,_be quinidine_be ,_be sirolimus_be ,_be tacrolimus_be ,_be ergot_be alkaloids_be (ergotamine_be ,_be dihydroergotamine)_be administered_be caution_be patients_be receiving_be OTHER_DRUG ._af"
1207,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",terfenadine,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf DRUG ,_be cisapride_be ,_be cyclosporine_be ,_be fentanyl_be ,_be pimozide_be ,_be quinidine_be ,_be sirolimus_be ,_be tacrolimus_be ,_be ergot_be alkaloids_be (ergotamine_be ,_be dihydroergotamine)_be administered_be caution_be patients_be receiving_be OTHER_DRUG ._af"
1208,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",cisapride,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf terfenadine_bf ,_bf DRUG ,_be cyclosporine_be ,_be fentanyl_be ,_be pimozide_be ,_be quinidine_be ,_be sirolimus_be ,_be tacrolimus_be ,_be ergot_be alkaloids_be (ergotamine_be ,_be dihydroergotamine)_be administered_be caution_be patients_be receiving_be OTHER_DRUG ._af"
1209,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",cyclosporine,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf terfenadine_bf ,_bf cisapride_bf ,_bf DRUG ,_be fentanyl_be ,_be pimozide_be ,_be quinidine_be ,_be sirolimus_be ,_be tacrolimus_be ,_be ergot_be alkaloids_be (ergotamine_be ,_be dihydroergotamine)_be administered_be caution_be patients_be receiving_be OTHER_DRUG ._af"
1210,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",fentanyl,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf terfenadine_bf ,_bf cisapride_bf ,_bf cyclosporine_bf ,_bf DRUG ,_be pimozide_be ,_be quinidine_be ,_be sirolimus_be ,_be tacrolimus_be ,_be ergot_be alkaloids_be (ergotamine_be ,_be dihydroergotamine)_be administered_be caution_be patients_be receiving_be OTHER_DRUG ._af"
1211,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",pimozide,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf terfenadine_bf ,_bf cisapride_bf ,_bf cyclosporine_bf ,_bf fentanyl_bf ,_bf DRUG ,_be quinidine_be ,_be sirolimus_be ,_be tacrolimus_be ,_be ergot_be alkaloids_be (ergotamine_be ,_be dihydroergotamine)_be administered_be caution_be patients_be receiving_be OTHER_DRUG ._af"
1212,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",quinidine,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf terfenadine_bf ,_bf cisapride_bf ,_bf cyclosporine_bf ,_bf fentanyl_bf ,_bf pimozide_bf ,_bf DRUG ,_be sirolimus_be ,_be tacrolimus_be ,_be ergot_be alkaloids_be (ergotamine_be ,_be dihydroergotamine)_be administered_be caution_be patients_be receiving_be OTHER_DRUG ._af"
1213,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",sirolimus,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf terfenadine_bf ,_bf cisapride_bf ,_bf cyclosporine_bf ,_bf fentanyl_bf ,_bf pimozide_bf ,_bf quinidine_bf ,_bf DRUG ,_be tacrolimus_be ,_be ergot_be alkaloids_be (ergotamine_be ,_be dihydroergotamine)_be administered_be caution_be patients_be receiving_be OTHER_DRUG ._af"
1214,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",tacrolimus,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf terfenadine_bf ,_bf cisapride_bf ,_bf cyclosporine_bf ,_bf fentanyl_bf ,_bf pimozide_bf ,_bf quinidine_bf ,_bf sirolimus_bf ,_bf DRUG ,_be ergot_be alkaloids_be (ergotamine_be ,_be dihydroergotamine)_be administered_be caution_be patients_be receiving_be OTHER_DRUG ._af"
1215,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",ergot alkaloids,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf terfenadine_bf ,_bf cisapride_bf ,_bf cyclosporine_bf ,_bf fentanyl_bf ,_bf pimozide_bf ,_bf quinidine_bf ,_bf sirolimus_bf ,_bf tacrolimus_bf ,_bf ergot_bf alkaloids_bf (ergotamine_bf ,_bf dihydroergotamine)_bf administered_bf caution_bf patients_bf receiving_bf OTHER_DRUG ._be"
1216,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",ergotamine,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf terfenadine_bf ,_bf cisapride_bf ,_bf cyclosporine_bf ,_bf fentanyl_bf ,_bf pimozide_bf ,_bf quinidine_bf ,_bf sirolimus_bf ,_bf tacrolimus_bf ,_bf ergot_bf alkaloids_bf (ergotamine_bf ,_bf dihydroergotamine)_bf administered_bf caution_bf patients_bf receiving_bf OTHER_DRUG ._be"
1217,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",dihydroergotamine,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf terfenadine_bf ,_bf cisapride_bf ,_bf cyclosporine_bf ,_bf fentanyl_bf ,_bf pimozide_bf ,_bf quinidine_bf ,_bf sirolimus_bf ,_bf tacrolimus_bf ,_bf ergot_bf alkaloids_bf (ergotamine_bf ,_bf dihydroergotamine)_bf administered_bf caution_bf patients_bf receiving_bf OTHER_DRUG ._be"
1218,Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.,Cerubidine,doxorubicin,effect,Use_bf DRUG patient_be previously_be received_be OTHER_DRUG increases_af risk_af cardiotoxicity_af ._af
1219,Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.,Cerubidine,doxorubicin,advise,DRUG used_be patients_be previously_be received_be recommended_be maximum_be cumulative_be doses_be OTHER_DRUG DRUG ._af
1220,Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.,Cyclophosphamide,Cerubidine,effect,DRUG used_be concurrently_be OTHER_DRUG may_af also_af result_af increased_af cardiotoxicity_af ._af
1221,"Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.",Exjade,aluminum,advise,"Although_bf deferasirox_bf lower_bf affinity_bf OTHER_DRUG iron_be ,_be DRUG taken_af aluminum-containing_af antacid_af preparations_af ._af"
1222,Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.,HUMORSOL,succinylcholine,int,Possible_bf drug_bf interactions_bf DRUG OTHER_DRUG anticholinesterase_af agents_af ._af
1223,Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.,HUMORSOL,anticholinesterase agents,int,Possible_bf drug_bf interactions_bf DRUG succinylcholine_be anticholinesterase_be agents_be ._be
1224,"Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.",tetracyclines,anticoagulant,advise,"Because_bf DRUG shown_be depress_be plasma_be prothrombin_be activity_be ,_be patients_be OTHER_DRUG therapy_af may_af require_af downward_af adjustment_af OTHER_DRUG dosage_af ._af"
1225,"Since bacteriostatic drugs, such as the tetracycline class of antibiotics, may interfere with the bactericidal action of penicillins, it is not advisable to administer these drugs concomitantly.",tetracycline class,penicillins,effect,"Since_bf bacteriostatic_bf drugs_bf ,_bf tetracycline_bf class_bf antibiotics_bf ,_bf may_bf interfere_bf bactericidal_bf action_bf OTHER_DRUG ,_be advisable_be administer_be drugs_be concomitantly_be ._be"
1226,Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.,tetracyclines,contraceptives,effect,Concurrent_bf use_bf DRUG oral_be OTHER_DRUG may_af render_af oral_af OTHER_DRUG less_af effective_af ._af
1227,Taking a rauwolfia alkaloid while you are taking or within 2 weeks of taking MAO inhibitors may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction.,rauwolfia alkaloid,MAO inhibitors,effect,Taking_bf rauwolfia_bf alkaloid_bf taking_bf within_bf 2_bf weeks_bf taking_bf MAO_bf inhibitors_bf may_bf increase_bf risk_bf central_bf nervous_bf system_bf depression_bf may_bf cause_bf severe_bf high_bf blood_bf pressure_bf reaction_bf ._bf
1228,Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids.,Aminoglutethimide,corticosteroids,effect,Aminoglutethimide:_bf DRUG may_be diminish_be adrenal_be suppression_be OTHER_DRUG ._af
1229,"Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.",corticosteroids,amphotericin B,advise,"Amphotericin_bf B_bf injection_bf potassium-depleting_bf agents:_bf When_bf DRUG administered_be concomitantly_be potassium-depleting_be agents_be (e_be ._be g_be ._be ,_be amphotericin_be B_be ,_be diuretics)_be ,_be patients_be observed_be closely_be development_be hypokalemia_be ._be"
1230,"Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.",corticosteroids,diuretics,advise,"Amphotericin_bf B_bf injection_bf potassium-depleting_bf agents:_bf When_bf DRUG administered_be concomitantly_be potassium-depleting_be agents_be (e_be ._be g_be ._be ,_be amphotericin_be B_be ,_be diuretics)_be ,_be patients_be observed_be closely_be development_be hypokalemia_be ._be"
1231,"In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.",amphotericin B,hydrocortisone,effect,"In_bf addition_bf ,_bf cases_bf reported_bf concomitant_bf use_bf amphotericin_bf B_bf OTHER_DRUG followed_be cardiac_be enlargement_be congestive_be heart_be failure_be ._be"
1232,Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.,Macrolide antibiotics,corticosteroid,mechanism,Antibiotics:_bf Macrolide_bf antibiotics_bf reported_bf cause_bf significant_bf decrease_bf OTHER_DRUG clearance_be ._be
1233,Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis.,anticholinesterase agents,corticosteroids,effect,Anticholinesterases:_bf Concomitant_bf use_bf anticholinesterase_bf agents_bf OTHER_DRUG may_be produce_be severe_be weakness_be patients_be myasthenia_be gravis_be ._be
1234,"If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.",anticholinesterase agents,corticosteroid,advise,"If_bf possible_bf ,_bf anticholinesterase_bf agents_bf withdrawn_bf least_bf 24_bf hours_bf initiating_bf OTHER_DRUG therapy_be ._be"
1235,"Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.",corticosteroids,warfarin,effect,"Anticoagulants_bf ,_bf oral:_bf Co-administration_bf DRUG OTHER_DRUG usually_af results_af inhibition_af response_af OTHER_DRUG ,_af although_af conflicting_af reports_af ._af"
1236,"Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.",corticosteroids,antidiabetic agents,effect,"Antidiabetics:_bf Because_bf DRUG may_be increase_be blood_be glucose_be concentrations_be ,_be dosage_be adjustments_be antidiabetic_be agents_be may_be required_be ._be"
1237,Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.,Cholestyramine,corticosteroids,mechanism,Cholestyramine:_bf DRUG may_be increase_be clearance_be OTHER_DRUG ._af
1238,Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently.,cyclosporine,corticosteroids,effect,Cyclosporine:_bf Increased_bf activity_bf DRUG OTHER_DRUG may_af occur_af two_af used_af concurrently_af ._af
1239,"Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.",Ephedrine,corticosteroids,mechanism,"Ephedrine:_bf DRUG may_be enhance_be metabolic_be clearance_be OTHER_DRUG ,_af resulting_af decreased_af blood_af levels_af lessened_af physiologic_af activity_af ,_af thus_af requiring_af increase_af corticosteroid_af dosage_af ._af"
1240,"Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.",Estrogens,corticosteroids,mechanism,"DRUG ,_be including_be oral_be contraceptives:_be DRUG may_af decrease_af hepatic_af metabolism_af certain_af OTHER_DRUG ,_af thereby_af increasing_af effect_af ._af"
1241,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",barbiturates,corticosteroids,mechanism,"Hepatic_bf Enzyme_bf Inducers_bf ,_bf Inhibitors_bf Substrates:_bf Drugs_bf induce_bf cytochrome_bf P450_bf 3A4_bf (CYP_bf 3A4)_bf enzyme_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be phenytoin_be ,_be carbamazepine_be ,_be rifampin)_be may_be enhance_be metabolism_be OTHER_DRUG require_af dosage_af corticosteroid_af increased_af ._af"
1242,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",phenytoin,corticosteroids,mechanism,"Hepatic_bf Enzyme_bf Inducers_bf ,_bf Inhibitors_bf Substrates:_bf Drugs_bf induce_bf cytochrome_bf P450_bf 3A4_bf (CYP_bf 3A4)_bf enzyme_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf barbiturates_bf ,_bf DRUG ,_be carbamazepine_be ,_be rifampin)_be may_be enhance_be metabolism_be OTHER_DRUG require_af dosage_af corticosteroid_af increased_af ._af"
1243,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",carbamazepine,corticosteroids,mechanism,"Hepatic_bf Enzyme_bf Inducers_bf ,_bf Inhibitors_bf Substrates:_bf Drugs_bf induce_bf cytochrome_bf P450_bf 3A4_bf (CYP_bf 3A4)_bf enzyme_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf barbiturates_bf ,_bf phenytoin_bf ,_bf DRUG ,_be rifampin)_be may_be enhance_be metabolism_be OTHER_DRUG require_af dosage_af corticosteroid_af increased_af ._af"
1244,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",rifampin,corticosteroids,mechanism,"Hepatic_bf Enzyme_bf Inducers_bf ,_bf Inhibitors_bf Substrates:_bf Drugs_bf induce_bf cytochrome_bf P450_bf 3A4_bf (CYP_bf 3A4)_bf enzyme_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf barbiturates_bf ,_bf phenytoin_bf ,_bf carbamazepine_bf ,_bf rifampin)_bf may_bf enhance_bf metabolism_bf OTHER_DRUG require_be dosage_be corticosteroid_be increased_be ._be"
1245,"Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.",ketoconazole,corticosteroids,mechanism,"Drugs_bf inhibit_bf CYP_bf 3A4_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be macrolide_be antibiotics_be erythromycin)_be potential_be result_be increased_be plasma_be concentrations_be OTHER_DRUG ._af"
1246,"Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.",macrolide antibiotics,corticosteroids,mechanism,"Drugs_bf inhibit_bf CYP_bf 3A4_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf macrolide_bf antibiotics_bf erythromycin)_bf potential_bf result_bf increased_bf plasma_bf concentrations_bf OTHER_DRUG ._be"
1247,"Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.",erythromycin,corticosteroids,mechanism,"Drugs_bf inhibit_bf CYP_bf 3A4_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf macrolide_bf antibiotics_bf erythromycin)_bf potential_bf result_bf increased_bf plasma_bf concentrations_bf OTHER_DRUG ._be"
1248,"Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.",Ketoconazole,corticosteroids,mechanism,"Ketoconazole:_bf DRUG reported_be decrease_be metabolism_be certain_be OTHER_DRUG 60%_af ,_af leading_af increased_af risk_af corticosteroid_af side_af effects_af ._af"
1249,"In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.",ketoconazole,corticosteroid,effect,"In_bf addition_bf ,_bf DRUG alone_be inhibit_be adrenal_be OTHER_DRUG synthesis_af may_af cause_af adrenal_af insufficiency_af OTHER_DRUG withdrawal_af ._af"
1250,Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.,aspirin,corticosteroids,effect,Nonsteroidal_bf anti-inflammatory_bf agents_bf (NSAIDS):_bf Concomitant_bf use_bf DRUG (or_be nonsteroidal_be antiinflammatory_be agents)_be OTHER_DRUG increases_af risk_af gastrointestinal_af side_af effects_af ._af
1251,Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.,nonsteroidal antiinflammatory agents,corticosteroids,effect,Nonsteroidal_bf anti-inflammatory_bf agents_bf (NSAIDS):_bf Concomitant_bf use_bf aspirin_bf (or_bf nonsteroidal_bf antiinflammatory_bf agents)_bf OTHER_DRUG increases_be risk_be gastrointestinal_be side_be effects_be ._be
1252,Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.,Aspirin,corticosteroids,advise,DRUG used_be cautiously_be conjunction_be OTHER_DRUG hypoprothrombinemia_af ._af
1253,The clearance of salicylates may be increased with concurrent use of corticosteroids.,salicylates,corticosteroids,mechanism,The_bf clearance_bf DRUG may_be increased_be concurrent_be use_be OTHER_DRUG ._af
1254,"Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.",phenytoin,dexamethasone,mechanism,"Phenytoin:_bf In_bf post-marketing_bf experience_bf ,_bf reports_bf increases_bf decreases_bf DRUG levels_be OTHER_DRUG co-administration_af ,_af leading_af alterations_af seizure_af control_af ._af"
1255,Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.,corticosteroid,live vaccines,effect,Vaccines:_bf Patients_bf DRUG therapy_be may_be exhibit_be diminished_be response_be toxoids_be live_be inactivated_be vaccines_be due_be inhibition_be antibody_be response_be ._be
1256,Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.,corticosteroid,inactivated vaccines,effect,Vaccines:_bf Patients_bf DRUG therapy_be may_be exhibit_be diminished_be response_be toxoids_be live_be inactivated_be vaccines_be due_be inhibition_be antibody_be response_be ._be
1257,Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines.,Corticosteroids,live attenuated vaccines,effect,DRUG may_be also_be potentiate_be replication_be organisms_be contained_be live_be attenuated_be vaccines_be ._be
1258,Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.,vaccines,corticosteroid,advise,Routine_bf administration_bf DRUG toxoids_be deferred_be OTHER_DRUG therapy_af discontinued_af possible_af ._af
1259,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,alcohol,int,"DRUG interact_be OTHER_DRUG CNS_af depressants_af (may_af potentiate_af CNS_af depressant_af effects_af either_af medications_af antihistamines)_af ,_af anticholinergics_af medications_af anticholinergic_af activity_af (anticholinergic_af effects_af may_af potentiated_af medications_af used_af concurrently_af antihistamines)_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af (concurrent_af use_af antihistamines_af may_af prolong_af intensify_af anticholinergic_af CNS_af depressant_af effects_af antihistamines)_af ._af"
1260,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,CNS depressants,int,"DRUG interact_be alcohol_be CNS_be depressants_be (may_be potentiate_be CNS_be depressant_be effects_be either_be medications_be antihistamines)_be ,_be anticholinergics_be medications_be anticholinergic_be activity_be (anticholinergic_be effects_be may_be potentiated_be medications_be used_be concurrently_be antihistamines)_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be (concurrent_be use_be antihistamines_be may_be prolong_be intensify_be anticholinergic_be CNS_be depressant_be effects_be antihistamines)_be ._be"
1261,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,anticholinergics,int,"DRUG interact_be alcohol_be CNS_be depressants_be (may_be potentiate_be CNS_be depressant_be effects_be either_be medications_be antihistamines)_be ,_be OTHER_DRUG medications_af anticholinergic_af activity_af (anticholinergic_af effects_af may_af potentiated_af medications_af used_af concurrently_af antihistamines)_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af (concurrent_af use_af antihistamines_af may_af prolong_af intensify_af anticholinergic_af CNS_af depressant_af effects_af antihistamines)_af ._af"
1262,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,monoamine oxidase (MAO) inhibitors,int,"DRUG interact_be alcohol_be CNS_be depressants_be (may_be potentiate_be CNS_be depressant_be effects_be either_be medications_be antihistamines)_be ,_be anticholinergics_be medications_be anticholinergic_be activity_be (anticholinergic_be effects_be may_be potentiated_be medications_be used_be concurrently_be antihistamines)_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be (concurrent_be use_be antihistamines_be may_be prolong_be intensify_be anticholinergic_be CNS_be depressant_be effects_be antihistamines)_be ._be"
1263,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,serotoninergic agents,effect,"In_bf patients_bf receiving_bf nonselective_bf monoamine_bf oxidase_bf inhibitors_bf (MAOIs)_bf (e_bf ._bf g_bf ._bf ,_bf selegiline_bf hydrochloride)_bf combination_bf serotoninergic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf paroxetine_bf ,_bf sertraline_bf ,_bf venlafaxine)_bf ,_bf reports_bf serious_bf ,_bf sometimes_bf fatal_bf ,_bf reactions_bf ._bf"
1264,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,fluoxetine,effect,"In_bf patients_bf receiving_bf nonselective_bf monoamine_bf oxidase_bf inhibitors_bf (MAOIs)_bf (e_bf ._bf g_bf ._bf ,_bf selegiline_bf hydrochloride)_bf combination_bf serotoninergic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be fluvoxamine_be ,_be paroxetine_be ,_be sertraline_be ,_be venlafaxine)_be ,_be reports_be serious_be ,_be sometimes_be fatal_be ,_be reactions_be ._be"
1265,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,fluvoxamine,effect,"In_bf patients_bf receiving_bf nonselective_bf monoamine_bf oxidase_bf inhibitors_bf (MAOIs)_bf (e_bf ._bf g_bf ._bf ,_bf selegiline_bf hydrochloride)_bf combination_bf serotoninergic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf OTHER_DRUG ,_be paroxetine_be ,_be sertraline_be ,_be venlafaxine)_be ,_be reports_be serious_be ,_be sometimes_be fatal_be ,_be reactions_be ._be"
1266,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,paroxetine,effect,"In_bf patients_bf receiving_bf nonselective_bf monoamine_bf oxidase_bf inhibitors_bf (MAOIs)_bf (e_bf ._bf g_bf ._bf ,_bf selegiline_bf hydrochloride)_bf combination_bf serotoninergic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf OTHER_DRUG ,_be sertraline_be ,_be venlafaxine)_be ,_be reports_be serious_be ,_be sometimes_be fatal_be ,_be reactions_be ._be"
1267,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,sertraline,effect,"In_bf patients_bf receiving_bf nonselective_bf monoamine_bf oxidase_bf inhibitors_bf (MAOIs)_bf (e_bf ._bf g_bf ._bf ,_bf selegiline_bf hydrochloride)_bf combination_bf serotoninergic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf paroxetine_bf ,_bf OTHER_DRUG ,_be venlafaxine)_be ,_be reports_be serious_be ,_be sometimes_be fatal_be ,_be reactions_be ._be"
1268,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,venlafaxine,effect,"In_bf patients_bf receiving_bf nonselective_bf monoamine_bf oxidase_bf inhibitors_bf (MAOIs)_bf (e_bf ._bf g_bf ._bf ,_bf selegiline_bf hydrochloride)_bf combination_bf serotoninergic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf paroxetine_bf ,_bf sertraline_bf ,_bf venlafaxine)_bf ,_bf reports_bf serious_bf ,_bf sometimes_bf fatal_bf ,_bf reactions_bf ._bf"
1269,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,serotoninergic agents,effect,"In_bf patients_bf receiving_bf nonselective_bf monoamine_bf oxidase_bf inhibitors_bf (MAOIs)_bf (e_bf ._bf g_bf ._bf ,_bf selegiline_bf hydrochloride)_bf combination_bf serotoninergic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf paroxetine_bf ,_bf sertraline_bf ,_bf venlafaxine)_bf ,_bf reports_bf serious_bf ,_bf sometimes_bf fatal_bf ,_bf reactions_bf ._bf"
1270,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,fluoxetine,effect,"In_bf patients_bf receiving_bf nonselective_bf monoamine_bf oxidase_bf inhibitors_bf (MAOIs)_bf (e_bf ._bf g_bf ._bf ,_bf selegiline_bf hydrochloride)_bf combination_bf serotoninergic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be fluvoxamine_be ,_be paroxetine_be ,_be sertraline_be ,_be venlafaxine)_be ,_be reports_be serious_be ,_be sometimes_be fatal_be ,_be reactions_be ._be"
1271,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,fluvoxamine,effect,"In_bf patients_bf receiving_bf nonselective_bf monoamine_bf oxidase_bf inhibitors_bf (MAOIs)_bf (e_bf ._bf g_bf ._bf ,_bf selegiline_bf hydrochloride)_bf combination_bf serotoninergic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf OTHER_DRUG ,_be paroxetine_be ,_be sertraline_be ,_be venlafaxine)_be ,_be reports_be serious_be ,_be sometimes_be fatal_be ,_be reactions_be ._be"
1272,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,paroxetine,effect,"In_bf patients_bf receiving_bf nonselective_bf monoamine_bf oxidase_bf inhibitors_bf (MAOIs)_bf (e_bf ._bf g_bf ._bf ,_bf selegiline_bf hydrochloride)_bf combination_bf serotoninergic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf OTHER_DRUG ,_be sertraline_be ,_be venlafaxine)_be ,_be reports_be serious_be ,_be sometimes_be fatal_be ,_be reactions_be ._be"
1273,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,sertraline,effect,"In_bf patients_bf receiving_bf nonselective_bf monoamine_bf oxidase_bf inhibitors_bf (MAOIs)_bf (e_bf ._bf g_bf ._bf ,_bf selegiline_bf hydrochloride)_bf combination_bf serotoninergic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf paroxetine_bf ,_bf OTHER_DRUG ,_be venlafaxine)_be ,_be reports_be serious_be ,_be sometimes_be fatal_be ,_be reactions_be ._be"
1274,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,venlafaxine,effect,"In_bf patients_bf receiving_bf nonselective_bf monoamine_bf oxidase_bf inhibitors_bf (MAOIs)_bf (e_bf ._bf g_bf ._bf ,_bf selegiline_bf hydrochloride)_bf combination_bf serotoninergic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf paroxetine_bf ,_bf sertraline_bf ,_bf venlafaxine)_bf ,_bf reports_bf serious_bf ,_bf sometimes_bf fatal_bf ,_bf reactions_bf ._bf"
1275,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,serotoninergic agents,effect,"In_bf patients_bf receiving_bf nonselective_bf monoamine_bf oxidase_bf inhibitors_bf (MAOIs)_bf (e_bf ._bf g_bf ._bf ,_bf selegiline_bf hydrochloride)_bf combination_bf serotoninergic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf paroxetine_bf ,_bf sertraline_bf ,_bf venlafaxine)_bf ,_bf reports_bf serious_bf ,_bf sometimes_bf fatal_bf ,_bf reactions_bf ._bf"
1276,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,fluoxetine,effect,"In_bf patients_bf receiving_bf nonselective_bf monoamine_bf oxidase_bf inhibitors_bf (MAOIs)_bf (e_bf ._bf g_bf ._bf ,_bf selegiline_bf hydrochloride)_bf combination_bf serotoninergic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be fluvoxamine_be ,_be paroxetine_be ,_be sertraline_be ,_be venlafaxine)_be ,_be reports_be serious_be ,_be sometimes_be fatal_be ,_be reactions_be ._be"
1277,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,fluvoxamine,effect,"In_bf patients_bf receiving_bf nonselective_bf monoamine_bf oxidase_bf inhibitors_bf (MAOIs)_bf (e_bf ._bf g_bf ._bf ,_bf selegiline_bf hydrochloride)_bf combination_bf serotoninergic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf OTHER_DRUG ,_be paroxetine_be ,_be sertraline_be ,_be venlafaxine)_be ,_be reports_be serious_be ,_be sometimes_be fatal_be ,_be reactions_be ._be"
1278,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,paroxetine,effect,"In_bf patients_bf receiving_bf nonselective_bf monoamine_bf oxidase_bf inhibitors_bf (MAOIs)_bf (e_bf ._bf g_bf ._bf ,_bf selegiline_bf hydrochloride)_bf combination_bf serotoninergic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf OTHER_DRUG ,_be sertraline_be ,_be venlafaxine)_be ,_be reports_be serious_be ,_be sometimes_be fatal_be ,_be reactions_be ._be"
1279,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,sertraline,effect,"In_bf patients_bf receiving_bf nonselective_bf monoamine_bf oxidase_bf inhibitors_bf (MAOIs)_bf (e_bf ._bf g_bf ._bf ,_bf selegiline_bf hydrochloride)_bf combination_bf serotoninergic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf paroxetine_bf ,_bf OTHER_DRUG ,_be venlafaxine)_be ,_be reports_be serious_be ,_be sometimes_be fatal_be ,_be reactions_be ._be"
1280,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,venlafaxine,effect,"In_bf patients_bf receiving_bf nonselective_bf monoamine_bf oxidase_bf inhibitors_bf (MAOIs)_bf (e_bf ._bf g_bf ._bf ,_bf selegiline_bf hydrochloride)_bf combination_bf serotoninergic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf paroxetine_bf ,_bf sertraline_bf ,_bf venlafaxine)_bf ,_bf reports_bf serious_bf ,_bf sometimes_bf fatal_bf ,_bf reactions_bf ._bf"
1281,"Because dexfenfluramine is a serotonin releaser and reuptake inhibitor, dexfenfluramine should not be used concomitantly with a MAO inhibitor.",dexfenfluramine,MAO inhibitor,advise,"Because_bf DRUG serotonin_be releaser_be reuptake_be inhibitor_be ,_be DRUG used_af concomitantly_af MAO_af inhibitor_af ._af"
1282,At least 14 days should elapse between discontinuation of a MAO inhibitor and initiation of treatment with dexfenfluramine.,MAO inhibitor,dexfenfluramine,advise,At_bf least_bf 14_bf days_bf elapse_bf discontinuation_bf MAO_bf inhibitor_bf initiation_bf treatment_bf OTHER_DRUG ._be
1283,At least 3 weeks should elapse between discontinuation of dexfenfluramine and initiation of treatment with a MAO inhibitor.,dexfenfluramine,MAO inhibitor,advise,At_bf least_bf 3_bf weeks_bf elapse_bf discontinuation_bf DRUG initiation_be treatment_be MAO_be inhibitor_be ._be
1284,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",selective serotonin reuptake inhibitors,Imitrex,effect,"A_bf rare_bf ,_bf serious_bf ,_bf constellation_bf symptoms_bf ,_bf termed_bf serotonin_bf syndrome_bf ,_bf reported_bf concomitant_bf use_bf selective_bf serotonin_bf reuptake_bf inhibitors_bf (SSRIs)_bf agents_bf migraine_bf therapy_bf ,_bf OTHER_DRUG (sumatriptan_be succinate)_be dihydroergotamine_be ._be"
1285,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",selective serotonin reuptake inhibitors,sumatriptan succinate,effect,"A_bf rare_bf ,_bf serious_bf ,_bf constellation_bf symptoms_bf ,_bf termed_bf serotonin_bf syndrome_bf ,_bf reported_bf concomitant_bf use_bf selective_bf serotonin_bf reuptake_bf inhibitors_bf (SSRIs)_bf agents_bf migraine_bf therapy_bf ,_bf Imitrex_bf (sumatriptan_bf succinate)_bf dihydroergotamine_bf ._bf"
1286,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",selective serotonin reuptake inhibitors,dihydroergotamine,effect,"A_bf rare_bf ,_bf serious_bf ,_bf constellation_bf symptoms_bf ,_bf termed_bf serotonin_bf syndrome_bf ,_bf reported_bf concomitant_bf use_bf selective_bf serotonin_bf reuptake_bf inhibitors_bf (SSRIs)_bf agents_bf migraine_bf therapy_bf ,_bf Imitrex_bf (sumatriptan_bf succinate)_bf OTHER_DRUG ._be"
1287,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",SSRIs,Imitrex,effect,"A_bf rare_bf ,_bf serious_bf ,_bf constellation_bf symptoms_bf ,_bf termed_bf serotonin_bf syndrome_bf ,_bf reported_bf concomitant_bf use_bf selective_bf serotonin_bf reuptake_bf inhibitors_bf (SSRIs)_bf agents_bf migraine_bf therapy_bf ,_bf OTHER_DRUG (sumatriptan_be succinate)_be dihydroergotamine_be ._be"
1288,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",SSRIs,sumatriptan succinate,effect,"A_bf rare_bf ,_bf serious_bf ,_bf constellation_bf symptoms_bf ,_bf termed_bf serotonin_bf syndrome_bf ,_bf reported_bf concomitant_bf use_bf selective_bf serotonin_bf reuptake_bf inhibitors_bf (SSRIs)_bf agents_bf migraine_bf therapy_bf ,_bf Imitrex_bf (sumatriptan_bf succinate)_bf dihydroergotamine_bf ._bf"
1289,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",SSRIs,dihydroergotamine,effect,"A_bf rare_bf ,_bf serious_bf ,_bf constellation_bf symptoms_bf ,_bf termed_bf serotonin_bf syndrome_bf ,_bf reported_bf concomitant_bf use_bf selective_bf serotonin_bf reuptake_bf inhibitors_bf (SSRIs)_bf agents_bf migraine_bf therapy_bf ,_bf Imitrex_bf (sumatriptan_bf succinate)_bf OTHER_DRUG ._be"
1290,Dexfenfluramine should not be administered with other serotoninergic agents.,Dexfenfluramine,serotoninergic agents,advise,DRUG administered_be serotoninergic_be agents_be ._be
1291,"Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",PRECEDEX,anesthetics,effect,"Anesthetics/Sedatives/Hypnotics/Opioids:_bf Co-administration_bf DRUG OTHER_DRUG ,_af sedatives_af ,_af hypnotics_af ,_af opioids_af likely_af lead_af enhancement_af effects_af ._af"
1292,"Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",PRECEDEX,sedatives,effect,"Anesthetics/Sedatives/Hypnotics/Opioids:_bf Co-administration_bf DRUG anesthetics_be ,_be OTHER_DRUG ,_af hypnotics_af ,_af opioids_af likely_af lead_af enhancement_af effects_af ._af"
1293,"Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",PRECEDEX,hypnotics,effect,"Anesthetics/Sedatives/Hypnotics/Opioids:_bf Co-administration_bf DRUG anesthetics_be ,_be sedatives_be ,_be OTHER_DRUG ,_af opioids_af likely_af lead_af enhancement_af effects_af ._af"
1294,"Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",PRECEDEX,opioids,effect,"Anesthetics/Sedatives/Hypnotics/Opioids:_bf Co-administration_bf DRUG anesthetics_be ,_be sedatives_be ,_be hypnotics_be ,_be OTHER_DRUG likely_af lead_af enhancement_af effects_af ._af"
1295,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",PRECEDEX,anesthetic,advise,"However_bf ,_bf due_bf possible_bf pharmacodynamic_bf interactions_bf ,_bf co-administered_bf DRUG ,_be reduction_be dosage_be DRUG concomitant_af OTHER_DRUG ,_af sedative_af ,_af hypnotic_af opioid_af may_af required_af ._af"
1296,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",PRECEDEX,sedative,advise,"However_bf ,_bf due_bf possible_bf pharmacodynamic_bf interactions_bf ,_bf co-administered_bf DRUG ,_be reduction_be dosage_be DRUG concomitant_af anesthetic_af ,_af OTHER_DRUG ,_af hypnotic_af opioid_af may_af required_af ._af"
1297,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",PRECEDEX,hypnotic,advise,"However_bf ,_bf due_bf possible_bf pharmacodynamic_bf interactions_bf ,_bf co-administered_bf DRUG ,_be reduction_be dosage_be DRUG concomitant_af anesthetic_af ,_af sedative_af ,_af OTHER_DRUG opioid_af may_af required_af ._af"
1298,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",PRECEDEX,opioid,advise,"However_bf ,_bf due_bf possible_bf pharmacodynamic_bf interactions_bf ,_bf co-administered_bf DRUG ,_be reduction_be dosage_be DRUG concomitant_af anesthetic_af ,_af sedative_af ,_af hypnotic_af OTHER_DRUG may_af required_af ._af"
1299,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",Gastrointestinal acidifying agents,amphetamines,mechanism,"Acidifying_bf agents:_bf Gastrointestinal_bf acidifying_bf agents_bf (guanethidine_bf ,_bf reserpine_bf ,_bf glutamic_bf acid_bf HCl_bf ,_bf ascorbic_bf acid_bf ,_bf fruit_bf juices_bf ,_bf etc_bf ._bf )_bf lower_bf absorption_bf OTHER_DRUG ._be"
1300,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",guanethidine,amphetamines,mechanism,"Acidifying_bf agents:_bf Gastrointestinal_bf acidifying_bf agents_bf (guanethidine_bf ,_bf reserpine_bf ,_bf glutamic_bf acid_bf HCl_bf ,_bf ascorbic_bf acid_bf ,_bf fruit_bf juices_bf ,_bf etc_bf ._bf )_bf lower_bf absorption_bf OTHER_DRUG ._be"
1301,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",reserpine,amphetamines,mechanism,"Acidifying_bf agents:_bf Gastrointestinal_bf acidifying_bf agents_bf (guanethidine_bf ,_bf DRUG ,_be glutamic_be acid_be HCl_be ,_be ascorbic_be acid_be ,_be fruit_be juices_be ,_be etc_be ._be )_be lower_be absorption_be OTHER_DRUG ._af"
1302,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",glutamic acid HCl,amphetamines,mechanism,"Acidifying_bf agents:_bf Gastrointestinal_bf acidifying_bf agents_bf (guanethidine_bf ,_bf reserpine_bf ,_bf glutamic_bf acid_bf HCl_bf ,_bf ascorbic_bf acid_bf ,_bf fruit_bf juices_bf ,_bf etc_bf ._bf )_bf lower_bf absorption_bf OTHER_DRUG ._be"
1303,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",ascorbic acid,amphetamines,mechanism,"Acidifying_bf agents:_bf Gastrointestinal_bf acidifying_bf agents_bf (guanethidine_bf ,_bf reserpine_bf ,_bf glutamic_bf acid_bf HCl_bf ,_bf ascorbic_bf acid_bf ,_bf fruit_bf juices_bf ,_bf etc_bf ._bf )_bf lower_bf absorption_bf OTHER_DRUG ._be"
1304,"Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",Urinary acidifying agents,amphetamine,mechanism,"Urinary_bf acidifying_bf agents_bf (ammonium_bf chloride_bf ,_bf sodium_bf acid_bf phosphate_bf ,_bf etc_bf ._bf )_bf increase_bf concentration_bf ionized_bf species_bf OTHER_DRUG molecule_be ,_be thereby_be increasing_be urinary_be excretion_be ._be"
1305,"Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",ammonium chloride,amphetamine,mechanism,"Urinary_bf acidifying_bf agents_bf (ammonium_bf chloride_bf ,_bf sodium_bf acid_bf phosphate_bf ,_bf etc_bf ._bf )_bf increase_bf concentration_bf ionized_bf species_bf OTHER_DRUG molecule_be ,_be thereby_be increasing_be urinary_be excretion_be ._be"
1306,"Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",sodium acid phosphate,amphetamine,mechanism,"Urinary_bf acidifying_bf agents_bf (ammonium_bf chloride_bf ,_bf sodium_bf acid_bf phosphate_bf ,_bf etc_bf ._bf )_bf increase_bf concentration_bf ionized_bf species_bf OTHER_DRUG molecule_be ,_be thereby_be increasing_be urinary_be excretion_be ._be"
1307,Adrenergic blockers: Adrenergic blockers are inhibited by amphetamines.,Adrenergic blockers,amphetamines,effect,Adrenergic_bf blockers:_bf Adrenergic_bf blockers_bf inhibited_bf OTHER_DRUG ._be
1308,"Alkalinizing agents: Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines.",sodium bicarbonate,amphetamines,mechanism,"Alkalinizing_bf agents:_bf Gastrointestinal_bf alkalinizing_bf agents_bf (sodium_bf bicarbonate_bf ,_bf etc_bf ._bf )_bf increase_bf absorption_bf OTHER_DRUG ._be"
1309,"Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.",acetazolamide,amphetamine,mechanism,"Urinary_bf alkalinizing_bf agents_bf (acetazolamide_bf ,_bf thiazides)_bf increase_bf concentration_bf non-ionized_bf species_bf OTHER_DRUG molecule_be ,_be thereby_be decreasing_be urinary_be excretion_be ._be"
1310,"Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.",thiazides,amphetamine,mechanism,"Urinary_bf alkalinizing_bf agents_bf (acetazolamide_bf ,_bf thiazides)_bf increase_bf concentration_bf non-ionized_bf species_bf OTHER_DRUG molecule_be ,_be thereby_be decreasing_be urinary_be excretion_be ._be"
1311,"Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;",Amphetamines,tricyclic,effect,"Antidepressants_bf ,_bf tricyclic:_bf DRUG may_be enhance_be activity_be OTHER_DRUG sympathomimetic_af agents;_af"
1312,"Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;",Amphetamines,sympathomimetic agents,effect,"Antidepressants_bf ,_bf tricyclic:_bf DRUG may_be enhance_be activity_be tricyclic_be sympathomimetic_be agents;_be"
1313,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,desipramine,mechanism,DRUG OTHER_DRUG protriptyline_af possibly_af tricyclics_af cause_af striking_af sustained_af increases_af concentration_af DRUG brain;_af
1314,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,protriptyline,mechanism,DRUG desipramine_be OTHER_DRUG possibly_af tricyclics_af cause_af striking_af sustained_af increases_af concentration_af DRUG brain;_af
1315,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,tricyclics,mechanism,DRUG desipramine_be protriptyline_be possibly_be OTHER_DRUG cause_af striking_af sustained_af increases_af concentration_af DRUG brain;_af
1316,"MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.",MAOI antidepressants,amphetamine,mechanism,"MAO_bf inhibitors:_bf MAOI_bf antidepressants_bf ,_bf well_bf metabolite_bf furazolidone_bf ,_bf slow_bf OTHER_DRUG metabolism_be ._be"
1317,"MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.",furazolidone,amphetamine,mechanism,"MAO_bf inhibitors:_bf MAOI_bf antidepressants_bf ,_bf well_bf metabolite_bf DRUG ,_be slow_be OTHER_DRUG metabolism_af ._af"
1318,Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.,Amphetamines,antihistamines,effect,Antihistamines:_bf DRUG may_be counteract_be sedative_be effect_be OTHER_DRUG ._af
1319,Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.,Amphetamines,antihypertensives,effect,Antihypertensives:_bf DRUG may_be antagonize_be hypotensive_be effects_be OTHER_DRUG ._af
1320,"Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.",Chlorpromazine,amphetamines,effect,"Chlorpromazine:_bf DRUG blocks_be dopamine_be norepinephrine_be reuptake_be ,_be thus_be inhibiting_be central_be stimulant_be effects_be OTHER_DRUG ,_af used_af treat_af amphetamine_af poisoning_af ._af"
1321,Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.,Amphetamines,ethosuximide,mechanism,Ethosuximide:_bf DRUG may_be delay_be intestinal_be absorption_be OTHER_DRUG ._af
1322,"Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.",Haloperidol,amphetamines,effect,"Haloperidol:_bf DRUG blocks_be dopamine_be norepinephrine_be reuptake_be ,_be thus_be inhibiting_be central_be stimulant_be effects_be OTHER_DRUG ._af"
1323,Lithium carbonate: The stimulatory effects of amphetamines may be inhibited by lithium carbonate.,amphetamines,lithium carbonate,effect,Lithium_bf carbonate:_bf The_bf stimulatory_bf effects_bf DRUG may_be inhibited_be lithium_be carbonate_be ._be
1324,Meperidine: Amphetamines potentiate the analgesic effect of meperidine.,Amphetamines,meperidine,effect,Meperidine:_bf DRUG potentiate_be analgesic_be effect_be OTHER_DRUG ._af
1325,"Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.",amphetamines,acidifying agents,mechanism,"Methenamine_bf therapy:_bf Urinary_bf excretion_bf DRUG increased_be ,_be efficacy_be reduced_be ,_be acidifying_be agents_be used_be methenamine_be therapy_be ._be"
1326,Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.,Amphetamines,norepinephrine,effect,Norepinephrine:_bf DRUG enhance_be adrenergic_be effect_be OTHER_DRUG ._af
1327,Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;,Amphetamines,phenobarbital,mechanism,Phenobarbital:_bf DRUG may_be delay_be intestinal_be absorption_be phenobarbital;_be
1328,Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;,Amphetamines,phenytoin,mechanism,Phenytoin:_bf DRUG may_be delay_be intestinal_be absorption_be phenytoin;_be
1329,"Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.",propoxyphene,amphetamine,effect,"Propoxyphene:_bf In_bf cases_bf DRUG overdosage_be ,_be OTHER_DRUG CNS_af stimulation_af potentiated_af fatal_af convulsions_af occur_af ._af"
1330,Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.,Amphetamines,veratrum alkaloids,effect,Veratrum_bf alkaloids:_bf DRUG inhibit_be hypotensive_be effect_be veratrum_be alkaloids_be ._be
1331,Drug/Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels.,Amphetamines,corticosteroid,,Drug/Laboratory_bf Test_bf Interactions:_bf DRUG cause_be significant_be elevation_be plasma_be OTHER_DRUG levels_af ._af
1332,"Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.",diclofenac,aspirin,advise,"Aspirin:_bf Concomitant_bf administration_bf DRUG OTHER_DRUG recommended_af DRUG displaced_af binding_af sites_af concomitant_af administration_af OTHER_DRUG ,_af resulting_af lower_af plasma_af concentrations_af ,_af peak_af plasma_af levels_af ,_af AUC_af values_af ._af"
1333,"Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.",diclofenac,aspirin,mechanism,"Aspirin:_bf Concomitant_bf administration_bf DRUG OTHER_DRUG recommended_af DRUG displaced_af binding_af sites_af concomitant_af administration_af OTHER_DRUG ,_af resulting_af lower_af plasma_af concentrations_af ,_af peak_af plasma_af levels_af ,_af AUC_af values_af ._af"
1334,"Anticoagulants: While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.",diclofenac,NSAIDs,advise,"Anticoagulants:_bf While_bf studies_bf shown_bf DRUG interact_be anticoagulants_be warfarin_be type_be ,_be caution_be exercised_be ,_be nonetheless_be ,_be since_be interactions_be seen_be OTHER_DRUG ._af"
1335,"Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.",NSAIDs,warfarin,advise,"Because_bf prostaglandins_bf play_bf important_bf role_bf hemostasis_bf ,_bf DRUG affect_be platelet_be function_be well_be ,_be concurrent_be therapy_be DRUG ,_af including_af diclofenac_af ,_af OTHER_DRUG requires_af close_af monitoring_af patients_af certain_af change_af anticoagulant_af dosage_af required_af ._af"
1336,"Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.",diclofenac,warfarin,advise,"Because_bf prostaglandins_bf play_bf important_bf role_bf hemostasis_bf ,_bf NSAIDs_bf affect_bf platelet_bf function_bf well_bf ,_bf concurrent_bf therapy_bf NSAIDs_bf ,_bf including_bf DRUG ,_be OTHER_DRUG requires_af close_af monitoring_af patients_af certain_af change_af anticoagulant_af dosage_af required_af ._af"
1337,Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.,diclofenac,digoxin,mechanism,Ingestion_bf DRUG may_be increase_be serum_be concentrations_be OTHER_DRUG methotrexate_af increase_af cyclosporine_af nephrotoxicity_af ._af
1338,Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.,diclofenac,methotrexate,mechanism,Ingestion_bf DRUG may_be increase_be serum_be concentrations_be digoxin_be OTHER_DRUG increase_af cyclosporine_af nephrotoxicity_af ._af
1339,Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.,diclofenac,cyclosporine,effect,Ingestion_bf DRUG may_be increase_be serum_be concentrations_be digoxin_be methotrexate_be increase_be OTHER_DRUG nephrotoxicity_af ._af
1340,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",diclofenac,digoxin,effect,"Patients_bf begin_bf taking_bf DRUG increase_be DRUG dose_af NSAID_af taking_af OTHER_DRUG ,_af methotrexate_af ,_af cyclosporine_af may_af develop_af toxicity_af characteristics_af drugs_af ._af"
1341,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",diclofenac,methotrexate,effect,"Patients_bf begin_bf taking_bf DRUG increase_be DRUG dose_af NSAID_af taking_af digoxin_af ,_af OTHER_DRUG ,_af cyclosporine_af may_af develop_af toxicity_af characteristics_af drugs_af ._af"
1342,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",diclofenac,cyclosporine,effect,"Patients_bf begin_bf taking_bf DRUG increase_be DRUG dose_af NSAID_af taking_af digoxin_af ,_af methotrexate_af ,_af OTHER_DRUG may_af develop_af toxicity_af characteristics_af drugs_af ._af"
1343,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",NSAID,digoxin,effect,"Patients_bf begin_bf taking_bf diclofenac_bf increase_bf diclofenac_bf dose_bf DRUG taking_be OTHER_DRUG ,_af methotrexate_af ,_af cyclosporine_af may_af develop_af toxicity_af characteristics_af drugs_af ._af"
1344,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",NSAID,methotrexate,effect,"Patients_bf begin_bf taking_bf diclofenac_bf increase_bf diclofenac_bf dose_bf DRUG taking_be digoxin_be ,_be OTHER_DRUG ,_af cyclosporine_af may_af develop_af toxicity_af characteristics_af drugs_af ._af"
1345,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",NSAID,cyclosporine,effect,"Patients_bf begin_bf taking_bf diclofenac_bf increase_bf diclofenac_bf dose_bf DRUG taking_be digoxin_be ,_be methotrexate_be ,_be OTHER_DRUG may_af develop_af toxicity_af characteristics_af drugs_af ._af"
1346,Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.,Diclofenac,lithium,mechanism,Lithium:_bf DRUG decreases_be OTHER_DRUG renal_af clearance_af increases_af OTHER_DRUG plasma_af levels_af ._af
1347,Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.,Diclofenac,lithium,mechanism,Lithium:_bf DRUG decreases_be OTHER_DRUG renal_af clearance_af increases_af OTHER_DRUG plasma_af levels_af ._af
1348,"In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.",diclofenac,lithium,effect,"In_bf patients_bf taking_bf DRUG OTHER_DRUG concomitantly_af ,_af OTHER_DRUG toxicity_af may_af develop_af ._af"
1349,"There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.",insulin,diclofenac,effect,"There_bf rare_bf reports_bf ,_bf however_bf ,_bf marketing_bf experiences_bf ,_bf changes_bf effects_bf DRUG oral_be hypoglycemic_be agents_be presence_be OTHER_DRUG necessitated_af changes_af doses_af agents_af ._af"
1350,"There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.",hypoglycemic agents,diclofenac,effect,"There_bf rare_bf reports_bf ,_bf however_bf ,_bf marketing_bf experiences_bf ,_bf changes_bf effects_bf insulin_bf oral_bf hypoglycemic_bf agents_bf presence_bf OTHER_DRUG necessitated_be changes_be doses_be agents_be ._be"
1351,"A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.",diclofenac,insulin,effect,"A_bf direct_bf causal_bf relationship_bf established_bf ,_bf physicians_bf consider_bf possibility_bf DRUG may_be alter_be diabetic_be patient_be response_be OTHER_DRUG oral_af hypoglycemic_af agents_af ._af"
1352,"A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.",diclofenac,hypoglycemic agents,effect,"A_bf direct_bf causal_bf relationship_bf established_bf ,_bf physicians_bf consider_bf possibility_bf DRUG may_be alter_be diabetic_be patient_be response_be insulin_be oral_be hypoglycemic_be agents_be ._be"
1353,Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.,Diclofenac,diuretics,effect,Diuretics:_bf DRUG NSAIDs_be inhibit_be activity_be OTHER_DRUG ._af
1354,Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.,NSAIDs,diuretics,effect,Diuretics:_bf Diclofenac_bf DRUG inhibit_be activity_be OTHER_DRUG ._af
1355,Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.,phenobarbital,diclofenac,effect,DRUG toxicity_be reported_be occurred_be patient_be chronic_be DRUG treatment_af following_af initiation_af OTHER_DRUG therapy_af ._af
1356,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",diclofenac,salicylic acid,mechanism,"Protein_bf Binding_bf In_bf vitro_bf ,_bf DRUG interferes_be minimally_be protein_be binding_be salicylic_be acid_be (20%_be decrease_be binding)_be ,_be tolbutamide_be ,_be prednisolone_be (10%_be decrease_be binding)_be ,_be warfarin_be ._be"
1357,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",diclofenac,tolbutamide,mechanism,"Protein_bf Binding_bf In_bf vitro_bf ,_bf DRUG interferes_be minimally_be protein_be binding_be salicylic_be acid_be (20%_be decrease_be binding)_be ,_be OTHER_DRUG ,_af prednisolone_af (10%_af decrease_af binding)_af ,_af warfarin_af ._af"
1358,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",diclofenac,prednisolone,mechanism,"Protein_bf Binding_bf In_bf vitro_bf ,_bf DRUG interferes_be minimally_be protein_be binding_be salicylic_be acid_be (20%_be decrease_be binding)_be ,_be tolbutamide_be ,_be OTHER_DRUG (10%_af decrease_af binding)_af ,_af warfarin_af ._af"
1359,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",diclofenac,warfarin,mechanism,"Protein_bf Binding_bf In_bf vitro_bf ,_bf DRUG interferes_be minimally_be protein_be binding_be salicylic_be acid_be (20%_be decrease_be binding)_be ,_be tolbutamide_be ,_be prednisolone_be (10%_be decrease_be binding)_be ,_be OTHER_DRUG ._af"
1360,"Tetracycline, a bacteriostatic antibiotic, may antagonize the bactercidal effect of penicillin and concurrent use of these drugs should be avoided.",Tetracycline,penicillin,effect,"DRUG ,_be bacteriostatic_be antibiotic_be ,_be may_be antagonize_be bactercidal_be effect_be OTHER_DRUG concurrent_af use_af drugs_af avoided_af ._af"
1361,"Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;",Anticholinergic agents,digoxin,mechanism,"Anticholinergic_bf agents_bf may_bf affect_bf gastrointestinal_bf absorption_bf various_bf drugs_bf ,_bf slowly_bf dissolving_bf dosage_bf forms_bf digoxin;_bf"
1362,"Anticholinergic drugs may antagonize the effects of the drugs that alter gastrointestinal motility, such as metoclopramide.",Anticholinergic drugs,metoclopramide,mechanism,"Anticholinergic_bf drugs_bf may_bf antagonize_bf effects_bf drugs_bf alter_bf gastrointestinal_bf motility_bf ,_bf OTHER_DRUG ._be"
1363,"Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.",antacids,anticholinergic agents,mechanism,"Because_bf DRUG may_be interfere_be absorption_be anticholinergic_be agents_be ,_be simultaneous_be use_be drugs_be avoided_be ._be"
1364,Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).,allopurinol,VIDEX,mechanism,Allopurinol:_bf The_bf AUC_bf didanosine_bf increased_bf 4-fold_bf DRUG 300_be mg/day_be coadministered_be single_be 200-mg_be dose_be OTHER_DRUG two_af patients_af renal_af impairment_af (CLcr=15_af 18_af mL/min)_af ._af
1365,Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.,antacids,VIDEX,effect,Antacids:_bf Concomitant_bf administration_bf DRUG containing_be magnesium_be aluminum_be OTHER_DRUG Chewable/Dispersible_af Buffered_af Tablets_af Pediatric_af Powder_af Oral_af Solution_af may_af potentiate_af adverse_af events_af associated_af antacid_af components_af ._af
1366,Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.,magnesium,VIDEX,effect,Antacids:_bf Concomitant_bf administration_bf antacids_bf containing_bf DRUG aluminum_be OTHER_DRUG Chewable/Dispersible_af Buffered_af Tablets_af Pediatric_af Powder_af Oral_af Solution_af may_af potentiate_af adverse_af events_af associated_af antacid_af components_af ._af
1367,Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.,aluminum,VIDEX,effect,Antacids:_bf Concomitant_bf administration_bf antacids_bf containing_bf magnesium_bf DRUG OTHER_DRUG Chewable/Dispersible_af Buffered_af Tablets_af Pediatric_af Powder_af Oral_af Solution_af may_af potentiate_af adverse_af events_af associated_af antacid_af components_af ._af
1368,Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.,ketoconazole,VIDEX,advise,Drugs_bf Whose_bf Absorption_bf Can_bf Be_bf Affected_bf Level_bf Acidity_bf Stomach:_bf Drugs_bf DRUG itraconazole_be administered_be least_be 2_be hours_be prior_be dosing_be OTHER_DRUG ._af
1369,Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.,itraconazole,VIDEX,advise,Drugs_bf Whose_bf Absorption_bf Can_bf Be_bf Affected_bf Level_bf Acidity_bf Stomach:_bf Drugs_bf ketoconazole_bf DRUG administered_be least_be 2_be hours_be prior_be dosing_be OTHER_DRUG ._af
1370,Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).,VIDEX,ganciclovir,mechanism,Ganciclovir:_bf Administration_bf DRUG 2_be hours_be prior_be concurrent_be oral_be OTHER_DRUG associated_af 111_af (114)%_af increase_af steady-state_af AUC_af didanosine_af (n_af =_af 12)_af ._af
1371,"A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).",VIDEX,ganciclovir,mechanism,"A_bf 21_bf (17)%_bf decrease_bf steady-state_bf AUC_bf OTHER_DRUG observed_be DRUG administered_af 2_af hours_af prior_af OTHER_DRUG ,_af two_af drugs_af administered_af simultaneously_af (n_af =_af 12)_af ._af"
1372,"Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",VIDEX,ciprofloxacin,advise,"Quinolone_bf Antibiotics:_bf DRUG administered_be least_be 2_be hours_be 6_be hours_be dosing_be OTHER_DRUG plasma_af concentrations_af OTHER_DRUG decreased_af administered_af antacids_af containing_af magnesium_af ,_af calcium_af ,_af aluminum_af ._af"
1373,"Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",ciprofloxacin,magnesium,mechanism,"Quinolone_bf Antibiotics:_bf VIDEX_bf administered_bf least_bf 2_bf hours_bf 6_bf hours_bf dosing_bf DRUG plasma_be concentrations_be DRUG decreased_af administered_af antacids_af containing_af OTHER_DRUG ,_af calcium_af ,_af aluminum_af ._af"
1374,"Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",ciprofloxacin,calcium,mechanism,"Quinolone_bf Antibiotics:_bf VIDEX_bf administered_bf least_bf 2_bf hours_bf 6_bf hours_bf dosing_bf DRUG plasma_be concentrations_be DRUG decreased_af administered_af antacids_af containing_af magnesium_af ,_af OTHER_DRUG ,_af aluminum_af ._af"
1375,"Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",ciprofloxacin,aluminum,mechanism,"Quinolone_bf Antibiotics:_bf VIDEX_bf administered_bf least_bf 2_bf hours_bf 6_bf hours_bf dosing_bf DRUG plasma_be concentrations_be DRUG decreased_af administered_af antacids_af containing_af magnesium_af ,_af calcium_af ,_af OTHER_DRUG ._af"
1376,"In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.",ciprofloxacin,VIDEX,mechanism,"In_bf eight_bf HIV-infected_bf patients_bf ,_bf steady-state_bf AUC_bf DRUG decreased_be average_be 26%_be (95%_be CI_be =_be 14%_be ,_be 37%)_be DRUG administered_af 2_af hours_af prior_af marketed_af chewable/dispersible_af tablet_af formulation_af OTHER_DRUG ._af"
1377,The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.,ciprofloxacin,didanosine,mechanism,The_bf AUC_bf DRUG decreased_be average_be 15-fold_be 12_be healthy_be subjects_be given_be DRUG didanosine-placebo_af tablets_af concurrently_af ._af
1378,"In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.",ciprofloxacin,didanosine,mechanism,"In_bf single_bf subject_bf given_bf one_bf dose_bf DRUG 2_be hours_be dose_be didanosine-placebo_be tablets_be ,_be greater_be 50%_be reduction_be AUC_be DRUG observed_af ._af"
1379,"Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.",quinolone antibiotics,magnesium,mechanism,"Plasma_bf concentrations_bf quinolone_bf antibiotics_bf decreased_bf administered_bf antacids_bf containing_bf OTHER_DRUG ,_be calcium_be ,_be aluminum_be ._be"
1380,"Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.",quinolone antibiotics,calcium,mechanism,"Plasma_bf concentrations_bf quinolone_bf antibiotics_bf decreased_bf administered_bf antacids_bf containing_bf magnesium_bf ,_bf OTHER_DRUG ,_be aluminum_be ._be"
1381,"Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.",quinolone antibiotics,aluminum,mechanism,"Plasma_bf concentrations_bf quinolone_bf antibiotics_bf decreased_bf administered_bf antacids_bf containing_bf magnesium_bf ,_bf calcium_bf ,_bf OTHER_DRUG ._be"
1382,Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.,delavirdine,VIDEX,mechanism,Interactions_bf Other_bf Antiretroviral_bf Drugs:_bf Significant_bf decreases_bf AUC_bf DRUG (20%)_be indinavir_be (84%)_be occurred_be following_be simultaneous_be administration_be agents_be OTHER_DRUG ._af
1383,Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.,indinavir,VIDEX,mechanism,Interactions_bf Other_bf Antiretroviral_bf Drugs:_bf Significant_bf decreases_bf AUC_bf delavirdine_bf (20%)_bf DRUG (84%)_be occurred_be following_be simultaneous_be administration_be agents_be OTHER_DRUG ._af
1384,"To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.",delavirdine,VIDEX,advise,"To_bf avoid_bf interaction_bf ,_bf DRUG indinavir_be given_be 1_be hour_be prior_be dosing_be OTHER_DRUG ._af"
1385,"To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.",indinavir,VIDEX,advise,"To_bf avoid_bf interaction_bf ,_bf delavirdine_bf DRUG given_be 1_be hour_be prior_be dosing_be OTHER_DRUG ._af"
1386,"Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.",diflunisal,warfarin,effect,"Oral_bf Anticoagulants:_bf In_bf normal_bf volunteers_bf ,_bf concomitant_bf administration_bf DRUG OTHER_DRUG ,_af acenocoumarol_af ,_af phenprocoumon_af resulted_af prolongation_af prothrombin_af time_af ._af"
1387,"Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.",diflunisal,acenocoumarol,effect,"Oral_bf Anticoagulants:_bf In_bf normal_bf volunteers_bf ,_bf concomitant_bf administration_bf DRUG warfarin_be ,_be OTHER_DRUG ,_af phenprocoumon_af resulted_af prolongation_af prothrombin_af time_af ._af"
1388,"Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.",diflunisal,phenprocoumon,effect,"Oral_bf Anticoagulants:_bf In_bf normal_bf volunteers_bf ,_bf concomitant_bf administration_bf DRUG warfarin_be ,_be acenocoumarol_be ,_be OTHER_DRUG resulted_af prolongation_af prothrombin_af time_af ._af"
1389,This may occur because diflunisal competitively displaces coumarins from protein binding sites.,diflunisal,coumarins,mechanism,This_bf may_bf occur_bf DRUG competitively_be displaces_be OTHER_DRUG protein_af binding_af sites_af ._af
1390,"Accordingly, when diflunisal is administered with oral anticoagulants, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.",diflunisal,anticoagulants,advise,"Accordingly_bf ,_bf DRUG administered_be oral_be OTHER_DRUG ,_af prothrombin_af time_af closely_af monitored_af several_af days_af concomitant_af drug_af administration_af ._af"
1391,"Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.",diflunisal,hydrochlorothiazide,mechanism,"Hydrochlorothiazide:_bf In_bf normal_bf volunteers_bf ,_bf concomitant_bf administration_bf DRUG OTHER_DRUG resulted_af significantly_af increased_af plasma_af levels_af OTHER_DRUG ._af"
1392,Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.,Diflunisal,hydrochlorothiazide,effect,DRUG decreased_be hyperuricemic_be effect_be OTHER_DRUG ._af
1393,Diflunisal decreased the hyperuricemic effect of furosemide.,Diflunisal,furosemide,effect,DRUG decreased_be hyperuricemic_be effect_be OTHER_DRUG ._af
1394,Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.,antacids,diflunisal,mechanism,Antacids:_bf Concomitant_bf administration_bf DRUG may_be reduce_be plasma_be levels_be OTHER_DRUG ._af
1395,"Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.",diflunisal,acetaminophen,mechanism,"Acetaminophen:_bf In_bf normal_bf volunteers_bf ,_bf concomitant_bf administration_bf DRUG OTHER_DRUG resulted_af approximate_af 50%_af increase_af plasma_af levels_af OTHER_DRUG ._af"
1396,"Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.",diflunisal,acetaminophen,advise,"Since_bf OTHER_DRUG high_be doses_be associated_be hepatotoxicity_be ,_be concomitant_be administration_be DRUG OTHER_DRUG used_af cautiously_af ,_af careful_af monitoring_af patients_af ._af"
1397,"Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.",diflunisal,acetaminophen,effect,"Concomitant_bf administration_bf DRUG OTHER_DRUG dogs_af ,_af rats_af ,_af approximately_af 2_af times_af recommended_af maximum_af human_af therapeutic_af dose_af (40_af 52_af mg/kg/day_af diflunisal/acetaminophen)_af resulted_af greater_af gastrointestinal_af toxicity_af either_af drug_af administered_af alone_af ._af"
1398,Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.,diflunisal,methotrexate,advise,Methotrexate:_bf Caution_bf used_bf DRUG administered_be concomitantly_be OTHER_DRUG ._af
1399,Nonsteroidal anti-inflammatory drugs have been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.,Nonsteroidal anti-inflammatory drugs,methotrexate,mechanism,Nonsteroidal_bf anti-inflammatory_bf drugs_bf reported_bf decrease_bf tubular_bf secretion_bf OTHER_DRUG potentiate_be toxicity_be ._be
1400,"Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.",nonsteroial anti-inflammatory drugs,cyclosporine,mechanism,"Cyclosporine:_bf Administration_bf nonsteroial_bf anti-inflammatory_bf drugs_bf concomitantly_bf OTHER_DRUG associated_be increase_be cyclosporine-induced_be toxicity_be ,_be possibly_be due_be decreased_be synthesis_be renal_be prostacyclin_be ._be"
1401,"NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.",NSAIDs,cyclosporine,advise,"DRUG used_be caution_be patients_be taking_be OTHER_DRUG ,_af renal_af function_af carefully_af monitored_af ._af"
1402,Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.,diflunisal,indomethacin,mechanism,Nonsteroidal_bf Anti-Inflammatory_bf Drugs:_bf The_bf administration_bf DRUG normal_be volunteers_be receiving_be OTHER_DRUG decreased_af renal_af clearance_af significantly_af increased_af plasma_af levels_af OTHER_DRUG ._af
1403,In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.,indomethacin,diflunisal,effect,In_bf patients_bf combined_bf use_bf DRUG OTHER_DRUG associated_af fatal_af gastrointestinal_af hemorrhage_af ._af
1404,"Therefore, indomethacin and diflunisal should not be used concomitantly.",indomethacin,diflunisal,advise,"Therefore_bf ,_bf DRUG OTHER_DRUG used_af concomitantly_af ._af"
1405,"The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.",diflunisal,NSAIDs,effect,"The_bf concomitant_bf use_bf DRUG tablets_be OTHER_DRUG recommended_af due_af increased_af possibility_af gastrointestinal_af toxicity_af ,_af little_af increase_af efficacy_af ._af"
1406,"Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.",diflunisal,aspirin,mechanism,"Aspirin:_bf In_bf normal_bf volunteers_bf ,_bf small_bf decrease_bf DRUG levels_be observed_be multiple_be doses_be DRUG OTHER_DRUG administered_af concomitantly_af ._af"
1407,Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.,diflunisal,sulindac,mechanism,Sulindac:_bf The_bf concomitant_bf administration_bf DRUG OTHER_DRUG normal_af volunteers_af resulted_af lowering_af plasma_af levels_af active_af OTHER_DRUG sulfide_af metabolite_af approximately_af one-third_af ._af
1408,"Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.",diflunisal,naproxen,mechanism,"Naproxen:_bf The_bf concomitant_bf administration_bf DRUG OTHER_DRUG normal_af volunteers_af effect_af plasma_af levels_af OTHER_DRUG ,_af significantly_af decreased_af urinary_af excretion_af OTHER_DRUG glucuronide_af metabolite_af ._af"
1409,Potassium-depleting diuretics are a major contributing factor to digitalis toxicity.,Potassium-depleting diuretics,digitalis,effect,Potassium-depleting_bf diuretics_bf major_bf contributing_bf factor_bf OTHER_DRUG toxicity_be ._be
1410,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",Quinidine,digoxin,mechanism,"DRUG ,_be verapamil_be ,_be amiodarone_be ,_be propafenone_be ,_be indomethacin_be ,_be itraconazole_be ,_be alprazolam_be ,_be spironolactone_be raise_be serum_be OTHER_DRUG concentration_af due_af reduction_af clearance_af and/or_af volume_af distribution_af drug_af ,_af implication_af digitalis_af intoxication_af may_af result_af ._af"
1411,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",verapamil,digoxin,mechanism,"Quinidine_bf ,_bf DRUG ,_be amiodarone_be ,_be propafenone_be ,_be indomethacin_be ,_be itraconazole_be ,_be alprazolam_be ,_be spironolactone_be raise_be serum_be OTHER_DRUG concentration_af due_af reduction_af clearance_af and/or_af volume_af distribution_af drug_af ,_af implication_af digitalis_af intoxication_af may_af result_af ._af"
1412,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",amiodarone,digoxin,mechanism,"Quinidine_bf ,_bf verapamil_bf ,_bf DRUG ,_be propafenone_be ,_be indomethacin_be ,_be itraconazole_be ,_be alprazolam_be ,_be spironolactone_be raise_be serum_be OTHER_DRUG concentration_af due_af reduction_af clearance_af and/or_af volume_af distribution_af drug_af ,_af implication_af digitalis_af intoxication_af may_af result_af ._af"
1413,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",propafenone,digoxin,mechanism,"Quinidine_bf ,_bf verapamil_bf ,_bf amiodarone_bf ,_bf DRUG ,_be indomethacin_be ,_be itraconazole_be ,_be alprazolam_be ,_be spironolactone_be raise_be serum_be OTHER_DRUG concentration_af due_af reduction_af clearance_af and/or_af volume_af distribution_af drug_af ,_af implication_af digitalis_af intoxication_af may_af result_af ._af"
1414,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",indomethacin,digoxin,mechanism,"Quinidine_bf ,_bf verapamil_bf ,_bf amiodarone_bf ,_bf propafenone_bf ,_bf DRUG ,_be itraconazole_be ,_be alprazolam_be ,_be spironolactone_be raise_be serum_be OTHER_DRUG concentration_af due_af reduction_af clearance_af and/or_af volume_af distribution_af drug_af ,_af implication_af digitalis_af intoxication_af may_af result_af ._af"
1415,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",itraconazole,digoxin,mechanism,"Quinidine_bf ,_bf verapamil_bf ,_bf amiodarone_bf ,_bf propafenone_bf ,_bf indomethacin_bf ,_bf DRUG ,_be alprazolam_be ,_be spironolactone_be raise_be serum_be OTHER_DRUG concentration_af due_af reduction_af clearance_af and/or_af volume_af distribution_af drug_af ,_af implication_af digitalis_af intoxication_af may_af result_af ._af"
1416,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",alprazolam,digoxin,mechanism,"Quinidine_bf ,_bf verapamil_bf ,_bf amiodarone_bf ,_bf propafenone_bf ,_bf indomethacin_bf ,_bf itraconazole_bf ,_bf DRUG ,_be spironolactone_be raise_be serum_be OTHER_DRUG concentration_af due_af reduction_af clearance_af and/or_af volume_af distribution_af drug_af ,_af implication_af digitalis_af intoxication_af may_af result_af ._af"
1417,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",spironolactone,digoxin,mechanism,"Quinidine_bf ,_bf verapamil_bf ,_bf amiodarone_bf ,_bf propafenone_bf ,_bf indomethacin_bf ,_bf itraconazole_bf ,_bf alprazolam_bf ,_bf DRUG raise_be serum_be OTHER_DRUG concentration_af due_af reduction_af clearance_af and/or_af volume_af distribution_af drug_af ,_af implication_af digitalis_af intoxication_af may_af result_af ._af"
1418,"Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",Erythromycin,digoxin,mechanism,"DRUG clarithromycin_be (and_be possibly_be macrolide_be antibiotics)_be tetracycline_be may_be increase_be OTHER_DRUG absorption_af patients_af inactivate_af OTHER_DRUG bacterial_af metabolism_af lower_af intestine_af ,_af digitalis_af intoxication_af may_af result_af ._af"
1419,"Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",clarithromycin,digoxin,mechanism,"Erythromycin_bf DRUG (and_be possibly_be macrolide_be antibiotics)_be tetracycline_be may_be increase_be OTHER_DRUG absorption_af patients_af inactivate_af OTHER_DRUG bacterial_af metabolism_af lower_af intestine_af ,_af digitalis_af intoxication_af may_af result_af ._af"
1420,"Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",macrolide antibiotics,digoxin,mechanism,"Erythromycin_bf clarithromycin_bf (and_bf possibly_bf macrolide_bf antibiotics)_bf tetracycline_bf may_bf increase_bf OTHER_DRUG absorption_be patients_be inactivate_be OTHER_DRUG bacterial_af metabolism_af lower_af intestine_af ,_af digitalis_af intoxication_af may_af result_af ._af"
1421,"Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",tetracycline,digoxin,mechanism,"Erythromycin_bf clarithromycin_bf (and_bf possibly_bf macrolide_bf antibiotics)_bf DRUG may_be increase_be OTHER_DRUG absorption_af patients_af inactivate_af OTHER_DRUG bacterial_af metabolism_af lower_af intestine_af ,_af digitalis_af intoxication_af may_af result_af ._af"
1422,"Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.",Propantheline,digoxin,mechanism,"DRUG diphenoxylate_be ,_be decreasing_be gut_be motility_be ,_be may_be increase_be OTHER_DRUG absorption_af ._af"
1423,"Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.",diphenoxylate,digoxin,mechanism,"Propantheline_bf DRUG ,_be decreasing_be gut_be motility_be ,_be may_be increase_be OTHER_DRUG absorption_af ._af"
1424,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",Antacids,digoxin,mechanism,"DRUG ,_be kaolin-pectin_be ,_be sulfasalazine_be ,_be neomycin_be ,_be cholestyramine_be ,_be certain_be anticancer_be drugs_be ,_be metoclopramide_be may_be interfere_be intestinal_be OTHER_DRUG absorption_af ,_af resulting_af unexpectedly_af low_af serum_af concentrations_af ._af"
1425,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",kaolin,digoxin,mechanism,"Antacids_bf ,_bf kaolin-pectin_bf ,_bf sulfasalazine_bf ,_bf neomycin_bf ,_bf cholestyramine_bf ,_bf certain_bf anticancer_bf drugs_bf ,_bf metoclopramide_bf may_bf interfere_bf intestinal_bf OTHER_DRUG absorption_be ,_be resulting_be unexpectedly_be low_be serum_be concentrations_be ._be"
1426,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",sulfasalazine,digoxin,mechanism,"Antacids_bf ,_bf kaolin-pectin_bf ,_bf DRUG ,_be neomycin_be ,_be cholestyramine_be ,_be certain_be anticancer_be drugs_be ,_be metoclopramide_be may_be interfere_be intestinal_be OTHER_DRUG absorption_af ,_af resulting_af unexpectedly_af low_af serum_af concentrations_af ._af"
1427,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",neomycin,digoxin,mechanism,"Antacids_bf ,_bf kaolin-pectin_bf ,_bf sulfasalazine_bf ,_bf DRUG ,_be cholestyramine_be ,_be certain_be anticancer_be drugs_be ,_be metoclopramide_be may_be interfere_be intestinal_be OTHER_DRUG absorption_af ,_af resulting_af unexpectedly_af low_af serum_af concentrations_af ._af"
1428,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",cholestyramine,digoxin,mechanism,"Antacids_bf ,_bf kaolin-pectin_bf ,_bf sulfasalazine_bf ,_bf neomycin_bf ,_bf DRUG ,_be certain_be anticancer_be drugs_be ,_be metoclopramide_be may_be interfere_be intestinal_be OTHER_DRUG absorption_af ,_af resulting_af unexpectedly_af low_af serum_af concentrations_af ._af"
1429,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",metoclopramide,digoxin,mechanism,"Antacids_bf ,_bf kaolin-pectin_bf ,_bf sulfasalazine_bf ,_bf neomycin_bf ,_bf cholestyramine_bf ,_bf certain_bf anticancer_bf drugs_bf ,_bf DRUG may_be interfere_be intestinal_be OTHER_DRUG absorption_af ,_af resulting_af unexpectedly_af low_af serum_af concentrations_af ._af"
1430,"Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.",Rifampin,digoxin,mechanism,"DRUG may_be decrease_be serum_be OTHER_DRUG concentration_af ,_af especially_af patients_af renal_af dysfunction_af ,_af increasing_af non-renal_af clearance_af OTHER_DRUG ._af"
1431,"Thyroid administration to a digitalized, hypothyroid patient may increase the dose requirement of digoxin.",Thyroid,digoxin,advise,"DRUG administration_be digitalized_be ,_be hypothyroid_be patient_be may_be increase_be dose_be requirement_be OTHER_DRUG ._af"
1432,Concomitant use of digoxin and sympathomimetics increases the risk of cardiac arrhythmias.,digoxin,sympathomimetics,effect,Concomitant_bf use_bf DRUG OTHER_DRUG increases_af risk_af cardiac_af arrhythmias_af ._af
1433,"Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.",beta-adrenergic blockers,digoxin,effect,"Although_bf beta-adrenergic_bf blockers_bf calcium_bf channel_bf blockers_bf OTHER_DRUG may_be useful_be combination_be control_be atrial_be fibrillation_be ,_be additive_be effects_be AV_be node_be conduction_be result_be advanced_be complete_be heart_be block_be ._be"
1434,"Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.",calcium channel blockers,digoxin,effect,"Although_bf beta-adrenergic_bf blockers_bf calcium_bf channel_bf blockers_bf OTHER_DRUG may_be useful_be combination_be control_be atrial_be fibrillation_be ,_be additive_be effects_be AV_be node_be conduction_be result_be advanced_be complete_be heart_be block_be ._be"
1435,"Vasoconstrictors: D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.",D.H.E. 45,peripheral vasoconstrictors,effect,"Vasoconstrictors:_bf D_bf ._bf H_bf ._bf E_bf ._bf 45_bf (dihydroergotamine_bf mesylate)_bf Injection_bf ,_bf USP_bf used_bf peripheral_bf vasoconstrictors_bf combination_bf may_bf cause_bf synergistic_bf elevation_bf blood_bf pressure_bf ._bf"
1436,"Vasoconstrictors: D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.",dihydroergotamine mesylate,peripheral vasoconstrictors,effect,"Vasoconstrictors:_bf D_bf ._bf H_bf ._bf E_bf ._bf 45_bf (dihydroergotamine_bf mesylate)_bf Injection_bf ,_bf USP_bf used_bf peripheral_bf vasoconstrictors_bf combination_bf may_bf cause_bf synergistic_bf elevation_bf blood_bf pressure_bf ._bf"
1437,"Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.",Sumatriptan,D.H.E. 45,effect,"Sumatriptan:_bf DRUG reported_be cause_be coronary_be artery_be vasospasm_be ,_be effect_be could_be additive_be D_be ._be H_be ._be E_be ._be 45_be (dihydroergotamine_be mesylate)_be Injection_be ,_be USP_be ._be"
1438,"Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.",Sumatriptan,dihydroergotamine mesylate,effect,"Sumatriptan:_bf DRUG reported_be cause_be coronary_be artery_be vasospasm_be ,_be effect_be could_be additive_be D_be ._be H_be ._be E_be ._be 45_be (dihydroergotamine_be mesylate)_be Injection_be ,_be USP_be ._be"
1439,"Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..",Sumatriptan,D.H.E. 45,advise,"DRUG D_be ._be H_be ._be E_be ._be 45_be (dihydroergotamine_be mesylate)_be Injection_be ,_be USP_be taken_be within_be 24_be hours_be ._be ._be"
1440,"Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..",Sumatriptan,dihydroergotamine mesylate,advise,"DRUG D_be ._be H_be ._be E_be ._be 45_be (dihydroergotamine_be mesylate)_be Injection_be ,_be USP_be taken_be within_be 24_be hours_be ._be ._be"
1441,"Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.",propranolol,ergotamine,effect,"Beta_bf Blockers:_bf Although_bf results_bf clinical_bf study_bf indicate_bf safe_bf problem_bf associated_bf administration_bf D_bf ._bf H_bf ._bf E_bf ._bf 45_bf (dihydroergotamine_bf mesylate)_bf Injection_bf ,_bf USP_bf subjects_bf already_bf receiving_bf DRUG ,_be reports_be DRUG may_af potentiate_af vasoconstrictive_af action_af OTHER_DRUG blocking_af vasodilating_af property_af epinephrine_af ._af"
1442,"Nicotine: Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.",Nicotine,ergot,effect,"Nicotine:_bf DRUG may_be provoke_be vasoconstriction_be patients_be ,_be predisposing_be greater_be ischemic_be response_be OTHER_DRUG therapy_af ._af"
1443,"Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.",ergot alkaloid class,macrolide class,mechanism,"Macrolide_bf Antibiotics_bf (e_bf ._bf g_bf ._bf erythromycin_bf troleandomycin):_bf Agents_bf ergot_bf alkaloid_bf class_bf ,_bf D_bf ._bf H_bf ._bf E_bf ._bf 45_bf (dihydroergotamine_bf mesylate)_bf Injection_bf ,_bf USP_bf member_bf ,_bf shown_bf interact_bf antibiotics_bf macrolide_bf class_bf ,_bf resulting_bf increased_bf plasma_bf levels_bf unchanged_bf alkaloids_bf peripheral_bf vasoconstriction_bf ._bf"
1444,"Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.",D.H.E. 45,macrolide class,mechanism,"Macrolide_bf Antibiotics_bf (e_bf ._bf g_bf ._bf erythromycin_bf troleandomycin):_bf Agents_bf ergot_bf alkaloid_bf class_bf ,_bf D_bf ._bf H_bf ._bf E_bf ._bf 45_bf (dihydroergotamine_bf mesylate)_bf Injection_bf ,_bf USP_bf member_bf ,_bf shown_bf interact_bf antibiotics_bf macrolide_bf class_bf ,_bf resulting_bf increased_bf plasma_bf levels_bf unchanged_bf alkaloids_bf peripheral_bf vasoconstriction_bf ._bf"
1445,"Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.",dihydroergotamine mesylate,macrolide class,mechanism,"Macrolide_bf Antibiotics_bf (e_bf ._bf g_bf ._bf erythromycin_bf troleandomycin):_bf Agents_bf ergot_bf alkaloid_bf class_bf ,_bf D_bf ._bf H_bf ._bf E_bf ._bf 45_bf (dihydroergotamine_bf mesylate)_bf Injection_bf ,_bf USP_bf member_bf ,_bf shown_bf interact_bf antibiotics_bf macrolide_bf class_bf ,_bf resulting_bf increased_bf plasma_bf levels_bf unchanged_bf alkaloids_bf peripheral_bf vasoconstriction_bf ._bf"
1446,Vasospastic reactions have been reported with therapeutic doses of ergotamine-containing drugs when co-administered with these antibiotics.,ergotamine,antibiotics,effect,Vasospastic_bf reactions_bf reported_bf therapeutic_bf doses_bf ergotamine-containing_bf drugs_bf co-administered_bf OTHER_DRUG ._be
1447,"SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with SSRIs (e. g.",5-HT1 agonists,SSRIs,effect,"SSRIs:_bf Weakness_bf hyperreflexia_bf ,_bf incoordination_bf reported_bf rarely_bf 5-HT1_bf agonists_bf co-administered_bf OTHER_DRUG (e_be ._be g_be ._be"
1448,Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with dihydrotachysterol may cause hypercalcemia.,thiazide diuretics,dihydrotachysterol,effect,Administration_bf thiazide_bf diuretics_bf hypoparathyroid_bf patients_bf concurrently_bf treated_bf OTHER_DRUG may_be cause_be hypercalcemia_be ._be
1449,Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.,beta-blockers,Tiazac,effect,Pharmacologic_bf studies_bf indicate_bf may_bf additive_bf effects_bf prolonging_bf AV_bf conduction_bf using_bf DRUG digitalis_be concomitantly_be OTHER_DRUG ._af
1450,Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.,digitalis,Tiazac,effect,Pharmacologic_bf studies_bf indicate_bf may_bf additive_bf effects_bf prolonging_bf AV_bf conduction_bf using_bf beta-blockers_bf DRUG concomitantly_be OTHER_DRUG ._af
1451,Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.,diltiazem hydrochloride,propranolol,mechanism,Administration_bf diltiazem_bf hydrochloride_bf concomitantly_bf OTHER_DRUG five_be normal_be volunteers_be resulted_be increased_be OTHER_DRUG levels_af subjects_af bioavailability_af OTHER_DRUG increased_af approximately_af 50%_af ._af
1452,"In vitro, propranolol appears to be displaced from its binding sites by diltiazem.",propranolol,diltiazem,mechanism,"In_bf vitro_bf ,_bf DRUG appears_be displaced_be binding_be sites_be OTHER_DRUG ._af"
1453,A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.,cimetidine,diltiazem,mechanism,A_bf study_bf six_bf healthy_bf volunteers_bf shown_bf significant_bf increase_bf peak_bf OTHER_DRUG plasma_be levels_be (58%)_be AUC_be (53%)_be 1-week_be course_be DRUG 1200_af mg/day_af single_af dose_af OTHER_DRUG 60mg_af ._af
1454,"The effect may be mediated by cimetidines known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem.",cimetidine,diltiazem,mechanism,"The_bf effect_bf may_bf mediated_bf cimetidines_bf known_bf inhibition_bf hepatic_bf cytochrome_bf P-450_bf ,_bf enzyme_bf system_bf responsible_bf first-pass_bf metabolism_bf OTHER_DRUG ._be"
1455,Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.,diltiazem,cimetidine,advise,Patients_bf currently_bf receiving_bf DRUG therapy_be carefully_be monitored_be change_be pharmacological_be effect_be initiating_be discontinuing_be therapy_be OTHER_DRUG ._af
1456,Administration of diltiazem hydrochloride with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.,diltiazem hydrochloride,digoxin,mechanism,Administration_bf diltiazem_bf hydrochloride_bf OTHER_DRUG 24_be healthy_be male_be subjects_be increased_be plasma_be OTHER_DRUG concentrations_af approximately_af 20%_af ._af
1457,"Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.",digoxin,diltiazem hydrochloride,advise,"Since_bf conflicting_bf results_bf regarding_bf effect_bf DRUG levels_be ,_be recommended_be DRUG levels_af monitored_af initiating_af ,_af adjusting_af ,_af discontinuing_af diltiazem_af hydrochloride_af therapy_af avoid_af possible_af over-_af under-digitalization_af ._af"
1458,"The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers.",anesthetics,calcium channel blockers,effect,"The_bf depression_bf cardiac_bf contractility_bf ,_bf conductivity_bf ,_bf automaticity_bf well_bf vascular_bf dilation_bf associated_bf DRUG may_be potentiated_be calcium_be channel_be blockers_be ._be"
1459,"When used concomitantly, anesthetics and calcium channel blockers should be titrated carefully.",anesthetics,calcium channel blockers,advise,"When_bf used_bf concomitantly_bf ,_bf DRUG calcium_be channel_be blockers_be titrated_be carefully_be ._be"
1460,A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.,diltiazem,cyclosporine,int,A_bf pharmacokinetic_bf interaction_bf DRUG OTHER_DRUG observed_af studies_af involving_af renal_af cardiac_af transplant_af patients_af ._af
1461,"In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.",cyclosporine,diltiazem,mechanism,"In_bf renal_bf cardiac_bf transplant_bf recipients_bf ,_bf reduction_bf DRUG dose_be ranging_be 15%_be 48%_be necessary_be maintain_be DRUG trough_af concentrations_af similar_af seen_af prior_af addition_af OTHER_DRUG ._af"
1462,"If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.",cyclosporine,diltiazem,advise,"If_bf agents_bf administered_bf concurrently_bf ,_bf DRUG concentrations_be monitored_be ,_be especially_be OTHER_DRUG therapy_af initiated_af ,_af adjusted_af ,_af discontinued_af ._af"
1463,"Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.",diltiazem,carbamazepine,mechanism,"Concomitant_bf administration_bf DRUG OTHER_DRUG reported_af result_af elevated_af serum_af levels_af OTHER_DRUG (40%_af 72%_af increase)_af ,_af resulting_af toxicity_af cases_af ._af"
1464,"Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.",diltiazem,midazolam,mechanism,"Studies_bf showed_bf DRUG increased_be AUC_be OTHER_DRUG triazolam_af 3-4_af fold_af Cmax_af 2-fold_af ,_af compared_af placebo_af ._af"
1465,"Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.",diltiazem,triazolam,mechanism,"Studies_bf showed_bf DRUG increased_be AUC_be midazolam_be OTHER_DRUG 3-4_af fold_af Cmax_af 2-fold_af ,_af compared_af placebo_af ._af"
1466,The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.,midazolam,diltiazem,mechanism,The_bf elimination_bf half_bf life_bf DRUG triazolam_be also_be increased_be (1_be ._be 5-2_be ._be 5_be fold)_be coadministration_be OTHER_DRUG ._af
1467,The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.,triazolam,diltiazem,mechanism,The_bf elimination_bf half_bf life_bf midazolam_bf DRUG also_be increased_be (1_be ._be 5-2_be ._be 5_be fold)_be coadministration_be OTHER_DRUG ._af
1468,"These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.",diltiazem,midazolam,effect,"These_bf pharmacokinetic_bf effects_bf seen_bf DRUG coadministration_be result_be increased_be clinical_be effects_be (e_be ._be g_be ._be ,_be prolonged_be sodation)of_be OTHER_DRUG triazolam_af ._af"
1469,"These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.",diltiazem,triazolam,effect,"These_bf pharmacokinetic_bf effects_bf seen_bf DRUG coadministration_be result_be increased_be clinical_be effects_be (e_be ._be g_be ._be ,_be prolonged_be sodation)of_be midazolam_be OTHER_DRUG ._af"
1470,"In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;",diltiazem,lovastatin,mechanism,"In_bf ten-subject_bf study_bf ,_bf coadministration_bf DRUG (120_be mg_be bid)_be OTHER_DRUG resulted_af 3-4_af times_af increase_af mean_af OTHER_DRUG AUC_af Cmax_af vs_af ._af OTHER_DRUG alone;_af"
1471,Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.,rifampin,diltiazem,mechanism,Coadministration_bf DRUG OTHER_DRUG lowered_af OTHER_DRUG plasma_af concentrations_af undetectable_af levels_af ._af
1472,"Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.",diltiazem,rifampin,advise,"Coadministration_bf DRUG OTHER_DRUG known_af CYP3A4_af inducer_af avoided_af possible_af ,_af alternative_af therapy_af considered_af ._af"
1473,Dimenhydrinate may decrease emetic response to apomorphine.,Dimenhydrinate,apomorphine,effect,DRUG may_be decrease_be emetic_be response_be OTHER_DRUG ._af
1474,"Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;",Oxytocin,dinoprost,effect,"DRUG oxytocics_be (concurrent_be use_be OTHER_DRUG may_af result_af uterine_af hypertonus_af ,_af possibly_af causing_af uterine_af rupture_af cervical_af laceration_af ,_af especially_af absence_af adequate_af cervical_af dilatation;_af"
1475,"Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;",oxytocics,dinoprost,effect,"Oxytocin_bf DRUG (concurrent_be use_be OTHER_DRUG may_af result_af uterine_af hypertonus_af ,_af possibly_af causing_af uterine_af rupture_af cervical_af laceration_af ,_af especially_af absence_af adequate_af cervical_af dilatation;_af"
1476,PROSTIN E2 may augment the activity of other oxytocic drugs.,PROSTIN E2,oxytocic drugs,effect,PROSTIN_bf E2_bf may_bf augment_bf activity_bf oxytocic_bf drugs_bf ._bf
1477,"Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",Diphenhydramine hydrochloride,alcohol,effect,"Diphenhydramine_bf hydrochloride_bf additive_bf effects_bf OTHER_DRUG CNS_be depressants_be (hypnotics_be ,_be sedatives_be ,_be tranquilizers_be ,_be etc)_be ._be"
1478,"Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",Diphenhydramine hydrochloride,CNS depressants,effect,"Diphenhydramine_bf hydrochloride_bf additive_bf effects_bf alcohol_bf CNS_bf depressants_bf (hypnotics_bf ,_bf sedatives_bf ,_bf tranquilizers_bf ,_bf etc)_bf ._bf"
1479,"Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",Diphenhydramine hydrochloride,hypnotics,effect,"Diphenhydramine_bf hydrochloride_bf additive_bf effects_bf alcohol_bf CNS_bf depressants_bf (hypnotics_bf ,_bf sedatives_bf ,_bf tranquilizers_bf ,_bf etc)_bf ._bf"
1480,"Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",Diphenhydramine hydrochloride,sedatives,effect,"Diphenhydramine_bf hydrochloride_bf additive_bf effects_bf alcohol_bf CNS_bf depressants_bf (hypnotics_bf ,_bf OTHER_DRUG ,_be tranquilizers_be ,_be etc)_be ._be"
1481,"Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",Diphenhydramine hydrochloride,tranquilizers,effect,"Diphenhydramine_bf hydrochloride_bf additive_bf effects_bf alcohol_bf CNS_bf depressants_bf (hypnotics_bf ,_bf sedatives_bf ,_bf OTHER_DRUG ,_be etc)_be ._be"
1482,MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.,MAO inhibitors,antihistamines,effect,MAO_bf inhibitors_bf prolong_bf intensify_bf anticholinergic_bf (drying)_bf effects_bf OTHER_DRUG ._be
1483,apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.,diphenidol,apomorphine,effect,OTHER_DRUG -_be prior_be ingestion_be DRUG may_af decrease_af emetic_af response_af OTHER_DRUG treatment_af poisoning_af ._af
1484,"Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.",Diphenoxylate HCl,MAO inhibitors,int,"Diphenoxylate_bf HCl_bf atropine_bf sulfate_bf may_bf interact_bf MAO_bf inhibitors_bf In_bf studies_bf male_bf rats_bf ,_bf diphenoxylate_bf hydrochloride_bf found_bf inhibit_bf hepatic_bf microsomal_bf enzyme_bf system_bf dose_bf 2_bf mg/kg/day_bf ._bf"
1485,"Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.",atropine sulfate,MAO inhibitors,int,"Diphenoxylate_bf HCl_bf atropine_bf sulfate_bf may_bf interact_bf MAO_bf inhibitors_bf In_bf studies_bf male_bf rats_bf ,_bf diphenoxylate_bf hydrochloride_bf found_bf inhibit_bf hepatic_bf microsomal_bf enzyme_bf system_bf dose_bf 2_bf mg/kg/day_bf ._bf"
1486,Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.,Dipyridamole,adenosine,mechanism,Adenosine:_bf DRUG reported_be increase_be plasma_be levels_be cardiovascular_be effects_be OTHER_DRUG ._af
1487,"Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.",Dipyridamole,cholinesterase inhibitors,effect,"Cholinesterase_bf Inhibitors:_bf DRUG may_be counteract_be anticholinesterase_be effect_be cholinesterase_be inhibitors_be ,_be thereby_be potentially_be aggravating_be myasthenia_be gravis_be ._be"
1488,"in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus dirithromycin.",terfenadine,dirithromycin,mechanism,"one_bf man_bf ,_bf C_bf max_bf DRUG 8_be ._be 1_be ng/mL_be DRUG alone_af 7_af ._af 2_af ng/mL_af DRUG plus_af OTHER_DRUG ._af"
1489,The mean QT c interval (msec) was 369 with terfenadine alone and 367 with terfenadine plus dirithromycin.,terfenadine,dirithromycin,effect,The_bf mean_bf QT_bf c_bf interval_bf (msec)_bf 369_bf DRUG alone_be 367_be DRUG plus_af OTHER_DRUG ._af
1490,"Thus, the interaction observed between erythromycin and terfenadine is not expected for dirithromycin.",erythromycin,terfenadine,int,"Thus_bf ,_bf interaction_bf observed_bf DRUG OTHER_DRUG expected_af dirithromycin_af ._af"
1491,"Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving terfenadine concomitantly with other macrolide antibiotics.",terfenadine,macrolide antibiotics,effect,"Serious_bf cardiac_bf dysrhythmias_bf ,_bf resulting_bf death_bf ,_bf occurred_bf patients_bf receiving_bf DRUG concomitantly_be macrolide_be antibiotics_be ._be"
1492,"In addition, most macrolides are contraindicated in patients receiving terfenadine therapy who have pre-existing cardiac abnormalities (arrhythmia, bradycardia, QT c interval prolongation, ischemic heart disease, congestive heart failure, etc.) or electrolyte disturbances.",macrolides,terfenadine,advise,"In_bf addition_bf ,_bf DRUG contraindicated_be patients_be receiving_be OTHER_DRUG therapy_af pre-existing_af cardiac_af abnormalities_af (arrhythmia_af ,_af bradycardia_af ,_af QT_af c_af interval_af prolongation_af ,_af ischemic_af heart_af disease_af ,_af congestive_af heart_af failure_af ,_af etc_af ._af )_af electrolyte_af disturbances_af ._af"
1493,"Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.",dirithromycin,antacids,mechanism,"OTHER_DRUG H_be 2_be receptor_be antagonists:_be When_be DRUG administered_af immediately_af following_af OTHER_DRUG H_af 2_af -receptor_af antagonists_af ,_af absorption_af DRUG slightly_af enhanced_af ._af"
1494,"Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.",dirithromycin,H 2 -receptor antagonists,mechanism,"Antacids_bf H_bf 2_bf receptor_bf antagonists:_bf When_bf DRUG administered_be immediately_be following_be antacids_be H_be 2_be -receptor_be antagonists_be ,_be absorption_be DRUG slightly_af enhanced_af ._af"
1495,"Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.",Erythromycin,triazolam,mechanism,"Triazolam:_bf DRUG reported_be decrease_be clearance_be OTHER_DRUG ,_af thus_af ,_af may_af increase_af pharmacologic_af effect_af OTHER_DRUG ._af"
1496,"Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.",Erythromycin,triazolam,effect,"Triazolam:_bf DRUG reported_be decrease_be clearance_be OTHER_DRUG ,_af thus_af ,_af may_af increase_af pharmacologic_af effect_af OTHER_DRUG ._af"
1497,Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.,erythromycin,digoxin,mechanism,Digoxin:_bf Concomitant_bf administration_bf DRUG OTHER_DRUG reported_af result_af elevated_af OTHER_DRUG serum_af levels_af ._af
1498,Anticoagulants: There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.,erythromycin,anticoagulants,effect,Anticoagulants:_bf There_bf reports_bf increased_bf anticoagulant_bf effects_bf DRUG oral_be OTHER_DRUG used_af concomitantly_af ._af
1499,Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.,erythromycin,ergotamine,effect,Ergotamine:_bf Concurrent_bf use_bf DRUG OTHER_DRUG dihydroergotamine_af associated_af patients_af acute_af ergot_af toxicity_af characterized_af severe_af peripheral_af vasospasm_af dysesthesia_af ._af
1500,Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.,erythromycin,dihydroergotamine,effect,Ergotamine:_bf Concurrent_bf use_bf DRUG ergotamine_be OTHER_DRUG associated_af patients_af acute_af ergot_af toxicity_af characterized_af severe_af peripheral_af vasospasm_af dysesthesia_af ._af
1501,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,cyclosporine,int,"Other_bf drugs_bf Drug_bf interactions_bf reported_bf concomitant_bf administration_bf DRUG medications_be ,_be including_be OTHER_DRUG ,_af hexobarbital_af ,_af carbamazepine_af ,_af alfentanil_af ,_af disopyramide_af ,_af phenytoin_af ,_af bromocriptine_af ,_af valproate_af ,_af astemizole_af ,_af lovastatin_af ._af"
1502,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,hexobarbital,int,"Other_bf drugs_bf Drug_bf interactions_bf reported_bf concomitant_bf administration_bf DRUG medications_be ,_be including_be cyclosporine_be ,_be OTHER_DRUG ,_af carbamazepine_af ,_af alfentanil_af ,_af disopyramide_af ,_af phenytoin_af ,_af bromocriptine_af ,_af valproate_af ,_af astemizole_af ,_af lovastatin_af ._af"
1503,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,carbamazepine,int,"Other_bf drugs_bf Drug_bf interactions_bf reported_bf concomitant_bf administration_bf DRUG medications_be ,_be including_be cyclosporine_be ,_be hexobarbital_be ,_be OTHER_DRUG ,_af alfentanil_af ,_af disopyramide_af ,_af phenytoin_af ,_af bromocriptine_af ,_af valproate_af ,_af astemizole_af ,_af lovastatin_af ._af"
1504,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,alfentanil,int,"Other_bf drugs_bf Drug_bf interactions_bf reported_bf concomitant_bf administration_bf DRUG medications_be ,_be including_be cyclosporine_be ,_be hexobarbital_be ,_be carbamazepine_be ,_be OTHER_DRUG ,_af disopyramide_af ,_af phenytoin_af ,_af bromocriptine_af ,_af valproate_af ,_af astemizole_af ,_af lovastatin_af ._af"
1505,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,disopyramide,int,"Other_bf drugs_bf Drug_bf interactions_bf reported_bf concomitant_bf administration_bf DRUG medications_be ,_be including_be cyclosporine_be ,_be hexobarbital_be ,_be carbamazepine_be ,_be alfentanil_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af bromocriptine_af ,_af valproate_af ,_af astemizole_af ,_af lovastatin_af ._af"
1506,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,phenytoin,int,"Other_bf drugs_bf Drug_bf interactions_bf reported_bf concomitant_bf administration_bf DRUG medications_be ,_be including_be cyclosporine_be ,_be hexobarbital_be ,_be carbamazepine_be ,_be alfentanil_be ,_be disopyramide_be ,_be OTHER_DRUG ,_af bromocriptine_af ,_af valproate_af ,_af astemizole_af ,_af lovastatin_af ._af"
1507,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,bromocriptine,int,"Other_bf drugs_bf Drug_bf interactions_bf reported_bf concomitant_bf administration_bf DRUG medications_be ,_be including_be cyclosporine_be ,_be hexobarbital_be ,_be carbamazepine_be ,_be alfentanil_be ,_be disopyramide_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af valproate_af ,_af astemizole_af ,_af lovastatin_af ._af"
1508,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,valproate,int,"Other_bf drugs_bf Drug_bf interactions_bf reported_bf concomitant_bf administration_bf DRUG medications_be ,_be including_be cyclosporine_be ,_be hexobarbital_be ,_be carbamazepine_be ,_be alfentanil_be ,_be disopyramide_be ,_be phenytoin_be ,_be bromocriptine_be ,_be OTHER_DRUG ,_af astemizole_af ,_af lovastatin_af ._af"
1509,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,astemizole,int,"Other_bf drugs_bf Drug_bf interactions_bf reported_bf concomitant_bf administration_bf DRUG medications_be ,_be including_be cyclosporine_be ,_be hexobarbital_be ,_be carbamazepine_be ,_be alfentanil_be ,_be disopyramide_be ,_be phenytoin_be ,_be bromocriptine_be ,_be valproate_be ,_be OTHER_DRUG ,_af lovastatin_af ._af"
1510,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,lovastatin,int,"Other_bf drugs_bf Drug_bf interactions_bf reported_bf concomitant_bf administration_bf DRUG medications_be ,_be including_be cyclosporine_be ,_be hexobarbital_be ,_be carbamazepine_be ,_be alfentanil_be ,_be disopyramide_be ,_be phenytoin_be ,_be bromocriptine_be ,_be valproate_be ,_be astemizole_be ,_be OTHER_DRUG ._af"
1511,Animal studies indicate that dobutamine may be ineffective if the patient has recently received a b-blocking drug.,dobutamine,b-blocking drug,effect,Animal_bf studies_bf indicate_bf DRUG may_be ineffective_be patient_be recently_be received_be b-blocking_be drug_be ._be
1512,"Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.",dobutamine,nitroprusside,effect,"Preliminary_bf studies_bf indicate_bf concomitant_bf use_bf DRUG OTHER_DRUG results_af higher_af cardiac_af output_af ,_af usually_af ,_af lower_af pulmonary_af wedge_af pressure_af either_af drug_af used_af alone_af ._af"
1513,"Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.",dolasetron,cimetidine,mechanism,"Blood_bf levels_bf hydrodolasetron_bf increased_bf 24%_bf DRUG coadministered_be OTHER_DRUG (nonselective_af inhibitor_af cytochrome_af P-450)_af 7_af days_af ,_af decreased_af 28%_af coadministration_af rifampin_af (potent_af inducer_af cytochrome_af P-450)_af 7_af days_af ._af"
1514,"Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.",dolasetron,rifampin,mechanism,"Blood_bf levels_bf hydrodolasetron_bf increased_bf 24%_bf DRUG coadministered_be cimetidine_be (nonselective_be inhibitor_be cytochrome_be P-450)_be 7_be days_be ,_be decreased_be 28%_be coadministration_be OTHER_DRUG (potent_af inducer_af cytochrome_af P-450)_af 7_af days_af ._af"
1515,Clearance of hydrodolasetron decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with atenolol.,dolasetron mesylate,atenolol,mechanism,Clearance_bf hydrodolasetron_bf decreased_bf 27%_bf dolasetron_bf mesylate_bf administered_bf intravenously_bf concomitantly_bf OTHER_DRUG ._be
1516,Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.,MAO inhibitors,dopamine HCl,advise,Patients_bf treated_bf MAO_bf inhibitors_bf within_bf two_bf three_bf weeks_bf prior_bf administration_bf dopamine_bf HCl_bf receive_bf initial_bf doses_bf dopamine_bf HCl_bf greater_bf one-tenth_bf (1/10)_bf usual_bf dose_bf ._bf
1517,Concurrent administration of low-dose dopamine HCl and diuretic agents may produce an additive or potentiating effect on urine flow.,dopamine HCl,diuretic agents,effect,Concurrent_bf administration_bf low-dose_bf dopamine_bf HCl_bf diuretic_bf agents_bf may_bf produce_bf additive_bf potentiating_bf effect_bf urine_bf flow_bf ._bf
1518,"Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.",dopamine,beta-adrenergic blocking agents,effect,"Cardiac_bf effects_bf DRUG antagonized_be beta-adrenergic_be blocking_be agents_be ,_be propranolol_be metoprolol_be ._be"
1519,"Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.",dopamine,propranolol,effect,"Cardiac_bf effects_bf DRUG antagonized_be beta-adrenergic_be blocking_be agents_be ,_be OTHER_DRUG metoprolol_af ._af"
1520,"Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.",dopamine,metoprolol,effect,"Cardiac_bf effects_bf DRUG antagonized_be beta-adrenergic_be blocking_be agents_be ,_be propranolol_be OTHER_DRUG ._af"
1521,The peripheral vasoconstriction caused by high doses of dopamine HCl is antagonized by alpha-adrenergic blocking agents.,dopamine HCl,alpha-adrenergic blocking agents,effect,The_bf peripheral_bf vasoconstriction_bf caused_bf high_bf doses_bf dopamine_bf HCl_bf antagonized_bf alpha-adrenergic_bf blocking_bf agents_bf ._bf
1522,Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.,Butyrophenones,dopamine,effect,DRUG (such_be haloperidol)_be phenothiazines_be suppress_be dopaminergic_be renal_be mesenteric_be vasodilation_be induced_be low_be dose_be OTHER_DRUG infusion_af ._af
1523,Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.,haloperidol,dopamine,effect,Butyrophenones_bf (such_bf haloperidol)_bf phenothiazines_bf suppress_bf dopaminergic_bf renal_bf mesenteric_bf vasodilation_bf induced_bf low_bf dose_bf OTHER_DRUG infusion_be ._be
1524,Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.,phenothiazines,dopamine,effect,Butyrophenones_bf (such_bf haloperidol)_bf DRUG suppress_be dopaminergic_be renal_be mesenteric_be vasodilation_be induced_be low_be dose_be OTHER_DRUG infusion_af ._af
1525,"Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.",Cyclopropane,catecholamines,effect,"DRUG halogenated_be hydrocarbon_be anesthetics_be increase_be cardiac_be autonomic_be irritability_be may_be sensitize_be myocardium_be action_be certain_be intravenously_be administered_be OTHER_DRUG ,_af dopamine_af ._af"
1526,"Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.",Cyclopropane,dopamine,effect,"DRUG halogenated_be hydrocarbon_be anesthetics_be increase_be cardiac_be autonomic_be irritability_be may_be sensitize_be myocardium_be action_be certain_be intravenously_be administered_be catecholamines_be ,_be OTHER_DRUG ._af"
1527,"Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.",halogenated hydrocarbon anesthetics,catecholamines,effect,"Cyclopropane_bf halogenated_bf hydrocarbon_bf anesthetics_bf increase_bf cardiac_bf autonomic_bf irritability_bf may_bf sensitize_bf myocardium_bf action_bf certain_bf intravenously_bf administered_bf OTHER_DRUG ,_be dopamine_be ._be"
1528,"Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.",halogenated hydrocarbon anesthetics,dopamine,effect,"Cyclopropane_bf halogenated_bf hydrocarbon_bf anesthetics_bf increase_bf cardiac_bf autonomic_bf irritability_bf may_bf sensitize_bf myocardium_bf action_bf certain_bf intravenously_bf administered_bf catecholamines_bf ,_bf OTHER_DRUG ._be"
1529,"Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.",dopamine HCl,cyclopropane,advise,"Therefore_bf ,_bf EXTREME_bf CAUTION_bf exercised_bf administering_bf dopamine_bf HCl_bf patients_bf receiving_bf OTHER_DRUG halogenated_be hydrocarbon_be anesthetics_be ._be"
1530,"Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.",dopamine HCl,halogenated hydrocarbon anesthetics,advise,"Therefore_bf ,_bf EXTREME_bf CAUTION_bf exercised_bf administering_bf dopamine_bf HCl_bf patients_bf receiving_bf cyclopropane_bf halogenated_bf hydrocarbon_bf anesthetics_bf ._bf"
1531,It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol.,dopamine,propranolol,effect,It_bf reported_bf results_bf studies_bf animals_bf indicate_bf dopamine-induced_bf ventricular_bf arrhythmias_bf anesthesia_bf reversed_bf OTHER_DRUG ._be
1532,"The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.",vasopressor,oxytocic drugs,effect,"The_bf concomitant_bf use_bf vasopressors_bf ,_bf vasoconstricting_bf agents_bf (such_bf ergonovine)_bf oxytocic_bf drugs_bf may_bf result_bf severe_bf hypertension_bf ._bf"
1533,"The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.",ergonovine,oxytocic drugs,effect,"The_bf concomitant_bf use_bf vasopressors_bf ,_bf vasoconstricting_bf agents_bf (such_bf ergonovine)_bf oxytocic_bf drugs_bf may_bf result_bf severe_bf hypertension_bf ._bf"
1534,Administration of phenytoin to patients receiving dopamine HCl has been reported to lead to hypotension and bradycardia.,phenytoin,dopamine HCl,effect,Administration_bf DRUG patients_be receiving_be dopamine_be HCl_be reported_be lead_be hypotension_be bradycardia_be ._be
1535,"It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.",dopamine HCl,phenytoin,advise,"It_bf suggested_bf patients_bf receiving_bf dopamine_bf HCl_bf ,_bf alternatives_bf OTHER_DRUG used_be anticonvulsant_be therapy_be needed_be ._be"
1536,"Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy).",dorzolamide,carbonic anhydrase inhibitors,effect,"Although_bf acid-base_bf electrolyte_bf disturbances_bf reported_bf clinical_bf trials_bf DRUG ,_be disturbances_be reported_be oral_be carbonic_be anhydrase_be inhibitors_be ,_be instances_be ,_be resulted_be drug_be interactions_be (e_be ._be g_be ._be ,_be toxicity_be associated_be high-dose_be salicylate_be therapy)_be ._be"
1537,"Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.",Isoflurane,NUROMAX,mechanism,"DRUG ,_be enflurane_be ,_be halothane_be decrease_be ED50_be OTHER_DRUG 30%_af 45%_af ._af"
1538,"Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.",enflurane,NUROMAX,mechanism,"Isoflurane_bf ,_bf DRUG ,_be halothane_be decrease_be ED50_be OTHER_DRUG 30%_af 45%_af ._af"
1539,"Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.",halothane,NUROMAX,mechanism,"Isoflurane_bf ,_bf enflurane_bf ,_bf DRUG decrease_be ED50_be OTHER_DRUG 30%_af 45%_af ._af"
1540,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,antibiotics,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be OTHER_DRUG (e_af ._af g_af ._af ,_af aminoglycosides_af ,_af tetracyclines_af ,_af bacitracin_af ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1541,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,aminoglycosides,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af tetracyclines_af ,_af bacitracin_af ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1542,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,tetracyclines,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be OTHER_DRUG ,_af bacitracin_af ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1543,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,bacitracin,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be OTHER_DRUG ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1544,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,polymyxins,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be OTHER_DRUG ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1545,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,lincomycin,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be OTHER_DRUG ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1546,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,clindamycin,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be OTHER_DRUG ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1547,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,colistin,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be OTHER_DRUG ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1548,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,sodium colistimethate,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1549,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,magnesium,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be OTHER_DRUG salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1550,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,lithium,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be OTHER_DRUG ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1551,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,anesthetics,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be OTHER_DRUG ,_af procainamide_af ,_af quinidine_af ._af"
1552,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,procainamide,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
1553,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,quinidine,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be OTHER_DRUG ._af"
1554,"As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.",nondepolarizing neuromuscular blocking agents,phenytoin,effect,"As_bf nondepolarizing_bf neuromuscular_bf blocking_bf agents_bf ,_bf time_bf onset_bf neuromuscular_bf block_bf induced_bf NUROMAX_bf lengthened_bf duration_bf block_bf shortened_bf patients_bf receiving_bf OTHER_DRUG carbamazepine_be ._be"
1555,"As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.",nondepolarizing neuromuscular blocking agents,carbamazepine,effect,"As_bf nondepolarizing_bf neuromuscular_bf blocking_bf agents_bf ,_bf time_bf onset_bf neuromuscular_bf block_bf induced_bf NUROMAX_bf lengthened_bf duration_bf block_bf shortened_bf patients_bf receiving_bf phenytoin_bf OTHER_DRUG ._be"
1556,"As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.",NUROMAX,phenytoin,effect,"As_bf nondepolarizing_bf neuromuscular_bf blocking_bf agents_bf ,_bf time_bf onset_bf neuromuscular_bf block_bf induced_bf DRUG lengthened_be duration_be block_be shortened_be patients_be receiving_be OTHER_DRUG carbamazepine_af ._af"
1557,"As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.",NUROMAX,carbamazepine,effect,"As_bf nondepolarizing_bf neuromuscular_bf blocking_bf agents_bf ,_bf time_bf onset_bf neuromuscular_bf block_bf induced_bf DRUG lengthened_be duration_be block_be shortened_be patients_be receiving_be phenytoin_be OTHER_DRUG ._af"
1558,Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .,doxapram,sympathomimetic,effect,Administration_bf DRUG patients_be receiving_be OTHER_DRUG monoamine_af oxidase_af inhibiting_af drugs_af may_af result_af additive_af pressor_af effect_af ._af
1559,Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .,doxapram,monoamine oxidase inhibiting drugs,effect,Administration_bf DRUG patients_be receiving_be sympathomimetic_be monoamine_be oxidase_be inhibiting_be drugs_be may_be result_be additive_be pressor_be effect_be ._be
1560,"In patients who have received muscle relaxants, doxapram may temporarily mask the residual effects of muscle relaxant drugs.",doxapram,muscle relaxant drugs,effect,"In_bf patients_bf received_bf muscle_bf relaxants_bf ,_bf DRUG may_be temporarily_be mask_be residual_be effects_be muscle_be relaxant_be drugs_be ._be"
1561,"In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.",doxazosin,cimetidine,mechanism,"In_bf placebo-controlled_bf trial_bf normal_bf volunteers_bf ,_bf administration_bf single_bf 1_bf mg_bf dose_bf DRUG day_be 1_be four-day_be regimen_be oral_be OTHER_DRUG (400_af mg_af twice_af daily)_af resulted_af 10%_af increase_af mean_af AUC_af DRUG (p=0_af ._af 006)_af ,_af slight_af statistically_af significant_af increase_af mean_af Cmax_af mean_af half-life_af DRUG ._af"
1562,"Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.",tetracyclines,anticoagulant,advise,"Because_bf DRUG shown_be depress_be plasma_be prothrombin_be activity_be ,_be patients_be OTHER_DRUG therapy_af may_af require_af downward_af adjustment_af OTHER_DRUG dosage_af ._af"
1563,"Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.",tetracyclines,penicillin,advise,"Since_bf bacteriostatic_bf drugs_bf may_bf interfere_bf bactericidal_bf action_bf OTHER_DRUG ,_be advisable_be avoid_be giving_be DRUG conjunction_af OTHER_DRUG ._af"
1564,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.",tetracyclines,aluminum,mechanism,"Absorption_bf DRUG impaired_be antacids_be containing_be OTHER_DRUG ,_af calcium_af ,_af magnesium_af ,_af iron-containing_af preparations_af ._af"
1565,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.",tetracyclines,calcium,mechanism,"Absorption_bf DRUG impaired_be antacids_be containing_be aluminum_be ,_be OTHER_DRUG ,_af magnesium_af ,_af iron-containing_af preparations_af ._af"
1566,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.",tetracyclines,magnesium,mechanism,"Absorption_bf DRUG impaired_be antacids_be containing_be aluminum_be ,_be calcium_be ,_be OTHER_DRUG ,_af iron-containing_af preparations_af ._af"
1567,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.",tetracyclines,iron,mechanism,"Absorption_bf DRUG impaired_be antacids_be containing_be aluminum_be ,_be calcium_be ,_be magnesium_be ,_be iron-containing_be preparations_be ._be"
1568,Absorption of tetracycline is impaired by bismuth subsalicylate.,tetracycline,bismuth subsalicylate,mechanism,Absorption_bf DRUG impaired_be bismuth_be subsalicylate_be ._be
1569,"Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.",Barbiturates,doxycycline,mechanism,"DRUG ,_be carbamazepine_be ,_be phenytoin_be decrease_be half-life_be OTHER_DRUG ._af"
1570,"Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.",carbamazepine,doxycycline,mechanism,"Barbiturates_bf ,_bf DRUG ,_be phenytoin_be decrease_be half-life_be OTHER_DRUG ._af"
1571,"Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.",phenytoin,doxycycline,mechanism,"Barbiturates_bf ,_bf carbamazepine_bf ,_bf DRUG decrease_be half-life_be OTHER_DRUG ._af"
1572,The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.,tetracycline,Penthrane,effect,The_bf concurrent_bf use_bf DRUG OTHER_DRUG (methoxyflurane)_af reported_af result_af fatal_af renal_af toxicity_af ._af
1573,The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.,tetracycline,methoxyflurane,effect,The_bf concurrent_bf use_bf DRUG Penthrane_be (methoxyflurane)_be reported_be result_be fatal_be renal_be toxicity_be ._be
1574,Concurrent use of tetracycline may render oral contraceptives less effective.,tetracycline,contraceptives,effect,Concurrent_bf use_bf DRUG may_be render_be oral_be OTHER_DRUG less_af effective_af ._af
1575,"Potential drug interactions for doxylamine include, increased sedation if doxylamine is combined with other CNS depressant drugs.",doxylamine,CNS depressant drugs,effect,"Potential_bf drug_bf interactions_bf DRUG include_be ,_be increased_be sedation_be DRUG combined_af CNS_af depressant_af drugs_af ._af"
1576,Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin.,Antihistamines,heparin,effect,DRUG may_be partially_be counteract_be anticoagulation_be effects_be OTHER_DRUG warfarin_af ._af
1577,Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin.,Antihistamines,warfarin,effect,DRUG may_be partially_be counteract_be anticoagulation_be effects_be heparin_be OTHER_DRUG ._af
1578,Doxylamine may enhance the effects of epinephrine.,Doxylamine,epinephrine,effect,DRUG may_be enhance_be effects_be OTHER_DRUG ._af
1579,Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.,oxyphenbutazone,androgens,mechanism,Concurrent_bf administration_bf DRUG OTHER_DRUG may_af result_af elevated_af serum_af levels_af DRUG ._af
1580,"In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.",androgens,insulin,effect,"In_bf diabetic_bf patients_bf ,_bf metabolic_bf effects_bf DRUG may_be decrease_be blood_be glucose_be therefore_be ,_be OTHER_DRUG requirements_af ._af"
1581,"Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.",CNS depressant drugs,INAPSINE,effect,"Other_bf CNS_bf depressant_bf drugs_bf (e_bf ._bf g_bf ._bf barbiturates_bf ,_bf tranquilizers_bf ,_bf opioids_bf general_bf anesthetics)_bf additive_bf potentiating_bf effects_bf OTHER_DRUG ._be"
1582,"Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.",barbiturates,INAPSINE,effect,"Other_bf CNS_bf depressant_bf drugs_bf (e_bf ._bf g_bf ._bf DRUG ,_be tranquilizers_be ,_be opioids_be general_be anesthetics)_be additive_be potentiating_be effects_be OTHER_DRUG ._af"
1583,"Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.",tranquilizers,INAPSINE,effect,"Other_bf CNS_bf depressant_bf drugs_bf (e_bf ._bf g_bf ._bf barbiturates_bf ,_bf DRUG ,_be opioids_be general_be anesthetics)_be additive_be potentiating_be effects_be OTHER_DRUG ._af"
1584,"Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.",opioids,INAPSINE,effect,"Other_bf CNS_bf depressant_bf drugs_bf (e_bf ._bf g_bf ._bf barbiturates_bf ,_bf tranquilizers_bf ,_bf DRUG general_be anesthetics)_be additive_be potentiating_be effects_be OTHER_DRUG ._af"
1585,"Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.",anesthetics,INAPSINE,effect,"Other_bf CNS_bf depressant_bf drugs_bf (e_bf ._bf g_bf ._bf barbiturates_bf ,_bf tranquilizers_bf ,_bf opioids_bf general_bf anesthetics)_bf additive_bf potentiating_bf effects_bf OTHER_DRUG ._be"
1586,"Following the administration of INAPSINE, the dose of other CNS depressant drugs should be reduced.",INAPSINE,CNS depressant drugs,advise,"Following_bf administration_bf DRUG ,_be dose_be CNS_be depressant_be drugs_be reduced_be ._be"
1587,"Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.",duloxetine,fluvoxamine,mechanism,"Inhibitors_bf CYP1A2:_bf Concomitant_bf use_bf DRUG OTHER_DRUG ,_af inhibitor_af CYP1A2_af ,_af results_af approximately_af 6-fold_af increase_af AUC_af 2_af ._af 5-fold_af increase_af Cmax_af DRUG ._af"
1588,"Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.",Paroxetine,duloxetine,mechanism,"DRUG (20_be mg_be QD)_be increased_be concentration_be OTHER_DRUG (40_af mg_af QD)_af 60%_af ,_af greater_af degrees_af inhibition_af expected_af higher_af doses_af DRUG ._af"
1589,"When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.",duloxetine,desipramine,mechanism,"When_bf DRUG administered_be (at_be dose_be 60_be mg_be BID)_be conjunction_be single_be 50-mg_be dose_be OTHER_DRUG ,_af CYP2D6_af substrate_af ,_af AUC_af OTHER_DRUG increased_af 3-fold_af ._af"
1590,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,antidepressants,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be extensively_be metabolized_be isozyme_be narrow_be therapeutic_be index_be ,_be including_be certain_be OTHER_DRUG (tricyclic_af OTHER_DRUG [TCAs]_af ,_af nortriptyline_af ,_af amitriptyline_af ,_af imipramine)_af ,_af phenothiazines_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af ._af"
1591,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,tricyclic antidepressants,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be extensively_be metabolized_be isozyme_be narrow_be therapeutic_be index_be ,_be including_be certain_be antidepressants_be (tricyclic_be antidepressants_be [TCAs]_be ,_be nortriptyline_be ,_be amitriptyline_be ,_be imipramine)_be ,_be phenothiazines_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide)_be ,_be approached_be caution_be ._be"
1592,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,TCAs,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be extensively_be metabolized_be isozyme_be narrow_be therapeutic_be index_be ,_be including_be certain_be antidepressants_be (tricyclic_be antidepressants_be [TCAs]_be ,_be nortriptyline_be ,_be amitriptyline_be ,_be imipramine)_be ,_be phenothiazines_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide)_be ,_be approached_be caution_be ._be"
1593,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,nortriptyline,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be extensively_be metabolized_be isozyme_be narrow_be therapeutic_be index_be ,_be including_be certain_be antidepressants_be (tricyclic_be antidepressants_be [TCAs]_be ,_be OTHER_DRUG ,_af amitriptyline_af ,_af imipramine)_af ,_af phenothiazines_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af ._af"
1594,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,amitriptyline,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be extensively_be metabolized_be isozyme_be narrow_be therapeutic_be index_be ,_be including_be certain_be antidepressants_be (tricyclic_be antidepressants_be [TCAs]_be ,_be nortriptyline_be ,_be OTHER_DRUG ,_af imipramine)_af ,_af phenothiazines_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af ._af"
1595,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,imipramine,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be extensively_be metabolized_be isozyme_be narrow_be therapeutic_be index_be ,_be including_be certain_be antidepressants_be (tricyclic_be antidepressants_be [TCAs]_be ,_be nortriptyline_be ,_be amitriptyline_be ,_be imipramine)_be ,_be phenothiazines_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide)_be ,_be approached_be caution_be ._be"
1596,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,phenothiazines,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be extensively_be metabolized_be isozyme_be narrow_be therapeutic_be index_be ,_be including_be certain_be antidepressants_be (tricyclic_be antidepressants_be [TCAs]_be ,_be nortriptyline_be ,_be amitriptyline_be ,_be imipramine)_be ,_be OTHER_DRUG Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af ._af"
1597,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,Type 1C antiarrhythmics,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be extensively_be metabolized_be isozyme_be narrow_be therapeutic_be index_be ,_be including_be certain_be antidepressants_be (tricyclic_be antidepressants_be [TCAs]_be ,_be nortriptyline_be ,_be amitriptyline_be ,_be imipramine)_be ,_be phenothiazines_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide)_be ,_be approached_be caution_be ._be"
1598,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,propafenone,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be extensively_be metabolized_be isozyme_be narrow_be therapeutic_be index_be ,_be including_be certain_be antidepressants_be (tricyclic_be antidepressants_be [TCAs]_be ,_be nortriptyline_be ,_be amitriptyline_be ,_be imipramine)_be ,_be phenothiazines_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af flecainide)_af ,_af approached_af caution_af ._af"
1599,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,flecainide,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be extensively_be metabolized_be isozyme_be narrow_be therapeutic_be index_be ,_be including_be certain_be antidepressants_be (tricyclic_be antidepressants_be [TCAs]_be ,_be nortriptyline_be ,_be amitriptyline_be ,_be imipramine)_be ,_be phenothiazines_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide)_be ,_be approached_be caution_be ._be"
1600,Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Duloxetine.,TCA,Duloxetine,advise,Plasma_bf DRUG concentrations_be may_be need_be monitored_be dose_be DRUG may_af need_af reduced_af DRUG co-administered_af OTHER_DRUG ._af
1601,"Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, Duloxetine and thioridazine should not be co-administered.",Duloxetine,thioridazine,advise,"Because_bf risk_bf serious_bf ventricular_bf arrhythmias_bf sudden_bf death_bf potentially_bf associated_bf elevated_bf plasma_bf levels_bf OTHER_DRUG ,_be DRUG OTHER_DRUG co-administered_af ._af"
1602,"Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.",xanthine bronchodilators,sympathomimetic bronchodilators,effect,"Synergism_bf xanthine_bf bronchodilators_bf (e_bf ._bf g_bf ._bf ,_bf theophylline)_bf ,_bf ephedrine_bf ,_bf sympathomimetic_bf bronchodilators_bf reported_bf ._bf"
1603,"Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.",theophylline,sympathomimetic bronchodilators,effect,"Synergism_bf xanthine_bf bronchodilators_bf (e_bf ._bf g_bf ._bf ,_bf theophylline)_bf ,_bf ephedrine_bf ,_bf sympathomimetic_bf bronchodilators_bf reported_bf ._bf"
1604,"Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.",ephedrine,sympathomimetic bronchodilators,effect,"Synergism_bf xanthine_bf bronchodilators_bf (e_bf ._bf g_bf ._bf ,_bf theophylline)_bf ,_bf DRUG ,_be sympathomimetic_be bronchodilators_be reported_be ._be"
1605,"Concurrent administration of dyphylline and probenecid, which competes for tubular secretion, has been shown to increase the plasma half-life of dyphylline .",dyphylline,probenecid,mechanism,"Concurrent_bf administration_bf DRUG OTHER_DRUG ,_af competes_af tubular_af secretion_af ,_af shown_af increase_af plasma_af half-life_af DRUG ._af"
1606,Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7,Steroids,edetate calcium disodium,effect,DRUG enhance_be renal_be toxicity_be edetate_be calcium_be disodium_be animals_be ._be 7_be Edetate_be calcium_be disodium_be interferes_be action_be zinc_be insulin_be preparations_be chelating_be zinc_be ._be 7_be
1607,Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7,Edetate calcium disodium,zinc insulin,mechanism,Steroids_bf enhance_bf renal_bf toxicity_bf edetate_bf calcium_bf disodium_bf animals_bf ._bf 7_bf Edetate_bf calcium_bf disodium_bf interferes_bf action_bf zinc_bf insulin_bf preparations_bf chelating_bf zinc_bf ._bf 7_bf
1608,RAPTIVA should not be used with other immunosuppressive drugs.,RAPTIVA,immunosuppressive drugs,advise,DRUG used_be immunosuppressive_be drugs_be ._be
1609,"Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.",Acellular vaccines,RAPTIVA,advise,"Acellular_bf ,_bf live_bf live-attenuated_bf vaccines_bf administered_bf OTHER_DRUG treatment_be ._be"
1610,"Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.",live vaccines,RAPTIVA,advise,"Acellular_bf ,_bf live_bf live-attenuated_bf vaccines_bf administered_bf OTHER_DRUG treatment_be ._be"
1611,"Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.",live-attenuated vaccines,RAPTIVA,advise,"Acellular_bf ,_bf live_bf live-attenuated_bf vaccines_bf administered_bf OTHER_DRUG treatment_be ._be"
1612,"Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.",phenobarbital,efavirenz,mechanism,"Drugs_bf induce_bf CYP3A4_bf activity_bf (eg_bf ,_bf DRUG ,_be rifampin_be ,_be rifabutin)_be would_be expected_be increase_be clearance_be OTHER_DRUG resulting_af lowered_af plasma_af concentrations_af ._af"
1613,"Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.",rifampin,efavirenz,mechanism,"Drugs_bf induce_bf CYP3A4_bf activity_bf (eg_bf ,_bf phenobarbital_bf ,_bf DRUG ,_be rifabutin)_be would_be expected_be increase_be clearance_be OTHER_DRUG resulting_af lowered_af plasma_af concentrations_af ._af"
1614,"Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.",rifabutin,efavirenz,mechanism,"Drugs_bf induce_bf CYP3A4_bf activity_bf (eg_bf ,_bf phenobarbital_bf ,_bf rifampin_bf ,_bf rifabutin)_bf would_bf expected_bf increase_bf clearance_bf OTHER_DRUG resulting_be lowered_be plasma_be concentrations_be ._be"
1615,"In uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin.",SUSTIVA,clarithromycin,effect,"In_bf uninfected_bf volunteers_bf ,_bf 46%_bf developed_bf rash_bf receiving_bf DRUG OTHER_DRUG ._af"
1616,Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.,indinavir,SUSTIVA,mechanism,Increasing_bf DRUG dose_be 1000_be mg_be every_be 8_be hours_be compensate_be increased_be DRUG metabolism_af due_af OTHER_DRUG ._af
1617,"When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.",indinavir,SUSTIVA,mechanism,"When_bf DRUG increased_be dose_be (1000_be mg_be every_be 8_be hours)_be given_be OTHER_DRUG (600_af mg_af daily)_af ,_af DRUG AUC_af Cmin_af decreased_af average_af 33-46%_af 39-57%_af ,_af respectively_af ,_af compared_af DRUG (800_af mg_af every_af 8_af hours)_af given_af alone_af ._af"
1618,A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.,lopinavir,SUSTIVA,advise,A_bf dose_bf increase_bf lopinavir/ritonavir_bf 533/133_bf mg_bf (4_bf capsules_bf 6_bf ._bf 5_bf mL)_bf twice_bf daily_bf taken_bf food_bf recommended_bf used_bf combination_bf OTHER_DRUG ._be
1619,A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.,ritonavir,SUSTIVA,advise,A_bf dose_bf increase_bf lopinavir/ritonavir_bf 533/133_bf mg_bf (4_bf capsules_bf 6_bf ._bf 5_bf mL)_bf twice_bf daily_bf taken_bf food_bf recommended_bf used_bf combination_bf OTHER_DRUG ._be
1620,"Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives.",efavirenz,contraceptives,advise,"Because_bf potential_bf interaction_bf DRUG oral_be OTHER_DRUG fully_af characterized_af ,_af reliable_af method_af barrier_af contraception_af used_af addition_af oral_af OTHER_DRUG ._af"
1621,Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.,SUSTIVA,ritonavir,advise,Monitoring_bf liver_bf enzymes_bf recommended_bf DRUG used_be combination_be OTHER_DRUG ._af
1622,Potential for reduction in anticonvulsant and/or efavirenz plasma levels;,anticonvulsant,efavirenz,mechanism,Potential_bf reduction_bf DRUG and/or_be OTHER_DRUG plasma_af levels;_af
1623,SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.,SUSTIVA,itraconazole,mechanism,DRUG potential_be decrease_be plasma_be concentrations_be OTHER_DRUG ketoconazole_af ._af
1624,SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.,SUSTIVA,ketoconazole,mechanism,DRUG potential_be decrease_be plasma_be concentrations_be itraconazole_be OTHER_DRUG ._af
1625,"Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.",diuretics,enalapril,effect,"Hypotension:_bf Patients_bf Diuretic_bf Therapy:_bf Patients_bf DRUG especially_be diuretic_be therapy_be recently_be instituted_be ,_be may_be occasionally_be experience_be excessive_be reduction_be blood_be pressure_be initiation_be therapy_be OTHER_DRUG enalaprilat_af ._af"
1626,"Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.",diuretics,enalaprilat,effect,"Hypotension:_bf Patients_bf Diuretic_bf Therapy:_bf Patients_bf DRUG especially_be diuretic_be therapy_be recently_be instituted_be ,_be may_be occasionally_be experience_be excessive_be reduction_be blood_be pressure_be initiation_be therapy_be enalapril_be OTHER_DRUG ._af"
1627,The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.,enalapril,diuretic,effect,The_bf possibility_bf hypotensive_bf effects_bf DRUG enalaprilat_be minimized_be either_be discontinuing_be OTHER_DRUG increasing_af salt_af intake_af prior_af initiation_af treatment_af DRUG enalaprilat_af ._af
1628,The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.,enalaprilat,diuretic,effect,The_bf possibility_bf hypotensive_bf effects_bf enalapril_bf DRUG minimized_be either_be discontinuing_be OTHER_DRUG increasing_af salt_af intake_af prior_af initiation_af treatment_af enalapril_af DRUG ._af
1629,"Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).",enalapril,antihypertensive agents,effect,"Agents_bf Causing_bf Renin_bf Release:_bf The_bf antihypertensive_bf effect_bf DRUG DRUG IV_af augmented_af antihypertensive_af agents_af cause_af renin_af release_af (e_af ._af g_af ._af ,_af diuretics)_af ._af"
1630,"Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).",enalapril,diuretics,effect,"Agents_bf Causing_bf Renin_bf Release:_bf The_bf antihypertensive_bf effect_bf DRUG DRUG IV_af augmented_af antihypertensive_af agents_af cause_af renin_af release_af (e_af ._af g_af ._af ,_af diuretics)_af ._af"
1631,"Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).",enalapril,antihypertensive agents,effect,"Agents_bf Causing_bf Renin_bf Release:_bf The_bf antihypertensive_bf effect_bf DRUG DRUG IV_af augmented_af antihypertensive_af agents_af cause_af renin_af release_af (e_af ._af g_af ._af ,_af diuretics)_af ._af"
1632,"Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).",enalapril,diuretics,effect,"Agents_bf Causing_bf Renin_bf Release:_bf The_bf antihypertensive_bf effect_bf DRUG DRUG IV_af augmented_af antihypertensive_af agents_af cause_af renin_af release_af (e_af ._af g_af ._af ,_af diuretics)_af ._af"
1633,"Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of enalapril may result in a further deterioration of renal function.",nonsteroidal anti-inflammatory drugs,enalapril,effect,"Non-steroidal_bf Anti-inflammatory_bf Agents:_bf In_bf patients_bf compromised_bf renal_bf function_bf treated_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf ,_bf co-administration_bf OTHER_DRUG may_be result_be deterioration_be renal_be function_be ._be"
1634,"However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.",NSAIDs,ACE inhibitors,effect,"However_bf ,_bf reports_bf suggest_bf DRUG may_be diminish_be antihypertensive_be effect_be ACE_be inhibitors_be ._be"
1635,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.,NSAIDs,ACE inhibitors,advise,This_bf interaction_bf given_bf consideration_bf patients_bf taking_bf DRUG concomitantly_be ACE_be inhibitors_be ._be
1636,Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.,Enalapril,thiazide-type diuretics,effect,Agents_bf Increasing_bf Serum_bf Potassium:_bf DRUG DRUG IV_af attenuate_af potassium_af loss_af caused_af thiazide-type_af diuretics_af ._af
1637,Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.,enalapril,thiazide-type diuretics,effect,Agents_bf Increasing_bf Serum_bf Potassium:_bf DRUG DRUG IV_af attenuate_af potassium_af loss_af caused_af thiazide-type_af diuretics_af ._af
1638,"Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.",lithium,ACE inhibitors,effect,"Lithium:_bf DRUG toxicity_be reported_be patients_be receiving_be DRUG concomitantly_af drugs_af cause_af elimination_af sodium_af ,_af including_af ACE_af inhibitors_af ._af"
1639,It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.,enalapril,lithium,advise,It_bf recommended_bf serum_bf OTHER_DRUG levels_be monitored_be frequently_be DRUG administered_af concomitantly_af OTHER_DRUG ._af
1640,"Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.",Bismuth subsalicylate,enoxacin,mechanism,"Bismuth:_bf Bismuth_bf subsalicylate_bf ,_bf given_bf concomitantly_bf OTHER_DRUG 60_be minutes_be following_be OTHER_DRUG administration_af ,_af decreased_af OTHER_DRUG bioavailability_af approximately_af 25%_af ._af"
1641,"Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.",enoxacin,bismuth subsalicylate,advise,"Thus_bf ,_bf concomitant_bf administration_bf DRUG bismuth_be subsalicylate_be avoided_be ._be"
1642,Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.,Enoxacin,methylxanthines,mechanism,Caffeine:_bf DRUG potent_be inhibitor_be cytochrome_be P-450_be isozymes_be responsible_be metabolism_be OTHER_DRUG ._af
1643,"In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.",enoxacin,caffeine,mechanism,"In_bf multiple-dose_bf study_bf ,_bf DRUG caused_be dose-related_be increase_be mean_be elimination_be half-life_be OTHER_DRUG ,_af thereby_af decreasing_af clearance_af OTHER_DRUG 80%_af leading_af five-fold_af increase_af AUC_af half-life_af OTHER_DRUG ._af"
1644,Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.,caffeine,enoxacin,mechanism,Trough_bf plasma_bf OTHER_DRUG levels_be also_be 20%_be higher_be DRUG OTHER_DRUG administered_af concomitantly_af ._af
1645,Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.,caffeine,enoxacin,effect,Caffeine-related_bf adverse_bf effects_bf occurred_bf patients_bf consuming_bf DRUG therapy_be OTHER_DRUG ._af
1646,Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.,cyclosporine,quinolone class,mechanism,Cyclosporine:_bf Elevated_bf serum_bf levels_bf DRUG reported_be concomitant_be use_be DRUG members_af quinolone_af class_af ._af
1647,Digoxin: Enoxacin may raise serum digoxin levels in some individuals.,Enoxacin,digoxin,mechanism,Digoxin:_bf DRUG may_be raise_be serum_be OTHER_DRUG levels_af individuals_af ._af
1648,"If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.",enoxacin,digoxin,effect,"If_bf signs_bf symptoms_bf suggestive_bf OTHER_DRUG toxicity_be occur_be DRUG OTHER_DRUG given_af concomitantly_af ,_af physicians_af advised_af obtain_af serum_af OTHER_DRUG levels_af adjust_af OTHER_DRUG doses_af appropriately_af ._af"
1649,Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.,enoxacin,fenbufen,effect,Non-steroidal_bf anti-inflammatory_bf agents:_bf Seizures_bf reported_bf patients_bf taking_bf DRUG concomitantly_be nonsteroidal_be anti-inflammatory_be drug_be OTHER_DRUG ._af
1650,or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.,zinc,quinolone,mechanism,multivitamins_bf containing_bf DRUG may_be substantially_be interfere_be drug_be absorption_be result_be insufficient_be plasma_be tissue_be OTHER_DRUG concentrations_af ._af
1651,Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.,aluminum hydroxide,enoxacin,mechanism,Antacids_bf containing_bf aluminum_bf hydroxide_bf magnesium_bf hydroxide_bf reduce_bf oral_bf absorption_bf OTHER_DRUG 75%_be ._be
1652,Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.,magnesium hydroxide,enoxacin,mechanism,Antacids_bf containing_bf aluminum_bf hydroxide_bf magnesium_bf hydroxide_bf reduce_bf oral_bf absorption_bf OTHER_DRUG 75%_be ._be
1653,The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.,enoxacin,ranitidine,mechanism,The_bf oral_bf bioavailability_bf DRUG reduced_be 60%_be coadministration_be OTHER_DRUG ._af
1654,Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.,Enoxacin,methylxanthines,mechanism,Theophylline:_bf DRUG potent_be inhibitor_be cytochrome_be P-450_be isozymes_be responsible_be metabolism_be OTHER_DRUG ._af
1655,Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.,Enoxacin,theophylline,mechanism,DRUG interferes_be metabolism_be OTHER_DRUG resulting_af 42%_af 74%_af dose-related_af decrease_af OTHER_DRUG clearance_af subsequent_af 260%_af 350%_af increase_af serum_af OTHER_DRUG levels_af ._af
1656,Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.,theophylline,enoxacin,effect,Theophylline-related_bf adverse_bf effects_bf occurred_bf patients_bf DRUG OTHER_DRUG coadministered_af ._af
1657,"Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.",Quinolones,R-warfarin,mechanism,"Warfarin:_bf DRUG ,_be including_be enoxacin_be ,_be decrease_be clearance_be OTHER_DRUG ,_af less_af active_af isomer_af racemic_af warfarin_af ._af"
1658,"Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.",enoxacin,R-warfarin,mechanism,"Warfarin:_bf Quinolones_bf ,_bf including_bf DRUG ,_be decrease_be clearance_be OTHER_DRUG ,_af less_af active_af isomer_af racemic_af warfarin_af ._af"
1659,"Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when warfarin or its derivatives and enoxacin are given concomitantly.",warfarin,enoxacin,advise,"Nevertheless_bf ,_bf prothrombin_bf time_bf suitable_bf coagulation_bf test_bf monitored_bf DRUG derivatives_be OTHER_DRUG given_af concomitantly_af ._af"
1660,All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.,vasopressors,monoamine oxidase (MAO) inhibitors,advise,All_bf DRUG used_be cautiously_be patients_be taking_be monoamine_be oxidase_be (MAO)_be inhibitors_be ._be
1661,Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.,Epinephrine,sympathomimetic drugs,advise,DRUG administered_be concomitantly_be sympathomimetic_be drugs_be (such_be isoproterenol)_be possible_be additive_be effects_be increased_be toxicity_be ._be
1662,Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.,Epinephrine,isoproterenol,advise,DRUG administered_be concomitantly_be sympathomimetic_be drugs_be (such_be isoproterenol)_be possible_be additive_be effects_be increased_be toxicity_be ._be
1663,"Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..",epinephrine,cyclopropane,effect,"Administration_bf DRUG patients_be receiving_be OTHER_DRUG halogenated_af hydrocarbon_af general_af anesthetics_af halothane_af sensitize_af myocardium_af ,_af may_af induce_af cardiac_af arrhythmia_af ._af ._af"
1664,"Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..",epinephrine,halogenated hydrocarbon general anesthetics,effect,"Administration_bf DRUG patients_be receiving_be cyclopropane_be halogenated_be hydrocarbon_be general_be anesthetics_be halothane_be sensitize_be myocardium_be ,_be may_be induce_be cardiac_be arrhythmia_be ._be ._be"
1665,"Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..",epinephrine,halothane,effect,"Administration_bf DRUG patients_be receiving_be cyclopropane_be halogenated_be hydrocarbon_be general_be anesthetics_be OTHER_DRUG sensitize_af myocardium_af ,_af may_af induce_af cardiac_af arrhythmia_af ._af ._af"
1666,"Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.",Epinephrine,digitalis,advise,"DRUG also_be used_be cautiously_be drugs_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af glycosides)_af sensitize_af myocardium_af actions_af sympathomimetic_af drugs_af ._af"
1667,"Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.",Epinephrine,glycosides,advise,"DRUG also_be used_be cautiously_be drugs_be (e_be ._be g_be ._be ,_be digitalis_be ,_be glycosides)_be sensitize_be myocardium_be actions_be sympathomimetic_be drugs_be ._be"
1668,Diuretic agents may decrease vascular response to pressor drugs such as epinephrine.,Diuretic agents,epinephrine,effect,Diuretic_bf agents_bf may_bf decrease_bf vascular_bf response_bf pressor_bf drugs_bf OTHER_DRUG ._be
1669,Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.,Epinephrine,guanethidine,effect,DRUG may_be antagonize_be neuron_be blockade_be produced_be OTHER_DRUG resulting_af decreased_af antihypertensive_af effect_af requiring_af increased_af dosage_af latter_af ._af
1670,"Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment.",ELLENCE,calcium channel blockers,advise,"Concomitant_bf use_bf DRUG cardioactive_be compounds_be could_be cause_be heart_be failure_be (e_be ._be g_be ._be ,_be calcium_be channel_be blockers)_be ,_be requires_be close_be monitoring_be cardiac_be function_be throughout_be treatment_be ._be"
1671,Cimetidine increased the AUC of epirubicin by 50%.,Cimetidine,epirubicin,mechanism,DRUG increased_be AUC_be OTHER_DRUG 50%_af ._af
1672,Cimetidine treatment should be stopped during treatment with ELLENCE.,Cimetidine,ELLENCE,advise,DRUG treatment_be stopped_be treatment_be OTHER_DRUG ._af
1673,"A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.",INSPRA,ketoconazole,mechanism,"A_bf pharmacokinetic_bf study_bf evaluating_bf administration_bf single_bf dose_bf DRUG 100_be mg_be OTHER_DRUG 200_af mg_af BID_af ,_af potent_af inhibitor_af CYP3A4_af pathway_af ,_af showed_af 1_af ._af 7-fold_af increase_af Cmax_af eplerenone_af 5_af ._af 4-fold_af increase_af AUC_af eplerenone_af ._af"
1674,"Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,erythromycin,mechanism,"Administration_bf DRUG CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be OTHER_DRUG 500_af mg_af BID_af ,_af verapamil_af 240_af mg_af QD_af ,_af saquinavir_af 1200_af mg_af TID_af ,_af fluconazole_af 200_af mg_af QD)_af resulted_af increases_af Cmax_af DRUG ranging_af 1_af ._af 4-_af 1_af ._af 6-_af fold_af AUC_af 2_af ._af 0-_af 2_af ._af 9-_af fold_af ._af"
1675,"Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,verapamil,mechanism,"Administration_bf DRUG CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be erythromycin_be 500_be mg_be BID_be ,_be OTHER_DRUG 240_af mg_af QD_af ,_af saquinavir_af 1200_af mg_af TID_af ,_af fluconazole_af 200_af mg_af QD)_af resulted_af increases_af Cmax_af DRUG ranging_af 1_af ._af 4-_af 1_af ._af 6-_af fold_af AUC_af 2_af ._af 0-_af 2_af ._af 9-_af fold_af ._af"
1676,"Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,saquinavir,mechanism,"Administration_bf DRUG CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be erythromycin_be 500_be mg_be BID_be ,_be verapamil_be 240_be mg_be QD_be ,_be OTHER_DRUG 1200_af mg_af TID_af ,_af fluconazole_af 200_af mg_af QD)_af resulted_af increases_af Cmax_af DRUG ranging_af 1_af ._af 4-_af 1_af ._af 6-_af fold_af AUC_af 2_af ._af 0-_af 2_af ._af 9-_af fold_af ._af"
1677,"Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,fluconazole,mechanism,"Administration_bf DRUG CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be erythromycin_be 500_be mg_be BID_be ,_be verapamil_be 240_be mg_be QD_be ,_be saquinavir_be 1200_be mg_be TID_be ,_be OTHER_DRUG 200_af mg_af QD)_af resulted_af increases_af Cmax_af DRUG ranging_af 1_af ._af 4-_af 1_af ._af 6-_af fold_af AUC_af 2_af ._af 0-_af 2_af ._af 9-_af fold_af ._af"
1678,"ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).",INSPRA,ACE inhibitors,effect,"ACE_bf Inhibitors_bf Angiotensin_bf II_bf Receptor_bf Antagonists_bf (Hypertension)-_bf In_bf clinical_bf studies_bf patients_bf hypertension_bf ,_bf addition_bf DRUG 50_be 100_be mg_be ACE_be inhibitors_be angiotensin_be II_be receptor_be antagonists_be increased_be mean_be serum_be potassium_be slightly_be (about_be 0_be ._be 09-0_be ._be 13_be mEq/L)_be ._be"
1679,"ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).",INSPRA,angiotensin II receptor antagonists,effect,"ACE_bf Inhibitors_bf Angiotensin_bf II_bf Receptor_bf Antagonists_bf (Hypertension)-_bf In_bf clinical_bf studies_bf patients_bf hypertension_bf ,_bf addition_bf DRUG 50_be 100_be mg_be ACE_be inhibitors_be angiotensin_be II_be receptor_be antagonists_be increased_be mean_be serum_be potassium_be slightly_be (about_be 0_be ._be 09-0_be ._be 13_be mEq/L)_be ._be"
1680,In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.,INSPRA,enalapril,effect,In_bf study_bf diabetics_bf microalbuminuria_bf DRUG 200_be mg_be combined_be ACE_be inhibitor_be OTHER_DRUG 10_af mg_af increased_af frequency_af hyperkalemia_af (serum_af potassium_af 5_af ._af 5_af mEq/L)_af 17%_af OTHER_DRUG alone_af 38%_af ._af
1681,Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.,INSPRA,lithium,advise,Serum_bf OTHER_DRUG levels_be monitored_be frequently_be DRUG administered_af concomitantly_af OTHER_DRUG ._af
1682,The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.,potassium-sparing antihypertensives,NSAIDs,effect,The_bf administration_bf potassium-sparing_bf antihypertensives_bf OTHER_DRUG shown_be reduce_be antihypertensive_be effect_be patients_be result_be severe_be hyperkalemia_be patients_be impaired_be renal_be function_be ._be
1683,"Therefore, when INSPRA and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.",INSPRA,NSAIDs,advise,"Therefore_bf ,_bf DRUG OTHER_DRUG used_af concomitantly_af ,_af patients_af observed_af determine_af whether_af desired_af effect_af blood_af pressure_af obtained_af ._af"
1684,"Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.",FLOLAN,diuretics,effect,"Additional_bf reductions_bf blood_bf pressure_bf may_bf occur_bf DRUG administered_be OTHER_DRUG ,_af antihypertensive_af agents_af ,_af vasodilators_af ._af"
1685,"Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.",FLOLAN,antihypertensive agents,effect,"Additional_bf reductions_bf blood_bf pressure_bf may_bf occur_bf DRUG administered_be diuretics_be ,_be antihypertensive_be agents_be ,_be vasodilators_be ._be"
1686,"Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.",FLOLAN,vasodilators,effect,"Additional_bf reductions_bf blood_bf pressure_bf may_bf occur_bf DRUG administered_be diuretics_be ,_be antihypertensive_be agents_be ,_be OTHER_DRUG ._af"
1687,"When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.",antiplatelet agents,FLOLAN,effect,"When_bf antiplatelet_bf agents_bf anticoagulants_bf used_bf concomitantly_bf ,_bf potential_bf OTHER_DRUG increase_be risk_be bleeding_be ._be"
1688,"When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.",anticoagulants,FLOLAN,effect,"When_bf antiplatelet_bf agents_bf DRUG used_be concomitantly_be ,_be potential_be OTHER_DRUG increase_af risk_af bleeding_af ._af"
1689,"In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",furosemide,FLOLAN,mechanism,"In_bf clinical_bf trials_bf ,_bf OTHER_DRUG used_be digoxin_be ,_be diuretics_be ,_be anticoagulants_be ,_be oral_be vasodilators_be ,_be supplemental_be oxygen_be ._be In_be pharmacokinetic_be substudy_be patients_be congestive_be heart_be failure_be receiving_be DRUG digoxin_af therapy_af OTHER_DRUG initiated_af ,_af apparent_af oral_af clearance_af values_af DRUG (n_af =_af 23)_af digoxin_af (n_af =_af 30)_af decreased_af 13%_af 15%_af ,_af respectively_af ,_af second_af day_af therapy_af returned_af baseline_af values_af day_af 87_af ._af"
1690,"In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",digoxin,FLOLAN,mechanism,"In_bf clinical_bf trials_bf ,_bf OTHER_DRUG used_be DRUG ,_af diuretics_af ,_af anticoagulants_af ,_af oral_af vasodilators_af ,_af supplemental_af oxygen_af ._af In_af pharmacokinetic_af substudy_af patients_af congestive_af heart_af failure_af receiving_af furosemide_af DRUG therapy_af OTHER_DRUG initiated_af ,_af apparent_af oral_af clearance_af values_af furosemide_af (n_af =_af 23)_af DRUG (n_af =_af 30)_af decreased_af 13%_af 15%_af ,_af respectively_af ,_af second_af day_af therapy_af returned_af baseline_af values_af day_af 87_af ._af"
1691,"However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.",digoxin,FLOLAN,mechanism,"However_bf ,_bf patients_bf DRUG may_be show_be elevations_be DRUG concentrations_af initiation_af therapy_af OTHER_DRUG ,_af may_af clinically_af significant_af patients_af prone_af DRUG toxicity_af ._af"
1692,"Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.",Mineral oil,fat-soluble vitamins,mechanism,"Mineral_bf oil_bf interferes_bf absorption_bf fat-soluble_bf vitamins_bf ,_bf including_bf vitamin_bf D_bf preparations_bf ._bf"
1693,"Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.",Mineral oil,vitamin D preparations,mechanism,"Mineral_bf oil_bf interferes_bf absorption_bf fat-soluble_bf vitamins_bf ,_bf including_bf vitamin_bf D_bf preparations_bf ._bf"
1694,Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia.,thiazide diuretics,ergocalciferol,effect,Administration_bf thiazide_bf diuretics_bf hypoparathyroid_bf patients_bf concurrently_bf treated_bf OTHER_DRUG may_be cause_be hypercalcemia_be ._be
1695,The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.,ERGOMAR,triacetyloleandomycin,mechanism,The_bf effects_bf DRUG may_be potentiated_be OTHER_DRUG inhibits_af metabolism_af ergotamine_af ._af
1696,The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.,triacetyloleandomycin,ergotamine,mechanism,The_bf effects_bf ERGOMAR_bf may_bf potentiated_bf DRUG inhibits_be metabolism_be OTHER_DRUG ._af
1697,The pressor effects of ERGOMAR and other vasoconstrictor drugs can combine to cause dangerous hypertension.,ERGOMAR,vasoconstrictor drugs,effect,The_bf pressor_bf effects_bf DRUG vasoconstrictor_be drugs_be combine_be cause_be dangerous_be hypertension_be ._be
1698,"When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.",probenecid,ertapenem,mechanism,"When_bf OTHER_DRUG co-administered_be DRUG (500_af mg_af p_af ._af ._af every_af 6_af hours)_af ,_af DRUG competes_af active_af tubular_af secretion_af reduces_af renal_af clearance_af OTHER_DRUG ._af"
1699,"Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.",ertapenem,probenecid,mechanism,"Based_bf total_bf DRUG concentrations_be ,_be OTHER_DRUG increased_af AUC_af 25%_af reduced_af plasma_af renal_af clearances_af 20%_af 35%_af ,_af respectively_af ._af"
1700,"Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.",probenecid,ertapenem,advise,"Because_bf small_bf effect_bf half-life_bf ,_bf coadministration_bf DRUG extend_be half-life_be OTHER_DRUG recommended_af ._af"
1701,Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.,Erythromycin,theophylline,effect,DRUG use_be patients_be receiving_be high_be doses_be OTHER_DRUG may_af associated_af increase_af serum_af OTHER_DRUG levels_af potential_af OTHER_DRUG toxicity_af ._af
1702,"In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.",theophylline,erythromycin,advise,"In_bf case_bf DRUG toxicity_be and/or_be elevated_be serum_be DRUG levels_af ,_af dose_af DRUG reduced_af patient_af receiving_af concomitant_af OTHER_DRUG therapy_af ._af"
1703,Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.,erythromycin,digoxin,mechanism,Concomitant_bf administration_bf DRUG OTHER_DRUG reported_af result_af elevated_af OTHER_DRUG serum_af levels_af ._af
1704,There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.,erythromycin,anticoagulants,effect,There_bf reports_bf increased_bf anticoagulant_bf effects_bf DRUG oral_be OTHER_DRUG used_af concomitantly_af ._af
1705,Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.,erythromycin,ergotamine,effect,Concurrent_bf use_bf DRUG OTHER_DRUG dihydroergotamine_af associated_af patients_af acute_af ergot_af toxicity_af characterized_af severe_af peripheral_af vasospasm_af dysesthesia_af ._af
1706,Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.,erythromycin,dihydroergotamine,effect,Concurrent_bf use_bf DRUG ergotamine_be OTHER_DRUG associated_af patients_af acute_af ergot_af toxicity_af characterized_af severe_af peripheral_af vasospasm_af dysesthesia_af ._af
1707,Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.,Erythromycin,triazolam,mechanism,DRUG reported_be decrease_be clearance_be OTHER_DRUG midazolam_af thus_af may_af increase_af pharmacologic_af effect_af benzodiazepines_af ._af
1708,Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.,Erythromycin,midazolam,mechanism,DRUG reported_be decrease_be clearance_be triazolam_be OTHER_DRUG thus_af may_af increase_af pharmacologic_af effect_af benzodiazepines_af ._af
1709,Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.,Erythromycin,benzodiazepines,effect,DRUG reported_be decrease_be clearance_be triazolam_be midazolam_be thus_be may_be increase_be pharmacologic_be effect_be OTHER_DRUG ._af
1710,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,carbamazepine,int,"There_bf reports_bf interactions_bf DRUG OTHER_DRUG ,_af cyclosporine_af ,_af tacrolimus_af ,_af hexobarbital_af ,_af phenytoin_af ,_af alfentanil_af ,_af cisapride_af ,_af disopyramide_af ,_af lovastatin_af ,_af bromocriptine_af ,_af valproate_af ,_af terfenadine_af ,_af astemizole_af ._af"
1711,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,cyclosporine,int,"There_bf reports_bf interactions_bf DRUG carbamazepine_be ,_be OTHER_DRUG ,_af tacrolimus_af ,_af hexobarbital_af ,_af phenytoin_af ,_af alfentanil_af ,_af cisapride_af ,_af disopyramide_af ,_af lovastatin_af ,_af bromocriptine_af ,_af valproate_af ,_af terfenadine_af ,_af astemizole_af ._af"
1712,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,tacrolimus,int,"There_bf reports_bf interactions_bf DRUG carbamazepine_be ,_be cyclosporine_be ,_be OTHER_DRUG ,_af hexobarbital_af ,_af phenytoin_af ,_af alfentanil_af ,_af cisapride_af ,_af disopyramide_af ,_af lovastatin_af ,_af bromocriptine_af ,_af valproate_af ,_af terfenadine_af ,_af astemizole_af ._af"
1713,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,hexobarbital,int,"There_bf reports_bf interactions_bf DRUG carbamazepine_be ,_be cyclosporine_be ,_be tacrolimus_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af alfentanil_af ,_af cisapride_af ,_af disopyramide_af ,_af lovastatin_af ,_af bromocriptine_af ,_af valproate_af ,_af terfenadine_af ,_af astemizole_af ._af"
1714,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,phenytoin,int,"There_bf reports_bf interactions_bf DRUG carbamazepine_be ,_be cyclosporine_be ,_be tacrolimus_be ,_be hexobarbital_be ,_be OTHER_DRUG ,_af alfentanil_af ,_af cisapride_af ,_af disopyramide_af ,_af lovastatin_af ,_af bromocriptine_af ,_af valproate_af ,_af terfenadine_af ,_af astemizole_af ._af"
1715,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,alfentanil,int,"There_bf reports_bf interactions_bf DRUG carbamazepine_be ,_be cyclosporine_be ,_be tacrolimus_be ,_be hexobarbital_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af cisapride_af ,_af disopyramide_af ,_af lovastatin_af ,_af bromocriptine_af ,_af valproate_af ,_af terfenadine_af ,_af astemizole_af ._af"
1716,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,cisapride,int,"There_bf reports_bf interactions_bf DRUG carbamazepine_be ,_be cyclosporine_be ,_be tacrolimus_be ,_be hexobarbital_be ,_be phenytoin_be ,_be alfentanil_be ,_be OTHER_DRUG ,_af disopyramide_af ,_af lovastatin_af ,_af bromocriptine_af ,_af valproate_af ,_af terfenadine_af ,_af astemizole_af ._af"
1717,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,disopyramide,int,"There_bf reports_bf interactions_bf DRUG carbamazepine_be ,_be cyclosporine_be ,_be tacrolimus_be ,_be hexobarbital_be ,_be phenytoin_be ,_be alfentanil_be ,_be cisapride_be ,_be OTHER_DRUG ,_af lovastatin_af ,_af bromocriptine_af ,_af valproate_af ,_af terfenadine_af ,_af astemizole_af ._af"
1718,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,lovastatin,int,"There_bf reports_bf interactions_bf DRUG carbamazepine_be ,_be cyclosporine_be ,_be tacrolimus_be ,_be hexobarbital_be ,_be phenytoin_be ,_be alfentanil_be ,_be cisapride_be ,_be disopyramide_be ,_be OTHER_DRUG ,_af bromocriptine_af ,_af valproate_af ,_af terfenadine_af ,_af astemizole_af ._af"
1719,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,bromocriptine,int,"There_bf reports_bf interactions_bf DRUG carbamazepine_be ,_be cyclosporine_be ,_be tacrolimus_be ,_be hexobarbital_be ,_be phenytoin_be ,_be alfentanil_be ,_be cisapride_be ,_be disopyramide_be ,_be lovastatin_be ,_be OTHER_DRUG ,_af valproate_af ,_af terfenadine_af ,_af astemizole_af ._af"
1720,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,valproate,int,"There_bf reports_bf interactions_bf DRUG carbamazepine_be ,_be cyclosporine_be ,_be tacrolimus_be ,_be hexobarbital_be ,_be phenytoin_be ,_be alfentanil_be ,_be cisapride_be ,_be disopyramide_be ,_be lovastatin_be ,_be bromocriptine_be ,_be OTHER_DRUG ,_af terfenadine_af ,_af astemizole_af ._af"
1721,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,terfenadine,int,"There_bf reports_bf interactions_bf DRUG carbamazepine_be ,_be cyclosporine_be ,_be tacrolimus_be ,_be hexobarbital_be ,_be phenytoin_be ,_be alfentanil_be ,_be cisapride_be ,_be disopyramide_be ,_be lovastatin_be ,_be bromocriptine_be ,_be valproate_be ,_be OTHER_DRUG ,_af astemizole_af ._af"
1722,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,astemizole,int,"There_bf reports_bf interactions_bf DRUG carbamazepine_be ,_be cyclosporine_be ,_be tacrolimus_be ,_be hexobarbital_be ,_be phenytoin_be ,_be alfentanil_be ,_be cisapride_be ,_be disopyramide_be ,_be lovastatin_be ,_be bromocriptine_be ,_be valproate_be ,_be terfenadine_be ,_be OTHER_DRUG ._af"
1723,Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.,Erythromycin,terfenadine,mechanism,DRUG reported_be significantly_be alter_be metabolism_be nonsedating_be antihistamines_be OTHER_DRUG astemizole_af taken_af concomitantly_af ._af
1724,Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.,Erythromycin,astemizole,mechanism,DRUG reported_be significantly_be alter_be metabolism_be nonsedating_be antihistamines_be terfenadine_be OTHER_DRUG taken_af concomitantly_af ._af
1725,"In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.",terfenadine,erythromycin,effect,"In_bf addition_bf ,_bf deaths_bf reported_bf rarely_bf concomitant_bf administration_bf DRUG OTHER_DRUG ._af"
1726,"There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.",erythromycin,cisapride,effect,"There_bf postmarketing_bf reports_bf drug_bf interactions_bf DRUG coadministered_be OTHER_DRUG ,_af resulting_af QT_af prolongation_af ,_af cardiac_af arrythmias_af ,_af ventricular_af tachycardia_af ,_af ventricular_af fibrulation_af ,_af torsades_af de_af pointes_af ,_af like_af due_af inhibition_af hepatic_af metabolism_af OTHER_DRUG DRUG ._af"
1727,"There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.",cisapride,erythromycin,mechanism,"There_bf postmarketing_bf reports_bf drug_bf interactions_bf OTHER_DRUG coadministered_be DRUG ,_af resulting_af QT_af prolongation_af ,_af cardiac_af arrythmias_af ,_af ventricular_af tachycardia_af ,_af ventricular_af fibrulation_af ,_af torsades_af de_af pointes_af ,_af like_af due_af inhibition_af hepatic_af metabolism_af DRUG OTHER_DRUG ._af"
1728,Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;,lovastatin,erythromycin,advise,Patients_bf receiving_bf concomitant_bf DRUG OTHER_DRUG carefully_af monitored;_af
1729,"Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.",psychotropic medications,LEXAPRO,advise,"Alcohol_bf -_bf Although_bf OTHER_DRUG potentiate_be cognitive_be motor_be effects_be alcohol_be clinical_be trial_be ,_be psychotropic_be medications_be ,_be use_be alcohol_be patients_be taking_be OTHER_DRUG recommended_af ._af"
1730,"Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.",alcohol,LEXAPRO,advise,"DRUG -_be Although_be OTHER_DRUG potentiate_af cognitive_af motor_af effects_af DRUG clinical_af trial_af ,_af psychotropic_af medications_af ,_af use_af DRUG patients_af taking_af OTHER_DRUG recommended_af ._af"
1731,Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.,psychotropic drugs,NSAID,effect,Epidemiological_bf studies_bf case-control_bf cohort_bf design_bf demonstrated_bf association_bf use_bf psychotropic_bf drugs_bf interfere_bf serotonin_bf reuptake_bf occurrence_bf upper_bf gastrointestinal_bf bleeding_bf also_bf shown_bf concurrent_bf use_bf OTHER_DRUG aspirin_be potentiated_be risk_be bleeding_be ._be
1732,Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.,psychotropic drugs,aspirin,effect,Epidemiological_bf studies_bf case-control_bf cohort_bf design_bf demonstrated_bf association_bf use_bf psychotropic_bf drugs_bf interfere_bf serotonin_bf reuptake_bf occurrence_bf upper_bf gastrointestinal_bf bleeding_bf also_bf shown_bf concurrent_bf use_bf NSAID_bf OTHER_DRUG potentiated_be risk_be bleeding_be ._be
1733,"Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.",citalopram,cimetidine,mechanism,"OTHER_DRUG -_be In_be subjects_be received_be 21_be days_be 40_be mg/day_be racemic_be DRUG ,_af combined_af administration_af 400_af mg/day_af OTHER_DRUG 8_af days_af resulted_af increase_af DRUG AUC_af Cmax_af 43%_af 39%_af ,_af respectively_af ._af"
1734,"Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.",lithium,escitalopram,effect,"Because_bf DRUG may_be enhance_be serotonergic_be effects_be OTHER_DRUG ,_af caution_af exercised_af LEXAPRO_af DRUG coadministered_af ._af"
1735,"Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.",LEXAPRO,lithium,advise,"Because_bf OTHER_DRUG may_be enhance_be serotonergic_be effects_be escitalopram_be ,_be caution_be exercised_be DRUG OTHER_DRUG coadministered_af ._af"
1736,"Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.",pimozide,citalopram,effect,"DRUG Celexa_be -_be In_be controlled_be study_be ,_be single_be dose_be DRUG 2_af mg_af co-administered_af racemic_af OTHER_DRUG 40_af mg_af given_af daily_af 11_af days_af associated_af mean_af increase_af QTc_af values_af approximately_af 10_af msec_af compared_af DRUG given_af alone_af ._af"
1737,"Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.",selective serotonin reuptake inhibitor,sumatriptan,effect,"OTHER_DRUG -_be There_be rare_be postmarketing_be reports_be describing_be patients_be weakness_be ,_be hyperreflexia_be ,_be incoordination_be following_be use_be selective_be serotonin_be reuptake_be inhibitor_be (SSRI)_be OTHER_DRUG ._af"
1738,"Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.",SSRI,sumatriptan,effect,"OTHER_DRUG -_be There_be rare_be postmarketing_be reports_be describing_be patients_be weakness_be ,_be hyperreflexia_be ,_be incoordination_be following_be use_be selective_be serotonin_be reuptake_be inhibitor_be (SSRI)_be OTHER_DRUG ._af"
1739,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,SSRI,advise,"If_bf concomitant_bf treatment_bf DRUG OTHER_DRUG (e_af ._af g_af ._af ,_af fluoxetine_af ,_af fluvoxamine_af ,_af paroxetine_af ,_af sertraline_af ,_af citalopram_af ,_af escitalopram)_af clinically_af warranted_af ,_af appropriate_af observation_af patient_af advised_af ._af"
1740,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,fluoxetine,advise,"If_bf concomitant_bf treatment_bf DRUG SSRI_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af fluvoxamine_af ,_af paroxetine_af ,_af sertraline_af ,_af citalopram_af ,_af escitalopram)_af clinically_af warranted_af ,_af appropriate_af observation_af patient_af advised_af ._af"
1741,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,fluvoxamine,advise,"If_bf concomitant_bf treatment_bf DRUG SSRI_be (e_be ._be g_be ._be ,_be fluoxetine_be ,_be OTHER_DRUG ,_af paroxetine_af ,_af sertraline_af ,_af citalopram_af ,_af escitalopram)_af clinically_af warranted_af ,_af appropriate_af observation_af patient_af advised_af ._af"
1742,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,paroxetine,advise,"If_bf concomitant_bf treatment_bf DRUG SSRI_be (e_be ._be g_be ._be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be OTHER_DRUG ,_af sertraline_af ,_af citalopram_af ,_af escitalopram)_af clinically_af warranted_af ,_af appropriate_af observation_af patient_af advised_af ._af"
1743,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,sertraline,advise,"If_bf concomitant_bf treatment_bf DRUG SSRI_be (e_be ._be g_be ._be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be paroxetine_be ,_be OTHER_DRUG ,_af citalopram_af ,_af escitalopram)_af clinically_af warranted_af ,_af appropriate_af observation_af patient_af advised_af ._af"
1744,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,citalopram,advise,"If_bf concomitant_bf treatment_bf DRUG SSRI_be (e_be ._be g_be ._be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be paroxetine_be ,_be sertraline_be ,_be OTHER_DRUG ,_af escitalopram)_af clinically_af warranted_af ,_af appropriate_af observation_af patient_af advised_af ._af"
1745,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,escitalopram,advise,"If_bf concomitant_bf treatment_bf DRUG SSRI_be (e_be ._be g_be ._be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be paroxetine_be ,_be sertraline_be ,_be citalopram_be ,_be escitalopram)_be clinically_be warranted_be ,_be appropriate_be observation_be patient_be advised_be ._be"
1746,"Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.",carbamazepine,escitalopram,mechanism,"Although_bf trough_bf citalopram_bf plasma_bf levels_bf unaffected_bf ,_bf given_bf enzyme-inducing_bf properties_bf DRUG ,_be possibility_be DRUG might_af increase_af clearance_af OTHER_DRUG considered_af two_af drugs_af coadministered_af ._af"
1747,"Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.",citalopram,ketoconazole,mechanism,"OTHER_DRUG -_be Combined_be administration_be racemic_be DRUG (40_af mg)_af OTHER_DRUG (200_af mg)_af decreased_af Cmax_af AUC_af OTHER_DRUG 21%_af 10%_af ,_af respectively_af ,_af significantly_af affect_af pharmacokinetics_af DRUG ._af"
1748,"However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.",escitalopram,desipramine,mechanism,"However_bf ,_bf limited_bf vivo_bf data_bf suggesting_bf modest_bf CYP2D6_bf inhibitory_bf effect_bf DRUG ,_be ._be ._be ,_be coadministration_be DRUG (20_af mg/day_af 21_af days)_af tricyclic_af antidepressant_af OTHER_DRUG (single_af dose_af 50_af mg)_af ,_af substrate_af CYP2D6_af ,_af resulted_af 40%_af increase_af Cmax_af 100%_af increase_af AUC_af OTHER_DRUG ._af"
1749,Metoprolol - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg).,LEXAPRO,metoprolol,mechanism,OTHER_DRUG -_be Administration_be 20_be mg/day_be DRUG 21_af days_af healthy_af volunteers_af resulted_af 50%_af increase_af Cmax_af 82%_af increase_af AUC_af beta-adrenergic_af blocker_af OTHER_DRUG (given_af single_af dose_af 100_af mg)_af ._af
1750,"Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.",escitalopram,citalopram,advise,"Concomitant_bf Administration_bf Racemic_bf OTHER_DRUG OTHER_DRUG -_af Since_af DRUG active_af isomer_af racemic_af OTHER_DRUG (Celexa)_af ,_af two_af agents_af coadministered_af ._af"
1751,"Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.",escitalopram,Celexa,advise,"Concomitant_bf Administration_bf Racemic_bf Citalopram_bf Citalopram_bf -_bf Since_bf DRUG active_be isomer_be racemic_be citalopram_be (Celexa)_be ,_be two_be agents_be coadministered_be ._be"
1752,"Catecholamine-depleting drugs, e.g., reserpine, may have an additive effect when given with beta blocking agents.",reserpine,beta blocking agents,effect,"Catecholamine-depleting_bf drugs_bf ,_bf ._bf g_bf ._bf ,_bf DRUG ,_be may_be additive_be effect_be given_be beta_be blocking_be agents_be ._be"
1753,"BREVIBLOC concentrations were equivocally higher when given with warfarin, but this is not likely to be clinically important.",BREVIBLOC,warfarin,mechanism,"DRUG concentrations_be equivocally_be higher_be given_be OTHER_DRUG ,_af likely_af clinically_af important_af ._af"
1754,"When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.",digoxin,BREVIBLOC,mechanism,"When_bf DRUG OTHER_DRUG concomitantly_af administered_af intravenously_af normal_af volunteers_af ,_af 10-20%_af increase_af DRUG blood_af levels_af time_af points_af ._af"
1755,"When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.",BREVIBLOC,morphine,mechanism,"When_bf intravenous_bf OTHER_DRUG DRUG concomitantly_af administered_af normal_af subjects_af ,_af effect_af OTHER_DRUG blood_af levels_af seen_af ,_af DRUG steady-state_af blood_af levels_af increased_af 46%_af presence_af OTHER_DRUG ._af"
1756,"The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.",succinylcholine,BREVIBLOC,effect,"The_bf onset_bf neuromuscular_bf blockade_bf DRUG unaffected_be OTHER_DRUG ,_af duration_af neuromuscular_af blockade_af prolonged_af 5_af minutes_af 8_af minutes_af ._af"
1757,"Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.",BREVIBLOC,digoxin,advise,"Although_bf interactions_bf observed_bf studies_bf appear_bf major_bf clinical_bf importance_bf ,_bf DRUG titrated_be caution_be patients_be treated_be concurrently_be OTHER_DRUG ,_af morphine_af ,_af succinylcholine_af warfarin_af ._af"
1758,"Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.",BREVIBLOC,morphine,advise,"Although_bf interactions_bf observed_bf studies_bf appear_bf major_bf clinical_bf importance_bf ,_bf DRUG titrated_be caution_be patients_be treated_be concurrently_be digoxin_be ,_be OTHER_DRUG ,_af succinylcholine_af warfarin_af ._af"
1759,"Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.",BREVIBLOC,succinylcholine,advise,"Although_bf interactions_bf observed_bf studies_bf appear_bf major_bf clinical_bf importance_bf ,_bf DRUG titrated_be caution_be patients_be treated_be concurrently_be digoxin_be ,_be morphine_be ,_be OTHER_DRUG warfarin_af ._af"
1760,"Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.",BREVIBLOC,warfarin,advise,"Although_bf interactions_bf observed_bf studies_bf appear_bf major_bf clinical_bf importance_bf ,_bf DRUG titrated_be caution_be patients_be treated_be concurrently_be digoxin_be ,_be morphine_be ,_be succinylcholine_be OTHER_DRUG ._af"
1761,Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.,BREVIBLOC,verapamil,advise,Caution_bf exercised_bf considering_bf use_bf DRUG OTHER_DRUG patients_af depressed_af myocardial_af function_af ._af
1762,"Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.",BREVIBLOC,dopamine,advise,"Additionally_bf ,_bf DRUG used_be control_be supraventricular_be tachycardia_be presence_be agents_be vasoconstrictive_be inotropic_be OTHER_DRUG ,_af epinephrine_af ,_af norepinephrine_af danger_af blocking_af cardiac_af contractility_af systemic_af vascular_af resistance_af high_af ._af"
1763,"Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.",BREVIBLOC,epinephrine,advise,"Additionally_bf ,_bf DRUG used_be control_be supraventricular_be tachycardia_be presence_be agents_be vasoconstrictive_be inotropic_be dopamine_be ,_be OTHER_DRUG ,_af norepinephrine_af danger_af blocking_af cardiac_af contractility_af systemic_af vascular_af resistance_af high_af ._af"
1764,"Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.",BREVIBLOC,norepinephrine,advise,"Additionally_bf ,_bf DRUG used_be control_be supraventricular_be tachycardia_be presence_be agents_be vasoconstrictive_be inotropic_be dopamine_be ,_be epinephrine_be ,_be OTHER_DRUG danger_af blocking_af cardiac_af contractility_af systemic_af vascular_af resistance_af high_af ._af"
1765,Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.,proton pump inhibitors,warfarin,effect,Patients_bf treated_bf proton_bf pump_bf inhibitors_bf OTHER_DRUG concomitantly_be may_be need_be monitored_be increases_be INR_be prothrombin_be time_be ._be
1766,"Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.",esomeprazole,diazepam,mechanism,"Coadministration_bf DRUG 30_be mg_be OTHER_DRUG ,_af CYP2C19_af substrate_af ,_af resulted_af 45%_af decrease_af clearance_af OTHER_DRUG ._af"
1767,"Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).",esomeprazole,ketoconazole,mechanism,"Therefore_bf ,_bf DRUG may_be interfere_be absorption_be drugs_be gastric_be pH_be important_be determinant_be bioavailability_be (eg_be ,_be OTHER_DRUG ,_af iron_af salts_af digoxin)_af ._af"
1768,"Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).",esomeprazole,iron,mechanism,"Therefore_bf ,_bf DRUG may_be interfere_be absorption_be drugs_be gastric_be pH_be important_be determinant_be bioavailability_be (eg_be ,_be ketoconazole_be ,_be OTHER_DRUG salts_af digoxin)_af ._af"
1769,"Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).",esomeprazole,digoxin,mechanism,"Therefore_bf ,_bf DRUG may_be interfere_be absorption_be drugs_be gastric_be pH_be important_be determinant_be bioavailability_be (eg_be ,_be ketoconazole_be ,_be iron_be salts_be digoxin)_be ._be"
1770,Concomitant administration of clarithromycin with pimozide is contraindicated.,clarithromycin,pimozide,advise,Concomitant_bf administration_bf DRUG OTHER_DRUG contraindicated_af ._af
1771,"Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.",calcium,EMCYT,mechanism,"Milk_bf ,_bf milk_bf products_bf ,_bf calcium-rich_bf foods_bf drugs_bf may_bf impair_bf absorption_bf OTHER_DRUG ._be"
1772,CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.,eszopiclone,ethanol,effect,CNS-Active_bf Drugs_bf OTHER_DRUG An_be additive_be effect_be psychomotor_be performance_be seen_be coadministration_be DRUG OTHER_DRUG 0_af ._af 70_af g/kg_af 4_af hours_af OTHER_DRUG administration_af ._af
1773,Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.,eszopiclone,olanzapine,effect,Olanzapine:_bf Coadministration_bf DRUG 3_be mg_be OTHER_DRUG 10_af mg_af produced_af decrease_af DSST_af scores_af ._af
1774,"The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.",eszopiclone,ketoconazole,mechanism,"The_bf AUC_bf DRUG increased_be 2_be ._be 2-fold_be coadministration_be OTHER_DRUG ,_af potent_af inhibitor_af CYP3A4_af ,_af 400_af mg_af daily_af 5_af days_af ._af"
1775,"Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.",zopiclone,rifampicin,mechanism,"Drugs_bf That_bf Induce_bf CYP3A4_bf (Rifampicin)_bf Racemic_bf DRUG exposure_be decreased_be 80%_be concomitant_be useof_be OTHER_DRUG ,_af potent_af inducer_af CYP3A4_af ._af"
1776,"In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL  and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL  alone (0%).",ENBREL,anakinra,effect,"In_bf study_bf patients_bf active_bf RA_bf treated_bf 24_bf weeks_bf concurrent_bf DRUG OTHER_DRUG therapy_af ,_af 7%_af rate_af serious_af infections_af observed_af ,_af higher_af observed_af DRUG alone_af (0%)_af ._af"
1777,Two percent of patients treated concurrently with ENBREL  and anakinra developed neutropenia (ANC   1 x 109/L).,ENBREL,anakinra,effect,Two_bf percent_bf patients_bf treated_bf concurrently_bf DRUG OTHER_DRUG developed_af neutropenia_af (ANC_af 1_af x_af 109/L)_af ._af
1778,"Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.",sulfasalazine,ENBREL,effect,"Patients_bf clinical_bf study_bf established_bf therapy_bf DRUG ,_be OTHER_DRUG added_af ,_af noted_af develop_af mild_af decrease_af mean_af neutrophil_af counts_af comparison_af groups_af treated_af either_af OTHER_DRUG CI_af DRUG alone_af ._af"
1779,Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.,Lithium,diuretics,mechanism,DRUG generally_be given_be OTHER_DRUG reduce_af renal_af clearance_af add_af high_af risk_af DRUG toxicity_af ._af
1780,EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.,EDECRIN,aminoglycoside,effect,DRUG may_be increase_be ototoxic_be potential_be drugs_be OTHER_DRUG cephalosporin_af antibiotics_af ._af
1781,EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.,EDECRIN,cephalosporin antibiotics,effect,DRUG may_be increase_be ototoxic_be potential_be drugs_be aminoglycoside_be cephalosporin_be antibiotics_be ._be
1782,"A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein;",ethacrynic acid,warfarin,mechanism,"A_bf number_bf drugs_bf ,_bf including_bf ethacrynic_bf acid_bf ,_bf shown_bf displace_bf OTHER_DRUG plasma_be protein;_be"
1783,"In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.",non- steroidal antiinflammatory agent,loop diuretics,effect,"In_bf patients_bf ,_bf administration_bf non-_bf steroidal_bf antiinflammatory_bf agent_bf reduce_bf diuretic_bf ,_bf natriuretic_bf ,_bf antihypertensive_bf effects_bf loop_bf ,_bf potassium-_bf sparing_bf thiazide_bf diuretics_bf ._bf"
1784,"In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.",non- steroidal antiinflammatory agent,potassium- sparing diuretics,effect,"In_bf patients_bf ,_bf administration_bf non-_bf steroidal_bf antiinflammatory_bf agent_bf reduce_bf diuretic_bf ,_bf natriuretic_bf ,_bf antihypertensive_bf effects_bf loop_bf ,_bf potassium-_bf sparing_bf thiazide_bf diuretics_bf ._bf"
1785,"In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.",non- steroidal antiinflammatory agent,thiazide diuretics,effect,"In_bf patients_bf ,_bf administration_bf non-_bf steroidal_bf antiinflammatory_bf agent_bf reduce_bf diuretic_bf ,_bf natriuretic_bf ,_bf antihypertensive_bf effects_bf loop_bf ,_bf potassium-_bf sparing_bf thiazide_bf diuretics_bf ._bf"
1786,"Therefore, when EDECRIN and non- steroidal anti- inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.",EDECRIN,non- steroidal anti- inflammatory agents,effect,"Therefore_bf ,_bf DRUG non-_be steroidal_be anti-_be inflammatory_be agents_be used_be concomitantly_be ,_be patient_be observed_be closely_be determine_be desired_be effect_be diuretic_be obtained_be ._be"
1787,"Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.",alcohol,ethchlorvynol,effect,"Other_bf depressasnts_bf DRUG ,_be barbiturates_be ,_be MAOIs_be may_be enhance_be CNS_be depression_be administered_be OTHER_DRUG ._af"
1788,"Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.",barbiturates,ethchlorvynol,effect,"Other_bf depressasnts_bf alcohol_bf ,_bf DRUG ,_be MAOIs_be may_be enhance_be CNS_be depression_be administered_be OTHER_DRUG ._af"
1789,"Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.",MAOIs,ethchlorvynol,effect,"Other_bf depressasnts_bf alcohol_bf ,_bf barbiturates_bf ,_bf DRUG may_be enhance_be CNS_be depression_be administered_be OTHER_DRUG ._af"
1790,Trecator has been found to temporarily raise serum concentrations of isoniazid.,Trecator,isoniazid,mechanism,DRUG found_be temporarily_be raise_be serum_be concentrations_be OTHER_DRUG ._af
1791,Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly.,Trecator,antituberculous drugs,effect,DRUG may_be potentiate_be adverse_be effects_be antituberculous_be drugs_be administered_be concomitantly_be ._be
1792,"In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.",ethionamide,cycloserine,effect,"In_bf particular_bf ,_bf convulsions_bf reported_bf DRUG administered_be OTHER_DRUG special_af care_af taken_af treatment_af regimen_af includes_af drugs_af ._af"
1793,"Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.",Ethopropazine,alcohol,effect,"DRUG may_be interact_be OTHER_DRUG CNS_af depressants_af ,_af causing_af increased_af sedative_af effects_af ._af"
1794,"Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.",Ethopropazine,CNS depressants,effect,"DRUG may_be interact_be alcohol_be CNS_be depressants_be ,_be causing_be increased_be sedative_be effects_be ._be"
1795,"Ethopropazine can interact with chlorpromazine, increasing the metabolism of chlorpromazine.",Ethopropazine,chlorpromazine,mechanism,"DRUG interact_be OTHER_DRUG ,_af increasing_af metabolism_af OTHER_DRUG ._af"
1796,"Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",Zarontin,antiepileptic drugs,int,"Since_bf DRUG (ethosuximide)_be may_be interact_be concurrently_be administered_be antiepileptic_be drugs_be ,_be periodic_be serum_be level_be determinations_be drugs_be may_be necessary_be (eg_be ,_be ethosuximide_be may_be elevate_be phenytoin_be serum_be levels_be valproic_be acid_be reported_be increase_be decrease_be ethosuximide_be levels)_be ._be"
1797,"Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",ethosuximide,antiepileptic drugs,int,"Since_bf Zarontin_bf (ethosuximide)_bf may_bf interact_bf concurrently_bf administered_bf antiepileptic_bf drugs_bf ,_bf periodic_bf serum_bf level_bf determinations_bf drugs_bf may_bf necessary_bf (eg_bf ,_bf DRUG may_be elevate_be phenytoin_be serum_be levels_be valproic_be acid_be reported_be increase_be decrease_be DRUG levels)_af ._af"
1798,"Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",ethosuximide,phenytoin,mechanism,"Since_bf Zarontin_bf (ethosuximide)_bf may_bf interact_bf concurrently_bf administered_bf antiepileptic_bf drugs_bf ,_bf periodic_bf serum_bf level_bf determinations_bf drugs_bf may_bf necessary_bf (eg_bf ,_bf DRUG may_be elevate_be OTHER_DRUG serum_af levels_af valproic_af acid_af reported_af increase_af decrease_af DRUG levels)_af ._af"
1799,"Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",valproic acid,ethosuximide,mechanism,"Since_bf Zarontin_bf (ethosuximide)_bf may_bf interact_bf concurrently_bf administered_bf antiepileptic_bf drugs_bf ,_bf periodic_bf serum_bf level_bf determinations_bf drugs_bf may_bf necessary_bf (eg_bf ,_bf OTHER_DRUG may_be elevate_be phenytoin_be serum_be levels_be valproic_be acid_be reported_be increase_be decrease_be OTHER_DRUG levels)_af ._af"
1800,Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.,PEGANONE,Phenurone,advise,Considerable_bf caution_bf exercised_bf DRUG administered_be concurrently_be OTHER_DRUG (phenacemide)_af since_af paranoid_af symptoms_af reported_af therapy_af combination_af ._af
1801,Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.,PEGANONE,phenacemide,advise,Considerable_bf caution_bf exercised_bf DRUG administered_be concurrently_be Phenurone_be (phenacemide)_be since_be paranoid_be symptoms_be reported_be therapy_be combination_be ._be
1802,"A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.",hydantoin antiepileptic,phenytoin,int,"A_bf two-way_bf interaction_bf hydantoin_bf antiepileptic_bf ,_bf OTHER_DRUG ,_be coumarin_be anticoagulants_be suggested_be ._be"
1803,"A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.",hydantoin antiepileptic,coumarin anticoagulant,int,"A_bf two-way_bf interaction_bf hydantoin_bf antiepileptic_bf ,_bf phenytoin_bf ,_bf coumarin_bf anticoagulants_bf suggested_bf ._bf"
1804,"Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.",phenytoin,coumarin,mechanism,"Presumably_bf ,_bf DRUG acts_be stimulator_be OTHER_DRUG metabolism_af reported_af cause_af decreased_af serum_af levels_af OTHER_DRUG anticoagulants_af increased_af prothrombin-proconvertin_af concentrations_af ._af"
1805,"Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.",phenytoin,coumarin anticoagulants,mechanism,"Presumably_bf ,_bf DRUG acts_be stimulator_be coumarin_be metabolism_be reported_be cause_be decreased_be serum_be levels_be coumarin_be anticoagulants_be increased_be prothrombin-proconvertin_be concentrations_be ._be"
1806,"Conversely, the coumarin anticoagulants have been reported to increase the serum levels and prolong the serum half-life of phenytoin by inhibiting its metabolism.",coumarin anticoagulants,phenytoin,mechanism,"Conversely_bf ,_bf coumarin_bf anticoagulants_bf reported_bf increase_bf serum_bf levels_bf prolong_bf serum_bf half-life_bf OTHER_DRUG inhibiting_be metabolism_be ._be"
1807,Caution is therefore advised when administering PEGANONE to patients receiving coumarin anticoagulants.,PEGANONE,coumarin anticoagulants,advise,Caution_bf therefore_bf advised_bf administering_bf DRUG patients_be receiving_be coumarin_be anticoagulants_be ._be
1808,There have been isolated reports of patients experiencing increases in their prothrombin times when etidronate was added to warfarin therapy.,etidronate,warfarin,effect,There_bf isolated_bf reports_bf patients_bf experiencing_bf increases_bf prothrombin_bf times_bf DRUG added_be OTHER_DRUG therapy_af ._af
1809,ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.,NSAIDs,ACE-inhibitors,effect,OTHER_DRUG Reports_be suggest_be DRUG may_af diminish_af antihypertensive_af effect_af OTHER_DRUG ._af
1810,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.,NSAIDs,ACE-inhibitors,advise,This_bf interaction_bf given_bf consideration_bf patients_bf taking_bf DRUG concomitantly_be OTHER_DRUG ._af
1811,"Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.",Lodine,aspirin,mechanism,"Aspirin:_bf When_bf DRUG administered_be OTHER_DRUG ,_af protein_af binding_af reduced_af ,_af although_af clearance_af free_af etodolac_af altered_af ._af"
1812,"however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.",Lodine,aspirin,advise,"however_bf ,_bf NSAIDs_bf ,_bf concomitant_bf administration_bf DRUG OTHER_DRUG generally_af recommended_af potential_af increased_af adverse_af effects_af ._af"
1813,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",Lodine,cyclosporine,mechanism,"OTHER_DRUG ,_be Digoxin_be ,_be Methotrexate_be DRUG ,_af like_af NSAIDs_af ,_af effects_af renal_af prostaglandins_af ,_af may_af cause_af changes_af elimination_af drugs_af leading_af elevated_af serum_af levels_af OTHER_DRUG ,_af digoxin_af ,_af methotrexate_af ,_af increased_af toxicity_af ._af"
1814,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",Lodine,digoxin,mechanism,"Cyclosporine_bf ,_bf OTHER_DRUG ,_be Methotrexate_be DRUG ,_af like_af NSAIDs_af ,_af effects_af renal_af prostaglandins_af ,_af may_af cause_af changes_af elimination_af drugs_af leading_af elevated_af serum_af levels_af cyclosporine_af ,_af OTHER_DRUG ,_af methotrexate_af ,_af increased_af toxicity_af ._af"
1815,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",Lodine,methotrexate,mechanism,"Cyclosporine_bf ,_bf Digoxin_bf ,_bf OTHER_DRUG DRUG ,_af like_af NSAIDs_af ,_af effects_af renal_af prostaglandins_af ,_af may_af cause_af changes_af elimination_af drugs_af leading_af elevated_af serum_af levels_af cyclosporine_af ,_af digoxin_af ,_af OTHER_DRUG ,_af increased_af toxicity_af ._af"
1816,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",NSAIDs,cyclosporine,mechanism,"OTHER_DRUG ,_be Digoxin_be ,_be Methotrexate_be Lodine_be ,_be like_be DRUG ,_af effects_af renal_af prostaglandins_af ,_af may_af cause_af changes_af elimination_af drugs_af leading_af elevated_af serum_af levels_af OTHER_DRUG ,_af digoxin_af ,_af methotrexate_af ,_af increased_af toxicity_af ._af"
1817,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",NSAIDs,digoxin,mechanism,"Cyclosporine_bf ,_bf OTHER_DRUG ,_be Methotrexate_be Lodine_be ,_be like_be DRUG ,_af effects_af renal_af prostaglandins_af ,_af may_af cause_af changes_af elimination_af drugs_af leading_af elevated_af serum_af levels_af cyclosporine_af ,_af OTHER_DRUG ,_af methotrexate_af ,_af increased_af toxicity_af ._af"
1818,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",NSAIDs,methotrexate,mechanism,"Cyclosporine_bf ,_bf Digoxin_bf ,_bf OTHER_DRUG Lodine_be ,_be like_be DRUG ,_af effects_af renal_af prostaglandins_af ,_af may_af cause_af changes_af elimination_af drugs_af leading_af elevated_af serum_af levels_af cyclosporine_af ,_af digoxin_af ,_af OTHER_DRUG ,_af increased_af toxicity_af ._af"
1819,"Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.",Lodine,furosemide,effect,"Nevertheless_bf ,_bf clinical_bf studies_bf ,_bf well_bf postmarketing_bf observations_bf shown_bf DRUG reduce_be natriuretic_be effect_be OTHER_DRUG thiazides_af patients_af ._af"
1820,"Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.",Lodine,thiazides,effect,"Nevertheless_bf ,_bf clinical_bf studies_bf ,_bf well_bf postmarketing_bf observations_bf shown_bf DRUG reduce_be natriuretic_be effect_be furosemide_be OTHER_DRUG patients_af ._af"
1821,Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.,NSAIDs,lithium,mechanism,Lithium:_bf DRUG produced_be elevation_be plasma_be OTHER_DRUG levels_af reduction_af renal_af OTHER_DRUG clearance_af ._af
1822,"Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.",NSAIDs,lithium,effect,"Thus_bf ,_bf DRUG OTHER_DRUG administered_af concurrently_af ,_af subjects_af observed_af carefully_af signs_af OTHER_DRUG toxicity_af ._af"
1823,Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.,Phenylbutazone,etodolac,mechanism,Phenylbutazone:_bf DRUG causes_be increase_be (by_be 80%)_be free_be fraction_be OTHER_DRUG ._af
1824,"Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.",etodolac,phenylbutazone,advise,"Although_bf vivo_bf studies_bf done_bf see_bf DRUG clearance_be changed_be coadministration_be OTHER_DRUG ,_af recommended_af coadministered_af ._af"
1825,"Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.",warfarin,NSAIDs,effect,"Warfarin:_bf The_bf effects_bf DRUG OTHER_DRUG GI_af bleeding_af synergistic_af ,_af users_af drugs_af together_af risk_af serious_af GI_af bleeding_af higher_af users_af either_af drug_af alone_af ._af"
1826,"Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.",warfarin,Lodine,mechanism,"Short-term_bf pharmacokinetic_bf studies_bf demonstrated_bf concomitant_bf administration_bf DRUG OTHER_DRUG (etodolac_af capsules_af tablets)_af results_af reduced_af protein_af binding_af DRUG ,_af change_af clearance_af free_af DRUG ._af"
1827,"Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.",warfarin,etodolac,mechanism,"Short-term_bf pharmacokinetic_bf studies_bf demonstrated_bf concomitant_bf administration_bf DRUG Lodine_be (etodolac_be capsules_be tablets)_be results_be reduced_be protein_be binding_be DRUG ,_af change_af clearance_af free_af DRUG ._af"
1828,"However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in etodolac-treated patients receiving concomitant warfarin therapy.",etodolac,warfarin,effect,"However_bf ,_bf caution_bf exercised_bf spontaneous_bf reports_bf prolonged_bf prothrombin_bf times_bf ,_bf without_bf bleeding_bf ,_bf etodolac-treated_bf patients_bf receiving_bf concomitant_bf OTHER_DRUG therapy_be ._be"
1829,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,acetaminophen,int,"DRUG may_be interact_be following_be medications:_be OTHER_DRUG (Tylenol)_af ,_af antibiotics_af ampicillin_af tetracycline_af ,_af anticonvulsants_af (Dilantin_af ,_af Phenobarbital_af ,_af Tegretol_af ,_af Trileptal_af ,_af Topamax_af ,_af Felbatol)_af ,_af antifungals_af (Gris-PEG_af ,_af Nizoral_af ,_af Sporanox)_af ,_af atorvastatin_af (Lipitor)_af ,_af clofibrate_af (Atromid-S)_af ,_af cyclosporine_af (Neoral_af ,_af Sandimmune)_af ,_af HIV_af drugs_af classified_af protease_af inhibitors_af (Agenerase_af ,_af Crixivan_af ,_af Fortovase_af ,_af Invirase_af ,_af Kaletra_af ,_af Norvir_af ,_af Viracept)_af ,_af morphine_af (Astramorph_af ,_af Kadian_af ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1830,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Tylenol,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be rifadin_be (rifampin)_be ,_be St_be ._be Johns_be wort_be ,_be temazepam_be ,_be theophylline_be (Theo-Dur)_be ,_be vitamin_be C_be ._be"
1831,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,antibiotics,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be OTHER_DRUG ampicillin_af tetracycline_af ,_af anticonvulsants_af (Dilantin_af ,_af Phenobarbital_af ,_af Tegretol_af ,_af Trileptal_af ,_af Topamax_af ,_af Felbatol)_af ,_af antifungals_af (Gris-PEG_af ,_af Nizoral_af ,_af Sporanox)_af ,_af atorvastatin_af (Lipitor)_af ,_af clofibrate_af (Atromid-S)_af ,_af cyclosporine_af (Neoral_af ,_af Sandimmune)_af ,_af HIV_af drugs_af classified_af protease_af inhibitors_af (Agenerase_af ,_af Crixivan_af ,_af Fortovase_af ,_af Invirase_af ,_af Kaletra_af ,_af Norvir_af ,_af Viracept)_af ,_af morphine_af (Astramorph_af ,_af Kadian_af ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1832,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,ampicillin,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be OTHER_DRUG tetracycline_af ,_af anticonvulsants_af (Dilantin_af ,_af Phenobarbital_af ,_af Tegretol_af ,_af Trileptal_af ,_af Topamax_af ,_af Felbatol)_af ,_af antifungals_af (Gris-PEG_af ,_af Nizoral_af ,_af Sporanox)_af ,_af atorvastatin_af (Lipitor)_af ,_af clofibrate_af (Atromid-S)_af ,_af cyclosporine_af (Neoral_af ,_af Sandimmune)_af ,_af HIV_af drugs_af classified_af protease_af inhibitors_af (Agenerase_af ,_af Crixivan_af ,_af Fortovase_af ,_af Invirase_af ,_af Kaletra_af ,_af Norvir_af ,_af Viracept)_af ,_af morphine_af (Astramorph_af ,_af Kadian_af ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1833,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,tetracycline,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be OTHER_DRUG ,_af anticonvulsants_af (Dilantin_af ,_af Phenobarbital_af ,_af Tegretol_af ,_af Trileptal_af ,_af Topamax_af ,_af Felbatol)_af ,_af antifungals_af (Gris-PEG_af ,_af Nizoral_af ,_af Sporanox)_af ,_af atorvastatin_af (Lipitor)_af ,_af clofibrate_af (Atromid-S)_af ,_af cyclosporine_af (Neoral_af ,_af Sandimmune)_af ,_af HIV_af drugs_af classified_af protease_af inhibitors_af (Agenerase_af ,_af Crixivan_af ,_af Fortovase_af ,_af Invirase_af ,_af Kaletra_af ,_af Norvir_af ,_af Viracept)_af ,_af morphine_af (Astramorph_af ,_af Kadian_af ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1834,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,anticonvulsants,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be OTHER_DRUG (Dilantin_af ,_af Phenobarbital_af ,_af Tegretol_af ,_af Trileptal_af ,_af Topamax_af ,_af Felbatol)_af ,_af antifungals_af (Gris-PEG_af ,_af Nizoral_af ,_af Sporanox)_af ,_af atorvastatin_af (Lipitor)_af ,_af clofibrate_af (Atromid-S)_af ,_af cyclosporine_af (Neoral_af ,_af Sandimmune)_af ,_af HIV_af drugs_af classified_af protease_af inhibitors_af (Agenerase_af ,_af Crixivan_af ,_af Fortovase_af ,_af Invirase_af ,_af Kaletra_af ,_af Norvir_af ,_af Viracept)_af ,_af morphine_af (Astramorph_af ,_af Kadian_af ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1835,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Dilantin,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be rifadin_be (rifampin)_be ,_be St_be ._be Johns_be wort_be ,_be temazepam_be ,_be theophylline_be (Theo-Dur)_be ,_be vitamin_be C_be ._be"
1836,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Phenobarbital,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be OTHER_DRUG ,_af Tegretol_af ,_af Trileptal_af ,_af Topamax_af ,_af Felbatol)_af ,_af antifungals_af (Gris-PEG_af ,_af Nizoral_af ,_af Sporanox)_af ,_af atorvastatin_af (Lipitor)_af ,_af clofibrate_af (Atromid-S)_af ,_af cyclosporine_af (Neoral_af ,_af Sandimmune)_af ,_af HIV_af drugs_af classified_af protease_af inhibitors_af (Agenerase_af ,_af Crixivan_af ,_af Fortovase_af ,_af Invirase_af ,_af Kaletra_af ,_af Norvir_af ,_af Viracept)_af ,_af morphine_af (Astramorph_af ,_af Kadian_af ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1837,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Tegretol,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be OTHER_DRUG ,_af Trileptal_af ,_af Topamax_af ,_af Felbatol)_af ,_af antifungals_af (Gris-PEG_af ,_af Nizoral_af ,_af Sporanox)_af ,_af atorvastatin_af (Lipitor)_af ,_af clofibrate_af (Atromid-S)_af ,_af cyclosporine_af (Neoral_af ,_af Sandimmune)_af ,_af HIV_af drugs_af classified_af protease_af inhibitors_af (Agenerase_af ,_af Crixivan_af ,_af Fortovase_af ,_af Invirase_af ,_af Kaletra_af ,_af Norvir_af ,_af Viracept)_af ,_af morphine_af (Astramorph_af ,_af Kadian_af ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1838,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Trileptal,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be OTHER_DRUG ,_af Topamax_af ,_af Felbatol)_af ,_af antifungals_af (Gris-PEG_af ,_af Nizoral_af ,_af Sporanox)_af ,_af atorvastatin_af (Lipitor)_af ,_af clofibrate_af (Atromid-S)_af ,_af cyclosporine_af (Neoral_af ,_af Sandimmune)_af ,_af HIV_af drugs_af classified_af protease_af inhibitors_af (Agenerase_af ,_af Crixivan_af ,_af Fortovase_af ,_af Invirase_af ,_af Kaletra_af ,_af Norvir_af ,_af Viracept)_af ,_af morphine_af (Astramorph_af ,_af Kadian_af ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1839,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Topamax,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be OTHER_DRUG ,_af Felbatol)_af ,_af antifungals_af (Gris-PEG_af ,_af Nizoral_af ,_af Sporanox)_af ,_af atorvastatin_af (Lipitor)_af ,_af clofibrate_af (Atromid-S)_af ,_af cyclosporine_af (Neoral_af ,_af Sandimmune)_af ,_af HIV_af drugs_af classified_af protease_af inhibitors_af (Agenerase_af ,_af Crixivan_af ,_af Fortovase_af ,_af Invirase_af ,_af Kaletra_af ,_af Norvir_af ,_af Viracept)_af ,_af morphine_af (Astramorph_af ,_af Kadian_af ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1840,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Felbatol,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be rifadin_be (rifampin)_be ,_be St_be ._be Johns_be wort_be ,_be temazepam_be ,_be theophylline_be (Theo-Dur)_be ,_be vitamin_be C_be ._be"
1841,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,antifungals,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be OTHER_DRUG (Gris-PEG_af ,_af Nizoral_af ,_af Sporanox)_af ,_af atorvastatin_af (Lipitor)_af ,_af clofibrate_af (Atromid-S)_af ,_af cyclosporine_af (Neoral_af ,_af Sandimmune)_af ,_af HIV_af drugs_af classified_af protease_af inhibitors_af (Agenerase_af ,_af Crixivan_af ,_af Fortovase_af ,_af Invirase_af ,_af Kaletra_af ,_af Norvir_af ,_af Viracept)_af ,_af morphine_af (Astramorph_af ,_af Kadian_af ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1842,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Gris-PEG,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be rifadin_be (rifampin)_be ,_be St_be ._be Johns_be wort_be ,_be temazepam_be ,_be theophylline_be (Theo-Dur)_be ,_be vitamin_be C_be ._be"
1843,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Nizoral,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be OTHER_DRUG ,_af Sporanox)_af ,_af atorvastatin_af (Lipitor)_af ,_af clofibrate_af (Atromid-S)_af ,_af cyclosporine_af (Neoral_af ,_af Sandimmune)_af ,_af HIV_af drugs_af classified_af protease_af inhibitors_af (Agenerase_af ,_af Crixivan_af ,_af Fortovase_af ,_af Invirase_af ,_af Kaletra_af ,_af Norvir_af ,_af Viracept)_af ,_af morphine_af (Astramorph_af ,_af Kadian_af ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1844,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Sporanox,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be rifadin_be (rifampin)_be ,_be St_be ._be Johns_be wort_be ,_be temazepam_be ,_be theophylline_be (Theo-Dur)_be ,_be vitamin_be C_be ._be"
1845,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,atorvastatin,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be OTHER_DRUG (Lipitor)_af ,_af clofibrate_af (Atromid-S)_af ,_af cyclosporine_af (Neoral_af ,_af Sandimmune)_af ,_af HIV_af drugs_af classified_af protease_af inhibitors_af (Agenerase_af ,_af Crixivan_af ,_af Fortovase_af ,_af Invirase_af ,_af Kaletra_af ,_af Norvir_af ,_af Viracept)_af ,_af morphine_af (Astramorph_af ,_af Kadian_af ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1846,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Lipitor,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be rifadin_be (rifampin)_be ,_be St_be ._be Johns_be wort_be ,_be temazepam_be ,_be theophylline_be (Theo-Dur)_be ,_be vitamin_be C_be ._be"
1847,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,clofibrate,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be OTHER_DRUG (Atromid-S)_af ,_af cyclosporine_af (Neoral_af ,_af Sandimmune)_af ,_af HIV_af drugs_af classified_af protease_af inhibitors_af (Agenerase_af ,_af Crixivan_af ,_af Fortovase_af ,_af Invirase_af ,_af Kaletra_af ,_af Norvir_af ,_af Viracept)_af ,_af morphine_af (Astramorph_af ,_af Kadian_af ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1848,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Atromid-S,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be rifadin_be (rifampin)_be ,_be St_be ._be Johns_be wort_be ,_be temazepam_be ,_be theophylline_be (Theo-Dur)_be ,_be vitamin_be C_be ._be"
1849,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,cyclosporine,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be OTHER_DRUG (Neoral_af ,_af Sandimmune)_af ,_af HIV_af drugs_af classified_af protease_af inhibitors_af (Agenerase_af ,_af Crixivan_af ,_af Fortovase_af ,_af Invirase_af ,_af Kaletra_af ,_af Norvir_af ,_af Viracept)_af ,_af morphine_af (Astramorph_af ,_af Kadian_af ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1850,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Neoral,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be rifadin_be (rifampin)_be ,_be St_be ._be Johns_be wort_be ,_be temazepam_be ,_be theophylline_be (Theo-Dur)_be ,_be vitamin_be C_be ._be"
1851,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Sandimmune,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be rifadin_be (rifampin)_be ,_be St_be ._be Johns_be wort_be ,_be temazepam_be ,_be theophylline_be (Theo-Dur)_be ,_be vitamin_be C_be ._be"
1852,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,protease inhibitors,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be rifadin_be (rifampin)_be ,_be St_be ._be Johns_be wort_be ,_be temazepam_be ,_be theophylline_be (Theo-Dur)_be ,_be vitamin_be C_be ._be"
1853,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Agenerase,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be rifadin_be (rifampin)_be ,_be St_be ._be Johns_be wort_be ,_be temazepam_be ,_be theophylline_be (Theo-Dur)_be ,_be vitamin_be C_be ._be"
1854,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Crixivan,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be OTHER_DRUG ,_af Fortovase_af ,_af Invirase_af ,_af Kaletra_af ,_af Norvir_af ,_af Viracept)_af ,_af morphine_af (Astramorph_af ,_af Kadian_af ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1855,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Fortovase,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be OTHER_DRUG ,_af Invirase_af ,_af Kaletra_af ,_af Norvir_af ,_af Viracept)_af ,_af morphine_af (Astramorph_af ,_af Kadian_af ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1856,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Invirase,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be OTHER_DRUG ,_af Kaletra_af ,_af Norvir_af ,_af Viracept)_af ,_af morphine_af (Astramorph_af ,_af Kadian_af ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1857,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Kaletra,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be OTHER_DRUG ,_af Norvir_af ,_af Viracept)_af ,_af morphine_af (Astramorph_af ,_af Kadian_af ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1858,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Norvir,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be OTHER_DRUG ,_af Viracept)_af ,_af morphine_af (Astramorph_af ,_af Kadian_af ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1859,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Viracept,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be rifadin_be (rifampin)_be ,_be St_be ._be Johns_be wort_be ,_be temazepam_be ,_be theophylline_be (Theo-Dur)_be ,_be vitamin_be C_be ._be"
1860,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,morphine,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be OTHER_DRUG (Astramorph_af ,_af Kadian_af ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1861,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Astramorph,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be rifadin_be (rifampin)_be ,_be St_be ._be Johns_be wort_be ,_be temazepam_be ,_be theophylline_be (Theo-Dur)_be ,_be vitamin_be C_be ._be"
1862,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Kadian,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be OTHER_DRUG ,_af MS_af Contin)_af ,_af phenylbutazone_af ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1863,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,MS Contin,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be rifadin_be (rifampin)_be ,_be St_be ._be Johns_be wort_be ,_be temazepam_be ,_be theophylline_be (Theo-Dur)_be ,_be vitamin_be C_be ._be"
1864,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,phenylbutazone,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be OTHER_DRUG ,_af prednisolone_af (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1865,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,prednisolone,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be OTHER_DRUG (Prelone)_af ,_af rifadin_af (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1866,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Prelone,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be rifadin_be (rifampin)_be ,_be St_be ._be Johns_be wort_be ,_be temazepam_be ,_be theophylline_be (Theo-Dur)_be ,_be vitamin_be C_be ._be"
1867,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,rifadin,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be OTHER_DRUG (rifampin)_af ,_af St_af ._af Johns_af wort_af ,_af temazepam_af ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1868,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,rifampin,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be rifadin_be (rifampin)_be ,_be St_be ._be Johns_be wort_be ,_be temazepam_be ,_be theophylline_be (Theo-Dur)_be ,_be vitamin_be C_be ._be"
1869,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,temazepam,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be rifadin_be (rifampin)_be ,_be St_be ._be Johns_be wort_be ,_be OTHER_DRUG ,_af theophylline_af (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1870,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,theophylline,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be rifadin_be (rifampin)_be ,_be St_be ._be Johns_be wort_be ,_be temazepam_be ,_be OTHER_DRUG (Theo-Dur)_af ,_af vitamin_af C_af ._af"
1871,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Theo-Dur,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be rifadin_be (rifampin)_be ,_be St_be ._be Johns_be wort_be ,_be temazepam_be ,_be theophylline_be (Theo-Dur)_be ,_be vitamin_be C_be ._be"
1872,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,vitamin C,int,"DRUG may_be interact_be following_be medications:_be acetaminophen_be (Tylenol)_be ,_be antibiotics_be ampicillin_be tetracycline_be ,_be anticonvulsants_be (Dilantin_be ,_be Phenobarbital_be ,_be Tegretol_be ,_be Trileptal_be ,_be Topamax_be ,_be Felbatol)_be ,_be antifungals_be (Gris-PEG_be ,_be Nizoral_be ,_be Sporanox)_be ,_be atorvastatin_be (Lipitor)_be ,_be clofibrate_be (Atromid-S)_be ,_be cyclosporine_be (Neoral_be ,_be Sandimmune)_be ,_be HIV_be drugs_be classified_be protease_be inhibitors_be (Agenerase_be ,_be Crixivan_be ,_be Fortovase_be ,_be Invirase_be ,_be Kaletra_be ,_be Norvir_be ,_be Viracept)_be ,_be morphine_be (Astramorph_be ,_be Kadian_be ,_be MS_be Contin)_be ,_be phenylbutazone_be ,_be prednisolone_be (Prelone)_be ,_be rifadin_be (rifampin)_be ,_be St_be ._be Johns_be wort_be ,_be temazepam_be ,_be theophylline_be (Theo-Dur)_be ,_be vitamin_be C_be ._be"
1873,Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.,probenecid,penciclovir,mechanism,Concurrent_bf use_bf DRUG drugs_be significantly_be eliminated_be active_be renal_be tubular_be secretion_be may_be result_be increased_be plasma_be concentrations_be OTHER_DRUG ._af
1874,Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.,Felbatol,antiepileptic drugs,mechanism,Use_bf Conjunction_bf Other_bf Antiepileptic_bf Drugs:_bf The_bf addition_bf DRUG antiepileptic_be drugs_be (AEDs)_be affects_be steady-state_be plasma_be concentrations_be AEDs_be ._be
1875,Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.,Felbatol,AEDs,mechanism,Use_bf Conjunction_bf Other_bf Antiepileptic_bf Drugs:_bf The_bf addition_bf DRUG antiepileptic_be drugs_be (AEDs)_be affects_be steady-state_be plasma_be concentrations_be OTHER_DRUG ._af
1876,Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.,Felbatol,phenytoin,mechanism,Specific_bf Effects_bf DRUG Other_be Antiepileptic_be Drugs_be Phenytoin:_be DRUG causes_af increase_af steady-state_af OTHER_DRUG plasma_af concentrations_af ._af
1877,Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25 7 micrograms/mL.,felbamate,phenytoin,mechanism,Increasing_bf DRUG dose_be 1800_be mg/day_be six_be subjects_be increased_be steady-state_be OTHER_DRUG Cmin_af 25_af 7_af micrograms/mL_af ._af
1878,"In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.",felbamate,phenytoin,advise,"In_bf order_bf maintain_bf OTHER_DRUG levels_be ,_be limit_be adverse_be experiences_be ,_be achieve_be DRUG dose_af 3600_af mg/day_af ,_af OTHER_DRUG dose_af reduction_af approximately_af 40%_af necessary_af eight_af 10_af subjects_af ._af"
1879,Carbamazepine: Felbatol  causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.,Felbatol,carbamazepine,mechanism,Carbamazepine:_bf DRUG causes_be decrease_be steady-state_be OTHER_DRUG plasma_af concentrations_af increase_af steady-state_af OTHER_DRUG epoxide_af plasma_af concentration_af ._af
1880,"The carbamazepine steady-state Cmin decreased 31% to 5 1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.",carbamazepine,felbamate,mechanism,"The_bf DRUG steady-state_be Cmin_be decreased_be 31%_be 5_be 1_be micrograms/mL_be OTHER_DRUG (3000_af mg/day_af ,_af divided_af three_af doses)_af coadministered_af ._af"
1881,Valproate: Felbatol  causes an increase in steady-state valproate concentrations.,Felbatol,valproate,mechanism,Valproate:_bf DRUG causes_be increase_be steady-state_be OTHER_DRUG concentrations_af ._af
1882,Increasing the felbamate dose to 2400 mg/day increased the steadystate valproate Cmin to 96 25 micrograms/mL.,felbamate,valproate,mechanism,Increasing_bf DRUG dose_be 2400_be mg/day_be increased_be steadystate_be OTHER_DRUG Cmin_af 96_af 25_af micrograms/mL_af ._af
1883,"Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.",felbamate,phenobarbital,mechanism,"Phenobarbital:_bf Coadministration_bf DRUG OTHER_DRUG causes_af increase_af OTHER_DRUG plasma_af concentrations_af ,_af In_af 12_af otherwise_af healthy_af male_af volunteers_af ingesting_af OTHER_DRUG ,_af steady-state_af trough_af (Cmin)_af OTHER_DRUG concentration_af 14_af ._af 2_af micrograms/mL_af ._af"
1884,"Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",Phenytoin,Felbatol,mechanism,"Effects_bf Other_bf Antiepileptic_bf Drugs_bf OTHER_DRUG Phenytoin:_be DRUG causes_af approximate_af doubling_af clearance_af OTHER_DRUG (felbamate)_af steady_af state_af ,_af therefore_af ,_af addition_af DRUG causes_af approximate_af 45%_af decrease_af steady-state_af trough_af concentrations_af OTHER_DRUG compared_af dose_af OTHER_DRUG given_af monotherapy_af ._af"
1885,"Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",Phenytoin,felbamate,mechanism,"Effects_bf Other_bf Antiepileptic_bf Drugs_bf Felbatol_bf Phenytoin:_bf DRUG causes_be approximate_be doubling_be clearance_be Felbatol_be (felbamate)_be steady_be state_be ,_be therefore_be ,_be addition_be DRUG causes_af approximate_af 45%_af decrease_af steady-state_af trough_af concentrations_af Felbatol_af compared_af dose_af Felbatol_af given_af monotherapy_af ._af"
1886,"Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",phenytoin,Felbatol,mechanism,"Effects_bf Other_bf Antiepileptic_bf Drugs_bf OTHER_DRUG Phenytoin:_be DRUG causes_af approximate_af doubling_af clearance_af OTHER_DRUG (felbamate)_af steady_af state_af ,_af therefore_af ,_af addition_af DRUG causes_af approximate_af 45%_af decrease_af steady-state_af trough_af concentrations_af OTHER_DRUG compared_af dose_af OTHER_DRUG given_af monotherapy_af ._af"
1887,"Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",Carbamazepine,Felbatol,mechanism,"Carbamazepine:_bf DRUG causes_be approximate_be 50%_be increase_be clearance_be OTHER_DRUG steady_af state_af ,_af therefore_af ,_af addition_af DRUG results_af approximate_af 40%_af decrease_af steady-state_af trough_af concentrations_af OTHER_DRUG compared_af dose_af OTHER_DRUG given_af monotherapy_af ._af"
1888,"Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",carbamazepine,Felbatol,mechanism,"Carbamazepine:_bf DRUG causes_be approximate_be 50%_be increase_be clearance_be OTHER_DRUG steady_af state_af ,_af therefore_af ,_af addition_af DRUG results_af approximate_af 40%_af decrease_af steady-state_af trough_af concentrations_af OTHER_DRUG compared_af dose_af OTHER_DRUG given_af monotherapy_af ._af"
1889,Phenobarbital: It appears that phenobarbital may reduce plasma felbamate concentrations.,phenobarbital,felbamate,mechanism,Phenobarbital:_bf It_bf appears_bf DRUG may_be reduce_be plasma_be OTHER_DRUG concentrations_af ._af
1890,"Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.",Felbamate,gestodene,mechanism,"DRUG treatment_be resulted_be 42%_be decrease_be OTHER_DRUG AUC_af 0-24_af ,_af clinically_af relevant_af effect_af observed_af pharmacokinetic_af parameters_af ethinyl_af estradiol_af ._af"
1891,"Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.",felodipine,anticonvulsant,mechanism,"Anticonvulsants:_bf In_bf pharmacokinetic_bf study_bf ,_bf maximum_bf plasma_bf concentrations_bf DRUG considerably_be lower_be epileptic_be patients_be long-term_be OTHER_DRUG therapy_af (eg_af ,_af phenytoin_af ,_af carbamazepine_af ,_af phenobarbital)_af healthy_af volunteers_af ._af"
1892,"Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.",felodipine,phenytoin,mechanism,"Anticonvulsants:_bf In_bf pharmacokinetic_bf study_bf ,_bf maximum_bf plasma_bf concentrations_bf DRUG considerably_be lower_be epileptic_be patients_be long-term_be anticonvulsant_be therapy_be (eg_be ,_be OTHER_DRUG ,_af carbamazepine_af ,_af phenobarbital)_af healthy_af volunteers_af ._af"
1893,"Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.",felodipine,carbamazepine,mechanism,"Anticonvulsants:_bf In_bf pharmacokinetic_bf study_bf ,_bf maximum_bf plasma_bf concentrations_bf DRUG considerably_be lower_be epileptic_be patients_be long-term_be anticonvulsant_be therapy_be (eg_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af phenobarbital)_af healthy_af volunteers_af ._af"
1894,"Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.",felodipine,phenobarbital,mechanism,"Anticonvulsants:_bf In_bf pharmacokinetic_bf study_bf ,_bf maximum_bf plasma_bf concentrations_bf DRUG considerably_be lower_be epileptic_be patients_be long-term_be anticonvulsant_be therapy_be (eg_be ,_be phenytoin_be ,_be carbamazepine_be ,_be phenobarbital)_be healthy_be volunteers_be ._be"
1895,The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.,aspirin,fenoprofen,mechanism,The_bf coadministration_bf DRUG decreases_be biologic_be half-life_be OTHER_DRUG increase_af metabolic_af clearance_af results_af greater_af amount_af hydroxylated_af OTHER_DRUG urine_af ._af
1896,"Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.",fenoprofen,aspirin,mechanism,"Although_bf mechanism_bf interaction_bf DRUG OTHER_DRUG totally_af known_af ,_af enzyme_af induction_af displacement_af DRUG plasma_af albumin_af binding_af sites_af possibilities_af ._af"
1897,"Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.",aspirin,Nalfon,mechanism,"Because_bf OTHER_DRUG shown_be produce_be additional_be effect_be beyond_be obtained_be DRUG alone_af DRUG increases_af rate_af excretion_af OTHER_DRUG ,_af concomitant_af use_af OTHER_DRUG salicylates_af recommended_af ._af"
1898,"Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.",Nalfon,salicylates,advise,"Because_bf DRUG shown_be produce_be additional_be effect_be beyond_be obtained_be aspirin_be alone_be aspirin_be increases_be rate_be excretion_be DRUG ,_af concomitant_af use_af DRUG OTHER_DRUG recommended_af ._af"
1899,"Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.",phenobarbital,fenoprofen,mechanism,"Chronic_bf administration_bf DRUG ,_be known_be enzyme_be inducer_be ,_be may_be associated_be decrease_be plasma_be half-life_be OTHER_DRUG ._af"
1900,"When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.",phenobarbital,Nalfon,advise,"When_bf DRUG added_be withdrawn_be treatment_be ,_be dosage_be adjustment_be OTHER_DRUG may_af required_af ._af"
1901,"In patients receiving coumarin-type anticoagulants, the addition of Nalfon to therapy could prolong the prothrombin time.",coumarin-type anticoagulants,Nalfon,effect,"In_bf patients_bf receiving_bf coumarin-type_bf anticoagulants_bf ,_bf addition_bf OTHER_DRUG therapy_be could_be prolong_be prothrombin_be time_be ._be"
1902,Patients treated with Nalfon may be resistant to the effects of loop diuretics.,Nalfon,loop diuretics,effect,Patients_bf treated_bf DRUG may_be resistant_be effects_be loop_be diuretics_be ._be
1903,"In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.",Nalfon,steroid,advise,"In_bf patients_bf receiving_bf DRUG OTHER_DRUG concomitantly_af ,_af reduction_af OTHER_DRUG dosage_af gradual_af order_af avoid_af possible_af complications_af sudden_af OTHER_DRUG withdrawal_af ._af"
1904,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,ritonavir,mechanism,"The_bf concomitant_bf use_bf transdermal_bf DRUG OTHER_DRUG potent_af 3A4_af inhibitors_af ketoconazole_af ,_af itraconazole_af ,_af troleandomycin_af ,_af clarithromycin_af ,_af nelfinavir_af ,_af nefazadone_af may_af result_af increase_af DRUG plasma_af concentrations_af ._af"
1905,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,ketoconazole,mechanism,"The_bf concomitant_bf use_bf transdermal_bf DRUG ritonavir_be potent_be 3A4_be inhibitors_be OTHER_DRUG ,_af itraconazole_af ,_af troleandomycin_af ,_af clarithromycin_af ,_af nelfinavir_af ,_af nefazadone_af may_af result_af increase_af DRUG plasma_af concentrations_af ._af"
1906,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,itraconazole,mechanism,"The_bf concomitant_bf use_bf transdermal_bf DRUG ritonavir_be potent_be 3A4_be inhibitors_be ketoconazole_be ,_be OTHER_DRUG ,_af troleandomycin_af ,_af clarithromycin_af ,_af nelfinavir_af ,_af nefazadone_af may_af result_af increase_af DRUG plasma_af concentrations_af ._af"
1907,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,troleandomycin,mechanism,"The_bf concomitant_bf use_bf transdermal_bf DRUG ritonavir_be potent_be 3A4_be inhibitors_be ketoconazole_be ,_be itraconazole_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af nelfinavir_af ,_af nefazadone_af may_af result_af increase_af DRUG plasma_af concentrations_af ._af"
1908,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,clarithromycin,mechanism,"The_bf concomitant_bf use_bf transdermal_bf DRUG ritonavir_be potent_be 3A4_be inhibitors_be ketoconazole_be ,_be itraconazole_be ,_be troleandomycin_be ,_be OTHER_DRUG ,_af nelfinavir_af ,_af nefazadone_af may_af result_af increase_af DRUG plasma_af concentrations_af ._af"
1909,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,nelfinavir,mechanism,"The_bf concomitant_bf use_bf transdermal_bf DRUG ritonavir_be potent_be 3A4_be inhibitors_be ketoconazole_be ,_be itraconazole_be ,_be troleandomycin_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af nefazadone_af may_af result_af increase_af DRUG plasma_af concentrations_af ._af"
1910,"The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.",diltiazem,fentanyl,mechanism,"The_bf concomitant_bf use_bf CYP3A4_bf inhibitors_bf DRUG erythromycin_be transdermal_be OTHER_DRUG may_af also_af result_af increase_af OTHER_DRUG plasma_af concentrations_af ,_af could_af increase_af prolong_af adverse_af drug_af effects_af may_af cause_af serious_af respiratory_af depression_af ._af"
1911,"The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.",erythromycin,fentanyl,mechanism,"The_bf concomitant_bf use_bf CYP3A4_bf inhibitors_bf diltiazem_bf DRUG transdermal_be OTHER_DRUG may_af also_af result_af increase_af OTHER_DRUG plasma_af concentrations_af ,_af could_af increase_af prolong_af adverse_af drug_af effects_af may_af cause_af serious_af respiratory_af depression_af ._af"
1912,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,central nervous system depressants,effect,"Central_bf Nervous_bf System_bf Depressants:_bf The_bf concomitant_bf use_bf DRUG (fentanyl_be transdermal_be system)_be central_be nervous_be system_be depressants_be ,_be including_be limited_be opioids_be ,_be sedatives_be ,_be hypnotics_be ,_be tranquilizers_be (e_be ._be g_be ._be ,_be benzodiazepines)_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be skeletal_be muscle_be relaxants_be ,_be alcohol_be ,_be may_be cause_be respiratory_be depression_be ,_be hypotension_be ,_be profound_be sedation_be ,_be potentially_be result_be coma_be death_be ._be"
1913,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,opioids,effect,"Central_bf Nervous_bf System_bf Depressants:_bf The_bf concomitant_bf use_bf DRUG (fentanyl_be transdermal_be system)_be central_be nervous_be system_be depressants_be ,_be including_be limited_be OTHER_DRUG ,_af sedatives_af ,_af hypnotics_af ,_af tranquilizers_af (e_af ._af g_af ._af ,_af benzodiazepines)_af ,_af general_af anesthetics_af ,_af phenothiazines_af ,_af skeletal_af muscle_af relaxants_af ,_af alcohol_af ,_af may_af cause_af respiratory_af depression_af ,_af hypotension_af ,_af profound_af sedation_af ,_af potentially_af result_af coma_af death_af ._af"
1914,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,sedatives,effect,"Central_bf Nervous_bf System_bf Depressants:_bf The_bf concomitant_bf use_bf DRUG (fentanyl_be transdermal_be system)_be central_be nervous_be system_be depressants_be ,_be including_be limited_be opioids_be ,_be OTHER_DRUG ,_af hypnotics_af ,_af tranquilizers_af (e_af ._af g_af ._af ,_af benzodiazepines)_af ,_af general_af anesthetics_af ,_af phenothiazines_af ,_af skeletal_af muscle_af relaxants_af ,_af alcohol_af ,_af may_af cause_af respiratory_af depression_af ,_af hypotension_af ,_af profound_af sedation_af ,_af potentially_af result_af coma_af death_af ._af"
1915,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,hypnotics,effect,"Central_bf Nervous_bf System_bf Depressants:_bf The_bf concomitant_bf use_bf DRUG (fentanyl_be transdermal_be system)_be central_be nervous_be system_be depressants_be ,_be including_be limited_be opioids_be ,_be sedatives_be ,_be OTHER_DRUG ,_af tranquilizers_af (e_af ._af g_af ._af ,_af benzodiazepines)_af ,_af general_af anesthetics_af ,_af phenothiazines_af ,_af skeletal_af muscle_af relaxants_af ,_af alcohol_af ,_af may_af cause_af respiratory_af depression_af ,_af hypotension_af ,_af profound_af sedation_af ,_af potentially_af result_af coma_af death_af ._af"
1916,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,tranquilizers,effect,"Central_bf Nervous_bf System_bf Depressants:_bf The_bf concomitant_bf use_bf DRUG (fentanyl_be transdermal_be system)_be central_be nervous_be system_be depressants_be ,_be including_be limited_be opioids_be ,_be sedatives_be ,_be hypnotics_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af benzodiazepines)_af ,_af general_af anesthetics_af ,_af phenothiazines_af ,_af skeletal_af muscle_af relaxants_af ,_af alcohol_af ,_af may_af cause_af respiratory_af depression_af ,_af hypotension_af ,_af profound_af sedation_af ,_af potentially_af result_af coma_af death_af ._af"
1917,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,benzodiazepines,effect,"Central_bf Nervous_bf System_bf Depressants:_bf The_bf concomitant_bf use_bf DRUG (fentanyl_be transdermal_be system)_be central_be nervous_be system_be depressants_be ,_be including_be limited_be opioids_be ,_be sedatives_be ,_be hypnotics_be ,_be tranquilizers_be (e_be ._be g_be ._be ,_be benzodiazepines)_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be skeletal_be muscle_be relaxants_be ,_be alcohol_be ,_be may_be cause_be respiratory_be depression_be ,_be hypotension_be ,_be profound_be sedation_be ,_be potentially_be result_be coma_be death_be ._be"
1918,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,anesthetics,effect,"Central_bf Nervous_bf System_bf Depressants:_bf The_bf concomitant_bf use_bf DRUG (fentanyl_be transdermal_be system)_be central_be nervous_be system_be depressants_be ,_be including_be limited_be opioids_be ,_be sedatives_be ,_be hypnotics_be ,_be tranquilizers_be (e_be ._be g_be ._be ,_be benzodiazepines)_be ,_be general_be OTHER_DRUG ,_af phenothiazines_af ,_af skeletal_af muscle_af relaxants_af ,_af alcohol_af ,_af may_af cause_af respiratory_af depression_af ,_af hypotension_af ,_af profound_af sedation_af ,_af potentially_af result_af coma_af death_af ._af"
1919,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,phenothiazines,effect,"Central_bf Nervous_bf System_bf Depressants:_bf The_bf concomitant_bf use_bf DRUG (fentanyl_be transdermal_be system)_be central_be nervous_be system_be depressants_be ,_be including_be limited_be opioids_be ,_be sedatives_be ,_be hypnotics_be ,_be tranquilizers_be (e_be ._be g_be ._be ,_be benzodiazepines)_be ,_be general_be anesthetics_be ,_be OTHER_DRUG ,_af skeletal_af muscle_af relaxants_af ,_af alcohol_af ,_af may_af cause_af respiratory_af depression_af ,_af hypotension_af ,_af profound_af sedation_af ,_af potentially_af result_af coma_af death_af ._af"
1920,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,skeletal muscle relaxants,effect,"Central_bf Nervous_bf System_bf Depressants:_bf The_bf concomitant_bf use_bf DRUG (fentanyl_be transdermal_be system)_be central_be nervous_be system_be depressants_be ,_be including_be limited_be opioids_be ,_be sedatives_be ,_be hypnotics_be ,_be tranquilizers_be (e_be ._be g_be ._be ,_be benzodiazepines)_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be skeletal_be muscle_be relaxants_be ,_be alcohol_be ,_be may_be cause_be respiratory_be depression_be ,_be hypotension_be ,_be profound_be sedation_be ,_be potentially_be result_be coma_be death_be ._be"
1921,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,alcohol,effect,"Central_bf Nervous_bf System_bf Depressants:_bf The_bf concomitant_bf use_bf DRUG (fentanyl_be transdermal_be system)_be central_be nervous_be system_be depressants_be ,_be including_be limited_be opioids_be ,_be sedatives_be ,_be hypnotics_be ,_be tranquilizers_be (e_be ._be g_be ._be ,_be benzodiazepines)_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be skeletal_be muscle_be relaxants_be ,_be OTHER_DRUG ,_af may_af cause_af respiratory_af depression_af ,_af hypotension_af ,_af profound_af sedation_af ,_af potentially_af result_af coma_af death_af ._af"
1922,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,central nervous system depressants,effect,"Central_bf Nervous_bf System_bf Depressants:_bf The_bf concomitant_bf use_bf DURAGESIC_bf (fentanyl_bf transdermal_bf system)_bf central_bf nervous_bf system_bf depressants_bf ,_bf including_bf limited_bf opioids_bf ,_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf (e_bf ._bf g_bf ._bf ,_bf benzodiazepines)_bf ,_bf general_bf anesthetics_bf ,_bf phenothiazines_bf ,_bf skeletal_bf muscle_bf relaxants_bf ,_bf alcohol_bf ,_bf may_bf cause_bf respiratory_bf depression_bf ,_bf hypotension_bf ,_bf profound_bf sedation_bf ,_bf potentially_bf result_bf coma_bf death_bf ._bf"
1923,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,opioids,effect,"Central_bf Nervous_bf System_bf Depressants:_bf The_bf concomitant_bf use_bf DURAGESIC_bf (fentanyl_bf transdermal_bf system)_bf central_bf nervous_bf system_bf depressants_bf ,_bf including_bf limited_bf OTHER_DRUG ,_be sedatives_be ,_be hypnotics_be ,_be tranquilizers_be (e_be ._be g_be ._be ,_be benzodiazepines)_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be skeletal_be muscle_be relaxants_be ,_be alcohol_be ,_be may_be cause_be respiratory_be depression_be ,_be hypotension_be ,_be profound_be sedation_be ,_be potentially_be result_be coma_be death_be ._be"
1924,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,sedatives,effect,"Central_bf Nervous_bf System_bf Depressants:_bf The_bf concomitant_bf use_bf DURAGESIC_bf (fentanyl_bf transdermal_bf system)_bf central_bf nervous_bf system_bf depressants_bf ,_bf including_bf limited_bf opioids_bf ,_bf OTHER_DRUG ,_be hypnotics_be ,_be tranquilizers_be (e_be ._be g_be ._be ,_be benzodiazepines)_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be skeletal_be muscle_be relaxants_be ,_be alcohol_be ,_be may_be cause_be respiratory_be depression_be ,_be hypotension_be ,_be profound_be sedation_be ,_be potentially_be result_be coma_be death_be ._be"
1925,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,hypnotics,effect,"Central_bf Nervous_bf System_bf Depressants:_bf The_bf concomitant_bf use_bf DURAGESIC_bf (fentanyl_bf transdermal_bf system)_bf central_bf nervous_bf system_bf depressants_bf ,_bf including_bf limited_bf opioids_bf ,_bf sedatives_bf ,_bf OTHER_DRUG ,_be tranquilizers_be (e_be ._be g_be ._be ,_be benzodiazepines)_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be skeletal_be muscle_be relaxants_be ,_be alcohol_be ,_be may_be cause_be respiratory_be depression_be ,_be hypotension_be ,_be profound_be sedation_be ,_be potentially_be result_be coma_be death_be ._be"
1926,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,tranquilizers,effect,"Central_bf Nervous_bf System_bf Depressants:_bf The_bf concomitant_bf use_bf DURAGESIC_bf (fentanyl_bf transdermal_bf system)_bf central_bf nervous_bf system_bf depressants_bf ,_bf including_bf limited_bf opioids_bf ,_bf sedatives_bf ,_bf hypnotics_bf ,_bf OTHER_DRUG (e_be ._be g_be ._be ,_be benzodiazepines)_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be skeletal_be muscle_be relaxants_be ,_be alcohol_be ,_be may_be cause_be respiratory_be depression_be ,_be hypotension_be ,_be profound_be sedation_be ,_be potentially_be result_be coma_be death_be ._be"
1927,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,benzodiazepines,effect,"Central_bf Nervous_bf System_bf Depressants:_bf The_bf concomitant_bf use_bf DURAGESIC_bf (fentanyl_bf transdermal_bf system)_bf central_bf nervous_bf system_bf depressants_bf ,_bf including_bf limited_bf opioids_bf ,_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf (e_bf ._bf g_bf ._bf ,_bf benzodiazepines)_bf ,_bf general_bf anesthetics_bf ,_bf phenothiazines_bf ,_bf skeletal_bf muscle_bf relaxants_bf ,_bf alcohol_bf ,_bf may_bf cause_bf respiratory_bf depression_bf ,_bf hypotension_bf ,_bf profound_bf sedation_bf ,_bf potentially_bf result_bf coma_bf death_bf ._bf"
1928,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,anesthetics,effect,"Central_bf Nervous_bf System_bf Depressants:_bf The_bf concomitant_bf use_bf DURAGESIC_bf (fentanyl_bf transdermal_bf system)_bf central_bf nervous_bf system_bf depressants_bf ,_bf including_bf limited_bf opioids_bf ,_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf (e_bf ._bf g_bf ._bf ,_bf benzodiazepines)_bf ,_bf general_bf OTHER_DRUG ,_be phenothiazines_be ,_be skeletal_be muscle_be relaxants_be ,_be alcohol_be ,_be may_be cause_be respiratory_be depression_be ,_be hypotension_be ,_be profound_be sedation_be ,_be potentially_be result_be coma_be death_be ._be"
1929,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,phenothiazines,effect,"Central_bf Nervous_bf System_bf Depressants:_bf The_bf concomitant_bf use_bf DURAGESIC_bf (fentanyl_bf transdermal_bf system)_bf central_bf nervous_bf system_bf depressants_bf ,_bf including_bf limited_bf opioids_bf ,_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf (e_bf ._bf g_bf ._bf ,_bf benzodiazepines)_bf ,_bf general_bf anesthetics_bf ,_bf OTHER_DRUG ,_be skeletal_be muscle_be relaxants_be ,_be alcohol_be ,_be may_be cause_be respiratory_be depression_be ,_be hypotension_be ,_be profound_be sedation_be ,_be potentially_be result_be coma_be death_be ._be"
1930,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,skeletal muscle relaxants,effect,"Central_bf Nervous_bf System_bf Depressants:_bf The_bf concomitant_bf use_bf DURAGESIC_bf (fentanyl_bf transdermal_bf system)_bf central_bf nervous_bf system_bf depressants_bf ,_bf including_bf limited_bf opioids_bf ,_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf (e_bf ._bf g_bf ._bf ,_bf benzodiazepines)_bf ,_bf general_bf anesthetics_bf ,_bf phenothiazines_bf ,_bf skeletal_bf muscle_bf relaxants_bf ,_bf alcohol_bf ,_bf may_bf cause_bf respiratory_bf depression_bf ,_bf hypotension_bf ,_bf profound_bf sedation_bf ,_bf potentially_bf result_bf coma_bf death_bf ._bf"
1931,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,alcohol,effect,"Central_bf Nervous_bf System_bf Depressants:_bf The_bf concomitant_bf use_bf DURAGESIC_bf (fentanyl_bf transdermal_bf system)_bf central_bf nervous_bf system_bf depressants_bf ,_bf including_bf limited_bf opioids_bf ,_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf (e_bf ._bf g_bf ._bf ,_bf benzodiazepines)_bf ,_bf general_bf anesthetics_bf ,_bf phenothiazines_bf ,_bf skeletal_bf muscle_bf relaxants_bf ,_bf OTHER_DRUG ,_be may_be cause_be respiratory_be depression_be ,_be hypotension_be ,_be profound_be sedation_be ,_be potentially_be result_be coma_be death_be ._be"
1932,MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics,DURAGESIC,MAOI,advise,MAO_bf Inhibitors:_bf DRUG recommended_be use_be patients_be received_be OTHER_DRUG within_af 14_af days_af severe_af unpredictable_af potentiation_af MAO_af inhibitors_af reported_af opioid_af analgesics_af
1933,MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics,MAO inhibitors,opioid analgesics,advise,MAO_bf Inhibitors:_bf DURAGESIC_bf recommended_bf use_bf patients_bf received_bf MAOI_bf within_bf 14_bf days_bf severe_bf unpredictable_bf potentiation_bf MAO_bf inhibitors_bf reported_bf opioid_bf analgesics_bf
1934,"However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.",fexofenadine hydrochloride,ketoconazole,mechanism,"However_bf ,_bf co_bf administration_bf fexofenadine_bf hydrochloride_bf either_bf OTHER_DRUG erythromycin_be led_be increased_be plasma_be concentrations_be fexofenadine_be ._be"
1935,"However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.",fexofenadine hydrochloride,erythromycin,mechanism,"However_bf ,_bf co_bf administration_bf fexofenadine_bf hydrochloride_bf either_bf ketoconazole_bf OTHER_DRUG led_be increased_be plasma_be concentrations_be fexofenadine_be ._be"
1936,These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.,ketoconazole,fexofenadine,mechanism,These_bf studies_bf indicate_bf DRUG erythromycin_be co-administration_be enhances_be OTHER_DRUG gastrointestinal_af absorption_af ._af
1937,These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.,erythromycin,fexofenadine,mechanism,These_bf studies_bf indicate_bf ketoconazole_bf DRUG co-administration_be enhances_be OTHER_DRUG gastrointestinal_af absorption_af ._af
1938,"This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.",ketoconazole,fexofenadine,mechanism,"This_bf observed_bf increase_bf bioavailability_bf OTHER_DRUG may_be due_be transport-related_be effects_be ,_be p-glycoprotein_be ._be vivo_be animal_be studies_be also_be suggest_be addition_be enhancing_be absorption_be ,_be DRUG decreases_af OTHER_DRUG gastrointestinal_af secretion_af ,_af erythromycin_af may_af also_af decrease_af biliary_af excretion_af ._af"
1939,Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.,fexofenadine hydrochloride,aluminum,mechanism,Drug_bf Interactions_bf Antacids_bf Administration_bf 120_bf mg_bf fexofenadine_bf hydrochloride_bf (2_bf x_bf 60_bf mg_bf capsule)_bf within_bf 15_bf minutes_bf OTHER_DRUG magnesium_be containing_be antacid_be (Maalox_be )_be decreased_be fexofenadine_be AUC_be 41%_be cmax_be 43%_be ._be
1940,Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.,fexofenadine hydrochloride,magnesium,mechanism,Drug_bf Interactions_bf Antacids_bf Administration_bf 120_bf mg_bf fexofenadine_bf hydrochloride_bf (2_bf x_bf 60_bf mg_bf capsule)_bf within_bf 15_bf minutes_bf aluminum_bf OTHER_DRUG containing_be antacid_be (Maalox_be )_be decreased_be fexofenadine_be AUC_be 41%_be cmax_be 43%_be ._be
1941,Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.,fexofenadine hydrochloride,antacid,mechanism,Drug_bf Interactions_bf Antacids_bf Administration_bf 120_bf mg_bf fexofenadine_bf hydrochloride_bf (2_bf x_bf 60_bf mg_bf capsule)_bf within_bf 15_bf minutes_bf aluminum_bf magnesium_bf containing_bf OTHER_DRUG (Maalox_be )_be decreased_be fexofenadine_be AUC_be 41%_be cmax_be 43%_be ._be
1942,Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.,fexofenadine hydrochloride,Maalox,mechanism,Drug_bf Interactions_bf Antacids_bf Administration_bf 120_bf mg_bf fexofenadine_bf hydrochloride_bf (2_bf x_bf 60_bf mg_bf capsule)_bf within_bf 15_bf minutes_bf aluminum_bf magnesium_bf containing_bf antacid_bf (Maalox_bf )_bf decreased_bf fexofenadine_bf AUC_bf 41%_bf cmax_bf 43%_bf ._bf
1943,ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.,ALLEGRA,aluminum,advise,DRUG taken_be closely_be time_be OTHER_DRUG magnesium_af containing_af antacids_af ._af
1944,ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.,ALLEGRA,magnesium,advise,DRUG taken_be closely_be time_be aluminum_be OTHER_DRUG containing_af antacids_af ._af
1945,"During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.",TAMBOCOR,digoxin,mechanism,"During_bf administration_bf multiple_bf oral_bf doses_bf DRUG healthy_be subjects_be stabilized_be maintenance_be dose_be OTHER_DRUG ,_af 13%-19%_af increase_af plasma_af OTHER_DRUG levels_af occurred_af six_af hours_af postdose_af ._af"
1946,"In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.",TAMBOCOR,propranolol,mechanism,"In_bf study_bf involving_bf healthy_bf subjects_bf receiving_bf DRUG OTHER_DRUG concurrently_af ,_af plasma_af flecainide_af levels_af increased_af 20%_af OTHER_DRUG levels_af increased_af 30%_af compared_af control_af values_af ._af"
1947,The effects of concomitant administration of TAMBOCOR and propranolol on the PR interval were less than additive.,TAMBOCOR,propranolol,effect,The_bf effects_bf concomitant_bf administration_bf DRUG OTHER_DRUG PR_af interval_af less_af additive_af ._af
1948,"Nevertheless, the possibility of additive negative inotropic effects of beta blockers and flecainide should be recognized.",beta blockers,flecainide,effect,"Nevertheless_bf ,_bf possibility_bf additive_bf negative_bf inotropic_bf effects_bf beta_bf blockers_bf OTHER_DRUG recognized_be ._be"
1949,"Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.",phenytoin,flecainide,mechanism,"Limited_bf data_bf patients_bf receiving_bf known_bf enzyme_bf inducers_bf (_bf DRUG ,_be phenobarbital_be ,_be carbamazepine_be )_be indicate_be 30%_be increase_be rate_be OTHER_DRUG elimination_af ._af"
1950,"Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.",phenobarbital,flecainide,mechanism,"Limited_bf data_bf patients_bf receiving_bf known_bf enzyme_bf inducers_bf (_bf phenytoin_bf ,_bf DRUG ,_be carbamazepine_be )_be indicate_be 30%_be increase_be rate_be OTHER_DRUG elimination_af ._af"
1951,"Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.",carbamazepine,flecainide,mechanism,"Limited_bf data_bf patients_bf receiving_bf known_bf enzyme_bf inducers_bf (_bf phenytoin_bf ,_bf phenobarbital_bf ,_bf DRUG )_be indicate_be 30%_be increase_be rate_be OTHER_DRUG elimination_af ._af"
1952,"In healthy subjects receiving cimetidine (1 gm daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%.",cimetidine,flecainide,mechanism,"In_bf healthy_bf subjects_bf receiving_bf DRUG (1_be gm_be daily)_be one_be week_be ,_be plasma_be OTHER_DRUG levels_af increased_af 30%_af half-life_af increased_af 10%_af ._af"
1953,"When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.",amiodarone,flecainide,mechanism,"When_bf DRUG added_be OTHER_DRUG therapy_af ,_af plasma_af OTHER_DRUG levels_af may_af increase_af two-fold_af patients_af ,_af OTHER_DRUG dosage_af reduced_af ._af"
1954,"Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy;",quinidine,flecainide,mechanism,"Drugs_bf inhibit_bf cytochrome_bf P450IID6_bf ,_bf DRUG ,_be might_be increase_be plasma_be concentrations_be OTHER_DRUG patients_af chronic_af OTHER_DRUG therapy;_af"
1955,"Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.",disopyramide,TAMBOCOR,advise,"Because_bf drugs_bf negative_bf inotropic_bf properties_bf effects_bf coadministration_bf OTHER_DRUG unknown_be ,_be neither_be DRUG verapamil_af administered_af concurrently_af OTHER_DRUG unless_af ,_af judgment_af physician_af ,_af benefits_af combination_af outweigh_af risks_af ._af"
1956,"Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.",verapamil,TAMBOCOR,advise,"Because_bf drugs_bf negative_bf inotropic_bf properties_bf effects_bf coadministration_bf OTHER_DRUG unknown_be ,_be neither_be disopyramide_be DRUG administered_af concurrently_af OTHER_DRUG unless_af ,_af judgment_af physician_af ,_af benefits_af combination_af outweigh_af risks_af ._af"
1957,Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy.,steroids,aspirin,effect,Rarely_bf salicylate_bf toxicity_bf may_bf occur_bf patients_bf discontinue_bf DRUG concurrent_be high-dose_be OTHER_DRUG therapy_af ._af
1958,"Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.",Barbiturates,fludrocortisone acetate,mechanism,"DRUG ,_be phenytoin_be ,_be rifampin_be increased_be metabolic_be clearance_be fludrocortisone_be acetate_be induction_be hepatic_be enzymes_be ._be"
1959,"Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.",phenytoin,fludrocortisone acetate,mechanism,"Barbiturates_bf ,_bf DRUG ,_be rifampin_be increased_be metabolic_be clearance_be fludrocortisone_be acetate_be induction_be hepatic_be enzymes_be ._be"
1960,"Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.",rifampin,fludrocortisone acetate,mechanism,"Barbiturates_bf ,_bf phenytoin_bf ,_bf DRUG increased_be metabolic_be clearance_be fludrocortisone_be acetate_be induction_be hepatic_be enzymes_be ._be"
1961,Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.,ROMAZICON,cyclic antidepressants,effect,Particular_bf caution_bf necessary_bf using_bf DRUG cases_be mixed_be drug_be overdosage_be since_be toxic_be effects_be (such_be convulsions_be cardiac_be dysrhythmias)_be drugs_be taken_be overdose_be (especially_be cyclic_be antidepressants)_be may_be emerge_be reversal_be benzodiazepine_be effect_be flumazenil_be ._be
1962,"Although ROMAZICON exerts a slight intrinsic anticonvulsant effect, its abrupt suppression of the protective effect of a benzodiazepine agonist can give rise to convulsions in epileptic patients.",ROMAZICON,benzodiazepine,effect,"Although_bf DRUG exerts_be slight_be intrinsic_be anticonvulsant_be effect_be ,_be abrupt_be suppression_be protective_be effect_be OTHER_DRUG agonist_af give_af rise_af convulsions_af epileptic_af patients_af ._af"
1963,ROMAZICON blocks the central effects of benzodiazepines by competitive interaction at the receptor level.,ROMAZICON,benzodiazepines,effect,DRUG blocks_be central_be effects_be OTHER_DRUG competitive_af interaction_af receptor_af level_af ._af
1964,"The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as zopiclone, triazolopyridazines and others, are also blocked by ROMAZICON.",zopiclone,ROMAZICON,effect,"The_bf effects_bf nonbenzodiazepine_bf agonists_bf benzodiazepine_bf receptors_bf ,_bf DRUG ,_be triazolopyridazines_be others_be ,_be also_be blocked_be OTHER_DRUG ._af"
1965,Wait 5 weeks after stopping escitalopram before starting a non-selective MAO inhibitor.,escitalopram,non-selective MAO inhibitor,advise,Wait_bf 5_bf weeks_bf stopping_bf DRUG starting_be non-selective_be MAO_be inhibitor_be ._be
1966,Wait 2 weeks after stopping an MAO inhibitor before starting escitalopram.,MAO inhibitor,escitalopram,advise,Wait_bf 2_bf weeks_bf stopping_bf MAO_bf inhibitor_bf starting_bf OTHER_DRUG ._be
1967,Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.,oxyphenbutazone,androgens,mechanism,Concurrent_bf administration_bf DRUG OTHER_DRUG may_af result_af elevated_af serum_af levels_af DRUG ._af
1968,"In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.",androgens,insulin,effect,"In_bf diabetic_bf patients_bf ,_bf metabolic_bf effects_bf DRUG may_be decrease_be blood_be glucose_be therefore_be ,_be OTHER_DRUG requirements_af ._af"
1969,"Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",Flupenthixol,Monoamine oxidase inhibitors,int,"Drug_bf Interactions:_bf DRUG may_be interact_be drugs_be ,_be like_be Monoamine_be oxidase_be inhibitors_be (MAOI):_be MAOI_be could_be theoretically_be affect_be DRUG pharmacodynamics_af -_af Arecoline_af -_af Eproxindine_af -_af Ethanol:_af DRUG Ethanol_af cause_af additive_af CNS_af depression_af -_af Tricyclic_af antidepressants:_af DRUG increases_af effect_af Tricyclic_af antidepressants_af"
1970,"Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",Flupenthixol,MAOI,int,"Drug_bf Interactions:_bf DRUG may_be interact_be drugs_be ,_be like_be Monoamine_be oxidase_be inhibitors_be (MAOI):_be OTHER_DRUG could_af theoretically_af affect_af DRUG pharmacodynamics_af -_af Arecoline_af -_af Eproxindine_af -_af Ethanol:_af DRUG Ethanol_af cause_af additive_af CNS_af depression_af -_af Tricyclic_af antidepressants:_af DRUG increases_af effect_af Tricyclic_af antidepressants_af"
1971,"Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",MAOI,flupenthixol,effect,"Drug_bf Interactions:_bf OTHER_DRUG may_be interact_be drugs_be ,_be like_be Monoamine_be oxidase_be inhibitors_be (MAOI):_be DRUG could_af theoretically_af affect_af OTHER_DRUG pharmacodynamics_af -_af Arecoline_af -_af Eproxindine_af -_af Ethanol:_af OTHER_DRUG Ethanol_af cause_af additive_af CNS_af depression_af -_af Tricyclic_af antidepressants:_af OTHER_DRUG increases_af effect_af Tricyclic_af antidepressants_af"
1972,"Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",Flupenthixol,Ethanol,effect,"Drug_bf Interactions:_bf DRUG may_be interact_be drugs_be ,_be like_be Monoamine_be oxidase_be inhibitors_be (MAOI):_be MAOI_be could_be theoretically_be affect_be DRUG pharmacodynamics_af -_af Arecoline_af -_af Eproxindine_af -_af Ethanol:_af DRUG OTHER_DRUG cause_af additive_af CNS_af depression_af -_af Tricyclic_af antidepressants:_af DRUG increases_af effect_af Tricyclic_af antidepressants_af"
1973,"Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",Flupenthixol,Tricyclic antidepressants,effect,"Drug_bf Interactions:_bf DRUG may_be interact_be drugs_be ,_be like_be Monoamine_be oxidase_be inhibitors_be (MAOI):_be MAOI_be could_be theoretically_be affect_be DRUG pharmacodynamics_af -_af Arecoline_af -_af Eproxindine_af -_af Ethanol:_af DRUG Ethanol_af cause_af additive_af CNS_af depression_af -_af Tricyclic_af antidepressants:_af DRUG increases_af effect_af Tricyclic_af antidepressants_af"
1974,Increases in prothrombin time have been noted in patients receiving long- term warfarin therapy after flutamide was initiated.,warfarin,flutamide,effect,Increases_bf prothrombin_bf time_bf noted_bf patients_bf receiving_bf long-_bf term_bf DRUG therapy_be OTHER_DRUG initiated_af ._af
1975,"Therefore, close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when EULEXIN Capsules are administered concomitantly with warfarin.",EULEXIN,warfarin,advise,"Therefore_bf ,_bf close_bf monitoring_bf prothrombin_bf time_bf recommended_bf adjustment_bf anticoagulant_bf dose_bf may_bf necessary_bf DRUG Capsules_be administered_be concomitantly_be OTHER_DRUG ._af"
1976,"In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.",serotonin reuptake inhibitor drug,monoamine oxidase inhibitors,effect,"In_bf patients_bf receiving_bf another_bf serotonin_bf reuptake_bf inhibitor_bf drug_bf combination_bf monoamine_bf oxidase_bf inhibitors_bf (MAOI)_bf ,_bf reports_bf serious_bf ,_bf sometimes_bf fatal_bf ,_bf reactions_bf including_bf hyperthermia_bf ,_bf rigidity_bf ,_bf myoclonus_bf ,_bf autonomic_bf instability_bf possible_bf rapid_bf fluctuations_bf vital_bf signs_bf ,_bf mental_bf status_bf changes_bf include_bf extreme_bf agitation_bf progressing_bf delirium_bf coma_bf ._bf"
1977,"In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.",serotonin reuptake inhibitor drug,MAOI,effect,"In_bf patients_bf receiving_bf another_bf serotonin_bf reuptake_bf inhibitor_bf drug_bf combination_bf monoamine_bf oxidase_bf inhibitors_bf (MAOI)_bf ,_bf reports_bf serious_bf ,_bf sometimes_bf fatal_bf ,_bf reactions_bf including_bf hyperthermia_bf ,_bf rigidity_bf ,_bf myoclonus_bf ,_bf autonomic_bf instability_bf possible_bf rapid_bf fluctuations_bf vital_bf signs_bf ,_bf mental_bf status_bf changes_bf include_bf extreme_bf agitation_bf progressing_bf delirium_bf coma_bf ._bf"
1978,"Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.",Fluvoxamine,MAOIs,advise,"Therefore_bf ,_bf recommended_bf DRUG Tablets_be used_be combination_be OTHER_DRUG ,_af within_af 14_af days_af discontinuing_af treatment_af MAOI_af ._af"
1979,"Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.",Fluvoxamine,MAOI,advise,"Therefore_bf ,_bf recommended_bf DRUG Tablets_be used_be combination_be MAOIs_be ,_be within_be 14_be days_be discontinuing_be treatment_be OTHER_DRUG ._af"
1980,"After stopping Fluvoxamine Tablets, at least 2 weeks should be allowed before starting a MAOI.",Fluvoxamine,MAOI,advise,"After_bf stopping_bf DRUG Tablets_be ,_be least_be 2_be weeks_be allowed_be starting_be OTHER_DRUG ._af"
1981,"Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.",Terfenadine,ketoconazole,mechanism,"DRUG ,_be astemizole_be cisapride_be metabolized_be cytochrome_be P450IIIA4_be isozyme_be ,_be demonstrated_be OTHER_DRUG ,_af potent_af inhibitor_af IIIA4_af ,_af blocks_af metabolism_af drugs_af ,_af resulting_af increased_af plasma_af concentrations_af parent_af drug_af ._af"
1982,"Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.",astemizole,ketoconazole,mechanism,"Terfenadine_bf ,_bf DRUG cisapride_be metabolized_be cytochrome_be P450IIIA4_be isozyme_be ,_be demonstrated_be OTHER_DRUG ,_af potent_af inhibitor_af IIIA4_af ,_af blocks_af metabolism_af drugs_af ,_af resulting_af increased_af plasma_af concentrations_af parent_af drug_af ._af"
1983,"Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.",cisapride,ketoconazole,mechanism,"Terfenadine_bf ,_bf astemizole_bf DRUG metabolized_be cytochrome_be P450IIIA4_be isozyme_be ,_be demonstrated_be OTHER_DRUG ,_af potent_af inhibitor_af IIIA4_af ,_af blocks_af metabolism_af drugs_af ,_af resulting_af increased_af plasma_af concentrations_af parent_af drug_af ._af"
1984,"Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.",fluvoxamine,alprazolam,int,"Although_bf definitively_bf demonstrated_bf DRUG potent_be IIIA4_be inhibitor_be ,_be likely_be ,_be given_be substantial_be interaction_be DRUG OTHER_DRUG ._af"
1985,"Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.",fluvoxamine,terbinafine,advise,"Consequently_bf ,_bf recommended_bf DRUG used_be combination_be either_be OTHER_DRUG ,_af astemizole_af ,_af cisapride_af ._af"
1986,"Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.",fluvoxamine,astemizole,advise,"Consequently_bf ,_bf recommended_bf DRUG used_be combination_be either_be terbinafine_be ,_be OTHER_DRUG ,_af cisapride_af ._af"
1987,"Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.",fluvoxamine,cisapride,advise,"Consequently_bf ,_bf recommended_bf DRUG used_be combination_be either_be terbinafine_be ,_be astemizole_be ,_be OTHER_DRUG ._af"
1988,"Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.",Benzodiazepines,fluvoxamine,mechanism,"Other_bf Potentially_bf Important_bf Drug_bf Interactions:_bf Benzodiazepines:_bf DRUG metabolized_be hepatic_be oxidation_be (e_be ._be g_be ._be ,_be alprazolam_be ,_be midazolam_be ,_be triazolam_be elc_be ._be )_be used_be caution_be clearance_be drugs_be likely_be reduced_be OTHER_DRUG ._af"
1989,"Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.",alprazolam,fluvoxamine,mechanism,"Other_bf Potentially_bf Important_bf Drug_bf Interactions:_bf Benzodiazepines:_bf Benzodiazepines_bf metabolized_bf hepatic_bf oxidation_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be midazolam_be ,_be triazolam_be elc_be ._be )_be used_be caution_be clearance_be drugs_be likely_be reduced_be OTHER_DRUG ._af"
1990,"Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.",midazolam,fluvoxamine,mechanism,"Other_bf Potentially_bf Important_bf Drug_bf Interactions:_bf Benzodiazepines:_bf Benzodiazepines_bf metabolized_bf hepatic_bf oxidation_bf (e_bf ._bf g_bf ._bf ,_bf alprazolam_bf ,_bf DRUG ,_be triazolam_be elc_be ._be )_be used_be caution_be clearance_be drugs_be likely_be reduced_be OTHER_DRUG ._af"
1991,"Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.",triazolam,fluvoxamine,mechanism,"Other_bf Potentially_bf Important_bf Drug_bf Interactions:_bf Benzodiazepines:_bf Benzodiazepines_bf metabolized_bf hepatic_bf oxidation_bf (e_bf ._bf g_bf ._bf ,_bf alprazolam_bf ,_bf midazolam_bf ,_bf DRUG elc_be ._be )_be used_be caution_be clearance_be drugs_be likely_be reduced_be OTHER_DRUG ._af"
1992,"Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;",fluvoxamine maleate,alprazolam,mechanism,"Alprazolam:_bf When_bf fluvoxamine_bf maleate_bf (100_bf mg_bf qd)_bf OTHER_DRUG (1_be mg_be q_be ._be ._be co-administered_be steady_be state_be ,_be plasma_be concentration_be pharmacokinetics_be parameters_be (AUC_be ,_be Cmax_be ,_be T1/2_be ,_be )_be OTHER_DRUG approximately_af twice_af observed_af OTHER_DRUG administered_af alone;_af"
1993,"This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.",alprazolam,Fluvoxamine,advise,"This_bf interaction_bf ,_bf investigated_bf using_bf higher_bf doses_bf OTHER_DRUG ,_be may_be pronounced_be 300_be mg_be daily_be dose_be co-administered_be ,_be particularly_be since_be OTHER_DRUG exhibits_af non-linear_af pharmacokinetics_af dosage_af range_af 100-300_af mg_af ._af If_af DRUG co-administered_af OTHER_DRUG Tablets_af ,_af initial_af DRUG dosage_af least_af halved_af titration_af lowest_af effective_af dose_af recommended_af ._af"
1994,Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.,Fluvoxamine,diazepam,advise,Diazepam:_bf The_bf co-administration_bf DRUG Tablets_be OTHER_DRUG generally_af advisable_af ._af
1995,"Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.",fluvoxamine,diazepam,mechanism,"Because_bf DRUG reduces_be clearance_be OTHER_DRUG active_af metabolite_af ,_af N-desmethyldiazepam_af ,_af strong_af likelihood_af substantial_af accumulation_af species_af chronic_af co-administration_af ._af"
1996,"Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.",fluvoxamine,N-desmethyldiazepam,mechanism,"Because_bf DRUG reduces_be clearance_be diazepam_be active_be metabolite_be ,_be OTHER_DRUG ,_af strong_af likelihood_af substantial_af accumulation_af species_af chronic_af co-administration_af ._af"
1997,Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.,fluvoxamine,diazepam,advise,Evidence_bf supporting_bf conclusion_bf inadvisable_bf co-administer_bf DRUG OTHER_DRUG derived_af study_af healthy_af volunteers_af taking_af 150_af mg/day_af DRUG administered_af single_af oral_af dose_af 10_af mg_af OTHER_DRUG ._af
1998,"Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.",alprazolam,fluvoxamine,effect,"Moreover_bf ,_bf noted_bf DRUG ,_be effect_be OTHER_DRUG may_af even_af pronounced_af administered_af higher_af doses_af ._af"
1999,"Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.",diazepam,fluvoxamine,advise,"Accordingly_bf ,_bf DRUG OTHER_DRUG ordinarily_af co-administered_af ._af"
2000,"Therefore, if theophylline is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.",theophylline,fluvoxamine maleate,advise,"Therefore_bf ,_bf DRUG co-administered_be fluvoxamine_be maleate_be ,_be dose_be reduced_be one_be third_be usual_be daily_be maintenance_be dose_be plasma_be concentrations_be DRUG monitored_af ._af"
2001,"Warfarin: When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.",fluvoxamine maleate,warfarin,mechanism,"Warfarin:_bf When_bf fluvoxamine_bf maleate_bf (50_bf mg_bf tid)_bf administered_bf concomitantly_bf OTHER_DRUG two_be weeks_be ,_be OTHER_DRUG plasma_af concentrations_af increased_af 98%_af prothrombin_af times_af prolonged_af ._af"
2002,Thus patients receiving oral anticoagulants and Fluvoxamine Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly.,anticoagulants,Fluvoxamine,advise,Thus_bf patients_bf receiving_bf oral_bf DRUG OTHER_DRUG Tablets_af prothrombin_af time_af monitored_af anticoagulant_af dose_af adjusted_af accordingly_af ._af
2003,"Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.",vitamin B12,folic acid,int,"Medications_bf interfere_bf folate_bf utilization_bf ,_bf including:_bf anticonvulsant_bf medications_bf (such_bf phenytoin_bf ,_bf primidone)_bf metformin_bf (sometimes_bf prescribed_bf control_bf blood_bf sugar_bf type_bf 2_bf diabetes)_bf sulfasalazine_bf (used_bf control_bf inflammation_bf associated_bf Crohns_bf disease_bf ulcerative_bf colitis)_bf triamterene_bf (a_bf diuretic)_bf Methotrexate_bf There_bf concern_bf interaction_bf vitamin_bf B12_bf folic_bf acid_bf ._bf"
2004,Concomitant administration of other sympathomimetic agents may potentiate the undesirable effects of FORADIL.,sympathomimetic agents,FORADIL,effect,Concomitant_bf administration_bf sympathomimetic_bf agents_bf may_bf potentiate_bf undesirable_bf effects_bf OTHER_DRUG ._be
2005,Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.,FORADIL,monoamine oxidase inhibitors,advise,Monoamine_bf Oxidase_bf Inhibitors_bf Tricyclic_bf Antidepressants:_bf DRUG administered_be extreme_be caution_be patients_be treated_be monoamine_be oxidase_be inhibitors_be tricyclic_be antidepressants_be action_be formoterol_be cardiovascular_be system_be may_be potentiated_be agents_be ._be
2006,Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.,FORADIL,tricyclic antidepressants,advise,Monoamine_bf Oxidase_bf Inhibitors_bf Tricyclic_bf Antidepressants:_bf DRUG administered_be extreme_be caution_be patients_be treated_be monoamine_be oxidase_be inhibitors_be tricyclic_be antidepressants_be action_be formoterol_be cardiovascular_be system_be may_be potentiated_be agents_be ._be
2007,"Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.",xanthine derivatives,beta2-agonists.,effect,"Corticosteroids_bf ,_bf Methylxanthines_bf Diuretics:_bf Concomitant_bf treatment_bf xanthine_bf derivatives_bf ,_bf steroids_bf ,_bf diuretics_bf may_bf potentiate_bf possible_bf hypokalemic_bf effect_bf beta2-agonists_bf ._bf"
2008,"Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.",steroids,beta2-agonists.,effect,"Corticosteroids_bf ,_bf Methylxanthines_bf Diuretics:_bf Concomitant_bf treatment_bf xanthine_bf derivatives_bf ,_bf DRUG ,_be diuretics_be may_be potentiate_be possible_be hypokalemic_be effect_be beta2-agonists_be ._be"
2009,"Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.",diuretics,beta2-agonists.,effect,"Corticosteroids_bf ,_bf Methylxanthines_bf Diuretics:_bf Concomitant_bf treatment_bf xanthine_bf derivatives_bf ,_bf steroids_bf ,_bf DRUG may_be potentiate_be possible_be hypokalemic_be effect_be beta2-agonists_be ._be"
2010,A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.,FOSCAVIR,pentamidine,int,A_bf possible_bf drug_bf interaction_bf DRUG intravenous_be OTHER_DRUG described_af ._af
2011,Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;,FOSCAVIR,pentamidine,effect,Concomitant_bf treatment_bf four_bf patients_bf United_bf Kingdom_bf DRUG intravenous_be OTHER_DRUG may_af caused_af hypocalcemia;_af
2012,"Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.",FOSCAVIR,aminoglycosides,advise,"Because_bf foscarnets_bf tendency_bf cause_bf renal_bf impairment_bf ,_bf use_bf DRUG avoided_be combination_be potentially_be nephrotoxic_be drugs_be OTHER_DRUG ,_af amphotericin_af B_af intravenous_af pentamidine_af unless_af potential_af benefits_af outweigh_af risks_af patient_af ._af"
2013,"Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.",FOSCAVIR,amphotericin B,advise,"Because_bf foscarnets_bf tendency_bf cause_bf renal_bf impairment_bf ,_bf use_bf DRUG avoided_be combination_be potentially_be nephrotoxic_be drugs_be aminoglycosides_be ,_be amphotericin_be B_be intravenous_be pentamidine_be unless_be potential_be benefits_be outweigh_be risks_be patient_be ._be"
2014,"Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.",FOSCAVIR,pentamidine,advise,"Because_bf foscarnets_bf tendency_bf cause_bf renal_bf impairment_bf ,_bf use_bf DRUG avoided_be combination_be potentially_be nephrotoxic_be drugs_be aminoglycosides_be ,_be amphotericin_be B_be intravenous_be OTHER_DRUG unless_af potential_af benefits_af outweigh_af risks_af patient_af ._af"
2015,"Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.",MONUROL,metoclopramide,mechanism,"Metoclopramide:_bf When_bf coadministered_bf DRUG ,_be OTHER_DRUG ,_af drug_af increases_af gastrointestinal_af motility_af ,_af lowers_af serum_af concentration_af urinary_af excretion_af fosfomycin_af ._af"
2016,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",ergotamine,FROVA,advise,"Due_bf theoretical_bf risk_bf pharmacodynamic_bf interaction_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf dihydroergotamine_bf methysergide)_bf OTHER_DRUG within_be 24_be hours_be avoided_be (see_be href=_be frova_od_be ._be htm#CI_be CONTRAINDICATIONS)_be ._be"
2017,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",ergot-type medications,FROVA,advise,"Due_bf theoretical_bf risk_bf pharmacodynamic_bf interaction_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf dihydroergotamine_bf methysergide)_bf OTHER_DRUG within_be 24_be hours_be avoided_be (see_be href=_be frova_od_be ._be htm#CI_be CONTRAINDICATIONS)_be ._be"
2018,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",dihydroergotamine,FROVA,advise,"Due_bf theoretical_bf risk_bf pharmacodynamic_bf interaction_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf DRUG methysergide)_be OTHER_DRUG within_af 24_af hours_af avoided_af (see_af href=_af frova_od_af ._af htm#CI_af CONTRAINDICATIONS)_af ._af"
2019,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",methysergide,FROVA,advise,"Due_bf theoretical_bf risk_bf pharmacodynamic_bf interaction_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf dihydroergotamine_bf methysergide)_bf OTHER_DRUG within_be 24_be hours_be avoided_be (see_be href=_be frova_od_be ._be htm#CI_be CONTRAINDICATIONS)_be ._be"
2020,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",Selective serotonin reuptake inhibitors,5-HT1 agonists,effect,"Selective_bf serotonin_bf reuptake_bf inhibitors_bf (SSRIs)_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf paroxetine_bf ,_bf sertraline)_bf reported_bf ,_bf rarely_bf ,_bf cause_bf weakness_bf ,_bf hyperreflexia_bf ,_bf incoordination_bf coadministered_bf 5-HT1_bf agonists_bf ._bf"
2021,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",SSRIs,5-HT1 agonists,effect,"Selective_bf serotonin_bf reuptake_bf inhibitors_bf (SSRIs)_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf paroxetine_bf ,_bf sertraline)_bf reported_bf ,_bf rarely_bf ,_bf cause_bf weakness_bf ,_bf hyperreflexia_bf ,_bf incoordination_bf coadministered_bf 5-HT1_bf agonists_bf ._bf"
2022,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",fluoxetine,5-HT1 agonists,effect,"Selective_bf serotonin_bf reuptake_bf inhibitors_bf (SSRIs)_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be fluvoxamine_be ,_be paroxetine_be ,_be sertraline)_be reported_be ,_be rarely_be ,_be cause_be weakness_be ,_be hyperreflexia_be ,_be incoordination_be coadministered_be 5-HT1_be agonists_be ._be"
2023,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",fluvoxamine,5-HT1 agonists,effect,"Selective_bf serotonin_bf reuptake_bf inhibitors_bf (SSRIs)_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf DRUG ,_be paroxetine_be ,_be sertraline)_be reported_be ,_be rarely_be ,_be cause_be weakness_be ,_be hyperreflexia_be ,_be incoordination_be coadministered_be 5-HT1_be agonists_be ._be"
2024,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",paroxetine,5-HT1 agonists,effect,"Selective_bf serotonin_bf reuptake_bf inhibitors_bf (SSRIs)_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf DRUG ,_be sertraline)_be reported_be ,_be rarely_be ,_be cause_be weakness_be ,_be hyperreflexia_be ,_be incoordination_be coadministered_be 5-HT1_be agonists_be ._be"
2025,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",sertraline,5-HT1 agonists,effect,"Selective_bf serotonin_bf reuptake_bf inhibitors_bf (SSRIs)_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf paroxetine_bf ,_bf sertraline)_bf reported_bf ,_bf rarely_bf ,_bf cause_bf weakness_bf ,_bf hyperreflexia_bf ,_bf incoordination_bf coadministered_bf 5-HT1_bf agonists_bf ._bf"
2026,"If concomitant treatment with frovatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.",frovatriptan,SSRI,advise,"If_bf concomitant_bf treatment_bf DRUG OTHER_DRUG clinically_af warranted_af ,_af appropriate_af observation_af patient_af advised_af ._af"
2027,"Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function.",Furosemide,aminoglycoside antibiotics,effect,"DRUG may_be increase_be ototoxic_be potential_be aminoglycoside_be antibiotics_be ,_be especially_be presence_be impaired_be renal_be function_be ._be"
2028,Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.,Furosemide,ethacrynic acid,advise,DRUG used_be concomitantly_be ethacrynic_be acid_be possibility_be ototoxicity_be ._be
2029,"Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.",salicylates,furosemide,effect,"Patients_bf receiving_bf high_bf doses_bf DRUG concomitantly_be OTHER_DRUG ,_af rheumatic_af disease_af ,_af may_af experience_af salicylate_af toxicity_af lower_af doses_af competitive_af renal_af excretory_af sites_af ._af"
2030,Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.,Furosemide,tubocurarine,effect,DRUG tendency_be antagonize_be skeletal_be muscle_be relaxing_be effect_be OTHER_DRUG may_af potentiate_af action_af succinylcholine_af ._af
2031,Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.,Furosemide,succinylcholine,effect,DRUG tendency_be antagonize_be skeletal_be muscle_be relaxing_be effect_be tubocurarine_be may_be potentiate_be action_be OTHER_DRUG ._af
2032,Lithium generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of lithium toxicity.,Lithium,diuretics,advise,DRUG generally_be given_be OTHER_DRUG reduce_af lithiums_af renal_af clearance_af add_af high_af risk_af DRUG toxicity_af ._af
2033,Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs.,Furosemide,antihypertensive drugs,effect,DRUG may_be add_be potentiate_be therapeutic_be effect_be antihypertensive_be drugs_be ._be
2034,Furosemide may decrease arterial responsiveness to norepinephrine.,Furosemide,norepinephrine,effect,DRUG may_be decrease_be arterial_be responsiveness_be OTHER_DRUG ._af
2035,Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide.,sucralfate,furosemide,effect,Tablets_bf Simultaneous_bf administration_bf DRUG OTHER_DRUG tablets_af may_af reduce_af natriuretic_af antihypertensive_af effects_af OTHER_DRUG ._af
2036,The intake of furosemide and sucralfate should be separated by at least two hours.,furosemide,sucralfate,advise,The_bf intake_bf DRUG OTHER_DRUG separated_af least_af two_af hours_af ._af
2037,"Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.",furosemide,acetylsalicylic acid,effect,"Tablets_bf ,_bf Injection_bf ,_bf Oral_bf Solution_bf One_bf study_bf six_bf subjects_bf demonstrated_bf combination_bf DRUG acetylsalicylic_be acid_be temporarily_be reduced_be creatinine_be clearance_be patients_be chronic_be renal_be insufficiency_be ._be"
2038,"There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.",furosemide,NSAIDs,effect,"There_bf case_bf reports_bf patients_bf developed_bf increased_bf BUN_bf ,_bf serum_bf creatinine_bf serum_bf potassium_bf levels_bf ,_bf weight_bf gain_bf DRUG used_be conjunction_be OTHER_DRUG ._af"
2039,Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.,indomethacin,furosemide,effect,Literature_bf reports_bf indicate_bf coadministration_bf DRUG may_be reduce_be natriuretic_be antihypertensive_be effects_be OTHER_DRUG patients_af inhibiting_af prostaglandin_af synthesis_af ._af
2040,Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.,indomethacin,furosemide,advise,Patients_bf receiving_bf DRUG OTHER_DRUG observed_af closely_af determine_af desired_af diuretic_af and/or_af antihypertensive_af effect_af OTHER_DRUG achieved_af ._af
2041,Naproxen: Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.,naproxen sodium,Neurontin,mechanism,Naproxen:_bf Coadministration_bf (N=18)_bf naproxen_bf sodium_bf capsules_bf (250_bf mg)_bf OTHER_DRUG (125_be mg)_be appears_be increase_be amount_be gabapentin_be absorbed_be 12%_be 15%_be ._be
2042,Hydrocodone increases gabapentin AUC values by 14%.,Hydrocodone,gabapentin,mechanism,DRUG increases_be OTHER_DRUG AUC_af values_af 14%_af ._af
2043,"Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.",morphine,Neurontin,mechanism,"Morphine:_bf A_bf literature_bf article_bf reported_bf 60-mg_bf controlled-release_bf DRUG capsule_be administered_be 2_be hours_be prior_be 600-mg_be OTHER_DRUG capsule_af (N=12)_af ,_af mean_af gabapentin_af AUC_af increased_af 44%_af compared_af gabapentin_af administered_af without_af DRUG ._af"
2044,Cimetidine: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.,cimetidine,gabapentin,mechanism,Cimetidine:_bf In_bf presence_bf DRUG 300_be mg_be QID_be (N=12)_be mean_be apparent_be oral_be clearance_be OTHER_DRUG fell_af 14%_af creatinine_af clearance_af fell_af 10%_af ._af
2045,"Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function.",cimetidine,gabapentin,mechanism,"Thus_bf DRUG appeared_be alter_be renal_be excretion_be OTHER_DRUG creatinine_af ,_af endogenous_af marker_af renal_af function_af ._af"
2046,This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.,gabapentin,cimetidine,mechanism,This_bf small_bf decrease_bf excretion_bf DRUG OTHER_DRUG expected_af clinical_af importance_af ._af
2047,The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;,norethindrone,gabapentin,mechanism,The_bf Cmax_bf DRUG 13%_be higher_be coadministered_be gabapentin;_be
2048,Antacid (Maalox ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.,Maalox,gabapentin,mechanism,Antacid_bf (Maalox_bf ):_bf DRUG reduced_be bioavailability_be OTHER_DRUG (N=16)_af 20%_af ._af
2049,This decrease in bioavailability was about 5% when gabapentin was administered 2 hours after Maalox.,gabapentin,Maalox,mechanism,This_bf decrease_bf bioavailability_bf 5%_bf DRUG administered_be 2_be hours_be OTHER_DRUG ._af
2050,It is recommended that gabapentin be taken at least 2 hours following Maalox administration.,gabapentin,Maalox,advise,It_bf recommended_bf DRUG taken_be least_be 2_be hours_be following_be OTHER_DRUG administration_af ._af
2051,International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy.,warfarin,IRESSA,effect,International_bf Normalized_bf Ratio_bf (INR)_bf elevations_bf and/or_bf bleeding_bf events_bf reported_bf patients_bf taking_bf DRUG OTHER_DRUG therapy_af ._af
2052,"Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.",ketoconazole,gefitinib,mechanism,"Substances_bf potent_bf inhibitors_bf CYP3A4_bf activity_bf (eg_bf ,_bf DRUG itraconazole)_be decrease_be OTHER_DRUG metabolism_af increase_af OTHER_DRUG plasma_af concentrations_af ._af"
2053,"Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.",ketoconazole,gefitinib,mechanism,"Substances_bf potent_bf inhibitors_bf CYP3A4_bf activity_bf (eg_bf ,_bf DRUG itraconazole)_be decrease_be OTHER_DRUG metabolism_af increase_af OTHER_DRUG plasma_af concentrations_af ._af"
2054,"Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.",itraconazole,gefitinib,mechanism,"Substances_bf potent_bf inhibitors_bf CYP3A4_bf activity_bf (eg_bf ,_bf ketoconazole_bf itraconazole)_bf decrease_bf OTHER_DRUG metabolism_be increase_be OTHER_DRUG plasma_af concentrations_af ._af"
2055,"Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.",itraconazole,gefitinib,mechanism,"Substances_bf potent_bf inhibitors_bf CYP3A4_bf activity_bf (eg_bf ,_bf ketoconazole_bf itraconazole)_bf decrease_bf OTHER_DRUG metabolism_be increase_be OTHER_DRUG plasma_af concentrations_af ._af"
2056,Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.,histamine H2-receptor antagonists,IRESSA,mechanism,Drugs_bf cause_bf significant_bf sustained_bf elevation_bf gastric_bf pH_bf (histamine_bf H2-receptor_bf antagonists_bf ranitidine_bf cimetidine)_bf may_bf reduce_bf plasma_bf concentrations_bf OTHER_DRUG therefore_be potentially_be may_be reduce_be efficacy_be ._be
2057,Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.,ranitidine,IRESSA,mechanism,Drugs_bf cause_bf significant_bf sustained_bf elevation_bf gastric_bf pH_bf (histamine_bf H2-receptor_bf antagonists_bf DRUG cimetidine)_be may_be reduce_be plasma_be concentrations_be OTHER_DRUG therefore_af potentially_af may_af reduce_af efficacy_af ._af
2058,Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.,cimetidine,IRESSA,mechanism,Drugs_bf cause_bf significant_bf sustained_bf elevation_bf gastric_bf pH_bf (histamine_bf H2-receptor_bf antagonists_bf ranitidine_bf cimetidine)_bf may_bf reduce_bf plasma_bf concentrations_bf OTHER_DRUG therefore_be potentially_be may_be reduce_be efficacy_be ._be
2059,"Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.",IRESSA,vinorelbine,effect,"Phase_bf II_bf clinical_bf trial_bf data_bf ,_bf DRUG OTHER_DRUG used_af concomitantly_af ,_af indicate_af DRUG may_af exacerbate_af neutropenic_af effect_af OTHER_DRUG ._af"
2060,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,calcium carbonate,mechanism,"Concomitant_bf administration_bf DRUG calcium_be carbonate_be ,_be cimetidine_be ,_be omeprazole_be ,_be estrogen/progesterone_be oral_be contraceptive_be produced_be minor_be changes_be pharmacokinetics_be gemifloxacin_be ,_be considered_be without_be clinical_be significance_be ._be"
2061,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,cimetidine,mechanism,"Concomitant_bf administration_bf DRUG calcium_be carbonate_be ,_be OTHER_DRUG ,_af omeprazole_af ,_af estrogen/progesterone_af oral_af contraceptive_af produced_af minor_af changes_af pharmacokinetics_af gemifloxacin_af ,_af considered_af without_af clinical_af significance_af ._af"
2062,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,omeprazole,mechanism,"Concomitant_bf administration_bf DRUG calcium_be carbonate_be ,_be cimetidine_be ,_be OTHER_DRUG ,_af estrogen/progesterone_af oral_af contraceptive_af produced_af minor_af changes_af pharmacokinetics_af gemifloxacin_af ,_af considered_af without_af clinical_af significance_af ._af"
2063,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,estrogen,mechanism,"Concomitant_bf administration_bf DRUG calcium_be carbonate_be ,_be cimetidine_be ,_be omeprazole_be ,_be estrogen/progesterone_be oral_be contraceptive_be produced_be minor_be changes_be pharmacokinetics_be gemifloxacin_be ,_be considered_be without_be clinical_be significance_be ._be"
2064,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,progesterone,mechanism,"Concomitant_bf administration_bf DRUG calcium_be carbonate_be ,_be cimetidine_be ,_be omeprazole_be ,_be estrogen/progesterone_be oral_be contraceptive_be produced_be minor_be changes_be pharmacokinetics_be gemifloxacin_be ,_be considered_be without_be clinical_be significance_be ._be"
2065,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,contraceptive,mechanism,"Concomitant_bf administration_bf DRUG calcium_be carbonate_be ,_be cimetidine_be ,_be omeprazole_be ,_be estrogen/progesterone_be oral_be OTHER_DRUG produced_af minor_af changes_af pharmacokinetics_af gemifloxacin_af ,_af considered_af without_af clinical_af significance_af ._af"
2066,Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.,FACTIVE,probenecid,mechanism,Concomitant_bf administration_bf DRUG OTHER_DRUG resulted_af 45%_af increase_af systemic_af exposure_af gemifloxacin_af ._af
2067,"However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.",quinolones,warfarin,effect,"However_bf ,_bf DRUG reported_be enhance_be anticoagulant_be effects_be OTHER_DRUG derivatives_af patients_af ,_af prothrombin_af time_af suitable_af coagulation_af test_af closely_af monitored_af quinolone_af antimicrobial_af administered_af concomitantly_af OTHER_DRUG derivatives_af ._af"
2068,"However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.",quinolone antimicrobial,warfarin,advise,"However_bf ,_bf quinolones_bf reported_bf enhance_bf anticoagulant_bf effects_bf OTHER_DRUG derivatives_be patients_be ,_be prothrombin_be time_be suitable_be coagulation_be test_be closely_be monitored_be quinolone_be antimicrobial_be administered_be concomitantly_be OTHER_DRUG derivatives_af ._af"
2069,The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.,gemifloxacin,aluminum,mechanism,The_bf absorption_bf oral_bf DRUG significantly_be reduced_be concomitant_be administration_be antacid_be containing_be OTHER_DRUG magnesium_af ._af
2070,The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.,gemifloxacin,magnesium,mechanism,The_bf absorption_bf oral_bf DRUG significantly_be reduced_be concomitant_be administration_be antacid_be containing_be aluminum_be OTHER_DRUG ._af
2071,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",Magnesium,FACTIVE,advise,"Magnesium-_bf and/or_bf aluminum-containing_bf antacids_bf ,_bf products_bf containing_bf ferrous_bf sulfate_bf (iron)_bf ,_bf multivitamin_bf preparations_bf containing_bf zinc_bf metal_bf cations_bf ,_bf Videx_bf (didanosine)_bf chewable/buffered_bf tablets_bf pediatric_bf powder_bf oral_bf solution_bf taken_bf within_bf 3_bf hours_bf 2_bf hours_bf OTHER_DRUG ._be"
2072,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",aluminum,FACTIVE,advise,"Magnesium-_bf and/or_bf aluminum-containing_bf antacids_bf ,_bf products_bf containing_bf ferrous_bf sulfate_bf (iron)_bf ,_bf multivitamin_bf preparations_bf containing_bf zinc_bf metal_bf cations_bf ,_bf Videx_bf (didanosine)_bf chewable/buffered_bf tablets_bf pediatric_bf powder_bf oral_bf solution_bf taken_bf within_bf 3_bf hours_bf 2_bf hours_bf OTHER_DRUG ._be"
2073,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",ferrous sulfate,FACTIVE,advise,"Magnesium-_bf and/or_bf aluminum-containing_bf antacids_bf ,_bf products_bf containing_bf ferrous_bf sulfate_bf (iron)_bf ,_bf multivitamin_bf preparations_bf containing_bf zinc_bf metal_bf cations_bf ,_bf Videx_bf (didanosine)_bf chewable/buffered_bf tablets_bf pediatric_bf powder_bf oral_bf solution_bf taken_bf within_bf 3_bf hours_bf 2_bf hours_bf OTHER_DRUG ._be"
2074,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",iron,FACTIVE,advise,"Magnesium-_bf and/or_bf aluminum-containing_bf antacids_bf ,_bf products_bf containing_bf ferrous_bf sulfate_bf (iron)_bf ,_bf multivitamin_bf preparations_bf containing_bf zinc_bf metal_bf cations_bf ,_bf Videx_bf (didanosine)_bf chewable/buffered_bf tablets_bf pediatric_bf powder_bf oral_bf solution_bf taken_bf within_bf 3_bf hours_bf 2_bf hours_bf OTHER_DRUG ._be"
2075,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",multivitamin preparations,FACTIVE,advise,"Magnesium-_bf and/or_bf aluminum-containing_bf antacids_bf ,_bf products_bf containing_bf ferrous_bf sulfate_bf (iron)_bf ,_bf multivitamin_bf preparations_bf containing_bf zinc_bf metal_bf cations_bf ,_bf Videx_bf (didanosine)_bf chewable/buffered_bf tablets_bf pediatric_bf powder_bf oral_bf solution_bf taken_bf within_bf 3_bf hours_bf 2_bf hours_bf OTHER_DRUG ._be"
2076,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",zinc,FACTIVE,advise,"Magnesium-_bf and/or_bf aluminum-containing_bf antacids_bf ,_bf products_bf containing_bf ferrous_bf sulfate_bf (iron)_bf ,_bf multivitamin_bf preparations_bf containing_bf DRUG metal_be cations_be ,_be Videx_be (didanosine)_be chewable/buffered_be tablets_be pediatric_be powder_be oral_be solution_be taken_be within_be 3_be hours_be 2_be hours_be OTHER_DRUG ._af"
2077,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",Videx,FACTIVE,advise,"Magnesium-_bf and/or_bf aluminum-containing_bf antacids_bf ,_bf products_bf containing_bf ferrous_bf sulfate_bf (iron)_bf ,_bf multivitamin_bf preparations_bf containing_bf zinc_bf metal_bf cations_bf ,_bf DRUG (didanosine)_be chewable/buffered_be tablets_be pediatric_be powder_be oral_be solution_be taken_be within_be 3_be hours_be 2_be hours_be OTHER_DRUG ._af"
2078,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",didanosine,FACTIVE,advise,"Magnesium-_bf and/or_bf aluminum-containing_bf antacids_bf ,_bf products_bf containing_bf ferrous_bf sulfate_bf (iron)_bf ,_bf multivitamin_bf preparations_bf containing_bf zinc_bf metal_bf cations_bf ,_bf Videx_bf (didanosine)_bf chewable/buffered_bf tablets_bf pediatric_bf powder_bf oral_bf solution_bf taken_bf within_bf 3_bf hours_bf 2_bf hours_bf OTHER_DRUG ._be"
2079,Sucralfate should not be taken within 2 hours of FACTIVE.,Sucralfate,FACTIVE,advise,DRUG taken_be within_be 2_be hours_be OTHER_DRUG ._af
2080,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,nonsteroidal anti-inflammatory agents,effect,"The_bf hypoglycemic_bf action_bf DRUG may_be potentiated_be certain_be drugs_be including_be nonsteroidal_be anti-inflammatory_be agents_be drugs_be highly_be protein_be bound_be ,_be salicylates_be ,_be sulfonamides_be ,_be chloramphenicol_be ,_be probenecid_be ,_be coumarins_be ,_be monoamine_be oxidase_be inhibitors_be ,_be beta_be adrenergic_be blocking_be agents_be ._be"
2081,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,salicylates,effect,"The_bf hypoglycemic_bf action_bf DRUG may_be potentiated_be certain_be drugs_be including_be nonsteroidal_be anti-inflammatory_be agents_be drugs_be highly_be protein_be bound_be ,_be OTHER_DRUG ,_af sulfonamides_af ,_af chloramphenicol_af ,_af probenecid_af ,_af coumarins_af ,_af monoamine_af oxidase_af inhibitors_af ,_af beta_af adrenergic_af blocking_af agents_af ._af"
2082,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,sulfonamides,effect,"The_bf hypoglycemic_bf action_bf DRUG may_be potentiated_be certain_be drugs_be including_be nonsteroidal_be anti-inflammatory_be agents_be drugs_be highly_be protein_be bound_be ,_be salicylates_be ,_be OTHER_DRUG ,_af chloramphenicol_af ,_af probenecid_af ,_af coumarins_af ,_af monoamine_af oxidase_af inhibitors_af ,_af beta_af adrenergic_af blocking_af agents_af ._af"
2083,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,chloramphenicol,effect,"The_bf hypoglycemic_bf action_bf DRUG may_be potentiated_be certain_be drugs_be including_be nonsteroidal_be anti-inflammatory_be agents_be drugs_be highly_be protein_be bound_be ,_be salicylates_be ,_be sulfonamides_be ,_be OTHER_DRUG ,_af probenecid_af ,_af coumarins_af ,_af monoamine_af oxidase_af inhibitors_af ,_af beta_af adrenergic_af blocking_af agents_af ._af"
2084,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,probenecid,effect,"The_bf hypoglycemic_bf action_bf DRUG may_be potentiated_be certain_be drugs_be including_be nonsteroidal_be anti-inflammatory_be agents_be drugs_be highly_be protein_be bound_be ,_be salicylates_be ,_be sulfonamides_be ,_be chloramphenicol_be ,_be OTHER_DRUG ,_af coumarins_af ,_af monoamine_af oxidase_af inhibitors_af ,_af beta_af adrenergic_af blocking_af agents_af ._af"
2085,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,coumarins,effect,"The_bf hypoglycemic_bf action_bf DRUG may_be potentiated_be certain_be drugs_be including_be nonsteroidal_be anti-inflammatory_be agents_be drugs_be highly_be protein_be bound_be ,_be salicylates_be ,_be sulfonamides_be ,_be chloramphenicol_be ,_be probenecid_be ,_be OTHER_DRUG ,_af monoamine_af oxidase_af inhibitors_af ,_af beta_af adrenergic_af blocking_af agents_af ._af"
2086,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,monoamine oxidase inhibitors,effect,"The_bf hypoglycemic_bf action_bf DRUG may_be potentiated_be certain_be drugs_be including_be nonsteroidal_be anti-inflammatory_be agents_be drugs_be highly_be protein_be bound_be ,_be salicylates_be ,_be sulfonamides_be ,_be chloramphenicol_be ,_be probenecid_be ,_be coumarins_be ,_be monoamine_be oxidase_be inhibitors_be ,_be beta_be adrenergic_be blocking_be agents_be ._be"
2087,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,beta adrenergic blocking agents,effect,"The_bf hypoglycemic_bf action_bf DRUG may_be potentiated_be certain_be drugs_be including_be nonsteroidal_be anti-inflammatory_be agents_be drugs_be highly_be protein_be bound_be ,_be salicylates_be ,_be sulfonamides_be ,_be chloramphenicol_be ,_be probenecid_be ,_be coumarins_be ,_be monoamine_be oxidase_be inhibitors_be ,_be beta_be adrenergic_be blocking_be agents_be ._be"
2088,"A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.",glyburide,ciprofloxacin,int,"A_bf possible_bf interaction_bf DRUG OTHER_DRUG ,_af fluoroquinolone_af antibiotic_af ,_af reported_af ,_af resulting_af potentiation_af hypoglycemic_af action_af DRUG ._af"
2089,A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.,miconazole,hypoglycemic agents,effect,A_bf potential_bf interaction_bf oral_bf DRUG oral_be hypoglycemic_be agents_be leading_be severe_be hypoglycemia_be reported_be ._be
2090,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,aspirin,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be OTHER_DRUG another_af salicylate_af magnesium/choline_af salicylate_af (Trilisate)_af ,_af salsalate_af (Disalcid_af ,_af others)_af ,_af choline_af salicylate_af (Arthropan)_af ,_af magnesium_af salicylate_af (Magan)_af ,_af bismuth_af subsalicylate_af (Pepto-Bismol);_af"
2091,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,salicylate,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be OTHER_DRUG magnesium/choline_af OTHER_DRUG (Trilisate)_af ,_af salsalate_af (Disalcid_af ,_af others)_af ,_af choline_af OTHER_DRUG (Arthropan)_af ,_af magnesium_af OTHER_DRUG (Magan)_af ,_af bismuth_af subsalicylate_af (Pepto-Bismol);_af"
2092,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,magnesium/choline salicylate,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be salicylate_be magnesium/choline_be salicylate_be (Trilisate)_be ,_be salsalate_be (Disalcid_be ,_be others)_be ,_be choline_be salicylate_be (Arthropan)_be ,_be magnesium_be salicylate_be (Magan)_be ,_be bismuth_be subsalicylate_be (Pepto-Bismol);_be"
2093,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Trilisate,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be salicylate_be magnesium/choline_be salicylate_be (Trilisate)_be ,_be salsalate_be (Disalcid_be ,_be others)_be ,_be choline_be salicylate_be (Arthropan)_be ,_be magnesium_be salicylate_be (Magan)_be ,_be bismuth_be subsalicylate_be (Pepto-Bismol);_be"
2094,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,salsalate,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be salicylate_be magnesium/choline_be salicylate_be (Trilisate)_be ,_be OTHER_DRUG (Disalcid_af ,_af others)_af ,_af choline_af salicylate_af (Arthropan)_af ,_af magnesium_af salicylate_af (Magan)_af ,_af bismuth_af subsalicylate_af (Pepto-Bismol);_af"
2095,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Disalcid,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be salicylate_be magnesium/choline_be salicylate_be (Trilisate)_be ,_be salsalate_be (Disalcid_be ,_be others)_be ,_be choline_be salicylate_be (Arthropan)_be ,_be magnesium_be salicylate_be (Magan)_be ,_be bismuth_be subsalicylate_be (Pepto-Bismol);_be"
2096,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,choline salicylate,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be salicylate_be magnesium/choline_be salicylate_be (Trilisate)_be ,_be salsalate_be (Disalcid_be ,_be others)_be ,_be choline_be salicylate_be (Arthropan)_be ,_be magnesium_be salicylate_be (Magan)_be ,_be bismuth_be subsalicylate_be (Pepto-Bismol);_be"
2097,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Arthropan,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be salicylate_be magnesium/choline_be salicylate_be (Trilisate)_be ,_be salsalate_be (Disalcid_be ,_be others)_be ,_be choline_be salicylate_be (Arthropan)_be ,_be magnesium_be salicylate_be (Magan)_be ,_be bismuth_be subsalicylate_be (Pepto-Bismol);_be"
2098,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,magnesium salicylate,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be salicylate_be magnesium/choline_be salicylate_be (Trilisate)_be ,_be salsalate_be (Disalcid_be ,_be others)_be ,_be choline_be salicylate_be (Arthropan)_be ,_be magnesium_be salicylate_be (Magan)_be ,_be bismuth_be subsalicylate_be (Pepto-Bismol);_be"
2099,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Magan,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be salicylate_be magnesium/choline_be salicylate_be (Trilisate)_be ,_be salsalate_be (Disalcid_be ,_be others)_be ,_be choline_be salicylate_be (Arthropan)_be ,_be magnesium_be salicylate_be (Magan)_be ,_be bismuth_be subsalicylate_be (Pepto-Bismol);_be"
2100,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,bismuth subsalicylate,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be salicylate_be magnesium/choline_be salicylate_be (Trilisate)_be ,_be salsalate_be (Disalcid_be ,_be others)_be ,_be choline_be salicylate_be (Arthropan)_be ,_be magnesium_be salicylate_be (Magan)_be ,_be bismuth_be subsalicylate_be (Pepto-Bismol);_be"
2101,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Pepto-Bismol,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be salicylate_be magnesium/choline_be salicylate_be (Trilisate)_be ,_be salsalate_be (Disalcid_be ,_be others)_be ,_be choline_be salicylate_be (Arthropan)_be ,_be magnesium_be salicylate_be (Magan)_be ,_be bismuth_be subsalicylate_be (Pepto-Bismol);_be"
2102,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,nonsteroidal anti-inflammatory agents,effect,"Immediate_bf Extended_bf Release_bf Tablets_bf The_bf hypoglycemic_bf action_bf DRUG may_be potentiated_be certain_be drugs_be including_be nonsteroidal_be anti-inflammatory_be agents_be ,_be azoles_be drugs_be highly_be protein_be bound_be ,_be salicylates_be ,_be sulfonamides_be ,_be chloramphenicol_be ,_be probenecid_be ,_be coumarins_be ,_be monoamine_be oxidase_be inhibitors_be ,_be beta_be adrenergic_be blocking_be agents_be ._be"
2103,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,azoles,effect,"Immediate_bf Extended_bf Release_bf Tablets_bf The_bf hypoglycemic_bf action_bf DRUG may_be potentiated_be certain_be drugs_be including_be nonsteroidal_be anti-inflammatory_be agents_be ,_be OTHER_DRUG drugs_af highly_af protein_af bound_af ,_af salicylates_af ,_af sulfonamides_af ,_af chloramphenicol_af ,_af probenecid_af ,_af coumarins_af ,_af monoamine_af oxidase_af inhibitors_af ,_af beta_af adrenergic_af blocking_af agents_af ._af"
2104,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,salicylates,effect,"Immediate_bf Extended_bf Release_bf Tablets_bf The_bf hypoglycemic_bf action_bf DRUG may_be potentiated_be certain_be drugs_be including_be nonsteroidal_be anti-inflammatory_be agents_be ,_be azoles_be drugs_be highly_be protein_be bound_be ,_be OTHER_DRUG ,_af sulfonamides_af ,_af chloramphenicol_af ,_af probenecid_af ,_af coumarins_af ,_af monoamine_af oxidase_af inhibitors_af ,_af beta_af adrenergic_af blocking_af agents_af ._af"
2105,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,sulfonamides,effect,"Immediate_bf Extended_bf Release_bf Tablets_bf The_bf hypoglycemic_bf action_bf DRUG may_be potentiated_be certain_be drugs_be including_be nonsteroidal_be anti-inflammatory_be agents_be ,_be azoles_be drugs_be highly_be protein_be bound_be ,_be salicylates_be ,_be OTHER_DRUG ,_af chloramphenicol_af ,_af probenecid_af ,_af coumarins_af ,_af monoamine_af oxidase_af inhibitors_af ,_af beta_af adrenergic_af blocking_af agents_af ._af"
2106,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,chloramphenicol,effect,"Immediate_bf Extended_bf Release_bf Tablets_bf The_bf hypoglycemic_bf action_bf DRUG may_be potentiated_be certain_be drugs_be including_be nonsteroidal_be anti-inflammatory_be agents_be ,_be azoles_be drugs_be highly_be protein_be bound_be ,_be salicylates_be ,_be sulfonamides_be ,_be OTHER_DRUG ,_af probenecid_af ,_af coumarins_af ,_af monoamine_af oxidase_af inhibitors_af ,_af beta_af adrenergic_af blocking_af agents_af ._af"
2107,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,probenecid,effect,"Immediate_bf Extended_bf Release_bf Tablets_bf The_bf hypoglycemic_bf action_bf DRUG may_be potentiated_be certain_be drugs_be including_be nonsteroidal_be anti-inflammatory_be agents_be ,_be azoles_be drugs_be highly_be protein_be bound_be ,_be salicylates_be ,_be sulfonamides_be ,_be chloramphenicol_be ,_be OTHER_DRUG ,_af coumarins_af ,_af monoamine_af oxidase_af inhibitors_af ,_af beta_af adrenergic_af blocking_af agents_af ._af"
2108,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,coumarins,effect,"Immediate_bf Extended_bf Release_bf Tablets_bf The_bf hypoglycemic_bf action_bf DRUG may_be potentiated_be certain_be drugs_be including_be nonsteroidal_be anti-inflammatory_be agents_be ,_be azoles_be drugs_be highly_be protein_be bound_be ,_be salicylates_be ,_be sulfonamides_be ,_be chloramphenicol_be ,_be probenecid_be ,_be OTHER_DRUG ,_af monoamine_af oxidase_af inhibitors_af ,_af beta_af adrenergic_af blocking_af agents_af ._af"
2109,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,monoamine oxidase inhibitors,effect,"Immediate_bf Extended_bf Release_bf Tablets_bf The_bf hypoglycemic_bf action_bf DRUG may_be potentiated_be certain_be drugs_be including_be nonsteroidal_be anti-inflammatory_be agents_be ,_be azoles_be drugs_be highly_be protein_be bound_be ,_be salicylates_be ,_be sulfonamides_be ,_be chloramphenicol_be ,_be probenecid_be ,_be coumarins_be ,_be monoamine_be oxidase_be inhibitors_be ,_be beta_be adrenergic_be blocking_be agents_be ._be"
2110,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,beta adrenergic blocking agents,effect,"Immediate_bf Extended_bf Release_bf Tablets_bf The_bf hypoglycemic_bf action_bf DRUG may_be potentiated_be certain_be drugs_be including_be nonsteroidal_be anti-inflammatory_be agents_be ,_be azoles_be drugs_be highly_be protein_be bound_be ,_be salicylates_be ,_be sulfonamides_be ,_be chloramphenicol_be ,_be probenecid_be ,_be coumarins_be ,_be monoamine_be oxidase_be inhibitors_be ,_be beta_be adrenergic_be blocking_be agents_be ._be"
2111,A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.,miconazole,hypoglycemic agents,int,A_bf potential_bf interaction_bf oral_bf DRUG oral_be hypoglycemic_be agents_be leading_be severe_be hypoglycemia_be reported_be ._be
2112,The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.,fluconazole,glipizide,int,The_bf effect_bf concomitant_bf administration_bf DRUG OTHER_DRUG demonstrated_af placebo-controlled_af crossover_af study_af normal_af volunteers_af ._af
2113,The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).,glipizide,fluconazole,mechanism,The_bf mean_bf percentage_bf increase_bf DRUG AUC_be OTHER_DRUG administration_af 56_af ._af 9%_af (range:_af 35_af 81)_af ._af
2114,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",Robinul,anticholinergics,effect,"The_bf concurrent_bf use_bf DRUG Injection_be OTHER_DRUG medications_af anticholinergic_af activity_af ,_af phenothiazines_af ,_af antiparkinson_af drugs_af ,_af tricyclic_af antidepressants_af ,_af may_af intensify_af antimuscarinic_af effects_af may_af result_af increase_af anticholinergic_af side_af effects_af ._af"
2115,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",Robinul,phenothiazines,effect,"The_bf concurrent_bf use_bf DRUG Injection_be anticholinergics_be medications_be anticholinergic_be activity_be ,_be OTHER_DRUG ,_af antiparkinson_af drugs_af ,_af tricyclic_af antidepressants_af ,_af may_af intensify_af antimuscarinic_af effects_af may_af result_af increase_af anticholinergic_af side_af effects_af ._af"
2116,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",Robinul,antiparkinson drugs,effect,"The_bf concurrent_bf use_bf DRUG Injection_be anticholinergics_be medications_be anticholinergic_be activity_be ,_be phenothiazines_be ,_be antiparkinson_be drugs_be ,_be tricyclic_be antidepressants_be ,_be may_be intensify_be antimuscarinic_be effects_be may_be result_be increase_be anticholinergic_be side_be effects_be ._be"
2117,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",Robinul,tricyclic antidepressants,effect,"The_bf concurrent_bf use_bf DRUG Injection_be anticholinergics_be medications_be anticholinergic_be activity_be ,_be phenothiazines_be ,_be antiparkinson_be drugs_be ,_be tricyclic_be antidepressants_be ,_be may_be intensify_be antimuscarinic_be effects_be may_be result_be increase_be anticholinergic_be side_be effects_be ._be"
2118,Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.,Robinul,potassium chloride,mechanism,Concomitant_bf administration_bf DRUG Injection_be potassium_be chloride_be wax_be matrix_be may_be increase_be severity_be potassium_be chloride-induced_be gastrointestinal_be lesions_be result_be slower_be gastrointestinal_be transit_be time_be ._be
2119,The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.,Factrel,phenothiazines,effect,The_bf response_bf DRUG may_be blunted_be OTHER_DRUG dopamine_af antagonists_af cause_af rise_af prolactin_af ._af
2120,The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.,Factrel,dopamine antagonists,effect,The_bf response_bf DRUG may_be blunted_be phenothiazines_be dopamine_be antagonists_be cause_be rise_be prolactin_be ._be
2121,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,aluminum,mechanism,"Administration_bf DRUG antacids_be containing_be OTHER_DRUG ,_af magnesium_af ,_af calcium_af ,_af sucralfate_af ,_af metal_af cations_af iron_af ,_af multivitamins_af containing_af iron_af zinc_af ,_af formulations_af containing_af divalent_af trivalent_af cations_af VIDEX_af (didanosine)_af chewable/buffered_af tablets_af pediatric_af powder_af oral_af solution_af ,_af may_af substantially_af interfere_af absorption_af DRUG ,_af resulting_af systemic_af concentrations_af considerably_af lower_af desired_af ._af"
2122,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,magnesium,mechanism,"Administration_bf DRUG antacids_be containing_be aluminum_be ,_be OTHER_DRUG ,_af calcium_af ,_af sucralfate_af ,_af metal_af cations_af iron_af ,_af multivitamins_af containing_af iron_af zinc_af ,_af formulations_af containing_af divalent_af trivalent_af cations_af VIDEX_af (didanosine)_af chewable/buffered_af tablets_af pediatric_af powder_af oral_af solution_af ,_af may_af substantially_af interfere_af absorption_af DRUG ,_af resulting_af systemic_af concentrations_af considerably_af lower_af desired_af ._af"
2123,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,calcium,mechanism,"Administration_bf DRUG antacids_be containing_be aluminum_be ,_be magnesium_be ,_be OTHER_DRUG ,_af sucralfate_af ,_af metal_af cations_af iron_af ,_af multivitamins_af containing_af iron_af zinc_af ,_af formulations_af containing_af divalent_af trivalent_af cations_af VIDEX_af (didanosine)_af chewable/buffered_af tablets_af pediatric_af powder_af oral_af solution_af ,_af may_af substantially_af interfere_af absorption_af DRUG ,_af resulting_af systemic_af concentrations_af considerably_af lower_af desired_af ._af"
2124,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,sucralfate,mechanism,"Administration_bf DRUG antacids_be containing_be aluminum_be ,_be magnesium_be ,_be calcium_be ,_be OTHER_DRUG ,_af metal_af cations_af iron_af ,_af multivitamins_af containing_af iron_af zinc_af ,_af formulations_af containing_af divalent_af trivalent_af cations_af VIDEX_af (didanosine)_af chewable/buffered_af tablets_af pediatric_af powder_af oral_af solution_af ,_af may_af substantially_af interfere_af absorption_af DRUG ,_af resulting_af systemic_af concentrations_af considerably_af lower_af desired_af ._af"
2125,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,iron,mechanism,"Administration_bf DRUG antacids_be containing_be aluminum_be ,_be magnesium_be ,_be calcium_be ,_be sucralfate_be ,_be metal_be cations_be OTHER_DRUG ,_af multivitamins_af containing_af OTHER_DRUG zinc_af ,_af formulations_af containing_af divalent_af trivalent_af cations_af VIDEX_af (didanosine)_af chewable/buffered_af tablets_af pediatric_af powder_af oral_af solution_af ,_af may_af substantially_af interfere_af absorption_af DRUG ,_af resulting_af systemic_af concentrations_af considerably_af lower_af desired_af ._af"
2126,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,multivitamins,mechanism,"Administration_bf DRUG antacids_be containing_be aluminum_be ,_be magnesium_be ,_be calcium_be ,_be sucralfate_be ,_be metal_be cations_be iron_be ,_be OTHER_DRUG containing_af iron_af zinc_af ,_af formulations_af containing_af divalent_af trivalent_af cations_af VIDEX_af (didanosine)_af chewable/buffered_af tablets_af pediatric_af powder_af oral_af solution_af ,_af may_af substantially_af interfere_af absorption_af DRUG ,_af resulting_af systemic_af concentrations_af considerably_af lower_af desired_af ._af"
2127,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,iron,mechanism,"Administration_bf DRUG antacids_be containing_be aluminum_be ,_be magnesium_be ,_be calcium_be ,_be sucralfate_be ,_be metal_be cations_be OTHER_DRUG ,_af multivitamins_af containing_af OTHER_DRUG zinc_af ,_af formulations_af containing_af divalent_af trivalent_af cations_af VIDEX_af (didanosine)_af chewable/buffered_af tablets_af pediatric_af powder_af oral_af solution_af ,_af may_af substantially_af interfere_af absorption_af DRUG ,_af resulting_af systemic_af concentrations_af considerably_af lower_af desired_af ._af"
2128,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,zinc,mechanism,"Administration_bf DRUG antacids_be containing_be aluminum_be ,_be magnesium_be ,_be calcium_be ,_be sucralfate_be ,_be metal_be cations_be iron_be ,_be multivitamins_be containing_be iron_be OTHER_DRUG ,_af formulations_af containing_af divalent_af trivalent_af cations_af VIDEX_af (didanosine)_af chewable/buffered_af tablets_af pediatric_af powder_af oral_af solution_af ,_af may_af substantially_af interfere_af absorption_af DRUG ,_af resulting_af systemic_af concentrations_af considerably_af lower_af desired_af ._af"
2129,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,VIDEX,mechanism,"Administration_bf DRUG antacids_be containing_be aluminum_be ,_be magnesium_be ,_be calcium_be ,_be sucralfate_be ,_be metal_be cations_be iron_be ,_be multivitamins_be containing_be iron_be zinc_be ,_be formulations_be containing_be divalent_be trivalent_be cations_be OTHER_DRUG (didanosine)_af chewable/buffered_af tablets_af pediatric_af powder_af oral_af solution_af ,_af may_af substantially_af interfere_af absorption_af DRUG ,_af resulting_af systemic_af concentrations_af considerably_af lower_af desired_af ._af"
2130,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,didanosine,mechanism,"Administration_bf DRUG antacids_be containing_be aluminum_be ,_be magnesium_be ,_be calcium_be ,_be sucralfate_be ,_be metal_be cations_be iron_be ,_be multivitamins_be containing_be iron_be zinc_be ,_be formulations_be containing_be divalent_be trivalent_be cations_be VIDEX_be (didanosine)_be chewable/buffered_be tablets_be pediatric_be powder_be oral_be solution_be ,_be may_be substantially_be interfere_be absorption_be DRUG ,_af resulting_af systemic_af concentrations_af considerably_af lower_af desired_af ._af"
2131,"Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.",Grepafloxacin,caffeine,mechanism,"OTHER_DRUG Theobromine_be DRUG ,_af like_af quinolones_af ,_af may_af inhibit_af metabolism_af OTHER_DRUG theobromine_af ._af"
2132,"Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.",Grepafloxacin,theobromine,mechanism,"Caffeine_bf OTHER_DRUG DRUG ,_af like_af quinolones_af ,_af may_af inhibit_af metabolism_af caffeine_af OTHER_DRUG ._af"
2133,"Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.",quinolones,caffeine,mechanism,"OTHER_DRUG Theobromine_be Grepafloxacin_be ,_be like_be DRUG ,_af may_af inhibit_af metabolism_af OTHER_DRUG theobromine_af ._af"
2134,"Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.",quinolones,theobromine,mechanism,"Caffeine_bf OTHER_DRUG Grepafloxacin_be ,_be like_be DRUG ,_af may_af inhibit_af metabolism_af caffeine_af OTHER_DRUG ._af"
2135,Theophylline: Grepafloxacin is a competitive inhibitor of the metabolism of theophylline.,Grepafloxacin,theophylline,mechanism,Theophylline:_bf DRUG competitive_be inhibitor_be metabolism_be OTHER_DRUG ._af
2136,Serum theophylline concentrations increase when grepafloxacin is initiated in a patient maintained on theophylline.,grepafloxacin,theophylline,mechanism,Serum_bf OTHER_DRUG concentrations_be increase_be DRUG initiated_af patient_af maintained_af OTHER_DRUG ._af
2137,"When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.",theophylline,grepafloxacin,advise,"When_bf initiating_bf multi-day_bf course_bf OTHER_DRUG patient_be maintained_be DRUG ,_af DRUG maintenance_af dose_af halved_af period_af concurrent_af use_af OTHER_DRUG monitoring_af serum_af DRUG concentrations_af initiated_af guide_af dosage_af adjustments_af ._af"
2138,"However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.",quinolones,warfarin,effect,"However_bf ,_bf DRUG reported_be enhance_be effects_be OTHER_DRUG derivatives_af ,_af prothrombin_af time_af suitable_af anticoagulation_af test_af monitored_af closely_af quinolone_af antimicrobial_af administered_af OTHER_DRUG derivatives_af ._af"
2139,"However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.",quinolone antimicrobial,warfarin,advise,"However_bf ,_bf quinolones_bf reported_bf enhance_bf effects_bf OTHER_DRUG derivatives_be ,_be prothrombin_be time_be suitable_be anticoagulation_be test_be monitored_be closely_be quinolone_be antimicrobial_be administered_be OTHER_DRUG derivatives_af ._af"
2140,"Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.",grepafloxacin,theophylline,mechanism,"Drugs_bf Metabolized_bf Cytochrome_bf P450_bf Enzymes_bf The_bf drug_bf interaction_bf study_bf evaluating_bf effect_bf DRUG OTHER_DRUG indicates_af DRUG inhibits_af OTHER_DRUG metabolism_af ,_af mediated_af CYP1A2_af ._af"
2141,"In addition, other quinolones have been reported to decrease the CYP3A4-mediated metabolism of cyclosporine.",quinolones,cyclosporine,mechanism,"In_bf addition_bf ,_bf DRUG reported_be decrease_be CYP3A4-mediated_be metabolism_be OTHER_DRUG ._af"
2142,Nonsteroidal Anti-inflammatory Drugs (NSAIDs): The concomitant administration of a nonsteroidal anti inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions.,nonsteroidal anti inflammatory drug,quinolone,effect,Nonsteroidal_bf Anti-inflammatory_bf Drugs_bf (NSAIDs):_bf The_bf concomitant_bf administration_bf nonsteroidal_bf anti_bf inflammatory_bf drug_bf OTHER_DRUG may_be increase_be risks_be CNS_be stimulation_be convulsions_be ._be
2143,"Antidiabetic Agents: Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with quinolones and an antidiabetic agent.",quinolones,antidiabetic agent,effect,"Antidiabetic_bf Agents:_bf Disturbances_bf blood_bf glucose_bf ,_bf including_bf hyperglycemia_bf hypoglycemia_bf ,_bf reported_bf patients_bf treated_bf concomitantly_bf DRUG antidiabetic_be agent_be ._be"
2144,Patients on warfarin-type anticoagulant therapy may require dosage adjustment of the anticoagulant during and after griseofulvin therapy.,warfarin-type anticoagulant,griseofulvin,advise,Patients_bf warfarin-type_bf anticoagulant_bf therapy_bf may_bf require_bf dosage_bf adjustment_bf anticoagulant_bf OTHER_DRUG therapy_be ._be
2145,Concomitant use of barbiturates usually depresses griseofulvin activity and may necessitate raising the dosage.,barbiturates,griseofulvin,effect,Concomitant_bf use_bf DRUG usually_be depresses_be OTHER_DRUG activity_af may_af necessitate_af raising_af dosage_af ._af
2146,The concomitant administration of griseofulvin has been reported to reduce the efficacy of oral contraceptives and to increase the incidence of breakthrough bleeding.,griseofulvin,contraceptives,effect,The_bf concomitant_bf administration_bf DRUG reported_be reduce_be efficacy_be oral_be OTHER_DRUG increase_af incidence_af breakthrough_af bleeding_af ._af
2147,The potential for increased sedation when guanfacine is given with other CNS-depressant drug should be appreciated.,guanfacine,CNS-depressant drug,effect,The_bf potential_bf increased_bf sedation_bf DRUG given_be CNS-depressant_be drug_be appreciated_be ._be
2148,The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.,guanfacine,phenobarbital,mechanism,The_bf administration_bf DRUG concomitantly_be known_be microsomal_be enzyme_be inducer_be (phenobarbital_be phenytoin)_be two_be patients_be renal_be impairment_be reportedly_be resulted_be significant_be reductions_be elimination_be half-life_be plasma_be concentration_be ._be
2149,The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.,guanfacine,phenytoin,mechanism,The_bf administration_bf DRUG concomitantly_be known_be microsomal_be enzyme_be inducer_be (phenobarbital_be phenytoin)_be two_be patients_be renal_be impairment_be reportedly_be resulted_be significant_be reductions_be elimination_be half-life_be plasma_be concentration_be ._be
2150,TCAs decrease the hypotensive effect of guanfacine.,TCAs,guanfacine,effect,DRUG decrease_be hypotensive_be effect_be OTHER_DRUG ._af
2151,"Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.",Noncardioselective beta-blockers,guanfacine,effect,"Noncardioselective_bf beta-blockers_bf (nadolol_bf ,_bf porpranolol_bf ,_bf timolol)_bf may_bf exacerbate_bf rebound_bf hypertension_bf OTHER_DRUG withdrawn_be ._be"
2152,"Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.",nadolol,guanfacine,effect,"Noncardioselective_bf beta-blockers_bf (nadolol_bf ,_bf porpranolol_bf ,_bf timolol)_bf may_bf exacerbate_bf rebound_bf hypertension_bf OTHER_DRUG withdrawn_be ._be"
2153,"Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.",timolol,guanfacine,effect,"Noncardioselective_bf beta-blockers_bf (nadolol_bf ,_bf porpranolol_bf ,_bf timolol)_bf may_bf exacerbate_bf rebound_bf hypertension_bf OTHER_DRUG withdrawn_be ._be"
2154,"An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.",lithium,HALDOL,effect,"An_bf encephalopathic_bf syndrome_bf (characterized_bf weakness_bf ,_bf lethargy_bf ,_bf fever_bf ,_bf tremulousness_bf confusion_bf ,_bf extrapyramidal_bf symptoms_bf ,_bf leukocytosis_bf ,_bf elevated_bf serum_bf enzymes_bf ,_bf BUN_bf ,_bf FBS)_bf followed_bf irreversible_bf brain_bf damage_bf occurred_bf patients_bf treated_bf DRUG plus_be OTHER_DRUG ._af"
2155,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",antipsychotic agents,CNS depressants,effect,"As_bf antipsychotic_bf agents_bf ,_bf noted_bf HALDOL_bf may_bf capable_bf potentiating_bf CNS_bf depressants_bf anesthetics_bf ,_bf opiates_bf ,_bf alcohol_bf ._bf"
2156,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",antipsychotic agents,anesthetics,effect,"As_bf antipsychotic_bf agents_bf ,_bf noted_bf HALDOL_bf may_bf capable_bf potentiating_bf CNS_bf depressants_bf OTHER_DRUG ,_be opiates_be ,_be alcohol_be ._be"
2157,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",antipsychotic agents,opiates,effect,"As_bf antipsychotic_bf agents_bf ,_bf noted_bf HALDOL_bf may_bf capable_bf potentiating_bf CNS_bf depressants_bf anesthetics_bf ,_bf OTHER_DRUG ,_be alcohol_be ._be"
2158,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",antipsychotic agents,alcohol,effect,"As_bf antipsychotic_bf agents_bf ,_bf noted_bf HALDOL_bf may_bf capable_bf potentiating_bf CNS_bf depressants_bf anesthetics_bf ,_bf opiates_bf ,_bf OTHER_DRUG ._be"
2159,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",HALDOL,CNS depressants,effect,"As_bf antipsychotic_bf agents_bf ,_bf noted_bf DRUG may_be capable_be potentiating_be CNS_be depressants_be anesthetics_be ,_be opiates_be ,_be alcohol_be ._be"
2160,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",HALDOL,anesthetics,effect,"As_bf antipsychotic_bf agents_bf ,_bf noted_bf DRUG may_be capable_be potentiating_be CNS_be depressants_be OTHER_DRUG ,_af opiates_af ,_af alcohol_af ._af"
2161,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",HALDOL,opiates,effect,"As_bf antipsychotic_bf agents_bf ,_bf noted_bf DRUG may_be capable_be potentiating_be CNS_be depressants_be anesthetics_be ,_be OTHER_DRUG ,_af alcohol_af ._af"
2162,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",HALDOL,alcohol,effect,"As_bf antipsychotic_bf agents_bf ,_bf noted_bf DRUG may_be capable_be potentiating_be CNS_be depressants_be anesthetics_be ,_be opiates_be ,_be OTHER_DRUG ._af"
2163,"In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.",haloperidol,rifampin,mechanism,"In_bf study_bf 12_bf schizophrenic_bf patients_bf coadministered_bf oral_bf DRUG OTHER_DRUG ,_af plasma_af DRUG levels_af decreased_af mean_af 70%_af mean_af scores_af Brief_af Psychiatric_af Rating_af Scale_af increased_af baseline_af ._af"
2164,"In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.",rifampin,haloperidol,mechanism,"In_bf 5_bf schizophrenic_bf patients_bf treated_bf oral_bf OTHER_DRUG DRUG ,_af discontinuation_af DRUG produced_af mean_af 3_af ._af 3-fold_af increase_af OTHER_DRUG concentrations_af ._af"
2165,"Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.",rifampin,haloperidol,advise,"Thus_bf ,_bf careful_bf monitoring_bf clinical_bf status_bf warranted_bf DRUG administered_be discontinued_be haloperidol-treated_be patients_be ._be"
2166,FLUOTHANE augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of aminoglycosides.,FLUOTHANE,non-depolarising muscle relaxant,effect,DRUG augments_be action_be non-depolarising_be muscle_be relaxants_be muscle_be relaxant_be effects_be aminoglycosides_be ._be
2167,FLUOTHANE augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of aminoglycosides.,FLUOTHANE,aminoglycosides,effect,DRUG augments_be action_be non-depolarising_be muscle_be relaxants_be muscle_be relaxant_be effects_be OTHER_DRUG ._af
2168,FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.,FLUOTHANE,tubocurarine,effect,DRUG may_be augment_be hypotension_be caused_be ganglionic-blocking_be effect_be OTHER_DRUG ._af
2169,Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.,adrenaline,FLUOTHANE,advise,Caution_bf exercised_bf administration_bf DRUG patients_be anaesthetised_be OTHER_DRUG arrhythmias_af may_af precipitated_af ._af
2170,"Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.",heparin sodium,dicumarol,advise,"Therefore_bf ,_bf heparin_bf sodium_bf given_bf OTHER_DRUG warfarin_be sodium_be ,_be period_be least_be 5_be hours_be last_be intravenous_be dose_be 24_be hours_be last_be subcutaneous_be dose_be elapse_be blood_be drawn_be valid_be prothrombin_be time_be obtained_be ._be"
2171,"Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.",heparin sodium,warfarin sodium,advise,"Therefore_bf ,_bf heparin_bf sodium_bf given_bf dicumarol_bf warfarin_bf sodium_bf ,_bf period_bf least_bf 5_bf hours_bf last_bf intravenous_bf dose_bf 24_bf hours_bf last_bf subcutaneous_bf dose_bf elapse_bf blood_bf drawn_bf valid_bf prothrombin_bf time_bf obtained_bf ._bf"
2172,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",acetylsalicylic acid,heparin sodium,effect,"Platelet_bf inhibitors:_bf Drugs_bf acetylsalicylic_bf acid_bf ,_bf dextran_bf ,_bf phenylbutazone_bf ,_bf ibuprofen_bf ,_bf indomethacin_bf ,_bf dipyridamole_bf ,_bf hydroxychloroquine_bf others_bf interfere_bf platelet-aggregation_bf reactions_bf (the_bf main_bf hemostatic_bf defense_bf heparinized_bf patients)_bf may_bf induce_bf bleeding_bf used_bf caution_bf patients_bf receiving_bf heparin_bf sodium_bf ._bf"
2173,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",dextran,heparin sodium,effect,"Platelet_bf inhibitors:_bf Drugs_bf acetylsalicylic_bf acid_bf ,_bf DRUG ,_be phenylbutazone_be ,_be ibuprofen_be ,_be indomethacin_be ,_be dipyridamole_be ,_be hydroxychloroquine_be others_be interfere_be platelet-aggregation_be reactions_be (the_be main_be hemostatic_be defense_be heparinized_be patients)_be may_be induce_be bleeding_be used_be caution_be patients_be receiving_be heparin_be sodium_be ._be"
2174,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",phenylbutazone,heparin sodium,effect,"Platelet_bf inhibitors:_bf Drugs_bf acetylsalicylic_bf acid_bf ,_bf dextran_bf ,_bf DRUG ,_be ibuprofen_be ,_be indomethacin_be ,_be dipyridamole_be ,_be hydroxychloroquine_be others_be interfere_be platelet-aggregation_be reactions_be (the_be main_be hemostatic_be defense_be heparinized_be patients)_be may_be induce_be bleeding_be used_be caution_be patients_be receiving_be heparin_be sodium_be ._be"
2175,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",ibuprofen,heparin sodium,effect,"Platelet_bf inhibitors:_bf Drugs_bf acetylsalicylic_bf acid_bf ,_bf dextran_bf ,_bf phenylbutazone_bf ,_bf DRUG ,_be indomethacin_be ,_be dipyridamole_be ,_be hydroxychloroquine_be others_be interfere_be platelet-aggregation_be reactions_be (the_be main_be hemostatic_be defense_be heparinized_be patients)_be may_be induce_be bleeding_be used_be caution_be patients_be receiving_be heparin_be sodium_be ._be"
2176,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",indomethacin,heparin sodium,effect,"Platelet_bf inhibitors:_bf Drugs_bf acetylsalicylic_bf acid_bf ,_bf dextran_bf ,_bf phenylbutazone_bf ,_bf ibuprofen_bf ,_bf DRUG ,_be dipyridamole_be ,_be hydroxychloroquine_be others_be interfere_be platelet-aggregation_be reactions_be (the_be main_be hemostatic_be defense_be heparinized_be patients)_be may_be induce_be bleeding_be used_be caution_be patients_be receiving_be heparin_be sodium_be ._be"
2177,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",dipyridamole,heparin sodium,effect,"Platelet_bf inhibitors:_bf Drugs_bf acetylsalicylic_bf acid_bf ,_bf dextran_bf ,_bf phenylbutazone_bf ,_bf ibuprofen_bf ,_bf indomethacin_bf ,_bf DRUG ,_be hydroxychloroquine_be others_be interfere_be platelet-aggregation_be reactions_be (the_be main_be hemostatic_be defense_be heparinized_be patients)_be may_be induce_be bleeding_be used_be caution_be patients_be receiving_be heparin_be sodium_be ._be"
2178,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",hydroxychloroquine,heparin sodium,effect,"Platelet_bf inhibitors:_bf Drugs_bf acetylsalicylic_bf acid_bf ,_bf dextran_bf ,_bf phenylbutazone_bf ,_bf ibuprofen_bf ,_bf indomethacin_bf ,_bf dipyridamole_bf ,_bf DRUG others_be interfere_be platelet-aggregation_be reactions_be (the_be main_be hemostatic_be defense_be heparinized_be patients)_be may_be induce_be bleeding_be used_be caution_be patients_be receiving_be heparin_be sodium_be ._be"
2179,The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency.,heparin,antithrombin III,effect,The_bf anticoagulant_bf effect_bf DRUG enhanced_be concurrent_be treatment_be antithrombin_be III_be (human)_be patients_be hereditary_be antithrombin_be III_be deficiency_be ._be
2180,"Thus in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with antithrombin III (human).",heparin,antithrombin III,advise,"Thus_bf order_bf avoid_bf bleeding_bf ,_bf reduced_bf dosage_bf DRUG recommended_be treatment_be antithrombin_be III_be (human)_be ._be"
2181,"Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.",Digitalis,heparin sodium,effect,"Drugs_bf Decreasing_bf Heparin_bf Effect:_bf DRUG ,_be tetracyclines_be ,_be nicotine_be ,_be antihistamines_be may_be partially_be counteract_be anticoagulant_be action_be heparin_be sodium_be ._be"
2182,"Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.",tetracyclines,heparin sodium,effect,"Drugs_bf Decreasing_bf Heparin_bf Effect:_bf Digitalis_bf ,_bf DRUG ,_be nicotine_be ,_be antihistamines_be may_be partially_be counteract_be anticoagulant_be action_be heparin_be sodium_be ._be"
2183,"Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.",nicotine,heparin sodium,effect,"Drugs_bf Decreasing_bf Heparin_bf Effect:_bf Digitalis_bf ,_bf tetracyclines_bf ,_bf DRUG ,_be antihistamines_be may_be partially_be counteract_be anticoagulant_be action_be heparin_be sodium_be ._be"
2184,"Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.",antihistamines,heparin sodium,effect,"Drugs_bf Decreasing_bf Heparin_bf Effect:_bf Digitalis_bf ,_bf tetracyclines_bf ,_bf nicotine_bf ,_bf DRUG may_be partially_be counteract_be anticoagulant_be action_be heparin_be sodium_be ._be"
2185,"In combination with other central nervous system depressants, heroin may still kill even experienced users, particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased.",central nervous system depressants,heroin,effect,"In_bf combination_bf central_bf nervous_bf system_bf depressants_bf ,_bf OTHER_DRUG may_be still_be kill_be even_be experienced_be users_be ,_be particularly_be tolerance_be drug_be reduced_be strength_be usual_be dose_be increased_be ._be"
2186,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,central nervous system depressants,effect,"Toxicology_bf studies_bf heroin-related_bf deaths_bf reveal_bf frequent_bf involvement_bf central_bf nervous_bf system_bf depressants_bf ,_bf including_bf alcohol_bf ,_bf benzodiazepines_bf diazepam_bf (Valium)_bf ,_bf ,_bf rising_bf degree_bf ,_bf methadone_bf ._bf"
2187,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,alcohol,effect,"Toxicology_bf studies_bf heroin-related_bf deaths_bf reveal_bf frequent_bf involvement_bf central_bf nervous_bf system_bf depressants_bf ,_bf including_bf OTHER_DRUG ,_be benzodiazepines_be diazepam_be (Valium)_be ,_be ,_be rising_be degree_be ,_be methadone_be ._be"
2188,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,benzodiazepines,effect,"Toxicology_bf studies_bf heroin-related_bf deaths_bf reveal_bf frequent_bf involvement_bf central_bf nervous_bf system_bf depressants_bf ,_bf including_bf alcohol_bf ,_bf OTHER_DRUG diazepam_be (Valium)_be ,_be ,_be rising_be degree_be ,_be methadone_be ._be"
2189,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,diazepam,effect,"Toxicology_bf studies_bf heroin-related_bf deaths_bf reveal_bf frequent_bf involvement_bf central_bf nervous_bf system_bf depressants_bf ,_bf including_bf alcohol_bf ,_bf benzodiazepines_bf OTHER_DRUG (Valium)_be ,_be ,_be rising_be degree_be ,_be methadone_be ._be"
2190,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,Valium,effect,"Toxicology_bf studies_bf heroin-related_bf deaths_bf reveal_bf frequent_bf involvement_bf central_bf nervous_bf system_bf depressants_bf ,_bf including_bf alcohol_bf ,_bf benzodiazepines_bf diazepam_bf (Valium)_bf ,_bf ,_bf rising_bf degree_bf ,_bf methadone_bf ._bf"
2191,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,methadone,effect,"Toxicology_bf studies_bf heroin-related_bf deaths_bf reveal_bf frequent_bf involvement_bf central_bf nervous_bf system_bf depressants_bf ,_bf including_bf alcohol_bf ,_bf benzodiazepines_bf diazepam_bf (Valium)_bf ,_bf ,_bf rising_bf degree_bf ,_bf OTHER_DRUG ._be"
2192,Cocaine sometimes proves to be fatal when used in combination with heroin.,Cocaine,heroin,effect,DRUG sometimes_be proves_be fatal_be used_be combination_be OTHER_DRUG ._af
2193,MAO inhibitors should be used with caution in patients receiving hydralazine.,MAO inhibitors,hydralazine,advise,MAO_bf inhibitors_bf used_bf caution_bf patients_bf receiving_bf OTHER_DRUG ._be
2194,"When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.",antihypertensive drugs,diazoxide,effect,"When_bf potent_bf parental_bf antihypertensive_bf drugs_bf ,_bf OTHER_DRUG ,_be used_be combination_be hydralazine_be ,_be patients_be continuously_be observed_be several_be hours_be excessive_be fall_be blood_be pressure_be ._be"
2195,"When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.",antihypertensive drugs,hydralazine,effect,"When_bf potent_bf parental_bf antihypertensive_bf drugs_bf ,_bf diazoxide_bf ,_bf used_bf combination_bf OTHER_DRUG ,_be patients_be continuously_be observed_be several_be hours_be excessive_be fall_be blood_be pressure_be ._be"
2196,Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.,diazoxide,hydralazine,effect,Profound_bf hypotensive_bf episodes_bf may_bf occur_bf DRUG infection_be OTHER_DRUG used_af concomitantly_af ._af
2197,Propranolol increases hydralazines serum concentrations.,Propranolol,hydralazine,mechanism,DRUG increases_be hydralazines_be serum_be concentrations_be ._be
2198,NSAIDs may decrease the hemodynamic effects of hydralazine;,NSAIDs,hydralazine,effect,DRUG may_be decrease_be hemodynamic_be effects_be hydralazine;_be
2199,Cholestyramine and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.,hydrochlorothiazide,anionic exchange resins,mechanism,Cholestyramine_bf colestipol_bf resins:_bf Absorption_bf DRUG impaired_be presence_be anionic_be exchange_be resins_be ._be
2200,"Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.",cholestyramine,hydrochlorothiazide,mechanism,"Single_bf doses_bf either_bf DRUG colestipol_be resins_be bind_be OTHER_DRUG reduce_af absorption_af gastrointestinal_af tract_af 85_af 43_af percent_af ,_af respectively_af ._af"
2201,"Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.",colestipol,hydrochlorothiazide,mechanism,"Single_bf doses_bf either_bf cholestyramine_bf DRUG resins_be bind_be OTHER_DRUG reduce_af absorption_af gastrointestinal_af tract_af 85_af 43_af percent_af ,_af respectively_af ._af"
2202,Lithium: generally should not be given with diuretics.,Lithium,diuretics,advise,Lithium:_bf generally_bf given_bf OTHER_DRUG ._be
2203,Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.,Diuretic agents,lithium,mechanism,Diuretic_bf agents_bf reduce_bf renal_bf clearance_bf OTHER_DRUG add_be high_be risk_be OTHER_DRUG toxicity_af ._af
2204,Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.,Diuretic agents,lithium,effect,Diuretic_bf agents_bf reduce_bf renal_bf clearance_bf OTHER_DRUG add_be high_be risk_be OTHER_DRUG toxicity_af ._af
2205,Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.,lithium,Hydrochlorothiazide,advise,Refer_bf package_bf insert_bf DRUG preparations_be use_be preparations_be OTHER_DRUG ._af
2206,"Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,loop diuretics,effect,"Non-steroidal_bf Anti-inflammatory_bf Drugs:_bf In_bf patients_bf ,_bf administration_bf non-steroidal_bf anti-inflammatory_bf agent_bf reduce_bf diuretic_bf ,_bf natriuretic_bf ,_bf antihypertensive_bf effects_bf loop_bf ,_bf potassium-sparing_bf thiazide_bf diuretics_bf ._bf"
2207,"Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,potassium-sparing diuretics,effect,"Non-steroidal_bf Anti-inflammatory_bf Drugs:_bf In_bf patients_bf ,_bf administration_bf non-steroidal_bf anti-inflammatory_bf agent_bf reduce_bf diuretic_bf ,_bf natriuretic_bf ,_bf antihypertensive_bf effects_bf loop_bf ,_bf potassium-sparing_bf thiazide_bf diuretics_bf ._bf"
2208,"Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,thiazide diuretics,effect,"Non-steroidal_bf Anti-inflammatory_bf Drugs:_bf In_bf patients_bf ,_bf administration_bf non-steroidal_bf anti-inflammatory_bf agent_bf reduce_bf diuretic_bf ,_bf natriuretic_bf ,_bf antihypertensive_bf effects_bf loop_bf ,_bf potassium-sparing_bf thiazide_bf diuretics_bf ._bf"
2209,"Therefore, when Hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.",Hydrochlorothiazide,non-steroidal anti-inflammatory agents,advise,"Therefore_bf ,_bf DRUG non-steroidal_be anti-inflammatory_be agents_be used_be concomitantly_be ,_be patient_be observed_be closely_be determine_be desired_be effect_be diuretic_be obtained_be ._be"
2210,"Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",narcotic analgesics,hydrocodone,effect,"Patients_bf receiving_bf narcotic_bf analgesics_bf ,_bf antipsychotics_bf ,_bf antianxiety_bf agents_bf ,_bf CNS_bf depressants_bf (including_bf alcohol)_bf concomitantly_bf OTHER_DRUG acetaminophen_be tablets_be may_be exhibit_be additive_be CNS_be depression_be ._be"
2211,"Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",antipsychotics,hydrocodone,effect,"Patients_bf receiving_bf narcotic_bf analgesics_bf ,_bf DRUG ,_be antianxiety_be agents_be ,_be CNS_be depressants_be (including_be alcohol)_be concomitantly_be OTHER_DRUG acetaminophen_af tablets_af may_af exhibit_af additive_af CNS_af depression_af ._af"
2212,"Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",antianxiety agents,hydrocodone,effect,"Patients_bf receiving_bf narcotic_bf analgesics_bf ,_bf antipsychotics_bf ,_bf antianxiety_bf agents_bf ,_bf CNS_bf depressants_bf (including_bf alcohol)_bf concomitantly_bf OTHER_DRUG acetaminophen_be tablets_be may_be exhibit_be additive_be CNS_be depression_be ._be"
2213,"Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",CNS depressants,hydrocodone,effect,"Patients_bf receiving_bf narcotic_bf analgesics_bf ,_bf antipsychotics_bf ,_bf antianxiety_bf agents_bf ,_bf CNS_bf depressants_bf (including_bf alcohol)_bf concomitantly_bf OTHER_DRUG acetaminophen_be tablets_be may_be exhibit_be additive_be CNS_be depression_be ._be"
2214,"Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",alcohol,hydrocodone,effect,"Patients_bf receiving_bf narcotic_bf analgesics_bf ,_bf antipsychotics_bf ,_bf antianxiety_bf agents_bf ,_bf CNS_bf depressants_bf (including_bf alcohol)_bf concomitantly_bf OTHER_DRUG acetaminophen_be tablets_be may_be exhibit_be additive_be CNS_be depression_be ._be"
2215,The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.,MAO inhibitors,hydrocodone,effect,The_bf use_bf MAO_bf inhibitors_bf tricyclic_bf antidepressants_bf OTHER_DRUG preparations_be may_be increase_be effect_be either_be antidepressant_be OTHER_DRUG ._af
2216,The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.,tricyclic antidepressants,hydrocodone,effect,The_bf use_bf MAO_bf inhibitors_bf tricyclic_bf antidepressants_bf OTHER_DRUG preparations_be may_be increase_be effect_be either_be antidepressant_be OTHER_DRUG ._af
2217,The concurrent use of anticholinergics with hydrocodone may produce paralytic ileus.,anticholinergics,hydrocodone,effect,The_bf concurrent_bf use_bf DRUG OTHER_DRUG may_af produce_af paralytic_af ileus_af ._af
2218,(Concurrent use with thiazide diuretics may enhance the possibility of digitalis toxicity associated with hypokalemia.),thiazide diuretics,digitalis,effect,(Concurrent_bf use_bf thiazide_bf diuretics_bf may_bf enhance_bf possibility_bf OTHER_DRUG toxicity_be associated_be hypokalemia_be ._be )_be
2219,"for adult-onset diabetics, dosage adjustment of hypoglycemic medications may be necessary during and after thiazide diuretic therapy;",hypoglycemic medications,thiazide diuretic,advise,"adult-onset_bf diabetics_bf ,_bf dosage_bf adjustment_bf hypoglycemic_bf medications_bf may_bf necessary_bf thiazide_bf diuretic_bf therapy;_bf"
2220,"(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.",steroidal anti-inflammatory agent,loop diuretics,effect,"(In_bf patients_bf ,_bf steroidal_bf anti-inflammatory_bf agent_bf reduce_bf diuretic_bf ,_bf natriuretic_bf ,_bf antihypertensive_bf effects_bf loop_bf ,_bf potassium_bf sparing_bf ,_bf thiazide_bf diuretics_bf ._bf"
2221,"(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.",steroidal anti-inflammatory agent,potassium sparing diuretics,effect,"(In_bf patients_bf ,_bf steroidal_bf anti-inflammatory_bf agent_bf reduce_bf diuretic_bf ,_bf natriuretic_bf ,_bf antihypertensive_bf effects_bf loop_bf ,_bf potassium_bf sparing_bf ,_bf thiazide_bf diuretics_bf ._bf"
2222,"(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.",steroidal anti-inflammatory agent,thiazide diuretics,effect,"(In_bf patients_bf ,_bf steroidal_bf anti-inflammatory_bf agent_bf reduce_bf diuretic_bf ,_bf natriuretic_bf ,_bf antihypertensive_bf effects_bf loop_bf ,_bf potassium_bf sparing_bf ,_bf thiazide_bf diuretics_bf ._bf"
2223,"Therefore, when hydroflumethiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.)",hydroflumethiazide,nonsteroidal anti-inflammatory agents,advise,"Therefore_bf ,_bf DRUG nonsteroidal_be anti-inflammatory_be agents_be used_be concomitantly_be ,_be patient_be observed_be closely_be determine_be desired_be effect_be diuretic_be obtained_be ._be )_be"
2224,(Thiazides may decrease arterial responsiveness to norepinephrine.,Thiazides,norepinephrine,effect,(Thiazides_bf may_bf decrease_bf arterial_bf responsiveness_bf OTHER_DRUG ._be
2225,(Thiazide drugs may increase the responsiveness to tubocurarine.),Thiazide drugs,tubocurarine,effect,(Thiazide_bf drugs_bf may_bf increase_bf responsiveness_bf OTHER_DRUG ._be )_be
2226,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",narcotic analgesic,DILAUDID,effect,"Patients_bf receiving_bf narcotic_bf analgesics_bf ,_bf general_bf anesthetics_bf ,_bf phenothiazines_bf ,_bf tranquilizers_bf ,_bf sedative-hypnotics_bf ,_bf tricyclic_bf antidepressants_bf CNS_bf depressants_bf (including_bf alcohol)_bf concomitantly_bf OTHER_DRUG may_be exhibit_be additive_be CNS_be depression_be ._be"
2227,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",anesthetics,DILAUDID,effect,"Patients_bf receiving_bf narcotic_bf analgesics_bf ,_bf general_bf DRUG ,_be phenothiazines_be ,_be tranquilizers_be ,_be sedative-hypnotics_be ,_be tricyclic_be antidepressants_be CNS_be depressants_be (including_be alcohol)_be concomitantly_be OTHER_DRUG may_af exhibit_af additive_af CNS_af depression_af ._af"
2228,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",phenothiazines,DILAUDID,effect,"Patients_bf receiving_bf narcotic_bf analgesics_bf ,_bf general_bf anesthetics_bf ,_bf DRUG ,_be tranquilizers_be ,_be sedative-hypnotics_be ,_be tricyclic_be antidepressants_be CNS_be depressants_be (including_be alcohol)_be concomitantly_be OTHER_DRUG may_af exhibit_af additive_af CNS_af depression_af ._af"
2229,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",tranquilizers,DILAUDID,effect,"Patients_bf receiving_bf narcotic_bf analgesics_bf ,_bf general_bf anesthetics_bf ,_bf phenothiazines_bf ,_bf DRUG ,_be sedative-hypnotics_be ,_be tricyclic_be antidepressants_be CNS_be depressants_be (including_be alcohol)_be concomitantly_be OTHER_DRUG may_af exhibit_af additive_af CNS_af depression_af ._af"
2230,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",sedative-hypnotics,DILAUDID,effect,"Patients_bf receiving_bf narcotic_bf analgesics_bf ,_bf general_bf anesthetics_bf ,_bf phenothiazines_bf ,_bf tranquilizers_bf ,_bf DRUG ,_be tricyclic_be antidepressants_be CNS_be depressants_be (including_be alcohol)_be concomitantly_be OTHER_DRUG may_af exhibit_af additive_af CNS_af depression_af ._af"
2231,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",tricyclic antidepressants,DILAUDID,effect,"Patients_bf receiving_bf narcotic_bf analgesics_bf ,_bf general_bf anesthetics_bf ,_bf phenothiazines_bf ,_bf tranquilizers_bf ,_bf sedative-hypnotics_bf ,_bf tricyclic_bf antidepressants_bf CNS_bf depressants_bf (including_bf alcohol)_bf concomitantly_bf OTHER_DRUG may_be exhibit_be additive_be CNS_be depression_be ._be"
2232,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",CNS depressants,DILAUDID,effect,"Patients_bf receiving_bf narcotic_bf analgesics_bf ,_bf general_bf anesthetics_bf ,_bf phenothiazines_bf ,_bf tranquilizers_bf ,_bf sedative-hypnotics_bf ,_bf tricyclic_bf antidepressants_bf CNS_bf depressants_bf (including_bf alcohol)_bf concomitantly_bf OTHER_DRUG may_be exhibit_be additive_be CNS_be depression_be ._be"
2233,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",alcohol,DILAUDID,effect,"Patients_bf receiving_bf narcotic_bf analgesics_bf ,_bf general_bf anesthetics_bf ,_bf phenothiazines_bf ,_bf tranquilizers_bf ,_bf sedative-hypnotics_bf ,_bf tricyclic_bf antidepressants_bf CNS_bf depressants_bf (including_bf alcohol)_bf concomitantly_bf OTHER_DRUG may_be exhibit_be additive_be CNS_be depression_be ._be"
2234,"Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary",hydroxyurea,uricosuric medication,effect,"Since_bf DRUG may_be raise_be serum_be uric_be acid_be level_be ,_be dosage_be adjustment_be uricosuric_be medication_be may_be necessary_be"
2235,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.",HYDROXYZINE,CENTRAL NERVOUS SYSTEM DEPRESSANTS,effect,"THE_bf POTENTIATING_bf ACTION_bf OF_bf DRUG MUST_be BE_be CONSIDERED_be WHEN_be THE_be DRUG_be IS_be USED_be IN_be CONJUNCTION_be WITH_be CENTRAL_be NERVOUS_be SYSTEM_be DEPRESSANTS_be SUCH_be AS_be NARCOTICS_be ,_be NON-NARCOTIC_be ANALGESICS_be AND_be BARBITURATES_be ._be"
2236,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.",HYDROXYZINE,NARCOTICS,effect,"THE_bf POTENTIATING_bf ACTION_bf OF_bf DRUG MUST_be BE_be CONSIDERED_be WHEN_be THE_be DRUG_be IS_be USED_be IN_be CONJUNCTION_be WITH_be CENTRAL_be NERVOUS_be SYSTEM_be DEPRESSANTS_be SUCH_be AS_be OTHER_DRUG ,_af NON-NARCOTIC_af ANALGESICS_af AND_af BARBITURATES_af ._af"
2237,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.",HYDROXYZINE,NON-NARCOTIC ANALGESICS,effect,"THE_bf POTENTIATING_bf ACTION_bf OF_bf DRUG MUST_be BE_be CONSIDERED_be WHEN_be THE_be DRUG_be IS_be USED_be IN_be CONJUNCTION_be WITH_be CENTRAL_be NERVOUS_be SYSTEM_be DEPRESSANTS_be SUCH_be AS_be NARCOTICS_be ,_be NON-NARCOTIC_be ANALGESICS_be AND_be BARBITURATES_be ._be"
2238,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.",HYDROXYZINE,BARBITURATES,effect,"THE_bf POTENTIATING_bf ACTION_bf OF_bf DRUG MUST_be BE_be CONSIDERED_be WHEN_be THE_be DRUG_be IS_be USED_be IN_be CONJUNCTION_be WITH_be CENTRAL_be NERVOUS_be SYSTEM_be DEPRESSANTS_be SUCH_be AS_be NARCOTICS_be ,_be NON-NARCOTIC_be ANALGESICS_be AND_be OTHER_DRUG ._af"
2239,Therefore when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced.,central nervous system depressants,hydroxyzine,advise,Therefore_bf central_bf nervous_bf system_bf depressants_bf administered_bf concomitantly_bf OTHER_DRUG dosage_be reduced_be ._be
2240,"Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.",calcium,Ibandronate,mechanism,"Products_bf containing_bf DRUG multivalent_be cations_be (such_be aluminum_be ,_be magnesium_be ,_be iron)_be likely_be interfere_be absorption_be OTHER_DRUG ._af"
2241,"Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.",aluminum,Ibandronate,mechanism,"Products_bf containing_bf calcium_bf multivalent_bf cations_bf (such_bf DRUG ,_be magnesium_be ,_be iron)_be likely_be interfere_be absorption_be OTHER_DRUG ._af"
2242,"Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.",magnesium,Ibandronate,mechanism,"Products_bf containing_bf calcium_bf multivalent_bf cations_bf (such_bf aluminum_bf ,_bf DRUG ,_be iron)_be likely_be interfere_be absorption_be OTHER_DRUG ._af"
2243,"Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.",iron,Ibandronate,mechanism,"Products_bf containing_bf calcium_bf multivalent_bf cations_bf (such_bf aluminum_bf ,_bf magnesium_bf ,_bf iron)_bf likely_bf interfere_bf absorption_bf OTHER_DRUG ._be"
2244,"Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).",Ibandronate,antacids,advise,"DRUG taken_be least_be 60_be minutes_be oral_be medications_be containing_be multivalent_be cations_be (including_be OTHER_DRUG ,_af supplements_af vitamins)_af ._af"
2245,"Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).",Ibandronate,vitamins,advise,"DRUG taken_be least_be 60_be minutes_be oral_be medications_be containing_be multivalent_be cations_be (including_be antacids_be ,_be supplements_be vitamins)_be ._be"
2246,"However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.",aspirin,Ibandronate,advise,"However_bf ,_bf since_bf DRUG ,_be NSAIDs_be ,_be bisphosphonates_be associated_be gastrointestinal_be irritation_be ,_be caution_be exercised_be concomitant_be use_be DRUG NSAIDs_af OTHER_DRUG ._af"
2247,"However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.",NSAIDs,Ibandronate,advise,"However_bf ,_bf since_bf aspirin_bf ,_bf DRUG ,_be bisphosphonates_be associated_be gastrointestinal_be irritation_be ,_be caution_be exercised_be concomitant_be use_be aspirin_be DRUG OTHER_DRUG ._af"
2248,"However, appropriate monitoring of blood glucose should be performed when initiating EXTRANEAL in diabetic patients and insulin dosage should be adjusted if needed.",EXTRANEAL,insulin,advise,"However_bf ,_bf appropriate_bf monitoring_bf blood_bf glucose_bf performed_bf initiating_bf DRUG diabetic_be patients_be OTHER_DRUG dosage_af adjusted_af needed_af ._af"
2249,Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).,EPA,aspirin,int,Interactions_bf may_bf occur_bf DRUG supplements_be OTHER_DRUG non-steroidal_af anti-inflammatory_af drugs_af herbs_af garlic_af (Allium_af sativum)_af ginkgo_af (Ginkgo_af biloba)_af ._af
2250,Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).,EPA,non-steroidal anti-inflammatory drugs,int,Interactions_bf may_bf occur_bf DRUG supplements_be aspirin_be non-steroidal_be anti-inflammatory_be drugs_be herbs_be garlic_be (Allium_be sativum)_be ginkgo_be (Ginkgo_be biloba)_be ._be
2251,Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).,EPA,ginkgo,int,Interactions_bf may_bf occur_bf DRUG supplements_be aspirin_be non-steroidal_be anti-inflammatory_be drugs_be herbs_be garlic_be (Allium_be sativum)_be OTHER_DRUG (Ginkgo_af biloba)_af ._af
2252,Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).,EPA,Ginkgo biloba,int,Interactions_bf may_bf occur_bf DRUG supplements_be aspirin_be non-steroidal_be anti-inflammatory_be drugs_be herbs_be garlic_be (Allium_be sativum)_be ginkgo_be (Ginkgo_be biloba)_be ._be
2253,"When you are using idoxuridine, it is especially important that your health care professional know if you are using the following: Eye product containing boric acid.",idoxuridine,boric acid,advise,"When_bf using_bf DRUG ,_be especially_be important_be health_be care_be professional_be know_be using_be following:_be Eye_be product_be containing_be boric_be acid_be ._be"
2254,Boric acid may interact with the idoxuridine preparation causing a gritty substance to form or may interact with the preservative in the idoxuridine preparation causing a toxic effect in the eye.,Boric acid,idoxuridine,mechanism,Boric_bf acid_bf may_bf interact_bf OTHER_DRUG preparation_be causing_be gritty_be substance_be form_be may_be interact_be preservative_be OTHER_DRUG preparation_af causing_af toxic_af effect_af eye_af ._af
2255,"However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.",iloprost,vasodilators,effect,"However_bf ,_bf DRUG potential_be increase_be hypotensive_be effect_be OTHER_DRUG antihypertensive_af agents_af ._af"
2256,"However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.",iloprost,antihypertensive agents,effect,"However_bf ,_bf DRUG potential_be increase_be hypotensive_be effect_be vasodilators_be antihypertensive_be agents_be ._be"
2257,"Since iloprost inhibits platelet function, there is a potential for increased risk of bleeding, particularly in patients maintained on anticoagulants.",iloprost,anticoagulants,effect,"Since_bf DRUG inhibits_be platelet_be function_be ,_be potential_be increased_be risk_be bleeding_be ,_be particularly_be patients_be maintained_be OTHER_DRUG ._af"
2258,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).",Gleevec,ketoconazole,advise,"Drugs_bf may_bf alter_bf imatinib_bf plasma_bf concentrations_bf Drugs_bf may_bf increase_bf imatinib_bf plasma_bf concentrations:_bf Caution_bf recommended_bf administering_bf DRUG inhibitors_be CYP3A4_be family_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af itraconazole_af ,_af erythromycin_af ,_af clarithromycin)_af ._af"
2259,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).",Gleevec,itraconazole,advise,"Drugs_bf may_bf alter_bf imatinib_bf plasma_bf concentrations_bf Drugs_bf may_bf increase_bf imatinib_bf plasma_bf concentrations:_bf Caution_bf recommended_bf administering_bf DRUG inhibitors_be CYP3A4_be family_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be OTHER_DRUG ,_af erythromycin_af ,_af clarithromycin)_af ._af"
2260,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).",Gleevec,erythromycin,advise,"Drugs_bf may_bf alter_bf imatinib_bf plasma_bf concentrations_bf Drugs_bf may_bf increase_bf imatinib_bf plasma_bf concentrations:_bf Caution_bf recommended_bf administering_bf DRUG inhibitors_be CYP3A4_be family_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be OTHER_DRUG ,_af clarithromycin)_af ._af"
2261,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).",Gleevec,clarithromycin,advise,"Drugs_bf may_bf alter_bf imatinib_bf plasma_bf concentrations_bf Drugs_bf may_bf increase_bf imatinib_bf plasma_bf concentrations:_bf Caution_bf recommended_bf administering_bf DRUG inhibitors_be CYP3A4_be family_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be clarithromycin)_be ._be"
2262,There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).,Gleevec,ketoconazole,mechanism,There_bf significant_bf increase_bf exposure_bf imatinib_bf DRUG coadministered_be OTHER_DRUG (CYP3A4_af inhibitor)_af ._af
2263,"Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).",rifampin,Gleevec,mechanism,"Pretreatment_bf healthy_bf volunteers_bf multiple_bf doses_bf DRUG followed_be single_be dose_be OTHER_DRUG ,_af increased_af OTHER_DRUG oral-dose_af clearance_af 3_af ._af 8-fold_af ,_af significantly_af (p_af 0_af ._af 05)_af decreased_af mean_af cmax_af AUC(0-8)_af ._af"
2264,"Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.",Gleevec,simvastatin,mechanism,"Drugs_bf may_bf plasma_bf concentration_bf altered_bf DRUG DRUG increases_af mean_af cmax_af AUC_af OTHER_DRUG (CYP3A4_af substrate)_af 2-_af 3_af ._af 5-fold_af ,_af respectively_af ,_af suggesting_af inhibition_af CYP3A4_af DRUG ._af"
2265,"Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).",Gleevec,cyclosporine,advise,"Particular_bf caution_bf recommended_bf administering_bf DRUG CYP3A4_be substrates_be narrow_be therapeutic_be window_be (e_be ._be g_be ._be ,_be OTHER_DRUG pimozide)_af ._af"
2266,"Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).",Gleevec,pimozide,advise,"Particular_bf caution_bf recommended_bf administering_bf DRUG CYP3A4_be substrates_be narrow_be therapeutic_be window_be (e_be ._be g_be ._be ,_be cyclosporine_be pimozide)_be ._be"
2267,"Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).",Gleevec,benzodiazepines,mechanism,"DRUG increase_be plasmaconcentration_be CYP3A4_be metabolized_be drugs_be (e_be ._be g_be ._be ,_be triazolo-benzodiazepines_be ,_be dihydropyridine_be calcium_be channel_be blockers_be ,_be certain_be HMG-CoA_be reductase_be inhibitors_be ,_be etc_be ._be )_be ._be"
2268,"Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).",Gleevec,dihydropyridine calcium channel blockers,mechanism,"DRUG increase_be plasmaconcentration_be CYP3A4_be metabolized_be drugs_be (e_be ._be g_be ._be ,_be triazolo-benzodiazepines_be ,_be dihydropyridine_be calcium_be channel_be blockers_be ,_be certain_be HMG-CoA_be reductase_be inhibitors_be ,_be etc_be ._be )_be ._be"
2269,"Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).",Gleevec,HMG-CoA reductase inhibitors,mechanism,"DRUG increase_be plasmaconcentration_be CYP3A4_be metabolized_be drugs_be (e_be ._be g_be ._be ,_be triazolo-benzodiazepines_be ,_be dihydropyridine_be calcium_be channel_be blockers_be ,_be certain_be HMG-CoA_be reductase_be inhibitors_be ,_be etc_be ._be )_be ._be"
2270,Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec.,acetaminophen,Gleevec,mechanism,Systemic_bf exposure_bf DRUG expected_be increased_be coadministered_be OTHER_DRUG ._af
2271,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",decongestants,tricyclic antidepressants,advise,"Avoid_bf use_bf preparations_bf DRUG local_be anesthetics_be contain_be sympathomimetic_be amine_be (e_be ._be g_be ._be ,_be epinephrine_be ,_be norepinephrine)_be ,_be since_be reported_be tricyclic_be antidepressants_be potentiate_be effects_be catecholamines_be ._be"
2272,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",anesthetics,tricyclic antidepressants,advise,"Avoid_bf use_bf preparations_bf decongestants_bf local_bf DRUG contain_be sympathomimetic_be amine_be (e_be ._be g_be ._be ,_be epinephrine_be ,_be norepinephrine)_be ,_be since_be reported_be tricyclic_be antidepressants_be potentiate_be effects_be catecholamines_be ._be"
2273,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",sympathomimetic amine,tricyclic antidepressants,advise,"Avoid_bf use_bf preparations_bf decongestants_bf local_bf anesthetics_bf contain_bf sympathomimetic_bf amine_bf (e_bf ._bf g_bf ._bf ,_bf epinephrine_bf ,_bf norepinephrine)_bf ,_bf since_bf reported_bf tricyclic_bf antidepressants_bf potentiate_bf effects_bf catecholamines_bf ._bf"
2274,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",epinephrine,tricyclic antidepressants,advise,"Avoid_bf use_bf preparations_bf decongestants_bf local_bf anesthetics_bf contain_bf sympathomimetic_bf amine_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be norepinephrine)_be ,_be since_be reported_be tricyclic_be antidepressants_be potentiate_be effects_be catecholamines_be ._be"
2275,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",norepinephrine,tricyclic antidepressants,advise,"Avoid_bf use_bf preparations_bf decongestants_bf local_bf anesthetics_bf contain_bf sympathomimetic_bf amine_bf (e_bf ._bf g_bf ._bf ,_bf epinephrine_bf ,_bf norepinephrine)_bf ,_bf since_bf reported_bf tricyclic_bf antidepressants_bf potentiate_bf effects_bf catecholamines_bf ._bf"
2276,Imipramine hydrochloride may potentiate the effects of CNS depressant drugs.,Imipramine hydrochloride,CNS depressant drugs,effect,Imipramine_bf hydrochloride_bf may_bf potentiate_bf effects_bf CNS_bf depressant_bf drugs_bf ._bf
2277,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.",imipramine,cimetidine,mechanism,"The_bf plasma_bf concentration_bf DRUG may_be increase_be drug_be given_be concomitantly_be hepatic_be enzyme_be inhibitors_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af fluoxetine)_af decrease_af concomitant_af administration_af hepatic_af enzyme_af inducers_af (e_af ._af g_af ._af ,_af barbiturates_af ,_af phenytoin)_af ,_af adjustment_af dosage_af DRUG may_af therefore_af necessary_af ._af"
2278,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.",imipramine,fluoxetine,mechanism,"The_bf plasma_bf concentration_bf DRUG may_be increase_be drug_be given_be concomitantly_be hepatic_be enzyme_be inhibitors_be (e_be ._be g_be ._be ,_be cimetidine_be ,_be fluoxetine)_be decrease_be concomitant_be administration_be hepatic_be enzyme_be inducers_be (e_be ._be g_be ._be ,_be barbiturates_be ,_be phenytoin)_be ,_be adjustment_be dosage_be DRUG may_af therefore_af necessary_af ._af"
2279,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.",imipramine,barbiturates,mechanism,"The_bf plasma_bf concentration_bf DRUG may_be increase_be drug_be given_be concomitantly_be hepatic_be enzyme_be inhibitors_be (e_be ._be g_be ._be ,_be cimetidine_be ,_be fluoxetine)_be decrease_be concomitant_be administration_be hepatic_be enzyme_be inducers_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af phenytoin)_af ,_af adjustment_af dosage_af DRUG may_af therefore_af necessary_af ._af"
2280,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.",imipramine,phenytoin,mechanism,"The_bf plasma_bf concentration_bf DRUG may_be increase_be drug_be given_be concomitantly_be hepatic_be enzyme_be inhibitors_be (e_be ._be g_be ._be ,_be cimetidine_be ,_be fluoxetine)_be decrease_be concomitant_be administration_be hepatic_be enzyme_be inducers_be (e_be ._be g_be ._be ,_be barbiturates_be ,_be phenytoin)_be ,_be adjustment_be dosage_be DRUG may_af therefore_af necessary_af ._af"
2281,"The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the SSRI involved.",SSRI,TCA,int,"The_bf extent_bf SSRI-TCA_bf interactions_bf may_bf pose_bf clinical_bf problems_bf depend_bf degree_bf inhibition_bf ,_bf pharmacokinetics_bf DRUG involved_be ._be"
2282,Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.,CRIXIVAN,atazanavir,advise,Combinations_bf drugs_bf studied_bf coadministration_bf DRUG OTHER_DRUG recommended_af ._af
2283,Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.,CRIXIVAN,delavirdine,advise,Dose_bf reduction_bf DRUG 600_be mg_be every_be 8_be hours_be considered_be taking_be OTHER_DRUG 400_af mg_af three_af times_af day_af ._af
2284,Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.,Indinavir,didanosine,advise,DRUG OTHER_DRUG formulations_af containing_af buffer_af administered_af least_af one_af hour_af apart_af empty_af stomach_af ._af
2285,Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.,indinavir,efavirenz,mechanism,Increasing_bf DRUG dose_be 1000_be mg_be every_be 8_be hours_be compensate_be increased_be DRUG metabolism_af due_af OTHER_DRUG ._af
2286,Indinavir concentrations may be decreased in the presence of nevirapine.,Indinavir,nevirapine,mechanism,DRUG concentrations_be may_be decreased_be presence_be OTHER_DRUG ._af
2287,Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.,indinavir,ritonavir,effect,Preliminary_bf clinical_bf data_bf suggest_bf incidence_bf nephrolithiasis_bf higher_bf patients_bf receiving_bf DRUG combination_be OTHER_DRUG receiving_af CRIXIVAN_af 800_af mg_af q8h_af ._af
2288,Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics when coadministered with CRIXIVAN.,antiarrhythmics,CRIXIVAN,advise,Caution_bf warranted_bf therapeutic_bf concentration_bf monitoring_bf recommended_bf DRUG coadministered_be OTHER_DRUG ._af
2289,CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.,CRIXIVAN,indinavir,effect,DRUG may_be effective_be due_be decreased_be OTHER_DRUG concentrations_af patients_af taking_af agents_af concomitantly_af ._af
2290,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.",atorvastatin,CRIXIVAN,advise,"Use_bf lowest_bf possible_bf dose_bf DRUG careful_be monitoring_be ,_be consider_be HMG-CoA_be reductase_be inhibitors_be primarily_be metabolized_be CYP3A4_be ,_be pravastatin_be ,_be fluvastatin_be ,_be rosuvastatin_be combination_be OTHER_DRUG ._af"
2291,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.",HMG-CoA reductase inhibitors,CRIXIVAN,advise,"Use_bf lowest_bf possible_bf dose_bf atorvastatin_bf careful_bf monitoring_bf ,_bf consider_bf HMG-CoA_bf reductase_bf inhibitors_bf primarily_bf metabolized_bf CYP3A4_bf ,_bf pravastatin_bf ,_bf fluvastatin_bf ,_bf rosuvastatin_bf combination_bf OTHER_DRUG ._be"
2292,Dose reduction of CRIXIVAN to 600 mg every 8 hours is recommended when administering itraconazole concurrently.,CRIXIVAN,itraconazole,advise,Dose_bf reduction_bf DRUG 600_be mg_be every_be 8_be hours_be recommended_be administering_be OTHER_DRUG concurrently_af ._af
2293,Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.,rifabutin,CRIXIVAN,advise,Dose_bf reduction_bf DRUG half_be standard_be dose_be dose_be increase_be OTHER_DRUG 1000_af mg_af (three_af 333-mg_af capsules)_af every_af 8_af hours_af recommended_af DRUG OTHER_DRUG coadministered_af ._af
2294,Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.,Sildenafil,indinavir,advise,DRUG dose_be exceed_be maximum_be 25_be mg_be 48-_be hour_be period_be patients_be receiving_be concomitant_be OTHER_DRUG therapy_af ._af
2295,Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.,Tadalafil,indinavir,advise,DRUG dose_be exceed_be maximum_be 10_be mg_be 72-_be hour_be period_be patients_be receiving_be concomitant_be OTHER_DRUG therapy_af ._af
2296,Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.,Vardenafil,indinavir,advise,DRUG dose_be exceed_be maximum_be 2_be ._be 5_be mg_be 24-hour_be period_be patients_be receiving_be concomitant_be OTHER_DRUG therapy_af ._af
2297,"In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin.",diflunisal,indomethacin,mechanism,"In_bf normal_bf volunteers_bf receiving_bf OTHER_DRUG ,_be administration_be DRUG decreased_af renal_af clearance_af significantly_af increased_af plasma_af levels_af OTHER_DRUG ._af"
2298,"In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.",INDOCIN,diflunisal,effect,"In_bf patients_bf ,_bf combined_bf use_bf DRUG OTHER_DRUG associated_af fatal_af gastrointestinal_af hemorrhage_af ._af"
2299,"Therefore, diflunisal and INDOCIN should not be used concomitantly.",diflunisal,INDOCIN,advise,"Therefore_bf ,_bf DRUG OTHER_DRUG used_af concomitantly_af ._af"
2300,"In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.",aspirin,indomethacin,mechanism,"In_bf study_bf normal_bf volunteers_bf ,_bf found_bf chronic_bf concurrent_bf administration_bf 3_bf ._bf 6_bf g_bf DRUG per_be day_be decreases_be OTHER_DRUG blood_af levels_af approximately_af 20%_af ._af"
2301,"The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.",INDOCIN,NSAIDs,advise,"The_bf concomitant_bf use_bf DRUG OTHER_DRUG recommended_af due_af increased_af possibility_af gastrointestinal_af toxicity_af ,_af little_af increase_af efficacy_af ._af"
2302,"However, when any additional drug, including INDOCIN, is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time.",INDOCIN,anticoagulant,advise,"However_bf ,_bf additional_bf drug_bf ,_bf including_bf DRUG ,_be added_be treatment_be patients_be OTHER_DRUG therapy_af ,_af patients_af observed_af alterations_af prothrombin_af time_af ._af"
2303,"In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and INDOCIN.",anticoagulants,INDOCIN,effect,"In_bf post-marketing_bf experience_bf ,_bf bleeding_bf reported_bf patients_bf concomitant_bf treatment_bf DRUG OTHER_DRUG ._af"
2304,Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly.,INDOCIN,anticoagulants,advise,Caution_bf exercised_bf DRUG OTHER_DRUG administered_af concomitantly_af ._af
2305,"When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.",INDOCIN,probenecid,mechanism,"When_bf DRUG given_be patients_be receiving_be OTHER_DRUG ,_af plasma_af levels_af indomethacin_af likely_af increased_af ._af"
2306,Caution should be used if INDOCIN is administered simultaneously with methotrexate.,INDOCIN,methotrexate,advise,Caution_bf used_bf DRUG administered_be simultaneously_be OTHER_DRUG ._af
2307,INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.,INDOCIN,methotrexate,mechanism,DRUG reported_be decrease_be tubular_be secretion_be OTHER_DRUG potentiate_af toxicity_af ._af
2308,"Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.",non-steroidal anti-inflammatory drugs,cyclosporine,effect,"Administration_bf non-steroidal_bf anti-inflammatory_bf drugs_bf concomitantly_bf OTHER_DRUG associated_be increase_be cyclosporine-induced_be toxicity_be ,_be possibly_be due_be decreased_be synthesis_be renal_be prostacyclin_be ._be"
2309,"NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.",NSAIDs,cyclosporine,advise,"DRUG used_be caution_be patients_be taking_be OTHER_DRUG ,_af renal_af function_af carefully_af monitored_af ._af"
2310,Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.,INDOCIN,lithium,mechanism,Capsules_bf DRUG 50_be mg_be ._be ._be ._be produced_be clinically_be relevant_be elevation_be plasma_be OTHER_DRUG reduction_af renal_af OTHER_DRUG clearance_af psychiatric_af patients_af normal_af subjects_af steady_af state_af plasma_af OTHER_DRUG concentrations_af ._af
2311,"As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.",INDOCIN,lithium,advise,"As_bf consequence_bf ,_bf DRUG OTHER_DRUG given_af concomitantly_af ,_af patient_af carefully_af observed_af signs_af OTHER_DRUG toxicity_af ._af"
2312,INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.,INDOCIN,digoxin,mechanism,DRUG given_be concomitantly_be OTHER_DRUG reported_af increase_af serum_af concentration_af prolong_af half-life_af OTHER_DRUG ._af
2313,"Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.",INDOCIN,digoxin,advise,"Therefore_bf ,_bf DRUG OTHER_DRUG used_af concomitantly_af ,_af serum_af OTHER_DRUG levels_af closely_af monitored_af ._af"
2314,"In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.",INDOCIN,loop diuretics,effect,"In_bf patients_bf ,_bf administration_bf DRUG reduce_be diuretic_be ,_be natriuretic_be ,_be antihypertensive_be effects_be loop_be ,_be potassium-sparing_be ,_be thiazide_be diuretics_be ._be"
2315,"In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.",INDOCIN,potassium-sparing diuretics,effect,"In_bf patients_bf ,_bf administration_bf DRUG reduce_be diuretic_be ,_be natriuretic_be ,_be antihypertensive_be effects_be loop_be ,_be potassium-sparing_be ,_be thiazide_be diuretics_be ._be"
2316,"In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.",INDOCIN,thiazide diuretics,effect,"In_bf patients_bf ,_bf administration_bf DRUG reduce_be diuretic_be ,_be natriuretic_be ,_be antihypertensive_be effects_be loop_be ,_be potassium-sparing_be ,_be thiazide_be diuretics_be ._be"
2317,It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.,triamterene,INDOCIN,effect,It_bf reported_bf addition_bf DRUG maintenance_be schedule_be OTHER_DRUG resulted_af reversible_af acute_af renal_af failure_af two_af four_af healthy_af volunteers_af ._af
2318,INDOCIN and triamterene should not be administered together.,INDOCIN,triamterene,advise,DRUG OTHER_DRUG administered_af together_af ._af
2319,The potential effects of INDOCIN and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.,INDOCIN,potassium-sparing diuretics,effect,The_bf potential_bf effects_bf DRUG potassium-sparing_be diuretics_be potassium_be kinetics_be renal_be function_be considered_be agents_be administered_be concurrently_be ._be
2320,"Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by INDOCIN.",diuretics,INDOCIN,effect,"Most_bf effects_bf concerning_bf DRUG attributed_be ,_be least_be part_be ,_be mechanisms_be involving_be inhibition_be prostaglandin_be synthesis_be OTHER_DRUG ._af"
2321,Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.,beta-adrenoceptor blocking agents,non-steroidal antiinflammatory drugs,effect,Blunting_bf antihypertensive_bf effect_bf beta-adrenoceptor_bf blocking_bf agents_bf non-steroidal_bf antiinflammatory_bf drugs_bf including_bf INDOCIN_bf reported_bf ._bf
2322,Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.,beta-adrenoceptor blocking agents,INDOCIN,effect,Blunting_bf antihypertensive_bf effect_bf beta-adrenoceptor_bf blocking_bf agents_bf non-steroidal_bf antiinflammatory_bf drugs_bf including_bf OTHER_DRUG reported_be ._be
2323,INDOCIN can reduce the antihypertensive effects of captopril and losartan.,INDOCIN,captopril,effect,DRUG reduce_be antihypertensive_be effects_be OTHER_DRUG losartan_af ._af
2324,INDOCIN can reduce the antihypertensive effects of captopril and losartan.,INDOCIN,losartan,effect,DRUG reduce_be antihypertensive_be effects_be captopril_be OTHER_DRUG ._af
2325,"Concurrent administration of etanercept (another TNF -blocking agent) and anakinra (an interleukin-1 antagonist) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products alone.",etanercept,anakinra,effect,"Concurrent_bf administration_bf DRUG (another_be TNF_be -blocking_be agent)_be OTHER_DRUG (an_af interleukin-1_af antagonist)_af associated_af increased_af risk_af serious_af infections_af ,_af increased_af risk_af neutropenia_af additional_af benefit_af compared_af medicinal_af products_af alone_af ._af"
2326,Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.,TNFa-blocking agents,anakinra,effect,Other_bf TNFa-blocking_bf agents_bf (including_bf REMICADE)_bf used_bf combination_bf OTHER_DRUG may_be also_be result_be similar_be toxicities_be ._be
2327,Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.,REMICADE,anakinra,effect,Other_bf TNFa-blocking_bf agents_bf (including_bf REMICADE)_bf used_bf combination_bf OTHER_DRUG may_be also_be result_be similar_be toxicities_be ._be
2328,Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.,Betaseron,antipyrine,mechanism,DRUG administration_be three_be cancer_be patients_be dose_be range_be 0_be ._be 025_be mg_be 2_be ._be 2_be mg_be led_be dose-dependent_be inhibition_be OTHER_DRUG elimination_af ._af 14_af The_af effect_af alternate-day_af administration_af 0_af ._af 25_af mg_af DRUG drug_af metabolism_af MS_af patients_af unknown_af ._af
2329,"Anticholinergic agents: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications.",ipratropium bromide,anticholinergic medications,effect,"Anticholinergic_bf agents:_bf Although_bf ipratropium_bf bromide_bf minimally_bf absorbed_bf systemic_bf circulation_bf ,_bf potential_bf additive_bf interaction_bf concomitantly_bf used_bf anticholinergic_bf medications_bf ._bf"
2330,Caution is therefore advised in the coadministration of ATROVENT Inhalation Aerosol with other anticholinergic-containing drugs.,ATROVENT,anticholinergic,advise,Caution_bf therefore_bf advised_bf coadministration_bf DRUG Inhalation_be Aerosol_be anticholinergic-containing_be drugs_be ._be
2331,"The adverse effects of CAMPTOSAR, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.",CAMPTOSAR,antineoplastic agents,effect,"The_bf adverse_bf effects_bf DRUG ,_be myelosuppression_be diarrhea_be ,_be would_be expected_be exacerbated_be antineoplastic_be agents_be similar_be adverse_be effects_be ._be"
2332,"Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.",CAMPTOSAR,dexamethasone,effect,"Lymphocytopenia_bf reported_bf patients_bf receiving_bf DRUG ,_be possible_be administration_be OTHER_DRUG antiemetic_af prophylaxis_af may_af enhanced_af likelihood_af effect_af ._af"
2333,"The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).",prochlorperazine,CAMPTOSAR,effect,"The_bf incidence_bf akathisia_bf clinical_bf trials_bf weekly_bf dosage_bf schedule_bf greater_bf (8_bf ._bf 5%_bf ,_bf 4/47_bf patients)_bf DRUG administered_be day_be OTHER_DRUG drugs_af given_af separate_af days_af (1_af ._af 3%_af ,_af 1/80_af patients)_af ._af"
2334,"It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied.",laxative,CAMPTOSAR,effect,"It_bf would_bf expected_bf DRUG use_be therapy_be OTHER_DRUG would_af worsen_af incidence_af severity_af diarrhea_af ,_af studied_af ._af"
2335,"In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.",diuretics,CAMPTOSAR,effect,"In_bf view_bf potential_bf risk_bf dehydration_bf secondary_bf vomiting_bf and/or_bf diarrhea_bf induced_bf OTHER_DRUG ,_be physician_be may_be wish_be withhold_be DRUG dosing_af OTHER_DRUG ,_af certainly_af ,_af periods_af active_af vomiting_af diarrhea_af ._af"
2336,"Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).",Isocarboxazid,Antabuse,advise,"DRUG administered_be caution_be patients_be receiving_be OTHER_DRUG (disulfiram_af ,_af Wyeth-Ayerst_af Laboratories)_af ._af"
2337,"Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).",Isocarboxazid,disulfiram,advise,"DRUG administered_be caution_be patients_be receiving_be Antabuse_be (disulfiram_be ,_be Wyeth-Ayerst_be Laboratories)_be ._be"
2338,"In a single study, rats given high intraperitoneal doses of an MAO inhibitor plus disulfiram experienced severe toxicity, including convulsions and death.",MAO inhibitor,disulfiram,effect,"In_bf single_bf study_bf ,_bf rats_bf given_bf high_bf intraperitoneal_bf doses_bf MAO_bf inhibitor_bf plus_bf OTHER_DRUG experienced_be severe_be toxicity_be ,_be including_be convulsions_be death_be ._be"
2339,Concomitant use of Isocarboxazid and other psychotropic agents is generally not recommended because of possible potentiating effects.,Isocarboxazid,psychotropic agents,advise,Concomitant_bf use_bf DRUG psychotropic_be agents_be generally_be recommended_be possible_be potentiating_be effects_be ._be
2340,"Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.",Isoflurane,muscle relaxants,effect,"DRUG potentiates_be muscle_be relaxant_be effect_be muscle_be relaxants_be ,_be notably_be nondepolarizing_be muscle_be relaxants_be ,_be MAC_be (minimum_be alveolar_be concentration)_be reduced_be concomitant_be administration_be N_be 2O_be ._be"
2341,"Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.",Isoflurane,nondepolarizing muscle relaxants,effect,"DRUG potentiates_be muscle_be relaxant_be effect_be muscle_be relaxants_be ,_be notably_be nondepolarizing_be muscle_be relaxants_be ,_be MAC_be (minimum_be alveolar_be concentration)_be reduced_be concomitant_be administration_be N_be 2O_be ._be"
2342,Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid.,acetaminophen,Isoniazid,effect,Acetaminophen:_bf A_bf report_bf severe_bf DRUG toxicity_be reported_be patient_be receiving_be OTHER_DRUG ._af
2343,It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.,isoniazid,acetaminophen,effect,It_bf believed_bf toxicity_bf may_bf resulted_bf previously_bf unrecognized_bf interaction_bf DRUG OTHER_DRUG molecular_af basis_af interaction_af proposed_af ._af
2344,"Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.",isoniazid,acetaminophen,mechanism,"Furthermore_bf proposed_bf DRUG resulted_be In_be induction_be P-450IIE1_be patients_be liver_be ,_be turn_be ,_be resulted_be greater_be proportion_be ingested_be OTHER_DRUG converted_af toxic_af metabolites_af ._af"
2345,"Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.",Isoniazid,carbamazepine,mechanism,"Carbamazepine:_bf DRUG known_be slow_be metabolism_be OTHER_DRUG increase_af serum_af levels_af OTHER_DRUG levels_af determined_af prior_af concurrent_af administration_af DRUG ,_af signs_af symptoms_af OTHER_DRUG toxicity_af monitored_af closely_af ,_af appropriate_af dosage_af adjustment_af anticonvulsant_af made_af ._af"
2346,"Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.",Carbamazepine,isoniazid,advise,"Carbamazepine:_bf OTHER_DRUG known_be slow_be metabolism_be DRUG increase_af serum_af levels_af DRUG levels_af determined_af prior_af concurrent_af administration_af OTHER_DRUG ,_af signs_af symptoms_af DRUG toxicity_af monitored_af closely_af ,_af appropriate_af dosage_af adjustment_af anticonvulsant_af made_af ._af"
2347,Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.,Ketoconazole,Isoniazid,int,Ketoconazole:_bf Potential_bf interaction_bf DRUG OTHER_DRUG may_af exist_af ._af
2348,Phenytoin: Isoniazid may increase serum levels of phenytoin.,Isoniazid,phenytoin,mechanism,Phenytoin:_bf DRUG may_be increase_be serum_be levels_be OTHER_DRUG ._af
2349,"Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.",isoniazid,theophylline,mechanism,"Therophylline:_bf A_bf recent_bf study_bf shown_bf concomitan_bf administration_bf DRUG OTHER_DRUG may_af cause_af elevated_af plasma_af levels_af OTHER_DRUG ,_af instances_af slight_af decrease_af elimination_af DRUG ._af"
2350,Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.,valproate,isoniazid,mechanism,Valproate:_bf A_bf recent_bf case_bf study_bf shown_bf possible_bf increase_bf plasma_bf level_bf DRUG co_be administered_be OTHER_DRUG ._af
2351,"Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.",isoniazid,valproate,advise,"Plasma_bf OTHER_DRUG concentration_be monitored_be DRUG OTHER_DRUG co_af administered_af ,_af appropriate_af dosage_af adjustments_af OTHER_DRUG made_af ._af"
2352,Isoproterenol hydrochloride injection and epinephrine should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.,Isoproterenol hydrochloride,epinephrine,advise,Isoproterenol_bf hydrochloride_bf injection_bf OTHER_DRUG administered_be simultaneously_be drugs_be direct_be cardiac_be stimulants_be combined_be effects_be may_be induce_be serious_be arrhythmias_be ._be
2353,"ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.",ISUPREL,anesthetics,advise,"DRUG used_be caution_be ,_be ,_be potent_be inhalational_be OTHER_DRUG halothane_af employed_af potential_af sensitize_af myocardium_af effects_af sympathomimetic_af amines_af ._af"
2354,"ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.",ISUPREL,halothane,advise,"DRUG used_be caution_be ,_be ,_be potent_be inhalational_be anesthetics_be OTHER_DRUG employed_af potential_af sensitize_af myocardium_af effects_af sympathomimetic_af amines_af ._af"
2355,"Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects",Accutane,vitamin A,effect,"Vitamin_bf A:_bf Because_bf relationship_bf DRUG vitamin_be A_be ,_be patients_be advised_be taking_be vitamin_be supplements_be containing_be vitamin_be A_be avoid_be additive_be toxic_be effects_be"
2356,"Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines",Accutane,tetracyclines,advise,"Tetracyclines:_bf Concomitant_bf treatment_bf DRUG OTHER_DRUG avoided_af DRUG use_af associated_af number_af cases_af pseudotumor_af cerebri_af (benign_af intracranial_af hypertension)_af ,_af involved_af concomitant_af use_af OTHER_DRUG"
2357,"Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines",Accutane,tetracyclines,effect,"Tetracyclines:_bf Concomitant_bf treatment_bf DRUG OTHER_DRUG avoided_af DRUG use_af associated_af number_af cases_af pseudotumor_af cerebri_af (benign_af intracranial_af hypertension)_af ,_af involved_af concomitant_af use_af OTHER_DRUG"
2358,Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during Accutane therapy.,progesterone,Accutane,effect,Micro-dosed_bf DRUG Preparations:_be Micro-dosed_be DRUG preparations_af (minipills_af contain_af estrogen)_af may_af inadequate_af method_af contraception_af OTHER_DRUG therapy_af ._af
2359,"Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).",cimetidine,isradipine,mechanism,"Cimetidine:_bf In_bf study_bf healthy_bf volunteers_bf ,_bf one-week_bf course_bf DRUG 400_be mg_be b_be ._be ._be ._be single_be 5_be mg_be dose_be OTHER_DRUG sixth_af day_af showed_af increase_af OTHER_DRUG mean_af peak_af plasma_af concentrations_af (36%)_af significant_af increase_af area_af curve_af (50%)_af ._af"
2360,If isradipine therapy is initiated in a patient currently receiving cimetidine careful monitoring for adverse reactions is advised and downward dose adjustment may be required.,isradipine,cimetidine,advise,If_bf DRUG therapy_be initiated_be patient_be currently_be receiving_be OTHER_DRUG careful_af monitoring_af adverse_af reactions_af advised_af downward_af dose_af adjustment_af may_af required_af ._af
2361,"Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.",rifampicin,isradipine,mechanism,"Rifampicin:_bf In_bf study_bf healthy_bf volunteers_bf ,_bf six-day_bf course_bf DRUG 600_be mg/day_be followed_be single_be 5_be mg_be dose_be OTHER_DRUG resulted_af reduction_af OTHER_DRUG levels_af detectable_af limits_af ._af"
2362,"If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine.",rifampicin,isradipine,mechanism,"If_bf DRUG therapy_be required_be ,_be OTHER_DRUG concentrations_af therapeutic_af effects_af likely_af markedly_af reduced_af abolished_af consequence_af increased_af metabolism_af higher_af clearance_af OTHER_DRUG ._af"
2363,Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.,fentanyl,beta blocker,effect,DRUG Anesthesia:_be Severe_be hypotension_be reported_be DRUG anesthesia_af concomitant_af use_af beta_af blocker_af calcium_af channel_af blocker_af ._af
2364,Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.,fentanyl,calcium channel blocker,effect,DRUG Anesthesia:_be Severe_be hypotension_be reported_be DRUG anesthesia_af concomitant_af use_af beta_af blocker_af calcium_af channel_af blocker_af ._af
2365,"Coadministration of terfenadine with Itraconazole has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.",terfenadine,Itraconazole,mechanism,"Coadministration_bf DRUG OTHER_DRUG led_af elevated_af plasma_af concentrations_af DRUG ,_af resulting_af rare_af instances_af life-_af threatening_af cardiac_af dysrhythmias_af one_af death_af ._af"
2366,"Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.",ketoconazole,astemizole,mechanism,"Another_bf oral_bf azole_bf antifungal_bf ,_bf DRUG ,_be inhibits_be metabolism_be OTHER_DRUG ,_af resulting_af elevated_af plasma_af concentrations_af OTHER_DRUG active_af metabolite_af desmethylastermizole_af may_af prolong_af QT_af intervals_af ._af"
2367,"In vitro data suggest that itraconazole, when compared to ketoconazole, has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole.",itraconazole,astemizole,mechanism,"In_bf vitro_bf data_bf suggest_bf DRUG ,_be compared_be ketoconazole_be ,_be less_be pronounced_be effect_be biotransformation_be system_be responsible_be metabolism_be OTHER_DRUG ._af"
2368,"Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of astemizole with itraconazole is contraindicated.",astemizole,itraconazole,advise,"Based_bf chemical_bf resemblance_bf OTHER_DRUG ketoconazole_be ,_be coadministration_be DRUG OTHER_DRUG contraindicated_af ._af"
2369,Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.,ketoconazole,cisapride,mechanism,Human_bf pharmacokinetics_bf data_bf indicate_bf oral_bf DRUG potently_be inhibits_be metabolism_be OTHER_DRUG resulting_af eight-fold_af increase_af mean_af AUC_af OTHER_DRUG ._af
2370,Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.,ketoconazole,cisapride,effect,Data_bf suggest_bf coadministration_bf oral_bf DRUG OTHER_DRUG result_af prolongation_af QT_af interval_af ECG_af ._af
2371,In vitro data suggest that itraconazole also markedly inhibits the biotransformation system mainly responsible for the metabolism of cisapride;,itraconazole,cisapride,mechanism,In_bf vitro_bf data_bf suggest_bf DRUG also_be markedly_be inhibits_be biotransformation_be system_be mainly_be responsible_be metabolism_be cisapride;_be
2372,therefore concomitant administration of Itraconazole with cisapride is contraindicated.,Itraconazole,cisapride,advise,therefore_bf concomitant_bf administration_bf DRUG OTHER_DRUG contraindicated_af ._af
2373,Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.,Itraconazole,midazolam,mechanism,Coadministration_bf DRUG oral_be OTHER_DRUG triazolam_af resulted_af elevated_af plasma_af concentrations_af latter_af two_af drugs_af ._af
2374,Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.,Itraconazole,triazolam,mechanism,Coadministration_bf DRUG oral_be midazolam_be OTHER_DRUG resulted_af elevated_af plasma_af concentrations_af latter_af two_af drugs_af ._af
2375,"Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.",Itraconazole,cyclosporine,mechanism,"Coadministration_bf DRUG OTHER_DRUG ,_af tacrolimus_af digoxin_af led_af increased_af plasma_af concentrations_af latter_af three_af drugs_af ._af"
2376,"Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.",Itraconazole,tacrolimus,mechanism,"Coadministration_bf DRUG cyclosporine_be ,_be OTHER_DRUG digoxin_af led_af increased_af plasma_af concentrations_af latter_af three_af drugs_af ._af"
2377,"Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.",Itraconazole,digoxin,mechanism,"Coadministration_bf DRUG cyclosporine_be ,_be tacrolimus_be OTHER_DRUG led_af increased_af plasma_af concentrations_af latter_af three_af drugs_af ._af"
2378,"Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",Cyclosporine,Itraconazole,advise,"DRUG ,_be tacrolimus_be digoxin_be concentrations_be monitored_be initiation_be OTHER_DRUG therapy_af frequently_af thereafter_af ,_af dose_af three_af drug_af products_af adjusted_af appropriately_af ._af"
2379,"Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",tacrolimus,Itraconazole,advise,"Cyclosporine_bf ,_bf DRUG digoxin_be concentrations_be monitored_be initiation_be OTHER_DRUG therapy_af frequently_af thereafter_af ,_af dose_af three_af drug_af products_af adjusted_af appropriately_af ._af"
2380,"Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",digoxin,Itraconazole,advise,"Cyclosporine_bf ,_bf tacrolimus_bf DRUG concentrations_be monitored_be initiation_be OTHER_DRUG therapy_af frequently_af thereafter_af ,_af dose_af three_af drug_af products_af adjusted_af appropriately_af ._af"
2381,Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including cyclosporine.,HMG-CoA reductase inhibitors,immunosuppressive drugs,effect,Rhabdomyolysis_bf observed_bf patients_bf receiving_bf HMG-CoA_bf reductase_bf inhibitors_bf administered_bf alone_bf (at_bf recommended_bf dosages)_bf concomitantly_bf immunosuppressive_bf drugs_bf including_bf cyclosporine_bf ._bf
2382,Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including cyclosporine.,HMG-CoA reductase inhibitors,cyclosporine,effect,Rhabdomyolysis_bf observed_bf patients_bf receiving_bf HMG-CoA_bf reductase_bf inhibitors_bf administered_bf alone_bf (at_bf recommended_bf dosages)_bf concomitantly_bf immunosuppressive_bf drugs_bf including_bf OTHER_DRUG ._be
2383,"When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.",Itraconazole,phenytoin,mechanism,"When_bf DRUG coadministered_be OTHER_DRUG ,_af rifampin_af ,_af H2antagonists_af ,_af reduced_af plasma_af concentrations_af DRUG reported_af ._af"
2384,"When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.",Itraconazole,rifampin,mechanism,"When_bf DRUG coadministered_be phenytoin_be ,_be OTHER_DRUG ,_af H2antagonists_af ,_af reduced_af plasma_af concentrations_af DRUG reported_af ._af"
2385,"Although no studies have been conducted, concomitant administration of Itraconazole and phenytoin may alter the metabolism of phenytoin;",Itraconazole,phenytoin,mechanism,"Although_bf studies_bf conducted_bf ,_bf concomitant_bf administration_bf DRUG OTHER_DRUG may_af alter_af metabolism_af phenytoin;_af"
2386,"therefore, plasma concentrations of phenytoin should also be monitored when it is given concurrently with Itraconazole.",phenytoin,Itraconazole,advise,"therefore_bf ,_bf plasma_bf concentrations_bf DRUG also_be monitored_be given_be concurrently_be OTHER_DRUG ._af"
2387,It has been reported that Itraconazole enhances the anticoagulant effect of coumarin-like drugs.,Itraconazole,coumarin,effect,It_bf reported_bf DRUG enhances_be anticoagulant_be effect_be coumarin-like_be drugs_be ._be
2388,"Therefore, prothrombin time should be carefully monitored in patients receiving Itraconazole and coumarin-like drugs simultaneously.",Itraconazole,coumarin,advise,"Therefore_bf ,_bf prothrombin_bf time_bf carefully_bf monitored_bf patients_bf receiving_bf DRUG coumarin-like_be drugs_be simultaneously_be ._be"
2389,Plasma concentrations of azole antifungal agents are reduced when given concurrently with isoniazid.,azole antifungal agents,isoniazid,mechanism,Plasma_bf concentrations_bf azole_bf antifungal_bf agents_bf reduced_bf given_bf concurrently_bf OTHER_DRUG ._be
2390,Itraconazole plasma concentrations should be monitored when Itraconazole and isoniazid are coadministered.,Itraconazole,isoniazid,advise,DRUG plasma_be concentrations_be monitored_be DRUG OTHER_DRUG coadministered_af ._af
2391,Severe hypoglycemia has been reported in patients concomitantly receiving azole antifungal agents and oral hypoglycemic agents.,azole antifungal agents,hypoglycemic agents,effect,Severe_bf hypoglycemia_bf reported_bf patients_bf concomitantly_bf receiving_bf azole_bf antifungal_bf agents_bf oral_bf hypoglycemic_bf agents_bf ._bf
2392,Blood glucose concentrations should be carefully monitored when Itraconazole and oral hypoglycemic agents are coadministered.,Itraconazole,hypoglycemic agents,advise,Blood_bf glucose_bf concentrations_bf carefully_bf monitored_bf DRUG oral_be hypoglycemic_be agents_be coadministered_be ._be
2393,Tinnitus and decreased hearing have been reported in patients concomitantly receiving Itraconazole and quinidine.,Itraconazole,quinidine,effect,Tinnitus_bf decreased_bf hearing_bf reported_bf patients_bf concomitantly_bf receiving_bf DRUG OTHER_DRUG ._af
2394,Edema has been reported in patients concomitantly receiving Itraconazole and dihydropyridine calcium channel blockers.,Itraconazole,dihydropyridine calcium channel blockers,effect,Edema_bf reported_bf patients_bf concomitantly_bf receiving_bf DRUG dihydropyridine_be calcium_be channel_be blockers_be ._be
2395,In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.,aminoglycoside,antibiotics,effect,In_bf vitro_bf mixing_bf DRUG beta-lactamtype_be OTHER_DRUG (penicillins_af cephalosporins)_af may_af result_af significant_af mutual_af inactivation_af ._af
2396,In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.,aminoglycoside,penicillins,effect,In_bf vitro_bf mixing_bf DRUG beta-lactamtype_be antibiotics_be (penicillins_be cephalosporins)_be may_be result_be significant_be mutual_be inactivation_be ._be
2397,In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.,aminoglycoside,cephalosporins,effect,In_bf vitro_bf mixing_bf DRUG beta-lactamtype_be antibiotics_be (penicillins_be cephalosporins)_be may_be result_be significant_be mutual_be inactivation_be ._be
2398,"Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.",aminoglycoside,penicillin,mechanism,"Even_bf DRUG penicillin-type_be drug_be administered_be separately_be different_be routes_be ,_be reduction_be DRUG serum_af half-life_af serum_af levels_af reported_af patients_af impaired_af renal_af function_af patients_af normal_af renal_af function_af ._af"
2399,"The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.",Ketoconazole,terfenadine,mechanism,"The_bf following_bf drug_bf interactions_bf identified_bf involving_bf NIZORAL_bf Tablets_bf drugs_bf metabolized_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system:_bf DRUG tablets_be inhibit_be metabolism_be OTHER_DRUG ,_af resulting_af increased_af plasma_af concentration_af OTHER_DRUG delay_af elimination_af acid_af metabolite_af ._af"
2400,"Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.",ketoconazole,astemizole,effect,"Pharmacokinetic_bf data_bf indicate_bf oral_bf DRUG inhibits_be metabolism_be OTHER_DRUG ,_af resulting_af elevated_af plasma_af levels_af OTHER_DRUG active_af metabolite_af desmethylastemizole_af may_af prolong_af QT_af intervals_af ._af"
2401,Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.,astemizole,ketoconazole,advise,Coadministration_bf DRUG OTHER_DRUG tablets_af therefore_af contraindicated_af ._af
2402,Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.,ketoconazole,cisapride,mechanism,Human_bf pharmacokinetics_bf data_bf indicate_bf oral_bf DRUG potently_be inhibits_be metabolism_be OTHER_DRUG resulting_af mean_af eight-fold_af increase_af AUC_af OTHER_DRUG ._af
2403,Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.,ketoconazole,cisapride,effect,Data_bf suggest_bf coadministration_bf oral_bf DRUG OTHER_DRUG result_af prolongation_af QT_af interval_af ECG_af ._af
2404,Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.,ketoconazole,cisapride,advise,Therefore_bf concomitant_bf administration_bf DRUG tablets_be OTHER_DRUG contraindicated_af ._af
2405,"Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.",Ketoconazole,cyclosporine,mechanism,"DRUG tablets_be may_be alter_be metabolism_be OTHER_DRUG ,_af tacrolimus_af ,_af methylprednisolone_af ,_af resulting_af elevated_af plasma_af concentrations_af latter_af drugs_af ._af"
2406,"Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.",Ketoconazole,tacrolimus,mechanism,"DRUG tablets_be may_be alter_be metabolism_be cyclosporine_be ,_be OTHER_DRUG ,_af methylprednisolone_af ,_af resulting_af elevated_af plasma_af concentrations_af latter_af drugs_af ._af"
2407,"Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.",Ketoconazole,methylprednisolone,mechanism,"DRUG tablets_be may_be alter_be metabolism_be cyclosporine_be ,_be tacrolimus_be ,_be OTHER_DRUG ,_af resulting_af elevated_af plasma_af concentrations_af latter_af drugs_af ._af"
2408,Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.,NIZORAL,midazolam,mechanism,Coadministration_bf DRUG Tablets_be OTHER_DRUG triazolam_af resulted_af elevated_af plasma_af concentrations_af latter_af two_af drugs_af ._af
2409,Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.,NIZORAL,triazolam,mechanism,Coadministration_bf DRUG Tablets_be midazolam_be OTHER_DRUG resulted_af elevated_af plasma_af concentrations_af latter_af two_af drugs_af ._af
2410,"It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.",digoxin,ketoconazole,advise,"It_bf ,_bf therefore_bf ,_bf advisable_bf monitor_bf DRUG concentrations_be patients_be receiving_be OTHER_DRUG ._af"
2411,"When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.",imidazole compounds,coumarin,effect,"When_bf taken_bf orally_bf ,_bf imidazole_bf compounds_bf like_bf ketoconazole_bf may_bf enhance_bf anticoagulant_bf effect_bf coumarin-like_bf drugs_bf ._bf"
2412,"When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.",ketoconazole,coumarin,effect,"When_bf taken_bf orally_bf ,_bf imidazole_bf compounds_bf like_bf DRUG may_be enhance_be anticoagulant_be effect_be coumarin-like_be drugs_be ._be"
2413,"In simultaneous treatment with imidazole drugs and coumarin drugs, the anticoagulant effect should be carefully titrated and monitored.",imidazole drugs,coumarin drugs,advise,"In_bf simultaneous_bf treatment_bf imidazole_bf drugs_bf coumarin_bf drugs_bf ,_bf anticoagulant_bf effect_bf carefully_bf titrated_bf monitored_bf ._bf"
2414,"Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole) and oral hypoglycemic agents, such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole) can not be ruled out.",miconazole,hypoglycemic agents,effect,"Because_bf severe_bf hypoglycemia_bf reported_bf patients_bf concomitantly_bf receiving_bf oral_bf DRUG (an_be imidazole)_be oral_be hypoglycemic_be agents_be ,_be potential_be interaction_be involving_be latter_be agents_be used_be concomitantly_be ketoconazole_be tablets_be (an_be imidazole)_be ruled_be ._be"
2415,Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.,ketoconazole,phenytoin,mechanism,Concomitant_bf administration_bf DRUG tablets_be OTHER_DRUG may_af alter_af metabolism_af one_af drugs_af ._af
2416,It is suggested to monitor both ketoconazole and phenytoin.,ketoconazole,phenytoin,advise,It_bf suggested_bf monitor_bf DRUG OTHER_DRUG ._af
2417,Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.,rifampin,ketoconazole,mechanism,Concomitant_bf administration_bf DRUG OTHER_DRUG tablets_af reduces_af blood_af levels_af latter_af ._af
2418,INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.,INH,ketoconazole,mechanism,DRUG (Isoniazid)_be also_be reported_be affect_be OTHER_DRUG concentrations_af adversely_af ._af
2419,INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.,Isoniazid,ketoconazole,mechanism,INH_bf (Isoniazid)_bf also_bf reported_bf affect_bf OTHER_DRUG concentrations_be adversely_be ._be
2420,"After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.",ketoconazole,loratadine,mechanism,"After_bf coadministration_bf 200_bf mg_bf oral_bf DRUG twice_be daily_be one_be 20_be mg_be dose_be OTHER_DRUG 11_af subjects_af ,_af AUC_af Cmax_af OTHER_DRUG averaged_af 302%_af (_af 142_af S_af ._af D_af ._af )_af 251%_af (_af 68_af S_af ._af D_af ._af )_af ,_af respectively_af ,_af obtained_af co-treatment_af placebo_af ._af"
2421,"Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.",warfarin,ketorolac tromethamine,mechanism,"DRUG ,_be Digoxin_be ,_be Salicylate_be ,_be Heparin_be The_be vitro_be binding_be DRUG plasma_af proteins_af slightly_af reduced_af ketorolac_af tromethamine_af (99_af ._af 5%_af control_af vs_af 99_af ._af 3%)_af ketorolac_af plasma_af concentrations_af reach_af 5_af to10_af g/mL_af ._af"
2422,"In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.",salicylate,ketorolac,mechanism,"In_bf vitro_bf studies_bf indicate_bf ,_bf therapeutic_bf concentrations_bf DRUG (300_be g/mL)_be ,_be binding_be OTHER_DRUG reduced_af approximately_af 99_af ._af 2%_af 97_af ._af 5%_af ,_af representing_af potential_af twofold_af increase_af unbound_af OTHER_DRUG plasma_af levels_af ._af"
2423,"Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.",TORADOL,anticoagulants,advise,"Although_bf results_bf indicate_bf significant_bf interaction_bf DRUG warfarin_be heparin_be ,_be administration_be DRUG patients_af taking_af OTHER_DRUG done_af extremely_af cautiously_af ,_af patients_af closely_af monitored_af ._af"
2424,Furosemide: TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).,TORADOL,furosemide,effect,Furosemide:_bf DRUG IV/IM_be reduced_be diuretic_be response_be OTHER_DRUG normovolemic_af healthy_af subjects_af approximately_af 20%_af (mean_af sodium_af urinary_af output_af decreased_af 17%)_af ._af
2425,Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.,TORADOL,probenecid,mechanism,Probenecid:_bf Concomitant_bf administration_bf DRUG ORAL_be OTHER_DRUG resulted_af decreased_af clearance_af ketorolac_af significant_af increases_af ketorolac_af plasma_af levels_af (total_af AUC_af increased_af approximately_af threefold_af 5_af ._af 4_af 17_af ._af 8_af g/h/mL)_af terminal_af half-life_af increased_af approximately_af twofold_af 6_af ._af 6_af 15_af ._af 1_af hours_af ._af
2426,"Therefore, concomitant use of TORADOL and probenecid is contraindicated.",TORADOL,probenecid,advise,"Therefore_bf ,_bf concomitant_bf use_bf DRUG OTHER_DRUG contraindicated_af ._af"
2427,"The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.",lithium,TORADOL,mechanism,"The_bf effect_bf OTHER_DRUG plasma_be DRUG studied_af ,_af cases_af increased_af DRUG plasma_af levels_af OTHER_DRUG therapy_af reported_af ._af"
2428,"Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.",methotrexate,NSAIDs,mechanism,"Methotrexate:_bf Concomitant_bf administration_bf DRUG OTHER_DRUG reported_af reduce_af clearance_af DRUG ,_af enhancing_af toxicity_af DRUG ._af"
2429,"Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).",TORADOL,antiepileptic drugs,effect,"Antiepileptic_bf Drugs:_bf Sporadic_bf cases_bf seizures_bf reported_bf concomitant_bf use_bf DRUG antiepileptic_be drugs_be (phenytoin_be ,_be carbamazepine)_be ._be"
2430,"Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).",TORADOL,phenytoin,effect,"Antiepileptic_bf Drugs:_bf Sporadic_bf cases_bf seizures_bf reported_bf concomitant_bf use_bf DRUG antiepileptic_be drugs_be (phenytoin_be ,_be carbamazepine)_be ._be"
2431,"Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).",TORADOL,carbamazepine,effect,"Antiepileptic_bf Drugs:_bf Sporadic_bf cases_bf seizures_bf reported_bf concomitant_bf use_bf DRUG antiepileptic_be drugs_be (phenytoin_be ,_be carbamazepine)_be ._be"
2432,"Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).",TORADOL,psychoactive drugs,effect,"Psychoactive_bf Drugs:_bf Hallucinations_bf reported_bf DRUG used_be patients_be taking_be psychoactive_be drugs_be (fluoxetine_be ,_be thiothixene_be ,_be alprazolam)_be ._be"
2433,"Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).",TORADOL,fluoxetine,effect,"Psychoactive_bf Drugs:_bf Hallucinations_bf reported_bf DRUG used_be patients_be taking_be psychoactive_be drugs_be (fluoxetine_be ,_be thiothixene_be ,_be alprazolam)_be ._be"
2434,"Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).",TORADOL,thiothixene,effect,"Psychoactive_bf Drugs:_bf Hallucinations_bf reported_bf DRUG used_be patients_be taking_be psychoactive_be drugs_be (fluoxetine_be ,_be OTHER_DRUG ,_af alprazolam)_af ._af"
2435,"Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).",TORADOL,alprazolam,effect,"Psychoactive_bf Drugs:_bf Hallucinations_bf reported_bf DRUG used_be patients_be taking_be psychoactive_be drugs_be (fluoxetine_be ,_be thiothixene_be ,_be alprazolam)_be ._be"
2436,Cyclosporine - L-arginine may counteract the antinaturetic effect of cyclosporin.,L-arginine,cyclosporin,effect,Cyclosporine_bf -_bf DRUG may_be counteract_be antinaturetic_be effect_be OTHER_DRUG ._af
2437,Ibuprofen - L-arginine may increase the absorption of ibuprofen if taken concomitantly.,L-arginine,ibuprofen,mechanism,OTHER_DRUG -_be DRUG may_af increase_af absorption_af OTHER_DRUG taken_af concomitantly_af ._af
2438,Organic nitrates - L-arginine supplements theoretically may potentiate the effects of organic nitrates if taken concomitantly.,L-arginine,nitrates,effect,Organic_bf OTHER_DRUG -_be DRUG supplements_af theoretically_af may_af potentiate_af effects_af organic_af OTHER_DRUG taken_af concomitantly_af ._af
2439,"Sildenafil citrate - Theoretically, L-arginine supplements taken concomitantly with sildenafil citrate, may potentiate the effects of the drug.",L-arginine,sildenafil citrate,effect,"Sildenafil_bf citrate_bf -_bf Theoretically_bf ,_bf DRUG supplements_be taken_be concomitantly_be sildenafil_be citrate_be ,_be may_be potentiate_be effects_be drug_be ._be"
2440,Human growth hormone - Concomitant use of L-glutamine and human growth hormone may enhance nutrient absorption in those with severe short bowel syndrome.,L-glutamine,human growth hormone,mechanism,Human_bf growth_bf hormone_bf -_bf Concomitant_bf use_bf DRUG human_be growth_be hormone_be may_be enhance_be nutrient_be absorption_be severe_be short_be bowel_be syndrome_be ._be
2441,Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.,L-glutamine,indomethacin,effect,OTHER_DRUG -_be Concomitant_be use_be DRUG OTHER_DRUG may_af ameliorate_af increased_af intestinal_af permeability_af caused_af OTHER_DRUG ._af
2442,Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.,methotrexate,L-glutamine,effect,DRUG -_be There_be one_be report_be DRUG may_af decrease_af possible_af effectiveness_af supplemental_af OTHER_DRUG chemotherapy-induced_af mucositis_af ._af
2443,"In another report, nine patients with breast cancer were reported to have decreased symptoms of methotrexate-related toxicity when given supplemental L-glutamine at a dose of 0.5 gram/kilogram/day.",methotrexate,L-glutamine,effect,"In_bf another_bf report_bf ,_bf nine_bf patients_bf breast_bf cancer_bf reported_bf decreased_bf symptoms_bf methotrexate-related_bf toxicity_bf given_bf supplemental_bf OTHER_DRUG dose_be 0_be ._be 5_be gram/kilogram/day_be ._be"
2444,"Paclitaxel - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.",L-glutamine,paclitaxel,effect,"OTHER_DRUG -_be In_be one_be report_be ,_be DRUG dose_af 10_af grams_af three_af times_af daily_af ,_af given_af 24_af hours_af receiving_af OTHER_DRUG ,_af appeared_af prevent_af development_af myalgia_af arthralgia_af ,_af adverse_af reactions_af OTHER_DRUG ._af"
2445,Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.,L-histidine,medroxyprogesterone acetate,effect,Medroxyprogesterone_bf Acetate_bf -_bf DRUG observed_be enhance_be (in_be tissue_be culture)_be effect_be medroxyprogesterone_be acetate_be reducing_be number_be human_be breast_be cancer_be cells_be S_be phase_be ._be
2446,"H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.",L-histidine,H1 blockers,effect,"H1_bf H2_bf Blockers_bf -_bf Although_bf reported_bf ,_bf DRUG ,_be via_be metabolism_be histamine_be ,_be might_be decrease_be efficacy_be H1_be H2_be blockers_be ._be"
2447,"H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.",L-histidine,H2 blockers,effect,"H1_bf H2_bf Blockers_bf -_bf Although_bf reported_bf ,_bf DRUG ,_be via_be metabolism_be histamine_be ,_be might_be decrease_be efficacy_be H1_be H2_be blockers_be ._be"
2448,Concomitant use of calcium supplements and L-lysine may increase calcium absorption,calcium,L-lysine,mechanism,Concomitant_bf use_bf DRUG supplements_be OTHER_DRUG may_af increase_af DRUG absorption_af
2449,Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.,L-methionine,acetaminophen,effect,OTHER_DRUG methotrexate_be -_be DRUG may_af decrease_af hepatic_af toxicity_af OTHER_DRUG overdosage_af taking_af methotrexate_af ._af
2450,Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.,L-methionine,methotrexate,effect,Acetaminophen_bf OTHER_DRUG -_be DRUG may_af decrease_af hepatic_af toxicity_af acetaminophen_af overdosage_af taking_af OTHER_DRUG ._af
2451,Gentamicin - Methionine may protect against the ototoxic effects of gentamicin.,Methionine,gentamicin,effect,OTHER_DRUG -_be DRUG may_af protect_af ototoxic_af effects_af OTHER_DRUG ._af
2452,Concomitant use of L-phenylalanine and non-selective MAO inhibitors may cause hypertension.,L-phenylalanine,non-selective MAO inhibitors,effect,Concomitant_bf use_bf DRUG non-selective_be MAO_be inhibitors_be may_be cause_be hypertension_be ._be
2453,Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.,L-phenylalanine,selegiline,effect,OTHER_DRUG -_be DRUG selective_af MAO_af inhibitor_af OTHER_DRUG may_af synergistic_af antidepressant_af activity_af used_af concomitantly_af ._af
2454,Neuroleptic Drugs - L-phenylalanine may potentiate the tardive dyskinesia side reactions of neuroleptic drugs if used concomitantly with them.,Neuroleptic Drugs,L-phenylalanine,effect,Neuroleptic_bf Drugs_bf -_bf OTHER_DRUG may_be potentiate_be tardive_be dyskinesia_be side_be reactions_be neuroleptic_be drugs_be used_be concomitantly_be ._be
2455,"Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.",L-tyrosine,MAO inhibitors,effect,"Non-selective_bf MAO_bf inhibitors_bf including_bf tranylcypromine_bf sulfate_bf ,_bf phenelzine_bf sulfate_bf ,_bf pargyline_bf HC1:_bf Concomitant_bf use_bf DRUG non-selective_be MAO_be inhibitors_be may_be cause_be hypertension_be ._be"
2456,"In one survey, 2.3% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to 0.7% reported to occur with labetalol HCl alone.",labetalol HCl,tricyclic antidepressants,effect,"In_bf one_bf survey_bf ,_bf 2_bf ._bf 3%_bf patients_bf taking_bf labetalol_bf HCl_bf combination_bf tricyclic_bf antidepressants_bf experienced_bf tremor_bf ,_bf compared_bf 0_bf ._bf 7%_bf reported_bf occur_bf labetalol_bf HCl_bf alone_bf ._bf"
2457,Cimetidine has been shown to increase the bioavailability of labetalol HCl.,Cimetidine,labetalol HCl,mechanism,DRUG shown_be increase_be bioavailability_be labetalol_be HCl_be ._be
2458,Synergism has been shown between halothane anesthesia and intravenously administered labetalol HCl.,halothane,labetalol HCl,effect,Synergism_bf shown_bf DRUG anesthesia_be intravenously_be administered_be labetalol_be HCl_be ._be
2459,"During controlled hypotensive anesthesia using labetalol HCl in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.",labetalol HCl,halothane,effect,"During_bf controlled_bf hypotensive_bf anesthesia_bf using_bf labetalol_bf HCl_bf association_bf OTHER_DRUG ,_be high_be concentrations_be (3%_be above)_be OTHER_DRUG used_af degree_af hypotension_af increased_af possibility_af large_af reduction_af cardiac_af output_af increase_af central_af venous_af pressure_af ._af"
2460,Labetalol HCl blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effect.,Labetalol HCl,nitroglycerin,effect,Labetalol_bf HCl_bf blunts_bf reflex_bf tachycardia_bf produced_bf OTHER_DRUG without_be preventing_be hypotensive_be effect_be ._be
2461,"If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur.",labetalol HCl,nitroglycerin,effect,"If_bf labetalol_bf HCl_bf used_bf OTHER_DRUG patients_be angina_be pectoris_be ,_be additional_be antihypertensive_be effects_be may_be occur_be ._be"
2462,Care should be taken if labetalol is used concomitantly with calcium antagonists of the verapamil type.,labetalol,calcium antagonist,advise,Care_bf taken_bf DRUG used_be concomitantly_be calcium_be antagonists_be verapamil_be type_be ._be
2463,Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH.,antacids,lactulose,mechanism,Results_bf preliminary_bf studies_bf humans_bf rats_bf suggest_bf nonabsorbable_bf DRUG given_be concurrently_be OTHER_DRUG may_af inhibit_af desired_af lactulose-induced_af drop_af colonic_af pH_af ._af
2464,Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.,Lamivudine,zalcitabine,effect,DRUG OTHER_DRUG may_af inhibit_af intracellular_af phosphorylation_af one_af another_af ._af
2465,"Therefore, use of lamivudine in combination with zalcitabine is not recommended",lamivudine,zalcitabine,advise,"Therefore_bf ,_bf use_bf DRUG combination_be OTHER_DRUG recommended_af"
2466,"When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.",lansoprazole,theophylline,mechanism,"When_bf DRUG administered_be concomitantly_be OTHER_DRUG (CYP1A2_af ,_af CYP3A)_af ,_af minor_af increase_af (10%)_af clearance_af OTHER_DRUG seen_af ._af"
2467,"Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.",theophylline,lansoprazole,advise,"Nonetheless_bf ,_bf individual_bf patients_bf may_bf require_bf additional_bf titration_bf DRUG dosage_be OTHER_DRUG started_af stopped_af ensure_af clinically_af effective_af blood_af levels_af ._af"
2468,"In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.",proton pump inhibitors,sucralfate,mechanism,"In_bf single-dose_bf crossover_bf study_bf examining_bf lansoprazole_bf 30_bf mg_bf omeprazole_bf 20_bf mg_bf administered_bf alone_bf concomitantly_bf OTHER_DRUG 1_be gram_be ,_be absorption_be proton_be pump_be inhibitors_be delayed_be bioavailability_be reduced_be 17%_be 16%_be ,_be respectively_be ,_be administered_be concomitantly_be OTHER_DRUG ._af"
2469,"Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate.",proton pump inhibitors,sucralfate,advise,"Therefore_bf ,_bf proton_bf pump_bf inhibitors_bf taken_bf least_bf 30_bf minutes_bf prior_bf OTHER_DRUG ._be"
2470,"therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).",lansoprazole,ketoconazole,mechanism,"therefore_bf ,_bf theoretically_bf possible_bf DRUG may_be interfere_be absorption_be drugs_be gastric_be pH_be important_be determinant_be bioavailability_be (e_be ._be g_be ._be OTHER_DRUG ,_af ampicillin_af esters_af ,_af iron_af salts_af ,_af digoxin)_af ._af"
2471,"therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).",lansoprazole,ampicillin,mechanism,"therefore_bf ,_bf theoretically_bf possible_bf DRUG may_be interfere_be absorption_be drugs_be gastric_be pH_be important_be determinant_be bioavailability_be (e_be ._be g_be ._be ketoconazole_be ,_be OTHER_DRUG esters_af ,_af iron_af salts_af ,_af digoxin)_af ._af"
2472,"therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).",lansoprazole,iron,mechanism,"therefore_bf ,_bf theoretically_bf possible_bf DRUG may_be interfere_be absorption_be drugs_be gastric_be pH_be important_be determinant_be bioavailability_be (e_be ._be g_be ._be ketoconazole_be ,_be ampicillin_be esters_be ,_be OTHER_DRUG salts_af ,_af digoxin)_af ._af"
2473,"therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).",lansoprazole,digoxin,mechanism,"therefore_bf ,_bf theoretically_bf possible_bf DRUG may_be interfere_be absorption_be drugs_be gastric_be pH_be important_be determinant_be bioavailability_be (e_be ._be g_be ._be ketoconazole_be ,_be ampicillin_be esters_be ,_be iron_be salts_be ,_be digoxin)_be ._be"
2474,"Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.",ketoconazole,lapatinib,mechanism,"Ketoconazole:_bf In_bf healthy_bf subjects_bf receiving_bf DRUG ,_be CYP3A4_be inhibitor_be ,_be 200_be mg_be twice_be daily_be 7_be days_be ,_be systemic_be exposure_be (AUC)_be OTHER_DRUG increased_af approximately_af 3_af ._af 6-fold_af control_af half-life_af increased_af 1_af ._af 7-fold_af control_af ._af"
2475,"Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.",carbamazepine,lapatinib,mechanism,"Carbamazepine:_bf In_bf healthy_bf subjects_bf receiving_bf CYP3A4_bf inducer_bf ,_bf DRUG ,_be 100_be mg_be twice_be daily_be 3_be days_be 200_be mg_be twice_be daily_be 17_be days_be ,_be systemic_be exposure_be (AUC)_be OTHER_DRUG decreased_af approximately_af 72%_af ._af"
2476,Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .,cholestyramine,leflunomide,mechanism,DRUG Charcoal_be Administration_be DRUG activated_af charcoal_af patients_af (n=13)_af volunteers_af (n=96)_af resulted_af rapid_af significant_af decrease_af plasma_af M1_af (the_af active_af metabolite_af leflunomide)_af concentration_af ._af
2477,Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .,activated charcoal,leflunomide,mechanism,Cholestyramine_bf Charcoal_bf Administration_bf cholestyramine_bf activated_bf charcoal_bf patients_bf (n=13)_bf volunteers_bf (n=96)_bf resulted_bf rapid_bf significant_bf decrease_bf plasma_bf M1_bf (the_bf active_bf metabolite_bf leflunomide)_bf concentration_bf ._bf
2478,"In a small (n=30) combination study of ARAVA with methotrexate, a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.",ARAVA,methotrexate,effect,"In_bf small_bf (n=30)_bf combination_bf study_bf DRUG OTHER_DRUG ,_af 2-_af 3-fold_af elevation_af liver_af enzymes_af seen_af 5_af 30_af patients_af ._af"
2479,"Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.",ARAVA,rifampin,mechanism,"Rifampin:_bf Following_bf concomitant_bf administration_bf single_bf dose_bf DRUG subjects_be receiving_be multiple_be doses_be OTHER_DRUG ,_af M1_af peak_af levels_af increased_af (~40%)_af seen_af DRUG given_af alone_af ._af"
2480,"Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.",ARAVA,rifampin,advise,"Because_bf potential_bf DRUG levels_be continue_be increase_be multiple_be dosing_be ,_be caution_be used_be patients_be receiving_be DRUG OTHER_DRUG ._af"
2481,Warfarin: Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported.,ARAVA,warfarin,effect,Warfarin:_bf Increased_bf INR_bf (International_bf Normalized_bf Ratio)_bf DRUG OTHER_DRUG co-administered_af rarely_af reported_af ._af
2482,(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.,Femara,tamoxifen,mechanism,(See_bf CLINICAL_bf PHARMACOLOGY)_bf Coadministration_bf DRUG OTHER_DRUG 20_af mg_af daily_af resulted_af reduction_af letrozole_af plasma_af levels_af 38%_af average_af ._af
2483,"Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.",Folic acid,phenobarbital,effect,"Folic_bf acid_bf large_bf amounts_bf may_bf counteract_bf antiepileptic_bf effect_bf OTHER_DRUG ,_be phenytoin_be primidone_be ,_be increase_be frequency_be seizures_be susceptible_be pediatric_be patients_be ._be"
2484,"Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.",Folic acid,phenytoin,effect,"Folic_bf acid_bf large_bf amounts_bf may_bf counteract_bf antiepileptic_bf effect_bf phenobarbital_bf ,_bf OTHER_DRUG primidone_be ,_be increase_be frequency_be seizures_be susceptible_be pediatric_be patients_be ._be"
2485,"Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.",Folic acid,primidone,effect,"Folic_bf acid_bf large_bf amounts_bf may_bf counteract_bf antiepileptic_bf effect_bf phenobarbital_bf ,_bf phenytoin_bf OTHER_DRUG ,_be increase_be frequency_be seizures_be susceptible_be pediatric_be patients_be ._be"
2486,"However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.",leucovorin,methotrexate,effect,"However_bf ,_bf high_bf doses_bf DRUG may_be reduce_be efficacy_be intrathecally_be administered_be OTHER_DRUG ._af"
2487,Leucovorin may enhance the toxicity of 5-fluorouracil.,Leucovorin,5-fluorouracil,effect,DRUG may_be enhance_be toxicity_be OTHER_DRUG ._af
2488,ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.,ERGAMISOL,alcohol,effect,DRUG (levamisole_be hydrochloride)_be reported_be produce_be ANTABUSE-like_be side_be effects_be given_be concomitantly_be OTHER_DRUG ._af
2489,ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.,levamisole hydrochloride,alcohol,effect,ERGAMISOL_bf (levamisole_bf hydrochloride)_bf reported_bf produce_bf ANTABUSE-like_bf side_bf effects_bf given_bf concomitantly_bf OTHER_DRUG ._be
2490,"Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin sodium, it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin sodium or other coumarin-like drugs should be adjusted accordingly, in patients taking both drugs.",levamisole,warfarin sodium,advise,"Because_bf reports_bf prolongation_bf prothrombin_bf time_bf beyond_bf therapeutic_bf range_bf patients_bf taking_bf concurrent_bf DRUG warfarin_be sodium_be ,_be suggested_be prothrombin_be time_be monitored_be carefully_be ,_be dose_be warfarin_be sodium_be coumarin-like_be drugs_be adjusted_be accordingly_be ,_be patients_be taking_be drugs_be ._be"
2491,Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.,levetiracetam,AEDs,mechanism,Effect_bf OTHER_DRUG Pediatric_be Patients_be There_be 22%_be increase_be apparent_be total_be body_be clearance_be DRUG co-administered_af enzyme-inducing_af OTHER_DRUG ._af
2492,"Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.",BETAGAN,epinephrine,effect,"Although_bf DRUG used_be alone_be little_be effect_be pupil_be size_be ,_be mydriasis_be resulting_be concomitant_be therapy_be DRUG OTHER_DRUG may_af occur_af ._af"
2493,"Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.",beta-blocker,reserpine,advise,"Close_bf observation_bf patient_bf recommended_bf DRUG administered_be patients_be receiving_be catecholamine-depleting_be drugs_be OTHER_DRUG ,_af possible_af additive_af effects_af production_af hypotension_af and/or_af marked_af bradycardia_af ,_af may_af produce_af vertigo_af ,_af syncope_af postural_af hypotension_af ._af"
2494,"Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.",beta-adrenergic blocking agents,calcium antagonists,advise,"Patients_bf receiving_bf beta-adrenergic_bf blocking_bf agents_bf along_bf either_bf oral_bf intravenous_bf calcium_bf antagonists_bf monitored_bf possible_bf atrioventricular_bf conduction_bf disturbances_bf ,_bf left_bf ventricular_bf failure_bf hypotension_bf ._bf"
2495,The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.,beta-adrenergic blocking agents,digitalis,effect,The_bf concomitant_bf use_bf beta-adrenergic_bf blocking_bf agents_bf OTHER_DRUG calcium_be antagonists_be may_be additive_be effects_be prolonging_be atrioventricular_be conduction_be time_be ._be
2496,The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.,beta-adrenergic blocking agents,calcium antagonist,effect,The_bf concomitant_bf use_bf beta-adrenergic_bf blocking_bf agents_bf digitalis_bf calcium_bf antagonists_bf may_bf additive_bf effects_bf prolonging_bf atrioventricular_bf conduction_bf time_bf ._bf
2497,Phenothiazine-related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each other s metabolism.,Phenothiazine-related compounds,beta-adrenergic blocking agents,mechanism,Phenothiazine-related_bf compounds_bf beta-adrenergic_bf blocking_bf agents_bf may_bf additive_bf hypotensite_bf effects_bf due_bf inhibition_bf metabolism_bf ._bf
2498,Chirocaine   should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive.,Chirocaine,anesthetics,advise,DRUG used_be caution_be patients_be receiving_be local_be OTHER_DRUG agents_af structurally_af related_af amide-type_af local_af OTHER_DRUG since_af toxic_af effects_af drugs_af could_af additive_af ._af
2499,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;",levobupivacaine,phenytoin,mechanism,"Although_bf clinical_bf studies_bf conducted_bf ,_bf likely_bf metabolism_bf DRUG may_be affected_be known_be CYP3A4_be inducers_be (such_be OTHER_DRUG ,_af phenobarbital_af ,_af rifampin)_af ,_af CYP3A4_af inhibitors_af (azole_af antimycotics_af ._af g_af ._af ,_af ketoconazole;_af"
2500,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;",levobupivacaine,phenobarbital,mechanism,"Although_bf clinical_bf studies_bf conducted_bf ,_bf likely_bf metabolism_bf DRUG may_be affected_be known_be CYP3A4_be inducers_be (such_be phenytoin_be ,_be OTHER_DRUG ,_af rifampin)_af ,_af CYP3A4_af inhibitors_af (azole_af antimycotics_af ._af g_af ._af ,_af ketoconazole;_af"
2501,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;",levobupivacaine,rifampin,mechanism,"Although_bf clinical_bf studies_bf conducted_bf ,_bf likely_bf metabolism_bf DRUG may_be affected_be known_be CYP3A4_be inducers_be (such_be phenytoin_be ,_be phenobarbital_be ,_be rifampin)_be ,_be CYP3A4_be inhibitors_be (azole_be antimycotics_be ._be g_be ._be ,_be ketoconazole;_be"
2502,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;",levobupivacaine,ketoconazole,mechanism,"Although_bf clinical_bf studies_bf conducted_bf ,_bf likely_bf metabolism_bf DRUG may_be affected_be known_be CYP3A4_be inducers_be (such_be phenytoin_be ,_be phenobarbital_be ,_be rifampin)_be ,_be CYP3A4_be inhibitors_be (azole_be antimycotics_be ._be g_be ._be ,_be ketoconazole;_be"
2503,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",quinolones,theophylline,mechanism,"However_bf ,_bf systemic_bf administration_bf DRUG shown_be elevate_be plasma_be concentrations_be OTHER_DRUG ,_af interfere_af metabolism_af caffeine_af ,_af enhance_af effects_af oral_af anticoagulant_af warfarin_af derivatives_af ,_af associated_af transient_af elevations_af serum_af creatinine_af patients_af receiving_af systemic_af cyclosporine_af concomitantly_af ._af"
2504,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",quinolones,caffeine,mechanism,"However_bf ,_bf systemic_bf administration_bf DRUG shown_be elevate_be plasma_be concentrations_be theophylline_be ,_be interfere_be metabolism_be OTHER_DRUG ,_af enhance_af effects_af oral_af anticoagulant_af warfarin_af derivatives_af ,_af associated_af transient_af elevations_af serum_af creatinine_af patients_af receiving_af systemic_af cyclosporine_af concomitantly_af ._af"
2505,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",quinolones,warfarin,effect,"However_bf ,_bf systemic_bf administration_bf DRUG shown_be elevate_be plasma_be concentrations_be theophylline_be ,_be interfere_be metabolism_be caffeine_be ,_be enhance_be effects_be oral_be anticoagulant_be OTHER_DRUG derivatives_af ,_af associated_af transient_af elevations_af serum_af creatinine_af patients_af receiving_af systemic_af cyclosporine_af concomitantly_af ._af"
2506,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",quinolones,cyclosporine,effect,"However_bf ,_bf systemic_bf administration_bf DRUG shown_be elevate_be plasma_be concentrations_be theophylline_be ,_be interfere_be metabolism_be caffeine_be ,_be enhance_be effects_be oral_be anticoagulant_be warfarin_be derivatives_be ,_be associated_be transient_be elevations_be serum_be creatinine_be patients_be receiving_be systemic_be OTHER_DRUG concomitantly_af ._af"
2507,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,central nervous system depressants,effect,"Interactions_bf Other_bf CNS_bf Agents:_bf Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (eg_be ,_be alcohol_be ,_be sedatives_be ,_be hypnotics_be ,_be opioids_be ,_be general_be anesthetics_be ,_be barbiturates_be ,_be tricyclic_be antidepressants_be ,_be phenothiazines_be ,_be tranquilizers_be ,_be skeletal_be muscle_be relaxants_be antihistamines)_be may_be result_be additive_be central_be nervous_be system_be depressant_be effects_be ._be"
2508,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,alcohol,effect,"Interactions_bf Other_bf CNS_bf Agents:_bf Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (eg_be ,_be OTHER_DRUG ,_af sedatives_af ,_af hypnotics_af ,_af opioids_af ,_af general_af anesthetics_af ,_af barbiturates_af ,_af tricyclic_af antidepressants_af ,_af phenothiazines_af ,_af tranquilizers_af ,_af skeletal_af muscle_af relaxants_af antihistamines)_af may_af result_af additive_af central_af nervous_af system_af depressant_af effects_af ._af"
2509,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,sedatives,effect,"Interactions_bf Other_bf CNS_bf Agents:_bf Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (eg_be ,_be alcohol_be ,_be OTHER_DRUG ,_af hypnotics_af ,_af opioids_af ,_af general_af anesthetics_af ,_af barbiturates_af ,_af tricyclic_af antidepressants_af ,_af phenothiazines_af ,_af tranquilizers_af ,_af skeletal_af muscle_af relaxants_af antihistamines)_af may_af result_af additive_af central_af nervous_af system_af depressant_af effects_af ._af"
2510,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,hypnotics,effect,"Interactions_bf Other_bf CNS_bf Agents:_bf Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (eg_be ,_be alcohol_be ,_be sedatives_be ,_be OTHER_DRUG ,_af opioids_af ,_af general_af anesthetics_af ,_af barbiturates_af ,_af tricyclic_af antidepressants_af ,_af phenothiazines_af ,_af tranquilizers_af ,_af skeletal_af muscle_af relaxants_af antihistamines)_af may_af result_af additive_af central_af nervous_af system_af depressant_af effects_af ._af"
2511,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,opioids,effect,"Interactions_bf Other_bf CNS_bf Agents:_bf Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (eg_be ,_be alcohol_be ,_be sedatives_be ,_be hypnotics_be ,_be OTHER_DRUG ,_af general_af anesthetics_af ,_af barbiturates_af ,_af tricyclic_af antidepressants_af ,_af phenothiazines_af ,_af tranquilizers_af ,_af skeletal_af muscle_af relaxants_af antihistamines)_af may_af result_af additive_af central_af nervous_af system_af depressant_af effects_af ._af"
2512,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,anesthetics,effect,"Interactions_bf Other_bf CNS_bf Agents:_bf Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (eg_be ,_be alcohol_be ,_be sedatives_be ,_be hypnotics_be ,_be opioids_be ,_be general_be OTHER_DRUG ,_af barbiturates_af ,_af tricyclic_af antidepressants_af ,_af phenothiazines_af ,_af tranquilizers_af ,_af skeletal_af muscle_af relaxants_af antihistamines)_af may_af result_af additive_af central_af nervous_af system_af depressant_af effects_af ._af"
2513,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,barbiturates,effect,"Interactions_bf Other_bf CNS_bf Agents:_bf Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (eg_be ,_be alcohol_be ,_be sedatives_be ,_be hypnotics_be ,_be opioids_be ,_be general_be anesthetics_be ,_be OTHER_DRUG ,_af tricyclic_af antidepressants_af ,_af phenothiazines_af ,_af tranquilizers_af ,_af skeletal_af muscle_af relaxants_af antihistamines)_af may_af result_af additive_af central_af nervous_af system_af depressant_af effects_af ._af"
2514,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,tricyclic antidepressants,effect,"Interactions_bf Other_bf CNS_bf Agents:_bf Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (eg_be ,_be alcohol_be ,_be sedatives_be ,_be hypnotics_be ,_be opioids_be ,_be general_be anesthetics_be ,_be barbiturates_be ,_be tricyclic_be antidepressants_be ,_be phenothiazines_be ,_be tranquilizers_be ,_be skeletal_be muscle_be relaxants_be antihistamines)_be may_be result_be additive_be central_be nervous_be system_be depressant_be effects_be ._be"
2515,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,phenothiazines,effect,"Interactions_bf Other_bf CNS_bf Agents:_bf Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (eg_be ,_be alcohol_be ,_be sedatives_be ,_be hypnotics_be ,_be opioids_be ,_be general_be anesthetics_be ,_be barbiturates_be ,_be tricyclic_be antidepressants_be ,_be OTHER_DRUG ,_af tranquilizers_af ,_af skeletal_af muscle_af relaxants_af antihistamines)_af may_af result_af additive_af central_af nervous_af system_af depressant_af effects_af ._af"
2516,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,tranquilizers,effect,"Interactions_bf Other_bf CNS_bf Agents:_bf Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (eg_be ,_be alcohol_be ,_be sedatives_be ,_be hypnotics_be ,_be opioids_be ,_be general_be anesthetics_be ,_be barbiturates_be ,_be tricyclic_be antidepressants_be ,_be phenothiazines_be ,_be OTHER_DRUG ,_af skeletal_af muscle_af relaxants_af antihistamines)_af may_af result_af additive_af central_af nervous_af system_af depressant_af effects_af ._af"
2517,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,skeletal muscle relaxants,effect,"Interactions_bf Other_bf CNS_bf Agents:_bf Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (eg_be ,_be alcohol_be ,_be sedatives_be ,_be hypnotics_be ,_be opioids_be ,_be general_be anesthetics_be ,_be barbiturates_be ,_be tricyclic_be antidepressants_be ,_be phenothiazines_be ,_be tranquilizers_be ,_be skeletal_be muscle_be relaxants_be antihistamines)_be may_be result_be additive_be central_be nervous_be system_be depressant_be effects_be ._be"
2518,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,antihistamines,effect,"Interactions_bf Other_bf CNS_bf Agents:_bf Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (eg_be ,_be alcohol_be ,_be sedatives_be ,_be hypnotics_be ,_be opioids_be ,_be general_be anesthetics_be ,_be barbiturates_be ,_be tricyclic_be antidepressants_be ,_be phenothiazines_be ,_be tranquilizers_be ,_be skeletal_be muscle_be relaxants_be antihistamines)_be may_be result_be additive_be central_be nervous_be system_be depressant_be effects_be ._be"
2519,"Although no interaction between MAO inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO inhibitors.",Levo-Dromoran,MAO inhibitors,advise,"Although_bf interaction_bf MAO_bf inhibitors_bf DRUG observed_be ,_be recommended_be use_be MAO_be inhibitors_be ._be"
2520,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",Agonist/antagonist analgesics,Levo-Dromoran,advise,"Interactions_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (eg_bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf butorphanol_bf ,_bf dezocine_bf buprenorphine)_bf NOT_bf administered_bf patient_bf received_bf receiving_bf course_bf therapy_bf pure_bf agonist_bf opioid_bf analgesic_bf OTHER_DRUG ._be"
2521,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",pentazocine,Levo-Dromoran,advise,"Interactions_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (eg_bf ,_bf DRUG ,_be nalbuphine_be ,_be butorphanol_be ,_be dezocine_be buprenorphine)_be NOT_be administered_be patient_be received_be receiving_be course_be therapy_be pure_be agonist_be opioid_be analgesic_be OTHER_DRUG ._af"
2522,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",nalbuphine,Levo-Dromoran,advise,"Interactions_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (eg_bf ,_bf pentazocine_bf ,_bf DRUG ,_be butorphanol_be ,_be dezocine_be buprenorphine)_be NOT_be administered_be patient_be received_be receiving_be course_be therapy_be pure_be agonist_be opioid_be analgesic_be OTHER_DRUG ._af"
2523,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",butorphanol,Levo-Dromoran,advise,"Interactions_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (eg_bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf DRUG ,_be dezocine_be buprenorphine)_be NOT_be administered_be patient_be received_be receiving_be course_be therapy_be pure_be agonist_be opioid_be analgesic_be OTHER_DRUG ._af"
2524,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",dezocine,Levo-Dromoran,advise,"Interactions_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (eg_bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf butorphanol_bf ,_bf DRUG buprenorphine)_be NOT_be administered_be patient_be received_be receiving_be course_be therapy_be pure_be agonist_be opioid_be analgesic_be OTHER_DRUG ._af"
2525,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",buprenorphine,Levo-Dromoran,advise,"Interactions_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (eg_bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf butorphanol_bf ,_bf dezocine_bf buprenorphine)_bf NOT_bf administered_bf patient_bf received_bf receiving_bf course_bf therapy_bf pure_bf agonist_bf opioid_bf analgesic_bf OTHER_DRUG ._be"
2526,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",pure agonist opioid analgesic,Levo-Dromoran,advise,"Interactions_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (eg_bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf butorphanol_bf ,_bf dezocine_bf buprenorphine)_bf NOT_bf administered_bf patient_bf received_bf receiving_bf course_bf therapy_bf pure_bf agonist_bf opioid_bf analgesic_bf OTHER_DRUG ._be"
2527,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",epinephrine,monoamine oxidase inhibitors,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf DRUG norepinephrine_be patients_be receiving_be monoamine_be oxidase_be inhibitors_be tricyclic_be antidepressants_be may_be produce_be severe_be ,_be prolonged_be hypertension_be ._be"
2528,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",epinephrine,tricyclic antidepressants,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf DRUG norepinephrine_be patients_be receiving_be monoamine_be oxidase_be inhibitors_be tricyclic_be antidepressants_be may_be produce_be severe_be ,_be prolonged_be hypertension_be ._be"
2529,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",norepinephrine,monoamine oxidase inhibitors,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf epinephrine_bf DRUG patients_be receiving_be monoamine_be oxidase_be inhibitors_be tricyclic_be antidepressants_be may_be produce_be severe_be ,_be prolonged_be hypertension_be ._be"
2530,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",norepinephrine,tricyclic antidepressants,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf epinephrine_bf DRUG patients_be receiving_be monoamine_be oxidase_be inhibitors_be tricyclic_be antidepressants_be may_be produce_be severe_be ,_be prolonged_be hypertension_be ._be"
2531,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.,Phenothiazines,epinephrine,effect,DRUG butyrophenones_be may_be reduce_be reverse_be pressor_be effect_be OTHER_DRUG ._af
2532,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.,butyrophenones,epinephrine,effect,Phenothiazines_bf DRUG may_be reduce_be reverse_be pressor_be effect_be OTHER_DRUG ._af
2533,Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.,Lincomycin,neuromuscular blocking agents,effect,DRUG shown_be neuromuscular_be blocking_be properties_be may_be enhance_be action_be neuromuscular_be blocking_be agents_be ._be
2534,Antagonism between lincomycin and erythromycin in vitro has been demonstrated.,lincomycin,erythromycin,effect,Antagonism_bf DRUG OTHER_DRUG vitro_af demonstrated_af ._af
2535,Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started.,anticoagulants,thyroid,advise,Patients_bf stabilized_bf oral_bf DRUG found_be require_be OTHER_DRUG replacement_af therapy_af watched_af closely_af OTHER_DRUG started_af ._af
2536,"Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.",Cholestyramine,T4,mechanism,"Cholestyramine:_bf DRUG binds_be OTHER_DRUG T3_af intestine_af ,_af thus_af impairing_af absorption_af thyroid_af hormones_af ._af"
2537,"Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.",Cholestyramine,T3,mechanism,"Cholestyramine:_bf DRUG binds_be T4_be OTHER_DRUG intestine_af ,_af thus_af impairing_af absorption_af thyroid_af hormones_af ._af"
2538,"Therefore, 4 to 5 hours should elapse between administration of cholestyramine and thyroid hormones.",cholestyramine,thyroid hormones,advise,"Therefore_bf ,_bf 4_bf 5_bf hours_bf elapse_bf administration_bf DRUG thyroid_be hormones_be ._be"
2539,"In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.",levothyroxine,estrogens,mechanism,"In_bf patient_bf nonfunctioning_bf thyroid_bf gland_bf receiving_bf thyroid_bf replacement_bf therapy_bf ,_bf free_bf DRUG may_be decreased_be OTHER_DRUG started_af thus_af increasing_af thyroid_af requirements_af ._af"
2540,"Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.",thyroid,estrogens,advise,"Therefore_bf ,_bf patients_bf without_bf functioning_bf DRUG gland_be DRUG replacement_af therapy_af may_af need_af increase_af DRUG dose_af OTHER_DRUG estrogen-containing_af oral_af contraceptives_af given_af ._af"
2541,"Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.",thyroid,contraceptives,advise,"Therefore_bf ,_bf patients_bf without_bf functioning_bf DRUG gland_be DRUG replacement_af therapy_af may_af need_af increase_af DRUG dose_af estrogens_af estrogen-containing_af oral_af OTHER_DRUG given_af ._af"
2542,Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.,thyroid products,imipramine,effect,Tricyclic_bf Antidepressants:_bf Use_bf thyroid_bf products_bf OTHER_DRUG tricyclic_be antidepressants_be may_be increase_be receptor_be sensitivity_be enhance_be antidepressant_be activity_be transient_be cardiac_be arrhythmias_be observed_be ._be
2543,Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.,thyroid products,tricyclic antidepressants,effect,Tricyclic_bf Antidepressants:_bf Use_bf thyroid_bf products_bf imipramine_bf tricyclic_bf antidepressants_bf may_bf increase_bf receptor_bf sensitivity_bf enhance_bf antidepressant_bf activity_bf transient_bf cardiac_bf arrhythmias_bf observed_bf ._bf
2544,Digitalis: Thyroid preparations may potentiate the toxic effects of digitalis.,Thyroid preparations,digitalis,effect,Digitalis:_bf Thyroid_bf preparations_bf may_bf potentiate_bf toxic_bf effects_bf OTHER_DRUG ._be
2545,"Ketamine: When administered to patients on a thyroid preparation, this parenteral anesthetic may cause hypertension and tachycardia.",thyroid preparation,anesthetic,effect,"Ketamine:_bf When_bf administered_bf patients_bf thyroid_bf preparation_bf ,_bf parenteral_bf OTHER_DRUG may_be cause_be hypertension_be tachycardia_be ._be"
2546,Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.,Thyroxine,epinephrine,effect,Vasopressors:_bf DRUG increases_be adrenergic_be effect_be catecholamines_be OTHER_DRUG norepinephrine_af ._af
2547,Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.,Thyroxine,norepinephrine,effect,Vasopressors:_bf DRUG increases_be adrenergic_be effect_be catecholamines_be epinephrine_be OTHER_DRUG ._af
2548,"Urinary acidifying agents These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",ammonium chloride,amphetamine,mechanism,"Urinary_bf acidifying_bf agents_bf These_bf agents_bf (ammonium_bf chloride_bf ,_bf sodium_bf acid_bf phosphate_bf ,_bf etc_bf ._bf )_bf increase_bf concentration_bf ionized_bf species_bf OTHER_DRUG molecule_be ,_be thereby_be increasing_be urinary_be excretion_be ._be"
2549,"Urinary acidifying agents These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",sodium acid phosphate,amphetamine,mechanism,"Urinary_bf acidifying_bf agents_bf These_bf agents_bf (ammonium_bf chloride_bf ,_bf sodium_bf acid_bf phosphate_bf ,_bf etc_bf ._bf )_bf increase_bf concentration_bf ionized_bf species_bf OTHER_DRUG molecule_be ,_be thereby_be increasing_be urinary_be excretion_be ._be"
2550,Adrenergic blockers Adrenergic blockers are inhibited by amphetamines.,Adrenergic blockers,amphetamines,effect,Adrenergic_bf blockers_bf Adrenergic_bf blockers_bf inhibited_bf OTHER_DRUG ._be
2551,"Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;",Amphetamines,tricyclic antidepressants,effect,"Antidepressants_bf ,_bf tricyclic_bf DRUG may_be enhance_be activity_be tricyclic_be antidepressants_be sympathomimetic_be agents;_be"
2552,"Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;",Amphetamines,sympathomimetic agents,effect,"Antidepressants_bf ,_bf tricyclic_bf DRUG may_be enhance_be activity_be tricyclic_be antidepressants_be sympathomimetic_be agents;_be"
2553,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,desipramine,mechanism,DRUG OTHER_DRUG protriptyline_af possibly_af tricyclics_af cause_af striking_af sustained_af increases_af concentration_af DRUG brain;_af
2554,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,protriptyline,mechanism,DRUG desipramine_be OTHER_DRUG possibly_af tricyclics_af cause_af striking_af sustained_af increases_af concentration_af DRUG brain;_af
2555,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,tricyclics,mechanism,DRUG desipramine_be protriptyline_be possibly_be OTHER_DRUG cause_af striking_af sustained_af increases_af concentration_af DRUG brain;_af
2556,"MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.",MAOI antidepressants,amphetamine,mechanism,"MAO_bf inhibitors_bf MAOI_bf antidepressants_bf ,_bf well_bf metabolite_bf furazolidone_bf ,_bf slow_bf OTHER_DRUG metabolism_be ._be"
2557,"MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.",furazolidone,amphetamine,mechanism,"MAO_bf inhibitors_bf MAOI_bf antidepressants_bf ,_bf well_bf metabolite_bf DRUG ,_be slow_be OTHER_DRUG metabolism_af ._af"
2558,Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.,Amphetamines,antihistamines,effect,Antihistamines:_bf DRUG may_be counteract_be sedative_be effect_be OTHER_DRUG ._af
2559,Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.,Amphetamines,antihypertensives,effect,Antihypertensives:_bf DRUG may_be antagonize_be hypotensive_be effects_be OTHER_DRUG ._af
2560,"Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.",Chlorpromazine,amphetamines,effect,"Chlorpromazine:_bf DRUG blocks_be dopamine_be norepinephrine_be receptors_be ,_be thus_be inhibiting_be central_be stimulant_be effects_be OTHER_DRUG used_af treat_af amphetamine_af poisoning_af ._af"
2561,Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.,Amphetamines,ethosuximide,mechanism,Ethosuximide:_bf DRUG may_be delay_be intestinal_be absorption_be OTHER_DRUG ._af
2562,"Haloperidol: Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.",Haloperidol,amphetamines,effect,"Haloperidol:_bf DRUG blocks_be dopamine_be receptors_be ,_be thus_be inhibiting_be central_be stimulant_be effects_be OTHER_DRUG ._af"
2563,Lithium carbonate: The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate.,amphetamines,lithium carbonate,effect,Lithium_bf carbonate:_bf The_bf anorectic_bf stimulatory_bf effects_bf DRUG may_be inhibited_be lithium_be carbonate_be ._be
2564,Meperidine: Amphetamines potentiate the analgesic effect of meperidine.,Amphetamines,meperidine,effect,Meperidine:_bf DRUG potentiate_be analgesic_be effect_be OTHER_DRUG ._af
2565,"Methenamine therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.",amphetamines,methenamine,mechanism,"OTHER_DRUG therapy_be Urinary_be excretion_be DRUG increased_af ,_af efficacy_af reduced_af acidifying_af agents_af used_af OTHER_DRUG therapy_af ._af"
2566,Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.,Amphetamines,norepinephrine,effect,Norepinephrine:_bf DRUG enhance_be adrenergic_be effect_be OTHER_DRUG ._af
2567,Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;,Amphetamines,phenobarbital,mechanism,Phenobarbital:_bf DRUG may_be delay_be intestinal_be absorption_be phenobarbital;_be
2568,Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;,Amphetamines,phenytoin,mechanism,Phenytoin:_bf DRUG may_be delay_be intestinal_be absorption_be phenytoin;_be
2569,"Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.",propoxyphene,amphetamine,effect,"Propoxyphene:_bf In_bf cases_bf DRUG overdosage_be ,_be OTHER_DRUG CNS_af stimulation_af potentiated_af fatal_af convulsions_af occur_af ._af"
2570,Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.,Amphetamines,veratrum alkaloids,effect,Veratrum_bf alkaloids:_bf DRUG inhibit_be hypotensive_be effect_be veratrum_be alkaloids_be ._be
2571,"Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with PRINIVIL.",diuretics,PRINIVIL,effect,"Hypotension_bf -_bf Patients_bf Diuretic_bf Therapy:_bf Patients_bf DRUG ,_be especially_be diuretic_be therapy_be recently_be instituted_be ,_be may_be occasionally_be experience_be excessive_be reduction_be blood_be pressure_be initiation_be therapy_be OTHER_DRUG ._af"
2572,The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with PRINIVIL.,diuretic,PRINIVIL,effect,The_bf possibility_bf hypotensive_bf effects_bf OTHER_DRUG minimized_be either_be discontinuing_be DRUG increasing_af salt_af intake_af prior_af initiation_af treatment_af OTHER_DRUG ._af
2573,"If it is necessary to continue the diuretic, initiate therapy with PRINIVIL at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized.",diuretic,PRINIVIL,advise,"If_bf necessary_bf continue_bf DRUG ,_be initiate_be therapy_be OTHER_DRUG dose_af 5_af mg_af daily_af ,_af provide_af close_af medical_af supervision_af initial_af dose_af blood_af pressure_af stabilized_af ._af"
2574,"When a diuretic is added to the therapy of a patient receiving PRINIVIL, an additional antihypertensive effect is usually observed.",diuretic,PRINIVIL,effect,"When_bf DRUG added_be therapy_be patient_be receiving_be OTHER_DRUG ,_af additional_af antihypertensive_af effect_af usually_af observed_af ._af"
2575,Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic.,ACE inhibitor,diuretic,advise,Studies_bf ACE_bf inhibitors_bf combination_bf diuretics_bf indicate_bf dose_bf ACE_bf inhibitor_bf reduced_bf given_bf OTHER_DRUG ._be
2576,"Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of lisinopril may result in a further deterioration of renal function.",non-steroidal anti-inflammatory drugs,lisinopril,effect,"Non-steroidal_bf Anti-inflammatory_bf Agents:_bf In_bf patients_bf compromised_bf renal_bf function_bf treated_bf non-steroidal_bf anti-inflammatory_bf drugs_bf ,_bf co-administration_bf OTHER_DRUG may_be result_be deterioration_be renal_be function_be ._be"
2577,"Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril.",NSAIDs,ACE inhibitors,effect,"Reports_bf suggest_bf DRUG may_be diminish_be antihypertensive_be effect_be ACE_be inhibitors_be ,_be including_be lisinopril_be ._be"
2578,"Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril.",NSAIDs,lisinopril,effect,"Reports_bf suggest_bf DRUG may_be diminish_be antihypertensive_be effect_be ACE_be inhibitors_be ,_be including_be OTHER_DRUG ._af"
2579,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.,NSAIDs,ACE inhibitors,advise,This_bf interaction_bf given_bf consideration_bf patients_bf taking_bf DRUG concomitantly_be ACE_be inhibitors_be ._be
2580,Agents Increasing Serum Potassium: PRINIVIL attenuates potassium loss caused by thiazide-type diuretics.,PRINIVIL,thiazide-type diuretics,effect,Agents_bf Increasing_bf Serum_bf Potassium:_bf DRUG attenuates_be potassium_be loss_be caused_be thiazide-type_be diuretics_be ._be
2581,"Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",PRINIVIL,potassium-sparing diuretics,effect,"Use_bf DRUG potassium-sparing_be diuretics_be (e_be ._be g_be ._be ,_be spironolactone_be ,_be triamterene_be ,_be amiloride)_be ,_be potassium_be supplements_be ,_be potassium-containing_be salt_be substitutes_be may_be lead_be significant_be increases_be serum_be potassium_be ._be"
2582,"Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",PRINIVIL,spironolactone,effect,"Use_bf DRUG potassium-sparing_be diuretics_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af triamterene_af ,_af amiloride)_af ,_af potassium_af supplements_af ,_af potassium-containing_af salt_af substitutes_af may_af lead_af significant_af increases_af serum_af potassium_af ._af"
2583,"Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",PRINIVIL,triamterene,effect,"Use_bf DRUG potassium-sparing_be diuretics_be (e_be ._be g_be ._be ,_be spironolactone_be ,_be OTHER_DRUG ,_af amiloride)_af ,_af potassium_af supplements_af ,_af potassium-containing_af salt_af substitutes_af may_af lead_af significant_af increases_af serum_af potassium_af ._af"
2584,"Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",PRINIVIL,amiloride,effect,"Use_bf DRUG potassium-sparing_be diuretics_be (e_be ._be g_be ._be ,_be spironolactone_be ,_be triamterene_be ,_be amiloride)_be ,_be potassium_be supplements_be ,_be potassium-containing_be salt_be substitutes_be may_be lead_be significant_be increases_be serum_be potassium_be ._be"
2585,"Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",PRINIVIL,potassium,effect,"Use_bf DRUG potassium-sparing_be diuretics_be (e_be ._be g_be ._be ,_be spironolactone_be ,_be triamterene_be ,_be amiloride)_be ,_be OTHER_DRUG supplements_af ,_af potassium-containing_af salt_af substitutes_af may_af lead_af significant_af increases_af serum_af OTHER_DRUG ._af"
2586,"Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.",lithium,ACE inhibitors,effect,"Lithium:_bf DRUG toxicity_be reported_be patients_be receiving_be DRUG concomitantly_af drugs_af cause_af elimination_af sodium_af ,_af including_af ACE_af inhibitors_af ._af"
2587,Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor.,lithium,ACE inhibitor,effect,DRUG toxicity_be usually_be reversible_be upon_be discontinuation_be DRUG ACE_af inhibitor_af ._af
2588,It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.,PRINIVIL,lithium,advise,It_bf recommended_bf serum_bf OTHER_DRUG levels_be monitored_be frequently_be DRUG administered_af concomitantly_af OTHER_DRUG ._af
2589,"- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives",Lofexidine,alcohol,effect,"-_bf DRUG may_be enhance_be CNS_be depressive_be effects_be OTHER_DRUG ,_af barbiturates_af sedatives_af"
2590,"- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives",Lofexidine,barbiturates,effect,"-_bf DRUG may_be enhance_be CNS_be depressive_be effects_be alcohol_be ,_be OTHER_DRUG sedatives_af"
2591,"- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives",Lofexidine,sedatives,effect,"-_bf DRUG may_be enhance_be CNS_be depressive_be effects_be alcohol_be ,_be barbiturates_be OTHER_DRUG"
2592,- Lofexidine may enhance the effects of anti-hypertensive drug therapy,Lofexidine,anti-hypertensive drug,effect,-_bf DRUG may_be enhance_be effects_be anti-hypertensive_be drug_be therapy_be
2593,- Concomitant use of tricyclic antidepressants may reduce the efficacy of lofexidine.,tricyclic antidepressants,lofexidine,effect,-_bf Concomitant_bf use_bf tricyclic_bf antidepressants_bf may_bf reduce_bf efficacy_bf OTHER_DRUG ._be
2594,"Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",Sucralfate,lomefloxacin,mechanism,"Antacids_bf sucralfate:_bf DRUG antacids_be containing_be magnesium_be aluminum_be ,_be well_be formulations_be containing_be divalent_be trivalent_be cations_be Videx_be (didanosine)_be ,_be chewable/buffered_be tablets_be pediatric_be powder_be oral_be solution_be form_be chelation_be complexes_be OTHER_DRUG interfere_af bioavailability_af ._af"
2595,"Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",magnesium,lomefloxacin,mechanism,"Antacids_bf sucralfate:_bf Sucralfate_bf antacids_bf containing_bf DRUG aluminum_be ,_be well_be formulations_be containing_be divalent_be trivalent_be cations_be Videx_be (didanosine)_be ,_be chewable/buffered_be tablets_be pediatric_be powder_be oral_be solution_be form_be chelation_be complexes_be OTHER_DRUG interfere_af bioavailability_af ._af"
2596,"Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",aluminum,lomefloxacin,mechanism,"Antacids_bf sucralfate:_bf Sucralfate_bf antacids_bf containing_bf magnesium_bf DRUG ,_be well_be formulations_be containing_be divalent_be trivalent_be cations_be Videx_be (didanosine)_be ,_be chewable/buffered_be tablets_be pediatric_be powder_be oral_be solution_be form_be chelation_be complexes_be OTHER_DRUG interfere_af bioavailability_af ._af"
2597,"Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",Videx,lomefloxacin,mechanism,"Antacids_bf sucralfate:_bf Sucralfate_bf antacids_bf containing_bf magnesium_bf aluminum_bf ,_bf well_bf formulations_bf containing_bf divalent_bf trivalent_bf cations_bf DRUG (didanosine)_be ,_be chewable/buffered_be tablets_be pediatric_be powder_be oral_be solution_be form_be chelation_be complexes_be OTHER_DRUG interfere_af bioavailability_af ._af"
2598,"Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",didanosine,lomefloxacin,mechanism,"Antacids_bf sucralfate:_bf Sucralfate_bf antacids_bf containing_bf magnesium_bf aluminum_bf ,_bf well_bf formulations_bf containing_bf divalent_bf trivalent_bf cations_bf Videx_bf (didanosine)_bf ,_bf chewable/buffered_bf tablets_bf pediatric_bf powder_bf oral_bf solution_bf form_bf chelation_bf complexes_bf OTHER_DRUG interfere_be bioavailability_be ._be"
2599,Sucralfate administered 2 hours before lomefloxacin resulted in a slower absorption (mean C max decreased by 30% and mean T max increased by 1 hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%).,Sucralfate,lomefloxacin,mechanism,DRUG administered_be 2_be hours_be OTHER_DRUG resulted_af slower_af absorption_af (mean_af C_af max_af decreased_af 30%_af mean_af T_af max_af increased_af 1_af hour)_af lesser_af extent_af absorption_af (mean_af AUC_af decreased_af approximately_af 25%)_af ._af
2600,"Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.",Magnesium,lomefloxacin,mechanism,"Magnesium-_bf aluminum-containing_bf antacids_bf ,_bf administered_bf concomitantly_bf OTHER_DRUG ,_be significantly_be decreased_be bioavailability_be (48%)_be OTHER_DRUG ._af"
2601,"Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.",aluminum,lomefloxacin,mechanism,"Magnesium-_bf aluminum-containing_bf antacids_bf ,_bf administered_bf concomitantly_bf OTHER_DRUG ,_be significantly_be decreased_be bioavailability_be (48%)_be OTHER_DRUG ._af"
2602,"Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.",antacids,lomefloxacin,mechanism,"Magnesium-_bf aluminum-containing_bf DRUG ,_be administered_be concomitantly_be OTHER_DRUG ,_af significantly_af decreased_af bioavailability_af (48%)_af OTHER_DRUG ._af"
2603,Separating the doses of antacid and lomefloxacin minimizes this decrease in bioavailability;,antacid,lomefloxacin,mechanism,Separating_bf doses_bf DRUG OTHER_DRUG minimizes_af decrease_af bioavailability;_af
2604,"Other quinolones have demonstrated moderate to marked interference with the metabolism of caffeine, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of caffeine.",quinolones,caffeine,mechanism,"Other_bf DRUG demonstrated_be moderate_be marked_be interference_be metabolism_be OTHER_DRUG ,_af resulting_af reduced_af clearance_af ,_af prolongation_af plasma_af half-life_af ,_af increase_af symptoms_af accompany_af high_af levels_af OTHER_DRUG ._af"
2605,Cimetidine: Cimetidine has been demonstrated to interfere with the elimination of other quinolones.,Cimetidine,quinolones,mechanism,Cimetidine:_bf DRUG demonstrated_be interfere_be elimination_be OTHER_DRUG ._af
2606,Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.,cyclosporine,quinolone class,mechanism,Cyclosporine:_bf Elevated_bf serum_bf levels_bf DRUG reported_be concomitant_be use_be DRUG members_af quinolone_af class_af ._af
2607,"Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.",Quinolones,anticoagulant,effect,"Warfarin:_bf DRUG may_be enhance_be effects_be oral_be OTHER_DRUG ,_af warfarin_af ,_af derivatives_af ._af"
2608,"Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.",Quinolones,warfarin,effect,"Warfarin:_bf DRUG may_be enhance_be effects_be oral_be anticoagulant_be ,_be OTHER_DRUG ,_af derivatives_af ._af"
2609,"Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.",b-lactam antibiotics,probenecid,mechanism,"Probenecid:_bf As_bf b-lactam_bf antibiotics_bf ,_bf renal_bf excretion_bf loracarbef_bf inhibited_bf OTHER_DRUG resulted_be approximate_be 80%_be increase_be AUC_be loracarbef_be ._be"
2610,"Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.",loracarbef,probenecid,mechanism,"Probenecid:_bf As_bf b-lactam_bf antibiotics_bf ,_bf renal_bf excretion_bf DRUG inhibited_be OTHER_DRUG resulted_af approximate_af 80%_af increase_af AUC_af DRUG ._af"
2611,Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.,erythromycin,loratadine,mechanism,Plasma_bf concentrations_bf (AUC_bf 0-24_bf hrs)_bf DRUG decreased_be 15%_be coadministration_be OTHER_DRUG relative_af observed_af DRUG alone_af ._af
2612,"Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.",benzodiazepines,barbiturates,effect,"Tablets:_bf The_bf DRUG ,_be including_be lorazepam_be ,_be produce_be CNS-depressant_be effects_be administered_be medications_be OTHER_DRUG alcohol_af ._af"
2613,"Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.",benzodiazepines,alcohol,effect,"Tablets:_bf The_bf DRUG ,_be including_be lorazepam_be ,_be produce_be CNS-depressant_be effects_be administered_be medications_be barbiturates_be OTHER_DRUG ._af"
2614,"Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.",lorazepam,barbiturates,effect,"Tablets:_bf The_bf benzodiazepines_bf ,_bf including_bf DRUG ,_be produce_be CNS-depressant_be effects_be administered_be medications_be OTHER_DRUG alcohol_af ._af"
2615,"Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.",lorazepam,alcohol,effect,"Tablets:_bf The_bf benzodiazepines_bf ,_bf including_bf DRUG ,_be produce_be CNS-depressant_be effects_be administered_be medications_be barbiturates_be OTHER_DRUG ._af"
2616,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",Lorazepam,ethyl alcohol,effect,"Injection:_bf DRUG injection_be ,_be like_be injectable_be benzodiazepines_be ,_be produces_be depression_be central_be nervous_be system_be administered_be ethyl_be alcohol_be ,_be phenothiazines_be ,_be barbiturates_be ,_be MAO_be inhibitors_be ,_be antidepressants_be ._be When_be scopolamine_be used_be concomitantly_be injectable_be DRUG ,_af increased_af incidence_af sedation_af ,_af hallucinations_af ,_af irrational_af behavior_af observed_af ._af"
2617,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",Lorazepam,phenothiazines,effect,"Injection:_bf DRUG injection_be ,_be like_be injectable_be benzodiazepines_be ,_be produces_be depression_be central_be nervous_be system_be administered_be ethyl_be alcohol_be ,_be OTHER_DRUG ,_af barbiturates_af ,_af MAO_af inhibitors_af ,_af antidepressants_af ._af When_af scopolamine_af used_af concomitantly_af injectable_af DRUG ,_af increased_af incidence_af sedation_af ,_af hallucinations_af ,_af irrational_af behavior_af observed_af ._af"
2618,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",Lorazepam,barbiturates,effect,"Injection:_bf DRUG injection_be ,_be like_be injectable_be benzodiazepines_be ,_be produces_be depression_be central_be nervous_be system_be administered_be ethyl_be alcohol_be ,_be phenothiazines_be ,_be OTHER_DRUG ,_af MAO_af inhibitors_af ,_af antidepressants_af ._af When_af scopolamine_af used_af concomitantly_af injectable_af DRUG ,_af increased_af incidence_af sedation_af ,_af hallucinations_af ,_af irrational_af behavior_af observed_af ._af"
2619,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",Lorazepam,MAO inhibitors,effect,"Injection:_bf DRUG injection_be ,_be like_be injectable_be benzodiazepines_be ,_be produces_be depression_be central_be nervous_be system_be administered_be ethyl_be alcohol_be ,_be phenothiazines_be ,_be barbiturates_be ,_be MAO_be inhibitors_be ,_be antidepressants_be ._be When_be scopolamine_be used_be concomitantly_be injectable_be DRUG ,_af increased_af incidence_af sedation_af ,_af hallucinations_af ,_af irrational_af behavior_af observed_af ._af"
2620,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",Lorazepam,antidepressants,effect,"Injection:_bf DRUG injection_be ,_be like_be injectable_be benzodiazepines_be ,_be produces_be depression_be central_be nervous_be system_be administered_be ethyl_be alcohol_be ,_be phenothiazines_be ,_be barbiturates_be ,_be MAO_be inhibitors_be ,_be OTHER_DRUG ._af When_af scopolamine_af used_af concomitantly_af injectable_af DRUG ,_af increased_af incidence_af sedation_af ,_af hallucinations_af ,_af irrational_af behavior_af observed_af ._af"
2621,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",benzodiazepines,ethyl alcohol,effect,"Injection:_bf Lorazepam_bf injection_bf ,_bf like_bf injectable_bf DRUG ,_be produces_be depression_be central_be nervous_be system_be administered_be ethyl_be alcohol_be ,_be phenothiazines_be ,_be barbiturates_be ,_be MAO_be inhibitors_be ,_be antidepressants_be ._be When_be scopolamine_be used_be concomitantly_be injectable_be lorazepam_be ,_be increased_be incidence_be sedation_be ,_be hallucinations_be ,_be irrational_be behavior_be observed_be ._be"
2622,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",benzodiazepines,phenothiazines,effect,"Injection:_bf Lorazepam_bf injection_bf ,_bf like_bf injectable_bf DRUG ,_be produces_be depression_be central_be nervous_be system_be administered_be ethyl_be alcohol_be ,_be OTHER_DRUG ,_af barbiturates_af ,_af MAO_af inhibitors_af ,_af antidepressants_af ._af When_af scopolamine_af used_af concomitantly_af injectable_af lorazepam_af ,_af increased_af incidence_af sedation_af ,_af hallucinations_af ,_af irrational_af behavior_af observed_af ._af"
2623,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",benzodiazepines,barbiturates,effect,"Injection:_bf Lorazepam_bf injection_bf ,_bf like_bf injectable_bf DRUG ,_be produces_be depression_be central_be nervous_be system_be administered_be ethyl_be alcohol_be ,_be phenothiazines_be ,_be OTHER_DRUG ,_af MAO_af inhibitors_af ,_af antidepressants_af ._af When_af scopolamine_af used_af concomitantly_af injectable_af lorazepam_af ,_af increased_af incidence_af sedation_af ,_af hallucinations_af ,_af irrational_af behavior_af observed_af ._af"
2624,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",benzodiazepines,MAO inhibitors,effect,"Injection:_bf Lorazepam_bf injection_bf ,_bf like_bf injectable_bf DRUG ,_be produces_be depression_be central_be nervous_be system_be administered_be ethyl_be alcohol_be ,_be phenothiazines_be ,_be barbiturates_be ,_be MAO_be inhibitors_be ,_be antidepressants_be ._be When_be scopolamine_be used_be concomitantly_be injectable_be lorazepam_be ,_be increased_be incidence_be sedation_be ,_be hallucinations_be ,_be irrational_be behavior_be observed_be ._be"
2625,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",benzodiazepines,antidepressants,effect,"Injection:_bf Lorazepam_bf injection_bf ,_bf like_bf injectable_bf DRUG ,_be produces_be depression_be central_be nervous_be system_be administered_be ethyl_be alcohol_be ,_be phenothiazines_be ,_be barbiturates_be ,_be MAO_be inhibitors_be ,_be OTHER_DRUG ._af When_af scopolamine_af used_af concomitantly_af injectable_af lorazepam_af ,_af increased_af incidence_af sedation_af ,_af hallucinations_af ,_af irrational_af behavior_af observed_af ._af"
2626,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",scopolamine,lorazepam,effect,"Injection:_bf OTHER_DRUG injection_be ,_be like_be injectable_be benzodiazepines_be ,_be produces_be depression_be central_be nervous_be system_be administered_be ethyl_be alcohol_be ,_be phenothiazines_be ,_be barbiturates_be ,_be MAO_be inhibitors_be ,_be antidepressants_be ._be When_be DRUG used_af concomitantly_af injectable_af OTHER_DRUG ,_af increased_af incidence_af sedation_af ,_af hallucinations_af ,_af irrational_af behavior_af observed_af ._af"
2627,"Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite.",Rifampin,losartan,mechanism,"DRUG ,_be inducer_be drug_be metabolism_be ,_be decreased_be concentrations_be OTHER_DRUG active_af metabolite_af ._af"
2628,"Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.",Fluconazole,losartan,mechanism,"DRUG ,_be inhibitor_be P450_be 2C9_be ,_be decreased_be active_be metabolite_be concentration_be increased_be OTHER_DRUG concentration_af ._af"
2629,"As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin",losartan,indomethacin,effect,"As_bf antihypertensive_bf agents_bf ,_bf antihypertensive_bf effect_bf DRUG may_be blunted_be non-steroidal_be anti-inflammatory_be drug_be OTHER_DRUG"
2630,"Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).",danazol,lovastatin,effect,"Danazol:_bf The_bf risk_bf myopathy/rhabdomyolysis_bf increased_bf concomitant_bf administration_bf DRUG particularly_be higher_be doses_be OTHER_DRUG (see_af WARNINGS_af ,_af Myopathy/Rhabdomyolysis)_af ._af"
2631,"Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).",amiodarone,HMG-CoA reductase inhibitor class,effect,"DRUG Verapamil:_be The_be risk_be myopathy/rhabdomyolysis_be increased_be either_be DRUG verapamil_af used_af concomitantly_af closely_af related_af member_af HMG-CoA_af reductase_af inhibitor_af class_af (see_af WARNINGS_af ,_af Myopathy/Rhabdomyolysis)_af ._af"
2632,"Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).",verapamil,HMG-CoA reductase inhibitor class,effect,"Amiodarone_bf Verapamil:_bf The_bf risk_bf myopathy/rhabdomyolysis_bf increased_bf either_bf amiodarone_bf DRUG used_be concomitantly_be closely_be related_be member_be HMG-CoA_be reductase_be inhibitor_be class_be (see_be WARNINGS_be ,_be Myopathy/Rhabdomyolysis)_be ._be"
2633,"However, another HMG-CoA reductase inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin.",HMG-CoA reductase inhibitor,warfarin,effect,"However_bf ,_bf another_bf HMG-CoA_bf reductase_bf inhibitor_bf found_bf produce_bf less_bf two-second_bf increase_bf prothrombin_bf time_bf healthy_bf volunteers_bf receiving_bf low_bf doses_bf OTHER_DRUG ._be"
2634,"Also, bleeding and/or increased prothrombin time have been reported in a few patients taking coumarin anticoagulants concomitantly with lovastatin.",coumarin anticoagulant,lovastatin,effect,"Also_bf ,_bf bleeding_bf and/or_bf increased_bf prothrombin_bf time_bf reported_bf patients_bf taking_bf coumarin_bf anticoagulants_bf concomitantly_bf OTHER_DRUG ._be"
2635,"It is recommended that in patients taking anticoagulants, prothrombin time be determined before starting lovastatin and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs.",anticoagulants,lovastatin,advise,"It_bf recommended_bf patients_bf taking_bf DRUG ,_be prothrombin_be time_be determined_be starting_be OTHER_DRUG frequently_af enough_af early_af therapy_af insure_af significant_af alteration_af prothrombin_af time_af occurs_af ._af"
2636,"There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam.",loxapine,lorazepam,effect,"There_bf rare_bf reports_bf significant_bf respiratory_bf depression_bf ,_bf stupor_bf and/or_bf hypotension_bf concomitant_bf use_bf DRUG OTHER_DRUG ._af"
2637,"The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.",lymecycline,iron,mechanism,"The_bf absorption_bf DRUG may_be affected_be simultaneous_be administration_be indigestion_be remedies_be ,_be OTHER_DRUG zinc_af supplements_af ._af"
2638,"The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.",lymecycline,zinc,mechanism,"The_bf absorption_bf DRUG may_be affected_be simultaneous_be administration_be indigestion_be remedies_be ,_be iron_be OTHER_DRUG supplements_af ._af"
2639,Oral contraceptives may be less effective while you are taking lymecycline.,contraceptives,lymecycline,effect,Oral_bf DRUG may_be less_be effective_be taking_be OTHER_DRUG ._af
2640,Warfarin: Meclofenamate sodium enhances the effect of warfarin.,Warfarin,Meclofenamate sodium,effect,Warfarin:_bf Meclofenamate_bf sodium_bf enhances_bf effect_bf DRUG ._be
2641,"Therefore, when meclofenamate sodium is given to a patient receiving warfarin, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.",meclofenamate sodium,warfarin,advise,"Therefore_bf ,_bf meclofenamate_bf sodium_bf given_bf patient_bf receiving_bf OTHER_DRUG ,_be dosage_be OTHER_DRUG reduced_af prevent_af excessive_af prolongation_af prothrombin_af time_af ._af"
2642,"Aspirin: Concurrent administration of aspirin may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.",aspirin,meclofenamate sodium,mechanism,"Aspirin:_bf Concurrent_bf administration_bf DRUG may_be lower_be meclofenamate_be sodium_be plasma_be levels_be ,_be possibly_be competing_be protein-binding_be sites_be ._be"
2643,"Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.",NSAIDs,aspirin,advise,"Aspirin:_bf As_bf DRUG ,_be concomitant_be administration_be Ponstel_be OTHER_DRUG generally_af recommended_af potential_af increased_af adverse_af effects_af ._af"
2644,"Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.",Ponstel,aspirin,advise,"Aspirin:_bf As_bf NSAIDs_bf ,_bf concomitant_bf administration_bf DRUG OTHER_DRUG generally_af recommended_af potential_af increased_af adverse_af effects_af ._af"
2645,Methotrexate: NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices.,NSAIDs,methotrexate,mechanism,Methotrexate:_bf DRUG reported_be competitively_be inhibit_be OTHER_DRUG accumulation_af rabbit_af kidney_af slices_af ._af
2646,Caution should be used when NSAIDs are administered concomitantly with methotrexate.,NSAIDs,methotrexate,advise,Caution_bf used_bf DRUG administered_be concomitantly_be OTHER_DRUG ._af
2647,ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.,NSAIDs,ACE inhibitors,effect,ACE_bf inhibitors:_bf Reports_bf suggest_bf DRUG may_be diminish_be antihypertensive_be effect_be ACE_be inhibitors_be ._be
2648,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.,NSAIDs,ACE inhibitors,advise,This_bf interaction_bf given_bf consideration_bf patients_bf taking_bf DRUG concomitantly_be ACE_be inhibitors_be ._be
2649,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,furosemide,effect,"Furosemide:_bf Clinical_bf studies_bf ,_bf well_bf post-marketing_bf observations_bf ,_bf shown_bf DRUG reduce_be natriuretic_be effect_be OTHER_DRUG thiazides_af patients_af ._af"
2650,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,thiazides,effect,"Furosemide:_bf Clinical_bf studies_bf ,_bf well_bf post-marketing_bf observations_bf ,_bf shown_bf DRUG reduce_be natriuretic_be effect_be furosemide_be OTHER_DRUG patients_af ._af"
2651,"During concomitant therapy of Ponstel with furosemide, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.",Ponstel,furosemide,advise,"During_bf concomitant_bf therapy_bf DRUG OTHER_DRUG ,_af patient_af observed_af closely_af signs_af renal_af failure_af ,_af well_af assure_af diuretic_af efficacy_af ._af"
2652,Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.,NSAIDs,lithium,mechanism,Lithium:_bf DRUG produced_be elevation_be plasma_be OTHER_DRUG levels_af reduction_af renal_af OTHER_DRUG clearance_af ._af
2653,Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.,NSAIDs,lithium,mechanism,Lithium:_bf DRUG produced_be elevation_be plasma_be OTHER_DRUG levels_af reduction_af renal_af OTHER_DRUG clearance_af ._af
2654,"Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.",NSAIDs,lithium,advise,"Thus_bf ,_bf DRUG OTHER_DRUG administered_af concurrently_af ,_af subjects_af observed_af carefully_af signs_af OTHER_DRUG toxicity_af ._af"
2655,"Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.",warfarin,NSAIDs,effect,"Warfarin:_bf The_bf effects_bf DRUG OTHER_DRUG GI_af bleeding_af synergistic_af ,_af users_af drugs_af together_af risk_af serious_af GI_af bleeding_af higher_af users_af either_af drug_af alone_af ._af"
2656,"Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.",magnesium hydroxide,mefenamic acid,mechanism,"Antacids:_bf In_bf single_bf dose_bf study_bf (n=6)_bf ,_bf ingestion_bf antacid_bf containing_bf 1_bf ._bf 7-gram_bf magnesium_bf hydroxide_bf 500-mg_bf mefenamic_bf acid_bf increased_bf Cmax_bf AUC_bf mefenamic_bf acid_bf 125%_bf 36%_bf ,_bf respectively_bf ._bf A_bf number_bf compounds_bf inhibitors_bf CYP2C9_bf including_bf fluconazole_bf ,_bf lovastatin_bf trimethoprim_bf ._bf"
2657,"Because of the danger of a potentially fatal prolongation of the QTc interval, halofantrine must not be given simultaneously with or subsequent to Mefloquine.",halofantrine,Mefloquine,advise,"Because_bf danger_bf potentially_bf fatal_bf prolongation_bf QTc_bf interval_bf ,_bf DRUG must_be given_be simultaneously_be subsequent_be OTHER_DRUG ._af"
2658,"Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.",Mefloquine,quinine,effect,"Concomitant_bf administration_bf DRUG related_be compounds_be (eg_be ,_be OTHER_DRUG ,_af quinidine_af chloroquine)_af may_af produce_af electrocardiographic_af abnormalities_af increase_af risk_af convulsions_af ._af"
2659,"Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.",Mefloquine,quinidine,effect,"Concomitant_bf administration_bf DRUG related_be compounds_be (eg_be ,_be quinine_be ,_be OTHER_DRUG chloroquine)_af may_af produce_af electrocardiographic_af abnormalities_af increase_af risk_af convulsions_af ._af"
2660,"Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.",Mefloquine,chloroquine,effect,"Concomitant_bf administration_bf DRUG related_be compounds_be (eg_be ,_be quinine_be ,_be quinidine_be chloroquine)_be may_be produce_be electrocardiographic_be abnormalities_be increase_be risk_be convulsions_be ._be"
2661,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,anti-arrhythmic,effect,"This_bf appears_bf clinically_bf relevant_bf interaction_bf kind_bf DRUG ,_be although_be theoretically_be ,_be coadministration_be drugs_be known_be alter_be cardiac_be conduction_be (eg_be ,_be OTHER_DRUG beta-adrenergic_af blocking_af agents_af ,_af calcium_af channel_af blockers_af ,_af antihistamines_af H1-blocking_af agents_af ,_af tricyclic_af antidepressants_af phenothiazines)_af might_af also_af contribute_af prolongation_af QTc_af interval_af ._af"
2662,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,beta-adrenergic blocking agents,effect,"This_bf appears_bf clinically_bf relevant_bf interaction_bf kind_bf DRUG ,_be although_be theoretically_be ,_be coadministration_be drugs_be known_be alter_be cardiac_be conduction_be (eg_be ,_be anti-arrhythmic_be beta-adrenergic_be blocking_be agents_be ,_be calcium_be channel_be blockers_be ,_be antihistamines_be H1-blocking_be agents_be ,_be tricyclic_be antidepressants_be phenothiazines)_be might_be also_be contribute_be prolongation_be QTc_be interval_be ._be"
2663,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,calcium channel blockers,effect,"This_bf appears_bf clinically_bf relevant_bf interaction_bf kind_bf DRUG ,_be although_be theoretically_be ,_be coadministration_be drugs_be known_be alter_be cardiac_be conduction_be (eg_be ,_be anti-arrhythmic_be beta-adrenergic_be blocking_be agents_be ,_be calcium_be channel_be blockers_be ,_be antihistamines_be H1-blocking_be agents_be ,_be tricyclic_be antidepressants_be phenothiazines)_be might_be also_be contribute_be prolongation_be QTc_be interval_be ._be"
2664,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,antihistamines,effect,"This_bf appears_bf clinically_bf relevant_bf interaction_bf kind_bf DRUG ,_be although_be theoretically_be ,_be coadministration_be drugs_be known_be alter_be cardiac_be conduction_be (eg_be ,_be anti-arrhythmic_be beta-adrenergic_be blocking_be agents_be ,_be calcium_be channel_be blockers_be ,_be OTHER_DRUG H1-blocking_af agents_af ,_af tricyclic_af antidepressants_af phenothiazines)_af might_af also_af contribute_af prolongation_af QTc_af interval_af ._af"
2665,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,H1-blocking agents,effect,"This_bf appears_bf clinically_bf relevant_bf interaction_bf kind_bf DRUG ,_be although_be theoretically_be ,_be coadministration_be drugs_be known_be alter_be cardiac_be conduction_be (eg_be ,_be anti-arrhythmic_be beta-adrenergic_be blocking_be agents_be ,_be calcium_be channel_be blockers_be ,_be antihistamines_be H1-blocking_be agents_be ,_be tricyclic_be antidepressants_be phenothiazines)_be might_be also_be contribute_be prolongation_be QTc_be interval_be ._be"
2666,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,tricyclic antidepressants,effect,"This_bf appears_bf clinically_bf relevant_bf interaction_bf kind_bf DRUG ,_be although_be theoretically_be ,_be coadministration_be drugs_be known_be alter_be cardiac_be conduction_be (eg_be ,_be anti-arrhythmic_be beta-adrenergic_be blocking_be agents_be ,_be calcium_be channel_be blockers_be ,_be antihistamines_be H1-blocking_be agents_be ,_be tricyclic_be antidepressants_be phenothiazines)_be might_be also_be contribute_be prolongation_be QTc_be interval_be ._be"
2667,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,phenothiazines,effect,"This_bf appears_bf clinically_bf relevant_bf interaction_bf kind_bf DRUG ,_be although_be theoretically_be ,_be coadministration_be drugs_be known_be alter_be cardiac_be conduction_be (eg_be ,_be anti-arrhythmic_be beta-adrenergic_be blocking_be agents_be ,_be calcium_be channel_be blockers_be ,_be antihistamines_be H1-blocking_be agents_be ,_be tricyclic_be antidepressants_be phenothiazines)_be might_be also_be contribute_be prolongation_be QTc_be interval_be ._be"
2668,"In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",anticonvulsant,Mefloquine,effect,"In_bf patients_bf taking_bf DRUG (eg_be ,_be valproic_be acid_be ,_be carbamazepine_be ,_be phenobarbital_be phenytoin)_be ,_be concomitant_be use_be OTHER_DRUG may_af reduce_af seizure_af control_af lowering_af plasma_af levels_af DRUG ._af"
2669,"In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",valproic acid,Mefloquine,effect,"In_bf patients_bf taking_bf anticonvulsant_bf (eg_bf ,_bf valproic_bf acid_bf ,_bf carbamazepine_bf ,_bf phenobarbital_bf phenytoin)_bf ,_bf concomitant_bf use_bf OTHER_DRUG may_be reduce_be seizure_be control_be lowering_be plasma_be levels_be anticonvulsant_be ._be"
2670,"In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",carbamazepine,Mefloquine,effect,"In_bf patients_bf taking_bf anticonvulsant_bf (eg_bf ,_bf valproic_bf acid_bf ,_bf DRUG ,_be phenobarbital_be phenytoin)_be ,_be concomitant_be use_be OTHER_DRUG may_af reduce_af seizure_af control_af lowering_af plasma_af levels_af anticonvulsant_af ._af"
2671,"In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",phenobarbital,Mefloquine,effect,"In_bf patients_bf taking_bf anticonvulsant_bf (eg_bf ,_bf valproic_bf acid_bf ,_bf carbamazepine_bf ,_bf DRUG phenytoin)_be ,_be concomitant_be use_be OTHER_DRUG may_af reduce_af seizure_af control_af lowering_af plasma_af levels_af anticonvulsant_af ._af"
2672,"In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",phenytoin,Mefloquine,effect,"In_bf patients_bf taking_bf anticonvulsant_bf (eg_bf ,_bf valproic_bf acid_bf ,_bf carbamazepine_bf ,_bf phenobarbital_bf phenytoin)_bf ,_bf concomitant_bf use_bf OTHER_DRUG may_be reduce_be seizure_be control_be lowering_be plasma_be levels_be anticonvulsant_be ._be"
2673,"When Mefloquine is taken concurrently with oral live typhoid vaccines, attenuation of immunization cannot be excluded.",Mefloquine,live typhoid vaccines,effect,"When_bf DRUG taken_be concurrently_be oral_be live_be typhoid_be vaccines_be ,_be attenuation_be immunization_be cannot_be excluded_be ._be"
2674,"Nevertheless, the effects of Mefloquine on travelers receiving comedication, particularly diabetics or patients using anticoagulants, should be checked before departure.",Mefloquine,anticoagulants,advise,"Nevertheless_bf ,_bf effects_bf DRUG travelers_be receiving_be comedication_be ,_be particularly_be diabetics_be patients_be using_be OTHER_DRUG ,_af checked_af departure_af ._af"
2675,Cholestyramine-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of vitamin K.,cholestyramine,vitamin K,mechanism,Cholestyramine-Concomitant_bf intake_bf DRUG vitamin_be K_be may_be reduce_be absorption_be vitamin_be K_be ._be
2676,Colestipol-Concomitant intake of colestipol and vitamin K may reduce the absorption of vitamin K.,colestipol,vitamin K,mechanism,Colestipol-Concomitant_bf intake_bf DRUG vitamin_be K_be may_be reduce_be absorption_be vitamin_be K_be ._be
2677,Mineral Oil-Concomitant intake of mineral oil and vitamin K may reduce the absorption of vitamin K.,mineral oil,vitamin K,mechanism,Mineral_bf Oil-Concomitant_bf intake_bf mineral_bf oil_bf vitamin_bf K_bf may_bf reduce_bf absorption_bf vitamin_bf K_bf ._bf
2678,Orlistat-Orlistat may decrease the absorption of vitamin K.,Orlistat,vitamin K,mechanism,Orlistat-Orlistat_bf may_bf decrease_bf absorption_bf vitamin_bf K_bf ._bf
2679,Warfarin-Vitamin K can antagonize the effect of warfarin,Vitamin K,warfarin,effect,Warfarin-Vitamin_bf K_bf antagonize_bf effect_bf OTHER_DRUG
2680,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,psychoactive drugs,advise,"DRUG administered_be caution_be patients_be taking_be psychoactive_be drugs_be CNS_be depressants_be ,_be including_be alcohol_be ,_be barbiturates_be narcotic_be analgesics_be ,_be history_be psychiatric_be disorder_be (including_be manic-depressive_be illness_be schizophrenia)_be ._be"
2681,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,CNS depressants,advise,"DRUG administered_be caution_be patients_be taking_be psychoactive_be drugs_be CNS_be depressants_be ,_be including_be alcohol_be ,_be barbiturates_be narcotic_be analgesics_be ,_be history_be psychiatric_be disorder_be (including_be manic-depressive_be illness_be schizophrenia)_be ._be"
2682,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,alcohol,advise,"DRUG administered_be caution_be patients_be taking_be psychoactive_be drugs_be CNS_be depressants_be ,_be including_be OTHER_DRUG ,_af barbiturates_af narcotic_af analgesics_af ,_af history_af psychiatric_af disorder_af (including_af manic-depressive_af illness_af schizophrenia)_af ._af"
2683,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,barbiturates,advise,"DRUG administered_be caution_be patients_be taking_be psychoactive_be drugs_be CNS_be depressants_be ,_be including_be alcohol_be ,_be OTHER_DRUG narcotic_af analgesics_af ,_af history_af psychiatric_af disorder_af (including_af manic-depressive_af illness_af schizophrenia)_af ._af"
2684,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,narcotic analgesics,advise,"DRUG administered_be caution_be patients_be taking_be psychoactive_be drugs_be CNS_be depressants_be ,_be including_be alcohol_be ,_be barbiturates_be narcotic_be analgesics_be ,_be history_be psychiatric_be disorder_be (including_be manic-depressive_be illness_be schizophrenia)_be ._be"
2685,"Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.",Nabilone,diazepam,effect,"DRUG shown_be additive_be CNS_be depressant_be effect_be given_be either_be OTHER_DRUG ,_af secobarbitone_af sodium_af ,_af alcohol_af codeine_af ._af"
2686,"Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.",Nabilone,secobarbitone sodium,effect,"DRUG shown_be additive_be CNS_be depressant_be effect_be given_be either_be diazepam_be ,_be secobarbitone_be sodium_be ,_be alcohol_be codeine_be ._be"
2687,"Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.",Nabilone,alcohol,effect,"DRUG shown_be additive_be CNS_be depressant_be effect_be given_be either_be diazepam_be ,_be secobarbitone_be sodium_be ,_be OTHER_DRUG codeine_af ._af"
2688,"Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.",Nabilone,codeine,effect,"DRUG shown_be additive_be CNS_be depressant_be effect_be given_be either_be diazepam_be ,_be secobarbitone_be sodium_be ,_be alcohol_be OTHER_DRUG ._af"
2689,Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.,nabumetone,warfarin,advise,Caution_bf exercised_bf administering_bf DRUG OTHER_DRUG since_af interactions_af seen_af NSAIDs_af ._af
2690,Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.,warfarin,NSAIDs,int,Caution_bf exercised_bf administering_bf nabumetone_bf DRUG since_be interactions_be seen_be OTHER_DRUG ._af
2691,"When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: Anesthetics, general: exaggeration of the hypotension induced by general anesthetics.",beta-adrenergic receptor blocking agents,Anesthetics,int,"When_bf administered_bf concurrently_bf ,_bf following_bf drugs_bf may_bf interact_bf beta-adrenergic_bf receptor_bf blocking_bf agents:_bf OTHER_DRUG ,_be general:_be exaggeration_be hypotension_be induced_be general_be OTHER_DRUG ._af"
2692,"Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.",Tetracycline,penicillin,effect,"DRUG ,_be bacteriostatic_be antibiotic_be ,_be may_be antagonize_be bactericidal_be effect_be OTHER_DRUG concurrent_af use_af drugs_af avoided_af ._af"
2693,Elevated plasma levels of theophylline have been reported with concomitant quinolone use.,theophylline,quinolone,mechanism,Elevated_bf plasma_bf levels_bf DRUG reported_be concomitant_be OTHER_DRUG use_af ._af
2694,There have been reports of theophylline-related side effects in patients on concomitant therapy with quinolones and theophylline.,quinolones,theophylline,effect,There_bf reports_bf theophylline-related_bf side_bf effects_bf patients_bf concomitant_bf therapy_bf DRUG OTHER_DRUG ._af
2695,Quinolones have been shown to interfere with the metabolism of caffeine.,Quinolones,caffeine,mechanism,DRUG shown_be interfere_be metabolism_be OTHER_DRUG ._af
2696,"Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.",Quinolones,warfarin,effect,"DRUG ,_be including_be nalidixic_be acid_be ,_be may_be enhance_be effects_be oral_be anticoagulant_be OTHER_DRUG derivatives_af ._af"
2697,"Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.",nalidixic acid,warfarin,effect,"Quinolones_bf ,_bf including_bf nalidixic_bf acid_bf ,_bf may_bf enhance_bf effects_bf oral_bf anticoagulant_bf OTHER_DRUG derivatives_be ._be"
2698,Nitrofurantoin interferes with the therapeutic action of nalidixic acid.,Nitrofurantoin,nalidixic acid,effect,DRUG interferes_be therapeutic_be action_be nalidixic_be acid_be ._be
2699,"and Videx , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.",Videx,quinolones,mechanism,"DRUG ,_be (Didanosine)_be ,_be chewable/buffered_be tablets_be pediatric_be powder_be oral_be solution_be may_be substantially_be interfere_be absorption_be OTHER_DRUG ,_af resulting_af systemic_af levels_af considerably_af lower_af desired_af ._af"
2700,"and Videx , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.",Didanosine,quinolones,mechanism,"Videx_bf ,_bf (Didanosine)_bf ,_bf chewable/buffered_bf tablets_bf pediatric_bf powder_bf oral_bf solution_bf may_bf substantially_bf interfere_bf absorption_bf OTHER_DRUG ,_be resulting_be systemic_be levels_be considerably_be lower_be desired_be ._be"
2701,Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine.,quinolones,cyclosporine,mechanism,Elevated_bf serum_bf levels_bf OTHER_DRUG reported_be concomitant_be use_be DRUG OTHER_DRUG ._af
2702,"The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.",REVIA,disulfiram,effect,"The_bf safety_bf efficacy_bf concomitant_bf use_bf DRUG OTHER_DRUG unknown_af ,_af concomitant_af use_af two_af potentially_af hepatotoxic_af medications_af ordinarily_af recommended_af unless_af probable_af benefits_af outweigh_af known_af risks_af ._af"
2703,Lethargy and somnolence have been reported following doses of REVIA and thioridazine.,REVIA,thioridazine,effect,Lethargy_bf somnolence_bf reported_bf following_bf doses_bf DRUG OTHER_DRUG ._af
2704,"Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.",REVIA,opioid,effect,"Patients_bf taking_bf DRUG may_be benefit_be OTHER_DRUG containing_af medicines_af ,_af cough_af cold_af preparations_af ,_af antidiarrheal_af preparations_af ,_af OTHER_DRUG analgesics_af ._af"
2705,"Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.",REVIA,opioid analgesics,effect,"Patients_bf taking_bf DRUG may_be benefit_be opioid_be containing_be medicines_be ,_be cough_be cold_be preparations_be ,_be antidiarrheal_be preparations_be ,_be opioid_be analgesics_be ._be"
2706,"In an emergency situation when opioid analgesia must be administered to a patient receiving REVIA, the amount of opioid required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.",REVIA,opioid,effect,"In_bf emergency_bf situation_bf OTHER_DRUG analgesia_be must_be administered_be patient_be receiving_be DRUG ,_af amount_af OTHER_DRUG required_af may_af greater_af usual_af ,_af resulting_af respiratory_af depression_af may_af deeper_af prolonged_af ._af"
2707,The use of NSAIDs in patients who are receiving ACE inhibitors may potentiate renal disease states.,NSAIDs,ACE inhibitors,effect,The_bf use_bf DRUG patients_be receiving_be ACE_be inhibitors_be may_be potentiate_be renal_be disease_be states_be ._be
2708,"Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.",naproxen,aspirin,advise,"Concomitant_bf administration_bf DRUG OTHER_DRUG recommended_af DRUG displaced_af binding_af sites_af concomitant_af administration_af OTHER_DRUG ,_af resulting_af lower_af plasma_af concentrations_af peak_af plasma_af levels_af ._af"
2709,"Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.",naproxen,aspirin,advise,"Concomitant_bf administration_bf DRUG OTHER_DRUG recommended_af DRUG displaced_af binding_af sites_af concomitant_af administration_af OTHER_DRUG ,_af resulting_af lower_af plasma_af concentrations_af peak_af plasma_af levels_af ._af"
2710,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.,Naproxen,propranolol,effect,DRUG NSAIDs_be reduce_be antihypertensive_be effect_be OTHER_DRUG beta-blockers_af ._af
2711,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.,Naproxen,beta-blockers,effect,DRUG NSAIDs_be reduce_be antihypertensive_be effect_be propranolol_be OTHER_DRUG ._af
2712,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.,NSAIDs,propranolol,effect,Naproxen_bf DRUG reduce_be antihypertensive_be effect_be OTHER_DRUG beta-blockers_af ._af
2713,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.,NSAIDs,beta-blockers,effect,Naproxen_bf DRUG reduce_be antihypertensive_be effect_be propranolol_be OTHER_DRUG ._af
2714,Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.,Probenecid,naproxen,mechanism,DRUG given_be concurrently_be increases_be OTHER_DRUG anion_af plasma_af levels_af extends_af plasma_af half-life_af significantly_af ._af
2715,Caution should be used if naproxen is administered concomitantly with methotrexate.,naproxen,methotrexate,advise,Caution_bf used_bf DRUG administered_be concomitantly_be OTHER_DRUG ._af
2716,"Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.",Naproxen,methotrexate,mechanism,"DRUG ,_be DRUG sodium_af NSAIDs_af reported_af reduce_af tubular_af secretion_af OTHER_DRUG animal_af model_af ,_af possibly_af increasing_af toxicity_af OTHER_DRUG ._af"
2717,"Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.",naproxen sodium,methotrexate,mechanism,"Naproxen_bf ,_bf naproxen_bf sodium_bf NSAIDs_bf reported_bf reduce_bf tubular_bf secretion_bf OTHER_DRUG animal_be model_be ,_be possibly_be increasing_be toxicity_be OTHER_DRUG ._af"
2718,"Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.",NSAIDs,methotrexate,mechanism,"Naproxen_bf ,_bf naproxen_bf sodium_bf DRUG reported_be reduce_be tubular_be secretion_be OTHER_DRUG animal_af model_af ,_af possibly_af increasing_af toxicity_af OTHER_DRUG ._af"
2719,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.",ergotamine,naratriptan,advise,"Because_bf theoretical_bf basis_bf effects_bf may_bf additive_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf dihydroergotamine_bf methysergide)_bf OTHER_DRUG within_be 24_be hours_be contraindicated_be ._be"
2720,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.",ergot-type medications,naratriptan,advise,"Because_bf theoretical_bf basis_bf effects_bf may_bf additive_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf dihydroergotamine_bf methysergide)_bf OTHER_DRUG within_be 24_be hours_be contraindicated_be ._be"
2721,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.",dihydroergotamine,naratriptan,advise,"Because_bf theoretical_bf basis_bf effects_bf may_bf additive_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf DRUG methysergide)_be OTHER_DRUG within_af 24_af hours_af contraindicated_af ._af"
2722,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.",methysergide,naratriptan,advise,"Because_bf theoretical_bf basis_bf effects_bf may_bf additive_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf dihydroergotamine_bf methysergide)_bf OTHER_DRUG within_be 24_be hours_be contraindicated_be ._be"
2723,"Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended.",naratriptan,5-HT1 agonists,advise,"Because_bf vasospastic_bf effects_bf may_bf additive_bf ,_bf coadministration_bf DRUG 5-HT1_be agonists_be within_be 24_be hours_be recommended_be ._be"
2724,"If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.",naratriptan,SSRI,advise,"If_bf concomitant_bf treatment_bf DRUG OTHER_DRUG clinically_af warranted_af ,_af appropriate_af observation_af patient_af advised_af ._af"
2725,"After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.",interferon beta-1a,TYSABRI,mechanism,"After_bf multiple_bf dosing_bf ,_bf interferon_bf beta-1a_bf (AVONEX_bf 30_bf mcg_bf IM_bf weekly)_bf reduced_bf OTHER_DRUG clearance_be approximately_be 30%_be ._be"
2726,"After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.",AVONEX,TYSABRI,mechanism,"After_bf multiple_bf dosing_bf ,_bf interferon_bf beta-1a_bf (AVONEX_bf 30_bf mcg_bf IM_bf weekly)_bf reduced_bf OTHER_DRUG clearance_be approximately_be 30%_be ._be"
2727,Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide.,Starlix,tolbutamide,mechanism,DRUG potential_be inhibitor_be CYP2C9_be isoenzyme_be vivo_be indicated_be ability_be inhibit_be vitro_be metabolism_be OTHER_DRUG ._af
2728,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",nonsteroidal anti-inflammatory agents,Starlix,effect,"Certain_bf drugs_bf ,_bf including_bf nonsteroidal_bf anti-inflammatory_bf agents_bf (NSAIDs)_bf ,_bf salicylates_bf ,_bf monoamine_bf oxidase_bf inhibitors_bf ,_bf non-selective_bf beta-adrenergic-blocking_bf agents_bf may_bf potentiate_bf hypoglycemic_bf action_bf OTHER_DRUG oral_be antidiabetic_be drugs_be ._be"
2729,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",nonsteroidal anti-inflammatory agents,antidiabetic drugs,effect,"Certain_bf drugs_bf ,_bf including_bf nonsteroidal_bf anti-inflammatory_bf agents_bf (NSAIDs)_bf ,_bf salicylates_bf ,_bf monoamine_bf oxidase_bf inhibitors_bf ,_bf non-selective_bf beta-adrenergic-blocking_bf agents_bf may_bf potentiate_bf hypoglycemic_bf action_bf Starlix_bf oral_bf antidiabetic_bf drugs_bf ._bf"
2730,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",NSAIDs,Starlix,effect,"Certain_bf drugs_bf ,_bf including_bf nonsteroidal_bf anti-inflammatory_bf agents_bf (NSAIDs)_bf ,_bf salicylates_bf ,_bf monoamine_bf oxidase_bf inhibitors_bf ,_bf non-selective_bf beta-adrenergic-blocking_bf agents_bf may_bf potentiate_bf hypoglycemic_bf action_bf OTHER_DRUG oral_be antidiabetic_be drugs_be ._be"
2731,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",NSAIDs,antidiabetic drugs,effect,"Certain_bf drugs_bf ,_bf including_bf nonsteroidal_bf anti-inflammatory_bf agents_bf (NSAIDs)_bf ,_bf salicylates_bf ,_bf monoamine_bf oxidase_bf inhibitors_bf ,_bf non-selective_bf beta-adrenergic-blocking_bf agents_bf may_bf potentiate_bf hypoglycemic_bf action_bf Starlix_bf oral_bf antidiabetic_bf drugs_bf ._bf"
2732,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",salicylates,Starlix,effect,"Certain_bf drugs_bf ,_bf including_bf nonsteroidal_bf anti-inflammatory_bf agents_bf (NSAIDs)_bf ,_bf DRUG ,_be monoamine_be oxidase_be inhibitors_be ,_be non-selective_be beta-adrenergic-blocking_be agents_be may_be potentiate_be hypoglycemic_be action_be OTHER_DRUG oral_af antidiabetic_af drugs_af ._af"
2733,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",salicylates,antidiabetic drugs,effect,"Certain_bf drugs_bf ,_bf including_bf nonsteroidal_bf anti-inflammatory_bf agents_bf (NSAIDs)_bf ,_bf DRUG ,_be monoamine_be oxidase_be inhibitors_be ,_be non-selective_be beta-adrenergic-blocking_be agents_be may_be potentiate_be hypoglycemic_be action_be Starlix_be oral_be antidiabetic_be drugs_be ._be"
2734,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",monoamine oxidase inhibitors,Starlix,effect,"Certain_bf drugs_bf ,_bf including_bf nonsteroidal_bf anti-inflammatory_bf agents_bf (NSAIDs)_bf ,_bf salicylates_bf ,_bf monoamine_bf oxidase_bf inhibitors_bf ,_bf non-selective_bf beta-adrenergic-blocking_bf agents_bf may_bf potentiate_bf hypoglycemic_bf action_bf OTHER_DRUG oral_be antidiabetic_be drugs_be ._be"
2735,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",monoamine oxidase inhibitors,antidiabetic drugs,effect,"Certain_bf drugs_bf ,_bf including_bf nonsteroidal_bf anti-inflammatory_bf agents_bf (NSAIDs)_bf ,_bf salicylates_bf ,_bf monoamine_bf oxidase_bf inhibitors_bf ,_bf non-selective_bf beta-adrenergic-blocking_bf agents_bf may_bf potentiate_bf hypoglycemic_bf action_bf Starlix_bf oral_bf antidiabetic_bf drugs_bf ._bf"
2736,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",non-selective beta-adrenergic-blocking agents,Starlix,effect,"Certain_bf drugs_bf ,_bf including_bf nonsteroidal_bf anti-inflammatory_bf agents_bf (NSAIDs)_bf ,_bf salicylates_bf ,_bf monoamine_bf oxidase_bf inhibitors_bf ,_bf non-selective_bf beta-adrenergic-blocking_bf agents_bf may_bf potentiate_bf hypoglycemic_bf action_bf OTHER_DRUG oral_be antidiabetic_be drugs_be ._be"
2737,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",non-selective beta-adrenergic-blocking agents,antidiabetic drugs,effect,"Certain_bf drugs_bf ,_bf including_bf nonsteroidal_bf anti-inflammatory_bf agents_bf (NSAIDs)_bf ,_bf salicylates_bf ,_bf monoamine_bf oxidase_bf inhibitors_bf ,_bf non-selective_bf beta-adrenergic-blocking_bf agents_bf may_bf potentiate_bf hypoglycemic_bf action_bf Starlix_bf oral_bf antidiabetic_bf drugs_bf ._bf"
2738,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",thiazides,Starlix,effect,"Certain_bf drugs_bf including_bf DRUG ,_be corticosteroids_be ,_be thyroid_be products_be ,_be sympathomimetics_be may_be reduce_be hypoglycemic_be action_be OTHER_DRUG oral_af antidiabetic_af drugs_af ._af"
2739,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",thiazides,antidiabetic drugs,effect,"Certain_bf drugs_bf including_bf DRUG ,_be corticosteroids_be ,_be thyroid_be products_be ,_be sympathomimetics_be may_be reduce_be hypoglycemic_be action_be Starlix_be oral_be antidiabetic_be drugs_be ._be"
2740,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",corticosteroids,Starlix,effect,"Certain_bf drugs_bf including_bf thiazides_bf ,_bf DRUG ,_be thyroid_be products_be ,_be sympathomimetics_be may_be reduce_be hypoglycemic_be action_be OTHER_DRUG oral_af antidiabetic_af drugs_af ._af"
2741,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",corticosteroids,antidiabetic drugs,effect,"Certain_bf drugs_bf including_bf thiazides_bf ,_bf DRUG ,_be thyroid_be products_be ,_be sympathomimetics_be may_be reduce_be hypoglycemic_be action_be Starlix_be oral_be antidiabetic_be drugs_be ._be"
2742,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",thyroid products,Starlix,effect,"Certain_bf drugs_bf including_bf thiazides_bf ,_bf corticosteroids_bf ,_bf thyroid_bf products_bf ,_bf sympathomimetics_bf may_bf reduce_bf hypoglycemic_bf action_bf OTHER_DRUG oral_be antidiabetic_be drugs_be ._be"
2743,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",thyroid products,antidiabetic drugs,effect,"Certain_bf drugs_bf including_bf thiazides_bf ,_bf corticosteroids_bf ,_bf thyroid_bf products_bf ,_bf sympathomimetics_bf may_bf reduce_bf hypoglycemic_bf action_bf Starlix_bf oral_bf antidiabetic_bf drugs_bf ._bf"
2744,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",sympathomimetics,Starlix,effect,"Certain_bf drugs_bf including_bf thiazides_bf ,_bf corticosteroids_bf ,_bf thyroid_bf products_bf ,_bf DRUG may_be reduce_be hypoglycemic_be action_be OTHER_DRUG oral_af antidiabetic_af drugs_af ._af"
2745,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",sympathomimetics,antidiabetic drugs,effect,"Certain_bf drugs_bf including_bf thiazides_bf ,_bf corticosteroids_bf ,_bf thyroid_bf products_bf ,_bf DRUG may_be reduce_be hypoglycemic_be action_be Starlix_be oral_be antidiabetic_be drugs_be ._be"
2746,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,Antiarrhythmics,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be astemizole_be ,_be terfenadine_be Antimigraine:_be ergot_be derivatives_be Antimycobacterial_be agents:_be rifampin_be Benzodiazepines_be midazolam_be ,_be triazolam_be GI_be motility_be agents:_be cisapride_be"
2747,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,amiodarone,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be OTHER_DRUG ,_af quinidine_af Antihistamines:_af astemizole_af ,_af terfenadine_af Antimigraine:_af ergot_af derivatives_af Antimycobacterial_af agents:_af rifampin_af Benzodiazepines_af midazolam_af ,_af triazolam_af GI_af motility_af agents:_af cisapride_af"
2748,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,quinidine,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be OTHER_DRUG Antihistamines:_af astemizole_af ,_af terfenadine_af Antimigraine:_af ergot_af derivatives_af Antimycobacterial_af agents:_af rifampin_af Benzodiazepines_af midazolam_af ,_af triazolam_af GI_af motility_af agents:_af cisapride_af"
2749,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,Antihistamines,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be astemizole_be ,_be terfenadine_be Antimigraine:_be ergot_be derivatives_be Antimycobacterial_be agents:_be rifampin_be Benzodiazepines_be midazolam_be ,_be triazolam_be GI_be motility_be agents:_be cisapride_be"
2750,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,astemizole,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be OTHER_DRUG ,_af terfenadine_af Antimigraine:_af ergot_af derivatives_af Antimycobacterial_af agents:_af rifampin_af Benzodiazepines_af midazolam_af ,_af triazolam_af GI_af motility_af agents:_af cisapride_af"
2751,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,terfenadine,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be astemizole_be ,_be OTHER_DRUG Antimigraine:_af ergot_af derivatives_af Antimycobacterial_af agents:_af rifampin_af Benzodiazepines_af midazolam_af ,_af triazolam_af GI_af motility_af agents:_af cisapride_af"
2752,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,ergot derivatives,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be astemizole_be ,_be terfenadine_be Antimigraine:_be ergot_be derivatives_be Antimycobacterial_be agents:_be rifampin_be Benzodiazepines_be midazolam_be ,_be triazolam_be GI_be motility_be agents:_be cisapride_be"
2753,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,Antimycobacterial agents,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be astemizole_be ,_be terfenadine_be Antimigraine:_be ergot_be derivatives_be Antimycobacterial_be agents:_be rifampin_be Benzodiazepines_be midazolam_be ,_be triazolam_be GI_be motility_be agents:_be cisapride_be"
2754,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,rifampin,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be astemizole_be ,_be terfenadine_be Antimigraine:_be ergot_be derivatives_be Antimycobacterial_be agents:_be OTHER_DRUG Benzodiazepines_af midazolam_af ,_af triazolam_af GI_af motility_af agents:_af cisapride_af"
2755,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,Benzodiazepines,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be astemizole_be ,_be terfenadine_be Antimigraine:_be ergot_be derivatives_be Antimycobacterial_be agents:_be rifampin_be OTHER_DRUG midazolam_af ,_af triazolam_af GI_af motility_af agents:_af cisapride_af"
2756,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,midazolam,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be astemizole_be ,_be terfenadine_be Antimigraine:_be ergot_be derivatives_be Antimycobacterial_be agents:_be rifampin_be Benzodiazepines_be OTHER_DRUG ,_af triazolam_af GI_af motility_af agents:_af cisapride_af"
2757,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,triazolam,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be astemizole_be ,_be terfenadine_be Antimigraine:_be ergot_be derivatives_be Antimycobacterial_be agents:_be rifampin_be Benzodiazepines_be midazolam_be ,_be OTHER_DRUG GI_af motility_af agents:_af cisapride_af"
2758,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,cisapride,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be astemizole_be ,_be terfenadine_be Antimigraine:_be ergot_be derivatives_be Antimycobacterial_be agents:_be rifampin_be Benzodiazepines_be midazolam_be ,_be triazolam_be GI_be motility_be agents:_be OTHER_DRUG"
2759,Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin,VIRACEPT,Antimycobacterial agents,advise,Drugs_bf Which_bf Require_bf Dose_bf Reduction_bf When_bf Coadminstered_bf With_bf DRUG Antimycobacterial_be agents:_be rifabutin_be
2760,Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin,VIRACEPT,rifabutin,advise,Drugs_bf Which_bf Require_bf Dose_bf Reduction_bf When_bf Coadminstered_bf With_bf DRUG Antimycobacterial_be agents:_be OTHER_DRUG
2761,"therefore, VIRACEPT should not be administered concurrently with terfenadine because of the potential for serious and/or life-threatening cardiac arrhythmias.",VIRACEPT,terfenadine,advise,"therefore_bf ,_bf DRUG administered_be concurrently_be OTHER_DRUG potential_af serious_af and/or_af life-threatening_af cardiac_af arrhythmias_af ._af"
2762,"Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole.",VIRACEPT,astemizole,advise,"Because_bf similar_bf interaction_bf likely_bf ,_bf DRUG also_be administered_be concurrently_be OTHER_DRUG ._af"
2763,Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.,indinavir,VIRACEPT,mechanism,Indinavir:_bf Coadministration_bf DRUG OTHER_DRUG resulted_af 83%_af increase_af nelfinavir_af plasma_af AUC_af 51%_af increase_af DRUG plasma_af A_af ._af C_af ._af
2764,Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.,ritonavir,VIRACEPT,mechanism,Ritonavir:_bf Coadministration_bf DRUG OTHER_DRUG resulted_af 152%_af increase_af nelfinavir_af plasma_af AUC_af little_af change_af DRUG plasma_af A_af ._af C_af ._af
2765,Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.,saquinavir,VIRACEPT,mechanism,Saquinavir:_bf Coadministration_bf DRUG (using_be experimental_be soft-gelatin_be capsule_be formulation_be DRUG 1200mg)_af OTHER_DRUG resulted_af 18%_af increase_af nelfinavir_af plasma_af AUC_af 4-fold_af increase_af DRUG plasma_af A_af ._af C_af ._af
2766,Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.,ketoconazole,VIRACEPT,mechanism,Ketoconazole:_bf Coadministration_bf DRUG OTHER_DRUG resulted_af 35%_af increase_af nelfinavir_af plasma_af A_af ._af C_af ._af
2767,"therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.",nelfinavir,didanosine,advise,"therefore_bf ,_bf DRUG administered_be (with_be food)_be one_be hour_be two_be hours_be OTHER_DRUG ._af"
2768,A dose adjustment is not needed when zidovudine is administered with VIRACEPT.,zidovudine,VIRACEPT,advise,A_bf dose_bf adjustment_bf needed_bf DRUG administered_be OTHER_DRUG ._af
2769,Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.,rifabutin,VIRACEPT,mechanism,Rifabutin:_bf Coadministration_bf DRUG OTHER_DRUG resulted_af 32%_af decrease_af nelfinavir_af plasma_af AUC_af 207%_af increase_af DRUG plasma_af A_af ._af C_af ._af
2770,It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.,rifabutin,VIRACEPT,advise,It_bf recommended_bf dose_bf DRUG reduced_be one-half_be usual_be dose_be administered_be OTHER_DRUG ._af
2771,Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.,rifampin,VIRACEPT,mechanism,Rifampin:_bf Coadministration_bf DRUG OTHER_DRUG resulted_af 82%_af decrease_af nelfinavir_af plasma_af A_af ._af C_af ._af
2772,VIRACEPT and rifampin should not be coadministered.,VIRACEPT,rifampin,advise,DRUG OTHER_DRUG coadministered_af ._af
2773,Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.,VIRACEPT,OVCON-35,mechanism,Ethinyl_bf Estradiol_bf Norethindrone:_bf Coadministration_bf DRUG OTHER_DRUG resulted_af 47%_af decrease_af ethinyl_af estradiol_af 18%_af decrease_af norethindrone_af plasma_af concentrations_af ._af
2774,"These antibiotics should be used in the myasthenic patient only where definitely indicated, and then careful adjustment should be made of adjunctive anticholinesterase dosage.",antibiotics,anticholinesterase,advise,"These_bf DRUG used_be myasthenic_be patient_be definitely_be indicated_be ,_be careful_be adjustment_be made_be adjunctive_be OTHER_DRUG dosage_af ._af"
2775,Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.,Netilmicin,loop diuretics,advise,DRUG administered_be concomitantly_be potent_be loop_be diuretics_be furosemide_be ethacrynic_be acid_be potential_be ototoxicity_be enhanced_be combination_be ._be
2776,Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.,Netilmicin,furosemide,advise,DRUG administered_be concomitantly_be potent_be loop_be diuretics_be OTHER_DRUG ethacrynic_af acid_af potential_af ototoxicity_af enhanced_af combination_af ._af
2777,Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.,Netilmicin,ethacrynic acid,advise,DRUG administered_be concomitantly_be potent_be loop_be diuretics_be furosemide_be ethacrynic_be acid_be potential_be ototoxicity_be enhanced_be combination_be ._be
2778,The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex.,nevirapine,warfarin,int,The_bf vitro_bf interaction_bf DRUG antithrombotic_be agent_be OTHER_DRUG complex_af ._af
2779,"When warfarin is co-administered with nevirapine, anticoagulation levels should be monitored frequently.",warfarin,nevirapine,advise,"When_bf DRUG co-administered_be OTHER_DRUG ,_af anticoagulation_af levels_af monitored_af frequently_af ._af"
2780,Clarithromycin exposure was significantly decreased by nevirapine;,Clarithromycin,nevirapine,mechanism,DRUG exposure_be significantly_be decreased_be nevirapine;_be
2781,"Oral contraceptives and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking nevirapine, since nevirapinemay lower the plasma levels of thesemedications.",contraceptives,nevirapine,advise,"Oral_bf DRUG hormonalmethods_be birth_be control_be usedas_be sole_be method_be contraception_be inwomen_be taking_be OTHER_DRUG ,_af since_af nevirapinemay_af lower_af plasma_af levels_af thesemedications_af ._af"
2782,Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.,Nevirapine,ketoconazole,advise,DRUG OTHER_DRUG beadministered_af concomitantly_af becausedecreases_af OTHER_DRUG plasmaconcentrations_af may_af reduce_af efficacy_af drug_af ._af
2783,A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.,lopinavir,nevirapine,advise,A_bf dose_bf increase_bf lopinavir/ritonavir_bf 533/133_bf mg_bf twice_bf daily_bf food_bf isrecommended_bf combination_bf OTHER_DRUG ._be
2784,A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.,ritonavir,nevirapine,advise,A_bf dose_bf increase_bf lopinavir/ritonavir_bf 533/133_bf mg_bf twice_bf daily_bf food_bf isrecommended_bf combination_bf OTHER_DRUG ._be
2785,Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.,Methadone,nevirapine,advise,DRUG levels_be may_be decreased;_be increased_be dosages_be may_be required_be prevent_be symptoms_be opiate_be withdrawal_be ._be DRUG maintained_af patients_af beginning_af OTHER_DRUG therapy_af monitored_af forevidence_af withdrawal_af DRUG dose_af adjusted_af accordingly_af ._af
2786,Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.,Nevirapine,rifampin,advise,DRUG OTHER_DRUG beadministered_af concomitantly_af becausedecreases_af DRUG plasmaconcentrations_af may_af reduce_af efficacy_af ofthe_af drug_af ._af
2787,"aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone.",nevirapine,methadone,effect,"aBased_bf reports_bf narcotic_bf withdrawal_bf syndrome_bf patients_bf treated_bf DRUG OTHER_DRUG concurrently_af ,_af evidence_af decreased_af plasma_af concentrations_af OTHER_DRUG ._af"
2788,Interactions for Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.,Nicotinic acid,ganglionic blocking agents,effect,Interactions_bf Vitamin_bf B3_bf (Niacin):_bf Antihypertensive_bf Therapy:_bf Nicotinic_bf acid_bf may_bf potentiate_bf effects_bf ganglionic_bf blocking_bf agents_bf vasoactive_bf drugs_bf resulting_bf postural_bf hypotension_bf ._bf
2789,Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.,aspirin,nicotinic acid,mechanism,Aspirin:_bf Concomitant_bf DRUG may_be decrease_be metabolic_be clearance_be nicotinic_be acid_be ._be
2790,Cimetidine: Cimetidine increases nicardipine HCl plasma levels.,Cimetidine,nicardipine HCl,mechanism,Cimetidine:_bf DRUG increases_be nicardipine_be HCl_be plasma_be levels_be ._be
2791,Digoxin: Some calcium blockers may increase the concentration of digitalis preparations in the blood.,calcium blockers,digitalis preparations,mechanism,Digoxin:_bf Some_bf calcium_bf blockers_bf may_bf increase_bf concentration_bf digitalis_bf preparations_bf blood_bf ._bf
2792,"Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.",digoxin,nicardipine HCl,advise,"Nicardipine_bf HCl_bf usually_bf alter_bf plasma_bf levels_bf DRUG ,_be however_be ,_be serum_be DRUG levels_af evaluated_af concomitant_af therapy_af nicardipine_af HCl_af initiated_af ._af"
2793,"Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine.",cyclosporine,nicardipine,advise,"Plasma_bf concentrations_bf DRUG therefore_be closely_be monitored_be ,_be dosage_be reduced_be accordingly_be ,_be patients_be treated_be OTHER_DRUG ._af"
2794,"Beta-adrenergic Blocking Agents: Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.",nifedipine,beta-blocking agents,effect,"Beta-adrenergic_bf Blocking_bf Agents:_bf Experience_bf 1400_bf patients_bf non-comparative_bf clinical_bf trial_bf shown_bf concomitant_bf administration_bf DRUG beta-blocking_be agents_be usually_be well_be tolerated_be ,_be occasional_be literature_be reports_be suggesting_be combination_be may_be increase_be likelihood_be congestive_be heart_be failure_be ,_be severe_be hypotension_be exacerbation_be angina_be ._be"
2795,"Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.",digoxin,nifedipine,int,"Digitalis:_bf Immediate_bf Release_bf Capsules:_bf Since_bf isolated_bf reports_bf patients_bf elevated_bf DRUG levels_be ,_be possible_be interaction_be DRUG OTHER_DRUG ,_af recommended_af DRUG levels_af monitored_af initiating_af ,_af adjusting_af ,_af discontinuing_af OTHER_DRUG avoid_af possible_af over-_af under-digitalization_af ._af"
2796,"Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.",digoxin,nifedipine,advise,"Digitalis:_bf Immediate_bf Release_bf Capsules:_bf Since_bf isolated_bf reports_bf patients_bf elevated_bf DRUG levels_be ,_be possible_be interaction_be DRUG OTHER_DRUG ,_af recommended_af DRUG levels_af monitored_af initiating_af ,_af adjusting_af ,_af discontinuing_af OTHER_DRUG avoid_af possible_af over-_af under-digitalization_af ._af"
2797,Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.,digoxin,digoxin,mechanism,Extended_bf Release_bf Tablets:_bf Administration_bf nifedipine_bf DRUG increased_be DRUG levels_af 9_af 12_af normal_af volunteers_af ._af
2798,"Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.",digoxin,nifedipine,advise,"Since_bf isolated_bf reports_bf patients_bf elevated_bf DRUG levels_be ,_be recommended_be DRUG levels_af monitored_af initiating_af ,_af adjusting_af ,_af discontinuing_af OTHER_DRUG avoid_af possible_af over-_af under-digitalization_af ._af"
2799,Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).,quinidine,nifedipine,mechanism,Quinidine:_bf Immediate_bf Release_bf Capsules:_bf There_bf rare_bf reports_bf interaction_bf DRUG OTHER_DRUG (with_af decreased_af plasma_af level_af quinidine)_af ._af
2800,Coumarin Anticoagulants: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulants to whom nifedipine was administered.,coumarin anticoagulants,nifedipine,effect,Coumarin_bf Anticoagulants:_bf There_bf rare_bf reports_bf increased_bf prothrombin_bf time_bf patients_bf taking_bf coumarin_bf anticoagulants_bf OTHER_DRUG administered_be ._be
2801,Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.,cimetidine,nifedipine,mechanism,Cimetidine:_bf A_bf study_bf 6_bf healthy_bf volunteers_bf shown_bf significant_bf increase_bf peak_bf OTHER_DRUG plasma_be levels_be (80%)_be area-under-the-curve_be (74%)_be 1_be week_be course_be DRUG 1000_af mg_af per_af day_af OTHER_DRUG 40_af mg_af per_af day_af ._af
2802,"If nifedipine therapy is initiated in a patient currently receiving cimetidine, cautious titration is advised.",nifedipine,cimetidine,advise,"If_bf DRUG therapy_be initiated_be patient_be currently_be receiving_be OTHER_DRUG ,_af cautious_af titration_af advised_af ._af"
2803,"For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.",vitamin K antagonists,nilutamide,advise,"For_bf example_bf ,_bf vitamin_bf K_bf antagonists_bf administered_bf concomitantly_bf OTHER_DRUG ,_be prothrombin_be time_be carefully_be monitored_be necessary_be ,_be dosage_be vitamin_be K_be antagonists_be reduced_be ._be"
2804,A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.,nisoldipine,cimetidine 400 mg,mechanism,A_bf 30_bf 45%_bf increase_bf AUC_bf Cmax_bf DRUG observed_be concomitant_be administration_be cimetidine_be 400_be mg_be twice_be daily_be ._be
2805,Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.,phenytoin,SULAR,mechanism,Coadministration_bf DRUG 40_be mg_be OTHER_DRUG tablets_af epileptic_af patients_af lowered_af nisoldipine_af plasma_af concentrations_af undetectable_af levels_af ._af
2806,Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.,SULAR,phenytoin,advise,Coadministration_bf DRUG OTHER_DRUG known_af CYP3A4_af inducer_af avoided_af alternative_af antihypertensive_af therapy_af considered_af ._af
2807,Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.,Propranolol,nisoldipine,effect,DRUG attenuated_be heart_be rate_be increase_be following_be administration_be immediate_be release_be OTHER_DRUG ._af
2808,The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.,SULAR,atenolol,effect,The_bf blood_bf pressure_bf effect_bf DRUG tended_be greater_be patients_be OTHER_DRUG patients_af antihypertensive_af therapy_af ._af
2809,"Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.",Quinidine,nisoldipine,mechanism,"DRUG 648_be mg_be bid_be decreased_be bioavailability_be (AUC)_be OTHER_DRUG 26%_af ,_af peak_af concentration_af ._af"
2810,"The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%.",nisoldipine,quinidine,mechanism,"The_bf immediate_bf release_bf ,_bf coat-core_bf formulation_bf DRUG increased_be plasma_be OTHER_DRUG concentrations_af 20%_af ._af"
2811,"Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin).",nitazoxanide,warfarin,mechanism,"Therefore_bf ,_bf caution_bf used_bf administering_bf DRUG concurrently_be highly_be plasma_be protein-bound_be drugs_be narrow_be therapeutic_be indices_be ,_be competition_be binding_be sites_be may_be occur_be (e_be ._be g_be ._be ,_be warfarin)_be ._be"
2812,"Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.",nitric oxide donor compounds,INOmax,effect,"Although_bf study_bf data_bf evaluate_bf possibility_bf ,_bf nitric_bf oxide_bf donor_bf compounds_bf ,_bf including_bf sodium_bf nitroprusside_bf nitroglycerin_bf ,_bf may_bf additive_bf effect_bf OTHER_DRUG risk_be developing_be methemoglobinemia_be ._be"
2813,"Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.",sodium nitroprusside,INOmax,effect,"Although_bf study_bf data_bf evaluate_bf possibility_bf ,_bf nitric_bf oxide_bf donor_bf compounds_bf ,_bf including_bf sodium_bf nitroprusside_bf nitroglycerin_bf ,_bf may_bf additive_bf effect_bf OTHER_DRUG risk_be developing_be methemoglobinemia_be ._be"
2814,"Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.",nitroglycerin,INOmax,effect,"Although_bf study_bf data_bf evaluate_bf possibility_bf ,_bf nitric_bf oxide_bf donor_bf compounds_bf ,_bf including_bf sodium_bf nitroprusside_bf DRUG ,_be may_be additive_be effect_be OTHER_DRUG risk_af developing_af methemoglobinemia_af ._af"
2815,"Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.",magnesium trisilicate,nitrofurantoin,mechanism,"Antacids_bf containing_bf magnesium_bf trisilicate_bf ,_bf administered_bf concomitantly_bf OTHER_DRUG ,_be reduce_be rate_be extent_be absorption_be ._be"
2816,The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate.,nitrofurantoin,magnesium trisilicate,mechanism,The_bf mechanism_bf interaction_bf probably_bf adsorption_bf DRUG onto_be surface_be magnesium_be trisilicate_be ._be
2817,"Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.",Uricosuric drugs,nitrofurantoin,mechanism,"Uricosuric_bf drugs_bf ,_bf probenecid_bf sulfinpyrazone_bf ,_bf inhibit_bf renal_bf tubular_bf secretion_bf OTHER_DRUG ._be"
2818,"Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.",probenecid,nitrofurantoin,mechanism,"Uricosuric_bf drugs_bf ,_bf DRUG sulfinpyrazone_be ,_be inhibit_be renal_be tubular_be secretion_be OTHER_DRUG ._af"
2819,"Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.",sulfinpyrazone,nitrofurantoin,mechanism,"Uricosuric_bf drugs_bf ,_bf probenecid_bf DRUG ,_be inhibit_be renal_be tubular_be secretion_be OTHER_DRUG ._af"
2820,The vasodilating effects of nitroglycerin may be additive with those of other vasodilators.,nitroglycerin,vasodilators,effect,The_bf vasodilating_bf effects_bf DRUG may_be additive_be OTHER_DRUG ._af
2821,Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.,calcium channel blockers,nitrates,effect,Marked_bf symptomatic_bf orthostatic_bf hypotension_bf reported_bf calcium_bf channel_bf blockers_bf organic_bf OTHER_DRUG used_be combination_be ._be
2822,"The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.",sodium nitroprusside,hypotensive drugs,effect,"The_bf hypotensive_bf effect_bf sodium_bf nitroprusside_bf augmented_bf hypotensive_bf drugs_bf ,_bf including_bf ganglionic_bf blocking_bf agents_bf ,_bf negative_bf inotropic_bf agents_bf ,_bf inhaled_bf anesthetics_bf ._bf"
2823,"The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.",sodium nitroprusside,ganglionic blocking agents,effect,"The_bf hypotensive_bf effect_bf sodium_bf nitroprusside_bf augmented_bf hypotensive_bf drugs_bf ,_bf including_bf ganglionic_bf blocking_bf agents_bf ,_bf negative_bf inotropic_bf agents_bf ,_bf inhaled_bf anesthetics_bf ._bf"
2824,"The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.",sodium nitroprusside,anesthetics,effect,"The_bf hypotensive_bf effect_bf sodium_bf nitroprusside_bf augmented_bf hypotensive_bf drugs_bf ,_bf including_bf ganglionic_bf blocking_bf agents_bf ,_bf negative_bf inotropic_bf agents_bf ,_bf inhaled_bf OTHER_DRUG ._be"
2825,"In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.",aspirin,nizatidine,mechanism,"In_bf patients_bf given_bf high_bf doses_bf (3900_bf mg)_bf DRUG daily_be ,_be increases_be serum_be salicylate_be levels_be seen_be OTHER_DRUG ,_af 150_af mg_af b_af ._af ._af ._af ,_af administered_af concurrently_af ._af"
2826,"The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.",progestin,phenytoin,effect,"The_bf effectiveness_bf progestin-only_bf pills_bf reduced_bf hepatic_bf enzyme-inducing_bf drugs_bf anticonvulsants_bf OTHER_DRUG ,_be carbamazepine_be ,_be barbiturates_be ,_be antituberculosis_be drug_be rifampin_be ._be"
2827,"The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.",progestin,carbamazepine,effect,"The_bf effectiveness_bf progestin-only_bf pills_bf reduced_bf hepatic_bf enzyme-inducing_bf drugs_bf anticonvulsants_bf phenytoin_bf ,_bf OTHER_DRUG ,_be barbiturates_be ,_be antituberculosis_be drug_be rifampin_be ._be"
2828,"The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.",progestin,barbiturates,effect,"The_bf effectiveness_bf progestin-only_bf pills_bf reduced_bf hepatic_bf enzyme-inducing_bf drugs_bf anticonvulsants_bf phenytoin_bf ,_bf carbamazepine_bf ,_bf OTHER_DRUG ,_be antituberculosis_be drug_be rifampin_be ._be"
2829,"The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.",progestin,rifampin,effect,"The_bf effectiveness_bf progestin-only_bf pills_bf reduced_bf hepatic_bf enzyme-inducing_bf drugs_bf anticonvulsants_bf phenytoin_bf ,_bf carbamazepine_bf ,_bf barbiturates_bf ,_bf antituberculosis_bf drug_bf OTHER_DRUG ._be"
2830,Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen.,tricyclic antidepressants,cimetidine,mechanism,Steady-state_bf serum_bf concentrations_bf tricyclic_bf antidepressants_bf reported_bf fluctuate_bf significantly_bf OTHER_DRUG either_be added_be deleted_be drug_be regimen_be ._be
2831,"Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen.",tricyclic antidepressants,cimetidine,effect,"Serious_bf anticholinergic_bf symptoms_bf (severe_bf dry_bf mouth_bf ,_bf urinary_bf retention_bf ,_bf blurred_bf vision)_bf associated_bf elevations_bf serum_bf levels_bf tricyclic_bf antidepressants_bf OTHER_DRUG added_be drug_be regimen_be ._be"
2832,"In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine.",tricyclic antidepressants,cimetidine,mechanism,"In_bf addition_bf ,_bf higher-than_bf expected_bf steady-state_bf serum_bf concentrations_bf tricyclic_bf antidepressants_bf observed_bf therapy_bf initiated_bf patients_bf already_bf taking_bf OTHER_DRUG ._be"
2833,"In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued.",cimetidine,tricyclic antidepressants,mechanism,"In_bf well-controlled_bf patients_bf undergoing_bf concurrent_bf therapy_bf DRUG ,_be decrease_be steady-state_be serum_be concentrations_be tricyclic_be antidepressants_be may_be occur_be cime-tidine_be therapy_be discontinued_be ._be"
2834,The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued.,tricyclic antidepressants,cimetidine,effect,The_bf therapeutic_bf efficacy_bf tricyclic_bf antidepressants_bf may_bf compromised_bf patients_bf OTHER_DRUG discontinued_be ._be
2835,"There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.",antidepressants,fluoxetine hydrochloride,mechanism,"There_bf greater_bf 2-fold_bf increases_bf previously_bf stable_bf plasma_bf levels_bf DRUG ,_be including_be nortriptyline_be ,_be fluoxetine_be hydrochloride_be administered_be combination_be agents_be ._be"
2836,"There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.",nortriptyline,fluoxetine hydrochloride,mechanism,"There_bf greater_bf 2-fold_bf increases_bf previously_bf stable_bf plasma_bf levels_bf antidepressants_bf ,_bf including_bf DRUG ,_be fluoxetine_be hydrochloride_be administered_be combination_be agents_be ._be"
2837,Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a  stimulating  effect in some depressed patients.,reserpine,tricyclic antidepressant,effect,Administration_bf DRUG therapy_be tricyclic_be antidepressant_be shown_be produce_be stimulating_be effect_be depressed_be patients_be ._be
2838,Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.,nortriptyline hydrochloride,anticholinergic drugs,advise,Close_bf supervision_bf careful_bf adjustment_bf dosage_bf required_bf nortriptyline_bf hydrochloride_bf used_bf anticholinergic_bf drugs_bf sympathomimetic_bf drugs_bf ._bf
2839,Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.,nortriptyline hydrochloride,sympathomimetic drugs,advise,Close_bf supervision_bf careful_bf adjustment_bf dosage_bf required_bf nortriptyline_bf hydrochloride_bf used_bf anticholinergic_bf drugs_bf sympathomimetic_bf drugs_bf ._bf
2840,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,antidepressants,advise,"Therefore_bf ,_bf co-administration_bf tricyclic_bf OTHER_DRUG drugs_be metabolized_be isoenzyme_be ,_be including_be OTHER_DRUG ,_af phenothiazines_af ,_af carbamazepine_af ,_af Type_af 1C_af antiarrhythmics_af (eg_af ,_af propafenone_af ,_af flecainide_af ,_af encainide)_af ,_af inhibit_af enzyme_af (eg_af ,_af quinidine)_af ,_af approached_af caution_af ._af"
2841,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,phenothiazines,advise,"Therefore_bf ,_bf co-administration_bf tricyclic_bf antidepressants_bf drugs_bf metabolized_bf isoenzyme_bf ,_bf including_bf antidepressants_bf ,_bf OTHER_DRUG ,_be carbamazepine_be ,_be Type_be 1C_be antiarrhythmics_be (eg_be ,_be propafenone_be ,_be flecainide_be ,_be encainide)_be ,_be inhibit_be enzyme_be (eg_be ,_be quinidine)_be ,_be approached_be caution_be ._be"
2842,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,carbamazepine,advise,"Therefore_bf ,_bf co-administration_bf tricyclic_bf antidepressants_bf drugs_bf metabolized_bf isoenzyme_bf ,_bf including_bf antidepressants_bf ,_bf phenothiazines_bf ,_bf OTHER_DRUG ,_be Type_be 1C_be antiarrhythmics_be (eg_be ,_be propafenone_be ,_be flecainide_be ,_be encainide)_be ,_be inhibit_be enzyme_be (eg_be ,_be quinidine)_be ,_be approached_be caution_be ._be"
2843,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,Type 1C antiarrhythmics,advise,"Therefore_bf ,_bf co-administration_bf tricyclic_bf antidepressants_bf drugs_bf metabolized_bf isoenzyme_bf ,_bf including_bf antidepressants_bf ,_bf phenothiazines_bf ,_bf carbamazepine_bf ,_bf Type_bf 1C_bf antiarrhythmics_bf (eg_bf ,_bf propafenone_bf ,_bf flecainide_bf ,_bf encainide)_bf ,_bf inhibit_bf enzyme_bf (eg_bf ,_bf quinidine)_bf ,_bf approached_bf caution_bf ._bf"
2844,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,propafenone,advise,"Therefore_bf ,_bf co-administration_bf tricyclic_bf antidepressants_bf drugs_bf metabolized_bf isoenzyme_bf ,_bf including_bf antidepressants_bf ,_bf phenothiazines_bf ,_bf carbamazepine_bf ,_bf Type_bf 1C_bf antiarrhythmics_bf (eg_bf ,_bf OTHER_DRUG ,_be flecainide_be ,_be encainide)_be ,_be inhibit_be enzyme_be (eg_be ,_be quinidine)_be ,_be approached_be caution_be ._be"
2845,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,flecainide,advise,"Therefore_bf ,_bf co-administration_bf tricyclic_bf antidepressants_bf drugs_bf metabolized_bf isoenzyme_bf ,_bf including_bf antidepressants_bf ,_bf phenothiazines_bf ,_bf carbamazepine_bf ,_bf Type_bf 1C_bf antiarrhythmics_bf (eg_bf ,_bf propafenone_bf ,_bf OTHER_DRUG ,_be encainide)_be ,_be inhibit_be enzyme_be (eg_be ,_be quinidine)_be ,_be approached_be caution_be ._be"
2846,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,encainide,advise,"Therefore_bf ,_bf co-administration_bf tricyclic_bf antidepressants_bf drugs_bf metabolized_bf isoenzyme_bf ,_bf including_bf antidepressants_bf ,_bf phenothiazines_bf ,_bf carbamazepine_bf ,_bf Type_bf 1C_bf antiarrhythmics_bf (eg_bf ,_bf propafenone_bf ,_bf flecainide_bf ,_bf encainide)_bf ,_bf inhibit_bf enzyme_bf (eg_bf ,_bf quinidine)_bf ,_bf approached_bf caution_bf ._bf"
2847,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,quinidine,advise,"Therefore_bf ,_bf co-administration_bf tricyclic_bf antidepressants_bf drugs_bf metabolized_bf isoenzyme_bf ,_bf including_bf antidepressants_bf ,_bf phenothiazines_bf ,_bf carbamazepine_bf ,_bf Type_bf 1C_bf antiarrhythmics_bf (eg_bf ,_bf propafenone_bf ,_bf flecainide_bf ,_bf encainide)_bf ,_bf inhibit_bf enzyme_bf (eg_bf ,_bf quinidine)_bf ,_bf approached_bf caution_bf ._bf"
2848,"In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.",AED,oxcarbazepine,mechanism,"In_bf addition_bf ,_bf several_bf DRUG cytochrome_be P450_be inducers_be decrease_be plasma_be concentrations_be OTHER_DRUG MHD_af ._af"
2849,"1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.",phenytoin,Trileptal,mechanism,"1-_bf nc_bf denotes_bf mean_bf change_bf less_bf 10%_bf 2-_bf Pediatrics_bf 3-_bf Mean_bf increase_bf adults_bf high_bf OTHER_DRUG doses_be In_be vivo_be ,_be plasma_be levels_be DRUG increased_af 40%_af ,_af OTHER_DRUG given_af doses_af 1200_af mg/day_af ._af"
2850,"Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.",Trileptal,phenytoin,advise,"Therefore_bf ,_bf using_bf doses_bf DRUG greater_be 1200_be mg/day_be adjunctive_be therapy_be ,_be decrease_be dose_be OTHER_DRUG may_af required_af ._af"
2851,"The increase of phenobarbital level, however, is small (15%) when given with Trileptal.",phenobarbital,Trileptal,mechanism,"The_bf increase_bf DRUG level_be ,_be however_be ,_be small_be (15%)_be given_be OTHER_DRUG ._af"
2852,"Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).",Trileptal,contraceptive,mechanism,"Hormonal_bf contraceptives_bf Co-administration_bf DRUG oral_be OTHER_DRUG shown_af influence_af plasma_af concentrations_af two_af hormonal_af components_af ,_af ethinylestradiol_af (EE)_af levonorgestrel_af (LNG)_af ._af"
2853,"Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.",Trileptal,hormonal contraceptives,effect,"Therefore_bf ,_bf concurrent_bf use_bf DRUG hormonal_be contraceptives_be may_be render_be contraceptives_be less_be effective_be ._be"
2854,"Calcium Antagonists: After repeated co-administration of Trileptal, the AUC of felodipine was lowered by 28% [90% CI: 20-33].",Trileptal,felodipine,mechanism,"Calcium_bf Antagonists:_bf After_bf repeated_bf co-administration_bf DRUG ,_be AUC_be OTHER_DRUG lowered_af 28%_af [90%_af CI:_af 20-33]_af ._af"
2855,"In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).",TAXOL,cisplatin,effect,"In_bf Phase_bf I_bf trial_bf using_bf escalating_bf doses_bf DRUG (110-200_be mg/m2)_be OTHER_DRUG (50_af 75_af mg/m2)_af given_af sequential_af infusions_af ,_af myelosuppression_af profound_af DRUG given_af OTHER_DRUG alternate_af sequence_af (ie_af ,_af DRUG cisplatin)_af ._af"
2856,Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.,TAXOL,cisplatin,mechanism,Pharmacokinetic_bf data_bf patients_bf demonstrated_bf decrease_bf paclitaxel_bf clearance_bf approximately_bf 33%_bf DRUG administered_be following_be OTHER_DRUG ._af
2857,Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.,paclitaxel,doxorubicin,mechanism,Reports_bf literature_bf suggest_bf plasma_bf levels_bf OTHER_DRUG (and_be active_be metabolite_be doxorubicinol)_be may_be increased_be DRUG OTHER_DRUG used_af combination_af ._af
2858,"Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.",cyclosporin,TAXOL,advise,"Hypersensitivity_bf Reactions:_bf Patients_bf history_bf severe_bf hypersensitivity_bf reactions_bf products_bf containing_bf Cremophor_bf EL_bf (eg_bf ,_bf DRUG injection_be concentrate_be teniposide_be injection_be concentrate)_be treated_be OTHER_DRUG ._af"
2859,"Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.",teniposide,TAXOL,advise,"Hypersensitivity_bf Reactions:_bf Patients_bf history_bf severe_bf hypersensitivity_bf reactions_bf products_bf containing_bf Cremophor_bf EL_bf (eg_bf ,_bf cyclosporin_bf injection_bf concentrate_bf DRUG injection_be concentrate)_be treated_be OTHER_DRUG ._af"
2860,Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.,PEGASYS,theophylline,mechanism,Treatment_bf DRUG weekly_be 4_be weeks_be healthy_be subjects_be associated_be inhibition_be P450_be 1A2_be 25%_be increase_be OTHER_DRUG AUC_af ._af
2861,Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS.,theophylline,PEGASYS,advise,DRUG serum_be levels_be monitored_be appropriate_be dose_be adjustments_be considered_be patients_be given_be DRUG OTHER_DRUG ._af
2862,Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.,COPEGUS,didanosine,advise,Nucleoside_bf Analogues_bf OTHER_DRUG Co-administration_be DRUG OTHER_DRUG recommended_af ._af
2863,Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.,Ribavirin,stavudine,effect,OTHER_DRUG Zidovudine_be DRUG antagonize_af vitro_af antiviral_af activity_af OTHER_DRUG zidovudine_af HIV_af ._af
2864,Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.,Ribavirin,zidovudine,effect,Stavudine_bf OTHER_DRUG DRUG antagonize_af vitro_af antiviral_af activity_af stavudine_af OTHER_DRUG HIV_af ._af
2865,Aminoglycosides: The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside.,piperacillin,aminoglycoside,effect,Aminoglycosides:_bf The_bf mixing_bf DRUG OTHER_DRUG vitro_af result_af substantial_af inactivation_af OTHER_DRUG ._af
2866,"Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.",piperacillin,vecuronium,effect,"Vecuronium:_bf When_bf used_bf perioperative_bf period_bf ,_bf DRUG implicated_be prolongation_be neuromuscular_be blockade_be OTHER_DRUG ._af"
2867,"In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.",piperacillin,vecuronium,effect,"In_bf one_bf controlled_bf clinical_bf study_bf ,_bf ureidopenicillins_bf ,_bf including_bf DRUG ,_be reported_be prolong_be action_be OTHER_DRUG ._af"
2868,"Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin.",non-depolarizing muscle relaxants,piperacillin,effect,"Due_bf similar_bf mechanism_bf action_bf ,_bf expected_bf neuromuscular_bf blockade_bf produced_bf non-depolarizing_bf muscle_bf relaxants_bf could_bf prolonged_bf presence_bf OTHER_DRUG ._be"
2869,Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.,probenecid,PIPRACIL,mechanism,Probenecid:_bf The_bf oral_bf combination_bf DRUG intramuscular_be injection_be OTHER_DRUG produces_af increase_af piperacillin_af peak_af serum_af level_af 30%_af ._af
2870,Methotrexate: Piperacillin sodium may reduce the excretion of methotrexate.,Piperacillin sodium,methotrexate,mechanism,Methotrexate:_bf Piperacillin_bf sodium_bf may_bf reduce_bf excretion_bf OTHER_DRUG ._be
2871,Phenothiazines - Taking piperazine and a phenothiazine together may increase the risk of convulsions (seizures).,piperazine,phenothiazine,effect,Phenothiazines_bf -_bf Taking_bf DRUG OTHER_DRUG together_af may_af increase_af risk_af convulsions_af (seizures)_af ._af
2872,"Pyrantel (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of piperazine.",piperazine,pyrantel,effect,"OTHER_DRUG (e_be ._be g_be ._be ,_be Antiminth)_be -_be Taking_be DRUG OTHER_DRUG together_af may_af decrease_af effects_af DRUG ._af"
2873,ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.,NSAIDs,Angiotensin Converting Enzyme (ACE) inhibitors,effect,ACE_bf inhibitors:_bf Reports_bf suggest_bf DRUG may_be diminish_be antihypertensive_be effect_be Angiotensin_be Converting_be Enzyme_be (ACE)_be inhibitors_be ._be
2874,"In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.",VIOXX,benazepril,effect,"In_bf patients_bf mild_bf moderate_bf hypertension_bf ,_bf administration_bf 25_bf mg_bf daily_bf DRUG ACE_be inhibitor_be OTHER_DRUG ,_af 10_af 40_af mg_af 4_af weeks_af ,_af associated_af average_af increase_af mean_af arterial_af pressure_af 3_af mm_af Hg_af compared_af ACE_af inhibitor_af alone_af ._af"
2875,This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors.,VIOXX,ACE inhibitors,advise,This_bf interaction_bf given_bf consideration_bf patients_bf taking_bf DRUG concomitantly_be ACE_be inhibitors_be ._be
2876,"Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.",aspirin,VIOXX,effect,"Aspirin:_bf Concomitant_bf administration_bf low-dose_bf DRUG OTHER_DRUG may_af result_af increased_af rate_af GI_af ulceration_af complications_af ,_af compared_af use_af OTHER_DRUG alone_af ._af"
2877,"Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.",cimetidine,rofecoxib,mechanism,"Cimetidine:_bf Co-administration_bf high_bf doses_bf DRUG [800_be mg_be twice_be daily]_be increased_be Cmax_be OTHER_DRUG 21%_af ,_af AUC0-120hr_af 23%_af t1/2_af 15%_af ._af"
2878,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,furosemide,effect,"Furosemide:_bf Clinical_bf studies_bf ,_bf well_bf post-marketing_bf observations_bf ,_bf shown_bf DRUG reduce_be natriuretic_be effect_be OTHER_DRUG thiazides_af patients_af ._af"
2879,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,thiazides,effect,"Furosemide:_bf Clinical_bf studies_bf ,_bf well_bf post-marketing_bf observations_bf ,_bf shown_bf DRUG reduce_be natriuretic_be effect_be furosemide_be OTHER_DRUG patients_af ._af"
2880,Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.,NSAIDs,lithium,mechanism,Lithium:_bf DRUG produced_be elevation_be plasma_be OTHER_DRUG levels_af reduction_af renal_af OTHER_DRUG clearance_af ._af
2881,"Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.",VIOXX,lithium,advise,"Thus_bf ,_bf DRUG OTHER_DRUG administered_af concurrently_af ,_af subjects_af observed_af carefully_af signs_af OTHER_DRUG toxicity_af ._af"
2882,"At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.",VIOXX,methotrexate,mechanism,"At_bf higher_bf recommended_bf doses_bf ,_bf DRUG 75_be mg_be administered_be daily_be 10_be days_be increased_be plasma_be concentrations_be 23%_be measured_be AUC0-24hr_be patients_be receiving_be OTHER_DRUG 7_af ._af 5_af 15_af mg/week_af rheumatoid_af arthritis_af ._af"
2883,"At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).",methotrexate,rofecoxib,mechanism,"At_bf 24_bf hours_bf postdose_bf ,_bf similar_bf proportion_bf patients_bf treated_bf DRUG alone_be (94%)_be subsequently_be treated_be DRUG co-administered_af 75_af mg_af OTHER_DRUG (88%)_af DRUG plasma_af concentrations_af measurable_af limit_af (5_af ng/mL)_af ._af"
2884,Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.,VIOXX,methotrexate,advise,Standard_bf monitoring_bf methotrexate-related_bf toxicity_bf continued_bf DRUG OTHER_DRUG administered_af concomitantly_af ._af
2885,"Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.",VIOXX,rifampin,mechanism,"Rifampin:_bf Co-administration_bf DRUG OTHER_DRUG 600_af mg_af daily_af ,_af potent_af inducer_af hepatic_af metabolism_af ,_af produced_af approximate_af 50%_af decrease_af rofecoxib_af plasma_af concentrations_af ._af"
2886,"Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.",VIOXX,theophylline,mechanism,"OTHER_DRUG DRUG 12_af ._af 5_af ,_af 25_af ,_af 50_af mg_af administered_af daily_af 7_af days_af increased_af plasma_af OTHER_DRUG concentrations_af (AUC(0-_af ))_af 38_af 60%_af healthy_af subjects_af administered_af single_af 300-mg_af dose_af OTHER_DRUG ._af"
2887,Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.,VIOXX,theophylline,advise,Adequate_bf monitoring_bf OTHER_DRUG plasma_be concentrations_be considered_be therapy_be DRUG initiated_af changed_af patients_af receiving_af OTHER_DRUG ._af
2888,"Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.",VIOXX,warfarin,advise,"Warfarin:_bf Anticoagulant_bf activity_bf monitored_bf ,_bf particularly_bf first_bf days_bf initiating_bf changing_bf DRUG therapy_be patients_be receiving_be OTHER_DRUG similar_af agents_af ,_af since_af patients_af increased_af risk_af bleeding_af complications_af ._af"
2889,"In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%.",warfarin,rofecoxib,effect,"In_bf single_bf multiple_bf dose_bf studies_bf healthy_bf subjects_bf receiving_bf DRUG OTHER_DRUG ,_af prothrombin_af time_af (measured_af INR)_af increased_af approximately_af 8%_af 11%_af ._af"
2890,"In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin.",VIOXX,warfarin,effect,"In_bf post-marketing_bf experience_bf ,_bf bleeding_bf events_bf reported_bf ,_bf predominantly_bf elderly_bf ,_bf association_bf increases_bf prothrombin_bf time_bf patients_bf receiving_bf DRUG concurrently_be OTHER_DRUG ._af"
2891,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",calcium channel blockers,saquinavir,mechanism,"Although_bf specific_bf studies_bf performed_bf ,_bf coadministration_bf drugs_bf mainly_bf metabolized_bf CYP3A4_bf (eg_bf ,_bf calcium_bf channel_bf blockers_bf ,_bf dapsone_bf ,_bf disopyramide_bf ,_bf quinine_bf ,_bf amiodarone_bf ,_bf quinidine_bf ,_bf warfarin_bf ,_bf tacrolimus_bf ,_bf cyclosporine_bf ,_bf ergot_bf derivatives_bf ,_bf pimozide_bf ,_bf carbamazepine_bf ,_bf fentanyl_bf ,_bf alfentanyl_bf ,_bf alprazolam_bf ,_bf triazolam)_bf may_bf elevated_bf plasma_bf concentrations_bf coadministered_bf saquinavir;_bf"
2892,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",dapsone,saquinavir,mechanism,"Although_bf specific_bf studies_bf performed_bf ,_bf coadministration_bf drugs_bf mainly_bf metabolized_bf CYP3A4_bf (eg_bf ,_bf calcium_bf channel_bf blockers_bf ,_bf DRUG ,_be disopyramide_be ,_be quinine_be ,_be amiodarone_be ,_be quinidine_be ,_be warfarin_be ,_be tacrolimus_be ,_be cyclosporine_be ,_be ergot_be derivatives_be ,_be pimozide_be ,_be carbamazepine_be ,_be fentanyl_be ,_be alfentanyl_be ,_be alprazolam_be ,_be triazolam)_be may_be elevated_be plasma_be concentrations_be coadministered_be saquinavir;_be"
2893,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",disopyramide,saquinavir,mechanism,"Although_bf specific_bf studies_bf performed_bf ,_bf coadministration_bf drugs_bf mainly_bf metabolized_bf CYP3A4_bf (eg_bf ,_bf calcium_bf channel_bf blockers_bf ,_bf dapsone_bf ,_bf DRUG ,_be quinine_be ,_be amiodarone_be ,_be quinidine_be ,_be warfarin_be ,_be tacrolimus_be ,_be cyclosporine_be ,_be ergot_be derivatives_be ,_be pimozide_be ,_be carbamazepine_be ,_be fentanyl_be ,_be alfentanyl_be ,_be alprazolam_be ,_be triazolam)_be may_be elevated_be plasma_be concentrations_be coadministered_be saquinavir;_be"
2894,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",quinine,saquinavir,mechanism,"Although_bf specific_bf studies_bf performed_bf ,_bf coadministration_bf drugs_bf mainly_bf metabolized_bf CYP3A4_bf (eg_bf ,_bf calcium_bf channel_bf blockers_bf ,_bf dapsone_bf ,_bf disopyramide_bf ,_bf DRUG ,_be amiodarone_be ,_be quinidine_be ,_be warfarin_be ,_be tacrolimus_be ,_be cyclosporine_be ,_be ergot_be derivatives_be ,_be pimozide_be ,_be carbamazepine_be ,_be fentanyl_be ,_be alfentanyl_be ,_be alprazolam_be ,_be triazolam)_be may_be elevated_be plasma_be concentrations_be coadministered_be saquinavir;_be"
2895,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",amiodarone,saquinavir,mechanism,"Although_bf specific_bf studies_bf performed_bf ,_bf coadministration_bf drugs_bf mainly_bf metabolized_bf CYP3A4_bf (eg_bf ,_bf calcium_bf channel_bf blockers_bf ,_bf dapsone_bf ,_bf disopyramide_bf ,_bf quinine_bf ,_bf DRUG ,_be quinidine_be ,_be warfarin_be ,_be tacrolimus_be ,_be cyclosporine_be ,_be ergot_be derivatives_be ,_be pimozide_be ,_be carbamazepine_be ,_be fentanyl_be ,_be alfentanyl_be ,_be alprazolam_be ,_be triazolam)_be may_be elevated_be plasma_be concentrations_be coadministered_be saquinavir;_be"
2896,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",quinidine,saquinavir,mechanism,"Although_bf specific_bf studies_bf performed_bf ,_bf coadministration_bf drugs_bf mainly_bf metabolized_bf CYP3A4_bf (eg_bf ,_bf calcium_bf channel_bf blockers_bf ,_bf dapsone_bf ,_bf disopyramide_bf ,_bf quinine_bf ,_bf amiodarone_bf ,_bf DRUG ,_be warfarin_be ,_be tacrolimus_be ,_be cyclosporine_be ,_be ergot_be derivatives_be ,_be pimozide_be ,_be carbamazepine_be ,_be fentanyl_be ,_be alfentanyl_be ,_be alprazolam_be ,_be triazolam)_be may_be elevated_be plasma_be concentrations_be coadministered_be saquinavir;_be"
2897,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",warfarin,saquinavir,mechanism,"Although_bf specific_bf studies_bf performed_bf ,_bf coadministration_bf drugs_bf mainly_bf metabolized_bf CYP3A4_bf (eg_bf ,_bf calcium_bf channel_bf blockers_bf ,_bf dapsone_bf ,_bf disopyramide_bf ,_bf quinine_bf ,_bf amiodarone_bf ,_bf quinidine_bf ,_bf DRUG ,_be tacrolimus_be ,_be cyclosporine_be ,_be ergot_be derivatives_be ,_be pimozide_be ,_be carbamazepine_be ,_be fentanyl_be ,_be alfentanyl_be ,_be alprazolam_be ,_be triazolam)_be may_be elevated_be plasma_be concentrations_be coadministered_be saquinavir;_be"
2898,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",tacrolimus,saquinavir,mechanism,"Although_bf specific_bf studies_bf performed_bf ,_bf coadministration_bf drugs_bf mainly_bf metabolized_bf CYP3A4_bf (eg_bf ,_bf calcium_bf channel_bf blockers_bf ,_bf dapsone_bf ,_bf disopyramide_bf ,_bf quinine_bf ,_bf amiodarone_bf ,_bf quinidine_bf ,_bf warfarin_bf ,_bf DRUG ,_be cyclosporine_be ,_be ergot_be derivatives_be ,_be pimozide_be ,_be carbamazepine_be ,_be fentanyl_be ,_be alfentanyl_be ,_be alprazolam_be ,_be triazolam)_be may_be elevated_be plasma_be concentrations_be coadministered_be saquinavir;_be"
2899,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",cyclosporine,saquinavir,mechanism,"Although_bf specific_bf studies_bf performed_bf ,_bf coadministration_bf drugs_bf mainly_bf metabolized_bf CYP3A4_bf (eg_bf ,_bf calcium_bf channel_bf blockers_bf ,_bf dapsone_bf ,_bf disopyramide_bf ,_bf quinine_bf ,_bf amiodarone_bf ,_bf quinidine_bf ,_bf warfarin_bf ,_bf tacrolimus_bf ,_bf DRUG ,_be ergot_be derivatives_be ,_be pimozide_be ,_be carbamazepine_be ,_be fentanyl_be ,_be alfentanyl_be ,_be alprazolam_be ,_be triazolam)_be may_be elevated_be plasma_be concentrations_be coadministered_be saquinavir;_be"
2900,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",ergot derivatives,saquinavir,mechanism,"Although_bf specific_bf studies_bf performed_bf ,_bf coadministration_bf drugs_bf mainly_bf metabolized_bf CYP3A4_bf (eg_bf ,_bf calcium_bf channel_bf blockers_bf ,_bf dapsone_bf ,_bf disopyramide_bf ,_bf quinine_bf ,_bf amiodarone_bf ,_bf quinidine_bf ,_bf warfarin_bf ,_bf tacrolimus_bf ,_bf cyclosporine_bf ,_bf ergot_bf derivatives_bf ,_bf pimozide_bf ,_bf carbamazepine_bf ,_bf fentanyl_bf ,_bf alfentanyl_bf ,_bf alprazolam_bf ,_bf triazolam)_bf may_bf elevated_bf plasma_bf concentrations_bf coadministered_bf saquinavir;_bf"
2901,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",pimozide,saquinavir,mechanism,"Although_bf specific_bf studies_bf performed_bf ,_bf coadministration_bf drugs_bf mainly_bf metabolized_bf CYP3A4_bf (eg_bf ,_bf calcium_bf channel_bf blockers_bf ,_bf dapsone_bf ,_bf disopyramide_bf ,_bf quinine_bf ,_bf amiodarone_bf ,_bf quinidine_bf ,_bf warfarin_bf ,_bf tacrolimus_bf ,_bf cyclosporine_bf ,_bf ergot_bf derivatives_bf ,_bf DRUG ,_be carbamazepine_be ,_be fentanyl_be ,_be alfentanyl_be ,_be alprazolam_be ,_be triazolam)_be may_be elevated_be plasma_be concentrations_be coadministered_be saquinavir;_be"
2902,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",carbamazepine,saquinavir,mechanism,"Although_bf specific_bf studies_bf performed_bf ,_bf coadministration_bf drugs_bf mainly_bf metabolized_bf CYP3A4_bf (eg_bf ,_bf calcium_bf channel_bf blockers_bf ,_bf dapsone_bf ,_bf disopyramide_bf ,_bf quinine_bf ,_bf amiodarone_bf ,_bf quinidine_bf ,_bf warfarin_bf ,_bf tacrolimus_bf ,_bf cyclosporine_bf ,_bf ergot_bf derivatives_bf ,_bf pimozide_bf ,_bf DRUG ,_be fentanyl_be ,_be alfentanyl_be ,_be alprazolam_be ,_be triazolam)_be may_be elevated_be plasma_be concentrations_be coadministered_be saquinavir;_be"
2903,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",fentanyl,saquinavir,mechanism,"Although_bf specific_bf studies_bf performed_bf ,_bf coadministration_bf drugs_bf mainly_bf metabolized_bf CYP3A4_bf (eg_bf ,_bf calcium_bf channel_bf blockers_bf ,_bf dapsone_bf ,_bf disopyramide_bf ,_bf quinine_bf ,_bf amiodarone_bf ,_bf quinidine_bf ,_bf warfarin_bf ,_bf tacrolimus_bf ,_bf cyclosporine_bf ,_bf ergot_bf derivatives_bf ,_bf pimozide_bf ,_bf carbamazepine_bf ,_bf DRUG ,_be alfentanyl_be ,_be alprazolam_be ,_be triazolam)_be may_be elevated_be plasma_be concentrations_be coadministered_be saquinavir;_be"
2904,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",alfentanyl,saquinavir,mechanism,"Although_bf specific_bf studies_bf performed_bf ,_bf coadministration_bf drugs_bf mainly_bf metabolized_bf CYP3A4_bf (eg_bf ,_bf calcium_bf channel_bf blockers_bf ,_bf dapsone_bf ,_bf disopyramide_bf ,_bf quinine_bf ,_bf amiodarone_bf ,_bf quinidine_bf ,_bf warfarin_bf ,_bf tacrolimus_bf ,_bf cyclosporine_bf ,_bf ergot_bf derivatives_bf ,_bf pimozide_bf ,_bf carbamazepine_bf ,_bf fentanyl_bf ,_bf DRUG ,_be alprazolam_be ,_be triazolam)_be may_be elevated_be plasma_be concentrations_be coadministered_be saquinavir;_be"
2905,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",alprazolam,saquinavir,mechanism,"Although_bf specific_bf studies_bf performed_bf ,_bf coadministration_bf drugs_bf mainly_bf metabolized_bf CYP3A4_bf (eg_bf ,_bf calcium_bf channel_bf blockers_bf ,_bf dapsone_bf ,_bf disopyramide_bf ,_bf quinine_bf ,_bf amiodarone_bf ,_bf quinidine_bf ,_bf warfarin_bf ,_bf tacrolimus_bf ,_bf cyclosporine_bf ,_bf ergot_bf derivatives_bf ,_bf pimozide_bf ,_bf carbamazepine_bf ,_bf fentanyl_bf ,_bf alfentanyl_bf ,_bf DRUG ,_be triazolam)_be may_be elevated_be plasma_be concentrations_be coadministered_be saquinavir;_be"
2906,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",triazolam,saquinavir,mechanism,"Although_bf specific_bf studies_bf performed_bf ,_bf coadministration_bf drugs_bf mainly_bf metabolized_bf CYP3A4_bf (eg_bf ,_bf calcium_bf channel_bf blockers_bf ,_bf dapsone_bf ,_bf disopyramide_bf ,_bf quinine_bf ,_bf amiodarone_bf ,_bf quinidine_bf ,_bf warfarin_bf ,_bf tacrolimus_bf ,_bf cyclosporine_bf ,_bf ergot_bf derivatives_bf ,_bf pimozide_bf ,_bf carbamazepine_bf ,_bf fentanyl_bf ,_bf alfentanyl_bf ,_bf alprazolam_bf ,_bf triazolam)_bf may_bf elevated_bf plasma_bf concentrations_bf coadministered_bf saquinavir;_bf"
2907,"Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.",INVIRASE,ritonavir,advise,"Since_bf DRUG coadministered_be OTHER_DRUG ,_af OTHER_DRUG label_af reviewed_af additional_af drugs_af coadministered_af ._af"
2908,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.",phenobarbital,saquinavir,mechanism,"Coadministration_bf compounds_bf potent_bf inducers_bf CYP3A4_bf (eg_bf ,_bf DRUG ,_be phenytoin_be ,_be dexamethasone_be ,_be carbamazepine)_be may_be result_be decreased_be plasma_be levels_be OTHER_DRUG ._af"
2909,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.",phenytoin,saquinavir,mechanism,"Coadministration_bf compounds_bf potent_bf inducers_bf CYP3A4_bf (eg_bf ,_bf phenobarbital_bf ,_bf DRUG ,_be dexamethasone_be ,_be carbamazepine)_be may_be result_be decreased_be plasma_be levels_be OTHER_DRUG ._af"
2910,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.",dexamethasone,saquinavir,mechanism,"Coadministration_bf compounds_bf potent_bf inducers_bf CYP3A4_bf (eg_bf ,_bf phenobarbital_bf ,_bf phenytoin_bf ,_bf DRUG ,_be carbamazepine)_be may_be result_be decreased_be plasma_be levels_be OTHER_DRUG ._af"
2911,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.",carbamazepine,saquinavir,mechanism,"Coadministration_bf compounds_bf potent_bf inducers_bf CYP3A4_bf (eg_bf ,_bf phenobarbital_bf ,_bf phenytoin_bf ,_bf dexamethasone_bf ,_bf carbamazepine)_bf may_bf result_bf decreased_bf plasma_bf levels_bf OTHER_DRUG ._be"
2912,Sulfacetamide preparations are incompatible with silver preparations.,Sulfacetamide,silver,int,DRUG preparations_be incompatible_be OTHER_DRUG preparations_af ._af
2913,"Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or",Sulfapyridine,Acetaminophen,int,"DRUG may_be interact_be following:_be -_be OTHER_DRUG (e_af ._af g_af ._af ,_af Tylenol)_af (with_af long-term_af ,_af high-dose_af use)_af"
2914,"Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or",Sulfapyridine,Tylenol,int,"DRUG may_be interact_be following:_be -_be Acetaminophen_be (e_be ._be g_be ._be ,_be Tylenol)_be (with_be long-term_be ,_be high-dose_be use)_be"
2915,"- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics",antidiabetics,sulfapyridine,effect,"-_bf DRUG ,_be oral_be (diabetes_be medicine_be take_be mouth)_be Use_be oral_be DRUG OTHER_DRUG may_af increase_af chance_af side_af effects_af affecting_af blood_af and/or_af side_af effects_af oral_af DRUG"
2916,"- Methotrexate (e.g., Mexate) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate",methotrexate,sulfapyridine,effect,"-_bf DRUG (e_be ._be g_be ._be ,_be Mexate)_be Use_be DRUG OTHER_DRUG may_af increase_af chance_af side_af effects_af affecting_af liver_af and/or_af side_af effects_af DRUG"
2917,"- Methyldopa (e.g., Aldomet) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood",methyldopa,sulfapyridine,effect,"-_bf DRUG (e_be ._be g_be ._be ,_be Aldomet)_be Use_be DRUG OTHER_DRUG may_af increase_af chance_af side_af effects_af affecting_af liver_af and/or_af blood_af"
2918,"- Phenytoin (e.g., Dilantin) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin",phenytoin,sulfapyridine,effect,"-_bf DRUG (e_be ._be g_be ._be ,_be Dilantin)_be Use_be DRUG OTHER_DRUG may_af increase_af chance_af side_af effects_af affecting_af liver_af and/or_af side_af effects_af DRUG"
2919,Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.,Tiagabine,valproate,mechanism,Valproate:_bf DRUG causes_be slight_be decrease_be (about_be 10%)_be steady-state_be OTHER_DRUG concentrations_af ._af
2920,Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.,tiagabine,carbamazepine,mechanism,Effects_bf Antiepilepsy_bf Drugs_bf (AEDs)_bf GABITRIL_bf :_bf Carbamazepine:_bf Population_bf pharmacokinetic_bf analyses_bf indicate_bf DRUG clearance_be 60%_be greater_be patients_be taking_be OTHER_DRUG without_af enzyme-_af inducing_af AEDs_af ._af
2921,Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.,tiagabine,phenytoin,mechanism,Phenytoin:_bf Population_bf pharmacokinetic_bf analyses_bf indicate_bf DRUG clearance_be 60%_be greater_be patients_be taking_be OTHER_DRUG without_af enzyme-_af inducing_af AEDs_af ._af
2922,Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.,tiagabine,phenobarbital,mechanism,OTHER_DRUG (Primidone):_be Population_be pharmacokinetic_be analyses_be indicate_be DRUG clearance_af 60%_af greater_af patients_af taking_af OTHER_DRUG (primidone)_af without_af enzyme-inducing_af AEDs_af ._af
2923,Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.,tiagabine,primidone,mechanism,Phenobarbital_bf (Primidone):_bf Population_bf pharmacokinetic_bf analyses_bf indicate_bf DRUG clearance_be 60%_be greater_be patients_be taking_be phenobarbital_be (primidone)_be without_be enzyme-inducing_be AEDs_be ._be
2924,"Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.",valproate,tiagabine,mechanism,"Valproate:_bf The_bf addition_bf OTHER_DRUG patients_be taking_be DRUG chronically_af effect_af OTHER_DRUG pharmacokinetics_af ,_af DRUG significantly_af decreased_af OTHER_DRUG binding_af vitro_af 96_af ._af 3_af 94_af ._af 8%_af ,_af resulted_af increase_af approximately_af 40%_af free_af OTHER_DRUG concentration_af ._af"
2925,"Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.",ethanol,tiagabine,advise,"Because_bf possible_bf additive_bf effects_bf drugs_bf may_bf depress_bf nervous_bf system_bf ,_bf DRUG triazolam_be used_be cautiously_be combination_be OTHER_DRUG ._af"
2926,"Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.",triazolam,tiagabine,advise,"Because_bf possible_bf additive_bf effects_bf drugs_bf may_bf depress_bf nervous_bf system_bf ,_bf ethanol_bf DRUG used_be cautiously_be combination_be OTHER_DRUG ._af"
2927,Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.,aspirin,valdecoxib,effect,Aspirin:_bf Concomitant_bf administration_bf DRUG OTHER_DRUG may_af result_af increased_af risk_af GI_af ulceration_af complications_af compared_af OTHER_DRUG alone_af ._af
2928,ACE-inhibitors:Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.,NSAIDs,ACE-inhibitors,effect,ACE-inhibitors:Reports_bf suggest_bf DRUG may_be diminish_be antihypertensive_be effect_be OTHER_DRUG ._af
2929,This interaction should be given consideration in patients taking BEXTRA concomitantly with ACE-inhibitors.,BEXTRA,ACE-inhibitors,advise,This_bf interaction_bf given_bf consideration_bf patients_bf taking_bf DRUG concomitantly_be OTHER_DRUG ._af
2930,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,furosemide,effect,"Furosemide:_bf Clinical_bf studies_bf ,_bf well_bf post-marketing_bf observations_bf ,_bf shown_bf DRUG reduce_be natriuretic_be effect_be OTHER_DRUG thiazides_af patients_af ._af"
2931,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,thiazides,effect,"Furosemide:_bf Clinical_bf studies_bf ,_bf well_bf post-marketing_bf observations_bf ,_bf shown_bf DRUG reduce_be natriuretic_be effect_be furosemide_be OTHER_DRUG patients_af ._af"
2932,Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).,valdecoxib,phenytoin,mechanism,Anticonvulsants_bf (Phenytoin):_bf Steady_bf state_bf plasma_bf exposure_bf (AUC)_bf DRUG (40_be mg_be BID_be 12_be days)_be decreased_be 27%_be co-administered_be multiple_be doses_be (300_be mg_be QD_be 12_be days)_be OTHER_DRUG (a_af CYP_af 3A4_af inducer)_af ._af
2933,Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.,valdecoxib,phenytoin,advise,Patients_bf already_bf stabilized_bf DRUG closely_be monitored_be loss_be symptom_be control_be OTHER_DRUG coadministration_af ._af
2934,"Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.",valdecoxib,dextromethorphan,mechanism,"Coadministration_bf DRUG (40_be mg_be BID_be 7_be days)_be resulted_be significant_be increase_be OTHER_DRUG plasma_af levels_af suggesting_af ,_af doses_af ,_af DRUG weak_af inhibitor_af 2D6_af ._af"
2935,Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.,dextromethorphan,valdecoxib,mechanism,Even_bf DRUG plasma_be concentrations_be presence_be high_be doses_be OTHER_DRUG almost_af 5-fold_af lower_af seen_af CYP_af 2D6_af poor_af metabolizers_af suggesting_af dose_af adjustment_af necessary_af ._af
2936,Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.,Valdecoxib,lithium,mechanism,Lithium:_bf DRUG 40_be mg_be BID_be 7_be days_be produced_be significant_be decreases_be OTHER_DRUG serum_af clearance_af (25%)_af renal_af clearance_af (30%)_af 34%_af higher_af serum_af exposure_af compared_af OTHER_DRUG alone_af ._af
2937,Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.,BEXTRA,lithium,advise,OTHER_DRUG serum_be concentrations_be monitored_be closely_be initiating_be changing_be therapy_be DRUG patients_af receiving_af OTHER_DRUG ._af
2938,"Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.",Valdecoxib,R-warfarin,mechanism,"DRUG caused_be statistically_be significant_be increase_be plasma_be exposures_be OTHER_DRUG S-warfarin_af (12%_af 15%_af ,_af respectively)_af ,_af pharmacodynamic_af effects_af (prothrombin_af time_af ,_af measured_af INR)_af warfarin_af ._af"
2939,"Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.",Valdecoxib,S-warfarin,mechanism,"DRUG caused_be statistically_be significant_be increase_be plasma_be exposures_be R-warfarin_be OTHER_DRUG (12%_af 15%_af ,_af respectively)_af ,_af pharmacodynamic_af effects_af (prothrombin_af time_af ,_af measured_af INR)_af warfarin_af ._af"
2940,"Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.",Valdecoxib,warfarin,effect,"DRUG caused_be statistically_be significant_be increase_be plasma_be exposures_be R-warfarin_be S-warfarin_be (12%_be 15%_be ,_be respectively)_be ,_be pharmacodynamic_be effects_be (prothrombin_be time_be ,_be measured_be INR)_be OTHER_DRUG ._af"
2941,"Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents.",BEXTRA,warfarin,advise,"Anticoagulant_bf therapy_bf monitored_bf ,_bf particularly_bf first_bf weeks_bf ,_bf initiating_bf therapy_bf DRUG patients_be receiving_be OTHER_DRUG similar_af agents_af ._af"
2942,Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.,valdecoxib,ketoconazole,mechanism,Concomitant_bf single_bf dose_bf administration_bf DRUG 20_be mg_be multiple_be doses_be OTHER_DRUG fluconazole_af produced_af significant_af increase_af exposure_af DRUG ._af
2943,Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.,valdecoxib,fluconazole,mechanism,Concomitant_bf single_bf dose_bf administration_bf DRUG 20_be mg_be multiple_be doses_be ketoconazole_be OTHER_DRUG produced_af significant_af increase_af exposure_af DRUG ._af
2944,Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.,valdecoxib,fluconazole,mechanism,Plasma_bf exposure_bf (AUC)_bf DRUG increased_be 62%_be coadministered_be OTHER_DRUG 38%_af coadministered_af ketoconazole_af ._af
2945,Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.,valdecoxib,ketoconazole,mechanism,Plasma_bf exposure_bf (AUC)_bf DRUG increased_be 62%_be coadministered_be fluconazole_be 38%_be coadministered_be OTHER_DRUG ._af
2946,Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.,valdecoxib,glyburide,mechanism,Coadministration_bf DRUG (40_be mg_be BID_be (day_be 1)_be 40_be mg_be QD_be (days_be 2-7))_be OTHER_DRUG (10_af mg_af OTHER_DRUG BID)_af resulted_af 21%_af increase_af OTHER_DRUG AUC0-12_af 16%_af increase_af OTHER_DRUG Cmax_af leading_af 16%_af decrease_af glucose_af AUC0-24_af ._af
2947,"Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.",glyburide,valdecoxib,advise,"Because_bf changes_bf glucose_bf concentrations_bf OTHER_DRUG coadministration_be within_be normal_be variability_be individual_be glucose_be concentrations_be near_be 70_be mg/dL_be ,_be dose_be adjustment_be DRUG (5_af mg_af QD_af 10_af mg_af BID)_af OTHER_DRUG coadministration_af (up_af 40_af mg_af QD)_af indicated_af ._af"
2948,Coadministration with valdecoxib increased exposure of omeprazole (AUC) by 46%.,valdecoxib,omeprazole,mechanism,Coadministration_bf DRUG increased_be exposure_be OTHER_DRUG (AUC)_af 46%_af ._af
2949,"Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.",valdecoxib,Ortho-Novum,mechanism,"Coadministration_bf DRUG OTHER_DRUG 1/35_af increased_af exposure_af norethindrone_af ethinyl_af estradiol_af 20%_af 34%_af ,_af respectively_af ._af"
2950,These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.,contraceptive,valdecoxib,advise,These_bf increased_bf exposures_bf norethindrone_bf ethinyl_bf estradiol_bf taken_bf consideration_bf selecting_bf oral_bf DRUG women_be taking_be OTHER_DRUG ._af
2951,"Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.",diazepam,valdecoxib,mechanism,"Plasma_bf exposure_bf DRUG (10_be mg_be BID)_be increased_be 28%_be following_be administration_be OTHER_DRUG (40_af mg_af BID)_af 12_af days_af ,_af plasma_af exposure_af OTHER_DRUG (40_af mg_af BID)_af substantially_af increased_af following_af administration_af DRUG (10_af mg_af BID)_af 12_af days_af ._af"
2952,"Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.",valdecoxib,diazepam,effect,"Although_bf magnitude_bf changes_bf OTHER_DRUG plasma_be exposure_be coadministered_be DRUG sufficient_af warrant_af dosage_af adjustments_af ,_af patients_af may_af experience_af enhanced_af sedative_af side_af effects_af caused_af increased_af exposure_af OTHER_DRUG circumstance_af ._af"
2953,Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.,Erythromycin,vardenafil,mechanism,DRUG (500_be mg_be ._be ._be d)_be produced_be 4-fold_be increase_be OTHER_DRUG AUC_af 3-fold_af increase_af Cmax_af co-administered_af OTHER_DRUG 5_af mg_af healthy_af volunteers_af ._af
2954,It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.,Vardenafil,erythromycin,advise,It_bf recommended_bf exceed_bf single_bf 5_bf mg_bf dose_bf DRUG 24-hour_be period_be used_be combination_be OTHER_DRUG ._af
2955,Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.,Ketoconazole,vardenafil,mechanism,DRUG (200_be mg_be daily)_be produced_be 10-fold_be increase_be OTHER_DRUG AUC_af 4-fold_af increase_af Cmax_af co-administered_af OTHER_DRUG (5_af mg)_af healthy_af volunteers_af ._af
2956,A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.,Vardenafil,ketoconazole,advise,A_bf 5-mg_bf DRUG dose_be exceeded_be used_be combination_be 200_be mg_be daily_be OTHER_DRUG ._af
2957,"Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.",Vardenafil,ketoconazole,advise,"Since_bf higher_bf doses_bf OTHER_DRUG (400_be mg_be daily)_be may_be result_be higher_be increases_be Cmax_be AUC_be ,_be single_be 2_be ._be 5_be mg_be dose_be DRUG exceeded_af 24-hour_af period_af used_af combination_af OTHER_DRUG 400_af mg_af daily_af ._af"
2958,"HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.",Indinavir,Vardenafil,mechanism,"HIV_bf Protease_bf Inhibitors:_bf DRUG (800_be mg_be ._be ._be ._be )_be co-administered_be OTHER_DRUG 10_af mg_af resulted_af 16-fold_af increase_af OTHER_DRUG AUC_af ,_af 7-fold_af increase_af OTHER_DRUG Cmax_af 2-fold_af increase_af OTHER_DRUG half-life_af ._af"
2959,It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.,Vardenafil,indinavir,advise,It_bf recommended_bf exceed_bf single_bf 2_bf ._bf 5_bf mg_bf DRUG dose_be 24-hour_be period_be used_be combination_be OTHER_DRUG ._af
2960,Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.,Ritonavir,Vardenafil,mechanism,DRUG (600_be mg_be b_be ._be ._be ._be )_be co-administered_be OTHER_DRUG 5_af mg_af resulted_af 49-fold_af increase_af OTHER_DRUG AUC_af 13-fold_af increase_af OTHER_DRUG Cmax_af ._af
2961,"The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.",vardenafil,ritonavir,mechanism,"The_bf interaction_bf consequence_bf blocking_bf hepatic_bf metabolism_bf DRUG OTHER_DRUG ,_af highly_af potent_af CYP3A4_af inhibitor_af ,_af also_af inhibits_af CYP2C9_af ._af"
2962,Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.,Ritonavir,vardenafil,mechanism,DRUG significantly_be prolonged_be half-life_be OTHER_DRUG 26_af hours_af ._af
2963,"Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.",Vardenafil,ritonavir,advise,"Consequently_bf ,_bf recommended_bf exceed_bf single_bf 2_bf ._bf 5_bf mg_bf DRUG dose_be 72-hour_be period_be used_be combination_be OTHER_DRUG ._af"
2964,"In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.",nitrates,vardenafil,mechanism,"In_bf vivo_bf studies:_bf Nitrates:_bf The_bf blood_bf pressure_bf lowering_bf effects_bf sublingual_bf DRUG (0_be ._be 4_be mg)_be taken_be 1_be 4_be hours_be OTHER_DRUG increases_af heart_af rate_af taken_af 1_af ,_af 4_af 8_af hours_af potentiated_af 20_af mg_af dose_af OTHER_DRUG healthy_af middle-aged_af subjects_af ._af"
2965,"Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.",Vardenafil,nitrates,advise,"Potentiation_bf hypotensive_bf effects_bf OTHER_DRUG patients_be ischemic_be heart_be disease_be evaluated_be ,_be concomitant_be use_be DRUG OTHER_DRUG contraindicated_af ._af"
2966,"In these patients whose hypertension was controlled with nifedipine, Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.",nifedipine,Vardenafil,effect,"In_bf patients_bf whose_bf hypertension_bf controlled_bf DRUG ,_be OTHER_DRUG 20_af mg_af produced_af mean_af additional_af supine_af systolic/diastolic_af blood_af pressure_af reductions_af 6/5_af mm_af Hg_af compared_af placebo_af ._af"
2967,"Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.",Vardenafil,terazosin,effect,"Alpha-blockers:_bf When_bf DRUG 10_be 20_be mg_be given_be healthy_be volunteers_be either_be simultaneously_be 6_be hours_be 10_be mg_be dose_be OTHER_DRUG ,_af significant_af hypotension_af developed_af substantial_af number_af subjects_af ._af"
2968,"With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.",Vardenafil,terazosin,effect,"With_bf simultaneous_bf dosing_bf DRUG 10_be mg_be OTHER_DRUG 10_af mg_af ,_af 6_af 8_af subjects_af experienced_af standing_af systolic_af blood_af pressure_af less_af 85_af mm_af Hg_af ._af"
2969,"With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.",Vardenafil,terazosin,effect,"With_bf simultaneous_bf dosing_bf DRUG 20_be mg_be OTHER_DRUG 10_af mg_af ,_af 2_af 9_af subjects_af experienced_af standing_af systolic_af blood_af pressure_af less_af 85_af mm_af Hg_af ._af"
2970,"When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.",Vardenafil,terazosin,effect,"When_bf DRUG dosing_be separated_be OTHER_DRUG 10_af mg_af 6_af hours_af ,_af 7_af 28_af subjects_af received_af 20_af mg_af DRUG experienced_af decrease_af standing_af systolic_af blood_af pressure_af 85_af mm_af Hg_af ._af"
2971,"In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.",Vardenafil,tamsulosin,effect,"In_bf similar_bf study_bf OTHER_DRUG healthy_be volunteers_be ,_be 1_be 24_be subjects_be dosed_be DRUG 20_af mg_af OTHER_DRUG 0_af ._af 4_af mg_af separated_af 6_af hours_af experienced_af standing_af systolic_af blood_af pressure_af 85_af mm_af Hg_af ._af"
2972,Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.,Vardenafil,tamsulosin,effect,Two_bf 16_bf subjects_bf dosed_bf simultaneously_bf DRUG 10_be mg_be OTHER_DRUG 0_af ._af 4_af mg_af experienced_af standing_af systolic_af blood_af pressure_af 85_af mm_af Hg_af ._af
2973,"Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.",Vardenafil,alpha-blocker,advise,"Based_bf data_bf ,_bf DRUG used_be patients_be OTHER_DRUG therapy_af ._af"
2974,"Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.",Vardenafil,ritonavir,mechanism,"OTHER_DRUG indinavir:_be Upon_be concomitant_be administration_be 5_be mg_be DRUG 600_af mg_af BID_af OTHER_DRUG ,_af Cmax_af AUC_af OTHER_DRUG reduced_af approximately_af 20%_af ._af"
2975,"Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.",Vardenafil,indinavir,mechanism,"Upon_bf administration_bf 10_bf mg_bf DRUG 800_be mg_be TID_be OTHER_DRUG ,_af Cmax_af AUC_af OTHER_DRUG reduced_af 40%_af 30%_af ,_af respectively_af ._af"
2976,"Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).",Zalcitabine,ZDV,effect,"DRUG also_be significant_be effect_be intracellular_be phosphorylation_be OTHER_DRUG ,_af shown_af vitro_af peripheral_af blood_af mononuclear_af cells_af two_af cell_af lines_af (U937_af Molt-4)_af ._af"
2977,"Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.",lamivudine,zalcitabine,effect,"Lamivudine:_bf In_bf vitro_bf studies_bf peripheral_bf blood_bf mononuclear_bf cells_bf ,_bf U937_bf Molt-4_bf cells_bf revealed_bf DRUG significantly_be inhibited_be OTHER_DRUG phosphorylation_af dose_af dependent_af manner_af ._af"
2978,Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);,Zalcitabine,lamivudine,effect,DRUG inhibited_be OTHER_DRUG phosphorylation_af high_af concentration_af ratios_af (10_af 100);_af
2979,"These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.",zalcitabine,lamivudine,effect,"These_bf vitro_bf studies_bf suggest_bf concomitant_bf administration_bf DRUG OTHER_DRUG humans_af may_af result_af sub-therapeutic_af concentrations_af active_af phosphorylated_af DRUG ,_af may_af lead_af decreased_af antiretroviral_af effect_af DRUG ._af"
2980,Concomitant use of zalcitabine and lamivudine is not recommended.,zalcitabine,lamivudine,advise,Concomitant_bf use_bf DRUG OTHER_DRUG recommended_af ._af
2981,Concomitant use of HIVID with didanosine is not recommended.,HIVID,didanosine,advise,Concomitant_bf use_bf DRUG OTHER_DRUG recommended_af ._af
2982,Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.,pentamidine,HIVID,effect,Death_bf due_bf fulminant_bf pancreatitis_bf possibly_bf related_bf intravenous_bf DRUG OTHER_DRUG reported_af ._af
2983,"If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.",pentamidine,HIVID,advise,"If_bf intravenous_bf DRUG required_be treat_be Pneumocystis_be carinii_be pneumonia_be ,_be treatment_be OTHER_DRUG interrupted_af ._af"
2984,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",amphotericin,HIVID,effect,"DRUG ,_be Foscarnet_be ,_be Aminoglycosides:_be Drugs_be DRUG ,_af foscarnet_af ,_af aminoglycosides_af may_af increase_af risk_af developing_af peripheral_af neuropathy_af HIVID-associated_af adverse_af events_af interfering_af renal_af clearance_af zalcitabine_af (thereby_af raising_af systemic_af exposure)_af ._af"
2985,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",amphotericin,zalcitabine,mechanism,"DRUG ,_be Foscarnet_be ,_be Aminoglycosides:_be Drugs_be DRUG ,_af foscarnet_af ,_af aminoglycosides_af may_af increase_af risk_af developing_af peripheral_af neuropathy_af HIVID-associated_af adverse_af events_af interfering_af renal_af clearance_af OTHER_DRUG (thereby_af raising_af systemic_af exposure)_af ._af"
2986,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",foscarnet,HIVID,effect,"Amphotericin_bf ,_bf DRUG ,_be Aminoglycosides:_be Drugs_be amphotericin_be ,_be DRUG ,_af aminoglycosides_af may_af increase_af risk_af developing_af peripheral_af neuropathy_af HIVID-associated_af adverse_af events_af interfering_af renal_af clearance_af zalcitabine_af (thereby_af raising_af systemic_af exposure)_af ._af"
2987,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",foscarnet,zalcitabine,mechanism,"Amphotericin_bf ,_bf DRUG ,_be Aminoglycosides:_be Drugs_be amphotericin_be ,_be DRUG ,_af aminoglycosides_af may_af increase_af risk_af developing_af peripheral_af neuropathy_af HIVID-associated_af adverse_af events_af interfering_af renal_af clearance_af OTHER_DRUG (thereby_af raising_af systemic_af exposure)_af ._af"
2988,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",aminoglycosides,HIVID,effect,"Amphotericin_bf ,_bf Foscarnet_bf ,_bf Aminoglycosides:_bf Drugs_bf amphotericin_bf ,_bf foscarnet_bf ,_bf DRUG may_be increase_be risk_be developing_be peripheral_be neuropathy_be HIVID-associated_be adverse_be events_be interfering_be renal_be clearance_be zalcitabine_be (thereby_be raising_be systemic_be exposure)_be ._be"
2989,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",aminoglycosides,zalcitabine,mechanism,"Amphotericin_bf ,_bf Foscarnet_bf ,_bf Aminoglycosides:_bf Drugs_bf amphotericin_bf ,_bf foscarnet_bf ,_bf DRUG may_be increase_be risk_be developing_be peripheral_be neuropathy_be HIVID-associated_be adverse_be events_be interfering_be renal_be clearance_be OTHER_DRUG (thereby_af raising_af systemic_af exposure)_af ._af"
2990,"Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.",probenecid,zalcitabine,mechanism,"DRUG Cimetidine:_be Concomitant_be administration_be DRUG cimetidine_af decreases_af elimination_af OTHER_DRUG ,_af likely_af inhibition_af renal_af tubular_af secretion_af OTHER_DRUG ._af"
2991,"Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.",cimetidine,zalcitabine,mechanism,"Probenecid_bf Cimetidine:_bf Concomitant_bf administration_bf probenecid_bf DRUG decreases_be elimination_be OTHER_DRUG ,_af likely_af inhibition_af renal_af tubular_af secretion_af OTHER_DRUG ._af"
2992,"The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.",zalcitabine,magnesium,advise,"The_bf clinical_bf significance_bf reduction_bf known_bf ,_bf hence_bf DRUG recommended_be ingested_be simultaneously_be magnesium/aluminum-containing_be antacids_be ._be"
2993,"The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.",zalcitabine,aluminum,advise,"The_bf clinical_bf significance_bf reduction_bf known_bf ,_bf hence_bf DRUG recommended_be ingested_be simultaneously_be magnesium/aluminum-containing_be antacids_be ._be"
2994,"The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.",zalcitabine,antacids,advise,"The_bf clinical_bf significance_bf reduction_bf known_bf ,_bf hence_bf DRUG recommended_be ingested_be simultaneously_be magnesium/aluminum-containing_be OTHER_DRUG ._af"
2995,Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.,zalcitabine,metoclopramide,mechanism,Metoclopramide:_bf Bioavailability_bf mildly_bf reduced_bf (approximately_bf 10%)_bf DRUG OTHER_DRUG coadministered_af ._af
2996,Doxorubicin: Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.,Doxorubicin,zalcitabine,effect,Doxorubicin:_bf DRUG caused_be decrease_be OTHER_DRUG phosphorylation_af (_af 50%_af inhibition_af total_af phosphate_af formation)_af U937/Molt_af 4_af cells_af ._af
2997,"CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.",Sonata,ethanol,effect,"CNS-Active_bf Drugs_bf Ethanol:_bf DRUG 10_be mg_be potentiated_be CNS-impairing_be effects_be OTHER_DRUG 0_af ._af 75_af g/kg_af balance_af testing_af reaction_af time_af 1_af hour_af OTHER_DRUG administration_af digit_af symbol_af substitution_af test_af (DSST)_af ,_af symbol_af copying_af test_af ,_af variability_af component_af divided_af attention_af test_af 2_af ._af 5_af hours_af OTHER_DRUG administration_af ._af"
2998,Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.,Sonata,imipramine,effect,Imipramine:_bf Coadministration_bf single_bf doses_bf DRUG 20_be mg_be OTHER_DRUG 75_af mg_af produced_af additive_af effects_af decreased_af alertness_af impaired_af psychomotor_af performance_af 2_af 4_af hours_af administration_af ._af
2999,Thioridazine: Coadministration of single doses of Sonata 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.,Sonata,thioridazine,effect,Thioridazine:_bf Coadministration_bf single_bf doses_bf DRUG 20_be mg_be OTHER_DRUG 50_af mg_af produced_af additive_af effects_af decreased_af alertness_af impaired_af psychomotor_af performance_af 2_af 4_af hours_af administration_af ._af
3000,"Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.",zaleplon,promethazine,mechanism,"Promethazine:_bf Coadministration_bf single_bf dose_bf DRUG OTHER_DRUG (10_af 25_af mg_af ,_af respectively)_af resulted_af 15%_af decrease_af maximal_af plasma_af concentrations_af DRUG ,_af change_af area_af plasma_af concentration-time_af curve_af ._af"
3001,"Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.",rifampin,zaleplon,mechanism,"Multiple-dose_bf administration_bf potent_bf CYP3A4_bf inducer_bf DRUG (600_be mg_be every_be 24_be hours_be ,_be q24h_be ,_be 14_be days)_be ,_be however_be ,_be reduced_be OTHER_DRUG Cmax_af AUC_af approximately_af 80%_af ._af"
3002,"Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.",zaleplon,erythromycin,mechanism,"Coadministration_bf single_bf ,_bf oral_bf doses_bf DRUG OTHER_DRUG (10_af mg_af 800_af mg_af ,_af respectively)_af ,_af strong_af ,_af selective_af CYP3A4_af inhibitor_af produced_af 34%_af increase_af zaleplons_af maximal_af plasma_af concentrations_af 20%_af increase_af area_af plasma_af concentration-time_af curve_af ._af"
3003,Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.,ketoconazole,zaleplon,mechanism,Other_bf strong_bf selective_bf CYP3A4_bf inhibitors_bf DRUG also_be expected_be increase_be exposure_be OTHER_DRUG ._af
3004,"Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.",Cimetidine,zaleplon,mechanism,"Drugs_bf That_bf Inhibit_bf Both_bf Aldehyde_bf Oxidase_bf CYP3A4_bf Cimetidine:_bf DRUG inhibits_be aldehyde_be oxidase_be (in_be vitro)_be CYP3A4_be (in_be vitro_be vivo)_be ,_be primary_be secondary_be enzymes_be ,_be respectively_be ,_be responsible_be OTHER_DRUG metabolism_af ._af"
3005,Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.,Sonata,cimetidine,mechanism,Concomitant_bf administration_bf DRUG (10_be mg)_be OTHER_DRUG (800_af mg)_af produced_af 85%_af increase_af mean_af Cmax_af AUC_af zaleplon_af ._af
